drugbank_id,name,drug_classes,interactions,dosages,food_interactions
DB00001,Lepirudin,ANTITHROMBOTIC AGENTS; BLOOD AND BLOOD FORMING ORGANS; Direct thrombin inhibitors,"[DB06605] Apixaban: Apixaban may increase the anticoagulant activities of Lepirudin. | [DB06695] Dabigatran etexilate: Dabigatran etexilate may increase the anticoagulant activities of Lepirudin. | [DB01254] Dasatinib: The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin. | [DB01609] Deferasirox: The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox. | [DB01586] Ursodeoxycholic acid: The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid. | [DB02123] Glycochenodeoxycholic Acid: The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Glycochenodeoxycholic Acid. | [DB02659] Cholic Acid: The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Cholic Acid. | [DB02691] Glycocholic acid: The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Glycocholic acid. | [DB03619] Deoxycholic acid: The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Deoxycholic acid. | [DB04348] Taurocholic acid: The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Taurocholic acid. | [DB05990] Obeticholic acid: The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Obeticholic acid. | [DB06777] Chenodeoxycholic acid: The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Chenodeoxycholic acid. | [DB08833] Taurochenodeoxycholic acid: The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Taurochenodeoxycholic acid. | [DB08834] Tauroursodeoxycholic acid: The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Tauroursodeoxycholic acid. | [DB08857] Bamet-UD2: The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Bamet-UD2. | [DB11622] Dehydrocholic acid: The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Dehydrocholic acid. | [DB11789] Hyodeoxycholic Acid: The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Hyodeoxycholic Acid. | [DB09075] Edoxaban: The risk or severity of bleeding can be increased when Edoxaban is combined with Lepirudin. | [DB09053] Ibrutinib: The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Lepirudin. | [DB08935] Obinutuzumab: The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Obinutuzumab. | [DB06228] Rivaroxaban: Lepirudin may increase the anticoagulant activities of Rivaroxaban. | [DB06206] Sugammadex: The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Sugammadex. | [DB09070] Tibolone: Tibolone may increase the anticoagulant activities of Lepirudin. | [DB00932] Tipranavir: The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Lepirudin. | [DB00013] Urokinase: Urokinase may increase the anticoagulant activities of Lepirudin. | [DB00163] Vitamin E: Vitamin E may increase the anticoagulant activities of Lepirudin. | [DB09030] Vorapaxar: The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Lepirudin. | [DB01381] Ginkgo biloba: Ginkgo biloba may increase the anticoagulant activities of Lepirudin. | [DB01181] Ifosfamide: The risk or severity of bleeding can be increased when Ifosfamide is combined with Lepirudin. | [DB00468] Quinine: The therapeutic efficacy of Lepirudin can be increased when used in combination with Quinine. | [DB00908] Quinidine: The therapeutic efficacy of Lepirudin can be increased when used in combination with Quinidine. | [DB00675] Tamoxifen: The risk or severity of bleeding can be increased when Tamoxifen is combined with Lepirudin. | [DB00539] Toremifene: The risk or severity of bleeding can be increased when Toremifene is combined with Lepirudin. | [DB00806] Pentoxifylline: The therapeutic efficacy of Lepirudin can be increased when used in combination with Pentoxifylline. | [DB00686] Pentosan polysulfate: Pentosan polysulfate may increase the anticoagulant activities of Lepirudin. | [DB00583] Levocarnitine: The therapeutic efficacy of Lepirudin can be increased when used in combination with Levocarnitine. | [DB00255] Diethylstilbestrol: Diethylstilbestrol may decrease the anticoagulant activities of Lepirudin. | [DB00269] Chlorotrianisene: Chlorotrianisene may decrease the anticoagulant activities of Lepirudin. | [DB00286] Conjugated estrogens: Conjugated estrogens may decrease the anticoagulant activities of Lepirudin. | [DB01357] Mestranol: The risk or severity of adverse effects can be increased when Mestranol is combined with Lepirudin. | [DB04574] Estrone sulfate: Estrone sulfate may decrease the anticoagulant activities of Lepirudin. | [DB04575] Quinestrol: Quinestrol may decrease the anticoagulant activities of Lepirudin. | [DB07931] Hexestrol: Hexestrol may decrease the anticoagulant activities of Lepirudin. | [DB09317] Synthetic Conjugated Estrogens, A: Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Lepirudin. | [DB09318] Synthetic Conjugated Estrogens, B: Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Lepirudin. | [DB09369] Polyestradiol phosphate: Polyestradiol phosphate may decrease the anticoagulant activities of Lepirudin. | [DB09381] Esterified estrogens: Esterified estrogens may decrease the anticoagulant activities of Lepirudin. | [DB11478] Zeranol: Zeranol may decrease the anticoagulant activities of Lepirudin. | [DB11674] Equol: Equol may decrease the anticoagulant activities of Lepirudin. | [DB13143] Methallenestril: Methallenestril may decrease the anticoagulant activities of Lepirudin. | [DB13386] Epimestrol: Epimestrol may decrease the anticoagulant activities of Lepirudin. | [DB13418] Moxestrol: Moxestrol may decrease the anticoagulant activities of Lepirudin. | [DB13952] Estradiol acetate: Estradiol acetate may decrease the anticoagulant activities of Lepirudin. | [DB13953] Estradiol benzoate: Estradiol benzoate may decrease the anticoagulant activities of Lepirudin. | [DB13954] Estradiol cypionate: Estradiol cypionate may decrease the anticoagulant activities of Lepirudin. | [DB13956] Estradiol valerate: Estradiol valerate may decrease the anticoagulant activities of Lepirudin. | [DB15334] Biochanin A: Biochanin A may decrease the anticoagulant activities of Lepirudin. | [DB15335] Formononetin: Formononetin may decrease the anticoagulant activities of Lepirudin. | [DB04573] Estriol: Estriol may decrease the anticoagulant activities of Lepirudin. | [DB09211] Limaprost: The risk or severity of bleeding can be increased when Limaprost is combined with Lepirudin. | [DB00159] Icosapent: The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Lepirudin. | [DB00244] Mesalazine: The risk or severity of bleeding can be increased when Mesalazine is combined with Lepirudin. | [DB00328] Indomethacin: The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Lepirudin. | [DB00461] Nabumetone: The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Lepirudin. | [DB00465] Ketorolac: The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Lepirudin. | [DB00469] Tenoxicam: The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Lepirudin. | [DB00482] Celecoxib: The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Lepirudin. | [DB00500] Tolmetin: The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Lepirudin. | [DB00533] Rofecoxib: The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Lepirudin. | [DB00554] Piroxicam: The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Lepirudin. | [DB00573] Fenoprofen: The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Lepirudin. | [DB00580] Valdecoxib: The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Lepirudin. | [DB00586] Diclofenac: The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Lepirudin. | [DB00605] Sulindac: The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Lepirudin. | [DB00712] Flurbiprofen: The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Lepirudin. | [DB00749] Etodolac: The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Lepirudin. | [DB00784] Mefenamic acid: The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Lepirudin. | [DB00788] Naproxen: The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Lepirudin. | [DB00795] Sulfasalazine: The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Lepirudin. | [DB00812] Phenylbutazone: The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Lepirudin. | [DB00814] Meloxicam: The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Lepirudin. | [DB00821] Carprofen: The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Lepirudin. | [DB00861] Diflunisal: The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Lepirudin. | [DB00936] Salicylic acid: The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Lepirudin. | [DB00939] Meclofenamic acid: The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Lepirudin. | [DB00991] Oxaprozin: The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Lepirudin. | [DB01009] Ketoprofen: The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Lepirudin. | [DB01014] Balsalazide: The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Lepirudin. | [DB01250] Olsalazine: The risk or severity of bleeding can be increased when Olsalazine is combined with Lepirudin. | [DB01283] Lumiracoxib: The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Lepirudin. | [DB01397] Magnesium salicylate: The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Lepirudin. | [DB01399] Salsalate: The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Lepirudin. | [DB01401] Choline magnesium trisalicylate: The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Lepirudin. | [DB01419] Antrafenine: The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Lepirudin. | [DB01424] Aminophenazone: The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Lepirudin. | [DB01435] Antipyrine: The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Lepirudin. | [DB01600] Tiaprofenic acid: The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Lepirudin. | [DB01628] Etoricoxib: The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Lepirudin. | [DB02224] Taxifolin: The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Lepirudin. | [DB03585] Oxyphenbutazone: The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Lepirudin. | [DB04725] Licofelone: The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Lepirudin. | [DB04812] Benoxaprofen: The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Lepirudin. | [DB04828] Zomepirac: The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Lepirudin. | [DB05095] Cimicoxib: The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Lepirudin. | [DB06725] Lornoxicam: The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Lepirudin. | [DB06736] Aceclofenac: The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Lepirudin. | [DB06737] Zaltoprofen: The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Lepirudin. | [DB07402] Azapropazone: The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Lepirudin. | [DB08439] Parecoxib: The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Lepirudin. | [DB08797] Salicylamide: The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Lepirudin. | [DB08940] Kebuzone: The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Lepirudin. | [DB08942] Isoxicam: The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Lepirudin. | [DB08951] Indoprofen: The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Lepirudin. | [DB08955] Ibuproxam: The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Lepirudin. | [DB08976] Floctafenine: The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Lepirudin. | [DB08981] Fenbufen: The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Lepirudin. | [DB08984] Etofenamate: The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Lepirudin. | [DB08991] Epirizole: The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Lepirudin. | [DB09084] Benzydamine: The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Lepirudin. | [DB09214] Dexketoprofen: The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Lepirudin. | [DB09215] Droxicam: The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Lepirudin. | [DB09216] Tolfenamic acid: The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Lepirudin. | [DB09217] Firocoxib: The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Lepirudin. | [DB09218] Clonixin: The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Lepirudin. | [DB09285] Morniflumate: The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Lepirudin. | [DB09288] Propacetamol: The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Lepirudin. | [DB09295] Talniflumate: The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Lepirudin. | [DB11455] Robenacoxib: The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Lepirudin. | [DB11466] Tepoxalin: The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Lepirudin. | [DB11518] Flunixin: The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Lepirudin. | [DB12399] Polmacoxib: The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Lepirudin. | [DB12610] Ebselen: The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Lepirudin. | [DB13001] Tinoridine: The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Lepirudin. | [DB13167] Alclofenac: The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Lepirudin. | [DB13217] Fentiazac: The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Lepirudin. | [DB13232] Suxibuzone: The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Lepirudin. | [DB13286] Bumadizone: The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Lepirudin. | [DB13314] Alminoprofen: The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Lepirudin. | [DB13371] Difenpiramide: The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Lepirudin. | [DB13407] Nifenazone: The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Lepirudin. | [DB13432] Lonazolac: The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Lepirudin. | [DB13481] Tenidap: The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Lepirudin. | [DB13524] Propyphenazone: The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Lepirudin. | [DB13527] Proglumetacin: The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Lepirudin. | [DB13538] Guacetisal: The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Lepirudin. | [DB13544] Ethenzamide: The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Lepirudin. | [DB13612] Carbaspirin calcium: The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Lepirudin. | [DB13629] Mofebutazone: The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Lepirudin. | [DB13649] Proquazone: The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Lepirudin. | [DB13657] Benorilate: The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Lepirudin. | [DB13722] Pirprofen: The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Lepirudin. | [DB13860] Imidazole salicylate: The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Lepirudin. | [DB14059] SC-236: The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Lepirudin. | [DB14060] NS-398: The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Lepirudin. | [DB14938] Flurbiprofen axetil: The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Lepirudin. | [DB09212] Loxoprofen: The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Lepirudin. | [DB04552] Niflumic acid: The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Lepirudin. | [DB04865] Omacetaxine mepesuccinate: The risk or severity of bleeding can be increased when Lepirudin is combined with Omacetaxine mepesuccinate. | [DB11133] Omega-3 fatty acids: Omega-3 fatty acids may increase the anticoagulant activities of Lepirudin. | [DB00081] Tositumomab: The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Tositumomab. | [DB00048] Collagenase clostridium histolyticum: The risk or severity of adverse effects can be increased when Lepirudin is combined with Collagenase clostridium histolyticum. | [DB00389] Carbimazole: Carbimazole may increase the anticoagulant activities of Lepirudin. | [DB00550] Propylthiouracil: Propylthiouracil may increase the anticoagulant activities of Lepirudin. | [DB00763] Methimazole: Methimazole may increase the anticoagulant activities of Lepirudin. | [DB03374] 3,5-Diiodotyrosine: 3,5-Diiodotyrosine may increase the anticoagulant activities of Lepirudin. | [DB06715] Potassium Iodide: Potassium Iodide may increase the anticoagulant activities of Lepirudin. | [DB07637] Dibromotyrosine: Dibromotyrosine may increase the anticoagulant activities of Lepirudin. | [DB09418] Potassium perchlorate: Potassium perchlorate may increase the anticoagulant activities of Lepirudin. | [DB13644] Methylthiouracil: Methylthiouracil may increase the anticoagulant activities of Lepirudin. | [DB13804] Benzylthiouracil: Benzylthiouracil may increase the anticoagulant activities of Lepirudin. | [DB04682] Octylphenoxy polyethoxyethanol: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Octylphenoxy polyethoxyethanol. | [DB05830] Trestolone: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Trestolone. | [DB08867] Ulipristal: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ulipristal. | [DB11507] Cloprostenol: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cloprostenol. | [DB13044] Gossypol: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gossypol. | [DB00294] Etonogestrel: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Etonogestrel. | [DB00378] Dydrogesterone: Dydrogesterone may decrease the anticoagulant activities of Lepirudin. | [DB00396] Progesterone: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Progesterone. | [DB01431] Allylestrenol: Allylestrenol may decrease the anticoagulant activities of Lepirudin. | [DB06713] Norelgestromin: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Norelgestromin. | [DB06789] Hydroxyprogesterone caproate: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydroxyprogesterone caproate. | [DB09124] Medrogestone: Medrogestone may decrease the anticoagulant activities of Lepirudin. | [DB11372] Altrenogest: Altrenogest may decrease the anticoagulant activities of Lepirudin. | [DB11636] Nomegestrol: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Nomegestrol. | [DB13230] Gestonorone: Gestonorone may decrease the anticoagulant activities of Lepirudin. | [DB13533] Methylestrenolone: Methylestrenolone may decrease the anticoagulant activities of Lepirudin. | [DB13602] Promegestone: Promegestone may decrease the anticoagulant activities of Lepirudin. | [DB13866] Etynodiol: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Etynodiol. | [DB14570] Hydroxyprogesterone: Hydroxyprogesterone may decrease the anticoagulant activities of Lepirudin. | [DB14679] Quingestanol acetate: Quingestanol acetate may decrease the anticoagulant activities of Lepirudin. | [DB00233] Aminosalicylic acid: The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Lepirudin. | [DB01294] Bismuth subsalicylate: The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Lepirudin. | [DB06251] Dersalazine: The risk or severity of bleeding can be increased when Dersalazine is combined with Lepirudin. | [DB06807] Phenyl aminosalicylate: The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Lepirudin. | [DB09543] Methyl salicylate: The risk or severity of bleeding can be increased when Methyl salicylate is combined with Lepirudin. | [DB11079] Trolamine salicylate: The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Lepirudin. | [DB13509] Aloxiprin: The risk or severity of bleeding can be increased when Aloxiprin is combined with Lepirudin. | [DB14006] Choline salicylate: The risk or severity of bleeding can be increased when Choline salicylate is combined with Lepirudin. | [DB14026] Thiosalicylic acid: The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Lepirudin. | [DB00054] Abciximab: The risk or severity of bleeding can be increased when Abciximab is combined with Lepirudin. | [DB00063] Eptifibatide: The risk or severity of bleeding can be increased when Eptifibatide is combined with Lepirudin. | [DB00208] Ticlopidine: The risk or severity of bleeding can be increased when Ticlopidine is combined with Lepirudin. | [DB00261] Anagrelide: The risk or severity of bleeding can be increased when Anagrelide is combined with Lepirudin. | [DB00758] Clopidogrel: The risk or severity of bleeding can be increased when Clopidogrel is combined with Lepirudin. | [DB00775] Tirofiban: The risk or severity of bleeding can be increased when Tirofiban is combined with Lepirudin. | [DB00975] Dipyridamole: The risk or severity of bleeding can be increased when Dipyridamole is combined with Lepirudin. | [DB01088] Iloprost: Iloprost may increase the anticoagulant activities of Lepirudin. | [DB01138] Sulfinpyrazone: The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Lepirudin. | [DB01166] Cilostazol: The risk or severity of bleeding can be increased when Cilostazol is combined with Lepirudin. | [DB01207] Ridogrel: The risk or severity of bleeding can be increased when Ridogrel is combined with Lepirudin. | [DB01240] Epoprostenol: The risk or severity of bleeding can be increased when Epoprostenol is combined with Lepirudin. | [DB02709] Resveratrol: The risk or severity of bleeding can be increased when Resveratrol is combined with Lepirudin. | [DB04743] Nimesulide: The risk or severity of bleeding can be increased when Nimesulide is combined with Lepirudin. | [DB04905] Tesmilifene: The risk or severity of bleeding can be increased when Tesmilifene is combined with Lepirudin. | [DB04932] Defibrotide: The risk or severity of bleeding can be increased when Defibrotide is combined with Lepirudin. | [DB05229] Beraprost: The risk or severity of bleeding can be increased when Beraprost is combined with Lepirudin. | [DB05266] Ibudilast: The risk or severity of bleeding can be increased when Ibudilast is combined with Lepirudin. | [DB05767] Andrographolide: The risk or severity of bleeding can be increased when Andrographolide is combined with Lepirudin. | [DB06081] Caplacizumab: The risk or severity of bleeding can be increased when Caplacizumab is combined with Lepirudin. | [DB06209] Prasugrel: The risk or severity of bleeding can be increased when Prasugrel is combined with Lepirudin. | [DB06441] Cangrelor: The risk or severity of bleeding can be increased when Cangrelor is combined with Lepirudin. | [DB07615] Tranilast: The risk or severity of bleeding can be increased when Tranilast is combined with Lepirudin. | [DB08814] Triflusal: The risk or severity of bleeding can be increased when Triflusal is combined with Lepirudin. | [DB08816] Ticagrelor: The risk or severity of bleeding can be increased when Ticagrelor is combined with Lepirudin. | [DB08887] Icosapent ethyl: The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Lepirudin. | [DB09283] Trapidil: The risk or severity of bleeding can be increased when Trapidil is combined with Lepirudin. | [DB12092] Naftopidil: The risk or severity of bleeding can be increased when Naftopidil is combined with Lepirudin. | [DB12163] Sarpogrelate: The risk or severity of bleeding can be increased when Sarpogrelate is combined with Lepirudin. | [DB12321] Ifetroban: The risk or severity of bleeding can be increased when Ifetroban is combined with Lepirudin. | [DB12445] Nitroaspirin: The risk or severity of bleeding can be increased when Nitroaspirin is combined with Lepirudin. | [DB12545] Indobufen: The risk or severity of bleeding can be increased when Indobufen is combined with Lepirudin. | [DB12749] Butylphthalide: The risk or severity of bleeding can be increased when Butylphthalide is combined with Lepirudin. | [DB12771] Hydroxytyrosol: The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Lepirudin. | [DB13036] Ramatroban: The risk or severity of bleeding can be increased when Ramatroban is combined with Lepirudin. | [DB13327] Picotamide: The risk or severity of bleeding can be increased when Picotamide is combined with Lepirudin. | [DB13367] Cloricromen: The risk or severity of bleeding can be increased when Cloricromen is combined with Lepirudin. | [DB13400] Linsidomine: The risk or severity of bleeding can be increased when Linsidomine is combined with Lepirudin. | [DB13510] Buflomedil: The risk or severity of bleeding can be increased when Buflomedil is combined with Lepirudin. | [DB13929] Relcovaptan: The risk or severity of bleeding can be increased when Relcovaptan is combined with Lepirudin. | [DB15786] Maritime pine extract: The risk or severity of bleeding can be increased when Maritime pine extract is combined with Lepirudin. | [DB00374] Treprostinil: The risk or severity of bleeding can be increased when Treprostinil is combined with Lepirudin. | [DB03404] Hemin: Hemin may increase the anticoagulant activities of Lepirudin. | [DB13783] Acemetacin: The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Acemetacin. | [DB00624] Testosterone: Testosterone may increase the anticoagulant activities of Lepirudin. | [DB01420] Testosterone propionate: Testosterone propionate may increase the anticoagulant activities of Lepirudin. | [DB01481] 1-Testosterone: 1-Testosterone may increase the anticoagulant activities of Lepirudin. | [DB01485] 4-Hydroxytestosterone: 4-Hydroxytestosterone may increase the anticoagulant activities of Lepirudin. | [DB01510] Dehydrochloromethyltestosterone: Dehydrochloromethyltestosterone may increase the anticoagulant activities of Lepirudin. | [DB01541] Boldenone: Boldenone may increase the anticoagulant activities of Lepirudin. | [DB01543] 18-methyl-19-nortestosterone: 18-methyl-19-nortestosterone may increase the anticoagulant activities of Lepirudin. | [DB01564] Calusterone: Calusterone may increase the anticoagulant activities of Lepirudin. | [DB01569] Formebolone: Formebolone may increase the anticoagulant activities of Lepirudin. | [DB01572] Methyl-1-testosterone: Methyl-1-testosterone may increase the anticoagulant activities of Lepirudin. | [DB07447] 5beta-dihydrotestosterone: 5beta-dihydrotestosterone may increase the anticoagulant activities of Lepirudin. | [DB08619] Testosterone succinate: Testosterone succinate may increase the anticoagulant activities of Lepirudin. | [DB11429] Mibolerone: Mibolerone may increase the anticoagulant activities of Lepirudin. | [DB13943] Testosterone cypionate: Testosterone cypionate may increase the anticoagulant activities of Lepirudin. | [DB13944] Testosterone enanthate: Testosterone enanthate may increase the anticoagulant activities of Lepirudin. | [DB13946] Testosterone undecanoate: Testosterone undecanoate may increase the anticoagulant activities of Lepirudin. | [DB13947] Testosterone enantate benzilic acid hydrazone: Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Lepirudin. | [DB13951] Stanolone acetate: Stanolone acetate may increase the anticoagulant activities of Lepirudin. | [DB13958] Trestolone acetate: Trestolone acetate may increase the anticoagulant activities of Lepirudin. | [DB14093] (1,2,6,7-3H)Testosterone: (1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Lepirudin. | [DB14655] Drostanolone propionate: Drostanolone propionate may increase the anticoagulant activities of Lepirudin. | [DB02901] Stanolone: Stanolone may increase the anticoagulant activities of Lepirudin. | [DB11051] Azficel-T: The risk or severity of adverse effects can be increased when Lepirudin is combined with Azficel-T. | [DB09568] Omega-3-carboxylic acids: The therapeutic efficacy of Lepirudin can be increased when used in combination with Omega-3-carboxylic acids. | [DB00025] Antihemophilic factor, human recombinant: The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Lepirudin. | [DB00036] Coagulation factor VIIa Recombinant Human: The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Lepirudin. | [DB00100] Coagulation Factor IX (Recombinant): The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Lepirudin. | [DB01373] Calcium: The therapeutic efficacy of Calcium can be decreased when used in combination with Lepirudin. | [DB01783] Pantothenic acid: The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Lepirudin. | [DB01942] Formic acid: The therapeutic efficacy of Formic acid can be decreased when used in combination with Lepirudin. | [DB02261] Platelet Activating Factor: The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Lepirudin. | [DB09109] Turoctocog alfa: The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Lepirudin. | [DB09222] Fibrinogen human: The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Lepirudin. | [DB09310] Catridecacog: The therapeutic efficacy of Catridecacog can be decreased when used in combination with Lepirudin. | [DB09329] Antihemophilic factor (recombinant), PEGylated: The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Lepirudin. | [DB11311] Prothrombin: The therapeutic efficacy of Prothrombin can be decreased when used in combination with Lepirudin. | [DB11330] Factor IX Complex (Human): The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Lepirudin. | [DB11606] Susoctocog alfa: The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Lepirudin. | [DB11608] Eftrenonacog alfa: The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Lepirudin. | [DB11668] Rusalatide acetate: The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Lepirudin. | [DB12409] Vatreptacog alfa: The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Lepirudin. | [DB12909] Factor XIII (human): The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Lepirudin. | [DB13133] Von Willebrand factor human: The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Lepirudin. | [DB13148] Coagulation factor X human: The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Lepirudin. | [DB13150] Coagulation factor VII human: The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Lepirudin. | [DB13151] Anti-inhibitor coagulant complex: The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Lepirudin. | [DB13152] Coagulation Factor IX Human: The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Lepirudin. | [DB13192] Antihemophilic factor human: The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Lepirudin. | [DB13197] Kallidinogenase: The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Lepirudin. | [DB13201] Trenonacog alfa: The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Lepirudin. | [DB13884] Albutrepenonacog alfa: The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Lepirudin. | [DB13923] Emicizumab: The therapeutic efficacy of Emicizumab can be decreased when used in combination with Lepirudin. | [DB13933] Nonacog beta pegol: The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Lepirudin. | [DB13999] Moroctocog alfa: The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Lepirudin. | [DB14473] Beroctocog alfa: The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Lepirudin. | [DB14562] Andexanet alfa: The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Lepirudin. | [DB14577] Calcium cation: The therapeutic efficacy of Calcium cation can be decreased when used in combination with Lepirudin. | [DB14700] Damoctocog alfa pegol: The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Lepirudin. | [DB14738] Turoctocog alfa pegol: The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Lepirudin. | [DB00176] Fluvoxamine: The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Lepirudin. | [DB00215] Citalopram: The risk or severity of bleeding can be increased when Lepirudin is combined with Citalopram. | [DB00472] Fluoxetine: The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Lepirudin. | [DB00715] Paroxetine: The risk or severity of hemorrhage can be increased when Paroxetine is combined with Lepirudin. | [DB01149] Nefazodone: The risk or severity of hemorrhage can be increased when Nefazodone is combined with Lepirudin. | [DB04832] Zimelidine: The risk or severity of hemorrhage can be increased when Zimelidine is combined with Lepirudin. | [DB04884] Dapoxetine: The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Lepirudin. | [DB06731] Seproxetine: The risk or severity of hemorrhage can be increased when Seproxetine is combined with Lepirudin. | [DB08953] Indalpine: The risk or severity of hemorrhage can be increased when Indalpine is combined with Lepirudin. | [DB12693] Ritanserin: The risk or severity of hemorrhage can be increased when Ritanserin is combined with Lepirudin. | [DB13233] Alaproclate: The risk or severity of hemorrhage can be increased when Alaproclate is combined with Lepirudin. | [DB00476] Duloxetine: The risk or severity of hemorrhage can be increased when Duloxetine is combined with Lepirudin. | [DB01105] Sibutramine: The risk or severity of hemorrhage can be increased when Sibutramine is combined with Lepirudin. | [DB04896] Milnacipran: The risk or severity of hemorrhage can be increased when Milnacipran is combined with Lepirudin. | [DB06700] Desvenlafaxine: The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Lepirudin. | [DB08918] Levomilnacipran: The risk or severity of bleeding can be increased when Lepirudin is combined with Levomilnacipran. | [DB00285] Venlafaxine: The risk or severity of bleeding can be increased when Lepirudin is combined with Venlafaxine. | [DB00601] Linezolid: The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Lepirudin. | [DB00614] Furazolidone: The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Lepirudin. | [DB00721] Procaine: The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Lepirudin. | [DB00752] Tranylcypromine: The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Lepirudin. | [DB00780] Phenelzine: The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Lepirudin. | [DB00805] Minaprine: The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Lepirudin. | [DB01037] Selegiline: The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Lepirudin. | [DB01168] Procarbazine: The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Lepirudin. | [DB01171] Moclobemide: The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Lepirudin. | [DB01247] Isocarboxazid: The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Lepirudin. | [DB01367] Rasagiline: The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Lepirudin. | [DB01626] Pargyline: The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Lepirudin. | [DB04017] Clorgiline: The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Lepirudin. | [DB04818] Iproniazid: The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Lepirudin. | [DB04820] Nialamide: The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Lepirudin. | [DB06654] Safinamide: The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Lepirudin. | [DB08550] 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline: The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Lepirudin. | [DB09241] Methylene blue: The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Lepirudin. | [DB09243] Hydracarbazine: The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Lepirudin. | [DB09244] Pirlindole: The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Lepirudin. | [DB09245] Toloxatone: The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Lepirudin. | [DB09246] Benmoxin: The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Lepirudin. | [DB09248] Mebanazine: The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Lepirudin. | [DB09249] Octamoxin: The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Lepirudin. | [DB09250] Pheniprazine: The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Lepirudin. | [DB09251] Phenoxypropazine: The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Lepirudin. | [DB09252] Pivhydrazine: The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Lepirudin. | [DB09253] Safrazine: The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Lepirudin. | [DB09254] Caroxazone: The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Lepirudin. | [DB13875] Harmaline: The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Lepirudin. | [DB13876] Brofaromine: The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Lepirudin. | [DB00006] Bivalirudin: The risk or severity of bleeding can be increased when Lepirudin is combined with Bivalirudin. | [DB00266] Dicoumarol: The risk or severity of bleeding can be increased when Dicoumarol is combined with Lepirudin. | [DB00278] Argatroban: The risk or severity of bleeding can be increased when Lepirudin is combined with Argatroban. | [DB00407] Ardeparin: The risk or severity of bleeding can be increased when Lepirudin is combined with Ardeparin. | [DB00498] Phenindione: The risk or severity of bleeding can be increased when Lepirudin is combined with Phenindione. | [DB00569] Fondaparinux: The risk or severity of bleeding can be increased when Lepirudin is combined with Fondaparinux. | [DB00682] Warfarin: The risk or severity of bleeding can be increased when Warfarin is combined with Lepirudin. | [DB00946] Phenprocoumon: The risk or severity of bleeding can be increased when Phenprocoumon is combined with Lepirudin. | [DB00974] Edetic acid: The risk or severity of bleeding can be increased when Lepirudin is combined with Edetic acid. | [DB01109] Heparin: The risk or severity of bleeding can be increased when Lepirudin is combined with Heparin. | [DB01225] Enoxaparin: The risk or severity of bleeding can be increased when Lepirudin is combined with Enoxaparin. | [DB01418] Acenocoumarol: The risk or severity of bleeding can be increased when Acenocoumarol is combined with Lepirudin. | [DB04898] Ximelagatran: The risk or severity of bleeding can be increased when Lepirudin is combined with Ximelagatran. | [DB05099] Ancrod: The risk or severity of bleeding can be increased when Ancrod is combined with Lepirudin. | [DB06271] Sulodexide: The risk or severity of bleeding can be increased when Sulodexide is combined with Lepirudin. | [DB06406] Idraparinux: The risk or severity of bleeding can be increased when Lepirudin is combined with Idraparinux. | [DB06635] Otamixaban: The risk or severity of bleeding can be increased when Lepirudin is combined with Otamixaban. | [DB06754] Danaparoid: The risk or severity of bleeding can be increased when Lepirudin is combined with Danaparoid. | [DB06779] Dalteparin: The risk or severity of bleeding can be increased when Lepirudin is combined with Dalteparin. | [DB08794] Ethyl biscoumacetate: The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Lepirudin. | [DB08813] Nadroparin: The risk or severity of bleeding can be increased when Lepirudin is combined with Nadroparin. | [DB09255] Dextran: The risk or severity of bleeding can be increased when Lepirudin is combined with Dextran. | [DB11095] Desirudin: The risk or severity of bleeding can be increased when Lepirudin is combined with Desirudin. | [DB11268] Protocatechualdehyde: The risk or severity of bleeding can be increased when Lepirudin is combined with Protocatechualdehyde. | [DB11312] Protein C: The risk or severity of bleeding can be increased when Protein C is combined with Lepirudin. | [DB11598] Antithrombin III human: The risk or severity of bleeding can be increased when Lepirudin is combined with Antithrombin III human. | [DB11984] Letaxaban: The risk or severity of bleeding can be increased when Lepirudin is combined with Letaxaban. | [DB12289] Darexaban: The risk or severity of bleeding can be increased when Lepirudin is combined with Darexaban. | [DB12598] Nafamostat: The risk or severity of bleeding can be increased when Lepirudin is combined with Nafamostat. | [DB12831] Gabexate: The risk or severity of bleeding can be increased when Lepirudin is combined with Gabexate. | [DB13124] Troxerutin: The risk or severity of bleeding can be increased when Lepirudin is combined with Troxerutin. | [DB13136] Fluindione: The risk or severity of bleeding can be increased when Lepirudin is combined with Fluindione. | [DB13149] Protein S human: The therapeutic efficacy of Protein S human can be decreased when used in combination with Lepirudin. | [DB13616] Melagatran: The risk or severity of bleeding can be increased when Lepirudin is combined with Melagatran. | [DB09154] Sodium citrate: The risk or severity of bleeding can be increased when Lepirudin is combined with Sodium citrate. | [DB00031] Tenecteplase: The risk or severity of bleeding can be increased when Tenecteplase is combined with Lepirudin. | [DB00055] Drotrecogin alfa: The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lepirudin. | [DB06822] Tinzaparin: The risk or severity of bleeding can be increased when Lepirudin is combined with Tinzaparin. | [DB13199] Brinase: The risk or severity of bleeding can be increased when Brinase is combined with Lepirudin. | [DB13646] Saruplase: The risk or severity of bleeding can be increased when Saruplase is combined with Lepirudin. | [DB00086] Streptokinase: The risk or severity of bleeding can be increased when Streptokinase is combined with Lepirudin. | [DB04925] Desmoteplase: The risk or severity of bleeding can be increased when Desmoteplase is combined with Lepirudin. | [DB06543] Astaxanthin: The risk or severity of bleeding can be increased when Astaxanthin is combined with Lepirudin. | [DB08994] Ditazole: The risk or severity of bleeding can be increased when Lepirudin is combined with Ditazole. | [DB09258] Bemiparin: The risk or severity of bleeding can be increased when Lepirudin is combined with Bemiparin. | [DB09260] Parnaparin: The risk or severity of bleeding can be increased when Lepirudin is combined with Parnaparin. | [DB13275] Clorindione: The risk or severity of bleeding can be increased when Lepirudin is combined with Clorindione. | [DB13347] Diphenadione: The risk or severity of bleeding can be increased when Lepirudin is combined with Diphenadione. | [DB13451] Tioclomarol: The risk or severity of bleeding can be increased when Lepirudin is combined with Tioclomarol. | [DB00009] Alteplase: The risk or severity of bleeding can be increased when Alteplase is combined with Lepirudin. | [DB00015] Reteplase: The risk or severity of bleeding can be increased when Reteplase is combined with Lepirudin. | [DB00029] Anistreplase: The risk or severity of bleeding can be increased when Anistreplase is combined with Lepirudin. | [DB14094] Tocopherylquinone: The risk or severity of bleeding can be increased when Lepirudin is combined with Tocopherylquinone. | [DB06679] Amediplase: The risk or severity of bleeding can be increased when Amediplase is combined with Lepirudin. | [DB03410] 4-hydroxycoumarin: The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Lepirudin. | [DB08496] (R)-warfarin: The risk or severity of bleeding can be increased when Lepirudin is combined with (R)-warfarin. | [DB14055] (S)-Warfarin: The risk or severity of bleeding can be increased when Lepirudin is combined with (S)-Warfarin. | [DB12364] Betrixaban: The risk or severity of bleeding can be increased when Lepirudin is combined with Betrixaban. | [DB11166] Antithrombin Alfa: The risk or severity of bleeding can be increased when Lepirudin is combined with Antithrombin Alfa. | [DB04665] Coumarin: The risk or severity of bleeding can be increased when Lepirudin is combined with Coumarin. | [DB14726] Dabigatran: The risk or severity of bleeding can be increased when Lepirudin is combined with Dabigatran. | [DB06294] Semuloparin: The risk or severity of bleeding can be increased when Lepirudin is combined with Semuloparin. | [DB12726] Monteplase: The risk or severity of bleeding can be increased when Monteplase is combined with Lepirudin. | [DB09259] Reviparin: The risk or severity of bleeding can be increased when Lepirudin is combined with Reviparin. | [DB15880] Dermatan sulfate: The risk or severity of bleeding can be increased when Lepirudin is combined with Dermatan sulfate. | [DB05361] SR-123781A: The risk or severity of bleeding can be increased when Lepirudin is combined with SR-123781A. | [DB00203] Sildenafil: The risk or severity of hemorrhage can be increased when Lepirudin is combined with Sildenafil. | [DB00008] Peginterferon alfa-2a: The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2a. | [DB00011] Interferon alfa-n1: The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n1. | [DB00018] Interferon alfa-n3: The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n3. | [DB00022] Peginterferon alfa-2b: The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2b. | [DB00033] Interferon gamma-1b: The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon gamma-1b. | [DB00034] Interferon alfa-2a: The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-2a. | [DB00041] Aldesleukin: The risk or severity of bleeding can be increased when Lepirudin is combined with Aldesleukin. | [DB00056] Gemtuzumab ozogamicin: The risk or severity of bleeding can be increased when Lepirudin is combined with Gemtuzumab ozogamicin. | [DB00068] Interferon beta-1b: The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon beta-1b. | [DB00069] Interferon alfacon-1: The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfacon-1. | [DB00073] Rituximab: The risk or severity of bleeding can be increased when Lepirudin is combined with Rituximab. | [DB00078] Ibritumomab tiuxetan: The risk or severity of bleeding can be increased when Lepirudin is combined with Ibritumomab tiuxetan. | [DB00087] Alemtuzumab: The risk or severity of bleeding can be increased when Lepirudin is combined with Alemtuzumab. | [DB00105] Interferon alfa-2b: The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-2b. | [DB00120] Phenylalanine: The risk or severity of bleeding can be increased when Lepirudin is combined with Phenylalanine. | [DB00188] Bortezomib: The risk or severity of bleeding can be increased when Lepirudin is combined with Bortezomib. | [DB00242] Cladribine: The risk or severity of bleeding can be increased when Lepirudin is combined with Cladribine. | [DB00262] Carmustine: The risk or severity of bleeding can be increased when Lepirudin is combined with Carmustine. | [DB00276] Amsacrine: The risk or severity of bleeding can be increased when Lepirudin is combined with Amsacrine. | [DB00291] Chlorambucil: The risk or severity of bleeding can be increased when Lepirudin is combined with Chlorambucil. | [DB00293] Raltitrexed: The risk or severity of bleeding can be increased when Lepirudin is combined with Raltitrexed. | [DB00305] Mitomycin: The risk or severity of bleeding can be increased when Lepirudin is combined with Mitomycin. | [DB00307] Bexarotene: The risk or severity of bleeding can be increased when Lepirudin is combined with Bexarotene. | [DB00309] Vindesine: The risk or severity of bleeding can be increased when Lepirudin is combined with Vindesine. | [DB00322] Floxuridine: The risk or severity of bleeding can be increased when Lepirudin is combined with Floxuridine. | [DB00352] Tioguanine: The risk or severity of bleeding can be increased when Lepirudin is combined with Tioguanine. | [DB00361] Vinorelbine: The risk or severity of bleeding can be increased when Lepirudin is combined with Vinorelbine. | [DB00380] Dexrazoxane: The risk or severity of bleeding can be increased when Lepirudin is combined with Dexrazoxane. | [DB00398] Sorafenib: The risk or severity of bleeding can be increased when Lepirudin is combined with Sorafenib. | [DB00428] Streptozocin: The risk or severity of bleeding can be increased when Lepirudin is combined with Streptozocin. | [DB00441] Gemcitabine: The risk or severity of bleeding can be increased when Lepirudin is combined with Gemcitabine. | [DB00444] Teniposide: The risk or severity of bleeding can be increased when Lepirudin is combined with Teniposide. | [DB00445] Epirubicin: The risk or severity of bleeding can be increased when Lepirudin is combined with Epirubicin. | [DB00446] Chloramphenicol: The risk or severity of bleeding can be increased when Lepirudin is combined with Chloramphenicol. | [DB00480] Lenalidomide: The risk or severity of bleeding can be increased when Lepirudin is combined with Lenalidomide. | [DB00488] Altretamine: The risk or severity of bleeding can be increased when Lepirudin is combined with Altretamine. | [DB00495] Zidovudine: The risk or severity of bleeding can be increased when Lepirudin is combined with Zidovudine. | [DB00515] Cisplatin: The risk or severity of bleeding can be increased when Lepirudin is combined with Cisplatin. | [DB00526] Oxaliplatin: The risk or severity of hemorrhage can be increased when Oxaliplatin is combined with Lepirudin. | [DB00531] Cyclophosphamide: The risk or severity of bleeding can be increased when Lepirudin is combined with Cyclophosphamide. | [DB00544] Fluorouracil: The risk or severity of bleeding can be increased when Lepirudin is combined with Fluorouracil. | [DB00552] Pentostatin: The risk or severity of bleeding can be increased when Lepirudin is combined with Pentostatin. | [DB00563] Methotrexate: The risk or severity of bleeding can be increased when Lepirudin is combined with Methotrexate. | [DB00564] Carbamazepine: The risk or severity of bleeding can be increased when Lepirudin is combined with Carbamazepine. | [DB00570] Vinblastine: The risk or severity of bleeding can be increased when Lepirudin is combined with Vinblastine. | [DB00619] Imatinib: The risk or severity of bleeding can be increased when Lepirudin is combined with Imatinib. | [DB00631] Clofarabine: The risk or severity of bleeding can be increased when Lepirudin is combined with Clofarabine. | [DB00642] Pemetrexed: The risk or severity of bleeding can be increased when Lepirudin is combined with Pemetrexed. | [DB00694] Daunorubicin: The risk or severity of bleeding can be increased when Lepirudin is combined with Daunorubicin. | [DB00762] Irinotecan: The risk or severity of bleeding can be increased when Lepirudin is combined with Irinotecan. | [DB00773] Etoposide: The risk or severity of bleeding can be increased when Lepirudin is combined with Etoposide. | [DB00851] Dacarbazine: The risk or severity of bleeding can be increased when Lepirudin is combined with Dacarbazine. | [DB00853] Temozolomide: The risk or severity of bleeding can be increased when Lepirudin is combined with Temozolomide. | [DB00859] Penicillamine: The risk or severity of bleeding can be increased when Lepirudin is combined with Penicillamine. | [DB00864] Tacrolimus: The risk or severity of bleeding can be increased when Lepirudin is combined with Tacrolimus. | [DB00877] Sirolimus: The risk or severity of bleeding can be increased when Lepirudin is combined with Sirolimus. | [DB00888] Mechlorethamine: The risk or severity of bleeding can be increased when Lepirudin is combined with Mechlorethamine. | [DB00928] Azacitidine: The risk or severity of bleeding can be increased when Lepirudin is combined with Azacitidine. | [DB00958] Carboplatin: The risk or severity of bleeding can be increased when Lepirudin is combined with Carboplatin. | [DB00970] Dactinomycin: The risk or severity of bleeding can be increased when Lepirudin is combined with Dactinomycin. | [DB00987] Cytarabine: The risk or severity of bleeding can be increased when Lepirudin is combined with Cytarabine. | [DB00997] Doxorubicin: The risk or severity of bleeding can be increased when Lepirudin is combined with Doxorubicin. | [DB01005] Hydroxyurea: The risk or severity of bleeding can be increased when Lepirudin is combined with Hydroxyurea. | [DB01008] Busulfan: The risk or severity of bleeding can be increased when Lepirudin is combined with Busulfan. | [DB01030] Topotecan: The risk or severity of bleeding can be increased when Lepirudin is combined with Topotecan. | [DB01033] Mercaptopurine: The risk or severity of bleeding can be increased when Lepirudin is combined with Mercaptopurine. | [DB01041] Thalidomide: The risk or severity of bleeding can be increased when Lepirudin is combined with Thalidomide. | [DB01042] Melphalan: The risk or severity of bleeding can be increased when Lepirudin is combined with Melphalan. | [DB01073] Fludarabine: The risk or severity of bleeding can be increased when Lepirudin is combined with Fludarabine. | [DB01099] Flucytosine: The risk or severity of bleeding can be increased when Lepirudin is combined with Flucytosine. | [DB01101] Capecitabine: The risk or severity of bleeding can be increased when Lepirudin is combined with Capecitabine. | [DB01169] Arsenic trioxide: The risk or severity of bleeding can be increased when Lepirudin is combined with Arsenic trioxide. | [DB01177] Idarubicin: The risk or severity of bleeding can be increased when Lepirudin is combined with Idarubicin. | [DB01204] Mitoxantrone: The risk or severity of bleeding can be increased when Lepirudin is combined with Mitoxantrone. | [DB01206] Lomustine: The risk or severity of bleeding can be increased when Lepirudin is combined with Lomustine. | [DB01229] Paclitaxel: The risk or severity of bleeding can be increased when Lepirudin is combined with Paclitaxel. | [DB01248] Docetaxel: The risk or severity of bleeding can be increased when Lepirudin is combined with Docetaxel. | [DB01262] Decitabine: The risk or severity of bleeding can be increased when Lepirudin is combined with Decitabine. | [DB01280] Nelarabine: The risk or severity of bleeding can be increased when Lepirudin is combined with Nelarabine. | [DB01590] Everolimus: The risk or severity of bleeding can be increased when Lepirudin is combined with Everolimus. | [DB02546] Vorinostat: The risk or severity of bleeding can be increased when Lepirudin is combined with Vorinostat. | [DB04572] Thiotepa: The risk or severity of bleeding can be increased when Lepirudin is combined with Thiotepa. | [DB04845] Ixabepilone: The risk or severity of bleeding can be increased when Lepirudin is combined with Ixabepilone. | [DB04868] Nilotinib: The risk or severity of bleeding can be increased when Lepirudin is combined with Nilotinib. | [DB05015] Belinostat: The risk or severity of bleeding can be increased when Lepirudin is combined with Belinostat. | [DB05109] Trabectedin: The risk or severity of bleeding can be increased when Lepirudin is combined with Trabectedin. | [DB05258] Interferon alfa: The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa. | [DB05472] Human interferon omega-1: The risk or severity of bleeding can be increased when Lepirudin is combined with Human interferon omega-1. | [DB05773] Trastuzumab emtansine: The risk or severity of bleeding can be increased when Lepirudin is combined with Trastuzumab emtansine. | [DB06287] Temsirolimus: The risk or severity of bleeding can be increased when Lepirudin is combined with Temsirolimus. | [DB06616] Bosutinib: The risk or severity of bleeding can be increased when Lepirudin is combined with Bosutinib. | [DB06769] Bendamustine: The risk or severity of bleeding can be increased when Lepirudin is combined with Bendamustine. | [DB06772] Cabazitaxel: The risk or severity of bleeding can be increased when Lepirudin is combined with Cabazitaxel. | [DB08871] Eribulin: The risk or severity of bleeding can be increased when Lepirudin is combined with Eribulin. | [DB08877] Ruxolitinib: The risk or severity of bleeding can be increased when Lepirudin is combined with Ruxolitinib. | [DB08889] Carfilzomib: The risk or severity of bleeding can be increased when Lepirudin is combined with Carfilzomib. | [DB08895] Tofacitinib: The risk or severity of bleeding can be increased when Lepirudin is combined with Tofacitinib. | [DB08901] Ponatinib: The risk or severity of bleeding can be increased when Lepirudin is combined with Ponatinib. | [DB08910] Pomalidomide: The risk or severity of bleeding can be increased when Lepirudin is combined with Pomalidomide. | [DB09042] Tedizolid phosphate: The risk or severity of bleeding can be increased when Lepirudin is combined with Tedizolid phosphate. | [DB09052] Blinatumomab: The risk or severity of bleeding can be increased when Lepirudin is combined with Blinatumomab. | [DB09073] Palbociclib: The risk or severity of bleeding can be increased when Lepirudin is combined with Palbociclib. | [DB09074] Olaparib: The risk or severity of bleeding can be increased when Lepirudin is combined with Olaparib. | [DB09077] Dinutuximab: The risk or severity of bleeding can be increased when Lepirudin is combined with Dinutuximab. | [DB09122] Peginterferon beta-1a: The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon beta-1a. | [DB12814] Cepeginterferon alfa-2B: The risk or severity of bleeding can be increased when Lepirudin is combined with Cepeginterferon alfa-2B. | [DB00229] Cefotiam: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotiam. | [DB00267] Cefmenoxime: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefmenoxime. | [DB00274] Cefmetazole: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefmetazole. | [DB00430] Cefpiramide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpiramide. | [DB00438] Ceftazidime: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftazidime. | [DB00447] Loracarbef: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Loracarbef. | [DB00456] Cefalotin: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefalotin. | [DB00493] Cefotaxime: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotaxime. | [DB00535] Cefdinir: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefdinir. | [DB00567] Cephalexin: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cephalexin. | [DB00671] Cefixime: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefixime. | [DB00689] Cephaloglycin: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cephaloglycin. | [DB00833] Cefaclor: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefaclor. | [DB00923] Ceforanide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceforanide. | [DB01066] Cefditoren: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefditoren. | [DB01112] Cefuroxime: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefuroxime. | [DB01139] Cefapirin: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefapirin. | [DB01140] Cefadroxil: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefadroxil. | [DB01150] Cefprozil: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefprozil. | [DB01212] Ceftriaxone: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftriaxone. | [DB01326] Cefamandole: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefamandole. | [DB01327] Cefazolin: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefazolin. | [DB01328] Cefonicid: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefonicid. | [DB01329] Cefoperazone: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefoperazone. | [DB01330] Cefotetan: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotetan. | [DB01331] Cefoxitin: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefoxitin. | [DB01332] Ceftizoxime: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftizoxime. | [DB01333] Cefradine: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefradine. | [DB01413] Cefepime: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefepime. | [DB01414] Cefacetrile: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefacetrile. | [DB01415] Ceftibuten: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftibuten. | [DB01416] Cefpodoxime: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpodoxime. | [DB04570] Latamoxef: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Latamoxef. | [DB04918] Ceftobiprole: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftobiprole. | [DB06590] Ceftaroline fosamil: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftaroline fosamil. | [DB09008] Cefaloridine: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefaloridine. | [DB09050] Ceftolozane: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftolozane. | [DB09062] Cefminox: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefminox. | [DB11367] Cefroxadine: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefroxadine. | [DB11935] Flomoxef: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Flomoxef. | [DB13266] Cefatrizine: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefatrizine. | [DB13461] Cefcapene: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefcapene. | [DB13470] Cefodizime: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefodizime. | [DB13499] Cefsulodin: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefsulodin. | [DB13504] Cefetamet: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefetamet. | [DB13638] Cefbuperazone: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefbuperazone. | [DB13667] Cefozopran: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefozopran. | [DB13682] Cefpirome: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpirome. | [DB13778] Cefazedone: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefazedone. | [DB13821] Ceftezole: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftezole. | [DB14725] Cefamandole nafate: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefamandole nafate. | [DB00254] Doxycycline: The risk or severity of bleeding can be increased when Doxycycline is combined with Lepirudin. | [DB00207] Azithromycin: The risk or severity of adverse effects can be increased when Azithromycin is combined with Lepirudin. | [DB09539] Omega-3-acid ethyl esters: The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Lepirudin. | [DB00945] Acetylsalicylic acid: Acetylsalicylic acid may increase the anticoagulant activities of Lepirudin. | [DB01606] Tazobactam: The risk or severity of bleeding can be increased when Tazobactam is combined with Lepirudin. | [DB00199] Erythromycin: The risk or severity of bleeding can be increased when Erythromycin is combined with Lepirudin. | [DB00656] Trazodone: The risk or severity of bleeding can be increased when Trazodone is combined with Lepirudin. | [DB00620] Triamcinolone: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Triamcinolone. | [DB09079] Nintedanib: The risk or severity of bleeding can be increased when Nintedanib is combined with Lepirudin. | [DB01175] Escitalopram: The risk or severity of bleeding can be increased when Escitalopram is combined with Lepirudin. | [DB01104] Sertraline: The risk or severity of bleeding can be increased when Sertraline is combined with Lepirudin. | [DB00232] Methyclothiazide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Methyclothiazide. | [DB00436] Bendroflumethiazide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Bendroflumethiazide. | [DB00562] Benzthiazide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Benzthiazide. | [DB00606] Cyclothiazide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cyclothiazide. | [DB00774] Hydroflumethiazide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydroflumethiazide. | [DB00880] Chlorothiazide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Chlorothiazide. | [DB00999] Hydrochlorothiazide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydrochlorothiazide. | [DB01021] Trichlormethiazide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Trichlormethiazide. | [DB01324] Polythiazide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Polythiazide. | [DB13430] Mebutizide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Mebutizide. | [DB13532] Cyclopenthiazide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cyclopenthiazide. | [DB15861] Buthiazide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Buthiazide. | [DB00783] Estradiol: The risk or severity of adverse effects can be increased when Estradiol is combined with Lepirudin. | [DB00977] Ethinylestradiol: The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Lepirudin. | [DB00834] Mifepristone: The risk or severity of adverse effects can be increased when Mifepristone is combined with Lepirudin. | [DB13310] Ormeloxifene: The risk or severity of adverse effects can be increased when Ormeloxifene is combined with Lepirudin. | [DB00304] Desogestrel: The risk or severity of adverse effects can be increased when Desogestrel is combined with Lepirudin. | [DB00351] Megestrol acetate: The risk or severity of adverse effects can be increased when Megestrol acetate is combined with Lepirudin. | [DB00367] Levonorgestrel: The risk or severity of adverse effects can be increased when Levonorgestrel is combined with Lepirudin. | [DB00603] Medroxyprogesterone acetate: The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Lepirudin. | [DB00717] Norethisterone: The risk or severity of adverse effects can be increased when Norethisterone is combined with Lepirudin. | [DB00823] Ethynodiol diacetate: The risk or severity of adverse effects can be increased when Ethynodiol diacetate is combined with Lepirudin. | [DB00957] Norgestimate: The risk or severity of adverse effects can be increased when Norgestimate is combined with Lepirudin. | [DB01395] Drospirenone: The risk or severity of adverse effects can be increased when Drospirenone is combined with Lepirudin. | [DB04839] Cyproterone acetate: The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Lepirudin. | [DB06730] Gestodene: The risk or severity of adverse effects can be increased when Gestodene is combined with Lepirudin. | [DB09123] Dienogest: The risk or severity of adverse effects can be increased when Dienogest is combined with Lepirudin. | [DB09371] Norethynodrel: The risk or severity of adverse effects can be increased when Norethynodrel is combined with Lepirudin. | [DB09389] Norgestrel: The risk or severity of adverse effects can be increased when Norgestrel is combined with Lepirudin. | [DB11619] Gestrinone: The risk or severity of adverse effects can be increased when Gestrinone is combined with Lepirudin. | [DB12474] Lynestrenol: The risk or severity of adverse effects can be increased when Lynestrenol is combined with Lepirudin. | [DB13528] Chlormadinone: The risk or severity of adverse effects can be increased when Chlormadinone is combined with Lepirudin. | [DB13563] Norgestrienone: The risk or severity of adverse effects can be increased when Norgestrienone is combined with Lepirudin. | [DB13685] Quingestanol: The risk or severity of adverse effects can be increased when Quingestanol is combined with Lepirudin. | [DB13857] Demegestone: The risk or severity of adverse effects can be increased when Demegestone is combined with Lepirudin. | [DB13981] Nomegestrol acetate: The risk or severity of adverse effects can be increased when Nomegestrol acetate is combined with Lepirudin. | [DB14678] Norethindrone enanthate: The risk or severity of adverse effects can be increased when Norethindrone enanthate is combined with Lepirudin. | [DB15775] Algestone acetophenide: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Algestone acetophenide. | [DB12235] Estetrol: The risk or severity of adverse effects can be increased when Estetrol is combined with Lepirudin. | [DB11201] Menthyl salicylate: The risk or severity of bleeding and hemorrhage can be increased when Menthyl salicylate is combined with Lepirudin. | [DB11323] Glycol salicylate: The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Lepirudin. | [DB15119] Ropeginterferon alfa-2b: The risk or severity of bleeding can be increased when Lepirudin is combined with Ropeginterferon alfa-2b. | [DB15575] Padeliporfin: The risk or severity of bleeding can be increased when Lepirudin is combined with Padeliporfin. | [DB16007] Rurioctocog alfa pegol: The therapeutic efficacy of Rurioctocog alfa pegol can be decreased when used in combination with Lepirudin. | [DB14733] Ceftobiprole medocaril: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftobiprole medocaril. | [DB01051] Novobiocin: The risk or severity of bleeding can be increased when Novobiocin is combined with Lepirudin. | [DB03966] Clorobiocin: The risk or severity of bleeding can be increased when Clorobiocin is combined with Lepirudin. | [DB04571] Trioxsalen: The risk or severity of bleeding can be increased when Trioxsalen is combined with Lepirudin. | [DB04886] Calanolide A: The risk or severity of bleeding can be increased when Calanolide A is combined with Lepirudin. | [DB07118] Hymecromone: The risk or severity of bleeding can be increased when Hymecromone is combined with Lepirudin. | [DB11390] Coumaphos: The risk or severity of bleeding can be increased when Coumaphos is combined with Lepirudin. | [DB11419] Haloxon: The risk or severity of bleeding can be increased when Haloxon is combined with Lepirudin. | [DB12216] Bergapten: The risk or severity of bleeding can be increased when Bergapten is combined with Lepirudin. | [DB12823] Tecarfarin: The risk or severity of bleeding can be increased when Tecarfarin is combined with Lepirudin. | [DB13155] Esculin: The risk or severity of bleeding can be increased when Esculin is combined with Lepirudin. | [DB13177] 4-methylumbelliferyl beta-D-glucoside: The risk or severity of bleeding can be increased when 4-methylumbelliferyl beta-D-glucoside is combined with Lepirudin. | [DB13279] Carbocromen: The risk or severity of bleeding can be increased when Carbocromen is combined with Lepirudin. | [DB13912] Coumermycin A1: The risk or severity of bleeding can be increased when Coumermycin A1 is combined with Lepirudin. | [DB09422] Soybean oil: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Soybean oil. | [DB09567] Olive oil: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Olive oil. | [DB15434] Mosunetuzumab: The risk or severity of bleeding can be increased when Lepirudin is combined with Mosunetuzumab. | [DB17472] Pirtobrutinib: The risk or severity of bleeding can be increased when Lepirudin is combined with Pirtobrutinib. | [DB14713] Inotersen: The risk or severity of thrombocytopenia can be increased when Inotersen is combined with Lepirudin. | [DB16791] Etranacogene dezaparvovec: The therapeutic efficacy of Etranacogene dezaparvovec can be decreased when used in combination with Lepirudin. | [DB15903] Chlormadinone acetate: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Chlormadinone acetate. | [DB17048] Plumbagin: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Plumbagin. | [DB18000] Algestone: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Algestone. | [DB07767] Ferulic acid: The risk or severity of bleeding can be increased when Lepirudin is combined with Ferulic acid.",20 mg; 50 mg; 50 mg / vial; 50 mg/1mL; 5000000 mg,"Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include chamomile, garlic, ginger, ginkgo and ginseng."
DB00030,Insulin human,"ALIMENTARY TRACT AND METABOLISM; DRUGS USED IN DIABETES; INSULINS AND ANALOGUES; Insulins and analogues for inhalation; Insulins and analogues for injection, fast-acting; Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting; Insulins and analogues for injection, intermediate-acting; Insulins and analogues for injection, long-acting","[DB06655] Liraglutide: Liraglutide may increase the hypoglycemic activities of Insulin human. | [DB09046] Metreleptin: Metreleptin may increase the hypoglycemic activities of Insulin human. | [DB00082] Pegvisomant: The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin human. | [DB01132] Pioglitazone: The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin human. | [DB01278] Pramlintide: Pramlintide may increase the hypoglycemic activities of Insulin human. | [DB00412] Rosiglitazone: The risk or severity of congestive heart failure can be increased when Insulin human is combined with Rosiglitazone. | [DB00166] Lipoic acid: The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin human. | [DB00974] Edetic acid: Edetic acid may increase the hypoglycemic activities of Insulin human. | [DB00187] Esmolol: Esmolol may increase the hypoglycemic activities of Insulin human. | [DB12212] Landiolol: Landiolol may increase the hypoglycemic activities of Insulin human. | [DB00218] Moxifloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Moxifloxacin. | [DB00365] Grepafloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Grepafloxacin. | [DB00467] Enoxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Enoxacin. | [DB00487] Pefloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Pefloxacin. | [DB00537] Ciprofloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Ciprofloxacin. | [DB00685] Trovafloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Trovafloxacin. | [DB00779] Nalidixic acid: The therapeutic efficacy of Insulin human can be increased when used in combination with Nalidixic acid. | [DB00817] Rosoxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Rosoxacin. | [DB00827] Cinoxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Cinoxacin. | [DB00978] Lomefloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Lomefloxacin. | [DB01044] Gatifloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Gatifloxacin. | [DB01059] Norfloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Norfloxacin. | [DB01137] Levofloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Levofloxacin. | [DB01155] Gemifloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Gemifloxacin. | [DB01165] Ofloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Ofloxacin. | [DB01208] Sparfloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Sparfloxacin. | [DB01405] Temafloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Temafloxacin. | [DB04576] Fleroxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Fleroxacin. | [DB05488] Technetium Tc-99m ciprofloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Technetium Tc-99m ciprofloxacin. | [DB06160] Garenoxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Garenoxacin. | [DB06600] Nemonoxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Nemonoxacin. | [DB08972] Flumequine: The therapeutic efficacy of Insulin human can be increased when used in combination with Flumequine. | [DB11404] Enrofloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Enrofloxacin. | [DB11443] Orbifloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Orbifloxacin. | [DB11491] Sarafloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Sarafloxacin. | [DB11511] Difloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Difloxacin. | [DB11774] Pazufloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Pazufloxacin. | [DB11892] Prulifloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Prulifloxacin. | [DB11943] Delafloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Delafloxacin. | [DB13261] Sitafloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Sitafloxacin. | [DB13627] Oxolinic acid: The therapeutic efficacy of Insulin human can be increased when used in combination with Oxolinic acid. | [DB13772] Rufloxacin: The therapeutic efficacy of Insulin human can be increased when used in combination with Rufloxacin. | [DB13823] Pipemidic acid: The therapeutic efficacy of Insulin human can be increased when used in combination with Pipemidic acid. | [DB00232] Methyclothiazide: The risk or severity of hypoglycemia can be increased when Methyclothiazide is combined with Insulin human. | [DB00310] Chlorthalidone: The risk or severity of hypoglycemia can be increased when Chlorthalidone is combined with Insulin human. | [DB00436] Bendroflumethiazide: The risk or severity of hypoglycemia can be increased when Bendroflumethiazide is combined with Insulin human. | [DB00524] Metolazone: The risk or severity of hypoglycemia can be increased when Metolazone is combined with Insulin human. | [DB00562] Benzthiazide: The risk or severity of hypoglycemia can be increased when Benzthiazide is combined with Insulin human. | [DB00774] Hydroflumethiazide: The risk or severity of hypoglycemia can be increased when Hydroflumethiazide is combined with Insulin human. | [DB00808] Indapamide: The risk or severity of hypoglycemia can be increased when Indapamide is combined with Insulin human. | [DB00880] Chlorothiazide: The risk or severity of hypoglycemia can be increased when Chlorothiazide is combined with Insulin human. | [DB00999] Hydrochlorothiazide: The risk or severity of hypoglycemia can be increased when Hydrochlorothiazide is combined with Insulin human. | [DB01021] Trichlormethiazide: The risk or severity of hypoglycemia can be increased when Trichlormethiazide is combined with Insulin human. | [DB01324] Polythiazide: The risk or severity of hypoglycemia can be increased when Polythiazide is combined with Insulin human. | [DB01325] Quinethazone: The risk or severity of hypoglycemia can be increased when Quinethazone is combined with Insulin human. | [DB13532] Cyclopenthiazide: The risk or severity of hypoglycemia can be increased when Cyclopenthiazide is combined with Insulin human. | [DB13989] Epitizide: The therapeutic efficacy of Insulin human can be decreased when used in combination with Epitizide. | [DB00344] Protriptyline: Protriptyline may decrease the hypoglycemic activities of Insulin human. | [DB00543] Amoxapine: Amoxapine may decrease the hypoglycemic activities of Insulin human. | [DB00726] Trimipramine: Trimipramine may decrease the hypoglycemic activities of Insulin human. | [DB04836] Amineptine: Amineptine may decrease the hypoglycemic activities of Insulin human. | [DB08996] Dimetacrine: Dimetacrine may decrease the hypoglycemic activities of Insulin human. | [DB09016] Butriptyline: Butriptyline may decrease the hypoglycemic activities of Insulin human. | [DB09167] Dosulepin: Dosulepin may decrease the hypoglycemic activities of Insulin human. | [DB09289] Tianeptine: Tianeptine may decrease the hypoglycemic activities of Insulin human. | [DB09307] Oxaprotiline: Oxaprotiline may decrease the hypoglycemic activities of Insulin human. | [DB12930] Opipramol: Opipramol may decrease the hypoglycemic activities of Insulin human. | [DB13114] Amitriptylinoxide: Amitriptylinoxide may decrease the hypoglycemic activities of Insulin human. | [DB13225] Dibenzepin: Dibenzepin may decrease the hypoglycemic activities of Insulin human. | [DB13246] Quinupramine: Quinupramine may decrease the hypoglycemic activities of Insulin human. | [DB13384] Melitracen: Melitracen may decrease the hypoglycemic activities of Insulin human. | [DB13411] Lofepramine: Lofepramine may decrease the hypoglycemic activities of Insulin human. | [DB13496] Iprindole: Iprindole may decrease the hypoglycemic activities of Insulin human. | [DB13782] Imipramine oxide: Imipramine oxide may decrease the hypoglycemic activities of Insulin human. | [DB00540] Nortriptyline: Nortriptyline may decrease the hypoglycemic activities of Insulin human. | [DB01151] Desipramine: Desipramine may decrease the hypoglycemic activities of Insulin human. | [DB00321] Amitriptyline: Amitriptyline may decrease the hypoglycemic activities of Insulin human. | [DB00458] Imipramine: Imipramine may decrease the hypoglycemic activities of Insulin human. | [DB01142] Doxepin: Doxepin may decrease the hypoglycemic activities of Insulin human. | [DB01242] Clomipramine: Clomipramine may decrease the hypoglycemic activities of Insulin human. | [DB06292] Dapagliflozin: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Dapagliflozin. | [DB08907] Canagliflozin: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Canagliflozin. | [DB00007] Leuprolide: The therapeutic efficacy of Insulin human can be decreased when used in combination with Leuprolide. | [DB00014] Goserelin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Goserelin. | [DB00220] Nelfinavir: The therapeutic efficacy of Insulin human can be decreased when used in combination with Nelfinavir. | [DB00224] Indinavir: The therapeutic efficacy of Insulin human can be decreased when used in combination with Indinavir. | [DB00246] Ziprasidone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Ziprasidone. | [DB00294] Etonogestrel: The therapeutic efficacy of Insulin human can be decreased when used in combination with Etonogestrel. | [DB00304] Desogestrel: The therapeutic efficacy of Insulin human can be decreased when used in combination with Desogestrel. | [DB00334] Olanzapine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Olanzapine. | [DB00351] Megestrol acetate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Megestrol acetate. | [DB00363] Clozapine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Clozapine. | [DB00367] Levonorgestrel: The therapeutic efficacy of Insulin human can be decreased when used in combination with Levonorgestrel. | [DB00396] Progesterone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Progesterone. | [DB00477] Chlorpromazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Chlorpromazine. | [DB00502] Haloperidol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Haloperidol. | [DB00503] Ritonavir: The therapeutic efficacy of Insulin human can be decreased when used in combination with Ritonavir. | [DB00592] Piperazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Piperazine. | [DB00603] Medroxyprogesterone acetate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Medroxyprogesterone acetate. | [DB00627] Niacin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Niacin. | [DB00668] Epinephrine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Epinephrine. | [DB00717] Norethisterone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Norethisterone. | [DB00734] Risperidone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Risperidone. | [DB00738] Pentamidine: The risk or severity of hypoglycemia can be increased when Pentamidine is combined with Insulin human. | [DB00823] Ethynodiol diacetate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Ethynodiol diacetate. | [DB00852] Pseudoephedrine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Pseudoephedrine. | [DB00864] Tacrolimus: The therapeutic efficacy of Insulin human can be decreased when used in combination with Tacrolimus. | [DB00877] Sirolimus: The therapeutic efficacy of Insulin human can be decreased when used in combination with Sirolimus. | [DB00903] Etacrynic acid: The therapeutic efficacy of Insulin human can be decreased when used in combination with Etacrynic acid. | [DB00932] Tipranavir: The therapeutic efficacy of Insulin human can be decreased when used in combination with Tipranavir. | [DB00957] Norgestimate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Norgestimate. | [DB00977] Ethinylestradiol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Ethinylestradiol. | [DB01072] Atazanavir: The therapeutic efficacy of Insulin human can be decreased when used in combination with Atazanavir. | [DB01169] Arsenic trioxide: The therapeutic efficacy of Insulin human can be decreased when used in combination with Arsenic trioxide. | [DB01224] Quetiapine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Quetiapine. | [DB01232] Saquinavir: The therapeutic efficacy of Insulin human can be decreased when used in combination with Saquinavir. | [DB01238] Aripiprazole: The therapeutic efficacy of Insulin human can be decreased when used in combination with Aripiprazole. | [DB01267] Paliperidone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Paliperidone. | [DB01319] Fosamprenavir: The therapeutic efficacy of Insulin human can be decreased when used in combination with Fosamprenavir. | [DB01323] St. John's Wort: The therapeutic efficacy of Insulin human can be decreased when used in combination with St. John's Wort. | [DB01357] Mestranol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Mestranol. | [DB01363] Ephedra sinica root: The therapeutic efficacy of Insulin human can be decreased when used in combination with Ephedra sinica root. | [DB01395] Drospirenone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Drospirenone. | [DB01403] Methotrimeprazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Methotrimeprazine. | [DB01406] Danazol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Danazol. | [DB01590] Everolimus: The therapeutic efficacy of Insulin human can be decreased when used in combination with Everolimus. | [DB01601] Lopinavir: The therapeutic efficacy of Insulin human can be decreased when used in combination with Lopinavir. | [DB01621] Pipotiazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Pipotiazine. | [DB02546] Vorinostat: The therapeutic efficacy of Insulin human can be decreased when used in combination with Vorinostat. | [DB04574] Estrone sulfate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Estrone sulfate. | [DB04839] Cyproterone acetate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Cyproterone acetate. | [DB04868] Nilotinib: The therapeutic efficacy of Insulin human can be decreased when used in combination with Nilotinib. | [DB04946] Iloperidone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Iloperidone. | [DB06216] Asenapine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Asenapine. | [DB06287] Temsirolimus: The therapeutic efficacy of Insulin human can be decreased when used in combination with Temsirolimus. | [DB06663] Pasireotide: The risk or severity of hypoglycemia can be increased when Pasireotide is combined with Insulin human. | [DB06719] Buserelin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Buserelin. | [DB06788] Histrelin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Histrelin. | [DB06789] Hydroxyprogesterone caproate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Hydroxyprogesterone caproate. | [DB06791] Lanreotide: The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin human. | [DB06825] Triptorelin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Triptorelin. | [DB08815] Lurasidone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Lurasidone. | [DB08912] Dabrafenib: The therapeutic efficacy of Insulin human can be decreased when used in combination with Dabrafenib. | [DB09009] Articaine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Articaine. | [DB09063] Ceritinib: The therapeutic efficacy of Insulin human can be decreased when used in combination with Ceritinib. | [DB09123] Dienogest: The therapeutic efficacy of Insulin human can be decreased when used in combination with Dienogest. | [DB09128] Brexpiprazole: The therapeutic efficacy of Insulin human can be decreased when used in combination with Brexpiprazole. | [DB06343] Teprotumumab: The therapeutic efficacy of Insulin human can be decreased when used in combination with Teprotumumab. | [DB00621] Oxandrolone: Oxandrolone may increase the hypoglycemic activities of Insulin human. | [DB00624] Testosterone: Testosterone may increase the hypoglycemic activities of Insulin human. | [DB00984] Nandrolone phenpropionate: Nandrolone phenpropionate may increase the hypoglycemic activities of Insulin human. | [DB01185] Fluoxymesterone: Fluoxymesterone may increase the hypoglycemic activities of Insulin human. | [DB01420] Testosterone propionate: Testosterone propionate may increase the hypoglycemic activities of Insulin human. | [DB06412] Oxymetholone: Oxymetholone may increase the hypoglycemic activities of Insulin human. | [DB06710] Methyltestosterone: Methyltestosterone may increase the hypoglycemic activities of Insulin human. | [DB06718] Stanozolol: Stanozolol may increase the hypoglycemic activities of Insulin human. | [DB08804] Nandrolone decanoate: Nandrolone decanoate may increase the hypoglycemic activities of Insulin human. | [DB12461] GLPG-0492: GLPG-0492 may increase the hypoglycemic activities of Insulin human. | [DB13169] Nandrolone: Nandrolone may increase the hypoglycemic activities of Insulin human. | [DB13587] Mesterolone: Mesterolone may increase the hypoglycemic activities of Insulin human. | [DB13943] Testosterone cypionate: Testosterone cypionate may increase the hypoglycemic activities of Insulin human. | [DB13944] Testosterone enanthate: Testosterone enanthate may increase the hypoglycemic activities of Insulin human. | [DB02901] Stanolone: Stanolone may increase the hypoglycemic activities of Insulin human. | [DB00215] Citalopram: The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin human. | [DB00230] Pregabalin: The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Insulin human. | [DB00285] Venlafaxine: The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Insulin human. | [DB00328] Indomethacin: The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Insulin human. | [DB01104] Sertraline: The risk or severity of hypoglycemia can be increased when Sertraline is combined with Insulin human. | [DB01149] Nefazodone: The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Insulin human. | [DB01175] Escitalopram: The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Insulin human. | [DB04832] Zimelidine: The risk or severity of hypoglycemia can be increased when Zimelidine is combined with Insulin human. | [DB04884] Dapoxetine: The risk or severity of hypoglycemia can be increased when Dapoxetine is combined with Insulin human. | [DB04896] Milnacipran: The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Insulin human. | [DB06700] Desvenlafaxine: The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Insulin human. | [DB08918] Levomilnacipran: The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin human. | [DB08953] Indalpine: The risk or severity of hypoglycemia can be increased when Indalpine is combined with Insulin human. | [DB09270] Ubidecarenone: The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin human. | [DB12693] Ritanserin: The risk or severity of hypoglycemia can be increased when Ritanserin is combined with Insulin human. | [DB13233] Alaproclate: The risk or severity of hypoglycemia can be increased when Alaproclate is combined with Insulin human. | [DB13358] Cibenzoline: The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Insulin human. | [DB14025] Clinafloxacin: The risk or severity of hypoglycemia can be increased when Clinafloxacin is combined with Insulin human. | [DB09038] Empagliflozin: The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin human. | [DB00176] Fluvoxamine: The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Insulin human. | [DB00472] Fluoxetine: The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Insulin human. | [DB00476] Duloxetine: The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Insulin human. | [DB00715] Paroxetine: The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Insulin human. | [DB00233] Aminosalicylic acid: The risk or severity of hypoglycemia can be increased when Aminosalicylic acid is combined with Insulin human. | [DB00244] Mesalazine: The risk or severity of hypoglycemia can be increased when Mesalazine is combined with Insulin human. | [DB00795] Sulfasalazine: The risk or severity of hypoglycemia can be increased when Sulfasalazine is combined with Insulin human. | [DB00861] Diflunisal: The risk or severity of hypoglycemia can be increased when Diflunisal is combined with Insulin human. | [DB00936] Salicylic acid: The risk or severity of hypoglycemia can be increased when Salicylic acid is combined with Insulin human. | [DB01014] Balsalazide: The risk or severity of hypoglycemia can be increased when Balsalazide is combined with Insulin human. | [DB01250] Olsalazine: The risk or severity of hypoglycemia can be increased when Olsalazine is combined with Insulin human. | [DB01294] Bismuth subsalicylate: The risk or severity of hypoglycemia can be increased when Bismuth subsalicylate is combined with Insulin human. | [DB06251] Dersalazine: The risk or severity of hypoglycemia can be increased when Dersalazine is combined with Insulin human. | [DB06807] Phenyl aminosalicylate: The risk or severity of hypoglycemia can be increased when Phenyl aminosalicylate is combined with Insulin human. | [DB09543] Methyl salicylate: The risk or severity of hypoglycemia can be increased when Methyl salicylate is combined with Insulin human. | [DB11079] Trolamine salicylate: The risk or severity of hypoglycemia can be increased when Trolamine salicylate is combined with Insulin human. | [DB12445] Nitroaspirin: The risk or severity of hypoglycemia can be increased when Nitroaspirin is combined with Insulin human. | [DB13509] Aloxiprin: The risk or severity of hypoglycemia can be increased when Aloxiprin is combined with Insulin human. | [DB13538] Guacetisal: The risk or severity of hypoglycemia can be increased when Guacetisal is combined with Insulin human. | [DB13612] Carbaspirin calcium: The risk or severity of hypoglycemia can be increased when Carbaspirin calcium is combined with Insulin human. | [DB14006] Choline salicylate: The risk or severity of hypoglycemia can be increased when Choline salicylate is combined with Insulin human. | [DB14026] Thiosalicylic acid: The risk or severity of hypoglycemia can be increased when Thiosalicylic acid is combined with Insulin human. | [DB01261] Sitagliptin: The risk or severity of hypoglycemia can be increased when Sitagliptin is combined with Insulin human. | [DB04876] Vildagliptin: The risk or severity of hypoglycemia can be increased when Vildagliptin is combined with Insulin human. | [DB06011] AMG-222: The risk or severity of hypoglycemia can be increased when AMG-222 is combined with Insulin human. | [DB06127] Bisegliptin: The risk or severity of hypoglycemia can be increased when Bisegliptin is combined with Insulin human. | [DB06203] Alogliptin: The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Insulin human. | [DB06335] Saxagliptin: The risk or severity of hypoglycemia can be increased when Saxagliptin is combined with Insulin human. | [DB08382] Gosogliptin: The risk or severity of hypoglycemia can be increased when Gosogliptin is combined with Insulin human. | [DB08882] Linagliptin: The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin human. | [DB11723] Dutogliptin: The risk or severity of hypoglycemia can be increased when Dutogliptin is combined with Insulin human. | [DB11950] Teneligliptin: The risk or severity of hypoglycemia can be increased when Teneligliptin is combined with Insulin human. | [DB11992] Omarigliptin: The risk or severity of hypoglycemia can be increased when Omarigliptin is combined with Insulin human. | [DB12268] Carmegliptin: The risk or severity of hypoglycemia can be increased when Carmegliptin is combined with Insulin human. | [DB12412] Gemigliptin: The risk or severity of hypoglycemia can be increased when Gemigliptin is combined with Insulin human. | [DB12417] Anagliptin: The risk or severity of hypoglycemia can be increased when Anagliptin is combined with Insulin human. | [DB12625] Evogliptin: The risk or severity of hypoglycemia can be increased when Evogliptin is combined with Insulin human. | [DB01276] Exenatide: The risk or severity of hypoglycemia can be increased when Exenatide is combined with Insulin human. | [DB09043] Albiglutide: The risk or severity of hypoglycemia can be increased when Albiglutide is combined with Insulin human. | [DB09045] Dulaglutide: The risk or severity of hypoglycemia can be increased when Dulaglutide is combined with Insulin human. | [DB09265] Lixisenatide: The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Insulin human. | [DB13928] Semaglutide: The risk or severity of hypoglycemia can be increased when Semaglutide is combined with Insulin human. | [DB14027] Taspoglutide: The risk or severity of hypoglycemia can be increased when Taspoglutide is combined with Insulin human. | [DB00752] Tranylcypromine: The risk or severity of hypoglycemia can be increased when Tranylcypromine is combined with Insulin human. | [DB00780] Phenelzine: The risk or severity of hypoglycemia can be increased when Phenelzine is combined with Insulin human. | [DB01171] Moclobemide: The risk or severity of hypoglycemia can be increased when Moclobemide is combined with Insulin human. | [DB01247] Isocarboxazid: The risk or severity of hypoglycemia can be increased when Isocarboxazid is combined with Insulin human. | [DB01626] Pargyline: The risk or severity of hypoglycemia can be increased when Pargyline is combined with Insulin human. | [DB00805] Minaprine: The risk or severity of hypoglycemia can be increased when Minaprine is combined with Insulin human. | [DB04818] Iproniazid: The risk or severity of hypoglycemia can be increased when Iproniazid is combined with Insulin human. | [DB04820] Nialamide: The risk or severity of hypoglycemia can be increased when Nialamide is combined with Insulin human. | [DB09244] Pirlindole: The risk or severity of hypoglycemia can be increased when Pirlindole is combined with Insulin human. | [DB09245] Toloxatone: The risk or severity of hypoglycemia can be increased when Toloxatone is combined with Insulin human. | [DB09243] Hydracarbazine: The risk or severity of hypoglycemia can be increased when Hydracarbazine is combined with Insulin human. | [DB09241] Methylene blue: The risk or severity of hypoglycemia can be increased when Methylene blue is combined with Insulin human. | [DB09246] Benmoxin: The risk or severity of hypoglycemia can be increased when Benmoxin is combined with Insulin human. | [DB09248] Mebanazine: The risk or severity of hypoglycemia can be increased when Mebanazine is combined with Insulin human. | [DB09249] Octamoxin: The risk or severity of hypoglycemia can be increased when Octamoxin is combined with Insulin human. | [DB09250] Pheniprazine: The risk or severity of hypoglycemia can be increased when Pheniprazine is combined with Insulin human. | [DB09251] Phenoxypropazine: The risk or severity of hypoglycemia can be increased when Phenoxypropazine is combined with Insulin human. | [DB09252] Pivhydrazine: The risk or severity of hypoglycemia can be increased when Pivhydrazine is combined with Insulin human. | [DB09253] Safrazine: The risk or severity of hypoglycemia can be increased when Safrazine is combined with Insulin human. | [DB09254] Caroxazone: The risk or severity of hypoglycemia can be increased when Caroxazone is combined with Insulin human. | [DB00614] Furazolidone: The risk or severity of hypoglycemia can be increased when Furazolidone is combined with Insulin human. | [DB08550] 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline: The risk or severity of hypoglycemia can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Insulin human. | [DB13875] Harmaline: The risk or severity of hypoglycemia can be increased when Harmaline is combined with Insulin human. | [DB13876] Brofaromine: The risk or severity of hypoglycemia can be increased when Brofaromine is combined with Insulin human. | [DB00721] Procaine: The risk or severity of hypoglycemia can be increased when Procaine is combined with Insulin human. | [DB01168] Procarbazine: The risk or severity of hypoglycemia can be increased when Procarbazine is combined with Insulin human. | [DB00601] Linezolid: The risk or severity of hypoglycemia can be increased when Linezolid is combined with Insulin human. | [DB06654] Safinamide: The risk or severity of hypoglycemia can be increased when Safinamide is combined with Insulin human. | [DB04017] Clorgiline: The risk or severity of hypoglycemia can be increased when Clorgiline is combined with Insulin human. | [DB01037] Selegiline: The risk or severity of hypoglycemia can be increased when Selegiline is combined with Insulin human. | [DB01367] Rasagiline: The risk or severity of hypoglycemia can be increased when Rasagiline is combined with Insulin human. | [DB11827] Ertugliflozin: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Ertugliflozin. | [DB00214] Torasemide: The risk or severity of hypoglycemia can be increased when Torasemide is combined with Insulin human. | [DB00263] Sulfisoxazole: The risk or severity of hypoglycemia can be increased when Sulfisoxazole is combined with Insulin human. | [DB00311] Ethoxzolamide: The risk or severity of hypoglycemia can be increased when Ethoxzolamide is combined with Insulin human. | [DB00359] Sulfadiazine: The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Insulin human. | [DB00482] Celecoxib: The risk or severity of hypoglycemia can be increased when Celecoxib is combined with Insulin human. | [DB00559] Bosentan: The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin human. | [DB00576] Sulfamethizole: The risk or severity of hypoglycemia can be increased when Sulfamethizole is combined with Insulin human. | [DB00606] Cyclothiazide: The risk or severity of hypoglycemia can be increased when Cyclothiazide is combined with Insulin human. | [DB00664] Sulfametopyrazine: The risk or severity of hypoglycemia can be increased when Sulfametopyrazine is combined with Insulin human. | [DB00669] Sumatriptan: The risk or severity of hypoglycemia can be increased when Sumatriptan is combined with Insulin human. | [DB00695] Furosemide: The risk or severity of hypoglycemia can be increased when Furosemide is combined with Insulin human. | [DB00706] Tamsulosin: The risk or severity of hypoglycemia can be increased when Tamsulosin is combined with Insulin human. | [DB00819] Acetazolamide: The risk or severity of hypoglycemia can be increased when Acetazolamide is combined with Insulin human. | [DB00887] Bumetanide: The risk or severity of hypoglycemia can be increased when Bumetanide is combined with Insulin human. | [DB00891] Sulfapyridine: The risk or severity of hypoglycemia can be increased when Sulfapyridine is combined with Insulin human. | [DB00909] Zonisamide: The risk or severity of hypoglycemia can be increased when Zonisamide is combined with Insulin human. | [DB01015] Sulfamethoxazole: The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Insulin human. | [DB01032] Probenecid: The risk or severity of hypoglycemia can be increased when Probenecid is combined with Insulin human. | [DB01098] Rosuvastatin: The risk or severity of hypoglycemia can be increased when Rosuvastatin is combined with Insulin human. | [DB01119] Diazoxide: The risk or severity of hypoglycemia can be increased when Diazoxide is combined with Insulin human. | [DB01144] Diclofenamide: The risk or severity of hypoglycemia can be increased when Diclofenamide is combined with Insulin human. | [DB01264] Darunavir: The risk or severity of hypoglycemia can be increased when Darunavir is combined with Insulin human. | [DB01298] Sulfacytine: The risk or severity of hypoglycemia can be increased when Sulfacytine is combined with Insulin human. | [DB01299] Sulfadoxine: The risk or severity of hypoglycemia can be increased when Sulfadoxine is combined with Insulin human. | [DB01382] Glymidine: The risk or severity of hypoglycemia can be increased when Glymidine is combined with Insulin human. | [DB01581] Sulfamerazine: The risk or severity of hypoglycemia can be increased when Sulfamerazine is combined with Insulin human. | [DB01582] Sulfamethazine: The risk or severity of hypoglycemia can be increased when Sulfamethazine is combined with Insulin human. | [DB02925] Piretanide: The risk or severity of hypoglycemia can be increased when Piretanide is combined with Insulin human. | [DB04707] Hydroxyfasudil: The risk or severity of hypoglycemia can be increased when Hydroxyfasudil is combined with Insulin human. | [DB06150] Sulfadimethoxine: The risk or severity of hypoglycemia can be increased when Sulfadimethoxine is combined with Insulin human. | [DB06290] Simeprevir: The risk or severity of hypoglycemia can be increased when Simeprevir is combined with Insulin human. | [DB06729] Sulfaphenazole: The risk or severity of hypoglycemia can be increased when Sulfaphenazole is combined with Insulin human. | [DB06821] Sulfameter: The risk or severity of hypoglycemia can be increased when Sulfameter is combined with Insulin human. | [DB07996] 5-(2-methylpiperazine-1-sulfonyl)isoquinoline: The risk or severity of hypoglycemia can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Insulin human. | [DB08162] Fasudil: The risk or severity of hypoglycemia can be increased when Fasudil is combined with Insulin human. | [DB08798] Sulfamoxole: The risk or severity of hypoglycemia can be increased when Sulfamoxole is combined with Insulin human. | [DB08881] Vemurafenib: The risk or severity of hypoglycemia can be increased when Vemurafenib is combined with Insulin human. | [DB08961] Azosemide: The risk or severity of hypoglycemia can be increased when Azosemide is combined with Insulin human. | [DB11389] Clorsulon: The risk or severity of hypoglycemia can be increased when Clorsulon is combined with Insulin human. | [DB11461] Sulfachlorpyridazine: The risk or severity of hypoglycemia can be increased when Sulfachlorpyridazine is combined with Insulin human. | [DB11462] Sulfaethoxypyridazine: The risk or severity of hypoglycemia can be increased when Sulfaethoxypyridazine is combined with Insulin human. | [DB11463] Sulfanitran: The risk or severity of hypoglycemia can be increased when Sulfanitran is combined with Insulin human. | [DB11464] Sulfaquinoxaline: The risk or severity of hypoglycemia can be increased when Sulfaquinoxaline is combined with Insulin human. | [DB12051] Setrobuvir: The risk or severity of hypoglycemia can be increased when Setrobuvir is combined with Insulin human. | [DB12921] Chlorsulfaquinoxaline: The risk or severity of hypoglycemia can be increased when Chlorsulfaquinoxaline is combined with Insulin human. | [DB13214] Sulfadicramide: The risk or severity of hypoglycemia can be increased when Sulfadicramide is combined with Insulin human. | [DB13248] Phthalylsulfathiazole: The risk or severity of hypoglycemia can be increased when Phthalylsulfathiazole is combined with Insulin human. | [DB13283] Sulfaisodimidine: The risk or severity of hypoglycemia can be increased when Sulfaisodimidine is combined with Insulin human. | [DB13284] Meticrane: The risk or severity of hypoglycemia can be increased when Meticrane is combined with Insulin human. | [DB13320] Sulfaperin: The risk or severity of hypoglycemia can be increased when Sulfaperin is combined with Insulin human. | [DB13405] Mefruside: The risk or severity of hypoglycemia can be increased when Mefruside is combined with Insulin human. | [DB13430] Mebutizide: The risk or severity of hypoglycemia can be increased when Mebutizide is combined with Insulin human. | [DB13485] Sulfametomidine: The risk or severity of hypoglycemia can be increased when Sulfametomidine is combined with Insulin human. | [DB13547] Sulfatolamide: The risk or severity of hypoglycemia can be increased when Sulfatolamide is combined with Insulin human. | [DB13556] Sulfamazone: The risk or severity of hypoglycemia can be increased when Sulfamazone is combined with Insulin human. | [DB13580] Succinylsulfathiazole: The risk or severity of hypoglycemia can be increased when Succinylsulfathiazole is combined with Insulin human. | [DB13617] Clorexolone: The risk or severity of hypoglycemia can be increased when Clorexolone is combined with Insulin human. | [DB13663] Clofenamide: The risk or severity of hypoglycemia can be increased when Clofenamide is combined with Insulin human. | [DB13699] Sulfathiourea: The risk or severity of hypoglycemia can be increased when Sulfathiourea is combined with Insulin human. | [DB13708] Fenquizone: The risk or severity of hypoglycemia can be increased when Fenquizone is combined with Insulin human. | [DB13726] Sulfaguanidine: The risk or severity of hypoglycemia can be increased when Sulfaguanidine is combined with Insulin human. | [DB13773] Sulfamethoxypyridazine: The risk or severity of hypoglycemia can be increased when Sulfamethoxypyridazine is combined with Insulin human. | [DB13792] Clopamide: The risk or severity of hypoglycemia can be increased when Clopamide is combined with Insulin human. | [DB13803] Xipamide: The risk or severity of hypoglycemia can be increased when Xipamide is combined with Insulin human. | [DB14033] Acetyl sulfisoxazole: The risk or severity of hypoglycemia can be increased when Acetyl sulfisoxazole is combined with Insulin human. | [DB00703] Methazolamide: The risk or severity of hypoglycemia can be increased when Methazolamide is combined with Insulin human. | [DB06370] Indisulam: The risk or severity of hypoglycemia can be increased when Indisulam is combined with Insulin human. | [DB15861] Buthiazide: The risk or severity of hypoglycemia can be increased when Buthiazide is combined with Insulin human. | [DB15975] Sulfametrole: The risk or severity of hypoglycemia can be increased when Sulfametrole is combined with Insulin human. | [DB00046] Insulin lispro: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin lispro. | [DB00047] Insulin glargine: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin glargine. | [DB00071] Insulin pork: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin pork. | [DB00197] Troglitazone: The risk or severity of hypoglycemia can be increased when Troglitazone is combined with Insulin human. | [DB00222] Glimepiride: The risk or severity of hypoglycemia can be increased when Glimepiride is combined with Insulin human. | [DB00280] Disopyramide: The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin human. | [DB00284] Acarbose: The risk or severity of hypoglycemia can be increased when Acarbose is combined with Insulin human. | [DB00414] Acetohexamide: The risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Insulin human. | [DB00468] Quinine: The risk or severity of hypoglycemia can be increased when Quinine is combined with Insulin human. | [DB00491] Miglitol: The risk or severity of hypoglycemia can be increased when Miglitol is combined with Insulin human. | [DB00672] Chlorpropamide: The risk or severity of hypoglycemia can be increased when Chlorpropamide is combined with Insulin human. | [DB00731] Nateglinide: The risk or severity of hypoglycemia can be increased when Nateglinide is combined with Insulin human. | [DB00834] Mifepristone: The risk or severity of hypoglycemia can be increased when Mifepristone is combined with Insulin human. | [DB00839] Tolazamide: The risk or severity of hypoglycemia can be increased when Tolazamide is combined with Insulin human. | [DB00912] Repaglinide: The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Insulin human. | [DB00914] Phenformin: The risk or severity of hypoglycemia can be increased when Phenformin is combined with Insulin human. | [DB01016] Glyburide: The risk or severity of hypoglycemia can be increased when Glyburide is combined with Insulin human. | [DB01067] Glipizide: The risk or severity of hypoglycemia can be increased when Glipizide is combined with Insulin human. | [DB01120] Gliclazide: The risk or severity of hypoglycemia can be increased when Gliclazide is combined with Insulin human. | [DB01124] Tolbutamide: The risk or severity of hypoglycemia can be increased when Tolbutamide is combined with Insulin human. | [DB01200] Bromocriptine: The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Insulin human. | [DB01251] Gliquidone: The risk or severity of hypoglycemia can be increased when Gliquidone is combined with Insulin human. | [DB01252] Mitiglinide: The risk or severity of hypoglycemia can be increased when Mitiglinide is combined with Insulin human. | [DB01268] Sunitinib: The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Insulin human. | [DB01277] Mecasermin: The risk or severity of hypoglycemia can be increased when Mecasermin is combined with Insulin human. | [DB01289] Glisoxepide: The risk or severity of hypoglycemia can be increased when Glisoxepide is combined with Insulin human. | [DB01306] Insulin aspart: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin aspart. | [DB01307] Insulin detemir: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin detemir. | [DB01309] Insulin glulisine: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin glulisine. | [DB01700] AICA ribonucleotide: The risk or severity of hypoglycemia can be increased when AICA ribonucleotide is combined with Insulin human. | [DB04830] Buformin: The risk or severity of hypoglycemia can be increased when Buformin is combined with Insulin human. | [DB04878] Voglibose: The risk or severity of hypoglycemia can be increased when Voglibose is combined with Insulin human. | [DB05115] NN344: The risk or severity of hypoglycemia can be increased when Insulin human is combined with NN344. | [DB08962] Glibornuride: The risk or severity of hypoglycemia can be increased when Glibornuride is combined with Insulin human. | [DB09022] Benfluorex: The risk or severity of hypoglycemia can be increased when Benfluorex is combined with Insulin human. | [DB09198] Lobeglitazone: The risk or severity of hypoglycemia can be increased when Lobeglitazone is combined with Insulin human. | [DB09199] Netoglitazone: The risk or severity of hypoglycemia can be increased when Netoglitazone is combined with Insulin human. | [DB09200] Rivoglitazone: The risk or severity of hypoglycemia can be increased when Rivoglitazone is combined with Insulin human. | [DB09201] Ciglitazone: The risk or severity of hypoglycemia can be increased when Ciglitazone is combined with Insulin human. | [DB09456] Insulin beef: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin beef. | [DB09564] Insulin degludec: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin degludec. | [DB11567] Insulin peglispro: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin peglispro. | [DB11568] Insulin tregopil: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin tregopil. | [DB11698] Ipragliflozin: The risk or severity of hypoglycemia can be increased when Ipragliflozin is combined with Insulin human. | [DB11780] Allicin: The risk or severity of hypoglycemia can be increased when Allicin is combined with Insulin human. | [DB11824] Tofogliflozin: The risk or severity of hypoglycemia can be increased when Tofogliflozin is combined with Insulin human. | [DB11898] 2,4-thiazolidinedione: The risk or severity of hypoglycemia can be increased when Insulin human is combined with 2,4-thiazolidinedione. | [DB12713] Sotagliflozin: The risk or severity of hypoglycemia can be increased when Sotagliflozin is combined with Insulin human. | [DB12781] Balaglitazone: The risk or severity of hypoglycemia can be increased when Balaglitazone is combined with Insulin human. | [DB12935] Remogliflozin etabonate: The risk or severity of hypoglycemia can be increased when Remogliflozin etabonate is combined with Insulin human. | [DB13406] Carbutamide: The risk or severity of hypoglycemia can be increased when Carbutamide is combined with Insulin human. | [DB13446] Guar gum: The risk or severity of hypoglycemia can be increased when Guar gum is combined with Insulin human. | [DB13675] Metahexamide: The risk or severity of hypoglycemia can be increased when Metahexamide is combined with Insulin human. | [DB14035] Englitazone: The risk or severity of hypoglycemia can be increased when Englitazone is combined with Insulin human. | [DB15171] Tirzepatide: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Tirzepatide. | [DB15217] Gastric inhibitory polypeptide: The risk or severity of hypoglycemia can be increased when Gastric inhibitory polypeptide is combined with Insulin human. | [DB00270] Isradipine: The risk or severity of hypoglycemia can be increased when Isradipine is combined with Insulin human. | [DB00343] Diltiazem: The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Insulin human. | [DB00347] Trimethadione: The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Insulin human. | [DB00381] Amlodipine: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin human. | [DB00393] Nimodipine: The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Insulin human. | [DB00401] Nisoldipine: The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Insulin human. | [DB00528] Lercanidipine: The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Insulin human. | [DB00593] Ethosuximide: The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin human. | [DB00622] Nicardipine: The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Insulin human. | [DB00653] Magnesium sulfate: The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Insulin human. | [DB01054] Nitrendipine: The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Insulin human. | [DB01074] Perhexiline: The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Insulin human. | [DB01244] Bepridil: The risk or severity of hypoglycemia can be increased when Bepridil is combined with Insulin human. | [DB01388] Mibefradil: The risk or severity of hypoglycemia can be increased when Mibefradil is combined with Insulin human. | [DB04743] Nimesulide: The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Insulin human. | [DB04825] Prenylamine: The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Insulin human. | [DB04838] Cyclandelate: The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin human. | [DB04842] Fluspirilene: The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin human. | [DB04920] Clevidipine: The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin human. | [DB05246] Methsuximide: The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin human. | [DB05885] Seletracetam: The risk or severity of hypoglycemia can be increased when Seletracetam is combined with Insulin human. | [DB06152] Nylidrin: The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Insulin human. | [DB06283] Ziconotide: The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Insulin human. | [DB06446] Dotarizine: The risk or severity of hypoglycemia can be increased when Dotarizine is combined with Insulin human. | [DB06694] Xylometazoline: The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Insulin human. | [DB06712] Nilvadipine: The risk or severity of hypoglycemia can be increased when Nilvadipine is combined with Insulin human. | [DB07615] Tranilast: The risk or severity of hypoglycemia can be increased when Tranilast is combined with Insulin human. | [DB08838] Agmatine: The risk or severity of hypoglycemia can be increased when Agmatine is combined with Insulin human. | [DB08980] Fendiline: The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin human. | [DB08992] Eperisone: The risk or severity of hypoglycemia can be increased when Eperisone is combined with Insulin human. | [DB09089] Trimebutine: The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin human. | [DB09090] Pinaverium: The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Insulin human. | [DB09227] Barnidipine: The risk or severity of hypoglycemia can be increased when Barnidipine is combined with Insulin human. | [DB09229] Aranidipine: The risk or severity of hypoglycemia can be increased when Aranidipine is combined with Insulin human. | [DB09230] Azelnidipine: The risk or severity of hypoglycemia can be increased when Azelnidipine is combined with Insulin human. | [DB09231] Benidipine: The risk or severity of hypoglycemia can be increased when Benidipine is combined with Insulin human. | [DB09232] Cilnidipine: The risk or severity of hypoglycemia can be increased when Cilnidipine is combined with Insulin human. | [DB09234] Darodipine: The risk or severity of hypoglycemia can be increased when Darodipine is combined with Insulin human. | [DB09235] Efonidipine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Efonidipine. | [DB09236] Lacidipine: The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Insulin human. | [DB09238] Manidipine: The risk or severity of hypoglycemia can be increased when Manidipine is combined with Insulin human. | [DB09239] Niguldipine: The risk or severity of hypoglycemia can be increased when Niguldipine is combined with Insulin human. | [DB09240] Niludipine: The risk or severity of hypoglycemia can be increased when Niludipine is combined with Insulin human. | [DB11960] Carboxyamidotriazole: The risk or severity of hypoglycemia can be increased when Carboxyamidotriazole is combined with Insulin human. | [DB12092] Naftopidil: The risk or severity of hypoglycemia can be increased when Naftopidil is combined with Insulin human. | [DB12093] Tetrahydropalmatine: The risk or severity of hypoglycemia can be increased when Tetrahydropalmatine is combined with Insulin human. | [DB12131] Vinpocetine: The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Insulin human. | [DB12923] Gallopamil: The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Insulin human. | [DB13488] Bencyclane: The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Insulin human. | [DB13500] Otilonium: The risk or severity of hypoglycemia can be increased when Otilonium is combined with Insulin human. | [DB13725] Terodiline: The risk or severity of hypoglycemia can be increased when Terodiline is combined with Insulin human. | [DB13766] Lidoflazine: The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Insulin human. | [DB13791] Penfluridol: The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Insulin human. | [DB13835] Caroverine: The risk or severity of hypoglycemia can be increased when Caroverine is combined with Insulin human. | [DB13950] WIN 55212-2: The risk or severity of hypoglycemia can be increased when WIN 55212-2 is combined with Insulin human. | [DB14063] Dexverapamil: The risk or severity of hypoglycemia can be increased when Dexverapamil is combined with Insulin human. | [DB14064] Emopamil: The risk or severity of hypoglycemia can be increased when Emopamil is combined with Insulin human. | [DB14065] Lomerizine: The risk or severity of hypoglycemia can be increased when Lomerizine is combined with Insulin human. | [DB14066] Tetrandrine: The risk or severity of hypoglycemia can be increased when Tetrandrine is combined with Insulin human. | [DB14068] Dexniguldipine: The risk or severity of hypoglycemia can be increased when Dexniguldipine is combined with Insulin human. | [DB01023] Felodipine: The risk or severity of hypoglycemia can be increased when Felodipine is combined with Insulin human. | [DB01118] Amiodarone: The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Insulin human. | [DB00568] Cinnarizine: The risk or severity of hypoglycemia can be increased when Cinnarizine is combined with Insulin human. | [DB00661] Verapamil: The risk or severity of hypoglycemia can be increased when Verapamil is combined with Insulin human. | [DB01115] Nifedipine: The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Insulin human. | [DB04841] Flunarizine: The risk or severity of hypoglycemia can be increased when Flunarizine is combined with Insulin human. | [DB00191] Phentermine: The therapeutic efficacy of Insulin human can be increased when used in combination with Phentermine. | [DB00268] Ropinirole: The metabolism of Ropinirole can be increased when combined with Insulin human. | [DB13074] Macimorelin: The therapeutic efficacy of Macimorelin can be decreased when used in combination with Insulin human. | [DB00279] Liothyronine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Liothyronine. | [DB00331] Metformin: The risk or severity of adverse effects can be increased when Insulin human is combined with Metformin. | [DB00542] Benazepril: The risk or severity of hypoglycemia can be increased when Benazepril is combined with Insulin human. | [DB13946] Testosterone undecanoate: Testosterone undecanoate may increase the hypoglycemic activities of Insulin human. | [DB00945] Acetylsalicylic acid: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin human. | [DB00181] Baclofen: The therapeutic efficacy of Insulin human can be decreased when used in combination with Baclofen. | [DB00489] Sotalol: The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin human. | [DB00196] Fluconazole: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Fluconazole. | [DB00040] Glucagon: The therapeutic efficacy of Insulin human can be decreased when used in combination with Glucagon. | [DB00264] Metoprolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Metoprolol. | [DB00335] Atenolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Atenolol. | [DB00373] Timolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Timolol. | [DB00598] Labetalol: The therapeutic efficacy of Insulin human can be increased when used in combination with Labetalol. | [DB00612] Bisoprolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Bisoprolol. | [DB00866] Alprenolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Alprenolol. | [DB00960] Pindolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Pindolol. | [DB01193] Acebutolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Acebutolol. | [DB01203] Nadolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Nadolol. | [DB01295] Bevantolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Bevantolol. | [DB01297] Practolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Practolol. | [DB01359] Penbutolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Penbutolol. | [DB01580] Oxprenolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Oxprenolol. | [DB03322] Dexpropranolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Dexpropranolol. | [DB04846] Celiprolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Celiprolol. | [DB04861] Nebivolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Nebivolol. | [DB06726] Bufuralol: The therapeutic efficacy of Insulin human can be increased when used in combination with Bufuralol. | [DB08807] Bopindolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Bopindolol. | [DB08808] Bupranolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Bupranolol. | [DB08952] Indenolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Indenolol. | [DB09204] Arotinolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Arotinolol. | [DB09351] Levobetaxolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Levobetaxolol. | [DB11770] Talinolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Talinolol. | [DB11785] Anisodamine: The therapeutic efficacy of Insulin human can be increased when used in combination with Anisodamine. | [DB12752] Bucindolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Bucindolol. | [DB13443] Esatenolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Esatenolol. | [DB13508] Cloranolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Cloranolol. | [DB13530] Mepindolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Mepindolol. | [DB13757] Epanolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Epanolol. | [DB13775] Tertatolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Tertatolol. | [DB00195] Betaxolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Betaxolol. | [DB00571] Propranolol: The therapeutic efficacy of Insulin human can be increased when used in combination with Propranolol. | [DB01136] Carvedilol: The therapeutic efficacy of Insulin human can be increased when used in combination with Carvedilol. | [DB01182] Propafenone: The therapeutic efficacy of Insulin human can be increased when used in combination with Propafenone. | [DB01611] Hydroxychloroquine: The therapeutic efficacy of Insulin human can be increased when used in combination with Hydroxychloroquine. | [DB01233] Metoclopramide: The therapeutic efficacy of Insulin human can be increased when used in combination with Metoclopramide. | [DB00394] Beclomethasone dipropionate: The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Insulin human. | [DB00443] Betamethasone: The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Insulin human. | [DB00620] Triamcinolone: The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Insulin human. | [DB00635] Prednisone: The risk or severity of hyperglycemia can be increased when Prednisone is combined with Insulin human. | [DB00687] Fludrocortisone: The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Insulin human. | [DB00741] Hydrocortisone: The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Insulin human. | [DB00764] Mometasone: The risk or severity of hyperglycemia can be increased when Mometasone is combined with Insulin human. | [DB00860] Prednisolone: The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Insulin human. | [DB00959] Methylprednisolone: The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin human. | [DB01234] Dexamethasone: The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin human. | [DB01285] Corticotropin: The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Insulin human. | [DB01380] Cortisone acetate: The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Insulin human. | [DB01384] Paramethasone: The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Insulin human. | [DB01410] Ciclesonide: The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Insulin human. | [DB08906] Fluticasone furoate: The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Insulin human. | [DB08970] Fluprednidene: The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin human. | [DB08971] Fluocortolone: The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin human. | [DB09383] Meprednisone: The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Insulin human. | [DB11487] Dexamethasone isonicotinate: The risk or severity of hyperglycemia can be increased when Dexamethasone isonicotinate is combined with Insulin human. | [DB11750] Clobetasol: The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Insulin human. | [DB11921] Deflazacort: The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Insulin human. | [DB13003] Cortivazol: The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Insulin human. | [DB13208] Prednylidene: The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Insulin human. | [DB13843] Cloprednol: The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Insulin human. | [DB13867] Fluticasone: The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Insulin human. | [DB14512] Mometasone furoate: The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Insulin human. | [DB00180] Flunisolide: The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Insulin human. | [DB01108] Trilostane: The risk or severity of hyperglycemia can be increased when Trilostane is combined with Insulin human. | [DB01222] Budesonide: The risk or severity of hyperglycemia can be increased when Budesonide is combined with Insulin human. | [DB04630] Aldosterone: The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Insulin human. | [DB09378] Fluprednisolone: The risk or severity of hyperglycemia can be increased when Fluprednisolone is combined with Insulin human. | [DB11529] Melengestrol: The risk or severity of hyperglycemia can be increased when Melengestrol is combined with Insulin human. | [DB14681] Cortisone: The risk or severity of hyperglycemia can be increased when Cortisone is combined with Insulin human. | [DB00223] Diflorasone: The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin human. | [DB00240] Alclometasone: The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin human. | [DB00253] Medrysone: The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin human. | [DB00288] Amcinonide: The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Insulin human. | [DB00324] Fluorometholone: The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Insulin human. | [DB00547] Desoximetasone: The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Insulin human. | [DB00588] Fluticasone propionate: The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Insulin human. | [DB00591] Fluocinolone acetonide: The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Insulin human. | [DB00596] Ulobetasol: The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin human. | [DB00663] Flumethasone: The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Insulin human. | [DB00838] Clocortolone: The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Insulin human. | [DB00846] Flurandrenolide: The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Insulin human. | [DB00896] Rimexolone: The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Insulin human. | [DB01013] Clobetasol propionate: The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Insulin human. | [DB01047] Fluocinonide: The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Insulin human. | [DB01130] Prednicarbate: The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Insulin human. | [DB01260] Desonide: The risk or severity of hyperglycemia can be increased when Desonide is combined with Insulin human. | [DB06781] Difluprednate: The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin human. | [DB06786] Halcinonide: The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin human. | [DB09091] Tixocortol: The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Insulin human. | [DB09095] Difluocortolone: The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin human. | [DB13158] Clobetasone: The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin human. | [DB13223] Fluocortin: The risk or severity of hyperglycemia can be increased when Fluocortin is combined with Insulin human. | [DB13491] Fluperolone: The risk or severity of hyperglycemia can be increased when Fluperolone is combined with Insulin human. | [DB13664] Formocortal: The risk or severity of hyperglycemia can be increased when Formocortal is combined with Insulin human. | [DB13728] Halometasone: The risk or severity of hyperglycemia can be increased when Halometasone is combined with Insulin human. | [DB13856] Fluclorolone: The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Insulin human. | [DB14538] Hydrocortisone aceponate: The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Insulin human. | [DB14539] Hydrocortisone acetate: The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Insulin human. | [DB14540] Hydrocortisone butyrate: The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Insulin human. | [DB14541] Hydrocortisone cypionate: The risk or severity of hyperglycemia can be increased when Hydrocortisone cypionate is combined with Insulin human. | [DB14543] Hydrocortisone probutate: The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Insulin human. | [DB14544] Hydrocortisone valerate: The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin human. | [DB14545] Hydrocortisone succinate: The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Insulin human. | [DB00873] Loteprednol: The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin human. | [DB14631] Prednisolone phosphate: The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Insulin human. | [DB14633] Prednisolone hemisuccinate: The risk or severity of hyperglycemia can be increased when Prednisolone hemisuccinate is combined with Insulin human. | [DB14634] Fluprednidene acetate: The risk or severity of hyperglycemia can be increased when Fluprednidene acetate is combined with Insulin human. | [DB14643] Methylprednisolone aceponate: The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin human. | [DB14644] Methylprednisolone hemisuccinate: The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Insulin human. | [DB14646] Prednisone acetate: The risk or severity of hyperglycemia can be increased when Prednisone acetate is combined with Insulin human. | [DB14652] Clocortolone acetate: The risk or severity of hyperglycemia can be increased when Clocortolone acetate is combined with Insulin human. | [DB14659] Melengestrol acetate: The risk or severity of hyperglycemia can be increased when Melengestrol acetate is combined with Insulin human. | [DB14669] Betamethasone phosphate: The risk or severity of hyperglycemia can be increased when Betamethasone phosphate is combined with Insulin human. | [DB15566] Prednisolone acetate: The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Insulin human. | [DB00451] Levothyroxine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Levothyroxine. | [DB00024] Thyrotropin alfa: Thyrotropin alfa may decrease the hypoglycemic activities of Insulin human. | [DB01583] Liotrix: Liotrix may decrease the hypoglycemic activities of Insulin human. | [DB03604] Tiratricol: Tiratricol may decrease the hypoglycemic activities of Insulin human. | [DB09100] Thyroid, porcine: Thyroid, porcine may decrease the hypoglycemic activities of Insulin human. | [DB00104] Octreotide: The therapeutic efficacy of Insulin human can be decreased when used in combination with Octreotide. | [DB15093] Somapacitan: The therapeutic efficacy of Insulin human can be decreased when used in combination with Somapacitan. | [DB00052] Somatotropin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Somatotropin. | [DB09098] Somatrem: Somatrem may decrease the hypoglycemic activities of Insulin human. | [DB12950] Albusomatropin: Albusomatropin may decrease the hypoglycemic activities of Insulin human. | [DB15112] Somatropin pegol: Somatropin pegol may decrease the hypoglycemic activities of Insulin human. | [DB12235] Estetrol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Estetrol. | [DB16220] Lonapegsomatropin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Lonapegsomatropin. | [DB09237] Levamlodipine: The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Insulin human. | [DB14649] Dexamethasone acetate: The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Insulin human. | [DB14960] Somatrogon: The therapeutic efficacy of Insulin human can be decreased when used in combination with Somatrogon. | [DB00783] Estradiol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Estradiol. | [DB00252] Phenytoin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Phenytoin. | [DB00951] Isoniazid: The therapeutic efficacy of Insulin human can be decreased when used in combination with Isoniazid. | [DB16236] Mitapivat: The risk or severity of hypoglycemia can be increased when Mitapivat is combined with Insulin human. | [DB11564] Insulin argine: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin argine. | [DB00178] Ramipril: The risk or severity of hypoglycemia can be increased when Ramipril is combined with Insulin human. | [DB00492] Fosinopril: The risk or severity of hypoglycemia can be increased when Fosinopril is combined with Insulin human. | [DB00519] Trandolapril: The risk or severity of hypoglycemia can be increased when Trandolapril is combined with Insulin human. | [DB00584] Enalapril: The risk or severity of hypoglycemia can be increased when Enalapril is combined with Insulin human. | [DB00691] Moexipril: The risk or severity of hypoglycemia can be increased when Moexipril is combined with Insulin human. | [DB00722] Lisinopril: The risk or severity of hypoglycemia can be increased when Lisinopril is combined with Insulin human. | [DB00790] Perindopril: The risk or severity of hypoglycemia can be increased when Perindopril is combined with Insulin human. | [DB00881] Quinapril: The risk or severity of hypoglycemia can be increased when Quinapril is combined with Insulin human. | [DB00886] Omapatrilat: The risk or severity of hypoglycemia can be increased when Omapatrilat is combined with Insulin human. | [DB01180] Rescinnamine: The risk or severity of hypoglycemia can be increased when Rescinnamine is combined with Insulin human. | [DB01197] Captopril: The risk or severity of hypoglycemia can be increased when Captopril is combined with Insulin human. | [DB01340] Cilazapril: The risk or severity of hypoglycemia can be increased when Cilazapril is combined with Insulin human. | [DB01348] Spirapril: The risk or severity of hypoglycemia can be increased when Spirapril is combined with Insulin human. | [DB08836] Temocapril: The risk or severity of hypoglycemia can be increased when Temocapril is combined with Insulin human. | [DB09477] Enalaprilat: The risk or severity of hypoglycemia can be increased when Enalaprilat is combined with Insulin human. | [DB11783] Imidapril: The risk or severity of hypoglycemia can be increased when Imidapril is combined with Insulin human. | [DB13166] Zofenopril: The risk or severity of hypoglycemia can be increased when Zofenopril is combined with Insulin human. | [DB13312] Delapril: The risk or severity of hypoglycemia can be increased when Delapril is combined with Insulin human. | [DB14125] Benazeprilat: The risk or severity of hypoglycemia can be increased when Benazeprilat is combined with Insulin human. | [DB14207] Fosinoprilat: The risk or severity of hypoglycemia can be increased when Fosinoprilat is combined with Insulin human. | [DB14208] Ramiprilat: The risk or severity of hypoglycemia can be increased when Ramiprilat is combined with Insulin human. | [DB14209] Trandolaprilat: The risk or severity of hypoglycemia can be increased when Trandolaprilat is combined with Insulin human. | [DB14210] Moexiprilat: The risk or severity of hypoglycemia can be increased when Moexiprilat is combined with Insulin human. | [DB14213] Perindoprilat: The risk or severity of hypoglycemia can be increased when Perindoprilat is combined with Insulin human. | [DB14217] Quinaprilat: The risk or severity of hypoglycemia can be increased when Quinaprilat is combined with Insulin human. | [DB15565] Cilazaprilat: The risk or severity of hypoglycemia can be increased when Cilazaprilat is combined with Insulin human. | [DB00177] Valsartan: The risk or severity of hypoglycemia can be increased when Valsartan is combined with Insulin human. | [DB00678] Losartan: The risk or severity of hypoglycemia can be increased when Losartan is combined with Insulin human. | [DB00876] Eprosartan: The risk or severity of hypoglycemia can be increased when Eprosartan is combined with Insulin human. | [DB00966] Telmisartan: The risk or severity of hypoglycemia can be increased when Telmisartan is combined with Insulin human. | [DB01342] Forasartan: The risk or severity of hypoglycemia can be increased when Forasartan is combined with Insulin human. | [DB01347] Saprisartan: The risk or severity of hypoglycemia can be increased when Saprisartan is combined with Insulin human. | [DB08822] Azilsartan medoxomil: The risk or severity of hypoglycemia can be increased when Azilsartan medoxomil is combined with Insulin human. | [DB00636] Clofibrate: The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Insulin human. | [DB01039] Fenofibrate: The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Insulin human. | [DB01241] Gemfibrozil: The risk or severity of hypoglycemia can be increased when Gemfibrozil is combined with Insulin human. | [DB01393] Bezafibrate: The risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Insulin human. | [DB08983] Etofibrate: The risk or severity of hypoglycemia can be increased when Etofibrate is combined with Insulin human. | [DB09064] Ciprofibrate: The risk or severity of hypoglycemia can be increased when Ciprofibrate is combined with Insulin human. | [DB13433] Simfibrate: The risk or severity of hypoglycemia can be increased when Simfibrate is combined with Insulin human. | [DB13460] Ronifibrate: The risk or severity of hypoglycemia can be increased when Ronifibrate is combined with Insulin human. | [DB13780] Aluminium clofibrate: The risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Insulin human. | [DB13849] Clofibride: The risk or severity of hypoglycemia can be increased when Clofibride is combined with Insulin human. | [DB13873] Fenofibric acid: The risk or severity of hypoglycemia can be increased when Fenofibric acid is combined with Insulin human. | [DB00806] Pentoxifylline: The risk or severity of hypoglycemia can be increased when Pentoxifylline is combined with Insulin human. | [DB04894] Vapreotide: The risk or severity of hypoglycemia can be increased when Vapreotide is combined with Insulin human. | [DB09099] Somatostatin: The risk or severity of hypoglycemia can be increased when Somatostatin is combined with Insulin human. | [DB00259] Sulfanilamide: The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with Insulin human. | [DB00634] Sulfacetamide: The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin human. | [DB00869] Dorzolamide: The risk or severity of hypoglycemia can be increased when Dorzolamide is combined with Insulin human. | [DB01194] Brinzolamide: The risk or severity of hypoglycemia can be increased when Brinzolamide is combined with Insulin human. | [DB05245] Silver sulfadiazine: The risk or severity of hypoglycemia can be increased when Silver sulfadiazine is combined with Insulin human. | [DB06147] Sulfathiazole: The risk or severity of hypoglycemia can be increased when Sulfathiazole is combined with Insulin human. | [DB06795] Mafenide: The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin human. | [DB14708] Tosylchloramide: The risk or severity of hypoglycemia can be increased when Tosylchloramide is combined with Insulin human. | [DB04888] Bifeprunox: The therapeutic efficacy of Insulin human can be decreased when used in combination with Bifeprunox. | [DB06016] Cariprazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Cariprazine. | [DB06077] Lumateperone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Lumateperone. | [DB06144] Sertindole: The therapeutic efficacy of Insulin human can be decreased when used in combination with Sertindole. | [DB06288] Amisulpride: The therapeutic efficacy of Insulin human can be decreased when used in combination with Amisulpride. | [DB08922] Perospirone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Perospirone. | [DB09223] Blonanserin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Blonanserin. | [DB09224] Melperone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Melperone. | [DB09225] Zotepine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Zotepine. | [DB09226] Brilaroxazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Brilaroxazine. | [DB14185] Aripiprazole lauroxil: The therapeutic efficacy of Insulin human can be decreased when used in combination with Aripiprazole lauroxil. | [DB00384] Triamterene: The therapeutic efficacy of Insulin human can be decreased when used in combination with Triamterene. | [DB00421] Spironolactone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Spironolactone. | [DB00594] Amiloride: The therapeutic efficacy of Insulin human can be decreased when used in combination with Amiloride. | [DB00700] Eplerenone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Eplerenone. | [DB00742] Mannitol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Mannitol. | [DB00872] Conivaptan: The therapeutic efficacy of Insulin human can be decreased when used in combination with Conivaptan. | [DB01345] Potassium cation: The therapeutic efficacy of Insulin human can be decreased when used in combination with Potassium cation. | [DB01412] Theobromine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Theobromine. | [DB04831] Tienilic acid: The therapeutic efficacy of Insulin human can be decreased when used in combination with Tienilic acid. | [DB05034] Ularitide: The therapeutic efficacy of Insulin human can be decreased when used in combination with Ularitide. | [DB06212] Tolvaptan: The therapeutic efficacy of Insulin human can be decreased when used in combination with Tolvaptan. | [DB09015] Canrenoic acid: The therapeutic efficacy of Insulin human can be decreased when used in combination with Canrenoic acid. | [DB09125] Potassium citrate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Potassium citrate. | [DB09338] Mersalyl: The therapeutic efficacy of Insulin human can be decreased when used in combination with Mersalyl. | [DB09401] Isosorbide: The therapeutic efficacy of Insulin human can be decreased when used in combination with Isosorbide. | [DB12221] Canrenone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Canrenone. | [DB12670] Rolofylline: The therapeutic efficacy of Insulin human can be decreased when used in combination with Rolofylline. | [DB12704] Spiradoline: The therapeutic efficacy of Insulin human can be decreased when used in combination with Spiradoline. | [DB12766] Cicletanine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Cicletanine. | [DB13316] Ibopamine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Ibopamine. | [DB13801] Muzolimine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Muzolimine. | [DB14018] Bromotheophylline: The therapeutic efficacy of Insulin human can be decreased when used in combination with Bromotheophylline. | [DB14500] Potassium: The therapeutic efficacy of Insulin human can be decreased when used in combination with Potassium. | [DB15959] Tripamide: The therapeutic efficacy of Insulin human can be decreased when used in combination with Tripamide. | [DB00255] Diethylstilbestrol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Diethylstilbestrol. | [DB00269] Chlorotrianisene: The therapeutic efficacy of Insulin human can be decreased when used in combination with Chlorotrianisene. | [DB00286] Conjugated estrogens: The therapeutic efficacy of Insulin human can be decreased when used in combination with Conjugated estrogens. | [DB00655] Estrone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Estrone. | [DB00890] Dienestrol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Dienestrol. | [DB04573] Estriol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Estriol. | [DB04575] Quinestrol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Quinestrol. | [DB07931] Hexestrol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Hexestrol. | [DB09070] Tibolone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Tibolone. | [DB09317] Synthetic Conjugated Estrogens, A: The therapeutic efficacy of Insulin human can be decreased when used in combination with Synthetic Conjugated Estrogens, A. | [DB09318] Synthetic Conjugated Estrogens, B: The therapeutic efficacy of Insulin human can be decreased when used in combination with Synthetic Conjugated Estrogens, B. | [DB09369] Polyestradiol phosphate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Polyestradiol phosphate. | [DB09381] Esterified estrogens: The therapeutic efficacy of Insulin human can be decreased when used in combination with Esterified estrogens. | [DB11478] Zeranol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Zeranol. | [DB11674] Equol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Equol. | [DB12487] Promestriene: The therapeutic efficacy of Insulin human can be decreased when used in combination with Promestriene. | [DB13143] Methallenestril: The therapeutic efficacy of Insulin human can be decreased when used in combination with Methallenestril. | [DB13386] Epimestrol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Epimestrol. | [DB13418] Moxestrol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Moxestrol. | [DB13952] Estradiol acetate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Estradiol acetate. | [DB13953] Estradiol benzoate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Estradiol benzoate. | [DB13954] Estradiol cypionate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Estradiol cypionate. | [DB13956] Estradiol valerate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Estradiol valerate. | [DB15334] Biochanin A: The therapeutic efficacy of Insulin human can be decreased when used in combination with Biochanin A. | [DB15335] Formononetin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Formononetin. | [DB06730] Gestodene: The therapeutic efficacy of Insulin human can be decreased when used in combination with Gestodene. | [DB09371] Norethynodrel: The therapeutic efficacy of Insulin human can be decreased when used in combination with Norethynodrel. | [DB09389] Norgestrel: The therapeutic efficacy of Insulin human can be decreased when used in combination with Norgestrel. | [DB11619] Gestrinone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Gestrinone. | [DB12474] Lynestrenol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Lynestrenol. | [DB13310] Ormeloxifene: The therapeutic efficacy of Insulin human can be decreased when used in combination with Ormeloxifene. | [DB13528] Chlormadinone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Chlormadinone. | [DB13563] Norgestrienone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Norgestrienone. | [DB13685] Quingestanol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Quingestanol. | [DB13857] Demegestone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Demegestone. | [DB13981] Nomegestrol acetate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Nomegestrol acetate. | [DB14678] Norethindrone enanthate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Norethindrone enanthate. | [DB00372] Thiethylperazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Thiethylperazine. | [DB00420] Promazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Promazine. | [DB00433] Prochlorperazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Prochlorperazine. | [DB00508] Triflupromazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Triflupromazine. | [DB00623] Fluphenazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Fluphenazine. | [DB00679] Thioridazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Thioridazine. | [DB00680] Moricizine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Moricizine. | [DB00831] Trifluoperazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Trifluoperazine. | [DB00850] Perphenazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Perphenazine. | [DB00933] Mesoridazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Mesoridazine. | [DB01063] Acetophenazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Acetophenazine. | [DB01069] Promethazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Promethazine. | [DB01246] Alimemazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Alimemazine. | [DB01608] Periciazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Periciazine. | [DB01614] Acepromazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Acepromazine. | [DB01615] Aceprometazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Aceprometazine. | [DB01622] Thioproperazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Thioproperazine. | [DB05687] BL-1020: The therapeutic efficacy of Insulin human can be decreased when used in combination with BL-1020. | [DB09000] Cyamemazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Cyamemazine. | [DB11540] Propiopromazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Propiopromazine. | [DB12710] Perazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Perazine. | [DB13213] Butaperazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Butaperazine. | [DB13382] Chlorproethazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Chlorproethazine. | [DB13420] Thiazinam: The therapeutic efficacy of Insulin human can be decreased when used in combination with Thiazinam. | [DB13784] Dixyrazine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Dixyrazine. | [DB14651] Perphenazine enanthate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Perphenazine enanthate. | [DB00017] Salmon calcitonin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Salmon calcitonin. | [DB00066] Follitropin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Follitropin. | [DB00389] Carbimazole: The therapeutic efficacy of Insulin human can be decreased when used in combination with Carbimazole. | [DB00550] Propylthiouracil: The therapeutic efficacy of Insulin human can be decreased when used in combination with Propylthiouracil. | [DB00763] Methimazole: The therapeutic efficacy of Insulin human can be decreased when used in combination with Methimazole. | [DB03374] 3,5-Diiodotyrosine: The therapeutic efficacy of Insulin human can be decreased when used in combination with 3,5-Diiodotyrosine. | [DB05829] Parathyroid hormone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Parathyroid hormone. | [DB06285] Teriparatide: The therapeutic efficacy of Insulin human can be decreased when used in combination with Teriparatide. | [DB06715] Potassium Iodide: The therapeutic efficacy of Insulin human can be decreased when used in combination with Potassium Iodide. | [DB07637] Dibromotyrosine: The therapeutic efficacy of Insulin human can be decreased when used in combination with Dibromotyrosine. | [DB09418] Potassium perchlorate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Potassium perchlorate. | [DB09421] Protirelin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Protirelin. | [DB12629] 3,5-diiodothyropropionic acid: The therapeutic efficacy of Insulin human can be decreased when used in combination with 3,5-diiodothyropropionic acid. | [DB13644] Methylthiouracil: The therapeutic efficacy of Insulin human can be decreased when used in combination with Methylthiouracil. | [DB13742] Elcatonin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Elcatonin. | [DB13804] Benzylthiouracil: The therapeutic efficacy of Insulin human can be decreased when used in combination with Benzylthiouracil. | [DB15263] Thyrotropin: The therapeutic efficacy of Insulin human can be decreased when used in combination with Thyrotropin. | [DB00898] Ethanol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Ethanol. | [DB14506] Lithium hydroxide: The therapeutic efficacy of Insulin human can be increased when used in combination with Lithium hydroxide. | [DB14507] Lithium citrate: The therapeutic efficacy of Insulin human can be increased when used in combination with Lithium citrate. | [DB14509] Lithium carbonate: The therapeutic efficacy of Insulin human can be decreased when used in combination with Lithium carbonate. | [DB16607] Lithium chloride: The therapeutic efficacy of Insulin human can be increased when used in combination with Lithium chloride. | [DB00575] Clonidine: The therapeutic efficacy of Insulin human can be increased when used in combination with Clonidine. | [DB15775] Algestone acetophenide: The therapeutic efficacy of Insulin human can be decreased when used in combination with Algestone acetophenide. | [DB01001] Albuterol: The therapeutic efficacy of Insulin human can be decreased when used in combination with Salbutamol. | [DB00871] Terbutaline: The therapeutic efficacy of Insulin human can be decreased when used in combination with Terbutaline. | [DB12214] Luseogliflozin: The risk or severity of hypoglycemia can be increased when Luseogliflozin is combined with Insulin human. | [DB16165] Finerenone: The therapeutic efficacy of Insulin human can be decreased when used in combination with Finerenone. | [DB09368] Corticotropin zinc hydroxide: The risk or severity of hyperglycemia can be increased when Corticotropin zinc hydroxide is combined with Insulin human. | [DB15777] Fluocortolone pivalate: The risk or severity of hyperglycemia can be increased when Fluocortolone pivalate is combined with Insulin human. | [DB15821] Fluocortolone caproate: The risk or severity of hyperglycemia can be increased when Fluocortolone caproate is combined with Insulin human. | [DB15972] Desoxycortone: The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Insulin human. | [DB12236] Bexagliflozin: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Bexagliflozin. | [DB12548] Sparsentan: The risk or severity of hypoglycemia can be increased when Sparsentan is combined with Insulin human. | [DB15097] Gefapixant: The risk or severity of hypoglycemia can be increased when Gefapixant is combined with Insulin human. | [DB00580] Valdecoxib: The risk or severity of hypoglycemia can be increased when Valdecoxib is combined with Insulin human. | [DB15114] Vamorolone: The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Insulin human. | [DB06267] Udenafil: The risk or severity of hypoglycemia can be increased when Udenafil is combined with Insulin human. | [DB08329] Sulthiame: The risk or severity of hypoglycemia can be increased when Sulthiame is combined with Insulin human. | [DB12500] Fedratinib: The risk or severity of hypoglycemia can be increased when Fedratinib is combined with Insulin human. | [DB18676] Palopegteriparatide: The therapeutic efficacy of Insulin human can be decreased when used in combination with Palopegteriparatide. | [DB16693] Insulin icodec: The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin icodec. | [DB15212] Pemafibrate: The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Insulin human.",1 IU/ml; 1 UI/mL; 1 mg; 1 mg/1; 1 unit / mL; 1.00 [iU]/1mL; 100; 100 I.E./ML; 100 IE; 100 IE/ML; 100 IU; 100 IU/ML; 100 IU/mL; 100 IU/ml; 100 U/ML; 100 UI; 100 UI/ML; 100 UI/ml; 100 [USP'U]/1mL; 100 [iU]/1mL; 100 iu/1ml; 100 iu/ml; 100 unit / mL; 100 unit/mL; 100 units/mL; 100.00 UI; 100.000 UI; 1000 IU; 10000000 IU; 12 [arb'U]/1; 3 ML; 3 mg/1; 30 iu/1mL; 300 IU; 300 IU/ml; 4 1/1; 4 [arb'U]/1; 40 IE/ML; 40 IU/ML; 40 IU/ml; 40 UI/ML; 40 iu/ml; 40 units/mL; 400 IU/ml; 500 [iU]/1mL; 500 unit / mL; 70 IU/ml; 8 1/1; 8 [arb'U]/1,Avoid alcohol. Alcohol may impair blood glucose control.
DB00315,Zolmitriptan,ANALGESICS; ANTIMIGRAINE PREPARATIONS; NERVOUS SYSTEM; Selective serotonin (5HT1) agonists,"[DB01097] Leflunomide: The serum concentration of Zolmitriptan can be decreased when it is combined with Leflunomide. | [DB08880] Teriflunomide: The serum concentration of Zolmitriptan can be decreased when it is combined with Teriflunomide. | [DB00177] Valsartan: Zolmitriptan may decrease the antihypertensive activities of Valsartan. | [DB00178] Ramipril: Zolmitriptan may decrease the antihypertensive activities of Ramipril. | [DB00187] Esmolol: Zolmitriptan may decrease the antihypertensive activities of Esmolol. | [DB00212] Remikiren: Zolmitriptan may decrease the antihypertensive activities of Remikiren. | [DB00214] Torasemide: Zolmitriptan may decrease the antihypertensive activities of Torasemide. | [DB00226] Guanadrel: Zolmitriptan may decrease the antihypertensive activities of Guanadrel. | [DB00264] Metoprolol: Zolmitriptan may decrease the antihypertensive activities of Metoprolol. | [DB00270] Isradipine: Zolmitriptan may decrease the antihypertensive activities of Isradipine. | [DB00275] Olmesartan: Zolmitriptan may decrease the antihypertensive activities of Olmesartan. | [DB00310] Chlorthalidone: Zolmitriptan may decrease the antihypertensive activities of Chlorthalidone. | [DB00325] Nitroprusside: Zolmitriptan may decrease the antihypertensive activities of Nitroprusside. | [DB00335] Atenolol: Zolmitriptan may decrease the antihypertensive activities of Atenolol. | [DB00343] Diltiazem: Zolmitriptan may decrease the antihypertensive activities of Diltiazem. | [DB00350] Minoxidil: Zolmitriptan may decrease the antihypertensive activities of Minoxidil. | [DB00373] Timolol: Zolmitriptan may decrease the antihypertensive activities of Timolol. | [DB00374] Treprostinil: Zolmitriptan may decrease the antihypertensive activities of Treprostinil. | [DB00381] Amlodipine: Zolmitriptan may decrease the antihypertensive activities of Amlodipine. | [DB00393] Nimodipine: Zolmitriptan may decrease the antihypertensive activities of Nimodipine. | [DB00401] Nisoldipine: Zolmitriptan may decrease the antihypertensive activities of Nisoldipine. | [DB00436] Bendroflumethiazide: Zolmitriptan may decrease the antihypertensive activities of Bendroflumethiazide. | [DB00457] Prazosin: Zolmitriptan may decrease the antihypertensive activities of Prazosin. | [DB00492] Fosinopril: Zolmitriptan may decrease the antihypertensive activities of Fosinopril. | [DB00519] Trandolapril: Zolmitriptan may decrease the antihypertensive activities of Trandolapril. | [DB00524] Metolazone: Zolmitriptan may decrease the antihypertensive activities of Metolazone. | [DB00528] Lercanidipine: Zolmitriptan may decrease the antihypertensive activities of Lercanidipine. | [DB00542] Benazepril: Zolmitriptan may decrease the antihypertensive activities of Benazepril. | [DB00559] Bosentan: Zolmitriptan may decrease the antihypertensive activities of Bosentan. | [DB00584] Enalapril: Zolmitriptan may decrease the antihypertensive activities of Enalapril. | [DB00590] Doxazosin: Zolmitriptan may decrease the antihypertensive activities of Doxazosin. | [DB00598] Labetalol: Zolmitriptan may decrease the antihypertensive activities of Labetalol. | [DB00606] Cyclothiazide: Zolmitriptan may decrease the antihypertensive activities of Cyclothiazide. | [DB00612] Bisoprolol: Zolmitriptan may decrease the antihypertensive activities of Bisoprolol. | [DB00616] Candoxatril: Zolmitriptan may decrease the antihypertensive activities of Candoxatril. | [DB00657] Mecamylamine: Zolmitriptan may decrease the antihypertensive activities of Mecamylamine. | [DB00678] Losartan: Zolmitriptan may decrease the antihypertensive activities of Losartan. | [DB00691] Moexipril: Zolmitriptan may decrease the antihypertensive activities of Moexipril. | [DB00700] Eplerenone: Zolmitriptan may decrease the antihypertensive activities of Eplerenone. | [DB00722] Lisinopril: Zolmitriptan may decrease the antihypertensive activities of Lisinopril. | [DB00727] Nitroglycerin: Zolmitriptan may decrease the antihypertensive activities of Nitroglycerin. | [DB00774] Hydroflumethiazide: Zolmitriptan may decrease the antihypertensive activities of Hydroflumethiazide. | [DB00785] Cryptenamine: Zolmitriptan may decrease the antihypertensive activities of Cryptenamine. | [DB00790] Perindopril: Zolmitriptan may decrease the antihypertensive activities of Perindopril. | [DB00796] Candesartan cilexetil: Zolmitriptan may decrease the antihypertensive activities of Candesartan cilexetil. | [DB00800] Fenoldopam: Zolmitriptan may decrease the antihypertensive activities of Fenoldopam. | [DB00808] Indapamide: Zolmitriptan may decrease the antihypertensive activities of Indapamide. | [DB00820] Tadalafil: Zolmitriptan may decrease the antihypertensive activities of Tadalafil. | [DB00876] Eprosartan: Zolmitriptan may decrease the antihypertensive activities of Eprosartan. | [DB00880] Chlorothiazide: Zolmitriptan may decrease the antihypertensive activities of Chlorothiazide. | [DB00881] Quinapril: Zolmitriptan may decrease the antihypertensive activities of Quinapril. | [DB00966] Telmisartan: Zolmitriptan may decrease the antihypertensive activities of Telmisartan. | [DB00968] Methyldopa: Zolmitriptan may decrease the antihypertensive activities of Methyldopa. | [DB00999] Hydrochlorothiazide: Zolmitriptan may decrease the antihypertensive activities of Hydrochlorothiazide. | [DB01021] Trichlormethiazide: Zolmitriptan may decrease the antihypertensive activities of Trichlormethiazide. | [DB01023] Felodipine: Zolmitriptan may decrease the antihypertensive activities of Felodipine. | [DB01029] Irbesartan: Zolmitriptan may decrease the antihypertensive activities of Irbesartan. | [DB01054] Nitrendipine: Zolmitriptan may decrease the antihypertensive activities of Nitrendipine. | [DB01089] Deserpidine: Zolmitriptan may decrease the antihypertensive activities of Deserpidine. | [DB01090] Pentolinium: Zolmitriptan may decrease the antihypertensive activities of Pentolinium. | [DB01116] Trimethaphan: Zolmitriptan may decrease the antihypertensive activities of Trimethaphan. | [DB01119] Diazoxide: Zolmitriptan may decrease the antihypertensive activities of Diazoxide. | [DB01158] Bretylium: Zolmitriptan may decrease the antihypertensive activities of Bretylium. | [DB01162] Terazosin: Zolmitriptan may decrease the antihypertensive activities of Terazosin. | [DB01170] Guanethidine: Zolmitriptan may decrease the antihypertensive activities of Guanethidine. | [DB01193] Acebutolol: Zolmitriptan may decrease the antihypertensive activities of Acebutolol. | [DB01197] Captopril: Zolmitriptan may decrease the antihypertensive activities of Captopril. | [DB01203] Nadolol: Zolmitriptan may decrease the antihypertensive activities of Nadolol. | [DB01240] Epoprostenol: Zolmitriptan may decrease the antihypertensive activities of Epoprostenol. | [DB01244] Bepridil: Zolmitriptan may decrease the antihypertensive activities of Bepridil. | [DB01275] Hydralazine: Zolmitriptan may decrease the antihypertensive activities of Hydralazine. | [DB01295] Bevantolol: Zolmitriptan may decrease the antihypertensive activities of Bevantolol. | [DB01297] Practolol: Zolmitriptan may decrease the antihypertensive activities of Practolol. | [DB01324] Polythiazide: Zolmitriptan may decrease the antihypertensive activities of Polythiazide. | [DB01340] Cilazapril: Zolmitriptan may decrease the antihypertensive activities of Cilazapril. | [DB01347] Saprisartan: Zolmitriptan may decrease the antihypertensive activities of Saprisartan. | [DB01348] Spirapril: Zolmitriptan may decrease the antihypertensive activities of Spirapril. | [DB03322] Dexpropranolol: Zolmitriptan may decrease the antihypertensive activities of Dexpropranolol. | [DB04831] Tienilic acid: Zolmitriptan may decrease the antihypertensive activities of Tienilic acid. | [DB04840] Debrisoquine: Zolmitriptan may decrease the antihypertensive activities of Debrisoquine. | [DB04846] Celiprolol: Zolmitriptan may decrease the antihypertensive activities of Celiprolol. | [DB04861] Nebivolol: Zolmitriptan may decrease the antihypertensive activities of Nebivolol. | [DB06268] Sitaxentan: Zolmitriptan may decrease the antihypertensive activities of Sitaxentan. | [DB06403] Ambrisentan: Zolmitriptan may decrease the antihypertensive activities of Ambrisentan. | [DB06445] Diethylnorspermine: Zolmitriptan may decrease the antihypertensive activities of Diethylnorspermine. | [DB06712] Nilvadipine: Zolmitriptan may decrease the antihypertensive activities of Nilvadipine. | [DB06762] Pinacidil: Zolmitriptan may decrease the antihypertensive activities of Pinacidil. | [DB08808] Bupranolol: Zolmitriptan may decrease the antihypertensive activities of Bupranolol. | [DB08836] Temocapril: Zolmitriptan may decrease the antihypertensive activities of Temocapril. | [DB08931] Riociguat: Zolmitriptan may decrease the antihypertensive activities of Riociguat. | [DB08932] Macitentan: Zolmitriptan may decrease the antihypertensive activities of Macitentan. | [DB08952] Indenolol: Zolmitriptan may decrease the antihypertensive activities of Indenolol. | [DB09026] Aliskiren: Zolmitriptan may decrease the antihypertensive activities of Aliskiren. | [DB09206] Trimazosin: Zolmitriptan may decrease the antihypertensive activities of Trimazosin. | [DB09220] Nicorandil: Zolmitriptan may decrease the antihypertensive activities of Nicorandil. | [DB09235] Efonidipine: Zolmitriptan may decrease the antihypertensive activities of Efonidipine. | [DB09236] Lacidipine: Zolmitriptan may decrease the antihypertensive activities of Lacidipine. | [DB09238] Manidipine: Zolmitriptan may decrease the antihypertensive activities of Manidipine. | [DB09239] Niguldipine: Zolmitriptan may decrease the antihypertensive activities of Niguldipine. | [DB09363] Rauwolfia serpentina root: Zolmitriptan may decrease the antihypertensive activities of Rauwolfia serpentina root. | [DB09477] Enalaprilat: Zolmitriptan may decrease the antihypertensive activities of Enalaprilat. | [DB11362] Selexipag: Zolmitriptan may decrease the antihypertensive activities of Selexipag. | [DB11720] Angiotensin 1-7: Zolmitriptan may decrease the antihypertensive activities of Angiotensin 1-7. | [DB11770] Talinolol: Zolmitriptan may decrease the antihypertensive activities of Talinolol. | [DB11783] Imidapril: Zolmitriptan may decrease the antihypertensive activities of Imidapril. | [DB12054] BQ-123: Zolmitriptan may decrease the antihypertensive activities of BQ-123. | [DB12212] Landiolol: Zolmitriptan may decrease the antihypertensive activities of Landiolol. | [DB12766] Cicletanine: Zolmitriptan may decrease the antihypertensive activities of Cicletanine. | [DB13166] Zofenopril: Zolmitriptan may decrease the antihypertensive activities of Zofenopril. | [DB13211] Guanoxan: Zolmitriptan may decrease the antihypertensive activities of Guanoxan. | [DB13312] Delapril: Zolmitriptan may decrease the antihypertensive activities of Delapril. | [DB13374] Vincamine: Zolmitriptan may decrease the antihypertensive activities of Vincamine. | [DB13400] Linsidomine: Zolmitriptan may decrease the antihypertensive activities of Linsidomine. | [DB13410] Guanoxabenz: Zolmitriptan may decrease the antihypertensive activities of Guanoxabenz. | [DB13429] Tolonidine: Zolmitriptan may decrease the antihypertensive activities of Tolonidine. | [DB13435] Endralazine: Zolmitriptan may decrease the antihypertensive activities of Endralazine. | [DB13443] Esatenolol: Zolmitriptan may decrease the antihypertensive activities of Esatenolol. | [DB13452] Cadralazine: Zolmitriptan may decrease the antihypertensive activities of Cadralazine. | [DB13508] Cloranolol: Zolmitriptan may decrease the antihypertensive activities of Cloranolol. | [DB13532] Cyclopenthiazide: Zolmitriptan may decrease the antihypertensive activities of Cyclopenthiazide. | [DB13575] Bietaserpine: Zolmitriptan may decrease the antihypertensive activities of Bietaserpine. | [DB13604] Guanazodine: Zolmitriptan may decrease the antihypertensive activities of Guanazodine. | [DB13631] Methoserpidine: Zolmitriptan may decrease the antihypertensive activities of Methoserpidine. | [DB13757] Epanolol: Zolmitriptan may decrease the antihypertensive activities of Epanolol. | [DB13779] Guanoclor: Zolmitriptan may decrease the antihypertensive activities of Guanoclor. | [DB13801] Muzolimine: Zolmitriptan may decrease the antihypertensive activities of Muzolimine. | [DB13803] Xipamide: Zolmitriptan may decrease the antihypertensive activities of Xipamide. | [DB13919] Candesartan: Zolmitriptan may decrease the antihypertensive activities of Candesartan. | [DB14068] Dexniguldipine: Zolmitriptan may decrease the antihypertensive activities of Dexniguldipine. | [DB14094] Tocopherylquinone: Zolmitriptan may decrease the antihypertensive activities of Tocopherylquinone. | [DB14125] Benazeprilat: Zolmitriptan may decrease the antihypertensive activities of Benazeprilat. | [DB14207] Fosinoprilat: Zolmitriptan may decrease the antihypertensive activities of Fosinoprilat. | [DB14208] Ramiprilat: Zolmitriptan may decrease the antihypertensive activities of Ramiprilat. | [DB14213] Perindoprilat: Zolmitriptan may decrease the antihypertensive activities of Perindoprilat. | [DB14217] Quinaprilat: Zolmitriptan may decrease the antihypertensive activities of Quinaprilat. | [DB00695] Furosemide: Zolmitriptan may decrease the antihypertensive activities of Furosemide. | [DB09237] Levamlodipine: Zolmitriptan may decrease the antihypertensive activities of Levamlodipine. | [DB15861] Buthiazide: Zolmitriptan may decrease the antihypertensive activities of Buthiazide. | [DB08822] Azilsartan medoxomil: Zolmitriptan may decrease the antihypertensive activities of Azilsartan medoxomil. | [DB00921] Buprenorphine: Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. | [DB00366] Doxylamine: Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zolmitriptan. | [DB00470] Dronabinol: The metabolism of Zolmitriptan can be decreased when combined with Dronabinol. | [DB00450] Droperidol: Droperidol may increase the central nervous system depressant (CNS depressant) activities of Zolmitriptan. | [DB00956] Hydrocodone: Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. | [DB00557] Hydroxyzine: Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zolmitriptan. | [DB00653] Magnesium sulfate: The therapeutic efficacy of Zolmitriptan can be increased when used in combination with Magnesium sulfate. | [DB01403] Methotrimeprazine: Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. | [DB00765] Metyrosine: Zolmitriptan may increase the sedative activities of Metyrosine. | [DB01017] Minocycline: Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zolmitriptan. | [DB00486] Nabilone: Nabilone may increase the central nervous system depressant (CNS depressant) activities of Zolmitriptan. | [DB09117] Paraldehyde: Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. | [DB08883] Perampanel: Perampanel may increase the central nervous system depressant (CNS depressant) activities of Zolmitriptan. | [DB00413] Pramipexole: Zolmitriptan may increase the sedative activities of Pramipexole. | [DB00268] Ropinirole: Zolmitriptan may increase the sedative activities of Ropinirole. | [DB06201] Rufinamide: The risk or severity of adverse effects can be increased when Rufinamide is combined with Zolmitriptan. | [DB09072] Sodium oxybate: Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. | [DB09034] Suvorexant: Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. | [DB06204] Tapentadol: Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Zolmitriptan. | [DB01041] Thalidomide: Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. | [DB00425] Zolpidem: Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. | [DB00035] Desmopressin: The risk or severity of hypertension can be increased when Desmopressin is combined with Zolmitriptan. | [DB00091] Cyclosporine: The risk or severity of hypertension can be increased when Cyclosporine is combined with Zolmitriptan. | [DB00159] Icosapent: The risk or severity of hypertension can be increased when Icosapent is combined with Zolmitriptan. | [DB00211] Midodrine: The risk or severity of hypertension can be increased when Midodrine is combined with Zolmitriptan. | [DB00217] Bethanidine: Zolmitriptan may decrease the antihypertensive activities of Bethanidine. | [DB00221] Isoetharine: The risk or severity of hypertension can be increased when Isoetharine is combined with Zolmitriptan. | [DB00244] Mesalazine: The risk or severity of hypertension can be increased when Mesalazine is combined with Zolmitriptan. | [DB00328] Indomethacin: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Indomethacin. | [DB00368] Norepinephrine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Norepinephrine. | [DB00422] Methylphenidate: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Methylphenidate. | [DB00465] Ketorolac: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Ketorolac. | [DB00469] Tenoxicam: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Tenoxicam. | [DB00482] Celecoxib: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Celecoxib. | [DB00500] Tolmetin: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Tolmetin. | [DB00554] Piroxicam: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Piroxicam. | [DB00561] Doxapram: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Doxapram. | [DB00573] Fenoprofen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Fenoprofen. | [DB00580] Valdecoxib: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Valdecoxib. | [DB00605] Sulindac: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Sulindac. | [DB00610] Metaraminol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Metaraminol. | [DB00668] Epinephrine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Epinephrine. | [DB00692] Phentolamine: Zolmitriptan may decrease the antihypertensive activities of Phentolamine. | [DB00712] Flurbiprofen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Flurbiprofen. | [DB00723] Methoxamine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Methoxamine. | [DB00749] Etodolac: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Etodolac. | [DB00795] Sulfasalazine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Sulfasalazine. | [DB00797] Tolazoline: Zolmitriptan may decrease the antihypertensive activities of Tolazoline. | [DB00812] Phenylbutazone: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Phenylbutazone. | [DB00814] Meloxicam: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Meloxicam. | [DB00816] Orciprenaline: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Orciprenaline. | [DB00821] Carprofen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Carprofen. | [DB00830] Phenmetrazine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Phenmetrazine. | [DB00841] Dobutamine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Dobutamine. | [DB00861] Diflunisal: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Diflunisal. | [DB00867] Ritodrine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Ritodrine. | [DB00871] Terbutaline: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Terbutaline. | [DB00886] Omapatrilat: Zolmitriptan may decrease the antihypertensive activities of Omapatrilat. | [DB00901] Bitolterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Bitolterol. | [DB00925] Phenoxybenzamine: Zolmitriptan may decrease the antihypertensive activities of Phenoxybenzamine. | [DB00935] Oxymetazoline: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Oxymetazoline. | [DB00936] Salicylic acid: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Salicylic acid. | [DB00938] Salmeterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Salmeterol. | [DB00939] Meclofenamic acid: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Meclofenamic acid. | [DB00945] Acetylsalicylic acid: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Acetylsalicylic acid. | [DB00983] Formoterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Formoterol. | [DB00988] Dopamine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Dopamine. | [DB00991] Oxaprozin: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Oxaprozin. | [DB01001] Albuterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Salbutamol. | [DB01009] Ketoprofen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Ketoprofen. | [DB01014] Balsalazide: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Balsalazide. | [DB01050] Ibuprofen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Ibuprofen. | [DB01064] Isoprenaline: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Isoprenaline. | [DB01102] Arbutamine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Arbutamine. | [DB01126] Dutasteride: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Dutasteride. | [DB01180] Rescinnamine: Zolmitriptan may decrease the antihypertensive activities of Rescinnamine. | [DB01216] Finasteride: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Finasteride. | [DB01274] Arformoterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Arformoterol. | [DB01283] Lumiracoxib: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Lumiracoxib. | [DB01288] Fenoterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Fenoterol. | [DB01291] Pirbuterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Pirbuterol. | [DB01364] Ephedrine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Ephedrine. | [DB01366] Procaterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Procaterol. | [DB01397] Magnesium salicylate: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Magnesium salicylate. | [DB01399] Salsalate: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Salsalate. | [DB01401] Choline magnesium trisalicylate: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Choline magnesium trisalicylate. | [DB01407] Clenbuterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Clenbuterol. | [DB01408] Bambuterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Bambuterol. | [DB01419] Antrafenine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Antrafenine. | [DB01579] Phendimetrazine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Phendimetrazine. | [DB01600] Tiaprofenic acid: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Tiaprofenic acid. | [DB02032] Epicaptopril: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Epicaptopril. | [DB02224] Taxifolin: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Taxifolin. | [DB03585] Oxyphenbutazone: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Oxyphenbutazone. | [DB04581] 1-benzylimidazole: The risk or severity of hypertension can be increased when Zolmitriptan is combined with 1-benzylimidazole. | [DB04743] Nimesulide: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Nimesulide. | [DB04812] Benoxaprofen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Benoxaprofen. | [DB04817] Metamizole: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Metamizole. | [DB04828] Zomepirac: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Zomepirac. | [DB04855] Dronedarone: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Dronedarone. | [DB05039] Indacaterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Indacaterol. | [DB05095] Cimicoxib: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Cimicoxib. | [DB05395] Amibegron: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Amibegron. | [DB06152] Nylidrin: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Nylidrin. | [DB06190] Solabegron: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Solabegron. | [DB06694] Xylometazoline: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Xylometazoline. | [DB06706] Isometheptene: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Isometheptene. | [DB06707] Levonordefrin: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Levonordefrin. | [DB06711] Naphazoline: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Naphazoline. | [DB06725] Lornoxicam: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Lornoxicam. | [DB06736] Aceclofenac: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Aceclofenac. | [DB06737] Zaltoprofen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Zaltoprofen. | [DB06763] Saralasin: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Saralasin. | [DB06764] Tetryzoline: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Tetryzoline. | [DB07402] Azapropazone: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Azapropazone. | [DB08439] Parecoxib: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Parecoxib. | [DB08797] Salicylamide: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Salicylamide. | [DB08841] Tyramine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Tyramine. | [DB08893] Mirabegron: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Mirabegron. | [DB08925] Adrafinil: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Adrafinil. | [DB08940] Kebuzone: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Kebuzone. | [DB08941] Isoxsuprine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Isoxsuprine. | [DB08942] Isoxicam: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Isoxicam. | [DB08950] Indoramin: Zolmitriptan may decrease the antihypertensive activities of Indoramin. | [DB08951] Indoprofen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Indoprofen. | [DB08955] Ibuproxam: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Ibuproxam. | [DB08957] Hexoprenaline: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Hexoprenaline. | [DB08976] Floctafenine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Floctafenine. | [DB08981] Fenbufen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Fenbufen. | [DB08984] Etofenamate: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Etofenamate. | [DB08985] Etilefrine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Etilefrine. | [DB08991] Epirizole: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Epirizole. | [DB09080] Olodaterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Olodaterol. | [DB09082] Vilanterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Vilanterol. | [DB09084] Benzydamine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Benzydamine. | [DB09202] Cirazoline: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Cirazoline. | [DB09203] Synephrine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Synephrine. | [DB09205] Moxisylyte: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Moxisylyte. | [DB09213] Dexibuprofen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Dexibuprofen. | [DB09214] Dexketoprofen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Dexketoprofen. | [DB09215] Droxicam: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Droxicam. | [DB09216] Tolfenamic acid: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Tolfenamic acid. | [DB09217] Firocoxib: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Firocoxib. | [DB09218] Clonixin: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Clonixin. | [DB09242] Moxonidine: Zolmitriptan may decrease the antihypertensive activities of Moxonidine. | [DB09285] Morniflumate: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Morniflumate. | [DB09295] Talniflumate: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Talniflumate. | [DB11124] Racepinephrine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Racepinephrine. | [DB11278] DL-Methylephedrine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with DL-Methylephedrine. | [DB11373] Amitraz: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Amitraz. | [DB11455] Robenacoxib: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Robenacoxib. | [DB11466] Tepoxalin: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Tepoxalin. | [DB11481] Atipamezole: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Atipamezole. | [DB11518] Flunixin: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Flunixin. | [DB11541] Ractopamine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Ractopamine. | [DB11587] Etafedrine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Etafedrine. | [DB11738] Rilmenidine: Zolmitriptan may decrease the antihypertensive activities of Rilmenidine. | [DB11785] Anisodamine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Anisodamine. | [DB11871] PF-00610355: The risk or severity of hypertension can be increased when Zolmitriptan is combined with PF-00610355. | [DB12092] Naftopidil: Zolmitriptan may decrease the antihypertensive activities of Naftopidil. | [DB12100] Abediterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Abediterol. | [DB12248] Tulobuterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Tulobuterol. | [DB12313] Dopexamine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Dopexamine. | [DB12371] Siponimod: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Siponimod. | [DB12445] Nitroaspirin: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Nitroaspirin. | [DB12545] Indobufen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Indobufen. | [DB12551] Idazoxan: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Idazoxan. | [DB12610] Ebselen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Ebselen. | [DB12779] Higenamine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Higenamine. | [DB12846] Reproterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Reproterol. | [DB13001] Tinoridine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Tinoridine. | [DB13064] Tramazoline: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Tramazoline. | [DB13139] Levosalbutamol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Levosalbutamol. | [DB13167] Alclofenac: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Alclofenac. | [DB13217] Fentiazac: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Fentiazac. | [DB13232] Suxibuzone: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Suxibuzone. | [DB13251] Octopamine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Octopamine. | [DB13286] Bumadizone: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Bumadizone. | [DB13314] Alminoprofen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Alminoprofen. | [DB13341] Fenozolone: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Fenozolone. | [DB13371] Difenpiramide: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Difenpiramide. | [DB13378] Norfenefrine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Norfenefrine. | [DB13398] Oxyfedrine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Oxyfedrine. | [DB13407] Nifenazone: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Nifenazone. | [DB13432] Lonazolac: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Lonazolac. | [DB13453] Xenon: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Xenon. | [DB13481] Tenidap: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Tenidap. | [DB13510] Buflomedil: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Buflomedil. | [DB13524] Propyphenazone: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Propyphenazone. | [DB13527] Proglumetacin: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Proglumetacin. | [DB13538] Guacetisal: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Guacetisal. | [DB13544] Ethenzamide: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Ethenzamide. | [DB13559] Rimiterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Rimiterol. | [DB13612] Carbaspirin calcium: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Carbaspirin calcium. | [DB13629] Mofebutazone: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Mofebutazone. | [DB13649] Proquazone: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Proquazone. | [DB13657] Benorilate: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Benorilate. | [DB13692] Tretoquinol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Tretoquinol. | [DB13722] Pirprofen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Pirprofen. | [DB13777] Prenalterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Prenalterol. | [DB13781] Xamoterol: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Xamoterol. | [DB13783] Acemetacin: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Acemetacin. | [DB13852] Mefenorex: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Mefenorex. | [DB13860] Imidazole salicylate: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Imidazole salicylate. | [DB13917] Deoxyepinephrine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Deoxyepinephrine. | [DB14059] SC-236: The risk or severity of hypertension can be increased when Zolmitriptan is combined with SC-236. | [DB14060] NS-398: The risk or severity of hypertension can be increased when Zolmitriptan is combined with NS-398. | [DB14231] Quinoline Yellow WS: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Quinoline Yellow WS. | [DB15685] Selpercatinib: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Selpercatinib. | [DB09212] Loxoprofen: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Loxoprofen. | [DB15965] Naxitamab: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Naxitamab. | [DB16629] Serdexmethylphenidate: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Serdexmethylphenidate. | [DB00289] Atomoxetine: The risk or severity of hypertension can be increased when Atomoxetine is combined with Zolmitriptan. | [DB04552] Niflumic acid: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Niflumic acid. | [DB06262] Droxidopa: Zolmitriptan may increase the hypertensive activities of Droxidopa. | [DB00008] Peginterferon alfa-2a: The metabolism of Zolmitriptan can be decreased when combined with Peginterferon alfa-2a. | [DB00011] Interferon alfa-n1: The metabolism of Zolmitriptan can be decreased when combined with Interferon alfa-n1. | [DB00018] Interferon alfa-n3: The metabolism of Zolmitriptan can be decreased when combined with Interferon alfa-n3. | [DB00022] Peginterferon alfa-2b: The metabolism of Zolmitriptan can be decreased when combined with Peginterferon alfa-2b. | [DB00033] Interferon gamma-1b: The metabolism of Zolmitriptan can be decreased when combined with Interferon gamma-1b. | [DB00034] Interferon alfa-2a: The metabolism of Zolmitriptan can be decreased when combined with Interferon alfa-2a. | [DB00060] Interferon beta-1a: The metabolism of Zolmitriptan can be decreased when combined with Interferon beta-1a. | [DB00068] Interferon beta-1b: The metabolism of Zolmitriptan can be decreased when combined with Interferon beta-1b. | [DB00069] Interferon alfacon-1: The metabolism of Zolmitriptan can be decreased when combined with Interferon alfacon-1. | [DB00105] Interferon alfa-2b: The metabolism of Zolmitriptan can be decreased when combined with Interferon alfa-2b. | [DB00201] Caffeine: The metabolism of Zolmitriptan can be decreased when combined with Caffeine. | [DB00208] Ticlopidine: The metabolism of Zolmitriptan can be decreased when combined with Ticlopidine. | [DB00218] Moxifloxacin: The metabolism of Zolmitriptan can be decreased when combined with Moxifloxacin. | [DB00261] Anagrelide: The metabolism of Zolmitriptan can be decreased when combined with Anagrelide. | [DB00281] Lidocaine: The metabolism of Zolmitriptan can be decreased when combined with Lidocaine. | [DB00286] Conjugated estrogens: The metabolism of Zolmitriptan can be decreased when combined with Conjugated estrogens. | [DB00313] Valproic acid: The metabolism of Zolmitriptan can be decreased when combined with Valproic acid. | [DB00365] Grepafloxacin: The metabolism of Zolmitriptan can be decreased when combined with Grepafloxacin. | [DB00379] Mexiletine: The metabolism of Zolmitriptan can be decreased when combined with Mexiletine. | [DB00412] Rosiglitazone: The metabolism of Zolmitriptan can be decreased when combined with Rosiglitazone. | [DB00420] Promazine: The metabolism of Zolmitriptan can be decreased when combined with Promazine. | [DB00435] Nitric Oxide: The metabolism of Zolmitriptan can be decreased when combined with Nitric Oxide. | [DB00458] Imipramine: The metabolism of Zolmitriptan can be decreased when combined with Imipramine. | [DB00467] Enoxacin: The metabolism of Zolmitriptan can be decreased when combined with Enoxacin. | [DB00487] Pefloxacin: The metabolism of Zolmitriptan can be decreased when combined with Pefloxacin. | [DB00533] Rofecoxib: The metabolism of Zolmitriptan can be decreased when combined with Rofecoxib. | [DB00537] Ciprofloxacin: The metabolism of Zolmitriptan can be decreased when combined with Ciprofloxacin. | [DB00553] Methoxsalen: The metabolism of Zolmitriptan can be decreased when combined with Methoxsalen. | [DB00564] Carbamazepine: The metabolism of Zolmitriptan can be decreased when combined with Carbamazepine. | [DB00625] Efavirenz: The metabolism of Zolmitriptan can be decreased when combined with Efavirenz. | [DB00633] Dexmedetomidine: The metabolism of Zolmitriptan can be decreased when combined with Dexmedetomidine. | [DB00685] Trovafloxacin: The metabolism of Zolmitriptan can be decreased when combined with Trovafloxacin. | [DB00730] Thiabendazole: The metabolism of Zolmitriptan can be decreased when combined with Thiabendazole. | [DB00763] Methimazole: The metabolism of Zolmitriptan can be decreased when combined with Methimazole. | [DB00779] Nalidixic acid: The metabolism of Zolmitriptan can be decreased when combined with Nalidixic acid. | [DB00817] Rosoxacin: The metabolism of Zolmitriptan can be decreased when combined with Rosoxacin. | [DB00818] Propofol: The metabolism of Zolmitriptan can be decreased when combined with Propofol. | [DB00827] Cinoxacin: The metabolism of Zolmitriptan can be decreased when combined with Cinoxacin. | [DB00863] Ranitidine: The metabolism of Zolmitriptan can be decreased when combined with Ranitidine. | [DB00908] Quinidine: The metabolism of Zolmitriptan can be decreased when combined with Quinidine. | [DB00951] Isoniazid: The metabolism of Zolmitriptan can be decreased when combined with Isoniazid. | [DB00969] Alosetron: The metabolism of Zolmitriptan can be decreased when combined with Alosetron. | [DB00978] Lomefloxacin: The metabolism of Zolmitriptan can be decreased when combined with Lomefloxacin. | [DB01026] Ketoconazole: The metabolism of Zolmitriptan can be decreased when combined with Ketoconazole. | [DB01044] Gatifloxacin: The metabolism of Zolmitriptan can be decreased when combined with Gatifloxacin. | [DB01056] Tocainide: The metabolism of Zolmitriptan can be decreased when combined with Tocainide. | [DB01059] Norfloxacin: The metabolism of Zolmitriptan can be decreased when combined with Norfloxacin. | [DB01079] Tegaserod: The metabolism of Zolmitriptan can be decreased when combined with Tegaserod. | [DB01118] Amiodarone: The metabolism of Zolmitriptan can be decreased when combined with Amiodarone. | [DB01137] Levofloxacin: The metabolism of Zolmitriptan can be decreased when combined with Levofloxacin. | [DB01155] Gemifloxacin: The metabolism of Zolmitriptan can be decreased when combined with Gemifloxacin. | [DB01165] Ofloxacin: The metabolism of Zolmitriptan can be decreased when combined with Ofloxacin. | [DB01173] Orphenadrine: The metabolism of Zolmitriptan can be decreased when combined with Orphenadrine. | [DB01182] Propafenone: The metabolism of Zolmitriptan can be decreased when combined with Propafenone. | [DB01208] Sparfloxacin: The metabolism of Zolmitriptan can be decreased when combined with Sparfloxacin. | [DB01241] Gemfibrozil: The metabolism of Zolmitriptan can be decreased when combined with Gemfibrozil. | [DB01388] Mibefradil: The metabolism of Zolmitriptan can be decreased when combined with Mibefradil. | [DB01405] Temafloxacin: The metabolism of Zolmitriptan can be decreased when combined with Temafloxacin. | [DB01609] Deferasirox: The metabolism of Zolmitriptan can be decreased when combined with Deferasirox. | [DB01645] Genistein: The metabolism of Zolmitriptan can be decreased when combined with Genistein. | [DB02709] Resveratrol: The metabolism of Zolmitriptan can be decreased when combined with Resveratrol. | [DB04574] Estrone sulfate: The metabolism of Zolmitriptan can be decreased when combined with Estrone sulfate. | [DB04951] Pirfenidone: The metabolism of Zolmitriptan can be decreased when combined with Pirfenidone. | [DB05258] Interferon alfa: The metabolism of Zolmitriptan can be decreased when combined with Interferon alfa. | [DB05396] Albinterferon Alfa-2B: The metabolism of Zolmitriptan can be decreased when combined with Albinterferon Alfa-2B. | [DB05488] Technetium Tc-99m ciprofloxacin: The metabolism of Zolmitriptan can be decreased when combined with Technetium Tc-99m ciprofloxacin. | [DB05812] Abiraterone: The serum concentration of Zolmitriptan can be increased when it is combined with Abiraterone. | [DB05990] Obeticholic acid: The metabolism of Zolmitriptan can be decreased when combined with Obeticholic acid. | [DB06160] Garenoxacin: The metabolism of Zolmitriptan can be decreased when combined with Garenoxacin. | [DB06290] Simeprevir: The metabolism of Zolmitriptan can be decreased when combined with Simeprevir. | [DB06600] Nemonoxacin: The metabolism of Zolmitriptan can be decreased when combined with Nemonoxacin. | [DB06803] Niclosamide: The metabolism of Zolmitriptan can be decreased when combined with Niclosamide. | [DB08972] Flumequine: The metabolism of Zolmitriptan can be decreased when combined with Flumequine. | [DB09118] Stiripentol: The metabolism of Zolmitriptan can be decreased when combined with Stiripentol. | [DB09167] Dosulepin: The metabolism of Zolmitriptan can be decreased when combined with Dosulepin. | [DB09185] Viloxazine: The metabolism of Zolmitriptan can be decreased when combined with Viloxazine. | [DB09198] Lobeglitazone: The metabolism of Zolmitriptan can be decreased when combined with Lobeglitazone. | [DB11198] Peppermint oil: The metabolism of Zolmitriptan can be decreased when combined with Peppermint oil. | [DB11404] Enrofloxacin: The metabolism of Zolmitriptan can be decreased when combined with Enrofloxacin. | [DB11443] Orbifloxacin: The metabolism of Zolmitriptan can be decreased when combined with Orbifloxacin. | [DB11491] Sarafloxacin: The metabolism of Zolmitriptan can be decreased when combined with Sarafloxacin. | [DB11511] Difloxacin: The metabolism of Zolmitriptan can be decreased when combined with Difloxacin. | [DB11774] Pazufloxacin: The metabolism of Zolmitriptan can be decreased when combined with Pazufloxacin. | [DB11892] Prulifloxacin: The metabolism of Zolmitriptan can be decreased when combined with Prulifloxacin. | [DB11994] Diacerein: The metabolism of Zolmitriptan can be decreased when combined with Diacerein. | [DB12245] Triclabendazole: The metabolism of Zolmitriptan can be decreased when combined with Triclabendazole. | [DB12332] Rucaparib: The metabolism of Zolmitriptan can be decreased when combined with Rucaparib. | [DB12814] Cepeginterferon alfa-2B: The metabolism of Zolmitriptan can be decreased when combined with Cepeginterferon alfa-2B. | [DB12945] Dihydralazine: The metabolism of Zolmitriptan can be decreased when combined with Dihydralazine. | [DB13174] Rhein: The metabolism of Zolmitriptan can be decreased when combined with Rhein. | [DB13261] Sitafloxacin: The metabolism of Zolmitriptan can be decreased when combined with Sitafloxacin. | [DB13772] Rufloxacin: The metabolism of Zolmitriptan can be decreased when combined with Rufloxacin. | [DB13823] Pipemidic acid: The metabolism of Zolmitriptan can be decreased when combined with Pipemidic acid. | [DB13874] Enasidenib: The metabolism of Zolmitriptan can be decreased when combined with Enasidenib. | [DB13952] Estradiol acetate: The metabolism of Zolmitriptan can be decreased when combined with Estradiol acetate. | [DB13953] Estradiol benzoate: The metabolism of Zolmitriptan can be decreased when combined with Estradiol benzoate. | [DB13954] Estradiol cypionate: The metabolism of Zolmitriptan can be decreased when combined with Estradiol cypionate. | [DB13955] Estradiol dienanthate: The metabolism of Zolmitriptan can be decreased when combined with Estradiol dienanthate. | [DB13956] Estradiol valerate: The metabolism of Zolmitriptan can be decreased when combined with Estradiol valerate. | [DB13975] Black cohosh: The metabolism of Zolmitriptan can be decreased when combined with Black cohosh. | [DB14025] Clinafloxacin: The metabolism of Zolmitriptan can be decreased when combined with Clinafloxacin. | [DB14029] Furafylline: The metabolism of Zolmitriptan can be decreased when combined with Furafylline. | [DB15119] Ropeginterferon alfa-2b: The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Zolmitriptan. | [DB15131] Interferon alfa-2c: The metabolism of Zolmitriptan can be decreased when combined with Interferon alfa-2c. | [DB01115] Nifedipine: The metabolism of Zolmitriptan can be decreased when combined with Nifedipine. | [DB06442] Avasimibe: The metabolism of Zolmitriptan can be decreased when combined with Avasimibe. | [DB14635] Curcumin sulfate: The metabolism of Zolmitriptan can be decreased when combined with Curcumin sulfate. | [DB13878] Pibrentasvir: The metabolism of Zolmitriptan can be decreased when combined with Pibrentasvir. | [DB13879] Glecaprevir: The metabolism of Zolmitriptan can be decreased when combined with Glecaprevir. | [DB00783] Estradiol: The metabolism of Zolmitriptan can be decreased when combined with Estradiol. | [DB11837] Osilodrostat: The metabolism of Zolmitriptan can be decreased when combined with Osilodrostat. | [DB11791] Capmatinib: The metabolism of Zolmitriptan can be decreased when combined with Capmatinib. | [DB01072] Atazanavir: The metabolism of Zolmitriptan can be decreased when combined with Atazanavir. | [DB08912] Dabrafenib: The metabolism of Zolmitriptan can be decreased when combined with Dabrafenib. | [DB15442] Trilaciclib: The metabolism of Zolmitriptan can be decreased when combined with Trilaciclib. | [DB00571] Propranolol: The serum concentration of the active metabolites of Zolmitriptan can be reduced when Zolmitriptan is used in combination with Propranolol resulting in a loss in efficacy. | [DB00333] Methadone: The risk or severity of adverse effects can be increased when Methadone is combined with Zolmitriptan. | [DB00266] Dicoumarol: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Dicoumarol. | [DB00498] Phenindione: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Phenindione. | [DB00946] Phenprocoumon: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Phenprocoumon. | [DB03410] 4-hydroxycoumarin: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with 4-hydroxycoumarin. | [DB04665] Coumarin: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Coumarin. | [DB08794] Ethyl biscoumacetate: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ethyl biscoumacetate. | [DB13136] Fluindione: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluindione. | [DB13275] Clorindione: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Clorindione. | [DB13347] Diphenadione: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Diphenadione. | [DB13451] Tioclomarol: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tioclomarol. | [DB14055] (S)-Warfarin: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with (S)-Warfarin. | [DB09042] Tedizolid phosphate: The risk or severity of serotonin syndrome can be increased when Tedizolid phosphate is combined with Zolmitriptan. | [DB00370] Mirtazapine: Zolmitriptan may increase the serotonergic activities of Mirtazapine. | [DB04839] Cyproterone acetate: The metabolism of Zolmitriptan can be increased when combined with Cyproterone acetate. | [DB00898] Ethanol: Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Ethanol. | [DB00972] Azelastine: Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Azelastine. | [DB00484] Brimonidine: Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Zolmitriptan. | [DB09241] Methylene blue: Zolmitriptan may increase the serotonergic activities of Methylene blue. | [DB00572] Atropine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Atropine. | [DB00622] Nicardipine: Zolmitriptan may decrease the antihypertensive activities of Nicardipine. | [DB01591] Solifenacin: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Solifenacin. | [DB12278] Propiverine: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Propiverine. | [DB00540] Nortriptyline: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Nortriptyline. | [DB01151] Desipramine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Desipramine. | [DB00363] Clozapine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Clozapine. | [DB01198] Zopiclone: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Zopiclone. | [DB00206] Reserpine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Reserpine. | [DB00372] Thiethylperazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thiethylperazine. | [DB00391] Sulpiride: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sulpiride. | [DB00409] Remoxipride: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Remoxipride. | [DB00433] Prochlorperazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Prochlorperazine. | [DB00508] Triflupromazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Triflupromazine. | [DB00623] Fluphenazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluphenazine. | [DB00680] Moricizine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Moricizine. | [DB00933] Mesoridazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Mesoridazine. | [DB01063] Acetophenazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Acetophenazine. | [DB01239] Chlorprothixene: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Chlorprothixene. | [DB01246] Alimemazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Alimemazine. | [DB01608] Periciazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Periciazine. | [DB01614] Acepromazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Acepromazine. | [DB01615] Aceprometazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Aceprometazine. | [DB01618] Molindone: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Molindone. | [DB01621] Pipotiazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pipotiazine. | [DB01622] Thioproperazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thioproperazine. | [DB04872] Osanetant: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Osanetant. | [DB04888] Bifeprunox: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Bifeprunox. | [DB05687] BL-1020: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with BL-1020. | [DB06077] Lumateperone: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lumateperone. | [DB06288] Amisulpride: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amisulpride. | [DB08922] Perospirone: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Perospirone. | [DB08927] Amperozide: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amperozide. | [DB09000] Cyamemazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Cyamemazine. | [DB09224] Melperone: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Melperone. | [DB09226] Brilaroxazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Brilaroxazine. | [DB11376] Azaperone: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Azaperone. | [DB11540] Propiopromazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Propiopromazine. | [DB12093] Tetrahydropalmatine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tetrahydropalmatine. | [DB12273] Ecopipam: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ecopipam. | [DB12401] Bromperidol: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Bromperidol. | [DB12518] Raclopride: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Raclopride. | [DB12710] Perazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Perazine. | [DB12867] Benperidol: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Benperidol. | [DB12958] Prothipendyl: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Prothipendyl. | [DB13025] Tiapride: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tiapride. | [DB13213] Butaperazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Butaperazine. | [DB13256] Clothiapine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Clothiapine. | [DB13273] Sultopride: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sultopride. | [DB13382] Chlorproethazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Chlorproethazine. | [DB13403] Oxypertine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Oxypertine. | [DB13420] Thiazinam: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thiazinam. | [DB13523] Veralipride: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Veralipride. | [DB13552] Trifluperidol: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Trifluperidol. | [DB13554] Moperone: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Moperone. | [DB13557] Thiopropazate: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thiopropazate. | [DB13665] Fluanisone: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluanisone. | [DB13676] Mosapramine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Mosapramine. | [DB13784] Dixyrazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Dixyrazine. | [DB13791] Penfluridol: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Penfluridol. | [DB13841] Clopenthixol: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Clopenthixol. | [DB14651] Perphenazine enanthate: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Perphenazine enanthate. | [DB16021] Levosulpiride: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Levosulpiride. | [DB00794] Primidone: The metabolism of Zolmitriptan can be increased when combined with Primidone. | [DB01045] Rifampin: The metabolism of Zolmitriptan can be increased when combined with Rifampicin. | [DB00518] Albendazole: The metabolism of Zolmitriptan can be increased when combined with Albendazole. | [DB09195] Lorpiprazole: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lorpiprazole. | [DB00042] Botulinum toxin type B: The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Zolmitriptan. | [DB00083] Botulinum toxin type A: The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Zolmitriptan. | [DB00150] Tryptophan: The risk or severity of CNS depression can be increased when Tryptophan is combined with Zolmitriptan. | [DB00181] Baclofen: Baclofen may increase the central nervous system depressant (CNS depressant) activities of Zolmitriptan. | [DB00186] Lorazepam: The risk or severity of CNS depression can be increased when Lorazepam is combined with Zolmitriptan. | [DB00189] Ethchlorvynol: The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Zolmitriptan. | [DB00202] Succinylcholine: The risk or severity of CNS depression can be increased when Succinylcholine is combined with Zolmitriptan. | [DB00228] Enflurane: The risk or severity of CNS depression can be increased when Enflurane is combined with Zolmitriptan. | [DB00231] Temazepam: The risk or severity of CNS depression can be increased when Temazepam is combined with Zolmitriptan. | [DB00234] Reboxetine: The risk or severity of CNS depression can be increased when Reboxetine is combined with Zolmitriptan. | [DB00237] Butabarbital: The risk or severity of CNS depression can be increased when Butabarbital is combined with Zolmitriptan. | [DB00241] Butalbital: The risk or severity of CNS depression can be increased when Butalbital is combined with Zolmitriptan. | [DB00252] Phenytoin: The risk or severity of CNS depression can be increased when Phenytoin is combined with Zolmitriptan. | [DB00273] Topiramate: The risk or severity of CNS depression can be increased when Topiramate is combined with Zolmitriptan. | [DB00283] Clemastine: The risk or severity of CNS depression can be increased when Clemastine is combined with Zolmitriptan. | [DB00292] Etomidate: The risk or severity of CNS depression can be increased when Etomidate is combined with Zolmitriptan. | [DB00295] Morphine: The risk or severity of CNS depression can be increased when Morphine is combined with Zolmitriptan. | [DB00306] Talbutal: The risk or severity of CNS depression can be increased when Talbutal is combined with Zolmitriptan. | [DB00312] Pentobarbital: The risk or severity of CNS depression can be increased when Pentobarbital is combined with Zolmitriptan. | [DB00318] Codeine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Codeine. | [DB00323] Tolcapone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tolcapone. | [DB00327] Hydromorphone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Hydromorphone. | [DB00341] Cetirizine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cetirizine. | [DB00344] Protriptyline: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Protriptyline. | [DB00347] Trimethadione: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Trimethadione. | [DB00349] Clobazam: The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Zolmitriptan. | [DB00371] Meprobamate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Meprobamate. | [DB00377] Palonosetron: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Palonosetron. | [DB00404] Alprazolam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Alprazolam. | [DB00405] Dexbrompheniramine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dexbrompheniramine. | [DB00408] Loxapine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Loxapine. | [DB00416] Metocurine iodide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Metocurine iodide. | [DB00423] Methocarbamol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Methocarbamol. | [DB00427] Triprolidine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Triprolidine. | [DB00434] Cyproheptadine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cyproheptadine. | [DB00463] Metharbital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Metharbital. | [DB00474] Methohexital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Methohexital. | [DB00475] Chlordiazepoxide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Chlordiazepoxide. | [DB00483] Gallamine triethiodide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Gallamine triethiodide. | [DB00494] Entacapone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Entacapone. | [DB00497] Oxycodone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Oxycodone. | [DB00514] Dextromethorphan: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Dextromethorphan. | [DB00543] Amoxapine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amoxapine. | [DB00546] Adinazolam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Adinazolam. | [DB00555] Lamotrigine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Lamotrigine. | [DB00565] Cisatracurium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cisatracurium. | [DB00579] Mazindol: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Mazindol. | [DB00588] Fluticasone propionate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Fluticasone propionate. | [DB00593] Ethosuximide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ethosuximide. | [DB00599] Thiopental: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Thiopental. | [DB00604] Cisapride: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cisapride. | [DB00611] Butorphanol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Butorphanol. | [DB00617] Paramethadione: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Paramethadione. | [DB00628] Clorazepic acid: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Clorazepic acid. | [DB00645] Dyclonine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dyclonine. | [DB00647] Dextropropoxyphene: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dextropropoxyphene. | [DB00652] Pentazocine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pentazocine. | [DB00660] Metaxalone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Metaxalone. | [DB00662] Trimethobenzamide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Trimethobenzamide. | [DB00679] Thioridazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thioridazine. | [DB00683] Midazolam: The risk or severity of sedation and CNS depression can be increased when Midazolam is combined with Zolmitriptan. | [DB00690] Flurazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Flurazepam. | [DB00708] Sufentanil: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Sufentanil. | [DB00714] Apomorphine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Apomorphine. | [DB00726] Trimipramine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Trimipramine. | [DB00728] Rocuronium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Rocuronium. | [DB00732] Atracurium besylate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Atracurium besylate. | [DB00734] Risperidone: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Risperidone. | [DB00737] Meclizine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Meclizine. | [DB00747] Scopolamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Scopolamine. | [DB00748] Carbinoxamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Carbinoxamine. | [DB00753] Isoflurane: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Isoflurane. | [DB00754] Ethotoin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ethotoin. | [DB00757] Dolasetron: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dolasetron. | [DB00771] Clidinium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Clidinium. | [DB00776] Oxcarbazepine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Oxcarbazepine. | [DB00777] Propiomazine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Propiomazine. | [DB00801] Halazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Halazepam. | [DB00802] Alfentanil: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Alfentanil. | [DB00813] Fentanyl: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fentanyl. | [DB00819] Acetazolamide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Acetazolamide. | [DB00829] Diazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Diazepam. | [DB00832] Phensuximide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Phensuximide. | [DB00835] Brompheniramine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Brompheniramine. | [DB00837] Progabide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Progabide. | [DB00842] Oxazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Oxazepam. | [DB00843] Donepezil: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Donepezil. | [DB00844] Nalbuphine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Nalbuphine. | [DB00849] Methylphenobarbital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Methylphenobarbital. | [DB00854] Levorphanol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Levorphanol. | [DB00865] Benzphetamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Benzphetamine. | [DB00866] Alprenolol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Alprenolol. | [DB00875] Flupentixol: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Flupentixol. | [DB00889] Granisetron: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Granisetron. | [DB00897] Triazolam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Triazolam. | [DB00899] Remifentanil: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Remifentanil. | [DB00906] Tiagabine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tiagabine. | [DB00937] Diethylpropion: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Diethylpropion. | [DB00941] Hexafluronium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Hexafluronium. | [DB00949] Felbamate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Felbamate. | [DB00960] Pindolol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pindolol. | [DB00962] Zaleplon: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Zaleplon. | [DB00985] Dimenhydrinate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dimenhydrinate. | [DB00996] Gabapentin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Gabapentin. | [DB01018] Guanfacine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Guanfacine. | [DB01028] Methoxyflurane: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Methoxyflurane. | [DB01068] Clonazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Clonazepam. | [DB01069] Promethazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Promethazine. | [DB01075] Diphenhydramine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Diphenhydramine. | [DB01080] Vigabatrin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Vigabatrin. | [DB01081] Diphenoxylate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Diphenoxylate. | [DB01107] Methyprylon: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Methyprylon. | [DB01114] Chlorpheniramine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Chlorpheniramine. | [DB01121] Phenacemide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Phenacemide. | [DB01135] Doxacurium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Doxacurium. | [DB01154] Thiamylal: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Thiamylal. | [DB01156] Bupropion: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Bupropion. | [DB01159] Halothane: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Halothane. | [DB01176] Cyclizine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cyclizine. | [DB01178] Chlormezanone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Chlormezanone. | [DB01189] Desflurane: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Desflurane. | [DB01192] Oxymorphone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Oxymorphone. | [DB01199] Tubocurarine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tubocurarine. | [DB01202] Levetiracetam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Levetiracetam. | [DB01209] Dezocine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dezocine. | [DB01215] Estazolam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Estazolam. | [DB01219] Dantrolene: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dantrolene. | [DB01221] Ketamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ketamine. | [DB01224] Quetiapine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Quetiapine. | [DB01226] Mivacurium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Mivacurium. | [DB01227] Levacetylmethadol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Levacetylmethadol. | [DB01235] Levodopa: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Levodopa. | [DB01236] Sevoflurane: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Sevoflurane. | [DB01245] Decamethonium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Decamethonium. | [DB01267] Paliperidone: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Paliperidone. | [DB01323] St. John's Wort: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with St. John's Wort. | [DB01336] Metocurine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Metocurine. | [DB01337] Pancuronium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pancuronium. | [DB01338] Pipecuronium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pipecuronium. | [DB01339] Vecuronium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Vecuronium. | [DB01351] Amobarbital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Amobarbital. | [DB01352] Aprobarbital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Aprobarbital. | [DB01353] Butobarbital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Butobarbital. | [DB01354] Heptabarbital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Heptabarbital. | [DB01355] Hexobarbital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Hexobarbital. | [DB01356] Lithium cation: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lithium cation. | [DB01359] Penbutolol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Penbutolol. | [DB01392] Yohimbine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Yohimbine. | [DB01433] Methadyl acetate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Methadyl acetate. | [DB01437] Glutethimide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Glutethimide. | [DB01440] gamma-Hydroxybutyric acid: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with gamma-Hydroxybutyric acid. | [DB01445] Bufotenine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Bufotenine. | [DB01450] Dihydroetorphine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dihydroetorphine. | [DB01452] Diamorphine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Diamorphine. | [DB01454] Midomafetamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Midomafetamine. | [DB01463] Fencamfamin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Fencamfamin. | [DB01466] Ethylmorphine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ethylmorphine. | [DB01483] Barbital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Barbital. | [DB01484] 4-Bromo-2,5-dimethoxyamphetamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with 4-Bromo-2,5-dimethoxyamphetamine. | [DB01488] Dimethyltryptamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dimethyltryptamine. | [DB01489] Camazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Camazepam. | [DB01495] Dichloralphenazone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dichloralphenazone. | [DB01497] Etorphine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Etorphine. | [DB01501] Difenoxin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Difenoxin. | [DB01509] Tenamfetamine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tenamfetamine. | [DB01511] Delorazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Delorazepam. | [DB01529] Dextromoramide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dextromoramide. | [DB01531] Desomorphine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Desomorphine. | [DB01534] Chlorhexadol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Chlorhexadol. | [DB01535] Carfentanil: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Carfentanil. | [DB01544] Flunitrazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Flunitrazepam. | [DB01545] Ethyl loflazepate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ethyl loflazepate. | [DB01547] Drotebanol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Drotebanol. | [DB01551] Dihydrocodeine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dihydrocodeine. | [DB01553] Cloxazolam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cloxazolam. | [DB01555] Alphacetylmethadol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Alphacetylmethadol. | [DB01559] Clotiazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Clotiazepam. | [DB01560] Cathinone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cathinone. | [DB01563] Chloral hydrate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Chloral hydrate. | [DB01565] Dihydromorphine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dihydromorphine. | [DB01567] Fludiazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Fludiazepam. | [DB01580] Oxprenolol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Oxprenolol. | [DB01587] Ketazolam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ketazolam. | [DB01588] Prazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Prazepam. | [DB01589] Quazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Quazepam. | [DB01594] Cinolazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cinolazepam. | [DB01595] Nitrazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Nitrazepam. | [DB01616] Alverine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Alverine. | [DB01624] Zuclopenthixol: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Zuclopenthixol. | [DB01954] Rolipram: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Rolipram. | [DB02207] 7-Nitroindazole: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with 7-Nitroindazole. | [DB02234] S-Ethylisothiourea: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with S-Ethylisothiourea. | [DB02852] Domoic Acid: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Domoic Acid. | [DB02959] Oxitriptan: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Oxitriptan. | [DB03575] Phencyclidine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Phencyclidine. | [DB04165] Valpromide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Valpromide. | [DB04325] Phenethylamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Phenethylamine. | [DB04599] Aniracetam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Aniracetam. | [DB04819] Methapyrilene: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Methapyrilene. | [DB04821] Nomifensine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Nomifensine. | [DB04827] Urethane: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Urethane. | [DB04833] Methaqualone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Methaqualone. | [DB04834] Rapacuronium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Rapacuronium. | [DB04836] Amineptine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Amineptine. | [DB04842] Fluspirilene: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluspirilene. | [DB04885] Cilansetron: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cilansetron. | [DB04903] Pagoclone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pagoclone. | [DB04917] Renzapride: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Renzapride. | [DB04946] Iloperidone: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Iloperidone. | [DB04953] Ezogabine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ezogabine. | [DB05227] APD791: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with APD791. | [DB05232] Tetrodotoxin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tetrodotoxin. | [DB05246] Methsuximide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Methsuximide. | [DB05541] Brivaracetam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Brivaracetam. | [DB05542] Naronapride: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Naronapride. | [DB05607] PRX-08066: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with PRX-08066. | [DB05710] Gantacurium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Gantacurium. | [DB06109] YKP-1358: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with YKP-1358. | [DB06144] Sertindole: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sertindole. | [DB06153] Pizotifen: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pizotifen. | [DB06264] Tolperisone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tolperisone. | [DB06282] Levocetirizine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Levocetirizine. | [DB06283] Ziconotide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ziconotide. | [DB06446] Dotarizine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dotarizine. | [DB06458] Remacemide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Remacemide. | [DB06470] Clomethiazole: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Clomethiazole. | [DB06512] Deramciclane: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Deramciclane. | [DB06527] Tramiprosate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tramiprosate. | [DB06529] Ocinaplon: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ocinaplon. | [DB06554] Gaboxadol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Gaboxadol. | [DB06579] Adipiplon: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Adipiplon. | [DB06582] Dextofisopam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dextofisopam. | [DB06660] Saredutant: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Saredutant. | [DB06678] Esmirtazapine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Esmirtazapine. | [DB06690] Nitrous oxide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Nitrous oxide. | [DB06691] Mepyramine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Mepyramine. | [DB06701] Dexmethylphenidate: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Dexmethylphenidate. | [DB06716] Fospropofol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Fospropofol. | [DB06738] Ketobemidone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ketobemidone. | [DB06753] Triclofos: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Triclofos. | [DB06797] Mebutamate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Mebutamate. | [DB08059] Wortmannin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Wortmannin. | [DB08329] Sulthiame: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Sulthiame. | [DB08811] Tofisopam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tofisopam. | [DB08815] Lurasidone: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lurasidone. | [DB08839] Serotonin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Serotonin. | [DB08861] DPDPE: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with DPDPE. | [DB08872] Gabapentin enacarbil: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Gabapentin enacarbil. | [DB08892] Arbaclofen Placarbil: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Arbaclofen Placarbil. | [DB08954] Ifenprodil: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ifenprodil. | [DB08960] Hexamethonium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Hexamethonium. | [DB08986] Etifoxine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Etifoxine. | [DB08992] Eperisone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Eperisone. | [DB08996] Dimetacrine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dimetacrine. | [DB09001] Barbexaclone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Barbexaclone. | [DB09011] Beclamide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Beclamide. | [DB09014] Captodiame: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Captodiame. | [DB09016] Butriptyline: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Butriptyline. | [DB09017] Brotizolam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Brotizolam. | [DB09021] Benzoctamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Benzoctamine. | [DB09023] Benactyzine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Benactyzine. | [DB09119] Eslicarbazepine acetate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Eslicarbazepine acetate. | [DB09166] Etizolam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Etizolam. | [DB09174] Lofentanil: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Lofentanil. | [DB09184] Edivoxetine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Edivoxetine. | [DB09186] Nisoxetine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Nisoxetine. | [DB09187] Lortalamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Lortalamine. | [DB09190] Talopram: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Talopram. | [DB09194] Etoperidone: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Etoperidone. | [DB09223] Blonanserin: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Blonanserin. | [DB09247] Iproclozide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Iproclozide. | [DB09286] Pipamperone: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pipamperone. | [DB09289] Tianeptine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tianeptine. | [DB09307] Oxaprotiline: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Oxaprotiline. | [DB11130] Opium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Opium. | [DB11156] Pyrantel: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pyrantel. | [DB11371] Alfaxalone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Alfaxalone. | [DB11400] Doramectin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Doramectin. | [DB11428] Medetomidine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Medetomidine. | [DB11477] Xylazine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Xylazine. | [DB11543] Romifidine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Romifidine. | [DB11549] Tiletamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tiletamine. | [DB11552] Tricaine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tricaine. | [DB11555] Zolazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Zolazepam. | [DB11556] Detomidine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Detomidine. | [DB11582] Thiocolchicoside: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Thiocolchicoside. | [DB11609] Normethadone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Normethadone. | [DB11664] Psilocybin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Psilocybin. | [DB11675] Mosapride: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Mosapride. | [DB11686] Iferanserin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Iferanserin. | [DB11699] Tropisetron: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tropisetron. | [DB11859] Brexanolone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Brexanolone. | [DB11868] Etiracetam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Etiracetam. | [DB11889] Lanicemine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Lanicemine. | [DB11957] Idalopirdine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Idalopirdine. | [DB12071] Vabicaserin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Vabicaserin. | [DB12105] Imagabalin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Imagabalin. | [DB12110] m-Chlorophenylpiperazine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with m-Chlorophenylpiperazine. | [DB12111] MK-212: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with MK-212. | [DB12131] Vinpocetine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Vinpocetine. | [DB12163] Sarpogrelate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Sarpogrelate. | [DB12177] Eplivanserin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Eplivanserin. | [DB12184] Gepirone: The risk or severity of serotonin syndrome can be increased when Gepirone is combined with Zolmitriptan. | [DB12229] Cerlapirdine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cerlapirdine. | [DB12308] Eltanolone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Eltanolone. | [DB12327] Salvinorin A: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Salvinorin A. | [DB12338] Carisbamate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Carisbamate. | [DB12395] Esreboxetine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Esreboxetine. | [DB12427] Orvepitant: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Orvepitant. | [DB12492] Piritramide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Piritramide. | [DB12537] 1,2-Benzodiazepine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with 1,2-Benzodiazepine. | [DB12576] AZD-3043: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with AZD-3043. | [DB12590] Indiplon: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Indiplon. | [DB12661] Urapidil: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Urapidil. | [DB12725] Felcisetrag: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Felcisetrag. | [DB12833] Tandospirone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tandospirone. | [DB12883] Eltoprazine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Eltoprazine. | [DB12930] Opipramol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Opipramol. | [DB12951] Pivagabine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pivagabine. | [DB12989] Neosaxitoxin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Neosaxitoxin. | [DB13014] Hypericin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Hypericin. | [DB13082] Nefiracetam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Nefiracetam. | [DB13099] Valnoctamide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Valnoctamide. | [DB13114] Amitriptylinoxide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Amitriptylinoxide. | [DB13160] Alphaprodine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Alphaprodine. | [DB13219] Medifoxamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Medifoxamine. | [DB13221] Apronalide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Apronalide. | [DB13225] Dibenzepin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dibenzepin. | [DB13234] Propanidid: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Propanidid. | [DB13246] Quinupramine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Quinupramine. | [DB13253] Proxibarbal: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Proxibarbal. | [DB13295] Atracurium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Atracurium. | [DB13303] Febarbamate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Febarbamate. | [DB13323] Trichloroethylene: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Trichloroethylene. | [DB13324] Tetrazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tetrazepam. | [DB13331] Pyrithyldione: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pyrithyldione. | [DB13335] Pinazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pinazepam. | [DB13352] Deanol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Deanol. | [DB13354] Phenprobamate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Phenprobamate. | [DB13357] Styramate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Styramate. | [DB13362] Pheneturide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pheneturide. | [DB13370] Bromisoval: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Bromisoval. | [DB13377] Vinbarbital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Vinbarbital. | [DB13384] Melitracen: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Melitracen. | [DB13396] Neocitrullamon: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Neocitrullamon. | [DB13402] Acetylglycinamide chloral hydrate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Acetylglycinamide chloral hydrate. | [DB13411] Lofepramine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Lofepramine. | [DB13414] Fenyramidol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Fenyramidol. | [DB13437] Medazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Medazepam. | [DB13455] Phenibut: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Phenibut. | [DB13457] Oxaflozane: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Oxaflozane. | [DB13478] Meptazinol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Meptazinol. | [DB13496] Iprindole: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Iprindole. | [DB13505] Emepronium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Emepronium. | [DB13522] Mebicar: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Mebicar. | [DB13534] Gedocarnil: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Gedocarnil. | [DB13541] Iprazochrome: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Iprazochrome. | [DB13550] Bifemelane: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Bifemelane. | [DB13572] Emylcamate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Emylcamate. | [DB13577] Allobarbital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Allobarbital. | [DB13584] Gallamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Gallamine. | [DB13588] Naftidrofuryl: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Naftidrofuryl. | [DB13598] Diethyl ether: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Diethyl ether. | [DB13601] Oxiracetam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Oxiracetam. | [DB13605] Phenoperidine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Phenoperidine. | [DB13606] Phenazocine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Phenazocine. | [DB13623] Fabomotizole: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Fabomotizole. | [DB13642] Pridinol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pridinol. | [DB13643] Loprazolam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Loprazolam. | [DB13648] Alcuronium: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Alcuronium. | [DB13662] Hexapropymate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Hexapropymate. | [DB13687] Niaprazine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Niaprazine. | [DB13690] Vinyl ether: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Vinyl ether. | [DB13733] Methylpentynol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Methylpentynol. | [DB13737] Cyclobarbital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cyclobarbital. | [DB13745] Fazadinium bromide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Fazadinium bromide. | [DB13754] Mephenoxalone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Mephenoxalone. | [DB13770] Vinylbital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Vinylbital. | [DB13782] Imipramine oxide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Imipramine oxide. | [DB13787] Tilidine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tilidine. | [DB13799] Ethadione: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ethadione. | [DB13805] Reposal: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Reposal. | [DB13817] Carbromal: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Carbromal. | [DB13837] Doxefazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Doxefazepam. | [DB13872] Lormetazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Lormetazepam. | [DB13940] 2,5-Dimethoxy-4-ethylthioamphetamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with 2,5-Dimethoxy-4-ethylthioamphetamine. | [DB13948] N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. | [DB13984] Cyclopropane: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cyclopropane. | [DB13993] MRK-409: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with MRK-409. | [DB14028] Nordazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Nordazepam. | [DB14050] Cannabidivarin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cannabidivarin. | [DB14185] Aripiprazole lauroxil: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Aripiprazole lauroxil. | [DB14509] Lithium carbonate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Lithium carbonate. | [DB14575] Eslicarbazepine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Eslicarbazepine. | [DB14672] Oxazepam acetate: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Oxazepam acetate. | [DB14715] Cinazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cinazepam. | [DB14718] Pyrazolam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pyrazolam. | [DB14719] Bentazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Bentazepam. | [DB15203] JNJ-26489112: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with JNJ-26489112. | [DB15360] Carfentanil, C-11: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Carfentanil, C-11. | [DB00967] Desloratadine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Desloratadine. | [DB01174] Phenobarbital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Phenobarbital. | [DB11951] Lemborexant: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Lemborexant. | [DB12404] Remimazolam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Remimazolam. | [DB00751] Epinastine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Epinastine. | [DB00297] Bupivacaine: The risk or severity of CNS depression can be increased when Bupivacaine is combined with Zolmitriptan. | [DB00527] Cinchocaine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cinchocaine. | [DB01086] Benzocaine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Benzocaine. | [DB01161] Chloroprocaine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Chloroprocaine. | [DB09009] Articaine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Articaine. | [DB00961] Mepivacaine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Mepivacaine. | [DB09085] Tetracaine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tetracaine. | [DB00454] Meperidine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Meperidine. | [DB00750] Prilocaine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Prilocaine. | [DB00892] Oxybuprocaine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Oxybuprocaine. | [DB00904] Ondansetron: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ondansetron. | [DB09345] Pramocaine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pramocaine. | [DB00418] Secobarbital: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Secobarbital. | [DB00247] Methysergide: Methysergide may increase the vasoconstricting activities of Zolmitriptan. | [DB00353] Methylergometrine: Methylergometrine may increase the vasoconstricting activities of Zolmitriptan. | [DB00699] Nicergoline: Nicergoline may increase the vasoconstricting activities of Zolmitriptan. | [DB01049] Ergoloid mesylate: Ergoloid mesylate may increase the vasoconstricting activities of Zolmitriptan. | [DB01186] Pergolide: Pergolide may increase the vasoconstricting activities of Zolmitriptan. | [DB01200] Bromocriptine: Bromocriptine may increase the vasoconstricting activities of Zolmitriptan. | [DB01253] Ergometrine: Ergometrine may increase the vasoconstricting activities of Zolmitriptan. | [DB04829] Lysergic acid diethylamide: Lysergic acid diethylamide may increase the vasoconstricting activities of Zolmitriptan. | [DB11273] Dihydroergocornine: Dihydroergocornine may increase the vasoconstricting activities of Zolmitriptan. | [DB13345] Dihydroergocristine: Dihydroergocristine may increase the vasoconstricting activities of Zolmitriptan. | [DB13385] Dihydroergocryptine: Dihydroergocryptine may increase the vasoconstricting activities of Zolmitriptan. | [DB13399] Terguride: Terguride may increase the vasoconstricting activities of Zolmitriptan. | [DB13520] Metergoline: Metergoline may increase the vasoconstricting activities of Zolmitriptan. | [DB09330] Osimertinib: The serum concentration of Zolmitriptan can be decreased when it is combined with Osimertinib. | [DB00230] Pregabalin: The therapeutic efficacy of Zolmitriptan can be increased when used in combination with Pregabalin. | [DB08881] Vemurafenib: The serum concentration of Zolmitriptan can be increased when it is combined with Vemurafenib. | [DB04948] Lofexidine: The therapeutic efficacy of Zolmitriptan can be increased when used in combination with Lofexidine. | [DB00238] Nevirapine: The metabolism of Zolmitriptan can be decreased when combined with Nevirapine. | [DB00927] Famotidine: The metabolism of Zolmitriptan can be decreased when combined with Famotidine. | [DB00330] Ethambutol: The metabolism of Zolmitriptan can be decreased when combined with Ethambutol. | [DB05015] Belinostat: The metabolism of Zolmitriptan can be increased when combined with Belinostat. | [DB00071] Insulin pork: The metabolism of Zolmitriptan can be increased when combined with Insulin pork. | [DB00388] Phenylephrine: The metabolism of Zolmitriptan can be increased when combined with Phenylephrine. | [DB00607] Nafcillin: The metabolism of Zolmitriptan can be increased when combined with Nafcillin. | [DB01320] Fosphenytoin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Fosphenytoin. | [DB05115] NN344: The metabolism of Zolmitriptan can be increased when combined with NN344. | [DB05928] Dovitinib: The metabolism of Zolmitriptan can be increased when combined with Dovitinib. | [DB06413] Armodafinil: The metabolism of Zolmitriptan can be increased when combined with Armodafinil. | [DB06732] beta-Naphthoflavone: The metabolism of Zolmitriptan can be increased when combined with beta-Naphthoflavone. | [DB11567] Insulin peglispro: The metabolism of Zolmitriptan can be increased when combined with Insulin peglispro. | [DB11568] Insulin tregopil: The metabolism of Zolmitriptan can be increased when combined with Insulin tregopil. | [DB11642] Pitolisant: The metabolism of Zolmitriptan can be increased when combined with Pitolisant. | [DB09456] Insulin beef: The metabolism of Zolmitriptan can be increased when combined with Insulin beef. | [DB01087] Primaquine: The metabolism of Zolmitriptan can be increased when combined with Primaquine. | [DB00503] Ritonavir: The metabolism of Zolmitriptan can be increased when combined with Ritonavir. | [DB00052] Somatotropin: The metabolism of Zolmitriptan can be increased when combined with Somatotropin. | [DB15093] Somapacitan: The metabolism of Zolmitriptan can be increased when combined with Somapacitan. | [DB14009] Medical Cannabis: The metabolism of Zolmitriptan can be decreased when combined with Medical Cannabis. | [DB00784] Mefenamic acid: The metabolism of Mefenamic acid can be decreased when combined with Zolmitriptan. | [DB00195] Betaxolol: The metabolism of Zolmitriptan can be decreased when combined with Betaxolol. | [DB00262] Carmustine: The metabolism of Zolmitriptan can be decreased when combined with Carmustine. | [DB00277] Theophylline: The metabolism of Zolmitriptan can be decreased when combined with Theophylline. | [DB00280] Disopyramide: The metabolism of Zolmitriptan can be decreased when combined with Disopyramide. | [DB00296] Ropivacaine: The risk or severity of CNS depression can be increased when Ropivacaine is combined with Zolmitriptan. | [DB00316] Acetaminophen: The metabolism of Acetaminophen can be decreased when combined with Zolmitriptan. | [DB00321] Amitriptyline: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amitriptyline. | [DB00334] Olanzapine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Olanzapine. | [DB00356] Chlorzoxazone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Chlorzoxazone. | [DB00382] Tacrine: The metabolism of Tacrine can be decreased when combined with Zolmitriptan. | [DB00384] Triamterene: The metabolism of Triamterene can be decreased when combined with Zolmitriptan. | [DB00398] Sorafenib: The metabolism of Sorafenib can be decreased when combined with Zolmitriptan. | [DB00442] Entecavir: The metabolism of Entecavir can be decreased when combined with Zolmitriptan. | [DB00461] Nabumetone: The metabolism of Nabumetone can be decreased when combined with Zolmitriptan. | [DB00477] Chlorpromazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Chlorpromazine. | [DB00499] Flutamide: The metabolism of Flutamide can be decreased when combined with Zolmitriptan. | [DB00530] Erlotinib: The metabolism of Erlotinib can be decreased when combined with Zolmitriptan. | [DB00532] Mephenytoin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Mephenytoin. | [DB00544] Fluorouracil: The metabolism of Fluorouracil can be decreased when combined with Zolmitriptan. | [DB00568] Cinnarizine: The metabolism of Cinnarizine can be decreased when combined with Zolmitriptan. | [DB00586] Diclofenac: The metabolism of Diclofenac can be decreased when combined with Zolmitriptan. | [DB00619] Imatinib: The metabolism of Imatinib can be decreased when combined with Zolmitriptan. | [DB00629] Guanabenz: The metabolism of Guanabenz can be decreased when combined with Zolmitriptan. | [DB00642] Pemetrexed: The metabolism of Pemetrexed can be decreased when combined with Zolmitriptan. | [DB00661] Verapamil: The metabolism of Verapamil can be decreased when combined with Zolmitriptan. | [DB00682] Warfarin: The metabolism of Warfarin can be decreased when combined with Zolmitriptan. | [DB00697] Tizanidine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tizanidine. | [DB00740] Riluzole: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Riluzole. | [DB00744] Zileuton: The metabolism of Zolmitriptan can be decreased when combined with Zileuton. | [DB00758] Clopidogrel: The metabolism of Clopidogrel can be decreased when combined with Zolmitriptan. | [DB00773] Etoposide: The metabolism of Etoposide can be decreased when combined with Zolmitriptan. | [DB00787] Acyclovir: The metabolism of Acyclovir can be decreased when combined with Zolmitriptan. | [DB00788] Naproxen: The metabolism of Naproxen can be decreased when combined with Zolmitriptan. | [DB00806] Pentoxifylline: The metabolism of Pentoxifylline can be decreased when combined with Zolmitriptan. | [DB00831] Trifluoperazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Trifluoperazine. | [DB00850] Perphenazine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Perphenazine. | [DB00851] Dacarbazine: The metabolism of Dacarbazine can be decreased when combined with Zolmitriptan. | [DB00857] Terbinafine: The metabolism of Terbinafine can be decreased when combined with Zolmitriptan. | [DB00934] Maprotiline: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Maprotiline. | [DB00980] Ramelteon: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ramelteon. | [DB00993] Azathioprine: The metabolism of Azathioprine can be decreased when combined with Zolmitriptan. | [DB01002] Levobupivacaine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Levobupivacaine. | [DB01012] Cinacalcet: The metabolism of Cinacalcet can be decreased when combined with Zolmitriptan. | [DB01058] Praziquantel: The metabolism of Praziquantel can be decreased when combined with Zolmitriptan. | [DB01065] Melatonin: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Melatonin. | [DB01094] Hesperetin: The metabolism of Hesperetin can be decreased when combined with Zolmitriptan. | [DB01100] Pimozide: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pimozide. | [DB01136] Carvedilol: The metabolism of Carvedilol can be decreased when combined with Zolmitriptan. | [DB01142] Doxepin: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Doxepin. | [DB01166] Cilostazol: The metabolism of Cilostazol can be decreased when combined with Zolmitriptan. | [DB01184] Domperidone: The metabolism of Domperidone can be decreased when combined with Zolmitriptan. | [DB01191] Dexfenfluramine: The metabolism of Dexfenfluramine can be decreased when combined with Zolmitriptan. | [DB01223] Aminophylline: The metabolism of Aminophylline can be decreased when combined with Zolmitriptan. | [DB01242] Clomipramine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Clomipramine. | [DB01254] Dasatinib: The metabolism of Dasatinib can be decreased when combined with Zolmitriptan. | [DB01303] Oxtriphylline: The metabolism of Oxtriphylline can be decreased when combined with Zolmitriptan. | [DB01412] Theobromine: The metabolism of Theobromine can be decreased when combined with Zolmitriptan. | [DB01418] Acenocoumarol: The metabolism of Acenocoumarol can be decreased when combined with Zolmitriptan. | [DB01424] Aminophenazone: The metabolism of Aminophenazone can be decreased when combined with Zolmitriptan. | [DB01435] Antipyrine: The metabolism of Antipyrine can be decreased when combined with Zolmitriptan. | [DB01482] Fenethylline: The metabolism of Fenethylline can be decreased when combined with Zolmitriptan. | [DB01558] Bromazepam: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Bromazepam. | [DB01623] Thiothixene: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thiothixene. | [DB01628] Etoricoxib: The metabolism of Etoricoxib can be decreased when combined with Zolmitriptan. | [DB01667] 8-azaguanine: The metabolism of 8-azaguanine can be decreased when combined with Zolmitriptan. | [DB02134] Xanthine: The metabolism of Xanthine can be decreased when combined with Zolmitriptan. | [DB02489] 9-Methylguanine: The metabolism of 9-Methylguanine can be decreased when combined with Zolmitriptan. | [DB02568] Peldesine: The metabolism of Peldesine can be decreased when combined with Zolmitriptan. | [DB03783] Phenacetin: The metabolism of Phenacetin can be decreased when combined with Zolmitriptan. | [DB04076] Hypoxanthine: The metabolism of Hypoxanthine can be decreased when combined with Zolmitriptan. | [DB04356] 9-Deazaguanine: The metabolism of 9-Deazaguanine can be decreased when combined with Zolmitriptan. | [DB04841] Flunarizine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Flunarizine. | [DB04871] Lorcaserin: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lorcaserin. | [DB06148] Mianserin: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Mianserin. | [DB06210] Eltrombopag: The metabolism of Eltrombopag can be decreased when combined with Zolmitriptan. | [DB06216] Asenapine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Asenapine. | [DB06235] Vadimezan: The metabolism of Vadimezan can be decreased when combined with Zolmitriptan. | [DB06479] Propentofylline: The metabolism of Propentofylline can be decreased when combined with Zolmitriptan. | [DB06589] Pazopanib: The metabolism of Pazopanib can be decreased when combined with Zolmitriptan. | [DB06594] Agomelatine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Agomelatine. | [DB06626] Axitinib: The metabolism of Axitinib can be decreased when combined with Zolmitriptan. | [DB06769] Bendamustine: The metabolism of Bendamustine can be decreased when combined with Zolmitriptan. | [DB06770] Benzyl alcohol: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Benzyl alcohol. | [DB08496] (R)-warfarin: The metabolism of (R)-warfarin can be decreased when combined with Zolmitriptan. | [DB08910] Pomalidomide: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pomalidomide. | [DB09071] Tasimelteon: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tasimelteon. | [DB09225] Zotepine: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Zotepine. | [DB09256] Tegafur: The metabolism of Tegafur can be decreased when combined with Zolmitriptan. | [DB09273] Doxofylline: The metabolism of Doxofylline can be decreased when combined with Zolmitriptan. | [DB09288] Propacetamol: The metabolism of Propacetamol can be decreased when combined with Zolmitriptan. | [DB09290] Ramosetron: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Ramosetron. | [DB11919] 6-O-benzylguanine: The metabolism of 6-O-benzylguanine can be decreased when combined with Zolmitriptan. | [DB11967] Binimetinib: The metabolism of Binimetinib can be decreased when combined with Zolmitriptan. | [DB12026] Voxilaprevir: The metabolism of Voxilaprevir can be decreased when combined with Zolmitriptan. | [DB12406] Lisofylline: The metabolism of Lisofylline can be decreased when combined with Zolmitriptan. | [DB12531] Lobucavir: The metabolism of Lobucavir can be decreased when combined with Zolmitriptan. | [DB12926] Cafedrine: The metabolism of Cafedrine can be decreased when combined with Zolmitriptan. | [DB12927] Theodrenaline: The metabolism of Theodrenaline can be decreased when combined with Zolmitriptan. | [DB13203] Bamifylline: The metabolism of Bamifylline can be decreased when combined with Zolmitriptan. | [DB13449] Proxyphylline: The metabolism of Proxyphylline can be decreased when combined with Zolmitriptan. | [DB13573] Acefylline: The metabolism of Acefylline can be decreased when combined with Zolmitriptan. | [DB13592] Etamiphylline: The metabolism of Etamiphylline can be decreased when combined with Zolmitriptan. | [DB13634] Pentifylline: The metabolism of Pentifylline can be decreased when combined with Zolmitriptan. | [DB13812] Bufylline: The metabolism of Bufylline can be decreased when combined with Zolmitriptan. | [DB14018] Bromotheophylline: The metabolism of Bromotheophylline can be decreased when combined with Zolmitriptan. | [DB14132] 8-chlorotheophylline: The metabolism of 8-chlorotheophylline can be decreased when combined with Zolmitriptan. | [DB00675] Tamoxifen: The metabolism of Tamoxifen can be decreased when combined with Zolmitriptan. | [DB00468] Quinine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Quinine. | [DB11757] Istradefylline: The metabolism of Istradefylline can be decreased when combined with Zolmitriptan. | [DB04889] Bicifadine: The metabolism of Bicifadine can be decreased when combined with Zolmitriptan. | [DB05708] GTS-21: The metabolism of GTS-21 can be decreased when combined with Zolmitriptan. | [DB01195] Flecainide: The metabolism of Flecainide can be decreased when combined with Zolmitriptan. | [DB00977] Ethinylestradiol: The metabolism of Ethinylestradiol can be decreased when combined with Zolmitriptan. | [DB11689] Selumetinib: The metabolism of Selumetinib can be decreased when combined with Zolmitriptan. | [DB00188] Bortezomib: The metabolism of Zolmitriptan can be decreased when combined with Bortezomib. | [DB00299] Penciclovir: The metabolism of Zolmitriptan can be decreased when combined with Penciclovir. | [DB00184] Nicotine: The metabolism of Zolmitriptan can be decreased when combined with Nicotine. | [DB00191] Phentermine: The metabolism of Zolmitriptan can be decreased when combined with Phentermine. | [DB00397] Phenylpropanolamine: The metabolism of Zolmitriptan can be decreased when combined with Phenylpropanolamine. | [DB00852] Pseudoephedrine: The metabolism of Zolmitriptan can be decreased when combined with Pseudoephedrine. | [DB00909] Zonisamide: The metabolism of Zolmitriptan can be decreased when combined with Zonisamide. | [DB01363] Ephedra sinica root: The metabolism of Zolmitriptan can be decreased when combined with Ephedra sinica root. | [DB01442] MMDA: The metabolism of Zolmitriptan can be decreased when combined with MMDA. | [DB01472] 4-Methoxyamphetamine: The metabolism of Zolmitriptan can be decreased when combined with 4-Methoxyamphetamine. | [DB01577] Metamfetamine: The metabolism of Zolmitriptan can be decreased when combined with Metamfetamine. | [DB06774] Capsaicin: The metabolism of Zolmitriptan can be decreased when combined with Capsaicin. | [DB08804] Nandrolone decanoate: The metabolism of Zolmitriptan can be decreased when combined with Nandrolone decanoate. | [DB01381] Ginkgo biloba: The metabolism of Zolmitriptan can be decreased when combined with Ginkgo biloba. | [DB05077] SLV319: The risk or severity of adverse effects can be increased when SLV319 is combined with Zolmitriptan. | [DB06155] Rimonabant: The risk or severity of adverse effects can be increased when Rimonabant is combined with Zolmitriptan. | [DB06624] Taranabant: The risk or severity of adverse effects can be increased when Taranabant is combined with Zolmitriptan. | [DB11903] GW842166: The risk or severity of adverse effects can be increased when GW842166 is combined with Zolmitriptan. | [DB12193] Lenabasum: The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Zolmitriptan. | [DB12649] Ibipinabant: The risk or severity of adverse effects can be increased when Ibipinabant is combined with Zolmitriptan. | [DB13070] Surinabant: The risk or severity of adverse effects can be increased when Surinabant is combined with Zolmitriptan. | [DB13950] WIN 55212-2: The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with Zolmitriptan. | [DB14011] Nabiximols: The risk or severity of adverse effects can be increased when Nabiximols is combined with Zolmitriptan. | [DB14043] Palmidrol: The risk or severity of adverse effects can be increased when Palmidrol is combined with Zolmitriptan. | [DB14737] Cannabinol: The risk or severity of adverse effects can be increased when Cannabinol is combined with Zolmitriptan. | [DB00490] Buspirone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Buspirone. | [DB00907] Cocaine: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Cocaine. | [DB00915] Amantadine: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Amantadine. | [DB01255] Lisdexamfetamine: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Lisdexamfetamine. | [DB01365] Mephentermine: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Mephentermine. | [DB01459] Bezitramide: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Bezitramide. | [DB01467] 2,5-Dimethoxy-4-ethylamphetamine: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with 2,5-Dimethoxy-4-ethylamphetamine. | [DB01556] Chlorphentermine: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Chlorphentermine. | [DB01576] Dextroamphetamine: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Dextroamphetamine. | [DB08167] Methylthioninium: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Methylthioninium. | [DB09272] Eluxadoline: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Eluxadoline. | [DB09480] Iofetamine I-123: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Iofetamine I-123. | [DB12080] Ritobegron: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Ritobegron. | [DB13108] Mephedrone: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Mephedrone. | [DB13454] Nicomorphine: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Nicomorphine. | [DB13624] Methoxyphenamine: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Methoxyphenamine. | [DB13703] Gepefrine: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Gepefrine. | [DB13910] Valproate bismuth: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Valproate bismuth. | [DB00182] Amphetamine: The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Zolmitriptan. | [DB12141] Gilteritinib: The therapeutic efficacy of Zolmitriptan can be decreased when used in combination with Gilteritinib. | [DB00005] Etanercept: The metabolism of Zolmitriptan can be increased when combined with Etanercept. | [DB00026] Anakinra: The metabolism of Zolmitriptan can be increased when combined with Anakinra. | [DB00051] Adalimumab: The metabolism of Zolmitriptan can be increased when combined with Adalimumab. | [DB00065] Infliximab: The metabolism of Zolmitriptan can be increased when combined with Infliximab. | [DB01281] Abatacept: The metabolism of Zolmitriptan can be increased when combined with Abatacept. | [DB04956] Afelimomab: The metabolism of Zolmitriptan can be increased when combined with Afelimomab. | [DB05676] Apremilast: The metabolism of Zolmitriptan can be increased when combined with Apremilast. | [DB06168] Canakinumab: The metabolism of Zolmitriptan can be increased when combined with Canakinumab. | [DB06273] Tocilizumab: The metabolism of Zolmitriptan can be increased when combined with Tocilizumab. | [DB06372] Rilonacept: The metabolism of Zolmitriptan can be increased when combined with Rilonacept. | [DB06674] Golimumab: The metabolism of Zolmitriptan can be increased when combined with Golimumab. | [DB08904] Certolizumab pegol: The metabolism of Zolmitriptan can be increased when combined with Certolizumab pegol. | [DB09029] Secukinumab: The metabolism of Zolmitriptan can be increased when combined with Secukinumab. | [DB09036] Siltuximab: The metabolism of Zolmitriptan can be increased when combined with Siltuximab. | [DB14724] Emapalumab: The metabolism of Zolmitriptan can be increased when combined with Emapalumab. | [DB11823] Esketamine: The risk or severity of hypertension can be increased when Esketamine is combined with Zolmitriptan. | [DB00395] Carisoprodol: The risk or severity of adverse effects can be increased when Carisoprodol is combined with Zolmitriptan. | [DB14754] Solriamfetol: The risk or severity of hypertension can be increased when Solriamfetol is combined with Zolmitriptan. | [DB13946] Testosterone undecanoate: Testosterone undecanoate may increase the hypertensive activities of Zolmitriptan. | [DB00402] Eszopiclone: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Eszopiclone. | [DB00575] Clonidine: The risk or severity of sedation can be increased when Clonidine is combined with Zolmitriptan. | [DB00924] Cyclobenzaprine: The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Zolmitriptan. | [DB01233] Metoclopramide: The risk or severity of sedation can be increased when Metoclopramide is combined with Zolmitriptan. | [DB11732] Lasmiditan: The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Zolmitriptan. | [DB15066] Givosiran: The serum concentration of Zolmitriptan can be increased when it is combined with Givosiran. | [DB00193] Tramadol: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Tramadol. | [DB00502] Haloperidol: The risk or severity of CNS depression can be increased when Haloperidol is combined with Zolmitriptan. | [DB00501] Cimetidine: The serum concentration of Zolmitriptan can be increased when it is combined with Cimetidine. | [DB05271] Rotigotine: The risk or severity of vasospastic reactions can be increased when Rotigotine is combined with Zolmitriptan. | [DB00216] Eletriptan: The risk or severity of vasospastic reactions can be increased when Eletriptan is combined with Zolmitriptan. | [DB00320] Dihydroergotamine: The risk or severity of vasospastic reactions can be increased when Dihydroergotamine is combined with Zolmitriptan. | [DB00669] Sumatriptan: The risk or severity of vasospastic reactions can be increased when Sumatriptan is combined with Zolmitriptan. | [DB00918] Almotriptan: The risk or severity of vasospastic reactions can be increased when Almotriptan is combined with Zolmitriptan. | [DB00952] Naratriptan: The risk or severity of vasospastic reactions can be increased when Naratriptan is combined with Zolmitriptan. | [DB00953] Rizatriptan: The risk or severity of vasospastic reactions can be increased when Rizatriptan is combined with Zolmitriptan. | [DB01238] Aripiprazole: The risk or severity of vasospastic reactions can be increased when Aripiprazole is combined with Zolmitriptan. | [DB04908] Flibanserin: The risk or severity of vasospastic reactions can be increased when Flibanserin is combined with Zolmitriptan. | [DB05562] Naluzotan: The risk or severity of vasospastic reactions can be increased when Naluzotan is combined with Zolmitriptan. | [DB06016] Cariprazine: The risk or severity of vasospastic reactions can be increased when Cariprazine is combined with Zolmitriptan. | [DB06684] Vilazodone: The risk or severity of vasospastic reactions can be increased when Vilazodone is combined with Zolmitriptan. | [DB08810] Cinitapride: The risk or severity of vasospastic reactions can be increased when Cinitapride is combined with Zolmitriptan. | [DB09068] Vortioxetine: The risk or severity of vasospastic reactions can be increased when Vortioxetine is combined with Zolmitriptan. | [DB09128] Brexpiprazole: The risk or severity of vasospastic reactions can be increased when Brexpiprazole is combined with Zolmitriptan. | [DB11755] Tetrahydrocannabivarin: The risk or severity of vasospastic reactions can be increased when Tetrahydrocannabivarin is combined with Zolmitriptan. | [DB12361] Piclozotan: The risk or severity of vasospastic reactions can be increased when Piclozotan is combined with Zolmitriptan. | [DB14010] 5-methoxy-N,N-dimethyltryptamine: The risk or severity of vasospastic reactions can be increased when 5-methoxy-N,N-dimethyltryptamine is combined with Zolmitriptan. | [DB00248] Cabergoline: The risk or severity of vasospastic reactions can be increased when Cabergoline is combined with Zolmitriptan. | [DB00589] Lisuride: The risk or severity of vasospastic reactions can be increased when Lisuride is combined with Zolmitriptan. | [DB00696] Ergotamine: The risk or severity of vasospastic reactions can be increased when Ergotamine is combined with Zolmitriptan. | [DB09061] Cannabidiol: The risk or severity of vasospastic reactions can be increased when Cannabidiol is combined with Zolmitriptan. | [DB00998] Frovatriptan: The risk or severity of vasospastic reactions can be increased when Frovatriptan is combined with Zolmitriptan. | [DB00246] Ziprasidone: The risk or severity of vasospastic reactions can be increased when Ziprasidone is combined with Zolmitriptan. | [DB00472] Fluoxetine: The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Zolmitriptan. | [DB00476] Duloxetine: The risk or severity of serotonin syndrome can be increased when Duloxetine is combined with Zolmitriptan. | [DB01104] Sertraline: The risk or severity of serotonin syndrome can be increased when Sertraline is combined with Zolmitriptan. | [DB01105] Sibutramine: The risk or severity of serotonin syndrome can be increased when Sibutramine is combined with Zolmitriptan. | [DB01149] Nefazodone: The risk or severity of serotonin syndrome can be increased when Nefazodone is combined with Zolmitriptan. | [DB01175] Escitalopram: The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Zolmitriptan. | [DB04884] Dapoxetine: The risk or severity of serotonin syndrome can be increased when Dapoxetine is combined with Zolmitriptan. | [DB04896] Milnacipran: The risk or severity of serotonin syndrome can be increased when Milnacipran is combined with Zolmitriptan. | [DB06700] Desvenlafaxine: The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Zolmitriptan. | [DB06731] Seproxetine: The risk or severity of serotonin syndrome can be increased when Seproxetine is combined with Zolmitriptan. | [DB08918] Levomilnacipran: The risk or severity of serotonin syndrome can be increased when Levomilnacipran is combined with Zolmitriptan. | [DB08953] Indalpine: The risk or severity of serotonin syndrome can be increased when Indalpine is combined with Zolmitriptan. | [DB12693] Ritanserin: The risk or severity of serotonin syndrome can be increased when Ritanserin is combined with Zolmitriptan. | [DB13233] Alaproclate: The risk or severity of serotonin syndrome can be increased when Alaproclate is combined with Zolmitriptan. | [DB04832] Zimelidine: The risk or severity of serotonin syndrome can be increased when Zimelidine is combined with Zolmitriptan. | [DB00176] Fluvoxamine: The risk or severity of serotonin syndrome can be increased when Fluvoxamine is combined with Zolmitriptan. | [DB00215] Citalopram: The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Zolmitriptan. | [DB00656] Trazodone: The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Zolmitriptan. | [DB00715] Paroxetine: The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Zolmitriptan. | [DB00285] Venlafaxine: The risk or severity of serotonin syndrome can be increased when Venlafaxine is combined with Zolmitriptan. | [DB00574] Fenfluramine: The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Fenfluramine. | [DB11932] Abametapir: The serum concentration of Zolmitriptan can be increased when it is combined with Abametapir. | [DB14881] Oliceridine: The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Zolmitriptan is combined with Oliceridine. | [DB15762] Satralizumab: The serum concentration of Zolmitriptan can be decreased when it is combined with Satralizumab. | [DB09098] Somatrem: The metabolism of Zolmitriptan can be increased when combined with Somatrem. | [DB12950] Albusomatropin: The metabolism of Zolmitriptan can be increased when combined with Albusomatropin. | [DB15112] Somatropin pegol: The metabolism of Zolmitriptan can be increased when combined with Somatropin pegol. | [DB00601] Linezolid: The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Zolmitriptan. | [DB00614] Furazolidone: The risk or severity of serotonin syndrome can be increased when Furazolidone is combined with Zolmitriptan. | [DB00721] Procaine: The risk or severity of serotonin syndrome can be increased when Procaine is combined with Zolmitriptan. | [DB00780] Phenelzine: The risk or severity of serotonin syndrome can be increased when Phenelzine is combined with Zolmitriptan. | [DB00805] Minaprine: The risk or severity of serotonin syndrome can be increased when Minaprine is combined with Zolmitriptan. | [DB01168] Procarbazine: The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Zolmitriptan. | [DB01171] Moclobemide: The risk or severity of serotonin syndrome can be increased when Moclobemide is combined with Zolmitriptan. | [DB01247] Isocarboxazid: The risk or severity of serotonin syndrome can be increased when Isocarboxazid is combined with Zolmitriptan. | [DB01367] Rasagiline: The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Zolmitriptan. | [DB01626] Pargyline: The risk or severity of serotonin syndrome can be increased when Pargyline is combined with Zolmitriptan. | [DB04017] Clorgiline: The risk or severity of serotonin syndrome can be increased when Clorgiline is combined with Zolmitriptan. | [DB04818] Iproniazid: The risk or severity of serotonin syndrome can be increased when Iproniazid is combined with Zolmitriptan. | [DB04820] Nialamide: The risk or severity of serotonin syndrome can be increased when Nialamide is combined with Zolmitriptan. | [DB08550] 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline: The risk or severity of serotonin syndrome can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Zolmitriptan. | [DB09243] Hydracarbazine: The risk or severity of serotonin syndrome can be increased when Hydracarbazine is combined with Zolmitriptan. | [DB09244] Pirlindole: The risk or severity of serotonin syndrome can be increased when Pirlindole is combined with Zolmitriptan. | [DB09245] Toloxatone: The risk or severity of serotonin syndrome can be increased when Toloxatone is combined with Zolmitriptan. | [DB09246] Benmoxin: The risk or severity of serotonin syndrome can be increased when Benmoxin is combined with Zolmitriptan. | [DB09248] Mebanazine: The risk or severity of serotonin syndrome can be increased when Mebanazine is combined with Zolmitriptan. | [DB09249] Octamoxin: The risk or severity of serotonin syndrome can be increased when Octamoxin is combined with Zolmitriptan. | [DB09250] Pheniprazine: The risk or severity of serotonin syndrome can be increased when Pheniprazine is combined with Zolmitriptan. | [DB09251] Phenoxypropazine: The risk or severity of serotonin syndrome can be increased when Phenoxypropazine is combined with Zolmitriptan. | [DB09252] Pivhydrazine: The risk or severity of serotonin syndrome can be increased when Pivhydrazine is combined with Zolmitriptan. | [DB09253] Safrazine: The risk or severity of serotonin syndrome can be increased when Safrazine is combined with Zolmitriptan. | [DB09254] Caroxazone: The risk or severity of serotonin syndrome can be increased when Caroxazone is combined with Zolmitriptan. | [DB13875] Harmaline: The risk or severity of serotonin syndrome can be increased when Harmaline is combined with Zolmitriptan. | [DB13876] Brofaromine: The risk or severity of serotonin syndrome can be increased when Brofaromine is combined with Zolmitriptan. | [DB00752] Tranylcypromine: The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Zolmitriptan. | [DB01037] Selegiline: The risk or severity of serotonin syndrome can be increased when Selegiline is combined with Zolmitriptan. | [DB06654] Safinamide: The risk or severity of serotonin syndrome can be increased when Safinamide is combined with Zolmitriptan. | [DB12265] Fexinidazole: The metabolism of Zolmitriptan can be decreased when combined with Fexinidazole. | [DB11672] Curcumin: The metabolism of Zolmitriptan can be decreased when combined with Curcumin. | [DB16220] Lonapegsomatropin: The metabolism of Zolmitriptan can be increased when combined with Lonapegsomatropin. | [DB15226] Dasiglucagon: Zolmitriptan may decrease the antihypertensive activities of Dasiglucagon. | [DB14960] Somatrogon: The metabolism of Zolmitriptan can be increased when combined with Somatrogon. | [DB15031] Daridorexant: The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Daridorexant. | [DB12917] Bimekizumab: The metabolism of Zolmitriptan can be increased when combined with Bimekizumab. | [DB04216] Quercetin: The metabolism of Zolmitriptan can be decreased when combined with Quercetin. | [DB11697] Pacritinib: The metabolism of Zolmitriptan can be decreased when combined with Pacritinib. | [DB01656] Roflumilast: The metabolism of Roflumilast can be decreased when combined with Zolmitriptan. | [DB05087] Ganaxolone: The risk or severity of sedation, somnolence, and CNS depression can be increased when Zolmitriptan is combined with Ganaxolone. | [DB00755] Tretinoin: The risk or severity of elevated intracranial pressure can be increased when Zolmitriptan is combined with Tretinoin. | [DB16217] Leniolisib: The metabolism of Zolmitriptan can be decreased when combined with Leniolisib. | [DB12543] Samidorphan: The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Samidorphan. | [DB15669] Fezolinetant: The metabolism of Fezolinetant can be decreased when combined with Zolmitriptan. | [DB16672] Epcoritamab: The serum concentration of Zolmitriptan can be increased when it is combined with Epcoritamab. | [DB16371] Glofitamab: The serum concentration of Zolmitriptan can be increased when it is combined with Glofitamab. | [DB14924] Ritlecitinib: The serum concentration of Zolmitriptan can be increased when it is combined with Ritlecitinib. | [DB15490] Zuranolone: The risk or severity of CNS depression can be increased when Zuranolone is combined with Zolmitriptan. | [DB00421] Spironolactone: Zolmitriptan may decrease the antihypertensive activities of Spironolactone. | [DB11718] Encorafenib: The metabolism of Zolmitriptan can be decreased when combined with Encorafenib. | [DB15059] Aprocitentan: Zolmitriptan may decrease the antihypertensive activities of Aprocitentan. | [DB17097] Vorasidenib: The metabolism of Vorasidenib can be decreased when combined with Zolmitriptan.",1 mg; 1.0 mg; 2.5 MG; 2.5 mg; 2.5 mg / act; 2.5 mg/1; 2.50 mg; 2.500 mg; 250000 mg; 5 MG; 5 mg; 5 mg/1; 5.0 mg / act; 500000 mg,Take with or without food. Food does not significantly impact the oral bioavalibility of zolmitriptan.
DB00316,Acetaminophen,ANALGESICS; Anilides; NERVOUS SYSTEM; OPIOIDS; OTHER ANALGESICS AND ANTIPYRETICS; Opioids in combination with non-opioid analgesics,"[DB08827] Lomitapide: The metabolism of Lomitapide can be decreased when combined with Acetaminophen. | [DB01238] Aripiprazole: The metabolism of Aripiprazole can be increased when combined with Acetaminophen. | [DB14185] Aripiprazole lauroxil: The metabolism of Aripiprazole lauroxil can be increased when combined with Acetaminophen. | [DB01609] Deferasirox: The serum concentration of Acetaminophen can be increased when it is combined with Deferasirox. | [DB00022] Peginterferon alfa-2b: The serum concentration of Acetaminophen can be increased when it is combined with Peginterferon alfa-2b. | [DB01097] Leflunomide: The serum concentration of Acetaminophen can be decreased when it is combined with Leflunomide. | [DB08880] Teriflunomide: The serum concentration of Acetaminophen can be decreased when it is combined with Teriflunomide. | [DB09039] Eliglustat: The metabolism of Eliglustat can be decreased when combined with Acetaminophen. | [DB09053] Ibrutinib: The metabolism of Ibrutinib can be decreased when combined with Acetaminophen. | [DB01166] Cilostazol: The metabolism of Cilostazol can be decreased when combined with Acetaminophen. | [DB01394] Colchicine: The metabolism of Colchicine can be decreased when combined with Acetaminophen. | [DB00813] Fentanyl: Acetaminophen may decrease the excretion rate of Fentanyl which could result in a higher serum level. | [DB04946] Iloperidone: The metabolism of Iloperidone can be decreased when combined with Acetaminophen. | [DB01256] Retapamulin: The metabolism of Retapamulin can be decreased when combined with Acetaminophen. | [DB08895] Tofacitinib: The metabolism of Tofacitinib can be decreased when combined with Acetaminophen. | [DB00862] Vardenafil: The metabolism of Vardenafil can be decreased when combined with Acetaminophen. | [DB01198] Zopiclone: The metabolism of Zopiclone can be decreased when combined with Acetaminophen. | [DB00227] Lovastatin: The metabolism of Lovastatin can be decreased when combined with Acetaminophen. | [DB00474] Methohexital: The metabolism of Acetaminophen can be increased when combined with Methohexital. | [DB00849] Methylphenobarbital: The metabolism of Acetaminophen can be increased when combined with Methylphenobarbital. | [DB01154] Thiamylal: The metabolism of Acetaminophen can be increased when combined with Thiamylal. | [DB01351] Amobarbital: The metabolism of Acetaminophen can be increased when combined with Amobarbital. | [DB01355] Hexobarbital: The metabolism of Acetaminophen can be increased when combined with Hexobarbital. | [DB01483] Barbital: The metabolism of Acetaminophen can be increased when combined with Barbital. | [DB09001] Barbexaclone: The metabolism of Acetaminophen can be increased when combined with Barbexaclone. | [DB00237] Butabarbital: The metabolism of Acetaminophen can be increased when combined with Butabarbital. | [DB00418] Secobarbital: The metabolism of Acetaminophen can be increased when combined with Secobarbital. | [DB00599] Thiopental: The metabolism of Acetaminophen can be increased when combined with Thiopental. | [DB00750] Prilocaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Prilocaine. | [DB01008] Busulfan: Acetaminophen may decrease the excretion rate of Busulfan which could result in a higher serum level. | [DB00317] Gefitinib: The serum concentration of Acetaminophen can be increased when it is combined with Gefitinib. | [DB01259] Lapatinib: The serum concentration of Acetaminophen can be increased when it is combined with Lapatinib. | [DB01645] Genistein: The serum concentration of Acetaminophen can be increased when it is combined with Genistein. | [DB02058] 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone: The serum concentration of Acetaminophen can be increased when it is combined with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone. | [DB02424] Geldanamycin: The serum concentration of Acetaminophen can be increased when it is combined with Geldanamycin. | [DB02567] PD173955: The serum concentration of Acetaminophen can be increased when it is combined with PD173955. | [DB03758] Radicicol: The serum concentration of Acetaminophen can be increased when it is combined with Radicicol. | [DB04849] Cediranib: The serum concentration of Acetaminophen can be increased when it is combined with Cediranib. | [DB04879] Vatalanib: The serum concentration of Acetaminophen can be increased when it is combined with Vatalanib. | [DB05424] Canertinib: The serum concentration of Acetaminophen can be increased when it is combined with Canertinib. | [DB05465] Tandutinib: The serum concentration of Acetaminophen can be increased when it is combined with Tandutinib. | [DB05575] Motesanib: The serum concentration of Acetaminophen can be increased when it is combined with Motesanib. | [DB05928] Dovitinib: The serum concentration of Acetaminophen can be increased when it is combined with Dovitinib. | [DB06302] Glesatinib: The serum concentration of Acetaminophen can be increased when it is combined with Glesatinib. | [DB06469] Lestaurtinib: The serum concentration of Acetaminophen can be increased when it is combined with Lestaurtinib. | [DB08399] Piceatannol: The serum concentration of Acetaminophen can be increased when it is combined with Piceatannol. | [DB08875] Cabozantinib: The serum concentration of Acetaminophen can be increased when it is combined with Cabozantinib. | [DB09078] Lenvatinib: The serum concentration of Acetaminophen can be increased when it is combined with Lenvatinib. | [DB09079] Nintedanib: The serum concentration of Acetaminophen can be increased when it is combined with Nintedanib. | [DB11697] Pacritinib: The serum concentration of Acetaminophen can be increased when it is combined with Pacritinib. | [DB11737] Icotinib: The serum concentration of Acetaminophen can be increased when it is combined with Icotinib. | [DB11805] Saracatinib: The serum concentration of Acetaminophen can be increased when it is combined with Saracatinib. | [DB11832] Crenolanib: The serum concentration of Acetaminophen can be increased when it is combined with Crenolanib. | [DB11904] Flumatinib: The serum concentration of Acetaminophen can be increased when it is combined with Flumatinib. | [DB11973] Tesevatinib: The serum concentration of Acetaminophen can be increased when it is combined with Tesevatinib. | [DB12048] Savolitinib: The serum concentration of Acetaminophen can be increased when it is combined with Savolitinib. | [DB12307] Foretinib: The serum concentration of Acetaminophen can be increased when it is combined with Foretinib. | [DB12323] Radotinib: The serum concentration of Acetaminophen can be increased when it is combined with Radotinib. | [DB12500] Fedratinib: The serum concentration of Acetaminophen can be increased when it is combined with Fedratinib. | [DB08916] Afatinib: The serum concentration of Acetaminophen can be increased when it is combined with Afatinib. | [DB14723] Larotrectinib: The serum concentration of Acetaminophen can be increased when it is combined with Larotrectinib. | [DB15133] Tepotinib: The serum concentration of Acetaminophen can be increased when it is combined with Tepotinib. | [DB11886] Infigratinib: The serum concentration of Acetaminophen can be increased when it is combined with Infigratinib. | [DB00951] Isoniazid: Isoniazid may increase the hepatotoxic activities of Acetaminophen. | [DB01011] Metyrapone: Metyrapone may increase the hepatotoxic activities of Acetaminophen. | [DB05528] Mipomersen: Acetaminophen may increase the hepatotoxic activities of Mipomersen. | [DB00346] Alfuzosin: The metabolism of Alfuzosin can be decreased when combined with Acetaminophen. | [DB00404] Alprazolam: The metabolism of Alprazolam can be decreased when combined with Acetaminophen. | [DB01181] Ifosfamide: The metabolism of Ifosfamide can be increased when combined with Acetaminophen. | [DB08883] Perampanel: The metabolism of Perampanel can be increased when combined with Acetaminophen. | [DB00266] Dicoumarol: Acetaminophen may increase the anticoagulant activities of Dicoumarol. | [DB00498] Phenindione: Acetaminophen may increase the anticoagulant activities of Phenindione. | [DB04665] Coumarin: Acetaminophen may increase the anticoagulant activities of Coumarin. | [DB13451] Tioclomarol: Acetaminophen may increase the anticoagulant activities of Tioclomarol. | [DB08794] Ethyl biscoumacetate: Acetaminophen may increase the anticoagulant activities of Ethyl biscoumacetate. | [DB13347] Diphenadione: Acetaminophen may increase the anticoagulant activities of Diphenadione. | [DB03410] 4-hydroxycoumarin: Acetaminophen may increase the anticoagulant activities of 4-hydroxycoumarin. | [DB13136] Fluindione: Acetaminophen may increase the anticoagulant activities of Fluindione. | [DB13275] Clorindione: Acetaminophen may increase the anticoagulant activities of Clorindione. | [DB01418] Acenocoumarol: The serum concentration of Acenocoumarol can be increased when it is combined with Acetaminophen. | [DB08496] (R)-warfarin: The serum concentration of (R)-warfarin can be increased when it is combined with Acetaminophen. | [DB08735] R,S-Warfarin alcohol: The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Acetaminophen. | [DB08736] S,R-Warfarin alcohol: The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Acetaminophen. | [DB14055] (S)-Warfarin: The serum concentration of (S)-Warfarin can be increased when it is combined with Acetaminophen. | [DB00683] Midazolam: The serum concentration of Midazolam can be increased when it is combined with Acetaminophen. | [DB00555] Lamotrigine: The metabolism of Acetaminophen can be increased when combined with Lamotrigine. | [DB01420] Testosterone propionate: The metabolism of Acetaminophen can be increased when combined with Testosterone propionate. | [DB00864] Tacrolimus: The serum concentration of Tacrolimus can be increased when it is combined with Acetaminophen. | [DB01076] Atorvastatin: The metabolism of Atorvastatin can be decreased when combined with Acetaminophen. | [DB08893] Mirabegron: The serum concentration of Acetaminophen can be increased when it is combined with Mirabegron. | [DB01432] Cholestyramine: Cholestyramine can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB05812] Abiraterone: The serum concentration of Acetaminophen can be increased when it is combined with Abiraterone. | [DB04839] Cyproterone acetate: The metabolism of Acetaminophen can be increased when combined with Cyproterone acetate. | [DB00250] Dapsone: The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Acetaminophen. | [DB00530] Erlotinib: The serum concentration of Erlotinib can be decreased when it is combined with Acetaminophen. | [DB01032] Probenecid: Probenecid may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00518] Albendazole: The metabolism of Acetaminophen can be increased when combined with Albendazole. | [DB00218] Moxifloxacin: The metabolism of Acetaminophen can be decreased when combined with Moxifloxacin. | [DB00379] Mexiletine: The metabolism of Acetaminophen can be decreased when combined with Mexiletine. | [DB01044] Gatifloxacin: The metabolism of Acetaminophen can be decreased when combined with Gatifloxacin. | [DB06290] Simeprevir: The metabolism of Acetaminophen can be decreased when combined with Simeprevir. | [DB09198] Lobeglitazone: The metabolism of Acetaminophen can be decreased when combined with Lobeglitazone. | [DB11774] Pazufloxacin: The metabolism of Acetaminophen can be decreased when combined with Pazufloxacin. | [DB11837] Osilodrostat: The metabolism of Acetaminophen can be decreased when combined with Osilodrostat. | [DB00091] Cyclosporine: The metabolism of Acetaminophen can be decreased when combined with Cyclosporine. | [DB00496] Darifenacin: The metabolism of Acetaminophen can be decreased when combined with Darifenacin. | [DB00285] Venlafaxine: Venlafaxine may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00264] Metoprolol: The metabolism of Acetaminophen can be decreased when combined with Metoprolol. | [DB00349] Clobazam: The serum concentration of Acetaminophen can be increased when it is combined with Clobazam. | [DB00468] Quinine: The metabolism of Acetaminophen can be decreased when combined with Quinine. | [DB00608] Chloroquine: The metabolism of Acetaminophen can be decreased when combined with Chloroquine. | [DB00622] Nicardipine: The metabolism of Acetaminophen can be decreased when combined with Nicardipine. | [DB06603] Panobinostat: The metabolism of Acetaminophen can be decreased when combined with Panobinostat. | [DB11586] Asunaprevir: The metabolism of Acetaminophen can be decreased when combined with Asunaprevir. | [DB00476] Duloxetine: The metabolism of Acetaminophen can be decreased when combined with Duloxetine. | [DB01087] Primaquine: The metabolism of Acetaminophen can be decreased when combined with Primaquine. | [DB09291] Rolapitant: The metabolism of Acetaminophen can be decreased when combined with Rolapitant. | [DB12332] Rucaparib: The metabolism of Acetaminophen can be decreased when combined with Rucaparib. | [DB06729] Sulfaphenazole: The metabolism of Acetaminophen can be decreased when combined with Sulfaphenazole. | [DB06819] Phenylbutyric acid: The metabolism of Acetaminophen can be decreased when combined with Phenylbutyric acid. | [DB12693] Ritanserin: The metabolism of Acetaminophen can be decreased when combined with Ritanserin. | [DB00169] Cholecalciferol: The metabolism of Acetaminophen can be decreased when combined with Cholecalciferol. | [DB00857] Terbinafine: The metabolism of Acetaminophen can be decreased when combined with Terbinafine. | [DB01074] Perhexiline: The metabolism of Acetaminophen can be decreased when combined with Perhexiline. | [DB02703] Fusidic acid: The metabolism of Acetaminophen can be decreased when combined with Fusidic acid. | [DB06684] Vilazodone: The metabolism of Acetaminophen can be decreased when combined with Vilazodone. | [DB06708] Lumefantrine: The metabolism of Acetaminophen can be decreased when combined with Lumefantrine. | [DB09238] Manidipine: The metabolism of Acetaminophen can be decreased when combined with Manidipine. | [DB09167] Dosulepin: The metabolism of Acetaminophen can be decreased when combined with Dosulepin. | [DB00176] Fluvoxamine: The metabolism of Acetaminophen can be decreased when combined with Fluvoxamine. | [DB00363] Clozapine: The serum concentration of Clozapine can be increased when it is combined with Acetaminophen. | [DB04871] Lorcaserin: The metabolism of Acetaminophen can be decreased when combined with Lorcaserin. | [DB15982] Berotralstat: The metabolism of Acetaminophen can be decreased when combined with Berotralstat. | [DB00752] Tranylcypromine: The metabolism of Acetaminophen can be decreased when combined with Tranylcypromine. | [DB00715] Paroxetine: The metabolism of Acetaminophen can be decreased when combined with Paroxetine. | [DB01012] Cinacalcet: The metabolism of Acetaminophen can be decreased when combined with Cinacalcet. | [DB01156] Bupropion: The metabolism of Acetaminophen can be decreased when combined with Bupropion. | [DB01182] Propafenone: The metabolism of Acetaminophen can be decreased when combined with Propafenone. | [DB01218] Halofantrine: The metabolism of Acetaminophen can be decreased when combined with Halofantrine. | [DB08909] Glycerol phenylbutyrate: The metabolism of Acetaminophen can be decreased when combined with Glycerol phenylbutyrate. | [DB00604] Cisapride: The metabolism of Acetaminophen can be decreased when combined with Cisapride. | [DB00312] Pentobarbital: The metabolism of Acetaminophen can be increased when combined with Pentobarbital. | [DB01006] Letrozole: The metabolism of Acetaminophen can be decreased when combined with Letrozole. | [DB09330] Osimertinib: The serum concentration of Acetaminophen can be decreased when it is combined with Osimertinib. | [DB08881] Vemurafenib: The serum concentration of Acetaminophen can be increased when it is combined with Vemurafenib. | [DB11642] Pitolisant: The serum concentration of Acetaminophen can be decreased when it is combined with Pitolisant. | [DB01377] Magnesium oxide: Magnesium oxide can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB06723] Aluminum hydroxide: Aluminum hydroxide can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB06724] Calcium carbonate: Calcium carbonate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB08938] Magaldrate: Magaldrate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB09104] Magnesium hydroxide: Magnesium hydroxide can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB09281] Magnesium trisilicate: Magnesium trisilicate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB09481] Magnesium carbonate: Magnesium carbonate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB13209] Bismuth subnitrate: Bismuth subnitrate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB13249] Magnesium silicate: Magnesium silicate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB13280] Aluminium acetoacetate: Aluminium acetoacetate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB13322] Hydrotalcite: Hydrotalcite can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB13486] Magnesium peroxide: Magnesium peroxide can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB13595] Almasilate: Almasilate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB13626] Aluminium glycinate: Aluminium glycinate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB13650] Aloglutamol: Aloglutamol can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB13829] Calcium silicate: Calcium silicate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB14517] Aluminium phosphate: Aluminium phosphate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB14583] Segesterone acetate: The metabolism of Segesterone acetate can be increased when combined with Acetaminophen. | [DB00229] Cefotiam: Cefotiam may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00267] Cefmenoxime: Cefmenoxime may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00274] Cefmetazole: Cefmetazole may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00282] Pamidronic acid: Pamidronic acid may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00300] Tenofovir disoproxil: Tenofovir disoproxil may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00369] Cidofovir: Cidofovir may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00430] Cefpiramide: Cefpiramide may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00438] Ceftazidime: Ceftazidime may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00447] Loracarbef: Loracarbef may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00456] Cefalotin: Cefalotin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00493] Cefotaxime: Cefotaxime may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00529] Foscarnet: Foscarnet may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00577] Valaciclovir: Valaciclovir may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00626] Bacitracin: Bacitracin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00681] Amphotericin B: Amphotericin B may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00689] Cephaloglycin: Cephaloglycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00718] Adefovir dipivoxil: Adefovir dipivoxil may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00738] Pentamidine: Pentamidine may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00833] Cefaclor: Cefaclor may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00923] Ceforanide: Ceforanide may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00958] Carboplatin: Carboplatin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01066] Cefditoren: Cefditoren may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01111] Colistimethate: Colistimethate may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01112] Cefuroxime: Cefuroxime may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01139] Cefapirin: Cefapirin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01140] Cefadroxil: Cefadroxil may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01150] Cefprozil: Cefprozil may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01326] Cefamandole: Cefamandole may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01327] Cefazolin: Cefazolin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01328] Cefonicid: Cefonicid may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01330] Cefotetan: Cefotetan may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01331] Cefoxitin: Cefoxitin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01332] Ceftizoxime: Ceftizoxime may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01333] Cefradine: Cefradine may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01413] Cefepime: Cefepime may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01414] Cefacetrile: Cefacetrile may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01415] Ceftibuten: Ceftibuten may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01416] Cefpodoxime: Cefpodoxime may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB02247] Hydrolyzed Cephalothin: Hydrolyzed Cephalothin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB03450] Cephalothin Group: Cephalothin Group may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB04570] Latamoxef: Latamoxef may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB04918] Ceftobiprole: Ceftobiprole may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB06590] Ceftaroline fosamil: Ceftaroline fosamil may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB09008] Cefaloridine: Cefaloridine may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB09062] Cefminox: Cefminox may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB11367] Cefroxadine: Cefroxadine may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB11935] Flomoxef: Flomoxef may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB13266] Cefatrizine: Cefatrizine may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB13461] Cefcapene: Cefcapene may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB13470] Cefodizime: Cefodizime may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB13499] Cefsulodin: Cefsulodin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB13504] Cefetamet: Cefetamet may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB13638] Cefbuperazone: Cefbuperazone may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB13667] Cefozopran: Cefozopran may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB13682] Cefpirome: Cefpirome may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB13778] Cefazedone: Cefazedone may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB13821] Ceftezole: Ceftezole may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB13868] Adefovir: Adefovir may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB14126] Tenofovir: Tenofovir may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB14713] Inotersen: Inotersen may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01212] Ceftriaxone: Ceftriaxone may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01329] Cefoperazone: Cefoperazone may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01356] Lithium cation: Lithium cation may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB14507] Lithium citrate: Lithium citrate may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00452] Framycetin: Framycetin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB01421] Paromomycin: Paromomycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB04263] Geneticin: Geneticin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB04626] Apramycin: Apramycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB04808] Neamine: Neamine may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB08437] Puromycin: Puromycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB11512] Dihydrostreptomycin: Dihydrostreptomycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB11520] Hygromycin B: Hygromycin B may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00007] Leuprolide: Leuprolide may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00014] Goserelin: Goserelin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00017] Salmon calcitonin: Salmon calcitonin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00035] Desmopressin: Desmopressin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00080] Daptomycin: Daptomycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00081] Tositumomab: Tositumomab may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00158] Folic acid: Folic acid may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00181] Baclofen: Baclofen may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00182] Amphetamine: Amphetamine may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00185] Cevimeline: Cevimeline may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00190] Carbidopa: Carbidopa may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00198] Oseltamivir: Oseltamivir may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00200] Hydroxocobalamin: Hydroxocobalamin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00225] Gadodiamide: Gadodiamide may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00230] Pregabalin: Pregabalin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00231] Temazepam: Temazepam may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00235] Milrinone: Milrinone may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00245] Benzatropine: Benzatropine may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00254] Doxycycline: Doxycycline may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00271] Diatrizoate: Diatrizoate may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00279] Liothyronine: Liothyronine may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00289] Atomoxetine: Atomoxetine may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00290] Bleomycin: Bleomycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00292] Etomidate: Etomidate may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00303] Ertapenem: Ertapenem may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00308] Ibutilide: Ibutilide may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00319] Piperacillin: Acetaminophen may decrease the excretion rate of Piperacillin which could result in a higher serum level. | [DB00322] Floxuridine: Acetaminophen may decrease the excretion rate of Floxuridine which could result in a higher serum level. | [DB00323] Tolcapone: Acetaminophen may decrease the excretion rate of Tolcapone which could result in a higher serum level. | [DB00327] Hydromorphone: Acetaminophen may decrease the excretion rate of Hydromorphone which could result in a higher serum level. | [DB00330] Ethambutol: Acetaminophen may decrease the excretion rate of Ethambutol which could result in a higher serum level. | [DB00339] Pyrazinamide: Acetaminophen may decrease the excretion rate of Pyrazinamide which could result in a higher serum level. | [DB00355] Aztreonam: Acetaminophen may decrease the excretion rate of Aztreonam which could result in a higher serum level. | [DB00364] Sucralfate: Acetaminophen may decrease the excretion rate of Sucralfate which could result in a higher serum level. | [DB00372] Thiethylperazine: Acetaminophen may decrease the excretion rate of Thiethylperazine which could result in a higher serum level. | [DB00377] Palonosetron: Acetaminophen may decrease the excretion rate of Palonosetron which could result in a higher serum level. | [DB00380] Dexrazoxane: Acetaminophen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. | [DB00413] Pramipexole: Acetaminophen may decrease the excretion rate of Pramipexole which could result in a higher serum level. | [DB00415] Ampicillin: Acetaminophen may decrease the excretion rate of Ampicillin which could result in a higher serum level. | [DB00432] Trifluridine: Acetaminophen may decrease the excretion rate of Trifluridine which could result in a higher serum level. | [DB00437] Allopurinol: Acetaminophen may decrease the excretion rate of Allopurinol which could result in a higher serum level. | [DB00441] Gemcitabine: Acetaminophen may decrease the excretion rate of Gemcitabine which could result in a higher serum level. | [DB00492] Fosinopril: Acetaminophen may decrease the excretion rate of Fosinopril which could result in a higher serum level. | [DB00535] Cefdinir: Acetaminophen may decrease the excretion rate of Cefdinir which could result in a higher serum level. | [DB00548] Azelaic acid: Acetaminophen may decrease the excretion rate of Azelaic acid which could result in a higher serum level. | [DB00558] Zanamivir: Acetaminophen may decrease the excretion rate of Zanamivir which could result in a higher serum level. | [DB00569] Fondaparinux: Acetaminophen may decrease the excretion rate of Fondaparinux which could result in a higher serum level. | [DB00583] Levocarnitine: Acetaminophen may decrease the excretion rate of Levocarnitine which could result in a higher serum level. | [DB00591] Fluocinolone acetonide: Acetaminophen may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level. | [DB00597] Gadoteridol: Acetaminophen may decrease the excretion rate of Gadoteridol which could result in a higher serum level. | [DB00612] Bisoprolol: Acetaminophen may decrease the excretion rate of Bisoprolol which could result in a higher serum level. | [DB00628] Clorazepic acid: Acetaminophen may decrease the excretion rate of Clorazepic acid which could result in a higher serum level. | [DB00631] Clofarabine: Acetaminophen may decrease the excretion rate of Clofarabine which could result in a higher serum level. | [DB00651] Dyphylline: Acetaminophen may decrease the excretion rate of Dyphylline which could result in a higher serum level. | [DB00657] Mecamylamine: Acetaminophen may decrease the excretion rate of Mecamylamine which could result in a higher serum level. | [DB00660] Metaxalone: Acetaminophen may decrease the excretion rate of Metaxalone which could result in a higher serum level. | [DB00665] Nilutamide: Acetaminophen may decrease the excretion rate of Nilutamide which could result in a higher serum level. | [DB00672] Chlorpropamide: Acetaminophen may decrease the excretion rate of Chlorpropamide which could result in a higher serum level. | [DB00706] Tamsulosin: Acetaminophen may decrease the excretion rate of Tamsulosin which could result in a higher serum level. | [DB00713] Oxacillin: Acetaminophen may decrease the excretion rate of Oxacillin which could result in a higher serum level. | [DB00716] Nedocromil: Acetaminophen may decrease the excretion rate of Nedocromil which could result in a higher serum level. | [DB00722] Lisinopril: Acetaminophen may decrease the excretion rate of Lisinopril which could result in a higher serum level. | [DB00731] Nateglinide: Acetaminophen may decrease the excretion rate of Nateglinide which could result in a higher serum level. | [DB00733] Pralidoxime: Acetaminophen may decrease the excretion rate of Pralidoxime which could result in a higher serum level. | [DB00743] Gadobenic acid: Acetaminophen may decrease the excretion rate of Gadobenic acid which could result in a higher serum level. | [DB00760] Meropenem: Acetaminophen may decrease the excretion rate of Meropenem which could result in a higher serum level. | [DB00761] Potassium chloride: Acetaminophen may decrease the excretion rate of Potassium chloride which could result in a higher serum level. | [DB00775] Tirofiban: Acetaminophen may decrease the excretion rate of Tirofiban which could result in a higher serum level. | [DB00782] Propantheline: Acetaminophen may decrease the excretion rate of Propantheline which could result in a higher serum level. | [DB00789] Gadopentetic acid: Acetaminophen may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. | [DB00790] Perindopril: Acetaminophen may decrease the excretion rate of Perindopril which could result in a higher serum level. | [DB00800] Fenoldopam: Acetaminophen may decrease the excretion rate of Fenoldopam which could result in a higher serum level. | [DB00804] Dicyclomine: Acetaminophen may decrease the excretion rate of Dicyclomine which could result in a higher serum level. | [DB00811] Ribavirin: Acetaminophen may decrease the excretion rate of Ribavirin which could result in a higher serum level. | [DB00828] Fosfomycin: Acetaminophen may decrease the excretion rate of Fosfomycin which could result in a higher serum level. | [DB00839] Tolazamide: Acetaminophen may decrease the excretion rate of Tolazamide which could result in a higher serum level. | [DB00841] Dobutamine: Acetaminophen may decrease the excretion rate of Dobutamine which could result in a higher serum level. | [DB00842] Oxazepam: Acetaminophen may decrease the excretion rate of Oxazepam which could result in a higher serum level. | [DB00853] Temozolomide: Acetaminophen may decrease the excretion rate of Temozolomide which could result in a higher serum level. | [DB00871] Terbutaline: Acetaminophen may decrease the excretion rate of Terbutaline which could result in a higher serum level. | [DB00894] Testolactone: Acetaminophen may decrease the excretion rate of Testolactone which could result in a higher serum level. | [DB00900] Didanosine: Acetaminophen may decrease the excretion rate of Didanosine which could result in a higher serum level. | [DB00911] Tinidazole: Acetaminophen may decrease the excretion rate of Tinidazole which could result in a higher serum level. | [DB00918] Almotriptan: Acetaminophen may decrease the excretion rate of Almotriptan which could result in a higher serum level. | [DB00928] Azacitidine: Acetaminophen may decrease the excretion rate of Azacitidine which could result in a higher serum level. | [DB00953] Rizatriptan: Acetaminophen may decrease the excretion rate of Rizatriptan which could result in a higher serum level. | [DB00960] Pindolol: Acetaminophen may decrease the excretion rate of Pindolol which could result in a higher serum level. | [DB00962] Zaleplon: Acetaminophen may decrease the excretion rate of Zaleplon which could result in a higher serum level. | [DB00968] Methyldopa: Acetaminophen may decrease the excretion rate of Methyldopa which could result in a higher serum level. | [DB00988] Dopamine: Acetaminophen may decrease the excretion rate of Dopamine which could result in a higher serum level. | [DB00995] Auranofin: Acetaminophen may decrease the excretion rate of Auranofin which could result in a higher serum level. | [DB01001] Albuterol: Acetaminophen may decrease the excretion rate of Salbutamol which could result in a higher serum level. | [DB01004] Ganciclovir: Acetaminophen may decrease the excretion rate of Ganciclovir which could result in a higher serum level. | [DB01010] Edrophonium: Acetaminophen may decrease the excretion rate of Edrophonium which could result in a higher serum level. | [DB01018] Guanfacine: Acetaminophen may decrease the excretion rate of Guanfacine which could result in a higher serum level. | [DB01022] Phylloquinone: Acetaminophen may decrease the excretion rate of Phylloquinone which could result in a higher serum level. | [DB01024] Mycophenolic acid: Acetaminophen may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level. | [DB01036] Tolterodine: Acetaminophen may decrease the excretion rate of Tolterodine which could result in a higher serum level. | [DB01043] Memantine: Acetaminophen may decrease the excretion rate of Memantine which could result in a higher serum level. | [DB01046] Lubiprostone: Acetaminophen may decrease the excretion rate of Lubiprostone which could result in a higher serum level. | [DB01048] Abacavir: Acetaminophen may decrease the excretion rate of Abacavir which could result in a higher serum level. | [DB01060] Amoxicillin: Acetaminophen may decrease the excretion rate of Amoxicillin which could result in a higher serum level. | [DB01067] Glipizide: Acetaminophen may decrease the excretion rate of Glipizide which could result in a higher serum level. | [DB01099] Flucytosine: Acetaminophen may decrease the excretion rate of Flucytosine which could result in a higher serum level. | [DB01101] Capecitabine: Acetaminophen may decrease the excretion rate of Capecitabine which could result in a higher serum level. | [DB01105] Sibutramine: Acetaminophen may decrease the excretion rate of Sibutramine which could result in a higher serum level. | [DB01124] Tolbutamide: Acetaminophen may decrease the excretion rate of Tolbutamide which could result in a higher serum level. | [DB01133] Tiludronic acid: Acetaminophen may decrease the excretion rate of Tiludronic acid which could result in a higher serum level. | [DB01135] Doxacurium: Acetaminophen may decrease the excretion rate of Doxacurium which could result in a higher serum level. | [DB01148] Flavoxate: Acetaminophen may decrease the excretion rate of Flavoxate which could result in a higher serum level. | [DB01157] Trimetrexate: Acetaminophen may decrease the excretion rate of Trimetrexate which could result in a higher serum level. | [DB01170] Guanethidine: Acetaminophen may decrease the excretion rate of Guanethidine which could result in a higher serum level. | [DB01205] Flumazenil: Acetaminophen may decrease the excretion rate of Flumazenil which could result in a higher serum level. | [DB01215] Estazolam: Acetaminophen may decrease the excretion rate of Estazolam which could result in a higher serum level. | [DB01221] Ketamine: Acetaminophen may decrease the excretion rate of Ketamine which could result in a higher serum level. | [DB01240] Epoprostenol: Acetaminophen may decrease the excretion rate of Epoprostenol which could result in a higher serum level. | [DB01249] Iodixanol: Acetaminophen may decrease the excretion rate of Iodixanol which could result in a higher serum level. | [DB01273] Varenicline: Acetaminophen may decrease the excretion rate of Varenicline which could result in a higher serum level. | [DB01275] Hydralazine: Acetaminophen may decrease the excretion rate of Hydralazine which could result in a higher serum level. | [DB01359] Penbutolol: Acetaminophen may decrease the excretion rate of Penbutolol which could result in a higher serum level. | [DB01409] Tiotropium: Acetaminophen may decrease the excretion rate of Tiotropium which could result in a higher serum level. | [DB01427] Amrinone: Acetaminophen may decrease the excretion rate of Amrinone which could result in a higher serum level. | [DB01428] Oxybenzone: Acetaminophen may decrease the excretion rate of Oxybenzone which could result in a higher serum level. | [DB01550] Fenproporex: Acetaminophen may decrease the excretion rate of Fenproporex which could result in a higher serum level. | [DB01563] Chloral hydrate: Acetaminophen may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. | [DB01577] Metamfetamine: Acetaminophen may decrease the excretion rate of Metamfetamine which could result in a higher serum level. | [DB01610] Valganciclovir: Acetaminophen may decrease the excretion rate of Valganciclovir which could result in a higher serum level. | [DB01638] Sorbitol: Acetaminophen may decrease the excretion rate of Sorbitol which could result in a higher serum level. | [DB01685] Topiroxostat: Acetaminophen may decrease the excretion rate of Topiroxostat which could result in a higher serum level. | [DB04895] Pegaptanib: Acetaminophen may decrease the excretion rate of Pegaptanib which could result in a higher serum level. | [DB04920] Clevidipine: Acetaminophen may decrease the excretion rate of Clevidipine which could result in a higher serum level. | [DB04953] Ezogabine: Acetaminophen may decrease the excretion rate of Ezogabine which could result in a higher serum level. | [DB05018] Migalastat: Acetaminophen may decrease the excretion rate of Migalastat which could result in a higher serum level. | [DB05541] Brivaracetam: Acetaminophen may decrease the excretion rate of Brivaracetam which could result in a higher serum level. | [DB06154] Pentaerythritol tetranitrate: Acetaminophen may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level. | [DB06186] Ipilimumab: Acetaminophen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. | [DB06196] Icatibant: Acetaminophen may decrease the excretion rate of Icatibant which could result in a higher serum level. | [DB06203] Alogliptin: Acetaminophen may decrease the excretion rate of Alogliptin which could result in a higher serum level. | [DB06209] Prasugrel: Acetaminophen may decrease the excretion rate of Prasugrel which could result in a higher serum level. | [DB06211] Doripenem: Acetaminophen may decrease the excretion rate of Doripenem which could result in a higher serum level. | [DB06230] Nalmefene: Acetaminophen may decrease the excretion rate of Nalmefene which could result in a higher serum level. | [DB06262] Droxidopa: Acetaminophen may decrease the excretion rate of Droxidopa which could result in a higher serum level. | [DB06335] Saxagliptin: Acetaminophen may decrease the excretion rate of Saxagliptin which could result in a higher serum level. | [DB06402] Telavancin: Acetaminophen may decrease the excretion rate of Telavancin which could result in a higher serum level. | [DB06623] Flupirtine: Acetaminophen may decrease the excretion rate of Flupirtine which could result in a higher serum level. | [DB06637] Dalfampridine: Acetaminophen may decrease the excretion rate of Dalfampridine which could result in a higher serum level. | [DB06705] Gadofosveset trisodium: Acetaminophen may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. | [DB06710] Methyltestosterone: Acetaminophen may decrease the excretion rate of Methyltestosterone which could result in a higher serum level. | [DB06782] Dimercaprol: Acetaminophen may decrease the excretion rate of Dimercaprol which could result in a higher serum level. | [DB06796] Mangafodipir: Acetaminophen may decrease the excretion rate of Mangafodipir which could result in a higher serum level. | [DB06800] Methylnaltrexone: Acetaminophen may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. | [DB06809] Plerixafor: Acetaminophen may decrease the excretion rate of Plerixafor which could result in a higher serum level. | [DB06813] Pralatrexate: Acetaminophen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. | [DB06823] Tiopronin: Acetaminophen may decrease the excretion rate of Tiopronin which could result in a higher serum level. | [DB06824] Triethylenetetramine: Acetaminophen may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. | [DB08824] Ioflupane I-123: Acetaminophen may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. | [DB08826] Deferiprone: Acetaminophen may decrease the excretion rate of Deferiprone which could result in a higher serum level. | [DB08840] N-methylnicotinamide: Acetaminophen may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level. | [DB08872] Gabapentin enacarbil: Acetaminophen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. | [DB08894] Peginesatide: Acetaminophen may decrease the excretion rate of Peginesatide which could result in a higher serum level. | [DB08897] Aclidinium: Acetaminophen may decrease the excretion rate of Aclidinium which could result in a higher serum level. | [DB08900] Teduglutide: Acetaminophen may decrease the excretion rate of Teduglutide which could result in a higher serum level. | [DB08905] Formestane: Acetaminophen may decrease the excretion rate of Formestane which could result in a higher serum level. | [DB08911] Trametinib: Acetaminophen may decrease the excretion rate of Trametinib which could result in a higher serum level. | [DB08932] Macitentan: Acetaminophen may decrease the excretion rate of Macitentan which could result in a higher serum level. | [DB09050] Ceftolozane: Acetaminophen may decrease the excretion rate of Ceftolozane which could result in a higher serum level. | [DB09066] Corifollitropin alfa: Acetaminophen may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. | [DB09081] Idebenone: Acetaminophen may decrease the excretion rate of Idebenone which could result in a higher serum level. | [DB09082] Vilanterol: Acetaminophen may decrease the excretion rate of Vilanterol which could result in a higher serum level. | [DB09089] Trimebutine: Acetaminophen may decrease the excretion rate of Trimebutine which could result in a higher serum level. | [DB09091] Tixocortol: Acetaminophen may decrease the excretion rate of Tixocortol which could result in a higher serum level. | [DB09103] Ancestim: Acetaminophen may decrease the excretion rate of Ancestim which could result in a higher serum level. | [DB09106] Hydroxyethyl Starch: Acetaminophen may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. | [DB09111] Pentastarch: Acetaminophen may decrease the excretion rate of Pentastarch which could result in a higher serum level. | [DB09121] Aurothioglucose: Acetaminophen may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. | [DB09129] Chromic chloride: Acetaminophen may decrease the excretion rate of Chromic chloride which could result in a higher serum level. | [DB09132] Gadoteric acid: Acetaminophen may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. | [DB09133] Iothalamic acid: Acetaminophen may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. | [DB09134] Ioversol: Acetaminophen may decrease the excretion rate of Ioversol which could result in a higher serum level. | [DB09135] Ioxilan: Acetaminophen may decrease the excretion rate of Ioxilan which could result in a higher serum level. | [DB09136] Isosulfan blue: Acetaminophen may decrease the excretion rate of Isosulfan blue which could result in a higher serum level. | [DB09137] Technetium Tc-99m mebrofenin: Acetaminophen may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level. | [DB09139] Technetium Tc-99m oxidronate: Acetaminophen may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level. | [DB09148] Florbetaben F-18: Acetaminophen may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. | [DB09149] Florbetapir F-18: Acetaminophen may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. | [DB09156] Iopromide: Acetaminophen may decrease the excretion rate of Iopromide which could result in a higher serum level. | [DB09163] Technetium Tc-99m exametazime: Acetaminophen may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level. | [DB09165] Technetium Tc-99m pyrophosphate: Acetaminophen may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. | [DB09185] Viloxazine: The metabolism of Acetaminophen can be decreased when combined with Viloxazine. | [DB09194] Etoperidone: Acetaminophen may decrease the excretion rate of Etoperidone which could result in a higher serum level. | [DB09195] Lorpiprazole: Acetaminophen may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. | [DB09204] Arotinolol: Acetaminophen may decrease the excretion rate of Arotinolol which could result in a higher serum level. | [DB09205] Moxisylyte: Acetaminophen may decrease the excretion rate of Moxisylyte which could result in a higher serum level. | [DB09209] Pholcodine: Acetaminophen may decrease the excretion rate of Pholcodine which could result in a higher serum level. | [DB09210] Piracetam: Acetaminophen may decrease the excretion rate of Piracetam which could result in a higher serum level. | [DB09219] Bisoxatin: Acetaminophen may decrease the excretion rate of Bisoxatin which could result in a higher serum level. | [DB09220] Nicorandil: Acetaminophen may decrease the excretion rate of Nicorandil which could result in a higher serum level. | [DB09223] Blonanserin: Acetaminophen may decrease the excretion rate of Blonanserin which could result in a higher serum level. | [DB09244] Pirlindole: Acetaminophen may decrease the excretion rate of Pirlindole which could result in a higher serum level. | [DB09245] Toloxatone: Acetaminophen may decrease the excretion rate of Toloxatone which could result in a higher serum level. | [DB09255] Dextran: Acetaminophen may decrease the excretion rate of Dextran which could result in a higher serum level. | [DB09257] Gimeracil: Acetaminophen may decrease the excretion rate of Gimeracil which could result in a higher serum level. | [DB09262] Imidafenacin: Acetaminophen may decrease the excretion rate of Imidafenacin which could result in a higher serum level. | [DB09264] Idarucizumab: Acetaminophen may decrease the excretion rate of Idarucizumab which could result in a higher serum level. | [DB09265] Lixisenatide: Acetaminophen may decrease the excretion rate of Lixisenatide which could result in a higher serum level. | [DB09268] Picosulfuric acid: Acetaminophen may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. | [DB09277] Choline C 11: Acetaminophen may decrease the excretion rate of Choline C 11 which could result in a higher serum level. | [DB09292] Sacubitril: Acetaminophen may decrease the excretion rate of Sacubitril which could result in a higher serum level. | [DB09317] Synthetic Conjugated Estrogens, A: Acetaminophen may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level. | [DB09318] Synthetic Conjugated Estrogens, B: Acetaminophen may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level. | [DB09320] Procaine benzylpenicillin: Acetaminophen may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. | [DB09324] Sulbactam: Acetaminophen may decrease the excretion rate of Sulbactam which could result in a higher serum level. | [DB09325] Sodium fluoride: Acetaminophen may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. | [DB09329] Antihemophilic factor (recombinant), PEGylated: Acetaminophen may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. | [DB09344] Invert sugar: Acetaminophen may decrease the excretion rate of Invert sugar which could result in a higher serum level. | [DB09357] Dexpanthenol: Acetaminophen may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. | [DB09394] Phosphoric acid: Acetaminophen may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. | [DB09395] Sodium acetate: Acetaminophen may decrease the excretion rate of Sodium acetate which could result in a higher serum level. | [DB09407] Magnesium chloride: Acetaminophen may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. | [DB09418] Potassium perchlorate: Acetaminophen may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level. | [DB09472] Sodium sulfate: Acetaminophen may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. | [DB09477] Enalaprilat: Acetaminophen may decrease the excretion rate of Enalaprilat which could result in a higher serum level. | [DB09488] Acrivastine: Acetaminophen may decrease the excretion rate of Acrivastine which could result in a higher serum level. | [DB09496] Octinoxate: Acetaminophen may decrease the excretion rate of Octinoxate which could result in a higher serum level. | [DB09502] Fludeoxyglucose (18F): Acetaminophen may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. | [DB09546] Iobenguane sulfate I-123: Acetaminophen may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level. | [DB11090] Potassium nitrate: Acetaminophen may decrease the excretion rate of Potassium nitrate which could result in a higher serum level. | [DB11098] Potassium bicarbonate: Acetaminophen may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level. | [DB11102] N-acetyltyrosine: Acetaminophen may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level. | [DB11114] Eucalyptus oil: Acetaminophen may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. | [DB11127] Selenious acid: Acetaminophen may decrease the excretion rate of Selenious acid which could result in a higher serum level. | [DB11130] Opium: Acetaminophen may decrease the excretion rate of Opium which could result in a higher serum level. | [DB11135] Selenium: Acetaminophen may decrease the excretion rate of Selenium which could result in a higher serum level. | [DB11136] Chromium: Acetaminophen may decrease the excretion rate of Chromium which could result in a higher serum level. | [DB11145] Oxyquinoline: Acetaminophen may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. | [DB11156] Pyrantel: Acetaminophen may decrease the excretion rate of Pyrantel which could result in a higher serum level. | [DB11164] Bicisate: Acetaminophen may decrease the excretion rate of Bicisate which could result in a higher serum level. | [DB11251] Tocopherol: Acetaminophen may decrease the excretion rate of Tocopherol which could result in a higher serum level. | [DB11328] Tetradecyl hydrogen sulfate (ester): Acetaminophen may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. | [DB11338] Clove oil: Acetaminophen may decrease the excretion rate of Clove oil which could result in a higher serum level. | [DB11358] Evening primrose oil: Acetaminophen may decrease the excretion rate of Evening primrose oil which could result in a higher serum level. | [DB11364] Pidotimod: Acetaminophen may decrease the excretion rate of Pidotimod which could result in a higher serum level. | [DB11560] Lesinurad: Acetaminophen may decrease the excretion rate of Lesinurad which could result in a higher serum level. | [DB11577] Indigotindisulfonic acid: Acetaminophen may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level. | [DB11587] Etafedrine: Acetaminophen may decrease the excretion rate of Etafedrine which could result in a higher serum level. | [DB11598] Antithrombin III human: Acetaminophen may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. | [DB11691] Naldemedine: Acetaminophen may decrease the excretion rate of Naldemedine which could result in a higher serum level. | [DB11699] Tropisetron: Acetaminophen may decrease the excretion rate of Tropisetron which could result in a higher serum level. | [DB11915] Valbenazine: Acetaminophen may decrease the excretion rate of Valbenazine which could result in a higher serum level. | [DB11989] Benznidazole: Acetaminophen may decrease the excretion rate of Benznidazole which could result in a higher serum level. | [DB12007] Isoflavone: Acetaminophen may decrease the excretion rate of Isoflavone which could result in a higher serum level. | [DB12107] Vaborbactam: Acetaminophen may decrease the excretion rate of Vaborbactam which could result in a higher serum level. | [DB12161] Deutetrabenazine: Acetaminophen may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level. | [DB12278] Propiverine: Acetaminophen may decrease the excretion rate of Propiverine which could result in a higher serum level. | [DB12783] Benserazide: Acetaminophen may decrease the excretion rate of Benserazide which could result in a higher serum level. | [DB13025] Tiapride: Acetaminophen may decrease the excretion rate of Tiapride which could result in a higher serum level. | [DB13156] Inosine pranobex: Acetaminophen may decrease the excretion rate of Inosine pranobex which could result in a higher serum level. | [DB13178] Inositol: Acetaminophen may decrease the excretion rate of Inositol which could result in a higher serum level. | [DB13185] Oxabolone cipionate: Acetaminophen may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level. | [DB13191] Phosphocreatine: Acetaminophen may decrease the excretion rate of Phosphocreatine which could result in a higher serum level. | [DB13269] Dichlorobenzyl alcohol: Acetaminophen may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. | [DB13293] Ipecac: Acetaminophen may decrease the excretion rate of Ipecac which could result in a higher serum level. | [DB13873] Fenofibric acid: Acetaminophen may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. | [DB13884] Albutrepenonacog alfa: Acetaminophen may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. | [DB13909] Bismuth subgallate: Acetaminophen may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. | [DB13967] Patent Blue: Acetaminophen may decrease the excretion rate of Patent Blue which could result in a higher serum level. | [DB14007] Pentetic acid: Acetaminophen may decrease the excretion rate of Pentetic acid which could result in a higher serum level. | [DB14498] Potassium acetate: Acetaminophen may decrease the excretion rate of Potassium acetate which could result in a higher serum level. | [DB14499] Potassium sulfate: Acetaminophen may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. | [DB14526] Chromic citrate: Acetaminophen may decrease the excretion rate of Chromic citrate which could result in a higher serum level. | [DB14527] Chromic nitrate: Acetaminophen may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. | [DB14528] Chromium gluconate: Acetaminophen may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. | [DB14529] Chromium nicotinate: Acetaminophen may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. | [DB14530] Chromous sulfate: Acetaminophen may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. | [DB14754] Solriamfetol: Acetaminophen may decrease the excretion rate of Solriamfetol which could result in a higher serum level. | [DB11085] Resorcinol: Acetaminophen may decrease the excretion rate of Resorcinol which could result in a higher serum level. | [DB15593] Golodirsen: Acetaminophen may decrease the excretion rate of Golodirsen which could result in a higher serum level. | [DB00373] Timolol: Acetaminophen may decrease the excretion rate of Timolol which could result in a higher serum level. | [DB00490] Buspirone: Acetaminophen may decrease the excretion rate of Buspirone which could result in a higher serum level. | [DB01203] Nadolol: Acetaminophen may decrease the excretion rate of Nadolol which could result in a higher serum level. | [DB01224] Quetiapine: Acetaminophen may decrease the excretion rate of Quetiapine which could result in a higher serum level. | [DB01267] Paliperidone: Acetaminophen may decrease the excretion rate of Paliperidone which could result in a higher serum level. | [DB06702] Fesoterodine: Acetaminophen may decrease the excretion rate of Fesoterodine which could result in a higher serum level. | [DB00206] Reserpine: Reserpine may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00213] Pantoprazole: Pantoprazole may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00273] Topiramate: Topiramate may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00440] Trimethoprim: Acetaminophen may decrease the excretion rate of Trimethoprim which could result in a higher serum level. | [DB00480] Lenalidomide: Acetaminophen may decrease the excretion rate of Lenalidomide which could result in a higher serum level. | [DB00624] Testosterone: Acetaminophen may decrease the excretion rate of Testosterone which could result in a higher serum level. | [DB00669] Sumatriptan: Acetaminophen may decrease the excretion rate of Sumatriptan which could result in a higher serum level. | [DB00688] Mycophenolate mofetil: Acetaminophen may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level. | [DB00709] Lamivudine: Acetaminophen may decrease the excretion rate of Lamivudine which could result in a higher serum level. | [DB00759] Tetracycline: Acetaminophen may decrease the excretion rate of Tetracycline which could result in a higher serum level. | [DB00820] Tadalafil: Acetaminophen may decrease the excretion rate of Tadalafil which could result in a higher serum level. | [DB01030] Topotecan: Acetaminophen may decrease the excretion rate of Topotecan which could result in a higher serum level. | [DB01169] Arsenic trioxide: Acetaminophen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. | [DB01222] Budesonide: Acetaminophen may decrease the excretion rate of Budesonide which could result in a higher serum level. | [DB01261] Sitagliptin: Acetaminophen may decrease the excretion rate of Sitagliptin which could result in a higher serum level. | [DB01587] Ketazolam: Acetaminophen may decrease the excretion rate of Ketazolam which could result in a higher serum level. | [DB06695] Dabigatran etexilate: Acetaminophen may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level. | [DB08934] Sofosbuvir: Acetaminophen may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. | [DB09027] Ledipasvir: Acetaminophen may decrease the excretion rate of Ledipasvir which could result in a higher serum level. | [DB09075] Edoxaban: Acetaminophen may decrease the excretion rate of Edoxaban which could result in a higher serum level. | [DB13943] Testosterone cypionate: Acetaminophen may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. | [DB13946] Testosterone undecanoate: Acetaminophen may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level. | [DB00401] Nisoldipine: Acetaminophen may decrease the excretion rate of Nisoldipine which could result in a higher serum level. | [DB00897] Triazolam: Acetaminophen may decrease the excretion rate of Triazolam which could result in a higher serum level. | [DB06228] Rivaroxaban: Acetaminophen may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. | [DB08996] Dimetacrine: Acetaminophen may decrease the excretion rate of Dimetacrine which could result in a higher serum level. | [DB13987] Strontium chloride: Acetaminophen may decrease the excretion rate of Strontium chloride which could result in a higher serum level. | [DB04890] Bepotastine: Acetaminophen may decrease the excretion rate of Bepotastine which could result in a higher serum level. | [DB00982] Isotretinoin: Acetaminophen may decrease the excretion rate of Isotretinoin which could result in a higher serum level. | [DB04930] Permethrin: Acetaminophen may decrease the excretion rate of Permethrin which could result in a higher serum level. | [DB09095] Difluocortolone: Acetaminophen may decrease the excretion rate of Difluocortolone which could result in a higher serum level. | [DB00186] Lorazepam: Lorazepam may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB13139] Levosalbutamol: Acetaminophen may decrease the excretion rate of Levosalbutamol which could result in a higher serum level. | [DB01129] Rabeprazole: Acetaminophen may decrease the excretion rate of Rabeprazole which could result in a higher serum level. | [DB00479] Amikacin: Acetaminophen may decrease the excretion rate of Amikacin which could result in a higher serum level. | [DB00684] Tobramycin: Acetaminophen may decrease the excretion rate of Tobramycin which could result in a higher serum level. | [DB00798] Gentamicin: Acetaminophen may decrease the excretion rate of Gentamicin which could result in a higher serum level. | [DB00955] Netilmicin: Acetaminophen may decrease the excretion rate of Netilmicin which could result in a higher serum level. | [DB00994] Neomycin: Acetaminophen may decrease the excretion rate of Neomycin which could result in a higher serum level. | [DB01082] Streptomycin: Acetaminophen may decrease the excretion rate of Streptomycin which could result in a higher serum level. | [DB01172] Kanamycin: Acetaminophen may decrease the excretion rate of Kanamycin which could result in a higher serum level. | [DB03615] Ribostamycin: Acetaminophen may decrease the excretion rate of Ribostamycin which could result in a higher serum level. | [DB04729] Gentamicin C1a: Acetaminophen may decrease the excretion rate of Gentamicin C1a which could result in a higher serum level. | [DB06696] Arbekacin: Acetaminophen may decrease the excretion rate of Arbekacin which could result in a higher serum level. | [DB12604] Sisomicin: Acetaminophen may decrease the excretion rate of Sisomicin which could result in a higher serum level. | [DB13540] Isepamicin: Acetaminophen may decrease the excretion rate of Isepamicin which could result in a higher serum level. | [DB00552] Pentostatin: Acetaminophen may decrease the excretion rate of Pentostatin which could result in a higher serum level. | [DB13145] Nedaplatin: Acetaminophen may decrease the excretion rate of Nedaplatin which could result in a higher serum level. | [DB00314] Capreomycin: Acetaminophen may decrease the excretion rate of Capreomycin which could result in a higher serum level. | [DB00512] Vancomycin: Acetaminophen may decrease the excretion rate of Vancomycin which could result in a higher serum level. | [DB00515] Cisplatin: Acetaminophen may decrease the excretion rate of Cisplatin which could result in a higher serum level. | [DB00642] Pemetrexed: Acetaminophen may decrease the excretion rate of Pemetrexed which could result in a higher serum level. | [DB12615] Plazomicin: Acetaminophen may decrease the excretion rate of Plazomicin which could result in a higher serum level. | [DB14509] Lithium carbonate: Acetaminophen may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. | [DB00390] Digoxin: Acetaminophen may decrease the excretion rate of Digoxin which could result in a higher serum level. | [DB00803] Colistin: Acetaminophen may decrease the excretion rate of Colistin which could result in a higher serum level. | [DB00903] Etacrynic acid: Etacrynic acid may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00999] Hydrochlorothiazide: Hydrochlorothiazide may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00524] Metolazone: Acetaminophen may decrease the excretion rate of Metolazone which could result in a higher serum level. | [DB00695] Furosemide: Furosemide may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00808] Indapamide: Acetaminophen may decrease the excretion rate of Indapamide which could result in a higher serum level. | [DB00887] Bumetanide: Bumetanide may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB09338] Mersalyl: Acetaminophen may decrease the excretion rate of Mersalyl which could result in a higher serum level. | [DB00214] Torasemide: Torasemide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00232] Methyclothiazide: Methyclothiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00310] Chlorthalidone: Chlorthalidone may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00311] Ethoxzolamide: Ethoxzolamide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00421] Spironolactone: Spironolactone may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00436] Bendroflumethiazide: Bendroflumethiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00562] Benzthiazide: Benzthiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00594] Amiloride: Amiloride may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00606] Cyclothiazide: Cyclothiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00774] Hydroflumethiazide: Hydroflumethiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00880] Chlorothiazide: Chlorothiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB01021] Trichlormethiazide: Trichlormethiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB01144] Diclofenamide: Diclofenamide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB01324] Polythiazide: Polythiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB01325] Quinethazone: Quinethazone may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB02925] Piretanide: Piretanide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB04831] Tienilic acid: Tienilic acid may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB05034] Ularitide: Ularitide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB08961] Azosemide: Azosemide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB09015] Canrenoic acid: Canrenoic acid may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB09125] Potassium citrate: Potassium citrate may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB12221] Canrenone: Canrenone may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB12670] Rolofylline: Rolofylline may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB12704] Spiradoline: Spiradoline may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB12766] Cicletanine: Cicletanine may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13284] Meticrane: Meticrane may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13405] Mefruside: Mefruside may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13430] Mebutizide: Mebutizide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13532] Cyclopenthiazide: Cyclopenthiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13617] Clorexolone: Clorexolone may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13663] Clofenamide: Clofenamide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13708] Fenquizone: Fenquizone may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13792] Clopamide: Clopamide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13801] Muzolimine: Muzolimine may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13803] Xipamide: Xipamide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13989] Epitizide: Epitizide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB14500] Potassium: Potassium may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00703] Methazolamide: Methazolamide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00819] Acetazolamide: Acetazolamide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB09235] Efonidipine: Efonidipine may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00742] Mannitol: Mannitol may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB00909] Zonisamide: Acetaminophen may decrease the excretion rate of Zonisamide which could result in a higher serum level. | [DB08907] Canagliflozin: Acetaminophen may decrease the excretion rate of Canagliflozin which could result in a higher serum level. | [DB00700] Eplerenone: Eplerenone may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB01345] Potassium cation: Acetaminophen may decrease the excretion rate of Potassium cation which could result in a higher serum level. | [DB15861] Buthiazide: Buthiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB15959] Tripamide: Tripamide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB09401] Isosorbide: Isosorbide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00325] Nitroprusside: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Nitroprusside. | [DB00359] Sulfadiazine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Sulfadiazine. | [DB00435] Nitric Oxide: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Nitric Oxide. | [DB00499] Flutamide: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Flutamide. | [DB00698] Nitrofurantoin: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Nitrofurantoin. | [DB00727] Nitroglycerin: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Nitroglycerin. | [DB00891] Sulfapyridine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Sulfapyridine. | [DB01020] Isosorbide mononitrate: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Isosorbide mononitrate. | [DB01438] Phenazopyridine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Phenazopyridine. | [DB01612] Amyl Nitrite: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Amyl Nitrite. | [DB06690] Nitrous oxide: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Nitrous oxide. | [DB06706] Isometheptene: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Isometheptene. | [DB00296] Ropivacaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Ropivacaine. | [DB00961] Mepivacaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Mepivacaine. | [DB01015] Sulfamethoxazole: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Sulfamethoxazole. | [DB00281] Lidocaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Lidocaine. | [DB01233] Metoclopramide: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Metoclopramide. | [DB00313] Valproic acid: The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Acetaminophen. | [DB00297] Bupivacaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Bupivacaine. | [DB00049] Rasburicase: The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Acetaminophen. | [DB00721] Procaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Procaine. | [DB01005] Hydroxyurea: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Hydroxyurea. | [DB09009] Articaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Articaine. | [DB09085] Tetracaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Tetracaine. | [DB09046] Metreleptin: The metabolism of Acetaminophen can be increased when combined with Metreleptin. | [DB00294] Etonogestrel: The metabolism of Etonogestrel can be increased when combined with Acetaminophen. | [DB00304] Desogestrel: The metabolism of Acetaminophen can be increased when combined with Desogestrel. | [DB00367] Levonorgestrel: The metabolism of Levonorgestrel can be increased when combined with Acetaminophen. | [DB00823] Ethynodiol diacetate: The metabolism of Ethynodiol diacetate can be increased when combined with Acetaminophen. | [DB00957] Norgestimate: The metabolism of Norgestimate can be increased when combined with Acetaminophen. | [DB01357] Mestranol: The metabolism of Mestranol can be increased when combined with Acetaminophen. | [DB01395] Drospirenone: The metabolism of Drospirenone can be increased when combined with Acetaminophen. | [DB04574] Estrone sulfate: The metabolism of Estrone sulfate can be increased when combined with Acetaminophen. | [DB04682] Octylphenoxy polyethoxyethanol: The metabolism of Octylphenoxy polyethoxyethanol can be increased when combined with Acetaminophen. | [DB05830] Trestolone: The metabolism of Trestolone can be increased when combined with Acetaminophen. | [DB06713] Norelgestromin: The metabolism of Norelgestromin can be increased when combined with Acetaminophen. | [DB06730] Gestodene: The metabolism of Gestodene can be increased when combined with Acetaminophen. | [DB06789] Hydroxyprogesterone caproate: The metabolism of Hydroxyprogesterone caproate can be increased when combined with Acetaminophen. | [DB09123] Dienogest: The metabolism of Dienogest can be increased when combined with Acetaminophen. | [DB09371] Norethynodrel: The metabolism of Norethynodrel can be increased when combined with Acetaminophen. | [DB09389] Norgestrel: The metabolism of Norgestrel can be increased when combined with Acetaminophen. | [DB11507] Cloprostenol: The metabolism of Cloprostenol can be increased when combined with Acetaminophen. | [DB11619] Gestrinone: The metabolism of Gestrinone can be increased when combined with Acetaminophen. | [DB11636] Nomegestrol: The metabolism of Nomegestrol can be increased when combined with Acetaminophen. | [DB12474] Lynestrenol: The metabolism of Lynestrenol can be increased when combined with Acetaminophen. | [DB13044] Gossypol: The metabolism of Gossypol can be increased when combined with Acetaminophen. | [DB13310] Ormeloxifene: The metabolism of Ormeloxifene can be increased when combined with Acetaminophen. | [DB13528] Chlormadinone: The metabolism of Chlormadinone can be increased when combined with Acetaminophen. | [DB13563] Norgestrienone: The metabolism of Norgestrienone can be increased when combined with Acetaminophen. | [DB13685] Quingestanol: The metabolism of Quingestanol can be increased when combined with Acetaminophen. | [DB13857] Demegestone: The metabolism of Demegestone can be increased when combined with Acetaminophen. | [DB13866] Etynodiol: The metabolism of Etynodiol can be increased when combined with Acetaminophen. | [DB13981] Nomegestrol acetate: The metabolism of Nomegestrol acetate can be increased when combined with Acetaminophen. | [DB14678] Norethindrone enanthate: The metabolism of Norethindrone enanthate can be increased when combined with Acetaminophen. | [DB00603] Medroxyprogesterone acetate: The metabolism of Medroxyprogesterone acetate can be increased when combined with Acetaminophen. | [DB08867] Ulipristal: The metabolism of Ulipristal can be increased when combined with Acetaminophen. | [DB00351] Megestrol acetate: The metabolism of Megestrol acetate can be increased when combined with Acetaminophen. | [DB13944] Testosterone enanthate: The metabolism of Testosterone enanthate can be increased when combined with Acetaminophen. | [DB13953] Estradiol benzoate: The metabolism of Estradiol benzoate can be increased when combined with Acetaminophen. | [DB13954] Estradiol cypionate: The metabolism of Estradiol cypionate can be increased when combined with Acetaminophen. | [DB13956] Estradiol valerate: The metabolism of Estradiol valerate can be increased when combined with Acetaminophen. | [DB00173] Adenine: The metabolism of Acetaminophen can be decreased when combined with Adenine. | [DB09183] Dasabuvir: The metabolism of Acetaminophen can be decreased when combined with Dasabuvir. | [DB09276] Sodium aurothiomalate: The metabolism of Acetaminophen can be decreased when combined with Sodium aurothiomalate. | [DB09296] Ombitasvir: The metabolism of Acetaminophen can be decreased when combined with Ombitasvir. | [DB09297] Paritaprevir: The metabolism of Acetaminophen can be decreased when combined with Paritaprevir. | [DB09298] Silibinin: The metabolism of Acetaminophen can be decreased when combined with Silibinin. | [DB12010] Fostamatinib: The serum concentration of Acetaminophen can be increased when it is combined with Fostamatinib. | [DB13878] Pibrentasvir: The metabolism of Acetaminophen can be decreased when combined with Pibrentasvir. | [DB13879] Glecaprevir: The metabolism of Acetaminophen can be decreased when combined with Glecaprevir. | [DB00567] Cephalexin: The metabolism of Cephalexin can be increased when combined with Acetaminophen. | [DB09299] Tenofovir alafenamide: The serum concentration of Tenofovir alafenamide can be increased when it is combined with Acetaminophen. | [DB01431] Allylestrenol: The metabolism of Allylestrenol can be increased when combined with Acetaminophen. | [DB01656] Roflumilast: The serum concentration of Roflumilast can be increased when it is combined with Acetaminophen. | [DB09071] Tasimelteon: The metabolism of Tasimelteon can be increased when combined with Acetaminophen. | [DB00717] Norethisterone: The metabolism of Norethisterone can be increased when combined with Acetaminophen. | [DB01098] Rosuvastatin: The metabolism of Rosuvastatin can be increased when combined with Acetaminophen. | [DB01624] Zuclopenthixol: The metabolism of Zuclopenthixol can be increased when combined with Acetaminophen. | [DB06218] Lacosamide: The metabolism of Lacosamide can be increased when combined with Acetaminophen. | [DB11273] Dihydroergocornine: The metabolism of Dihydroergocornine can be increased when combined with Acetaminophen. | [DB12515] 9-aminocamptothecin: The metabolism of 9-aminocamptothecin can be increased when combined with Acetaminophen. | [DB12952] Methylprednisone: The metabolism of Methylprednisone can be increased when combined with Acetaminophen. | [DB13345] Dihydroergocristine: The metabolism of Dihydroergocristine can be increased when combined with Acetaminophen. | [DB13385] Dihydroergocryptine: The metabolism of Dihydroergocryptine can be increased when combined with Acetaminophen. | [DB14009] Medical Cannabis: The metabolism of Medical Cannabis can be increased when combined with Acetaminophen. | [DB15444] Elexacaftor: The metabolism of Elexacaftor can be increased when combined with Acetaminophen. | [DB00246] Ziprasidone: The metabolism of Acetaminophen can be decreased when combined with Ziprasidone. | [DB06717] Fosaprepitant: The metabolism of Fosaprepitant can be increased when combined with Acetaminophen. | [DB00207] Azithromycin: The metabolism of Azithromycin can be increased when combined with Acetaminophen. | [DB00590] Doxazosin: The metabolism of Doxazosin can be increased when combined with Acetaminophen. | [DB01039] Fenofibrate: The metabolism of Fenofibrate can be increased when combined with Acetaminophen. | [DB08882] Linagliptin: The metabolism of Acetaminophen can be decreased when combined with Linagliptin. | [DB09030] Vorapaxar: The metabolism of Vorapaxar can be increased when combined with Acetaminophen. | [DB09034] Suvorexant: The metabolism of Suvorexant can be increased when combined with Acetaminophen. | [DB09048] Netupitant: The metabolism of Acetaminophen can be decreased when combined with Netupitant. | [DB11952] Duvelisib: The metabolism of Duvelisib can be increased when combined with Acetaminophen. | [DB12141] Gilteritinib: The serum concentration of Acetaminophen can be increased when it is combined with Gilteritinib. | [DB12887] Tazemetostat: The metabolism of Tazemetostat can be increased when combined with Acetaminophen. | [DB12825] Lefamulin: The metabolism of Lefamulin can be increased when combined with Acetaminophen. | [DB00247] Methysergide: The metabolism of Methysergide can be increased when combined with Acetaminophen. | [DB11742] Ebastine: The metabolism of Ebastine can be increased when combined with Acetaminophen. | [DB11633] Isavuconazole: The metabolism of Acetaminophen can be decreased when combined with Isavuconazole. | [DB00454] Meperidine: The metabolism of Meperidine can be increased when combined with Acetaminophen. | [DB05154] Pretomanid: The metabolism of Pretomanid can be increased when combined with Acetaminophen. | [DB05316] Pimavanserin: The metabolism of Pimavanserin can be increased when combined with Acetaminophen. | [DB12235] Estetrol: The metabolism of Estetrol can be increased when combined with Acetaminophen. | [DB01268] Sunitinib: The metabolism of Sunitinib can be increased when combined with Acetaminophen. | [DB05294] Vandetanib: The metabolism of Vandetanib can be increased when combined with Acetaminophen. | [DB06626] Axitinib: The metabolism of Axitinib can be increased when combined with Acetaminophen. | [DB08865] Crizotinib: The metabolism of Crizotinib can be increased when combined with Acetaminophen. | [DB08877] Ruxolitinib: The metabolism of Ruxolitinib can be increased when combined with Acetaminophen. | [DB08901] Ponatinib: The metabolism of Ponatinib can be increased when combined with Acetaminophen. | [DB09063] Ceritinib: The metabolism of Ceritinib can be increased when combined with Acetaminophen. | [DB11363] Alectinib: The metabolism of Alectinib can be increased when combined with Acetaminophen. | [DB11703] Acalabrutinib: The metabolism of Acalabrutinib can be increased when combined with Acetaminophen. | [DB11828] Neratinib: The metabolism of Neratinib can be increased when combined with Acetaminophen. | [DB12267] Brigatinib: The metabolism of Brigatinib can be increased when combined with Acetaminophen. | [DB00531] Cyclophosphamide: The metabolism of Cyclophosphamide can be increased when combined with Acetaminophen. | [DB00204] Dofetilide: The metabolism of Dofetilide can be increased when combined with Acetaminophen. | [DB00946] Phenprocoumon: The metabolism of Phenprocoumon can be increased when combined with Acetaminophen. | [DB01254] Dasatinib: The metabolism of Dasatinib can be increased when combined with Acetaminophen. | [DB09289] Tianeptine: The metabolism of Tianeptine can be increased when combined with Acetaminophen. | [DB09570] Ixazomib: The metabolism of Ixazomib can be increased when combined with Acetaminophen. | [DB08896] Regorafenib: The metabolism of Regorafenib can be increased when combined with Acetaminophen. | [DB13874] Enasidenib: The metabolism of Enasidenib can be increased when combined with Acetaminophen. | [DB00188] Bortezomib: The metabolism of Bortezomib can be increased when combined with Acetaminophen. | [DB11963] Dacomitinib: The metabolism of Dacomitinib can be increased when combined with Acetaminophen. | [DB01100] Pimozide: The metabolism of Pimozide can be increased when combined with Acetaminophen. | [DB12978] Pexidartinib: The metabolism of Pexidartinib can be increased when combined with Acetaminophen. | [DB01320] Fosphenytoin: The metabolism of Fosphenytoin can be increased when combined with Acetaminophen. | [DB05109] Trabectedin: The metabolism of Trabectedin can be increased when combined with Acetaminophen. | [DB05239] Cobimetinib: The metabolism of Cobimetinib can be increased when combined with Acetaminophen. | [DB09054] Idelalisib: The metabolism of Idelalisib can be increased when combined with Acetaminophen. | [DB12015] Alpelisib: The metabolism of Alpelisib can be increased when combined with Acetaminophen. | [DB00877] Sirolimus: The metabolism of Sirolimus can be increased when combined with Acetaminophen. | [DB01229] Paclitaxel: The metabolism of Paclitaxel can be increased when combined with Acetaminophen. | [DB01396] Digitoxin: The metabolism of Digitoxin can be increased when combined with Acetaminophen. | [DB01590] Everolimus: The metabolism of Everolimus can be increased when combined with Acetaminophen. | [DB06287] Temsirolimus: The metabolism of Temsirolimus can be increased when combined with Acetaminophen. | [DB00398] Sorafenib: The metabolism of Sorafenib can be increased when combined with Acetaminophen. | [DB00773] Etoposide: The metabolism of Etoposide can be increased when combined with Acetaminophen. | [DB06589] Pazopanib: The metabolism of Pazopanib can be increased when combined with Acetaminophen. | [DB08910] Pomalidomide: The metabolism of Pomalidomide can be increased when combined with Acetaminophen. | [DB00997] Doxorubicin: The serum concentration of Doxorubicin can be increased when it is combined with Acetaminophen. | [DB01128] Bicalutamide: The metabolism of Bicalutamide can be increased when combined with Acetaminophen. | [DB00361] Vinorelbine: The metabolism of Vinorelbine can be increased when combined with Acetaminophen. | [DB00570] Vinblastine: The metabolism of Vinblastine can be increased when combined with Acetaminophen. | [DB11817] Baricitinib: Acetaminophen may decrease the excretion rate of Baricitinib which could result in a higher serum level. | [DB06616] Bosutinib: The serum concentration of Bosutinib can be increased when it is combined with Acetaminophen. | [DB12147] Erdafitinib: The metabolism of Erdafitinib can be increased when combined with Acetaminophen. | [DB00563] Methotrexate: The metabolism of Methotrexate can be increased when combined with Acetaminophen. | [DB00540] Nortriptyline: The metabolism of Nortriptyline can be increased when combined with Acetaminophen. | [DB00575] Clonidine: The metabolism of Clonidine can be increased when combined with Acetaminophen. | [DB01242] Clomipramine: The metabolism of Clomipramine can be increased when combined with Acetaminophen. | [DB06212] Tolvaptan: The metabolism of Tolvaptan can be increased when combined with Acetaminophen. | [DB12371] Siponimod: The metabolism of Siponimod can be increased when combined with Acetaminophen. | [DB00541] Vincristine: The metabolism of Vincristine can be increased when combined with Acetaminophen. | [DB01248] Docetaxel: The metabolism of Docetaxel can be increased when combined with Acetaminophen. | [DB04572] Thiotepa: The metabolism of Thiotepa can be increased when combined with Acetaminophen. | [DB11581] Venetoclax: The metabolism of Venetoclax can be increased when combined with Acetaminophen. | [DB11641] Vinflunine: The metabolism of Vinflunine can be increased when combined with Acetaminophen. | [DB15035] Zanubrutinib: The metabolism of Zanubrutinib can be increased when combined with Acetaminophen. | [DB00309] Vindesine: The metabolism of Vindesine can be increased when combined with Acetaminophen. | [DB00444] Teniposide: The metabolism of Teniposide can be increased when combined with Acetaminophen. | [DB04845] Ixabepilone: The metabolism of Ixabepilone can be increased when combined with Acetaminophen. | [DB08870] Brentuximab vedotin: The metabolism of Brentuximab vedotin can be increased when combined with Acetaminophen. | [DB08912] Dabrafenib: The serum concentration of Acetaminophen can be decreased when it is combined with Dabrafenib. | [DB09073] Palbociclib: The metabolism of Palbociclib can be increased when combined with Acetaminophen. | [DB09143] Sonidegib: The metabolism of Sonidegib can be increased when combined with Acetaminophen. | [DB12483] Copanlisib: The metabolism of Copanlisib can be increased when combined with Acetaminophen. | [DB14568] Ivosidenib: The metabolism of Acetaminophen can be increased when combined with Ivosidenib. | [DB00762] Irinotecan: The metabolism of Irinotecan can be increased when combined with Acetaminophen. | [DB06176] Romidepsin: The metabolism of Romidepsin can be increased when combined with Acetaminophen. | [DB09074] Olaparib: The metabolism of Olaparib can be increased when combined with Acetaminophen. | [DB12001] Abemaciclib: The metabolism of Abemaciclib can be increased when combined with Acetaminophen. | [DB00320] Dihydroergotamine: The metabolism of Dihydroergotamine can be increased when combined with Acetaminophen. | [DB01227] Levacetylmethadol: The metabolism of Levacetylmethadol can be increased when combined with Acetaminophen. | [DB05773] Trastuzumab emtansine: The metabolism of Trastuzumab emtansine can be increased when combined with Acetaminophen. | [DB06772] Cabazitaxel: The metabolism of Cabazitaxel can be increased when combined with Acetaminophen. | [DB00908] Quinidine: The metabolism of Quinidine can be increased when combined with Acetaminophen. | [DB04896] Milnacipran: The metabolism of Milnacipran can be increased when combined with Acetaminophen. | [DB08918] Levomilnacipran: The metabolism of Levomilnacipran can be increased when combined with Acetaminophen. | [DB00564] Carbamazepine: The metabolism of Carbamazepine can be increased when combined with Acetaminophen. | [DB00627] Niacin: The metabolism of Acetaminophen can be decreased when combined with Niacin. | [DB08995] Diosmin: The metabolism of Acetaminophen can be decreased when combined with Diosmin. | [DB01204] Mitoxantrone: The metabolism of Acetaminophen can be increased when combined with Mitoxantrone. | [DB01093] Dimethyl sulfoxide: The metabolism of Acetaminophen can be decreased when combined with Dimethyl sulfoxide. | [DB00283] Clemastine: The metabolism of Acetaminophen can be decreased when combined with Clemastine. | [DB00574] Fenfluramine: The metabolism of Acetaminophen can be decreased when combined with Fenfluramine. | [DB00598] Labetalol: The metabolism of Acetaminophen can be decreased when combined with Labetalol. | [DB00792] Tripelennamine: The metabolism of Acetaminophen can be decreased when combined with Tripelennamine. | [DB00810] Biperiden: The metabolism of Acetaminophen can be decreased when combined with Biperiden. | [DB01171] Moclobemide: The metabolism of Acetaminophen can be decreased when combined with Moclobemide. | [DB01580] Oxprenolol: The metabolism of Acetaminophen can be decreased when combined with Oxprenolol. | [DB04818] Iproniazid: The metabolism of Acetaminophen can be decreased when combined with Iproniazid. | [DB06727] Sparteine: The metabolism of Acetaminophen can be decreased when combined with Sparteine. | [DB09224] Melperone: The metabolism of Acetaminophen can be decreased when combined with Melperone. | [DB11638] Artenimol: The metabolism of Acetaminophen can be decreased when combined with Artenimol. | [DB01096] Oxamniquine: The metabolism of Acetaminophen can be decreased when combined with Oxamniquine. | [DB01562] 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine: The metabolism of Acetaminophen can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine. | [DB00907] Cocaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Cocaine. | [DB01062] Oxybutynin: The metabolism of Acetaminophen can be decreased when combined with Oxybutynin. | [DB01621] Pipotiazine: The metabolism of Acetaminophen can be decreased when combined with Pipotiazine. | [DB05271] Rotigotine: The metabolism of Acetaminophen can be decreased when combined with Rotigotine. | [DB14011] Nabiximols: The metabolism of Acetaminophen can be decreased when combined with Nabiximols. | [DB14635] Curcumin sulfate: The metabolism of Acetaminophen can be decreased when combined with Curcumin sulfate. | [DB00215] Citalopram: The metabolism of Acetaminophen can be decreased when combined with Citalopram. | [DB00333] Methadone: The metabolism of Acetaminophen can be decreased when combined with Methadone. | [DB00439] Cerivastatin: The metabolism of Acetaminophen can be decreased when combined with Cerivastatin. | [DB00834] Mifepristone: The metabolism of Mifepristone can be increased when combined with Acetaminophen. | [DB01193] Acebutolol: The metabolism of Acetaminophen can be decreased when combined with Acebutolol. | [DB01244] Bepridil: The metabolism of Acetaminophen can be decreased when combined with Bepridil. | [DB01611] Hydroxychloroquine: The metabolism of Acetaminophen can be decreased when combined with Hydroxychloroquine. | [DB01023] Felodipine: The metabolism of Acetaminophen can be decreased when combined with Felodipine. | [DB08864] Rilpivirine: The serum concentration of Rilpivirine can be increased when it is combined with Acetaminophen. | [DB13975] Black cohosh: The metabolism of Acetaminophen can be decreased when combined with Black cohosh. | [DB00209] Trospium: The metabolism of Acetaminophen can be decreased when combined with Trospium. | [DB00494] Entacapone: The metabolism of Acetaminophen can be decreased when combined with Entacapone. | [DB06512] Deramciclane: The metabolism of Acetaminophen can be decreased when combined with Deramciclane. | [DB01131] Proguanil: The metabolism of Acetaminophen can be decreased when combined with Proguanil. | [DB04938] Ospemifene: The metabolism of Acetaminophen can be decreased when combined with Ospemifene. | [DB00234] Reboxetine: The metabolism of Acetaminophen can be decreased when combined with Reboxetine. | [DB00448] Lansoprazole: The metabolism of Acetaminophen can be decreased when combined with Lansoprazole. | [DB00921] Buprenorphine: The metabolism of Acetaminophen can be decreased when combined with Buprenorphine. | [DB01104] Sertraline: The metabolism of Acetaminophen can be decreased when combined with Sertraline. | [DB04911] Oritavancin: The metabolism of Acetaminophen can be decreased when combined with Oritavancin. | [DB00656] Trazodone: The metabolism of Acetaminophen can be decreased when combined with Trazodone. | [DB00187] Esmolol: The metabolism of Acetaminophen can be decreased when combined with Esmolol. | [DB00335] Atenolol: The metabolism of Atenolol can be decreased when combined with Acetaminophen. | [DB00409] Remoxipride: The metabolism of Remoxipride can be decreased when combined with Acetaminophen. | [DB00592] Piperazine: The metabolism of Piperazine can be decreased when combined with Acetaminophen. | [DB00699] Nicergoline: The metabolism of Nicergoline can be decreased when combined with Acetaminophen. | [DB00737] Meclizine: The metabolism of Meclizine can be decreased when combined with Acetaminophen. | [DB00805] Minaprine: The metabolism of Minaprine can be decreased when combined with Acetaminophen. | [DB00866] Alprenolol: The metabolism of Alprenolol can be decreased when combined with Acetaminophen. | [DB00914] Phenformin: The metabolism of Phenformin can be decreased when combined with Acetaminophen. | [DB00933] Mesoridazine: The metabolism of Mesoridazine can be decreased when combined with Acetaminophen. | [DB01177] Idarubicin: The metabolism of Idarubicin can be decreased when combined with Acetaminophen. | [DB01228] Encainide: The metabolism of Encainide can be decreased when combined with Acetaminophen. | [DB01295] Bevantolol: The metabolism of Bevantolol can be decreased when combined with Acetaminophen. | [DB01297] Practolol: The metabolism of Practolol can be decreased when combined with Acetaminophen. | [DB01429] Aprindine: The metabolism of Aprindine can be decreased when combined with Acetaminophen. | [DB01454] Midomafetamine: The metabolism of Midomafetamine can be decreased when combined with Acetaminophen. | [DB01472] 4-Methoxyamphetamine: The metabolism of 4-Methoxyamphetamine can be decreased when combined with Acetaminophen. | [DB01576] Dextroamphetamine: The metabolism of Dextroamphetamine can be decreased when combined with Acetaminophen. | [DB04844] Tetrabenazine: The metabolism of Tetrabenazine can be decreased when combined with Acetaminophen. | [DB06506] Repinotan: The metabolism of Repinotan can be decreased when combined with Acetaminophen. | [DB06608] Tafenoquine: The metabolism of Tafenoquine can be decreased when combined with Acetaminophen. | [DB06678] Esmirtazapine: The metabolism of Esmirtazapine can be decreased when combined with Acetaminophen. | [DB06726] Bufuralol: The metabolism of Bufuralol can be decreased when combined with Acetaminophen. | [DB06735] Enclomiphene: The metabolism of Enclomiphene can be decreased when combined with Acetaminophen. | [DB08807] Bopindolol: The metabolism of Bopindolol can be decreased when combined with Acetaminophen. | [DB08808] Bupranolol: The metabolism of Bupranolol can be decreased when combined with Acetaminophen. | [DB08952] Indenolol: The metabolism of Indenolol can be decreased when combined with Acetaminophen. | [DB09351] Levobetaxolol: The metabolism of Levobetaxolol can be decreased when combined with Acetaminophen. | [DB11785] Anisodamine: The metabolism of Anisodamine can be decreased when combined with Acetaminophen. | [DB12212] Landiolol: The metabolism of Landiolol can be decreased when combined with Acetaminophen. | [DB12752] Bucindolol: The metabolism of Bucindolol can be decreased when combined with Acetaminophen. | [DB13443] Esatenolol: The metabolism of Esatenolol can be decreased when combined with Acetaminophen. | [DB13508] Cloranolol: The metabolism of Cloranolol can be decreased when combined with Acetaminophen. | [DB13530] Mepindolol: The metabolism of Mepindolol can be decreased when combined with Acetaminophen. | [DB13757] Epanolol: The metabolism of Epanolol can be decreased when combined with Acetaminophen. | [DB13775] Tertatolol: The metabolism of Tertatolol can be decreased when combined with Acetaminophen. | [DB09173] Butyrfentanyl: The metabolism of Butyrfentanyl can be decreased when combined with Acetaminophen. | [DB14010] 5-methoxy-N,N-dimethyltryptamine: The metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Acetaminophen. | [DB00589] Lisuride: The metabolism of Lisuride can be decreased when combined with Acetaminophen. | [DB00757] Dolasetron: The metabolism of Dolasetron can be decreased when combined with Acetaminophen. | [DB01071] Mequitazine: The metabolism of Mequitazine can be decreased when combined with Acetaminophen. | [DB01095] Fluvastatin: The metabolism of Fluvastatin can be decreased when combined with Acetaminophen. | [DB01192] Oxymorphone: The metabolism of Oxymorphone can be decreased when combined with Acetaminophen. | [DB01410] Ciclesonide: The metabolism of Ciclesonide can be decreased when combined with Acetaminophen. | [DB01466] Ethylmorphine: The metabolism of Ethylmorphine can be decreased when combined with Acetaminophen. | [DB01591] Solifenacin: The metabolism of Solifenacin can be decreased when combined with Acetaminophen. | [DB04829] Lysergic acid diethylamide: The metabolism of Lysergic acid diethylamide can be decreased when combined with Acetaminophen. | [DB04861] Nebivolol: The metabolism of Nebivolol can be decreased when combined with Acetaminophen. | [DB06144] Sertindole: The metabolism of Sertindole can be decreased when combined with Acetaminophen. | [DB08922] Perospirone: The metabolism of Perospirone can be decreased when combined with Acetaminophen. | [DB09128] Brexpiprazole: The metabolism of Brexpiprazole can be decreased when combined with Acetaminophen. | [DB11614] Rupatadine: The metabolism of Rupatadine can be decreased when combined with Acetaminophen. | [DB00641] Simvastatin: The metabolism of Simvastatin can be decreased when combined with Acetaminophen. | [DB00843] Donepezil: The metabolism of Donepezil can be decreased when combined with Acetaminophen. | [DB01392] Yohimbine: The metabolism of Yohimbine can be decreased when combined with Acetaminophen. | [DB04840] Debrisoquine: The metabolism of Debrisoquine can be decreased when combined with Acetaminophen. | [DB04846] Celiprolol: The metabolism of Celiprolol can be decreased when combined with Acetaminophen. | [DB04905] Tesmilifene: The metabolism of Tesmilifene can be decreased when combined with Acetaminophen. | [DB09076] Umeclidinium: The metabolism of Umeclidinium can be decreased when combined with Acetaminophen. | [DB11770] Talinolol: The metabolism of Talinolol can be decreased when combined with Acetaminophen. | [DB11855] Revefenacin: The metabolism of Revefenacin can be decreased when combined with Acetaminophen. | [DB11979] Elagolix: The metabolism of Elagolix can be decreased when combined with Acetaminophen. | [DB00734] Risperidone: The metabolism of Risperidone can be decreased when combined with Acetaminophen. | [DB00674] Galantamine: The metabolism of Galantamine can be decreased when combined with Acetaminophen. | [DB00751] Epinastine: The metabolism of Acetaminophen can be decreased when combined with Epinastine. | [DB11718] Encorafenib: The metabolism of Acetaminophen can be decreased when combined with Encorafenib. | [DB04884] Dapoxetine: The metabolism of Dapoxetine can be decreased when combined with Acetaminophen. | [DB06217] Vernakalant: The metabolism of Vernakalant can be decreased when combined with Acetaminophen. | [DB00433] Prochlorperazine: The metabolism of Prochlorperazine can be decreased when combined with Acetaminophen. | [DB00489] Sotalol: The metabolism of Sotalol can be decreased when combined with Acetaminophen. | [DB01035] Procainamide: The metabolism of Procainamide can be decreased when combined with Acetaminophen. | [DB01195] Flecainide: The metabolism of Flecainide can be decreased when combined with Acetaminophen. | [DB00321] Amitriptyline: The metabolism of Amitriptyline can be decreased when combined with Acetaminophen. | [DB00543] Amoxapine: The metabolism of Amoxapine can be decreased when combined with Acetaminophen. | [DB00726] Trimipramine: The metabolism of Trimipramine can be decreased when combined with Acetaminophen. | [DB00685] Trovafloxacin: The metabolism of Acetaminophen can be decreased when combined with Trovafloxacin. | [DB13823] Pipemidic acid: The metabolism of Acetaminophen can be decreased when combined with Pipemidic acid. | [DB00927] Famotidine: The metabolism of Acetaminophen can be decreased when combined with Famotidine. | [DB05015] Belinostat: The metabolism of Acetaminophen can be increased when combined with Belinostat. | [DB00071] Insulin pork: The metabolism of Acetaminophen can be increased when combined with Insulin pork. | [DB05115] NN344: The metabolism of Acetaminophen can be increased when combined with NN344. | [DB06413] Armodafinil: The metabolism of Acetaminophen can be increased when combined with Armodafinil. | [DB06732] beta-Naphthoflavone: The metabolism of Acetaminophen can be increased when combined with beta-Naphthoflavone. | [DB11567] Insulin peglispro: The metabolism of Acetaminophen can be increased when combined with Insulin peglispro. | [DB11568] Insulin tregopil: The metabolism of Acetaminophen can be increased when combined with Insulin tregopil. | [DB09456] Insulin beef: The metabolism of Acetaminophen can be increased when combined with Insulin beef. | [DB00607] Nafcillin: The metabolism of Acetaminophen can be increased when combined with Nafcillin. | [DB00052] Somatotropin: The metabolism of Acetaminophen can be increased when combined with Somatotropin. | [DB15093] Somapacitan: The metabolism of Acetaminophen can be increased when combined with Somapacitan. | [DB01241] Gemfibrozil: The metabolism of Acetaminophen can be decreased when combined with Gemfibrozil. | [DB09241] Methylene blue: The metabolism of Acetaminophen can be decreased when combined with Methylene blue. | [DB00008] Peginterferon alfa-2a: The metabolism of Acetaminophen can be decreased when combined with Peginterferon alfa-2a. | [DB00011] Interferon alfa-n1: The metabolism of Acetaminophen can be decreased when combined with Interferon alfa-n1. | [DB00018] Interferon alfa-n3: The metabolism of Acetaminophen can be decreased when combined with Interferon alfa-n3. | [DB00033] Interferon gamma-1b: The metabolism of Acetaminophen can be decreased when combined with Interferon gamma-1b. | [DB00034] Interferon alfa-2a: The metabolism of Acetaminophen can be decreased when combined with Interferon alfa-2a. | [DB00060] Interferon beta-1a: The metabolism of Acetaminophen can be decreased when combined with Interferon beta-1a. | [DB00068] Interferon beta-1b: The metabolism of Acetaminophen can be decreased when combined with Interferon beta-1b. | [DB00069] Interferon alfacon-1: The metabolism of Acetaminophen can be decreased when combined with Interferon alfacon-1. | [DB00105] Interferon alfa-2b: The metabolism of Acetaminophen can be decreased when combined with Interferon alfa-2b. | [DB00420] Promazine: The metabolism of Acetaminophen can be decreased when combined with Promazine. | [DB00487] Pefloxacin: The metabolism of Acetaminophen can be decreased when combined with Pefloxacin. | [DB00553] Methoxsalen: The metabolism of Acetaminophen can be decreased when combined with Methoxsalen. | [DB00633] Dexmedetomidine: The metabolism of Acetaminophen can be decreased when combined with Dexmedetomidine. | [DB00730] Thiabendazole: The metabolism of Acetaminophen can be decreased when combined with Thiabendazole. | [DB00779] Nalidixic acid: The metabolism of Acetaminophen can be decreased when combined with Nalidixic acid. | [DB00817] Rosoxacin: The metabolism of Acetaminophen can be decreased when combined with Rosoxacin. | [DB00827] Cinoxacin: The metabolism of Acetaminophen can be decreased when combined with Cinoxacin. | [DB01059] Norfloxacin: The metabolism of Acetaminophen can be decreased when combined with Norfloxacin. | [DB01155] Gemifloxacin: The metabolism of Acetaminophen can be decreased when combined with Gemifloxacin. | [DB01388] Mibefradil: The metabolism of Acetaminophen can be decreased when combined with Mibefradil. | [DB05396] Albinterferon Alfa-2B: The metabolism of Acetaminophen can be decreased when combined with Albinterferon Alfa-2B. | [DB05990] Obeticholic acid: The metabolism of Acetaminophen can be decreased when combined with Obeticholic acid. | [DB06160] Garenoxacin: The metabolism of Acetaminophen can be decreased when combined with Garenoxacin. | [DB06600] Nemonoxacin: The metabolism of Acetaminophen can be decreased when combined with Nemonoxacin. | [DB06803] Niclosamide: The metabolism of Acetaminophen can be decreased when combined with Niclosamide. | [DB08972] Flumequine: The metabolism of Acetaminophen can be decreased when combined with Flumequine. | [DB11404] Enrofloxacin: The metabolism of Acetaminophen can be decreased when combined with Enrofloxacin. | [DB11443] Orbifloxacin: The metabolism of Acetaminophen can be decreased when combined with Orbifloxacin. | [DB11491] Sarafloxacin: The metabolism of Acetaminophen can be decreased when combined with Sarafloxacin. | [DB11511] Difloxacin: The metabolism of Acetaminophen can be decreased when combined with Difloxacin. | [DB12245] Triclabendazole: The metabolism of Acetaminophen can be decreased when combined with Triclabendazole. | [DB12945] Dihydralazine: The metabolism of Acetaminophen can be decreased when combined with Dihydralazine. | [DB13261] Sitafloxacin: The metabolism of Acetaminophen can be decreased when combined with Sitafloxacin. | [DB15119] Ropeginterferon alfa-2b: The metabolism of Acetaminophen can be decreased when combined with Ropeginterferon alfa-2b. | [DB15131] Interferon alfa-2c: The metabolism of Acetaminophen can be decreased when combined with Interferon alfa-2c. | [DB12814] Cepeginterferon alfa-2B: The metabolism of Acetaminophen can be decreased when combined with Cepeginterferon alfa-2B. | [DB06442] Avasimibe: The metabolism of Acetaminophen can be decreased when combined with Avasimibe. | [DB00365] Grepafloxacin: The metabolism of Acetaminophen can be decreased when combined with Grepafloxacin. | [DB01137] Levofloxacin: Acetaminophen may decrease the excretion rate of Levofloxacin which could result in a higher serum level. | [DB13952] Estradiol acetate: The metabolism of Acetaminophen can be decreased when combined with Estradiol acetate. | [DB05258] Interferon alfa: The metabolism of Acetaminophen can be decreased when combined with Interferon alfa. | [DB15442] Trilaciclib: The metabolism of Acetaminophen can be increased when combined with Trilaciclib. | [DB00787] Acyclovir: The metabolism of Acyclovir can be decreased when combined with Acetaminophen. | [DB00280] Disopyramide: The metabolism of Acetaminophen can be decreased when combined with Disopyramide. | [DB00806] Pentoxifylline: The metabolism of Pentoxifylline can be decreased when combined with Acetaminophen. | [DB00980] Ramelteon: The metabolism of Ramelteon can be decreased when combined with Acetaminophen. | [DB01002] Levobupivacaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Levobupivacaine. | [DB00195] Betaxolol: The metabolism of Acetaminophen can be decreased when combined with Betaxolol. | [DB00261] Anagrelide: The metabolism of Acetaminophen can be decreased when combined with Anagrelide. | [DB00262] Carmustine: The metabolism of Acetaminophen can be decreased when combined with Carmustine. | [DB00315] Zolmitriptan: The metabolism of Acetaminophen can be decreased when combined with Zolmitriptan. | [DB00370] Mirtazapine: The metabolism of Mirtazapine can be decreased when combined with Acetaminophen. | [DB00384] Triamterene: The metabolism of Triamterene can be decreased when combined with Acetaminophen. | [DB00442] Entecavir: The metabolism of Entecavir can be decreased when combined with Acetaminophen. | [DB00568] Cinnarizine: The metabolism of Cinnarizine can be decreased when combined with Acetaminophen. | [DB00629] Guanabenz: The metabolism of Guanabenz can be decreased when combined with Acetaminophen. | [DB00740] Riluzole: The metabolism of Riluzole can be decreased when combined with Acetaminophen. | [DB00744] Zileuton: The metabolism of Acetaminophen can be decreased when combined with Zileuton. | [DB00850] Perphenazine: The metabolism of Acetaminophen can be decreased when combined with Perphenazine. | [DB00851] Dacarbazine: The metabolism of Dacarbazine can be decreased when combined with Acetaminophen. | [DB00934] Maprotiline: The metabolism of Maprotiline can be decreased when combined with Acetaminophen. | [DB00993] Azathioprine: The metabolism of Azathioprine can be decreased when combined with Acetaminophen. | [DB00998] Frovatriptan: The metabolism of Frovatriptan can be decreased when combined with Acetaminophen. | [DB01056] Tocainide: The metabolism of Tocainide can be decreased when combined with Acetaminophen. | [DB01058] Praziquantel: The metabolism of Praziquantel can be decreased when combined with Acetaminophen. | [DB01065] Melatonin: The metabolism of Melatonin can be decreased when combined with Acetaminophen. | [DB01094] Hesperetin: The metabolism of Hesperetin can be decreased when combined with Acetaminophen. | [DB01303] Oxtriphylline: The metabolism of Oxtriphylline can be decreased when combined with Acetaminophen. | [DB01367] Rasagiline: The metabolism of Rasagiline can be decreased when combined with Acetaminophen. | [DB01405] Temafloxacin: The metabolism of Acetaminophen can be decreased when combined with Temafloxacin. | [DB01412] Theobromine: The metabolism of Theobromine can be decreased when combined with Acetaminophen. | [DB01482] Fenethylline: The metabolism of Fenethylline can be decreased when combined with Acetaminophen. | [DB01623] Thiothixene: The metabolism of Thiothixene can be decreased when combined with Acetaminophen. | [DB01667] 8-azaguanine: The metabolism of 8-azaguanine can be decreased when combined with Acetaminophen. | [DB02134] Xanthine: The metabolism of Xanthine can be decreased when combined with Acetaminophen. | [DB02489] 9-Methylguanine: The metabolism of 9-Methylguanine can be decreased when combined with Acetaminophen. | [DB02568] Peldesine: The metabolism of Peldesine can be decreased when combined with Acetaminophen. | [DB03783] Phenacetin: The metabolism of Phenacetin can be decreased when combined with Acetaminophen. | [DB04076] Hypoxanthine: The metabolism of Hypoxanthine can be decreased when combined with Acetaminophen. | [DB04356] 9-Deazaguanine: The metabolism of 9-Deazaguanine can be decreased when combined with Acetaminophen. | [DB04841] Flunarizine: The metabolism of Flunarizine can be decreased when combined with Acetaminophen. | [DB04948] Lofexidine: The metabolism of Lofexidine can be decreased when combined with Acetaminophen. | [DB06148] Mianserin: The metabolism of Mianserin can be decreased when combined with Acetaminophen. | [DB06216] Asenapine: The metabolism of Asenapine can be decreased when combined with Acetaminophen. | [DB06235] Vadimezan: The metabolism of Vadimezan can be decreased when combined with Acetaminophen. | [DB06479] Propentofylline: The metabolism of Propentofylline can be decreased when combined with Acetaminophen. | [DB06594] Agomelatine: The metabolism of Agomelatine can be decreased when combined with Acetaminophen. | [DB06769] Bendamustine: The metabolism of Bendamustine can be decreased when combined with Acetaminophen. | [DB06774] Capsaicin: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Capsaicin. | [DB09225] Zotepine: The metabolism of Zotepine can be decreased when combined with Acetaminophen. | [DB09273] Doxofylline: The metabolism of Doxofylline can be decreased when combined with Acetaminophen. | [DB09290] Ramosetron: The metabolism of Ramosetron can be decreased when combined with Acetaminophen. | [DB11919] 6-O-benzylguanine: The metabolism of 6-O-benzylguanine can be decreased when combined with Acetaminophen. | [DB11967] Binimetinib: The metabolism of Binimetinib can be decreased when combined with Acetaminophen. | [DB12406] Lisofylline: The metabolism of Lisofylline can be decreased when combined with Acetaminophen. | [DB12531] Lobucavir: The metabolism of Lobucavir can be decreased when combined with Acetaminophen. | [DB12926] Cafedrine: The metabolism of Cafedrine can be decreased when combined with Acetaminophen. | [DB12927] Theodrenaline: The metabolism of Theodrenaline can be decreased when combined with Acetaminophen. | [DB13203] Bamifylline: The metabolism of Bamifylline can be decreased when combined with Acetaminophen. | [DB13449] Proxyphylline: The metabolism of Proxyphylline can be decreased when combined with Acetaminophen. | [DB13573] Acefylline: The metabolism of Acefylline can be decreased when combined with Acetaminophen. | [DB13592] Etamiphylline: The metabolism of Etamiphylline can be decreased when combined with Acetaminophen. | [DB13634] Pentifylline: The metabolism of Pentifylline can be decreased when combined with Acetaminophen. | [DB13812] Bufylline: The metabolism of Bufylline can be decreased when combined with Acetaminophen. | [DB14132] 8-chlorotheophylline: The metabolism of 8-chlorotheophylline can be decreased when combined with Acetaminophen. | [DB11757] Istradefylline: The metabolism of Istradefylline can be decreased when combined with Acetaminophen. | [DB04889] Bicifadine: The metabolism of Bicifadine can be decreased when combined with Acetaminophen. | [DB05708] GTS-21: The metabolism of GTS-21 can be decreased when combined with Acetaminophen. | [DB00286] Conjugated estrogens: The metabolism of Acetaminophen can be decreased when combined with Conjugated estrogens. | [DB00334] Olanzapine: The metabolism of Olanzapine can be decreased when combined with Acetaminophen. | [DB00382] Tacrine: The metabolism of Tacrine can be decreased when combined with Acetaminophen. | [DB00571] Propranolol: The metabolism of Propranolol can be decreased when combined with Acetaminophen. | [DB00661] Verapamil: The metabolism of Acetaminophen can be decreased when combined with Verapamil. | [DB00758] Clopidogrel: The metabolism of Clopidogrel can be decreased when combined with Acetaminophen. | [DB00783] Estradiol: The metabolism of Estradiol can be increased when combined with Acetaminophen. | [DB00831] Trifluoperazine: The metabolism of Trifluoperazine can be decreased when combined with Acetaminophen. | [DB00863] Ranitidine: The metabolism of Acetaminophen can be decreased when combined with Ranitidine. | [DB01142] Doxepin: The metabolism of Doxepin can be decreased when combined with Acetaminophen. | [DB01184] Domperidone: The metabolism of Domperidone can be decreased when combined with Acetaminophen. | [DB12026] Voxilaprevir: The metabolism of Voxilaprevir can be decreased when combined with Acetaminophen. | [DB00532] Mephenytoin: The metabolism of Mephenytoin can be decreased when combined with Acetaminophen. | [DB00924] Cyclobenzaprine: The metabolism of Cyclobenzaprine can be decreased when combined with Acetaminophen. | [DB00619] Imatinib: The metabolism of Acetaminophen can be decreased when combined with Imatinib. | [DB04951] Pirfenidone: Pirfenidone may increase the hepatotoxic activities of Acetaminophen. | [DB00299] Penciclovir: The metabolism of Acetaminophen can be decreased when combined with Penciclovir. | [DB13955] Estradiol dienanthate: The metabolism of Estradiol dienanthate can be decreased when combined with Acetaminophen. | [DB00978] Lomefloxacin: The metabolism of Lomefloxacin can be decreased when combined with Acetaminophen. | [DB00904] Ondansetron: The metabolism of Ondansetron can be decreased when combined with Acetaminophen. | [DB01037] Selegiline: The metabolism of Selegiline can be decreased when combined with Acetaminophen. | [DB06739] Seratrodast: The metabolism of Acetaminophen can be decreased when combined with Seratrodast. | [DB00396] Progesterone: The metabolism of Progesterone can be increased when combined with Acetaminophen. | [DB00741] Hydrocortisone: The metabolism of Acetaminophen can be increased when combined with Hydrocortisone. | [DB00216] Eletriptan: The metabolism of Acetaminophen can be increased when combined with Eletriptan. | [DB14631] Prednisolone phosphate: The metabolism of Acetaminophen can be increased when combined with Prednisolone phosphate. | [DB00471] Montelukast: The metabolism of Montelukast can be decreased when combined with Acetaminophen. | [DB00983] Formoterol: The metabolism of Formoterol can be decreased when combined with Acetaminophen. | [DB01274] Arformoterol: The metabolism of Arformoterol can be decreased when combined with Acetaminophen. | [DB06470] Clomethiazole: The metabolism of Clomethiazole can be decreased when combined with Acetaminophen. | [DB09327] Tegafur-uracil: The metabolism of Tegafur-uracil can be decreased when combined with Acetaminophen. | [DB09068] Vortioxetine: The metabolism of Vortioxetine can be decreased when combined with Acetaminophen. | [DB00238] Nevirapine: The metabolism of Acetaminophen can be decreased when combined with Nevirapine. | [DB04977] Plitidepsin: The metabolism of Plitidepsin can be decreased when combined with Acetaminophen. | [DB00916] Metronidazole: The metabolism of Metronidazole can be decreased when combined with Acetaminophen. | [DB00544] Fluorouracil: The metabolism of Fluorouracil can be decreased when combined with Acetaminophen. | [DB09256] Tegafur: The metabolism of Tegafur can be decreased when combined with Acetaminophen. | [DB00197] Troglitazone: The metabolism of Acetaminophen can be decreased when combined with Troglitazone. | [DB06210] Eltrombopag: The metabolism of Acetaminophen can be decreased when combined with Eltrombopag. | [DB13609] Umifenovir: The metabolism of Acetaminophen can be decreased when combined with Umifenovir. | [DB09061] Cannabidiol: The metabolism of Acetaminophen can be decreased when combined with Cannabidiol. | [DB00005] Etanercept: The metabolism of Acetaminophen can be increased when combined with Etanercept. | [DB00026] Anakinra: The metabolism of Acetaminophen can be increased when combined with Anakinra. | [DB00051] Adalimumab: The metabolism of Acetaminophen can be increased when combined with Adalimumab. | [DB00065] Infliximab: The metabolism of Acetaminophen can be increased when combined with Infliximab. | [DB01281] Abatacept: The metabolism of Acetaminophen can be increased when combined with Abatacept. | [DB04956] Afelimomab: The metabolism of Acetaminophen can be increased when combined with Afelimomab. | [DB05676] Apremilast: The metabolism of Acetaminophen can be increased when combined with Apremilast. | [DB06168] Canakinumab: The metabolism of Acetaminophen can be increased when combined with Canakinumab. | [DB06273] Tocilizumab: The metabolism of Acetaminophen can be increased when combined with Tocilizumab. | [DB06372] Rilonacept: The metabolism of Acetaminophen can be increased when combined with Rilonacept. | [DB06674] Golimumab: The metabolism of Acetaminophen can be increased when combined with Golimumab. | [DB08904] Certolizumab pegol: The metabolism of Acetaminophen can be increased when combined with Certolizumab pegol. | [DB09029] Secukinumab: The metabolism of Acetaminophen can be increased when combined with Secukinumab. | [DB09036] Siltuximab: The metabolism of Acetaminophen can be increased when combined with Siltuximab. | [DB14724] Emapalumab: The metabolism of Acetaminophen can be increased when combined with Emapalumab. | [DB06480] Prucalopride: The metabolism of Prucalopride can be decreased when combined with Acetaminophen. | [DB00381] Amlodipine: The metabolism of Amlodipine can be increased when combined with Acetaminophen. | [DB01068] Clonazepam: The metabolism of Clonazepam can be increased when combined with Acetaminophen. | [DB00425] Zolpidem: The metabolism of Zolpidem can be increased when combined with Acetaminophen. | [DB11689] Selumetinib: Selumetinib may increase the hepatotoxic activities of Acetaminophen. | [DB00228] Enflurane: Enflurane may increase the hepatotoxic activities of Acetaminophen. | [DB00347] Trimethadione: Trimethadione may increase the hepatotoxic activities of Acetaminophen. | [DB00593] Ethosuximide: Ethosuximide may increase the hepatotoxic activities of Acetaminophen. | [DB00753] Isoflurane: Isoflurane may increase the hepatotoxic activities of Acetaminophen. | [DB01028] Methoxyflurane: Methoxyflurane may increase the hepatotoxic activities of Acetaminophen. | [DB01159] Halothane: Halothane may increase the hepatotoxic activities of Acetaminophen. | [DB01236] Sevoflurane: Sevoflurane may increase the hepatotoxic activities of Acetaminophen. | [DB06712] Nilvadipine: Nilvadipine may increase the hepatotoxic activities of Acetaminophen. | [DB06728] Aniline: Aniline may increase the hepatotoxic activities of Acetaminophen. | [DB06770] Benzyl alcohol: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Benzyl alcohol. | [DB00277] Theophylline: Theophylline may increase the hepatotoxic activities of Acetaminophen. | [DB01223] Aminophylline: Aminophylline may increase the hepatotoxic activities of Acetaminophen. | [DB00675] Tamoxifen: Tamoxifen may increase the hepatotoxic activities of Acetaminophen. | [DB01136] Carvedilol: Carvedilol may increase the hepatotoxic activities of Acetaminophen. | [DB00949] Felbamate: Felbamate may increase the hepatotoxic activities of Acetaminophen. | [DB01086] Benzocaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Benzocaine. | [DB00252] Phenytoin: Phenytoin may increase the hepatotoxic activities of Acetaminophen. | [DB00794] Primidone: Primidone may increase the hepatotoxic activities of Acetaminophen. | [DB08868] Fingolimod: Fingolimod may increase the hepatotoxic activities of Acetaminophen. | [DB00412] Rosiglitazone: Rosiglitazone may increase the hepatotoxic activities of Acetaminophen. | [DB00428] Streptozocin: Streptozocin may increase the hepatotoxic activities of Acetaminophen. | [DB00636] Clofibrate: Clofibrate may increase the hepatotoxic activities of Acetaminophen. | [DB00780] Phenelzine: Phenelzine may increase the hepatotoxic activities of Acetaminophen. | [DB01045] Rifampin: The metabolism of Acetaminophen can be increased when combined with Rifampin. | [DB01234] Dexamethasone: Dexamethasone may increase the hepatotoxic activities of Acetaminophen. | [DB09462] Glycerin: Glycerin may increase the hepatotoxic activities of Acetaminophen. | [DB11943] Delafloxacin: Delafloxacin may increase the hepatotoxic activities of Acetaminophen. | [DB13941] Piperaquine: Piperaquine may increase the hepatotoxic activities of Acetaminophen. | [DB00184] Nicotine: Nicotine may increase the hepatotoxic activities of Acetaminophen. | [DB00041] Aldesleukin: Aldesleukin may increase the hepatotoxic activities of Acetaminophen. | [DB00118] Ademetionine: Ademetionine may increase the hepatotoxic activities of Acetaminophen. | [DB00203] Sildenafil: Sildenafil may increase the hepatotoxic activities of Acetaminophen. | [DB00208] Ticlopidine: Ticlopidine may increase the hepatotoxic activities of Acetaminophen. | [DB00255] Diethylstilbestrol: Diethylstilbestrol may increase the hepatotoxic activities of Acetaminophen. | [DB00458] Imipramine: The metabolism of Acetaminophen can be decreased when combined with Imipramine. | [DB00477] Chlorpromazine: The metabolism of Acetaminophen can be decreased when combined with Chlorpromazine. | [DB00486] Nabilone: Nabilone may increase the hepatotoxic activities of Acetaminophen. | [DB00501] Cimetidine: Cimetidine may increase the hepatotoxic activities of Acetaminophen. | [DB00623] Fluphenazine: Fluphenazine may increase the hepatotoxic activities of Acetaminophen. | [DB00679] Thioridazine: Thioridazine may increase the hepatotoxic activities of Acetaminophen. | [DB00690] Flurazepam: Flurazepam may increase the hepatotoxic activities of Acetaminophen. | [DB00818] Propofol: Propofol may increase the hepatotoxic activities of Acetaminophen. | [DB00822] Disulfiram: Disulfiram may increase the hepatotoxic activities of Acetaminophen. | [DB00829] Diazepam: Diazepam may increase the hepatotoxic activities of Acetaminophen. | [DB00883] Isosorbide dinitrate: Isosorbide dinitrate may increase the hepatotoxic activities of Acetaminophen. | [DB00969] Alosetron: Alosetron may increase the hepatotoxic activities of Acetaminophen. | [DB00972] Azelastine: The metabolism of Azelastine can be decreased when combined with Acetaminophen. | [DB01079] Tegaserod: The metabolism of Acetaminophen can be decreased when combined with Tegaserod. | [DB01110] Miconazole: Miconazole may increase the hepatotoxic activities of Acetaminophen. | [DB01115] Nifedipine: Nifedipine may increase the hepatotoxic activities of Acetaminophen. | [DB01151] Desipramine: The metabolism of Acetaminophen can be decreased when combined with Desipramine. | [DB01191] Dexfenfluramine: Dexfenfluramine may increase the hepatotoxic activities of Acetaminophen. | [DB01213] Fomepizole: Fomepizole may increase the hepatotoxic activities of Acetaminophen. | [DB01403] Methotrimeprazine: Methotrimeprazine may increase the hepatotoxic activities of Acetaminophen. | [DB01544] Flunitrazepam: Flunitrazepam may increase the hepatotoxic activities of Acetaminophen. | [DB01558] Bromazepam: Bromazepam may increase the hepatotoxic activities of Acetaminophen. | [DB01595] Nitrazepam: Nitrazepam may increase the hepatotoxic activities of Acetaminophen. | [DB06201] Rufinamide: Rufinamide may increase the hepatotoxic activities of Acetaminophen. | [DB06370] Indisulam: Indisulam may increase the hepatotoxic activities of Acetaminophen. | [DB08846] Ellagic acid: Ellagic acid may increase the hepatotoxic activities of Acetaminophen. | [DB09328] Vayarin: Vayarin may increase the hepatotoxic activities of Acetaminophen. | [DB11994] Diacerein: Diacerein may increase the hepatotoxic activities of Acetaminophen. | [DB13174] Rhein: The metabolism of Acetaminophen can be decreased when combined with Rhein. | [DB04794] Bifonazole: Bifonazole may increase the hepatotoxic activities of Acetaminophen. | [DB12466] Favipiravir: Favipiravir may increase the hepatotoxic activities of Acetaminophen. | [DB01007] Tioconazole: Tioconazole may increase the hepatotoxic activities of Acetaminophen. | [DB00682] Warfarin: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Warfarin. | [DB00159] Icosapent: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Icosapent. | [DB00328] Indomethacin: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Indomethacin. | [DB00461] Nabumetone: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Nabumetone. | [DB00465] Ketorolac: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Ketorolac. | [DB00469] Tenoxicam: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Tenoxicam. | [DB00500] Tolmetin: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Tolmetin. | [DB00533] Rofecoxib: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Rofecoxib. | [DB00554] Piroxicam: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Piroxicam. | [DB00573] Fenoprofen: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Fenoprofen. | [DB00580] Valdecoxib: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Valdecoxib. | [DB00605] Sulindac: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Sulindac. | [DB00712] Flurbiprofen: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Flurbiprofen. | [DB00749] Etodolac: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Etodolac. | [DB00812] Phenylbutazone: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Phenylbutazone. | [DB00814] Meloxicam: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Meloxicam. | [DB00821] Carprofen: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Carprofen. | [DB00939] Meclofenamic acid: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Meclofenamic acid. | [DB00991] Oxaprozin: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Oxaprozin. | [DB01283] Lumiracoxib: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Lumiracoxib. | [DB01399] Salsalate: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Salsalate. | [DB01401] Choline magnesium trisalicylate: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Choline magnesium trisalicylate. | [DB01419] Antrafenine: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Antrafenine. | [DB01424] Aminophenazone: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Aminophenazone. | [DB01435] Antipyrine: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Antipyrine. | [DB01600] Tiaprofenic acid: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Tiaprofenic acid. | [DB01628] Etoricoxib: Etoricoxib may increase the hepatotoxic activities of Acetaminophen. | [DB02224] Taxifolin: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Taxifolin. | [DB03585] Oxyphenbutazone: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Oxyphenbutazone. | [DB04725] Licofelone: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Licofelone. | [DB04743] Nimesulide: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Nimesulide. | [DB04812] Benoxaprofen: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Benoxaprofen. | [DB04817] Metamizole: Metamizole may decrease the excretion rate of Acetaminophen which could result in a higher serum level. | [DB04828] Zomepirac: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Zomepirac. | [DB05095] Cimicoxib: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Cimicoxib. | [DB06737] Zaltoprofen: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Zaltoprofen. | [DB07402] Azapropazone: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Azapropazone. | [DB08439] Parecoxib: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Parecoxib. | [DB08940] Kebuzone: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Kebuzone. | [DB08942] Isoxicam: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Isoxicam. | [DB08951] Indoprofen: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Indoprofen. | [DB08955] Ibuproxam: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Ibuproxam. | [DB08976] Floctafenine: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Floctafenine. | [DB08981] Fenbufen: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Fenbufen. | [DB08984] Etofenamate: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Etofenamate. | [DB08991] Epirizole: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Epirizole. | [DB09084] Benzydamine: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Benzydamine. | [DB09215] Droxicam: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Droxicam. | [DB09216] Tolfenamic acid: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Tolfenamic acid. | [DB09217] Firocoxib: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Firocoxib. | [DB09218] Clonixin: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Clonixin. | [DB09285] Morniflumate: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Morniflumate. | [DB09288] Propacetamol: Acetaminophen may increase the hepatotoxic activities of Propacetamol. | [DB09295] Talniflumate: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Talniflumate. | [DB11455] Robenacoxib: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Robenacoxib. | [DB11466] Tepoxalin: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Tepoxalin. | [DB11518] Flunixin: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Flunixin. | [DB12399] Polmacoxib: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Polmacoxib. | [DB12545] Indobufen: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Indobufen. | [DB12610] Ebselen: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Ebselen. | [DB13001] Tinoridine: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Tinoridine. | [DB13167] Alclofenac: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Alclofenac. | [DB13217] Fentiazac: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Fentiazac. | [DB13232] Suxibuzone: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Suxibuzone. | [DB13286] Bumadizone: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Bumadizone. | [DB13314] Alminoprofen: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Alminoprofen. | [DB13371] Difenpiramide: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Difenpiramide. | [DB13407] Nifenazone: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Nifenazone. | [DB13432] Lonazolac: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Lonazolac. | [DB13481] Tenidap: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Tenidap. | [DB13527] Proglumetacin: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Proglumetacin. | [DB13629] Mofebutazone: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Mofebutazone. | [DB13649] Proquazone: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Proquazone. | [DB13657] Benorilate: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Benorilate. | [DB13722] Pirprofen: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Pirprofen. | [DB13783] Acemetacin: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Acemetacin. | [DB13860] Imidazole salicylate: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Imidazole salicylate. | [DB14059] SC-236: The risk or severity of adverse effects can be increased when Acetaminophen is combined with SC-236. | [DB14060] NS-398: The risk or severity of adverse effects can be increased when Acetaminophen is combined with NS-398. | [DB14938] Flurbiprofen axetil: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Flurbiprofen axetil. | [DB09212] Loxoprofen: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Loxoprofen. | [DB04552] Niflumic acid: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Niflumic acid. | [DB00861] Diflunisal: The serum concentration of Acetaminophen can be increased when it is combined with Diflunisal. | [DB00495] Zidovudine: The metabolism of Zidovudine can be decreased when combined with Acetaminophen. | [DB00233] Aminosalicylic acid: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Aminosalicylic acid. | [DB00244] Mesalazine: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Mesalazine. | [DB00795] Sulfasalazine: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Sulfasalazine. | [DB01014] Balsalazide: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Balsalazide. | [DB01250] Olsalazine: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Olsalazine. | [DB01294] Bismuth subsalicylate: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Bismuth subsalicylate. | [DB06251] Dersalazine: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Dersalazine. | [DB06807] Phenyl aminosalicylate: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Phenyl aminosalicylate. | [DB09543] Methyl salicylate: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Methyl salicylate. | [DB12445] Nitroaspirin: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Nitroaspirin. | [DB13509] Aloxiprin: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Aloxiprin. | [DB13538] Guacetisal: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Guacetisal. | [DB14006] Choline salicylate: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Choline salicylate. | [DB14026] Thiosalicylic acid: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Thiosalicylic acid. | [DB00402] Eszopiclone: The serum concentration of Eszopiclone can be decreased when it is combined with Acetaminophen. | [DB11986] Entrectinib: The metabolism of Entrectinib can be increased when combined with Acetaminophen. | [DB01175] Escitalopram: The serum concentration of Acetaminophen can be increased when it is combined with Escitalopram. | [DB04855] Dronedarone: The metabolism of Acetaminophen can be decreased when combined with Dronedarone. | [DB15066] Givosiran: The serum concentration of Acetaminophen can be increased when it is combined with Givosiran. | [DB14975] Voxelotor: The serum concentration of Voxelotor can be increased when it is combined with Acetaminophen. | [DB06119] Cenobamate: The serum concentration of Acetaminophen can be decreased when it is combined with Cenobamate. | [DB09237] Levamlodipine: The serum concentration of Levamlodipine can be increased when it is combined with Acetaminophen. | [DB11951] Lemborexant: The serum concentration of Lemborexant can be increased when it is combined with Acetaminophen. | [DB06077] Lumateperone: The serum concentration of Lumateperone can be decreased when it is combined with Acetaminophen. | [DB15328] Ubrogepant: The serum concentration of Ubrogepant can be increased when it is combined with Acetaminophen. | [DB00243] Ranolazine: The metabolism of Ranolazine can be increased when combined with Acetaminophen. | [DB01190] Clindamycin: The metabolism of Clindamycin can be increased when combined with Acetaminophen. | [DB12457] Rimegepant: The metabolism of Rimegepant can be increased when combined with Acetaminophen. | [DB00977] Ethinylestradiol: The serum concentration of Acetaminophen can be decreased when it is combined with Ethinylestradiol. | [DB00503] Ritonavir: The serum concentration of Acetaminophen can be increased when it is combined with Ritonavir. | [DB00502] Haloperidol: The serum concentration of Haloperidol can be increased when it is combined with Acetaminophen. | [DB11652] Tucatinib: The metabolism of Tucatinib can be decreased when combined with Acetaminophen. | [DB11791] Capmatinib: The serum concentration of Capmatinib can be decreased when it is combined with Acetaminophen. | [DB15685] Selpercatinib: The serum concentration of Selpercatinib can be increased when it is combined with Acetaminophen. | [DB00472] Fluoxetine: The serum concentration of Acetaminophen can be increased when it is combined with Fluoxetine. | [DB11932] Abametapir: The serum concentration of Acetaminophen can be increased when it is combined with Abametapir. | [DB14881] Oliceridine: The serum concentration of Oliceridine can be decreased when it is combined with Acetaminophen. | [DB15762] Satralizumab: The serum concentration of Acetaminophen can be decreased when it is combined with Satralizumab. | [DB09098] Somatrem: The metabolism of Acetaminophen can be increased when combined with Somatrem. | [DB12950] Albusomatropin: The metabolism of Acetaminophen can be increased when combined with Albusomatropin. | [DB15112] Somatropin pegol: The metabolism of Acetaminophen can be increased when combined with Somatropin pegol. | [DB11800] Tivozanib: The metabolism of Tivozanib can be increased when combined with Acetaminophen. | [DB15569] Sotorasib: The serum concentration of Acetaminophen can be decreased when it is combined with Sotorasib. | [DB16165] Finerenone: The serum concentration of Finerenone can be increased when it is combined with Acetaminophen. | [DB06700] Desvenlafaxine: The serum concentration of Acetaminophen can be increased when it is combined with Desvenlafaxine. | [DB00343] Diltiazem: The metabolism of Acetaminophen can be decreased when combined with Diltiazem. | [DB00196] Fluconazole: The metabolism of Acetaminophen can be decreased when combined with Fluconazole. | [DB00270] Isradipine: The metabolism of Acetaminophen can be decreased when combined with Isradipine. | [DB00199] Erythromycin: The serum concentration of Acetaminophen can be increased when it is combined with Erythromycin. | [DB00673] Aprepitant: The metabolism of Acetaminophen can be decreased when combined with Aprepitant. | [DB04832] Zimelidine: The metabolism of Acetaminophen can be decreased when combined with Zimelidine. | [DB06636] Isavuconazonium: The metabolism of Acetaminophen can be decreased when combined with Isavuconazonium. | [DB06731] Seproxetine: The metabolism of Acetaminophen can be decreased when combined with Seproxetine. | [DB08953] Indalpine: The metabolism of Acetaminophen can be decreased when combined with Indalpine. | [DB09227] Barnidipine: The metabolism of Acetaminophen can be decreased when combined with Barnidipine. | [DB09231] Benidipine: The metabolism of Acetaminophen can be decreased when combined with Benidipine. | [DB14019] Fosnetupitant: The metabolism of Acetaminophen can be decreased when combined with Fosnetupitant. | [DB00342] Terfenadine: The metabolism of Acetaminophen can be decreased when combined with Terfenadine. | [DB00932] Tipranavir: The metabolism of Acetaminophen can be decreased when combined with Tipranavir. | [DB01118] Amiodarone: The metabolism of Acetaminophen can be decreased when combined with Amiodarone. | [DB00705] Delavirdine: The metabolism of Acetaminophen can be decreased when combined with Delavirdine. | [DB01026] Ketoconazole: The metabolism of Acetaminophen can be decreased when combined with Ketoconazole. | [DB00763] Methimazole: The metabolism of Acetaminophen can be decreased when combined with Methimazole. | [DB01167] Itraconazole: The metabolism of Acetaminophen can be decreased when combined with Itraconazole. | [DB02520] Ditiocarb: The metabolism of Acetaminophen can be decreased when combined with Ditiocarb. | [DB11730] Ribociclib: The metabolism of Acetaminophen can be decreased when combined with Ribociclib. | [DB09118] Stiripentol: The metabolism of Acetaminophen can be decreased when combined with Stiripentol. | [DB00625] Efavirenz: The metabolism of Acetaminophen can be decreased when combined with Efavirenz. | [DB01072] Atazanavir: The metabolism of Acetaminophen can be decreased when combined with Atazanavir. | [DB01149] Nefazodone: The metabolism of Acetaminophen can be decreased when combined with Nefazodone. | [DB09065] Cobicistat: The metabolism of Acetaminophen can be decreased when combined with Cobicistat. | [DB00701] Amprenavir: The metabolism of Acetaminophen can be decreased when combined with Amprenavir. | [DB01601] Lopinavir: The metabolism of Acetaminophen can be decreased when combined with Lopinavir. | [DB01183] Naloxone: Acetaminophen may decrease the excretion rate of Naloxone which could result in a higher serum level. | [DB00224] Indinavir: The metabolism of Acetaminophen can be decreased when combined with Indinavir. | [DB00872] Conivaptan: The metabolism of Acetaminophen can be decreased when combined with Conivaptan. | [DB01232] Saquinavir: The metabolism of Acetaminophen can be decreased when combined with Saquinavir. | [DB00696] Ergotamine: The metabolism of Acetaminophen can be decreased when combined with Ergotamine. | [DB04868] Nilotinib: The metabolism of Acetaminophen can be decreased when combined with Nilotinib. | [DB00220] Nelfinavir: The metabolism of Acetaminophen can be decreased when combined with Nelfinavir. | [DB06595] Midostaurin: The metabolism of Acetaminophen can be decreased when combined with Midostaurin. | [DB01264] Darunavir: The metabolism of Acetaminophen can be decreased when combined with Darunavir. | [DB00582] Voriconazole: The metabolism of Acetaminophen can be decreased when combined with Voriconazole. | [DB01406] Danazol: The metabolism of Acetaminophen can be decreased when combined with Danazol. | [DB00976] Telithromycin: The metabolism of Acetaminophen can be decreased when combined with Telithromycin. | [DB01211] Clarithromycin: The metabolism of Acetaminophen can be decreased when combined with Clarithromycin. | [DB01263] Posaconazole: The metabolism of Acetaminophen can be decreased when combined with Posaconazole. | [DB05521] Telaprevir: The metabolism of Acetaminophen can be decreased when combined with Telaprevir. | [DB06448] Lonafarnib: The metabolism of Acetaminophen can be decreased when combined with Lonafarnib. | [DB08873] Boceprevir: The metabolism of Acetaminophen can be decreased when combined with Boceprevir. | [DB09101] Elvitegravir: The metabolism of Acetaminophen can be decreased when combined with Elvitegravir. | [DB11779] Danoprevir: The metabolism of Acetaminophen can be decreased when combined with Danoprevir. | [DB13179] Troleandomycin: The metabolism of Acetaminophen can be decreased when combined with Troleandomycin. | [DB00467] Enoxacin: The metabolism of Acetaminophen can be decreased when combined with Enoxacin. | [DB00537] Ciprofloxacin: The metabolism of Acetaminophen can be decreased when combined with Ciprofloxacin. | [DB05488] Technetium Tc-99m ciprofloxacin: The metabolism of Acetaminophen can be decreased when combined with Technetium Tc-99m ciprofloxacin. | [DB14025] Clinafloxacin: The metabolism of Acetaminophen can be decreased when combined with Clinafloxacin. | [DB14029] Furafylline: The metabolism of Acetaminophen can be decreased when combined with Furafylline. | [DB08899] Enzalutamide: The serum concentration of Acetaminophen can be decreased when it is combined with Enzalutamide. | [DB11901] Apalutamide: The serum concentration of Acetaminophen can be decreased when it is combined with Apalutamide. | [DB01323] St. John's Wort: The metabolism of Acetaminophen can be increased when combined with St. John's Wort. | [DB00648] Mitotane: The metabolism of Acetaminophen can be increased when combined with Mitotane. | [DB09280] Lumacaftor: The metabolism of Acetaminophen can be increased when combined with Lumacaftor. | [DB15233] Avapritinib: The serum concentration of Acetaminophen can be increased when it is combined with Avapritinib. | [DB01201] Rifapentine: The metabolism of Acetaminophen can be increased when combined with Rifapentine. | [DB12265] Fexinidazole: The metabolism of Acetaminophen can be decreased when combined with Fexinidazole. | [DB11672] Curcumin: The metabolism of Acetaminophen can be decreased when combined with Curcumin. | [DB16220] Lonapegsomatropin: The metabolism of Acetaminophen can be increased when combined with Lonapegsomatropin. | [DB11201] Menthyl salicylate: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Menthyl salicylate. | [DB11323] Glycol salicylate: The risk or severity of adverse effects can be increased when Acetaminophen is combined with Glycol salicylate. | [DB12597] Asciminib: The serum concentration of Acetaminophen can be increased when it is combined with Asciminib. | [DB14960] Somatrogon: The metabolism of Acetaminophen can be increased when combined with Somatrogon. | [DB05667] Levoketoconazole: The metabolism of Acetaminophen can be decreased when combined with Levoketoconazole. | [DB12917] Bimekizumab: The metabolism of Acetaminophen can be increased when combined with Bimekizumab. | [DB04216] Quercetin: The metabolism of Acetaminophen can be decreased when combined with Quercetin. | [DB16236] Mitapivat: The metabolism of Acetaminophen can be increased when combined with Mitapivat. | [DB14737] Cannabinol: The metabolism of Acetaminophen can be decreased when combined with Cannabinol. | [DB00470] Dronabinol: The serum concentration of Dronabinol can be increased when it is combined with Acetaminophen. | [DB16650] Deucravacitinib: The serum concentration of Acetaminophen can be increased when it is combined with Deucravacitinib. | [DB14921] Mavacamten: The serum concentration of Acetaminophen can be decreased when it is combined with Mavacamten. | [DB12095] Telotristat ethyl: The serum concentration of Acetaminophen can be decreased when it is combined with Telotristat ethyl. | [DB00527] Cinchocaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Cinchocaine. | [DB00645] Dyclonine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Dyclonine. | [DB00807] Proparacaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Proparacaine. | [DB00892] Oxybuprocaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Oxybuprocaine. | [DB01161] Chloroprocaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Chloroprocaine. | [DB03255] Phenol: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Phenol. | [DB05232] Tetrodotoxin: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Tetrodotoxin. | [DB08987] Etidocaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Etidocaine. | [DB09342] Propoxycaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Propoxycaine. | [DB09345] Pramocaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Pramocaine. | [DB11148] Butamben: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Butamben. | [DB11502] Butacaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Butacaine. | [DB12532] Oxetacaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Oxetacaine. | [DB13259] Ethyl chloride: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Ethyl chloride. | [DB13328] Butanilicaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Butanilicaine. | [DB13578] Metabutethamine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Metabutethamine. | [DB13683] Quinisocaine: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Quinisocaine. | [DB06237] Avanafil: The serum concentration of Avanafil can be increased when it is combined with Acetaminophen. | [DB17472] Pirtobrutinib: The serum concentration of Acetaminophen can be increased when it is combined with Pirtobrutinib. | [DB15568] Adagrasib: The metabolism of Acetaminophen can be decreased when combined with Adagrasib. | [DB12513] Omaveloxolone: The serum concentration of Acetaminophen can be decreased when it is combined with Omaveloxolone. | [DB16217] Leniolisib: The metabolism of Acetaminophen can be decreased when combined with Leniolisib. | [DB06742] Ambroxol: The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Ambroxol. | [DB08820] Ivacaftor: The serum concentration of Acetaminophen can be increased when it is combined with Ivacaftor. | [DB15669] Fezolinetant: The metabolism of Fezolinetant can be decreased when combined with Acetaminophen. | [DB16672] Epcoritamab: The serum concentration of Acetaminophen can be increased when it is combined with Epcoritamab. | [DB08906] Fluticasone furoate: The serum concentration of Fluticasone furoate can be increased when it is combined with Acetaminophen. | [DB12255] Vadadustat: The serum concentration of Acetaminophen can be increased when it is combined with Vadadustat. | [DB16371] Glofitamab: The serum concentration of Acetaminophen can be increased when it is combined with Glofitamab. | [DB14924] Ritlecitinib: The serum concentration of Acetaminophen can be increased when it is combined with Ritlecitinib. | [DB15490] Zuranolone: The serum concentration of Zuranolone can be decreased when it is combined with Acetaminophen. | [DB12184] Gepirone: The serum concentration of Gepirone can be increased when it is combined with Acetaminophen. | [DB12874] Quizartinib: The serum concentration of Acetaminophen can be increased when it is combined with Quizartinib. | [DB16826] Repotrectinib: The serum concentration of Acetaminophen can be increased when it is combined with Repotrectinib. | [DB16390] Mobocertinib: The serum concentration of Acetaminophen can be increased when it is combined with Mobocertinib. | [DB12005] Nirogacestat: The metabolism of Nirogacestat can be decreased when combined with Acetaminophen. | [DB16200] Iptacopan: The metabolism of Iptacopan can be decreased when combined with Acetaminophen. | [DB05501] Mavorixafor: The metabolism of Acetaminophen can be decreased when combined with Mavorixafor. | [DB15775] Algestone acetophenide: The metabolism of Algestone acetophenide can be increased when combined with Acetaminophen. | [DB15903] Chlormadinone acetate: The metabolism of Chlormadinone acetate can be increased when combined with Acetaminophen. | [DB17048] Plumbagin: The metabolism of Plumbagin can be increased when combined with Acetaminophen. | [DB18000] Algestone: The metabolism of Algestone can be increased when combined with Acetaminophen. | [DB17097] Vorasidenib: The metabolism of Vorasidenib can be decreased when combined with Acetaminophen. | [DB15357] Xanomeline: The metabolism of Xanomeline can be decreased when combined with Acetaminophen.",.8 mL/1mL; 0.032 g; 0.032000 g; 0.1 g; 0.1000 g; 0.300 g; 0.325 g/1g; 0.5 g/1g; 0.5 gr; 0.5 mg/5mL; 0.5 mg/60mL; 0.500 g; 1 % w/v; 1 G; 1 g; 1 g/100ml; 1 kg/1kg; 1 mg; 1 mg/5mL; 1 mg/5ml; 1.00 g/100ml; 1.000 g; 1.0000 g; 1.067 mg/5mL; 10 MG/ML; 10 g; 10 mg; 10 mg / mL; 10 mg/ ml; 10 mg/1mL; 10 mg/1ml; 10 mg/ml; 10.00 g; 10.00 mg; 10.000 g; 10.50 mg; 100 MG/ML; 100 mg; 100 mg / 10 mL; 100 mg/1mL; 100 ml; 100.00 mg; 100.000 mg; 100.0000 mg; 1000 MG; 1000 mg; 1000 mg / 100 mL; 1000 mg/1; 1000 mg/100mL; 1000 mg/30mL; 1000 mg/60mL; 1000.00 mg; 1000.000 mg; 100000 g; 1000000 g; 1000000 mg; 10000000 mg; 100000000 mg; 12.5 mg; 120 MG; 120 mg; 120 mg / 5 mL; 120 mg / sup; 120 mg/1; 120 mg/5mL; 120 mg/5ml; 125 MG; 125 mg; 125 mg/5ml; 12500000 mg; 135 mg/5mL; 15 mg; 15 ml; 15.000 mg; 150 MG; 150 mg; 150 mg/1ml; 150 mg/5mL; 150 mg/ml; 150 ml; 16.7 mg/5mL; 160 mg; 160 mg / 5 mL; 160 mg / sachet; 160 mg / sup; 160 mg / tab; 160 mg/1; 160 mg/1.6mL; 160 mg/10.15mL; 160 mg/100mL; 160 mg/5mL; 2 mg; 2 mg/5mL; 2.00 mg; 2.000 mg; 2.4 G/100ML; 2.4 g; 2.400 g; 2.4000 g; 2.5 g; 2.500 g; 2.500 mg; 2.5000 mg; 200 mg; 200 mg/2mL; 200 mg/5mL; 200.00 mg; 200000 g; 20000000 mg; 2166.79 mg; 240 mg; 240 mg/5mL; 25 mg; 250 MG; 250 mg; 250 mg/5mL; 250 mg/5ml; 250.000 mg; 250.0000 mg; 25000000 g; 25000000 mg; 275 mg; 275.000 mg; 3 g; 3.000 mg; 3.2 g; 3.20 g; 3.200 g; 3.250 g; 3.333 g/100mL; 30 mg; 30 ml; 300 MG; 300 mg; 300 mg/1; 300.00 mg; 3000 mg; 300000 g; 30000000 mg; 300000000 mg; 302000 g; 304000 g; 32 mg / mL; 32 mg/1mL; 32.5 mg; 320 mg/10mL; 3200 mg; 320000 g; 320000000 mg; 324.9 mg/361mg; 325 mg; 325 mg / sup; 325 mg / tab; 325 mg/1; 325 mg/10.15mL; 325 mg/1570mg; 325.00 mg; 325.000 mg; 32500000 mg; 333000 g; 35 mg; 350 mg; 37.5 mg; 37.50 mg; 37.500 mg; 375.000 mg; 4 mg; 4.00 mg; 40 mg/5mL; 40 mg/ml; 400 mg; 400.000 mg; 450 mg; 499.5 mg/1; 5 mg; 5.000 mg; 50 mg; 50 mg/5mL; 50 mg/ml; 500 1/1; 500 MG; 500 mg; 500 mg / 15 mL; 500 mg / 50 mL; 500 mg / cap; 500 mg / sachet; 500 mg / tab; 500 mg/0.95g; 500 mg/1; 500 mg/15mL; 500 mg/1U; 500 mg/5001; 500 mg/583mg; 500 mg/5mL; 500 mg/5ml; 500.0 mg; 500.00 mg; 500.000 mg; 500.04 mg; 500.4 mg/556mg; 500000 g; 50000000 mg; 51800000 mg; 55.000 mg; 555.000 mg; 55556000 mg; 60 MG/0.6ML; 60 mg; 60 mg/0.6ml; 600 MG; 600 mg; 600 mg/4ml; 628000 g; 65 mg; 650 mg; 650 mg / 15 mL; 650 mg / sup; 650 mg / tab; 650 mg/1; 650 mg/20.3mL; 650 mg/50mL; 650.0 mg; 650.00 mg; 650.000 mg; 665 MG; 665 mg; 675 mg/15mL; 7.6 mg; 75 MG; 75.000 mg; 750 mg/1; 750.000 mg; 8 mg; 80 mg; 80 mg / 5 mL; 80 mg / mL; 80 mg / tab; 80 mg/0.8mL; 80 mg/1; 80 mg/2.5mL; 80.000 mg; 8000000 mg; 89.605 mg/89.605mg; 9 mg; 90 mg/100mg; 90 mg/90mg,Avoid alcohol. Alcohol may increase the risk of hepatotoxicity.; Take with or without food. The absorption is unaffected by food.
DB00338,Omeprazole,ALIMENTARY TRACT AND METABOLISM; Combinations for eradication of Helicobacter pylori; DRUGS FOR ACID RELATED DISORDERS; DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD); Proton pump inhibitors,[DB00091] Cyclosporine: The serum concentration of Cyclosporine can be increased when it is combined with Omeprazole. | [DB01166] Cilostazol: The serum concentration of Cilostazol can be increased when it is combined with Omeprazole. | [DB08912] Dabrafenib: The serum concentration of Omeprazole can be decreased when it is combined with Dabrafenib. | [DB00182] Amphetamine: Omeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. | [DB01072] Atazanavir: Omeprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB06616] Bosutinib: Omeprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB01066] Cefditoren: The serum concentration of Cefditoren can be decreased when it is combined with Omeprazole. | [DB06695] Dabigatran etexilate: Omeprazole can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB01254] Dasatinib: Omeprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB00705] Delavirdine: Omeprazole can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB01576] Dextroamphetamine: Omeprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. | [DB00530] Erlotinib: Omeprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB00196] Fluconazole: The metabolism of Omeprazole can be decreased when combined with Fluconazole. | [DB00317] Gefitinib: Omeprazole can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB00224] Indinavir: Omeprazole can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB01167] Itraconazole: Omeprazole can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB09027] Ledipasvir: Omeprazole can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB00422] Methylphenidate: Omeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. | [DB06701] Dexmethylphenidate: Omeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. | [DB00220] Nelfinavir: The serum concentration of Nelfinavir can be decreased when it is combined with Omeprazole. | [DB04868] Nilotinib: The serum concentration of Nilotinib can be decreased when it is combined with Omeprazole. | [DB06589] Pazopanib: Omeprazole can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB01263] Posaconazole: Omeprazole can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB06817] Raltegravir: Omeprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. | [DB08864] Rilpivirine: Omeprazole can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB08931] Riociguat: Omeprazole can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB00884] Risedronic acid: Omeprazole can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. | [DB01232] Saquinavir: The serum concentration of Saquinavir can be increased when it is combined with Omeprazole. | [DB00932] Tipranavir: The metabolism of Omeprazole can be increased when combined with Tipranavir. | [DB00582] Voriconazole: The serum concentration of Omeprazole can be increased when it is combined with Voriconazole. | [DB08933] Luliconazole: The serum concentration of Omeprazole can be increased when it is combined with Luliconazole. | [DB00252] Phenytoin: The serum concentration of Phenytoin can be increased when it is combined with Omeprazole. | [DB01320] Fosphenytoin: The serum concentration of Fosphenytoin can be increased when it is combined with Omeprazole. | [DB00451] Levothyroxine: Omeprazole can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB01418] Acenocoumarol: The metabolism of Acenocoumarol can be decreased when combined with Omeprazole. | [DB08496] (R)-warfarin: The metabolism of (R)-warfarin can be decreased when combined with Omeprazole. | [DB14055] (S)-Warfarin: The metabolism of (S)-Warfarin can be decreased when combined with Omeprazole. | [DB09020] Bisacodyl: The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Omeprazole. | [DB01197] Captopril: Omeprazole can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB01112] Cefuroxime: The serum concentration of Cefuroxime can be decreased when it is combined with Omeprazole. | [DB01043] Memantine: Omeprazole may decrease the excretion rate of Memantine which could result in a higher serum level. | [DB00391] Sulpiride: The therapeutic efficacy of Sulpiride can be increased when used in combination with Omeprazole. | [DB00244] Mesalazine: Omeprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB01024] Mycophenolic acid: Omeprazole can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB01344] Tolevamer: The therapeutic efficacy of Tolevamer can be decreased when used in combination with Omeprazole. | [DB00630] Alendronic acid: The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Omeprazole. | [DB00710] Ibandronate: The therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole. | [DB00720] Clodronic acid: The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Omeprazole. | [DB01077] Etidronic acid: The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Omeprazole. | [DB01133] Tiludronic acid: The therapeutic efficacy of Tiludronic acid can be decreased when used in combination with Omeprazole. | [DB06255] Incadronic acid: The therapeutic efficacy of Incadronic acid can be decreased when used in combination with Omeprazole. | [DB00847] Cysteamine: The bioavailability of Cysteamine can be decreased when combined with Omeprazole. | [DB01026] Ketoconazole: Omeprazole can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB09280] Lumacaftor: The serum concentration of Omeprazole can be decreased when it is combined with Lumacaftor. | [DB00864] Tacrolimus: The metabolism of Tacrolimus can be decreased when combined with Omeprazole. | [DB06799] Methenamine: The therapeutic efficacy of Methenamine can be decreased when used in combination with Omeprazole. | [DB00176] Fluvoxamine: The metabolism of Omeprazole can be decreased when combined with Fluvoxamine. | [DB00208] Ticlopidine: The metabolism of Omeprazole can be decreased when combined with Ticlopidine. | [DB00446] Chloramphenicol: The metabolism of Omeprazole can be decreased when combined with Chloramphenicol. | [DB00448] Lansoprazole: The metabolism of Omeprazole can be decreased when combined with Lansoprazole. | [DB00472] Fluoxetine: The metabolism of Omeprazole can be decreased when combined with Fluoxetine. | [DB00951] Isoniazid: The metabolism of Omeprazole can be decreased when combined with Isoniazid. | [DB00549] Zafirlukast: The metabolism of Omeprazole can be decreased when combined with Zafirlukast. | [DB09119] Eslicarbazepine acetate: The metabolism of Omeprazole can be decreased when combined with Eslicarbazepine acetate. | [DB00949] Felbamate: The metabolism of Omeprazole can be decreased when combined with Felbamate. | [DB14009] Medical Cannabis: The metabolism of Medical Cannabis can be decreased when combined with Omeprazole. | [DB00619] Imatinib: The metabolism of Imatinib can be decreased when combined with Omeprazole. | [DB00313] Valproic acid: The metabolism of Omeprazole can be decreased when combined with Valproic acid. | [DB00622] Nicardipine: The metabolism of Omeprazole can be decreased when combined with Nicardipine. | [DB01110] Miconazole: The metabolism of Omeprazole can be decreased when combined with Miconazole. | [DB01241] Gemfibrozil: The metabolism of Omeprazole can be decreased when combined with Gemfibrozil. | [DB01685] Topiroxostat: The metabolism of Omeprazole can be decreased when combined with Topiroxostat. | [DB00468] Quinine: The metabolism of Quinine can be decreased when combined with Omeprazole. | [DB11901] Apalutamide: The serum concentration of Omeprazole can be increased when it is combined with Apalutamide. | [DB00624] Testosterone: The metabolism of Testosterone can be decreased when combined with Omeprazole. | [DB00688] Mycophenolate mofetil: Omeprazole can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB01016] Glyburide: The metabolism of Glyburide can be decreased when combined with Omeprazole. | [DB06605] Apixaban: The metabolism of Apixaban can be decreased when combined with Omeprazole. | [DB12332] Rucaparib: The metabolism of Omeprazole can be decreased when combined with Rucaparib. | [DB11689] Selumetinib: The metabolism of Selumetinib can be decreased when combined with Omeprazole. | [DB06730] Gestodene: The metabolism of Omeprazole can be decreased when combined with Gestodene. | [DB12474] Lynestrenol: The metabolism of Lynestrenol can be decreased when combined with Omeprazole. | [DB00518] Albendazole: The metabolism of Albendazole can be decreased when combined with Omeprazole. | [DB00590] Doxazosin: The metabolism of Doxazosin can be decreased when combined with Omeprazole. | [DB01039] Fenofibrate: The metabolism of Omeprazole can be decreased when combined with Fenofibrate. | [DB11633] Isavuconazole: The metabolism of Omeprazole can be decreased when combined with Isavuconazole. | [DB00188] Bortezomib: The metabolism of Omeprazole can be decreased when combined with Bortezomib. | [DB00675] Tamoxifen: The metabolism of Tamoxifen can be decreased when combined with Omeprazole. | [DB00531] Cyclophosphamide: The metabolism of Cyclophosphamide can be decreased when combined with Omeprazole. | [DB05109] Trabectedin: The metabolism of Trabectedin can be decreased when combined with Omeprazole. | [DB00564] Carbamazepine: The metabolism of Omeprazole can be decreased when combined with Carbamazepine. | [DB00444] Teniposide: The metabolism of Teniposide can be decreased when combined with Omeprazole. | [DB13874] Enasidenib: The metabolism of Enasidenib can be decreased when combined with Omeprazole. | [DB06626] Axitinib: The metabolism of Axitinib can be decreased when combined with Omeprazole. | [DB01242] Clomipramine: The metabolism of Omeprazole can be decreased when combined with Clomipramine. | [DB00665] Nilutamide: The metabolism of Nilutamide can be decreased when combined with Omeprazole. | [DB06712] Nilvadipine: The metabolism of Omeprazole can be decreased when combined with Nilvadipine. | [DB00977] Ethinylestradiol: The metabolism of Omeprazole can be decreased when combined with Ethinylestradiol. | [DB04216] Quercetin: The metabolism of Omeprazole can be decreased when combined with Quercetin. | [DB09241] Methylene blue: The metabolism of Methylene blue can be decreased when combined with Omeprazole. | [DB00347] Trimethadione: The metabolism of Trimethadione can be decreased when combined with Omeprazole. | [DB00395] Carisoprodol: The metabolism of Carisoprodol can be decreased when combined with Omeprazole. | [DB00849] Methylphenobarbital: The metabolism of Methylphenobarbital can be decreased when combined with Omeprazole. | [DB01058] Praziquantel: The metabolism of Praziquantel can be decreased when combined with Omeprazole. | [DB01131] Proguanil: The metabolism of Proguanil can be decreased when combined with Omeprazole. | [DB01355] Hexobarbital: The metabolism of Hexobarbital can be decreased when combined with Omeprazole. | [DB01483] Barbital: The metabolism of Barbital can be decreased when combined with Omeprazole. | [DB05246] Methsuximide: The metabolism of Methsuximide can be decreased when combined with Omeprazole. | [DB05351] Dexlansoprazole: The metabolism of Dexlansoprazole can be decreased when combined with Omeprazole. | [DB06218] Lacosamide: The metabolism of Lacosamide can be decreased when combined with Omeprazole. | [DB06697] Artemether: The metabolism of Artemether can be decreased when combined with Omeprazole. | [DB06739] Seratrodast: The metabolism of Seratrodast can be decreased when combined with Omeprazole. | [DB09166] Etizolam: The metabolism of Etizolam can be decreased when combined with Omeprazole. | [DB13762] Dexrabeprazole: The metabolism of Dexrabeprazole can be decreased when combined with Omeprazole. | [DB00898] Ethanol: The metabolism of Omeprazole can be decreased when combined with Ethanol. | [DB04911] Oritavancin: The metabolism of Omeprazole can be decreased when combined with Oritavancin. | [DB09238] Manidipine: The metabolism of Omeprazole can be decreased when combined with Manidipine. | [DB11638] Artenimol: The metabolism of Omeprazole can be decreased when combined with Artenimol. | [DB00983] Formoterol: The metabolism of Formoterol can be decreased when combined with Omeprazole. | [DB00679] Thioridazine: The metabolism of Thioridazine can be decreased when combined with Omeprazole. | [DB00738] Pentamidine: The metabolism of Pentamidine can be decreased when combined with Omeprazole. | [DB01120] Gliclazide: The metabolism of Gliclazide can be decreased when combined with Omeprazole. | [DB00598] Labetalol: The metabolism of Labetalol can be decreased when combined with Omeprazole. | [DB00980] Ramelteon: The metabolism of Ramelteon can be decreased when combined with Omeprazole. | [DB06414] Etravirine: The metabolism of Etravirine can be decreased when combined with Omeprazole. | [DB09068] Vortioxetine: The metabolism of Vortioxetine can be decreased when combined with Omeprazole. | [DB01628] Etoricoxib: The metabolism of Omeprazole can be decreased when combined with Etoricoxib. | [DB04861] Nebivolol: The metabolism of Nebivolol can be decreased when combined with Omeprazole. | [DB06684] Vilazodone: The metabolism of Vilazodone can be decreased when combined with Omeprazole. | [DB00203] Sildenafil: The metabolism of Omeprazole can be decreased when combined with Sildenafil. | [DB00829] Diazepam: The metabolism of Diazepam can be decreased when combined with Omeprazole. | [DB00213] Pantoprazole: The metabolism of Omeprazole can be decreased when combined with Pantoprazole. | [DB00349] Clobazam: The serum concentration of Clobazam can be increased when it is combined with Omeprazole. | [DB00736] Esomeprazole: The metabolism of Esomeprazole can be decreased when combined with Omeprazole. | [DB00909] Zonisamide: The metabolism of Zonisamide can be decreased when combined with Omeprazole. | [DB12500] Fedratinib: The serum concentration of Omeprazole can be increased when it is combined with Fedratinib. | [DB05928] Dovitinib: The metabolism of Omeprazole can be decreased when combined with Dovitinib. | [DB11837] Osilodrostat: The metabolism of Omeprazole can be decreased when combined with Osilodrostat. | [DB11823] Esketamine: The metabolism of Esketamine can be decreased when combined with Omeprazole. | [DB00363] Clozapine: The metabolism of Omeprazole can be decreased when combined with Clozapine. | [DB00333] Methadone: The metabolism of Methadone can be decreased when combined with Omeprazole. | [DB01259] Lapatinib: The metabolism of Lapatinib can be decreased when combined with Omeprazole. | [DB00330] Ethambutol: The metabolism of Omeprazole can be decreased when combined with Ethambutol. | [DB01086] Benzocaine: The metabolism of Benzocaine can be decreased when combined with Omeprazole. | [DB01129] Rabeprazole: The metabolism of Rabeprazole can be decreased when combined with Omeprazole. | [DB00752] Tranylcypromine: The metabolism of Omeprazole can be decreased when combined with Tranylcypromine. | [DB01093] Dimethyl sulfoxide: The metabolism of Omeprazole can be decreased when combined with Dimethyl sulfoxide. | [DB01171] Moclobemide: The metabolism of Moclobemide can be decreased when combined with Omeprazole. | [DB04920] Clevidipine: The metabolism of Omeprazole can be decreased when combined with Clevidipine. | [DB06268] Sitaxentan: The metabolism of Omeprazole can be decreased when combined with Sitaxentan. | [DB06731] Seproxetine: The metabolism of Omeprazole can be decreased when combined with Seproxetine. | [DB09198] Lobeglitazone: The metabolism of Omeprazole can be decreased when combined with Lobeglitazone. | [DB12319] Benzbromarone: The metabolism of Omeprazole can be decreased when combined with Benzbromarone. | [DB00776] Oxcarbazepine: The metabolism of Omeprazole can be decreased when combined with Oxcarbazepine. | [DB14575] Eslicarbazepine: The metabolism of Omeprazole can be decreased when combined with Eslicarbazepine. | [DB14635] Curcumin sulfate: The metabolism of Omeprazole can be decreased when combined with Curcumin sulfate. | [DB00273] Topiramate: The metabolism of Omeprazole can be decreased when combined with Topiramate. | [DB00966] Telmisartan: The metabolism of Omeprazole can be decreased when combined with Telmisartan. | [DB00532] Mephenytoin: The metabolism of Omeprazole can be decreased when combined with Mephenytoin. | [DB01006] Letrozole: The metabolism of Omeprazole can be decreased when combined with Letrozole. | [DB15093] Somapacitan: The metabolism of Omeprazole can be decreased when combined with Somapacitan. | [DB01201] Rifapentine: The metabolism of Omeprazole can be increased when combined with Rifapentine. | [DB00783] Estradiol: The metabolism of Estradiol can be decreased when combined with Omeprazole. | [DB00921] Buprenorphine: The metabolism of Omeprazole can be decreased when combined with Buprenorphine. | [DB00599] Thiopental: The metabolism of Thiopental can be decreased when combined with Omeprazole. | [DB09167] Dosulepin: The metabolism of Omeprazole can be decreased when combined with Dosulepin. | [DB00458] Imipramine: The metabolism of Omeprazole can be decreased when combined with Imipramine. | [DB00726] Trimipramine: The metabolism of Trimipramine can be decreased when combined with Omeprazole. | [DB04951] Pirfenidone: The metabolism of Pirfenidone can be decreased when combined with Omeprazole. | [DB00334] Olanzapine: The metabolism of Omeprazole can be decreased when combined with Olanzapine. | [DB01142] Doxepin: The metabolism of Doxepin can be decreased when combined with Omeprazole. | [DB06442] Avasimibe: The metabolism of Omeprazole can be decreased when combined with Avasimibe. | [DB00396] Progesterone: The metabolism of Progesterone can be decreased when combined with Omeprazole. | [DB00501] Cimetidine: The metabolism of Omeprazole can be decreased when combined with Cimetidine. | [DB00715] Paroxetine: The metabolism of Paroxetine can be decreased when combined with Omeprazole. | [DB01104] Sertraline: The metabolism of Sertraline can be decreased when combined with Omeprazole. | [DB09061] Cannabidiol: The metabolism of Cannabidiol can be decreased when combined with Omeprazole. | [DB00470] Dronabinol: The metabolism of Omeprazole can be decreased when combined with Dronabinol. | [DB01174] Phenobarbital: The metabolism of Phenobarbital can be decreased when combined with Omeprazole. | [DB11963] Dacomitinib: Omeprazole can cause a decrease in the absorption of Dacomitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB00325] Nitroprusside: The absorption of Nitroprusside can be decreased when combined with Omeprazole. | [DB00893] Iron Dextran: The absorption of Iron Dextran can be decreased when combined with Omeprazole. | [DB01592] Iron: The absorption of Iron can be decreased when combined with Omeprazole. | [DB06215] Ferumoxytol: The absorption of Ferumoxytol can be decreased when combined with Omeprazole. | [DB06783] Prussian blue: The absorption of Prussian blue can be decreased when combined with Omeprazole. | [DB08917] Ferric carboxymaltose: The absorption of Ferric carboxymaltose can be decreased when combined with Omeprazole. | [DB09146] Iron sucrose: The absorption of Iron sucrose can be decreased when combined with Omeprazole. | [DB09147] Ferric pyrophosphate: The absorption of Ferric pyrophosphate can be decreased when combined with Omeprazole. | [DB09501] Ferric ammonium citrate: The absorption of Ferric ammonium citrate can be decreased when combined with Omeprazole. | [DB09507] Ferumoxsil: The absorption of Ferumoxsil can be decreased when combined with Omeprazole. | [DB09508] Ferumoxides: The absorption of Ferumoxides can be decreased when combined with Omeprazole. | [DB11171] Ferric sulfate: The absorption of Ferric sulfate can be decreased when combined with Omeprazole. | [DB11210] Ferrous bisglycinate: The absorption of Ferrous bisglycinate can be decreased when combined with Omeprazole. | [DB11417] Gleptoferron: The absorption of Gleptoferron can be decreased when combined with Omeprazole. | [DB11576] Ferric oxide: The absorption of Ferric oxide can be decreased when combined with Omeprazole. | [DB12821] Perflubutane: The absorption of Perflubutane can be decreased when combined with Omeprazole. | [DB13257] Ferrous sulfate anhydrous: The absorption of Ferrous sulfate anhydrous can be decreased when combined with Omeprazole. | [DB13381] Sodium feredetate: The absorption of Sodium feredetate can be decreased when combined with Omeprazole. | [DB13423] Ferric hydroxide: The absorption of Ferric hydroxide can be decreased when combined with Omeprazole. | [DB13569] Ferrous chloride: The absorption of Ferrous chloride can be decreased when combined with Omeprazole. | [DB13949] Ferric cation: The absorption of Ferric cation can be decreased when combined with Omeprazole. | [DB14488] Ferrous gluconate: The absorption of Ferrous gluconate can be decreased when combined with Omeprazole. | [DB14489] Ferrous succinate: The absorption of Ferrous succinate can be decreased when combined with Omeprazole. | [DB14491] Ferrous fumarate: The absorption of Ferrous fumarate can be decreased when combined with Omeprazole. | [DB14520] Tetraferric tricitrate decahydrate: The absorption of Tetraferric tricitrate decahydrate can be decreased when combined with Omeprazole. | [DB14695] Ferric oxyhydroxide: The absorption of Ferric oxyhydroxide can be decreased when combined with Omeprazole. | [DB15598] Ferric maltol: The absorption of Ferric maltol can be decreased when combined with Omeprazole. | [DB12208] Iron isomaltoside 1000: The absorption of Iron isomaltoside 1000 can be decreased when combined with Omeprazole. | [DB15763] Iron polymaltose: The absorption of Iron polymaltose can be decreased when combined with Omeprazole. | [DB00005] Etanercept: The metabolism of Omeprazole can be increased when combined with Etanercept. | [DB00026] Anakinra: The metabolism of Omeprazole can be increased when combined with Anakinra. | [DB00051] Adalimumab: The metabolism of Omeprazole can be increased when combined with Adalimumab. | [DB00065] Infliximab: The metabolism of Omeprazole can be increased when combined with Infliximab. | [DB01281] Abatacept: The metabolism of Omeprazole can be increased when combined with Abatacept. | [DB04956] Afelimomab: The metabolism of Omeprazole can be increased when combined with Afelimomab. | [DB05676] Apremilast: The metabolism of Omeprazole can be increased when combined with Apremilast. | [DB06168] Canakinumab: The metabolism of Omeprazole can be increased when combined with Canakinumab. | [DB06372] Rilonacept: The metabolism of Omeprazole can be increased when combined with Rilonacept. | [DB06674] Golimumab: The metabolism of Omeprazole can be increased when combined with Golimumab. | [DB08904] Certolizumab pegol: The metabolism of Omeprazole can be increased when combined with Certolizumab pegol. | [DB09029] Secukinumab: The metabolism of Omeprazole can be increased when combined with Secukinumab. | [DB09036] Siltuximab: The metabolism of Omeprazole can be increased when combined with Siltuximab. | [DB14724] Emapalumab: The metabolism of Omeprazole can be increased when combined with Emapalumab. | [DB06273] Tocilizumab: The metabolism of Omeprazole can be increased when combined with Tocilizumab. | [DB11586] Asunaprevir: Omeprazole can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB01319] Fosamprenavir: Omeprazole can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB15623] TMC-310911: Omeprazole can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB00215] Citalopram: The risk or severity of QTc prolongation can be increased when Omeprazole is combined with Citalopram. | [DB12245] Triclabendazole: The metabolism of Omeprazole can be decreased when combined with Triclabendazole. | [DB00321] Amitriptyline: The metabolism of Amitriptyline can be decreased when combined with Omeprazole. | [DB01045] Rifampin: The serum concentration of Omeprazole can be decreased when it is combined with Rifampicin. | [DB01323] St. John's Wort: The serum concentration of Omeprazole can be decreased when it is combined with St. John's Wort. | [DB00563] Methotrexate: The serum concentration of Methotrexate can be increased when it is combined with Omeprazole. | [DB00425] Zolpidem: The metabolism of Zolpidem can be decreased when combined with Omeprazole. | [DB09073] Palbociclib: The absorption of Palbociclib can be decreased when combined with Omeprazole. | [DB00390] Digoxin: The serum concentration of Digoxin can be increased when it is combined with Omeprazole. | [DB13401] Metildigoxin: The serum concentration of Metildigoxin can be increased when it is combined with Omeprazole. | [DB13691] Acetyldigoxin: The serum concentration of Acetyldigoxin can be increased when it is combined with Omeprazole. | [DB12015] Alpelisib: The metabolism of Omeprazole can be decreased when combined with Alpelisib. | [DB00373] Timolol: The metabolism of Timolol can be decreased when combined with Omeprazole. | [DB00745] Modafinil: The metabolism of Omeprazole can be decreased when combined with Modafinil. | [DB06413] Armodafinil: The metabolism of Omeprazole can be decreased when combined with Armodafinil. | [DB00571] Propranolol: The serum concentration of Propranolol can be increased when it is combined with Omeprazole. | [DB00758] Clopidogrel: The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Omeprazole resulting in a loss in efficacy. | [DB12978] Pexidartinib: The serum concentration of Pexidartinib can be decreased when it is combined with Omeprazole. | [DB01175] Escitalopram: The serum concentration of Escitalopram can be increased when it is combined with Omeprazole. | [DB14975] Voxelotor: The metabolism of Voxelotor can be decreased when combined with Omeprazole. | [DB06119] Cenobamate: The serum concentration of Omeprazole can be increased when it is combined with Cenobamate. | [DB01222] Budesonide: Omeprazole can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB14513] Magnesium: The serum concentration of Magnesium can be decreased when it is combined with Omeprazole. | [DB00503] Ritonavir: The metabolism of Omeprazole can be decreased when combined with Ritonavir. | [DB15685] Selpercatinib: The serum concentration of Selpercatinib can be decreased when it is combined with Omeprazole. | [DB00104] Octreotide: Omeprazole can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB15762] Satralizumab: The serum concentration of Omeprazole can be decreased when it is combined with Satralizumab. | [DB00254] Doxycycline: Omeprazole can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB15569] Sotorasib: The therapeutic efficacy of Sotorasib can be decreased when used in combination with Omeprazole. | [DB11886] Infigratinib: The serum concentration of Infigratinib can be decreased when it is combined with Omeprazole. | [DB16703] Belumosudil: The serum concentration of Belumosudil can be decreased when it is combined with Omeprazole. | [DB09118] Stiripentol: The metabolism of Omeprazole can be decreased when combined with Stiripentol. | [DB01118] Amiodarone: The metabolism of Omeprazole can be decreased when combined with Amiodarone. | [DB00625] Efavirenz: The metabolism of Omeprazole can be decreased when combined with Efavirenz. | [DB00763] Methimazole: The metabolism of Omeprazole can be decreased when combined with Methimazole. | [DB00701] Amprenavir: The metabolism of Omeprazole can be decreased when combined with Amprenavir. | [DB01264] Darunavir: Omeprazole can cause a decrease in the absorption of Darunavir resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB06448] Lonafarnib: The metabolism of Omeprazole can be decreased when combined with Lonafarnib. | [DB00312] Pentobarbital: The metabolism of Pentobarbital can be decreased when combined with Omeprazole. | [DB00794] Primidone: The metabolism of Primidone can be decreased when combined with Omeprazole. | [DB08899] Enzalutamide: The serum concentration of Omeprazole can be decreased when it is combined with Enzalutamide. | [DB15463] Belzutifan: The serum concentration of Belzutifan can be increased when it is combined with Omeprazole. | [DB12265] Fexinidazole: The metabolism of Fexinidazole can be decreased when combined with Omeprazole. | [DB12597] Asciminib: The metabolism of Omeprazole can be decreased when combined with Asciminib. | [DB05667] Levoketoconazole: Omeprazole can cause a decrease in the absorption of Levoketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB12917] Bimekizumab: The metabolism of Omeprazole can be increased when combined with Bimekizumab. | [DB14973] Abrocitinib: The metabolism of Abrocitinib can be decreased when combined with Omeprazole. | [DB14921] Mavacamten: The serum concentration of Mavacamten can be increased when it is combined with Omeprazole. | [DB12020] Tecovirimat: The metabolism of Omeprazole can be decreased when combined with Tecovirimat. | [DB12095] Telotristat ethyl: The serum concentration of Telotristat ethyl can be increased when it is combined with Omeprazole. | [DB14218] Telotristat: The serum concentration of Telotristat can be increased when it is combined with Omeprazole. | [DB11739] Vonoprazan: The metabolism of Omeprazole can be decreased when combined with Vonoprazan. | [DB17472] Pirtobrutinib: The metabolism of Omeprazole can be decreased when combined with Pirtobrutinib. | [DB00381] Amlodipine: The metabolism of Omeprazole can be decreased when combined with Amlodipine. | [DB12548] Sparsentan: The therapeutic efficacy of Sparsentan can be decreased when used in combination with Omeprazole. | [DB16672] Epcoritamab: The serum concentration of Omeprazole can be increased when it is combined with Epcoritamab. | [DB16371] Glofitamab: The serum concentration of Omeprazole can be increased when it is combined with Glofitamab. | [DB06700] Desvenlafaxine: The metabolism of Desvenlafaxine can be decreased when combined with Omeprazole. | [DB11718] Encorafenib: The metabolism of Encorafenib can be decreased when combined with Omeprazole. | [DB11967] Binimetinib: The metabolism of Binimetinib can be decreased when combined with Omeprazole. | [DB11679] Fruquintinib: The metabolism of Fruquintinib can be decreased when combined with Omeprazole. | [DB12005] Nirogacestat: The serum concentration of Nirogacestat can be decreased when it is combined with Omeprazole. | [DB06636] Isavuconazonium: The metabolism of Omeprazole can be decreased when combined with Isavuconazonium.,1 kg/1kg; 10 MG; 10 mg; 10 mg/1; 10.000 mg; 1000000 mg; 126 mg; 15 MG; 2.5 mg/1; 20 MG; 20 mg; 20 mg/1; 20.0 mg; 20.00 mg; 20.000 mg; 20.0000 mg; 20.00007 mg; 20.6 mg/1; 2000000 mg; 2000007 mg; 2100000 mg; 232.8 mg; 23280000 mg; 235.290 mg; 235.294 mg; 235.3 mg; 235.300 mg; 236 mg; 40 MG; 40 mg; 40 mg/1; 40 mg/1vial; 40 mg/ml; 40.00 mg; 40.000 mg; 4000000 mg; 42.400 mg; 44.630 mg; 44.632 mg; 47059000 mg,Take before a meal. Allow 30-60 minutes before a meal.
DB00381,Amlodipine,"ACE INHIBITORS, COMBINATIONS; ACE inhibitors and calcium channel blockers; ACE inhibitors, other combinations; AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS; Angiotensin II receptor blockers (ARBs) and calcium channel blockers; Angiotensin II receptor blockers (ARBs), other combinations; BETA BLOCKING AGENTS; BETA BLOCKING AGENTS, OTHER COMBINATIONS; Beta blocking agents and calcium channel blockers; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNEL BLOCKERS AND DIURETICS; CARDIOVASCULAR SYSTEM; Calcium channel blockers and diuretics; Dihydropyridine derivatives; LIPID MODIFYING AGENTS; LIPID MODIFYING AGENTS, COMBINATIONS; Lipid modifying agents in combination with other drugs; OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; Renin-inhibitors; SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS","[DB00476] Duloxetine: The risk or severity of orthostatic hypotension and syncope can be increased when Amlodipine is combined with Duloxetine. | [DB01235] Levodopa: The risk or severity of hypotension and orthostatic hypotension can be increased when Amlodipine is combined with Levodopa. | [DB00734] Risperidone: Amlodipine may increase the hypotensive activities of Risperidone. | [DB09063] Ceritinib: Amlodipine may increase the bradycardic activities of Ceritinib. | [DB09083] Ivabradine: Amlodipine may increase the bradycardic activities of Ivabradine. | [DB08877] Ruxolitinib: Ruxolitinib may increase the bradycardic activities of Amlodipine. | [DB00346] Alfuzosin: Alfuzosin may increase the hypotensive activities of Amlodipine. | [DB01143] Amifostine: Amlodipine may increase the hypotensive activities of Amifostine. | [DB01119] Diazoxide: Diazoxide may increase the hypotensive activities of Amlodipine. | [DB00422] Methylphenidate: Methylphenidate may decrease the antihypertensive activities of Amlodipine. | [DB06701] Dexmethylphenidate: Dexmethylphenidate may decrease the antihypertensive activities of Amlodipine. | [DB08935] Obinutuzumab: Amlodipine may increase the hypotensive activities of Obinutuzumab. | [DB00806] Pentoxifylline: Pentoxifylline may increase the hypotensive activities of Amlodipine. | [DB00073] Rituximab: Amlodipine may increase the hypotensive activities of Rituximab. | [DB00035] Desmopressin: Desmopressin may decrease the antihypertensive activities of Amlodipine. | [DB00211] Midodrine: Midodrine may decrease the antihypertensive activities of Amlodipine. | [DB00221] Isoetharine: Isoetharine may decrease the antihypertensive activities of Amlodipine. | [DB00292] Etomidate: Etomidate may decrease the antihypertensive activities of Amlodipine. | [DB00315] Zolmitriptan: Zolmitriptan may decrease the antihypertensive activities of Amlodipine. | [DB00368] Norepinephrine: Norepinephrine may decrease the antihypertensive activities of Amlodipine. | [DB00397] Phenylpropanolamine: Phenylpropanolamine may decrease the antihypertensive activities of Amlodipine. | [DB00561] Doxapram: Doxapram may decrease the antihypertensive activities of Amlodipine. | [DB00610] Metaraminol: Metaraminol may decrease the antihypertensive activities of Amlodipine. | [DB00723] Methoxamine: Methoxamine may decrease the antihypertensive activities of Amlodipine. | [DB00816] Orciprenaline: Orciprenaline may decrease the antihypertensive activities of Amlodipine. | [DB00830] Phenmetrazine: Phenmetrazine may decrease the antihypertensive activities of Amlodipine. | [DB00841] Dobutamine: Dobutamine may decrease the antihypertensive activities of Amlodipine. | [DB00852] Pseudoephedrine: Pseudoephedrine may decrease the antihypertensive activities of Amlodipine. | [DB00867] Ritodrine: Ritodrine may decrease the antihypertensive activities of Amlodipine. | [DB00901] Bitolterol: Bitolterol may decrease the antihypertensive activities of Amlodipine. | [DB00937] Diethylpropion: Diethylpropion may decrease the antihypertensive activities of Amlodipine. | [DB00952] Naratriptan: Naratriptan may decrease the antihypertensive activities of Amlodipine. | [DB00953] Rizatriptan: Rizatriptan may decrease the antihypertensive activities of Amlodipine. | [DB00988] Dopamine: Dopamine may decrease the antihypertensive activities of Amlodipine. | [DB00998] Frovatriptan: Frovatriptan may decrease the antihypertensive activities of Amlodipine. | [DB01064] Isoprenaline: Isoprenaline may decrease the antihypertensive activities of Amlodipine. | [DB01102] Arbutamine: Arbutamine may decrease the antihypertensive activities of Amlodipine. | [DB01255] Lisdexamfetamine: Lisdexamfetamine may decrease the antihypertensive activities of Amlodipine. | [DB01288] Fenoterol: Fenoterol may decrease the antihypertensive activities of Amlodipine. | [DB01291] Pirbuterol: Pirbuterol may decrease the antihypertensive activities of Amlodipine. | [DB01363] Ephedra sinica root: Ephedra sinica root may decrease the antihypertensive activities of Amlodipine. | [DB01364] Ephedrine: Ephedrine may decrease the antihypertensive activities of Amlodipine. | [DB01365] Mephentermine: Mephentermine may decrease the antihypertensive activities of Amlodipine. | [DB01366] Procaterol: Procaterol may decrease the antihypertensive activities of Amlodipine. | [DB01407] Clenbuterol: Clenbuterol may decrease the antihypertensive activities of Amlodipine. | [DB01408] Bambuterol: Bambuterol may decrease the antihypertensive activities of Amlodipine. | [DB01442] MMDA: MMDA may decrease the antihypertensive activities of Amlodipine. | [DB01454] Midomafetamine: Midomafetamine may decrease the antihypertensive activities of Amlodipine. | [DB01467] 2,5-Dimethoxy-4-ethylamphetamine: 2,5-Dimethoxy-4-ethylamphetamine may decrease the antihypertensive activities of Amlodipine. | [DB01472] 4-Methoxyamphetamine: 4-Methoxyamphetamine may decrease the antihypertensive activities of Amlodipine. | [DB01484] 4-Bromo-2,5-dimethoxyamphetamine: 4-Bromo-2,5-dimethoxyamphetamine may decrease the antihypertensive activities of Amlodipine. | [DB01509] Tenamfetamine: Tenamfetamine may decrease the antihypertensive activities of Amlodipine. | [DB01556] Chlorphentermine: Chlorphentermine may decrease the antihypertensive activities of Amlodipine. | [DB01576] Dextroamphetamine: Dextroamphetamine may decrease the antihypertensive activities of Amlodipine. | [DB01577] Metamfetamine: Metamfetamine may decrease the antihypertensive activities of Amlodipine. | [DB01579] Phendimetrazine: Phendimetrazine may decrease the antihypertensive activities of Amlodipine. | [DB02032] Epicaptopril: Epicaptopril may decrease the antihypertensive activities of Amlodipine. | [DB04581] 1-benzylimidazole: 1-benzylimidazole may decrease the antihypertensive activities of Amlodipine. | [DB04836] Amineptine: Amineptine may decrease the antihypertensive activities of Amlodipine. | [DB05395] Amibegron: Amibegron may decrease the antihypertensive activities of Amlodipine. | [DB05562] Naluzotan: Naluzotan may decrease the antihypertensive activities of Amlodipine. | [DB06190] Solabegron: Solabegron may decrease the antihypertensive activities of Amlodipine. | [DB06262] Droxidopa: Droxidopa may decrease the antihypertensive activities of Amlodipine. | [DB06690] Nitrous oxide: Nitrous oxide may decrease the antihypertensive activities of Amlodipine. | [DB06706] Isometheptene: Isometheptene may decrease the antihypertensive activities of Amlodipine. | [DB06707] Levonordefrin: Levonordefrin may decrease the antihypertensive activities of Amlodipine. | [DB06711] Naphazoline: Naphazoline may decrease the antihypertensive activities of Amlodipine. | [DB06764] Tetryzoline: Tetryzoline may decrease the antihypertensive activities of Amlodipine. | [DB08810] Cinitapride: Cinitapride may decrease the antihypertensive activities of Amlodipine. | [DB08841] Tyramine: Tyramine may decrease the antihypertensive activities of Amlodipine. | [DB08925] Adrafinil: Adrafinil may decrease the antihypertensive activities of Amlodipine. | [DB08954] Ifenprodil: Ifenprodil may decrease the antihypertensive activities of Amlodipine. | [DB08957] Hexoprenaline: Hexoprenaline may decrease the antihypertensive activities of Amlodipine. | [DB08985] Etilefrine: Etilefrine may decrease the antihypertensive activities of Amlodipine. | [DB08996] Dimetacrine: Dimetacrine may decrease the antihypertensive activities of Amlodipine. | [DB09202] Cirazoline: Cirazoline may decrease the antihypertensive activities of Amlodipine. | [DB09203] Synephrine: Synephrine may decrease the antihypertensive activities of Amlodipine. | [DB09205] Moxisylyte: Moxisylyte may decrease the antihypertensive activities of Amlodipine. | [DB09307] Oxaprotiline: Oxaprotiline may decrease the antihypertensive activities of Amlodipine. | [DB09480] Iofetamine I-123: Iofetamine I-123 may decrease the antihypertensive activities of Amlodipine. | [DB11124] Racepinephrine: Racepinephrine may decrease the antihypertensive activities of Amlodipine. | [DB11278] DL-Methylephedrine: DL-Methylephedrine may decrease the antihypertensive activities of Amlodipine. | [DB11373] Amitraz: Amitraz may decrease the antihypertensive activities of Amlodipine. | [DB11428] Medetomidine: Medetomidine may decrease the antihypertensive activities of Amlodipine. | [DB11477] Xylazine: Xylazine may decrease the antihypertensive activities of Amlodipine. | [DB11481] Atipamezole: Atipamezole may decrease the antihypertensive activities of Amlodipine. | [DB11541] Ractopamine: Ractopamine may decrease the antihypertensive activities of Amlodipine. | [DB11543] Romifidine: Romifidine may decrease the antihypertensive activities of Amlodipine. | [DB11556] Detomidine: Detomidine may decrease the antihypertensive activities of Amlodipine. | [DB11587] Etafedrine: Etafedrine may decrease the antihypertensive activities of Amlodipine. | [DB11755] Tetrahydrocannabivarin: Tetrahydrocannabivarin may decrease the antihypertensive activities of Amlodipine. | [DB11871] PF-00610355: PF-00610355 may decrease the antihypertensive activities of Amlodipine. | [DB12080] Ritobegron: Ritobegron may decrease the antihypertensive activities of Amlodipine. | [DB12100] Abediterol: Abediterol may decrease the antihypertensive activities of Amlodipine. | [DB12248] Tulobuterol: Tulobuterol may decrease the antihypertensive activities of Amlodipine. | [DB12313] Dopexamine: Dopexamine may decrease the antihypertensive activities of Amlodipine. | [DB12361] Piclozotan: Piclozotan may decrease the antihypertensive activities of Amlodipine. | [DB12551] Idazoxan: Idazoxan may decrease the antihypertensive activities of Amlodipine. | [DB12779] Higenamine: Higenamine may decrease the antihypertensive activities of Amlodipine. | [DB12846] Reproterol: Reproterol may decrease the antihypertensive activities of Amlodipine. | [DB12927] Theodrenaline: Theodrenaline may decrease the antihypertensive activities of Amlodipine. | [DB13064] Tramazoline: Tramazoline may decrease the antihypertensive activities of Amlodipine. | [DB13108] Mephedrone: Mephedrone may decrease the antihypertensive activities of Amlodipine. | [DB13114] Amitriptylinoxide: Amitriptylinoxide may decrease the antihypertensive activities of Amlodipine. | [DB13225] Dibenzepin: Dibenzepin may decrease the antihypertensive activities of Amlodipine. | [DB13246] Quinupramine: Quinupramine may decrease the antihypertensive activities of Amlodipine. | [DB13251] Octopamine: Octopamine may decrease the antihypertensive activities of Amlodipine. | [DB13323] Trichloroethylene: Trichloroethylene may decrease the antihypertensive activities of Amlodipine. | [DB13341] Fenozolone: Fenozolone may decrease the antihypertensive activities of Amlodipine. | [DB13378] Norfenefrine: Norfenefrine may decrease the antihypertensive activities of Amlodipine. | [DB13398] Oxyfedrine: Oxyfedrine may decrease the antihypertensive activities of Amlodipine. | [DB13453] Xenon: Xenon may decrease the antihypertensive activities of Amlodipine. | [DB13496] Iprindole: Iprindole may decrease the antihypertensive activities of Amlodipine. | [DB13510] Buflomedil: Buflomedil may decrease the antihypertensive activities of Amlodipine. | [DB13520] Metergoline: Metergoline may decrease the antihypertensive activities of Amlodipine. | [DB13559] Rimiterol: Rimiterol may decrease the antihypertensive activities of Amlodipine. | [DB13624] Methoxyphenamine: Methoxyphenamine may decrease the antihypertensive activities of Amlodipine. | [DB13692] Tretoquinol: Tretoquinol may decrease the antihypertensive activities of Amlodipine. | [DB13703] Gepefrine: Gepefrine may decrease the antihypertensive activities of Amlodipine. | [DB13777] Prenalterol: Prenalterol may decrease the antihypertensive activities of Amlodipine. | [DB13781] Xamoterol: Xamoterol may decrease the antihypertensive activities of Amlodipine. | [DB13782] Imipramine oxide: Imipramine oxide may decrease the antihypertensive activities of Amlodipine. | [DB13852] Mefenorex: Mefenorex may decrease the antihypertensive activities of Amlodipine. | [DB13917] Deoxyepinephrine: Deoxyepinephrine may decrease the antihypertensive activities of Amlodipine. | [DB13940] 2,5-Dimethoxy-4-ethylthioamphetamine: 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the antihypertensive activities of Amlodipine. | [DB14010] 5-methoxy-N,N-dimethyltryptamine: 5-methoxy-N,N-dimethyltryptamine may decrease the antihypertensive activities of Amlodipine. | [DB14231] Quinoline Yellow WS: Quinoline Yellow WS may decrease the antihypertensive activities of Amlodipine. | [DB14754] Solriamfetol: Solriamfetol may decrease the antihypertensive activities of Amlodipine. | [DB00217] Bethanidine: Bethanidine may decrease the antihypertensive activities of Amlodipine. | [DB00629] Guanabenz: Guanabenz may decrease the antihypertensive activities of Amlodipine. | [DB09242] Moxonidine: Moxonidine may decrease the antihypertensive activities of Amlodipine. | [DB11738] Rilmenidine: Rilmenidine may decrease the antihypertensive activities of Amlodipine. | [DB00633] Dexmedetomidine: Dexmedetomidine may decrease the antihypertensive activities of Amlodipine. | [DB00899] Remifentanil: Remifentanil may decrease the antihypertensive activities of Amlodipine. | [DB08941] Isoxsuprine: Isoxsuprine may decrease the antihypertensive activities of Amlodipine. | [DB00191] Phentermine: Phentermine may decrease the antihypertensive activities of Amlodipine. | [DB00247] Methysergide: Methysergide may decrease the antihypertensive activities of Amlodipine. | [DB00353] Methylergometrine: Methylergometrine may decrease the antihypertensive activities of Amlodipine. | [DB00589] Lisuride: Lisuride may decrease the antihypertensive activities of Amlodipine. | [DB00668] Epinephrine: Epinephrine may decrease the antihypertensive activities of Amlodipine. | [DB00708] Sufentanil: Sufentanil may decrease the antihypertensive activities of Amlodipine. | [DB01018] Guanfacine: Guanfacine may decrease the antihypertensive activities of Amlodipine. | [DB01049] Ergoloid mesylate: Ergoloid mesylate may decrease the antihypertensive activities of Amlodipine. | [DB01186] Pergolide: Pergolide may decrease the antihypertensive activities of Amlodipine. | [DB04829] Lysergic acid diethylamide: Lysergic acid diethylamide may decrease the antihypertensive activities of Amlodipine. | [DB05271] Rotigotine: Rotigotine may decrease the antihypertensive activities of Amlodipine. | [DB06016] Cariprazine: Cariprazine may decrease the antihypertensive activities of Amlodipine. | [DB06684] Vilazodone: The metabolism of Vilazodone can be decreased when combined with Amlodipine. | [DB09289] Tianeptine: The metabolism of Tianeptine can be decreased when combined with Amlodipine. | [DB11273] Dihydroergocornine: Dihydroergocornine may decrease the antihypertensive activities of Amlodipine. | [DB12371] Siponimod: The metabolism of Siponimod can be decreased when combined with Amlodipine. | [DB13139] Levosalbutamol: Levosalbutamol may decrease the antihypertensive activities of Amlodipine. | [DB13345] Dihydroergocristine: Dihydroergocristine may decrease the antihypertensive activities of Amlodipine. | [DB13385] Dihydroergocryptine: Dihydroergocryptine may decrease the antihypertensive activities of Amlodipine. | [DB13399] Terguride: Terguride may decrease the antihypertensive activities of Amlodipine. | [DB00248] Cabergoline: The metabolism of Cabergoline can be decreased when combined with Amlodipine. | [DB00328] Indomethacin: The metabolism of Indomethacin can be decreased when combined with Amlodipine. | [DB00669] Sumatriptan: Sumatriptan may decrease the antihypertensive activities of Amlodipine. | [DB01253] Ergometrine: Ergometrine may decrease the antihypertensive activities of Amlodipine. | [DB04908] Flibanserin: Flibanserin may decrease the antihypertensive activities of Amlodipine. | [DB05039] Indacaterol: Indacaterol may decrease the antihypertensive activities of Amlodipine. | [DB13598] Diethyl ether: Diethyl ether may decrease the antihypertensive activities of Amlodipine. | [DB04948] Lofexidine: Lofexidine may decrease the antihypertensive activities of Amlodipine. | [DB00753] Isoflurane: Isoflurane may decrease the antihypertensive activities of Amlodipine. | [DB01159] Halothane: The metabolism of Halothane can be decreased when combined with Amlodipine. | [DB01189] Desflurane: Desflurane may decrease the antihypertensive activities of Amlodipine. | [DB01236] Sevoflurane: The risk or severity of hypotension can be increased when Sevoflurane is combined with Amlodipine. | [DB00159] Icosapent: Icosapent may decrease the antihypertensive activities of Amlodipine. | [DB00244] Mesalazine: Mesalazine may decrease the antihypertensive activities of Amlodipine. | [DB00370] Mirtazapine: Mirtazapine may decrease the antihypertensive activities of Amlodipine. | [DB00461] Nabumetone: The metabolism of Nabumetone can be decreased when combined with Amlodipine. | [DB00465] Ketorolac: The metabolism of Ketorolac can be decreased when combined with Amlodipine. | [DB00469] Tenoxicam: The metabolism of Tenoxicam can be decreased when combined with Amlodipine. | [DB00490] Buspirone: Buspirone may decrease the antihypertensive activities of Amlodipine. | [DB00500] Tolmetin: Tolmetin may decrease the antihypertensive activities of Amlodipine. | [DB00554] Piroxicam: The metabolism of Piroxicam can be decreased when combined with Amlodipine. | [DB00573] Fenoprofen: Fenoprofen may decrease the antihypertensive activities of Amlodipine. | [DB00580] Valdecoxib: The metabolism of Valdecoxib can be decreased when combined with Amlodipine. | [DB00586] Diclofenac: The metabolism of Diclofenac can be decreased when combined with Amlodipine. | [DB00605] Sulindac: Sulindac may decrease the antihypertensive activities of Amlodipine. | [DB00712] Flurbiprofen: The metabolism of Flurbiprofen can be decreased when combined with Amlodipine. | [DB00749] Etodolac: The metabolism of Etodolac can be decreased when combined with Amlodipine. | [DB00784] Mefenamic acid: The metabolism of Mefenamic acid can be decreased when combined with Amlodipine. | [DB00788] Naproxen: The metabolism of Naproxen can be decreased when combined with Amlodipine. | [DB00795] Sulfasalazine: Sulfasalazine may decrease the antihypertensive activities of Amlodipine. | [DB00802] Alfentanil: Alfentanil may decrease the antihypertensive activities of Amlodipine. | [DB00813] Fentanyl: Fentanyl may decrease the antihypertensive activities of Amlodipine. | [DB00814] Meloxicam: The metabolism of Meloxicam can be decreased when combined with Amlodipine. | [DB00818] Propofol: The metabolism of Propofol can be decreased when combined with Amlodipine. | [DB00821] Carprofen: Carprofen may decrease the antihypertensive activities of Amlodipine. | [DB00861] Diflunisal: Diflunisal may decrease the antihypertensive activities of Amlodipine. | [DB00865] Benzphetamine: Benzphetamine may decrease the antihypertensive activities of Amlodipine. | [DB00871] Terbutaline: Terbutaline may decrease the antihypertensive activities of Amlodipine. | [DB00918] Almotriptan: Almotriptan may decrease the antihypertensive activities of Amlodipine. | [DB00936] Salicylic acid: The metabolism of Salicylic acid can be decreased when combined with Amlodipine. | [DB00938] Salmeterol: Salmeterol may decrease the antihypertensive activities of Amlodipine. | [DB00939] Meclofenamic acid: Meclofenamic acid may decrease the antihypertensive activities of Amlodipine. | [DB00983] Formoterol: The metabolism of Formoterol can be decreased when combined with Amlodipine. | [DB00991] Oxaprozin: Oxaprozin may decrease the antihypertensive activities of Amlodipine. | [DB01001] Albuterol: Salbutamol may decrease the antihypertensive activities of Amlodipine. | [DB01009] Ketoprofen: Ketoprofen may decrease the antihypertensive activities of Amlodipine. | [DB01014] Balsalazide: Balsalazide may decrease the antihypertensive activities of Amlodipine. | [DB01028] Methoxyflurane: The metabolism of Methoxyflurane can be decreased when combined with Amlodipine. | [DB01050] Ibuprofen: The metabolism of Ibuprofen can be decreased when combined with Amlodipine. | [DB01126] Dutasteride: Dutasteride may decrease the antihypertensive activities of Amlodipine. | [DB01216] Finasteride: Finasteride may decrease the antihypertensive activities of Amlodipine. | [DB01274] Arformoterol: The metabolism of Arformoterol can be decreased when combined with Amlodipine. | [DB01283] Lumiracoxib: The metabolism of Lumiracoxib can be decreased when combined with Amlodipine. | [DB01399] Salsalate: Salsalate may decrease the antihypertensive activities of Amlodipine. | [DB01401] Choline magnesium trisalicylate: Choline magnesium trisalicylate may decrease the antihypertensive activities of Amlodipine. | [DB01419] Antrafenine: Antrafenine may decrease the antihypertensive activities of Amlodipine. | [DB01424] Aminophenazone: The metabolism of Aminophenazone can be decreased when combined with Amlodipine. | [DB01435] Antipyrine: The metabolism of Antipyrine can be decreased when combined with Amlodipine. | [DB01591] Solifenacin: Solifenacin may decrease the antihypertensive activities of Amlodipine. | [DB01600] Tiaprofenic acid: Tiaprofenic acid may decrease the antihypertensive activities of Amlodipine. | [DB01628] Etoricoxib: The metabolism of Etoricoxib can be decreased when combined with Amlodipine. | [DB02224] Taxifolin: Taxifolin may decrease the antihypertensive activities of Amlodipine. | [DB03585] Oxyphenbutazone: Oxyphenbutazone may decrease the antihypertensive activities of Amlodipine. | [DB04812] Benoxaprofen: Benoxaprofen may decrease the antihypertensive activities of Amlodipine. | [DB04828] Zomepirac: Zomepirac may decrease the antihypertensive activities of Amlodipine. | [DB05095] Cimicoxib: Cimicoxib may decrease the antihypertensive activities of Amlodipine. | [DB06148] Mianserin: Mianserin may decrease the antihypertensive activities of Amlodipine. | [DB06725] Lornoxicam: The metabolism of Lornoxicam can be decreased when combined with Amlodipine. | [DB06736] Aceclofenac: Aceclofenac may decrease the antihypertensive activities of Amlodipine. | [DB06737] Zaltoprofen: The metabolism of Zaltoprofen can be decreased when combined with Amlodipine. | [DB07402] Azapropazone: Azapropazone may decrease the antihypertensive activities of Amlodipine. | [DB08439] Parecoxib: The metabolism of Parecoxib can be decreased when combined with Amlodipine. | [DB08797] Salicylamide: Salicylamide may decrease the antihypertensive activities of Amlodipine. | [DB08815] Lurasidone: Lurasidone may decrease the antihypertensive activities of Amlodipine. | [DB08940] Kebuzone: Kebuzone may decrease the antihypertensive activities of Amlodipine. | [DB08942] Isoxicam: Isoxicam may decrease the antihypertensive activities of Amlodipine. | [DB08951] Indoprofen: Indoprofen may decrease the antihypertensive activities of Amlodipine. | [DB08955] Ibuproxam: Ibuproxam may decrease the antihypertensive activities of Amlodipine. | [DB08981] Fenbufen: Fenbufen may decrease the antihypertensive activities of Amlodipine. | [DB08984] Etofenamate: Etofenamate may decrease the antihypertensive activities of Amlodipine. | [DB08991] Epirizole: Epirizole may decrease the antihypertensive activities of Amlodipine. | [DB09016] Butriptyline: Butriptyline may decrease the antihypertensive activities of Amlodipine. | [DB09061] Cannabidiol: The metabolism of Cannabidiol can be decreased when combined with Amlodipine. | [DB09068] Vortioxetine: The metabolism of Vortioxetine can be decreased when combined with Amlodipine. | [DB09080] Olodaterol: The metabolism of Olodaterol can be decreased when combined with Amlodipine. | [DB09082] Vilanterol: Vilanterol may decrease the antihypertensive activities of Amlodipine. | [DB09084] Benzydamine: Benzydamine may decrease the antihypertensive activities of Amlodipine. | [DB09213] Dexibuprofen: The metabolism of Dexibuprofen can be decreased when combined with Amlodipine. | [DB09214] Dexketoprofen: Dexketoprofen may decrease the antihypertensive activities of Amlodipine. | [DB09215] Droxicam: Droxicam may decrease the antihypertensive activities of Amlodipine. | [DB09217] Firocoxib: Firocoxib may decrease the antihypertensive activities of Amlodipine. | [DB09218] Clonixin: Clonixin may decrease the antihypertensive activities of Amlodipine. | [DB09285] Morniflumate: Morniflumate may decrease the antihypertensive activities of Amlodipine. | [DB09288] Propacetamol: The metabolism of Propacetamol can be decreased when combined with Amlodipine. | [DB09295] Talniflumate: Talniflumate may decrease the antihypertensive activities of Amlodipine. | [DB11455] Robenacoxib: Robenacoxib may decrease the antihypertensive activities of Amlodipine. | [DB11466] Tepoxalin: Tepoxalin may decrease the antihypertensive activities of Amlodipine. | [DB11518] Flunixin: Flunixin may decrease the antihypertensive activities of Amlodipine. | [DB12445] Nitroaspirin: Nitroaspirin may decrease the antihypertensive activities of Amlodipine. | [DB12545] Indobufen: Indobufen may decrease the antihypertensive activities of Amlodipine. | [DB12610] Ebselen: Ebselen may decrease the antihypertensive activities of Amlodipine. | [DB13001] Tinoridine: Tinoridine may decrease the antihypertensive activities of Amlodipine. | [DB13167] Alclofenac: Alclofenac may decrease the antihypertensive activities of Amlodipine. | [DB13217] Fentiazac: Fentiazac may decrease the antihypertensive activities of Amlodipine. | [DB13232] Suxibuzone: Suxibuzone may decrease the antihypertensive activities of Amlodipine. | [DB13286] Bumadizone: Bumadizone may decrease the antihypertensive activities of Amlodipine. | [DB13314] Alminoprofen: Alminoprofen may decrease the antihypertensive activities of Amlodipine. | [DB13371] Difenpiramide: Difenpiramide may decrease the antihypertensive activities of Amlodipine. | [DB13384] Melitracen: Melitracen may decrease the antihypertensive activities of Amlodipine. | [DB13407] Nifenazone: Nifenazone may decrease the antihypertensive activities of Amlodipine. | [DB13411] Lofepramine: Lofepramine may decrease the antihypertensive activities of Amlodipine. | [DB13432] Lonazolac: Lonazolac may decrease the antihypertensive activities of Amlodipine. | [DB13481] Tenidap: Tenidap may decrease the antihypertensive activities of Amlodipine. | [DB13524] Propyphenazone: Propyphenazone may decrease the antihypertensive activities of Amlodipine. | [DB13527] Proglumetacin: Proglumetacin may decrease the antihypertensive activities of Amlodipine. | [DB13538] Guacetisal: Guacetisal may decrease the antihypertensive activities of Amlodipine. | [DB13544] Ethenzamide: Ethenzamide may decrease the antihypertensive activities of Amlodipine. | [DB13612] Carbaspirin calcium: Carbaspirin calcium may decrease the antihypertensive activities of Amlodipine. | [DB13629] Mofebutazone: Mofebutazone may decrease the antihypertensive activities of Amlodipine. | [DB13649] Proquazone: Proquazone may decrease the antihypertensive activities of Amlodipine. | [DB13657] Benorilate: Benorilate may decrease the antihypertensive activities of Amlodipine. | [DB13722] Pirprofen: Pirprofen may decrease the antihypertensive activities of Amlodipine. | [DB13783] Acemetacin: Acemetacin may decrease the antihypertensive activities of Amlodipine. | [DB13860] Imidazole salicylate: Imidazole salicylate may decrease the antihypertensive activities of Amlodipine. | [DB14059] SC-236: SC-236 may decrease the antihypertensive activities of Amlodipine. | [DB14060] NS-398: NS-398 may decrease the antihypertensive activities of Amlodipine. | [DB00344] Protriptyline: Protriptyline may decrease the antihypertensive activities of Amlodipine. | [DB01151] Desipramine: Desipramine may decrease the antihypertensive activities of Amlodipine. | [DB01242] Clomipramine: The metabolism of Clomipramine can be decreased when combined with Amlodipine. | [DB12930] Opipramol: Opipramol may decrease the antihypertensive activities of Amlodipine. | [DB15685] Selpercatinib: Selpercatinib may decrease the antihypertensive activities of Amlodipine. | [DB00216] Eletriptan: The metabolism of Eletriptan can be decreased when combined with Amlodipine. | [DB00289] Atomoxetine: Atomoxetine may decrease the antihypertensive activities of Amlodipine. | [DB01392] Yohimbine: Yohimbine may decrease the antihypertensive activities of Amlodipine. | [DB06678] Esmirtazapine: Esmirtazapine may decrease the antihypertensive activities of Amlodipine. | [DB08893] Mirabegron: Mirabegron may decrease the antihypertensive activities of Amlodipine. | [DB09167] Dosulepin: Dosulepin may decrease the antihypertensive activities of Amlodipine. | [DB09212] Loxoprofen: Loxoprofen may decrease the antihypertensive activities of Amlodipine. | [DB15965] Naxitamab: Naxitamab may decrease the antihypertensive activities of Amlodipine. | [DB00182] Amphetamine: Amphetamine may decrease the antihypertensive activities of Amlodipine. | [DB04817] Metamizole: Metamizole may decrease the antihypertensive activities of Amlodipine. | [DB09216] Tolfenamic acid: Tolfenamic acid may decrease the antihypertensive activities of Amlodipine. | [DB04552] Niflumic acid: Niflumic acid may decrease the antihypertensive activities of Amlodipine. | [DB00501] Cimetidine: The serum concentration of Amlodipine can be increased when it is combined with Cimetidine. | [DB00758] Clopidogrel: The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Amlodipine. | [DB00625] Efavirenz: The serum concentration of Amlodipine can be decreased when it is combined with Efavirenz. | [DB01065] Melatonin: The therapeutic efficacy of Amlodipine can be decreased when used in combination with Melatonin. | [DB00607] Nafcillin: The therapeutic efficacy of Amlodipine can be decreased when used in combination with Nafcillin. | [DB00325] Nitroprusside: Amlodipine may increase the hypotensive activities of Nitroprusside. | [DB01219] Dantrolene: The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Amlodipine. | [DB14507] Lithium citrate: The risk or severity of adverse effects can be increased when Amlodipine is combined with Lithium citrate. | [DB14509] Lithium carbonate: The risk or severity of adverse effects can be increased when Amlodipine is combined with Lithium carbonate. | [DB14506] Lithium hydroxide: The risk or severity of adverse effects can be increased when Amlodipine is combined with Lithium hydroxide. | [DB00641] Simvastatin: The serum concentration of Simvastatin can be increased when it is combined with Amlodipine. | [DB09220] Nicorandil: Nicorandil may increase the hypotensive activities of Amlodipine. | [DB09282] Molsidomine: Molsidomine may increase the hypotensive activities of Amlodipine. | [DB00869] Dorzolamide: Amlodipine may increase the hypotensive activities of Dorzolamide. | [DB00905] Bimatoprost: Amlodipine may increase the hypotensive activities of Bimatoprost. | [DB06826] Unoprostone: Amlodipine may increase the hypotensive activities of Unoprostone. | [DB00310] Chlorthalidone: Chlorthalidone may increase the hypotensive activities of Amlodipine. | [DB00350] Minoxidil: Minoxidil may increase the hypotensive activities of Amlodipine. | [DB00212] Remikiren: Remikiren may increase the hypotensive activities of Amlodipine. | [DB00226] Guanadrel: Guanadrel may increase the hypotensive activities of Amlodipine. | [DB00524] Metolazone: Amlodipine may increase the hypotensive activities of Metolazone. | [DB00616] Candoxatril: Amlodipine may increase the hypotensive activities of Candoxatril. | [DB00657] Mecamylamine: Amlodipine may increase the hypotensive activities of Mecamylamine. | [DB00765] Metyrosine: Amlodipine may increase the hypotensive activities of Metyrosine. | [DB00785] Cryptenamine: Amlodipine may increase the hypotensive activities of Cryptenamine. | [DB00800] Fenoldopam: Amlodipine may increase the hypotensive activities of Fenoldopam. | [DB00968] Methyldopa: Amlodipine may increase the hypotensive activities of Methyldopa. | [DB01089] Deserpidine: Amlodipine may increase the hypotensive activities of Deserpidine. | [DB01090] Pentolinium: Amlodipine may increase the hypotensive activities of Pentolinium. | [DB01116] Trimethaphan: Amlodipine may increase the hypotensive activities of Trimethaphan. | [DB04831] Tienilic acid: Amlodipine may increase the hypotensive activities of Tienilic acid. | [DB06445] Diethylnorspermine: Amlodipine may increase the hypotensive activities of Diethylnorspermine. | [DB08960] Hexamethonium: Amlodipine may increase the hypotensive activities of Hexamethonium. | [DB09363] Rauwolfia serpentina root: Amlodipine may increase the hypotensive activities of Rauwolfia serpentina root. | [DB11720] Angiotensin 1-7: Amlodipine may increase the hypotensive activities of Angiotensin 1-7. | [DB12054] BQ-123: Amlodipine may increase the hypotensive activities of BQ-123. | [DB12945] Dihydralazine: Amlodipine may increase the hypotensive activities of Dihydralazine. | [DB13211] Guanoxan: Amlodipine may increase the hypotensive activities of Guanoxan. | [DB13374] Vincamine: Amlodipine may increase the hypotensive activities of Vincamine. | [DB13400] Linsidomine: Amlodipine may increase the hypotensive activities of Linsidomine. | [DB13410] Guanoxabenz: Amlodipine may increase the hypotensive activities of Guanoxabenz. | [DB13429] Tolonidine: Amlodipine may increase the hypotensive activities of Tolonidine. | [DB13435] Endralazine: Amlodipine may increase the hypotensive activities of Endralazine. | [DB13452] Cadralazine: Amlodipine may increase the hypotensive activities of Cadralazine. | [DB13575] Bietaserpine: Amlodipine may increase the hypotensive activities of Bietaserpine. | [DB13604] Guanazodine: Amlodipine may increase the hypotensive activities of Guanazodine. | [DB13631] Methoserpidine: Amlodipine may increase the hypotensive activities of Methoserpidine. | [DB13779] Guanoclor: Amlodipine may increase the hypotensive activities of Guanoclor. | [DB13801] Muzolimine: Amlodipine may increase the hypotensive activities of Muzolimine. | [DB13803] Xipamide: Amlodipine may increase the hypotensive activities of Xipamide. | [DB14094] Tocopherylquinone: Amlodipine may increase the hypotensive activities of Tocopherylquinone. | [DB00695] Furosemide: Amlodipine may increase the hypotensive activities of Furosemide. | [DB01170] Guanethidine: Amlodipine may increase the hypotensive activities of Guanethidine. | [DB00559] Bosentan: The metabolism of Bosentan can be decreased when combined with Amlodipine. | [DB01275] Hydralazine: Amlodipine may increase the hypotensive activities of Hydralazine. | [DB06268] Sitaxentan: The metabolism of Sitaxentan can be decreased when combined with Amlodipine. | [DB06762] Pinacidil: Amlodipine may increase the hypotensive activities of Pinacidil. | [DB08932] Macitentan: Amlodipine may increase the hypotensive activities of Macitentan. | [DB00206] Reserpine: Reserpine may increase the hypotensive activities of Amlodipine. | [DB06403] Ambrisentan: Amlodipine may increase the hypotensive activities of Ambrisentan. | [DB00214] Torasemide: The metabolism of Torasemide can be decreased when combined with Amlodipine. | [DB08931] Riociguat: Amlodipine may increase the hypotensive activities of Riociguat. | [DB11362] Selexipag: Amlodipine may increase the hypotensive activities of Selexipag. | [DB04840] Debrisoquine: Amlodipine may increase the hypotensive activities of Debrisoquine. | [DB09237] Levamlodipine: Amlodipine may increase the hypotensive activities of Levamlodipine. | [DB00484] Brimonidine: Brimonidine may increase the antihypertensive activities of Amlodipine. | [DB05266] Ibudilast: Ibudilast may increase the antihypertensive activities of Amlodipine. | [DB06267] Udenafil: Udenafil may increase the antihypertensive activities of Amlodipine. | [DB09273] Doxofylline: Doxofylline may decrease the antihypertensive activities of Amlodipine. | [DB11792] Mirodenafil: Mirodenafil may increase the antihypertensive activities of Amlodipine. | [DB12010] Fostamatinib: Fostamatinib may increase the antihypertensive activities of Amlodipine. | [DB00820] Tadalafil: Amlodipine may increase the hypotensive activities of Tadalafil. | [DB06237] Avanafil: The serum concentration of Avanafil can be increased when it is combined with Amlodipine. | [DB00975] Dipyridamole: Dipyridamole may increase the antihypertensive activities of Amlodipine. | [DB00203] Sildenafil: The metabolism of Sildenafil can be decreased when combined with Amlodipine. | [DB00862] Vardenafil: The metabolism of Vardenafil can be decreased when combined with Amlodipine. | [DB06694] Xylometazoline: Amlodipine may increase the arrhythmogenic activities of Xylometazoline. | [DB00521] Carteolol: Amlodipine may increase the arrhythmogenic activities of Carteolol. | [DB01214] Metipranolol: Amlodipine may increase the arrhythmogenic activities of Metipranolol. | [DB00680] Moricizine: Amlodipine may increase the arrhythmogenic activities of Moricizine. | [DB01056] Tocainide: Amlodipine may increase the arrhythmogenic activities of Tocainide. | [DB08162] Fasudil: Amlodipine may increase the arrhythmogenic activities of Fasudil. | [DB11699] Tropisetron: Amlodipine may increase the arrhythmogenic activities of Tropisetron. | [DB12704] Spiradoline: Amlodipine may increase the arrhythmogenic activities of Spiradoline. | [DB13635] Tiracizine: Amlodipine may increase the arrhythmogenic activities of Tiracizine. | [DB13645] Ethacizine: Amlodipine may increase the arrhythmogenic activities of Ethacizine. | [DB13718] Hydroquinine: Amlodipine may increase the arrhythmogenic activities of Hydroquinine. | [DB13746] Bioallethrin: Amlodipine may increase the arrhythmogenic activities of Bioallethrin. | [DB13863] Fosfructose: Amlodipine may increase the arrhythmogenic activities of Fosfructose. | [DB15300] Hydroquinidine: Amlodipine may increase the arrhythmogenic activities of Hydroquinidine. | [DB15366] SOR-C13: Amlodipine may increase the arrhythmogenic activities of SOR-C13. | [DB00511] Acetyldigitoxin: Amlodipine may increase the arrhythmogenic activities of Acetyldigitoxin. | [DB01078] Deslanoside: Amlodipine may increase the arrhythmogenic activities of Deslanoside. | [DB13240] Cymarin: Amlodipine may increase the arrhythmogenic activities of Cymarin. | [DB09239] Niguldipine: Amlodipine may increase the arrhythmogenic activities of Niguldipine. | [DB00343] Diltiazem: Diltiazem may increase the arrhythmogenic activities of Amlodipine. | [DB00393] Nimodipine: Amlodipine may increase the arrhythmogenic activities of Nimodipine. | [DB00568] Cinnarizine: Amlodipine may increase the arrhythmogenic activities of Cinnarizine. | [DB00572] Atropine: Amlodipine may increase the arrhythmogenic activities of Atropine. | [DB00640] Adenosine: Amlodipine may increase the arrhythmogenic activities of Adenosine. | [DB00922] Levosimendan: Amlodipine may increase the arrhythmogenic activities of Levosimendan. | [DB04825] Prenylamine: Amlodipine may increase the arrhythmogenic activities of Prenylamine. | [DB04842] Fluspirilene: Amlodipine may increase the arrhythmogenic activities of Fluspirilene. | [DB04957] Azimilide: Amlodipine may increase the arrhythmogenic activities of Azimilide. | [DB06200] Tedisamil: Amlodipine may increase the arrhythmogenic activities of Tedisamil. | [DB06712] Nilvadipine: Amlodipine may increase the arrhythmogenic activities of Nilvadipine. | [DB08980] Fendiline: Amlodipine may increase the arrhythmogenic activities of Fendiline. | [DB08992] Eperisone: Amlodipine may increase the arrhythmogenic activities of Eperisone. | [DB09224] Melperone: Amlodipine may increase the arrhythmogenic activities of Melperone. | [DB09231] Benidipine: Amlodipine may increase the arrhythmogenic activities of Benidipine. | [DB12286] Simendan: Amlodipine may increase the arrhythmogenic activities of Simendan. | [DB13500] Otilonium: Amlodipine may increase the arrhythmogenic activities of Otilonium. | [DB13546] Nizofenone: Amlodipine may increase the arrhythmogenic activities of Nizofenone. | [DB13652] Bunaftine: Amlodipine may increase the arrhythmogenic activities of Bunaftine. | [DB13653] Lorcainide: Amlodipine may increase the arrhythmogenic activities of Lorcainide. | [DB13791] Penfluridol: Amlodipine may increase the arrhythmogenic activities of Penfluridol. | [DB14063] Dexverapamil: Amlodipine may increase the arrhythmogenic activities of Dexverapamil. | [DB00280] Disopyramide: Disopyramide may increase the arrhythmogenic activities of Amlodipine. | [DB00308] Ibutilide: Ibutilide may increase the arrhythmogenic activities of Amlodipine. | [DB01244] Bepridil: Amlodipine may increase the arrhythmogenic activities of Bepridil. | [DB13725] Terodiline: Amlodipine may increase the arrhythmogenic activities of Terodiline. | [DB00528] Lercanidipine: Amlodipine may increase the arrhythmogenic activities of Lercanidipine. | [DB00825] Levomenthol: Amlodipine may increase the arrhythmogenic activities of Levomenthol. | [DB00909] Zonisamide: Amlodipine may increase the arrhythmogenic activities of Zonisamide. | [DB01054] Nitrendipine: Amlodipine may increase the arrhythmogenic activities of Nitrendipine. | [DB04838] Cyclandelate: Amlodipine may increase the arrhythmogenic activities of Cyclandelate. | [DB04841] Flunarizine: Amlodipine may increase the arrhythmogenic activities of Flunarizine. | [DB05246] Methsuximide: Amlodipine may increase the arrhythmogenic activities of Methsuximide. | [DB05885] Seletracetam: Amlodipine may increase the arrhythmogenic activities of Seletracetam. | [DB06152] Nylidrin: Amlodipine may increase the arrhythmogenic activities of Nylidrin. | [DB06283] Ziconotide: Amlodipine may increase the arrhythmogenic activities of Ziconotide. | [DB06446] Dotarizine: Amlodipine may increase the arrhythmogenic activities of Dotarizine. | [DB07615] Tranilast: Amlodipine may increase the arrhythmogenic activities of Tranilast. | [DB08838] Agmatine: Amlodipine may increase the arrhythmogenic activities of Agmatine. | [DB09089] Trimebutine: Amlodipine may increase the arrhythmogenic activities of Trimebutine. | [DB09090] Pinaverium: Amlodipine may increase the arrhythmogenic activities of Pinaverium. | [DB09229] Aranidipine: Amlodipine may increase the arrhythmogenic activities of Aranidipine. | [DB09230] Azelnidipine: Amlodipine may increase the arrhythmogenic activities of Azelnidipine. | [DB09232] Cilnidipine: Amlodipine may increase the arrhythmogenic activities of Cilnidipine. | [DB09234] Darodipine: Amlodipine may increase the arrhythmogenic activities of Darodipine. | [DB09235] Efonidipine: Amlodipine may increase the arrhythmogenic activities of Efonidipine. | [DB09238] Manidipine: Amlodipine may increase the arrhythmogenic activities of Manidipine. | [DB09240] Niludipine: Amlodipine may increase the arrhythmogenic activities of Niludipine. | [DB11960] Carboxyamidotriazole: Amlodipine may increase the arrhythmogenic activities of Carboxyamidotriazole. | [DB12092] Naftopidil: Amlodipine may increase the arrhythmogenic activities of Naftopidil. | [DB12093] Tetrahydropalmatine: Amlodipine may increase the arrhythmogenic activities of Tetrahydropalmatine. | [DB12131] Vinpocetine: Amlodipine may increase the arrhythmogenic activities of Vinpocetine. | [DB12923] Gallopamil: Amlodipine may increase the arrhythmogenic activities of Gallopamil. | [DB13488] Bencyclane: Amlodipine may increase the arrhythmogenic activities of Bencyclane. | [DB13766] Lidoflazine: Amlodipine may increase the arrhythmogenic activities of Lidoflazine. | [DB13835] Caroverine: Amlodipine may increase the arrhythmogenic activities of Caroverine. | [DB13950] WIN 55212-2: Amlodipine may increase the arrhythmogenic activities of WIN 55212-2. | [DB13961] Fish oil: Amlodipine may increase the arrhythmogenic activities of Fish oil. | [DB14064] Emopamil: Amlodipine may increase the arrhythmogenic activities of Emopamil. | [DB14065] Lomerizine: Amlodipine may increase the arrhythmogenic activities of Lomerizine. | [DB14066] Tetrandrine: Amlodipine may increase the arrhythmogenic activities of Tetrandrine. | [DB14068] Dexniguldipine: Amlodipine may increase the arrhythmogenic activities of Dexniguldipine. | [DB14207] Fosinoprilat: Amlodipine may increase the arrhythmogenic activities of Fosinoprilat. | [DB04743] Nimesulide: Amlodipine may increase the arrhythmogenic activities of Nimesulide. | [DB00424] Hyoscyamine: Amlodipine may increase the arrhythmogenic activities of Hyoscyamine. | [DB01228] Encainide: Amlodipine may increase the arrhythmogenic activities of Encainide. | [DB01426] Ajmaline: Amlodipine may increase the arrhythmogenic activities of Ajmaline. | [DB06217] Vernakalant: Amlodipine may increase the arrhythmogenic activities of Vernakalant. | [DB06468] Cariporide: Amlodipine may increase the arrhythmogenic activities of Cariporide. | [DB12712] Pilsicainide: Amlodipine may increase the arrhythmogenic activities of Pilsicainide. | [DB13358] Cibenzoline: Amlodipine may increase the arrhythmogenic activities of Cibenzoline. | [DB13555] Prajmaline: Amlodipine may increase the arrhythmogenic activities of Prajmaline. | [DB13651] Lorajmine: Amlodipine may increase the arrhythmogenic activities of Lorajmine. | [DB00281] Lidocaine: Lidocaine may increase the arrhythmogenic activities of Amlodipine. | [DB00379] Mexiletine: Mexiletine may increase the arrhythmogenic activities of Amlodipine. | [DB01074] Perhexiline: Amlodipine may increase the arrhythmogenic activities of Perhexiline. | [DB01158] Bretylium: Amlodipine may increase the arrhythmogenic activities of Bretylium. | [DB12766] Cicletanine: Amlodipine may increase the arrhythmogenic activities of Cicletanine. | [DB00390] Digoxin: Amlodipine may increase the arrhythmogenic activities of Digoxin. | [DB13401] Metildigoxin: Amlodipine may increase the arrhythmogenic activities of Metildigoxin. | [DB13691] Acetyldigoxin: Amlodipine may increase the arrhythmogenic activities of Acetyldigoxin. | [DB01396] Digitoxin: Amlodipine may increase the arrhythmogenic activities of Digitoxin. | [DB00908] Quinidine: Amlodipine may increase the arrhythmogenic activities of Quinidine. | [DB00270] Isradipine: Isradipine may increase the arrhythmogenic activities of Amlodipine. | [DB00555] Lamotrigine: Amlodipine may increase the arrhythmogenic activities of Lamotrigine. | [DB00622] Nicardipine: Amlodipine may increase the arrhythmogenic activities of Nicardipine. | [DB00661] Verapamil: Amlodipine may increase the arrhythmogenic activities of Verapamil. | [DB01388] Mibefradil: Amlodipine may increase the arrhythmogenic activities of Mibefradil. | [DB00347] Trimethadione: Trimethadione may increase the arrhythmogenic activities of Amlodipine. | [DB00401] Nisoldipine: Amlodipine may increase the arrhythmogenic activities of Nisoldipine. | [DB01023] Felodipine: Amlodipine may increase the arrhythmogenic activities of Felodipine. | [DB04855] Dronedarone: Amlodipine may increase the arrhythmogenic activities of Dronedarone. | [DB01035] Procainamide: Amlodipine may increase the arrhythmogenic activities of Procainamide. | [DB01195] Flecainide: Amlodipine may increase the arrhythmogenic activities of Flecainide. | [DB01429] Aprindine: Amlodipine may increase the arrhythmogenic activities of Aprindine. | [DB06727] Sparteine: Amlodipine may increase the arrhythmogenic activities of Sparteine. | [DB00204] Dofetilide: Dofetilide may increase the arrhythmogenic activities of Amlodipine. | [DB00593] Ethosuximide: Amlodipine may increase the arrhythmogenic activities of Ethosuximide. | [DB12212] Landiolol: Amlodipine may increase the arrhythmogenic activities of Landiolol. | [DB00187] Esmolol: Esmolol may increase the arrhythmogenic activities of Amlodipine. | [DB00335] Atenolol: Atenolol may increase the arrhythmogenic activities of Amlodipine. | [DB00866] Alprenolol: Amlodipine may increase the arrhythmogenic activities of Alprenolol. | [DB00960] Pindolol: The risk or severity of bradycardia can be increased when Amlodipine is combined with Pindolol. | [DB01182] Propafenone: Amlodipine may increase the arrhythmogenic activities of Propafenone. | [DB01297] Practolol: Amlodipine may increase the arrhythmogenic activities of Practolol. | [DB01359] Penbutolol: The risk or severity of bradycardia can be increased when Amlodipine is combined with Penbutolol. | [DB03322] Dexpropranolol: Amlodipine may increase the arrhythmogenic activities of Dexpropranolol. | [DB04846] Celiprolol: Amlodipine may increase the arrhythmogenic activities of Celiprolol. | [DB06726] Bufuralol: The risk or severity of bradycardia can be increased when Amlodipine is combined with Bufuralol. | [DB08807] Bopindolol: The risk or severity of bradycardia can be increased when Amlodipine is combined with Bopindolol. | [DB08808] Bupranolol: Amlodipine may increase the arrhythmogenic activities of Bupranolol. | [DB09351] Levobetaxolol: The risk or severity of bradycardia can be increased when Amlodipine is combined with Levobetaxolol. | [DB11785] Anisodamine: Amlodipine may increase the arrhythmogenic activities of Anisodamine. | [DB13443] Esatenolol: The risk or severity of bradycardia can be increased when Amlodipine is combined with Esatenolol. | [DB13508] Cloranolol: The risk or severity of bradycardia can be increased when Amlodipine is combined with Cloranolol. | [DB13530] Mepindolol: The risk or severity of bradycardia can be increased when Amlodipine is combined with Mepindolol. | [DB13757] Epanolol: The risk or severity of bradycardia can be increased when Amlodipine is combined with Epanolol. | [DB13775] Tertatolol: Amlodipine may increase the arrhythmogenic activities of Tertatolol. | [DB00598] Labetalol: The risk or severity of bradycardia can be increased when Amlodipine is combined with Labetalol. | [DB01136] Carvedilol: Amlodipine may increase the arrhythmogenic activities of Carvedilol. | [DB01295] Bevantolol: The risk or severity of bradycardia can be increased when Amlodipine is combined with Bevantolol. | [DB12752] Bucindolol: The risk or severity of bradycardia can be increased when Amlodipine is combined with Bucindolol. | [DB00195] Betaxolol: Betaxolol may increase the arrhythmogenic activities of Amlodipine. | [DB00571] Propranolol: Amlodipine may increase the arrhythmogenic activities of Propranolol. | [DB01193] Acebutolol: Amlodipine may increase the arrhythmogenic activities of Acebutolol. | [DB01580] Oxprenolol: Amlodipine may increase the arrhythmogenic activities of Oxprenolol. | [DB08952] Indenolol: Amlodipine may increase the arrhythmogenic activities of Indenolol. | [DB00264] Metoprolol: Metoprolol may increase the arrhythmogenic activities of Amlodipine. | [DB01203] Nadolol: Amlodipine may increase the arrhythmogenic activities of Nadolol. | [DB11770] Talinolol: Amlodipine may increase the arrhythmogenic activities of Talinolol. | [DB00489] Sotalol: Amlodipine may increase the arrhythmogenic activities of Sotalol. | [DB01092] Ouabain: The serum concentration of Ouabain can be increased when it is combined with Amlodipine. | [DB12843] Oleandrin: The serum concentration of Oleandrin can be increased when it is combined with Amlodipine. | [DB13307] Proscillaridin: The serum concentration of Proscillaridin can be increased when it is combined with Amlodipine. | [DB13467] Lanatoside C: The serum concentration of Lanatoside C can be increased when it is combined with Amlodipine. | [DB13537] Gitoformate: The serum concentration of Gitoformate can be increased when it is combined with Amlodipine. | [DB13756] Peruvoside: The serum concentration of Peruvoside can be increased when it is combined with Amlodipine. | [DB00374] Treprostinil: Treprostinil may increase the hypotensive activities of Amlodipine. | [DB01088] Iloprost: Iloprost may increase the hypotensive activities of Amlodipine. | [DB01240] Epoprostenol: Epoprostenol may increase the hypotensive activities of Amlodipine. | [DB14337] Salvia miltiorrhiza root: Salvia miltiorrhiza root may increase the hypotensive activities of Amlodipine. | [DB00601] Linezolid: Linezolid may increase the hypotensive activities of Amlodipine. | [DB00614] Furazolidone: Furazolidone may increase the hypotensive activities of Amlodipine. | [DB00721] Procaine: Procaine may increase the hypotensive activities of Amlodipine. | [DB00752] Tranylcypromine: Tranylcypromine may increase the hypotensive activities of Amlodipine. | [DB00780] Phenelzine: Phenelzine may increase the hypotensive activities of Amlodipine. | [DB00805] Minaprine: Minaprine may increase the hypotensive activities of Amlodipine. | [DB01037] Selegiline: Selegiline may increase the hypotensive activities of Amlodipine. | [DB01168] Procarbazine: Procarbazine may increase the hypotensive activities of Amlodipine. | [DB01171] Moclobemide: Moclobemide may increase the hypotensive activities of Amlodipine. | [DB01247] Isocarboxazid: Isocarboxazid may increase the hypotensive activities of Amlodipine. | [DB01367] Rasagiline: Rasagiline may increase the hypotensive activities of Amlodipine. | [DB01626] Pargyline: Pargyline may increase the hypotensive activities of Amlodipine. | [DB04017] Clorgiline: Clorgiline may increase the hypotensive activities of Amlodipine. | [DB04818] Iproniazid: Iproniazid may increase the hypotensive activities of Amlodipine. | [DB04820] Nialamide: Nialamide may increase the hypotensive activities of Amlodipine. | [DB06654] Safinamide: Safinamide may increase the hypotensive activities of Amlodipine. | [DB08550] 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline: 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Amlodipine. | [DB09241] Methylene blue: Methylene blue may increase the hypotensive activities of Amlodipine. | [DB09243] Hydracarbazine: Hydracarbazine may increase the hypotensive activities of Amlodipine. | [DB09244] Pirlindole: Pirlindole may increase the hypotensive activities of Amlodipine. | [DB09245] Toloxatone: Toloxatone may increase the hypotensive activities of Amlodipine. | [DB09246] Benmoxin: Benmoxin may increase the hypotensive activities of Amlodipine. | [DB09248] Mebanazine: Mebanazine may increase the hypotensive activities of Amlodipine. | [DB09249] Octamoxin: Octamoxin may increase the hypotensive activities of Amlodipine. | [DB09250] Pheniprazine: Pheniprazine may increase the hypotensive activities of Amlodipine. | [DB09251] Phenoxypropazine: Phenoxypropazine may increase the hypotensive activities of Amlodipine. | [DB09252] Pivhydrazine: Pivhydrazine may increase the hypotensive activities of Amlodipine. | [DB09253] Safrazine: Safrazine may increase the hypotensive activities of Amlodipine. | [DB09254] Caroxazone: Caroxazone may increase the hypotensive activities of Amlodipine. | [DB13875] Harmaline: Harmaline may increase the hypotensive activities of Amlodipine. | [DB13876] Brofaromine: Brofaromine may increase the hypotensive activities of Amlodipine. | [DB00237] Butabarbital: Butabarbital may increase the hypotensive activities of Amlodipine. | [DB01355] Hexobarbital: Hexobarbital may increase the hypotensive activities of Amlodipine. | [DB00474] Methohexital: Methohexital may increase the hypotensive activities of Amlodipine. | [DB00599] Thiopental: The metabolism of Thiopental can be decreased when combined with Amlodipine. | [DB00258] Calcium acetate: The therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium acetate. | [DB00326] Calcium glucoheptonate: The therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium glucoheptonate. | [DB01164] Calcium chloride: The therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium chloride. | [DB11126] Calcium gluconate: The therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium gluconate. | [DB13142] Calcium glubionate anhydrous: The therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium glubionate anhydrous. | [DB13590] Calcium pangamate: The therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium pangamate. | [DB13800] Calcium levulinate: The therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium levulinate. | [DB14577] Calcium cation: The therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium cation. | [DB01373] Calcium: The therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium. | [DB00590] Doxazosin: The metabolism of Doxazosin can be decreased when combined with Amlodipine. | [DB00692] Phentolamine: Phentolamine may decrease the antihypertensive activities of Amlodipine. | [DB00699] Nicergoline: Nicergoline may decrease the antihypertensive activities of Amlodipine. | [DB00706] Tamsulosin: The risk or severity of hypotension can be increased when Tamsulosin is combined with Amlodipine. | [DB00777] Propiomazine: Propiomazine may decrease the antihypertensive activities of Amlodipine. | [DB00797] Tolazoline: Tolazoline may decrease the antihypertensive activities of Amlodipine. | [DB00925] Phenoxybenzamine: Phenoxybenzamine may decrease the antihypertensive activities of Amlodipine. | [DB01162] Terazosin: Amlodipine may increase the hypotensive activities of Terazosin. | [DB01403] Methotrimeprazine: Methotrimeprazine may decrease the antihypertensive activities of Amlodipine. | [DB01608] Periciazine: Periciazine may decrease the antihypertensive activities of Amlodipine. | [DB01614] Acepromazine: Acepromazine may decrease the antihypertensive activities of Amlodipine. | [DB01622] Thioproperazine: Thioproperazine may decrease the antihypertensive activities of Amlodipine. | [DB06153] Pizotifen: Pizotifen may decrease the antihypertensive activities of Amlodipine. | [DB08950] Indoramin: Indoramin may decrease the antihypertensive activities of Amlodipine. | [DB09128] Brexpiprazole: Brexpiprazole may decrease the antihypertensive activities of Amlodipine. | [DB09206] Trimazosin: Amlodipine may increase the hypotensive activities of Trimazosin. | [DB12230] Bunazosin: The risk or severity of hypotension can be increased when Bunazosin is combined with Amlodipine. | [DB12278] Propiverine: Propiverine may decrease the antihypertensive activities of Amlodipine. | [DB12661] Urapidil: Urapidil may decrease the antihypertensive activities of Amlodipine. | [DB00334] Olanzapine: The risk or severity of hypotension can be increased when Olanzapine is combined with Amlodipine. | [DB01142] Doxepin: The metabolism of Doxepin can be decreased when combined with Amlodipine. | [DB00320] Dihydroergotamine: The metabolism of Dihydroergotamine can be decreased when combined with Amlodipine. | [DB00831] Trifluoperazine: Trifluoperazine may decrease the antihypertensive activities of Amlodipine. | [DB00458] Imipramine: The metabolism of Imipramine can be decreased when combined with Amlodipine. | [DB00679] Thioridazine: The metabolism of Thioridazine can be decreased when combined with Amlodipine. | [DB00420] Promazine: The metabolism of Promazine can be decreased when combined with Amlodipine. | [DB00450] Droperidol: Droperidol may decrease the antihypertensive activities of Amlodipine. | [DB00875] Flupentixol: Flupentixol may decrease the antihypertensive activities of Amlodipine. | [DB01267] Paliperidone: Paliperidone may decrease the antihypertensive activities of Amlodipine. | [DB01624] Zuclopenthixol: Zuclopenthixol may decrease the antihypertensive activities of Amlodipine. | [DB04946] Iloperidone: Iloperidone may decrease the antihypertensive activities of Amlodipine. | [DB06216] Asenapine: Asenapine may decrease the antihypertensive activities of Amlodipine. | [DB00540] Nortriptyline: The metabolism of Nortriptyline can be decreased when combined with Amlodipine. | [DB00543] Amoxapine: Amoxapine may decrease the antihypertensive activities of Amlodipine. | [DB00726] Trimipramine: The metabolism of Trimipramine can be decreased when combined with Amlodipine. | [DB00321] Amitriptyline: The metabolism of Amitriptyline can be decreased when combined with Amlodipine. | [DB00416] Metocurine iodide: Amlodipine may increase the neuromuscular blocking activities of Metocurine iodide. | [DB00483] Gallamine triethiodide: Amlodipine may increase the neuromuscular blocking activities of Gallamine triethiodide. | [DB00565] Cisatracurium: Amlodipine may increase the neuromuscular blocking activities of Cisatracurium. | [DB00728] Rocuronium: Amlodipine may increase the neuromuscular blocking activities of Rocuronium. | [DB00732] Atracurium besylate: Amlodipine may increase the neuromuscular blocking activities of Atracurium besylate. | [DB01135] Doxacurium: Amlodipine may increase the neuromuscular blocking activities of Doxacurium. | [DB01199] Tubocurarine: Amlodipine may increase the neuromuscular blocking activities of Tubocurarine. | [DB01226] Mivacurium: Amlodipine may increase the neuromuscular blocking activities of Mivacurium. | [DB01336] Metocurine: Amlodipine may increase the neuromuscular blocking activities of Metocurine. | [DB01337] Pancuronium: Amlodipine may increase the neuromuscular blocking activities of Pancuronium. | [DB01338] Pipecuronium: Amlodipine may increase the neuromuscular blocking activities of Pipecuronium. | [DB01339] Vecuronium: Amlodipine may increase the neuromuscular blocking activities of Vecuronium. | [DB04834] Rapacuronium: Amlodipine may increase the neuromuscular blocking activities of Rapacuronium. | [DB13295] Atracurium: Amlodipine may increase the neuromuscular blocking activities of Atracurium. | [DB13584] Gallamine: Amlodipine may increase the neuromuscular blocking activities of Gallamine. | [DB13648] Alcuronium: Amlodipine may increase the neuromuscular blocking activities of Alcuronium. | [DB00653] Magnesium sulfate: Amlodipine may increase the arrhythmogenic activities of Magnesium sulfate. | [DB01377] Magnesium oxide: The risk or severity of hypotension can be increased when Magnesium oxide is combined with Amlodipine. | [DB08938] Magaldrate: The risk or severity of hypotension can be increased when Magaldrate is combined with Amlodipine. | [DB09104] Magnesium hydroxide: The risk or severity of hypotension can be increased when Magnesium hydroxide is combined with Amlodipine. | [DB09281] Magnesium trisilicate: The risk or severity of hypotension can be increased when Magnesium trisilicate is combined with Amlodipine. | [DB09407] Magnesium chloride: The risk or severity of hypotension can be increased when Magnesium chloride is combined with Amlodipine. | [DB09481] Magnesium carbonate: The risk or severity of hypotension can be increased when Magnesium carbonate is combined with Amlodipine. | [DB11110] Magnesium citrate: The risk or severity of hypotension can be increased when Magnesium citrate is combined with Amlodipine. | [DB13249] Magnesium silicate: The risk or severity of hypotension can be increased when Magnesium silicate is combined with Amlodipine. | [DB13322] Hydrotalcite: The risk or severity of hypotension can be increased when Hydrotalcite is combined with Amlodipine. | [DB13359] Magnesium aspartate: The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Amlodipine. | [DB13486] Magnesium peroxide: The risk or severity of hypotension can be increased when Magnesium peroxide is combined with Amlodipine. | [DB13749] Magnesium gluconate: The risk or severity of hypotension can be increased when Magnesium gluconate is combined with Amlodipine. | [DB13786] Magnesium orotate: The risk or severity of hypotension can be increased when Magnesium orotate is combined with Amlodipine. | [DB14514] Magnesium levulinate: The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Amlodipine. | [DB14515] Magnesium lactate: The risk or severity of hypotension can be increased when Magnesium lactate is combined with Amlodipine. | [DB01397] Magnesium salicylate: The risk or severity of hypotension can be increased when Magnesium salicylate is combined with Amlodipine. | [DB00086] Streptokinase: The risk or severity of adverse effects can be increased when Streptokinase is combined with Amlodipine. | [DB00268] Ropinirole: The risk or severity of adverse effects can be increased when Ropinirole is combined with Amlodipine. | [DB00323] Tolcapone: The risk or severity of adverse effects can be increased when Tolcapone is combined with Amlodipine. | [DB00413] Pramipexole: The risk or severity of adverse effects can be increased when Amlodipine is combined with Pramipexole. | [DB00486] Nabilone: The metabolism of Nabilone can be decreased when combined with Amlodipine. | [DB00631] Clofarabine: The risk or severity of adverse effects can be increased when Amlodipine is combined with Clofarabine. | [DB00887] Bumetanide: The risk or severity of adverse effects can be increased when Amlodipine is combined with Bumetanide. | [DB00903] Etacrynic acid: The risk or severity of adverse effects can be increased when Amlodipine is combined with Etacrynic acid. | [DB01144] Diclofenamide: The risk or severity of adverse effects can be increased when Amlodipine is combined with Diclofenamide. | [DB01282] Carbetocin: The risk or severity of adverse effects can be increased when Amlodipine is combined with Carbetocin. | [DB04899] Nesiritide: The risk or severity of adverse effects can be increased when Amlodipine is combined with Nesiritide. | [DB09077] Dinutuximab: The risk or severity of adverse effects can be increased when Amlodipine is combined with Dinutuximab. | [DB09112] Nitrous acid: The risk or severity of adverse effects can be increased when Amlodipine is combined with Nitrous acid. | [DB09286] Pipamperone: The risk or severity of adverse effects can be increased when Amlodipine is combined with Pipamperone. | [DB09292] Sacubitril: The risk or severity of adverse effects can be increased when Amlodipine is combined with Sacubitril. | [DB00703] Methazolamide: The risk or severity of adverse effects can be increased when Amlodipine is combined with Methazolamide. | [DB00041] Aldesleukin: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amlodipine. | [DB00296] Ropivacaine: The risk or severity of adverse effects can be increased when Ropivacaine is combined with Amlodipine. | [DB00297] Bupivacaine: The risk or severity of adverse effects can be increased when Bupivacaine is combined with Amlodipine. | [DB00435] Nitric Oxide: The risk or severity of adverse effects can be increased when Amlodipine is combined with Nitric Oxide. | [DB01002] Levobupivacaine: The risk or severity of adverse effects can be increased when Amlodipine is combined with Levobupivacaine. | [DB00697] Tizanidine: The risk or severity of adverse effects can be increased when Amlodipine is combined with Tizanidine. | [DB00714] Apomorphine: The risk or severity of adverse effects can be increased when Amlodipine is combined with Apomorphine. | [DB01041] Thalidomide: The metabolism of Amlodipine can be increased when combined with Thalidomide. | [DB01113] Papaverine: The risk or severity of adverse effects can be increased when Amlodipine is combined with Papaverine. | [DB01169] Arsenic trioxide: The risk or severity of adverse effects can be increased when Amlodipine is combined with Arsenic trioxide. | [DB00295] Morphine: The risk or severity of adverse effects can be increased when Morphine is combined with Amlodipine. | [DB00755] Tretinoin: Tretinoin may decrease the antihypertensive activities of Amlodipine. | [DB11632] Opicapone: The risk or severity of adverse effects can be increased when Amlodipine is combined with Opicapone. | [DB15456] Vericiguat: The risk or severity of adverse effects can be increased when Amlodipine is combined with Vericiguat. | [DB04897] Lucinactant: Amlodipine may increase the bradycardic activities of Lucinactant. | [DB06415] Calfactant: Amlodipine may increase the bradycardic activities of Calfactant. | [DB06761] Beractant: Amlodipine may increase the bradycardic activities of Beractant. | [DB06791] Lanreotide: Amlodipine may increase the bradycardic activities of Lanreotide. | [DB09113] Poractant alfa: Amlodipine may increase the bradycardic activities of Poractant alfa. | [DB00989] Rivastigmine: Amlodipine may increase the bradycardic activities of Rivastigmine. | [DB06218] Lacosamide: The risk or severity of ventricular arrhythmias, bradycardia, and heart block can be increased when Amlodipine is combined with Lacosamide. | [DB08895] Tofacitinib: Amlodipine may increase the bradycardic activities of Tofacitinib. | [DB00674] Galantamine: Amlodipine may increase the bradycardic activities of Galantamine. | [DB06663] Pasireotide: Amlodipine may increase the bradycardic activities of Pasireotide. | [DB08868] Fingolimod: Amlodipine may increase the bradycardic activities of Fingolimod. | [DB08896] Regorafenib: The metabolism of Regorafenib can be decreased when combined with Amlodipine. | [DB00843] Donepezil: The metabolism of Donepezil can be decreased when combined with Amlodipine. | [DB00230] Pregabalin: Pregabalin may increase the bradycardic activities of Amlodipine. | [DB00202] Succinylcholine: The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Amlodipine. | [DB00384] Triamterene: The risk or severity of adverse effects can be increased when Amlodipine is combined with Triamterene. | [DB00407] Ardeparin: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Ardeparin. | [DB00421] Spironolactone: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Spironolactone. | [DB00492] Fosinopril: Amlodipine may increase the hypotensive activities of Fosinopril. | [DB00519] Trandolapril: Amlodipine may increase the hypotensive activities of Trandolapril. | [DB00594] Amiloride: The risk or severity of adverse effects can be increased when Amlodipine is combined with Amiloride. | [DB00691] Moexipril: Amlodipine may increase the hypotensive activities of Moexipril. | [DB00698] Nitrofurantoin: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Nitrofurantoin. | [DB00876] Eprosartan: Amlodipine may increase the hypotensive activities of Eprosartan. | [DB00881] Quinapril: Amlodipine may increase the hypotensive activities of Quinapril. | [DB00886] Omapatrilat: Omapatrilat may decrease the antihypertensive activities of Amlodipine. | [DB01109] Heparin: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Heparin. | [DB01180] Rescinnamine: Rescinnamine may decrease the antihypertensive activities of Amlodipine. | [DB01197] Captopril: Amlodipine may increase the hypotensive activities of Captopril. | [DB01225] Enoxaparin: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Enoxaparin. | [DB01340] Cilazapril: Amlodipine may increase the hypotensive activities of Cilazapril. | [DB01342] Forasartan: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Forasartan. | [DB01347] Saprisartan: Amlodipine may increase the hypotensive activities of Saprisartan. | [DB01348] Spirapril: Amlodipine may increase the hypotensive activities of Spirapril. | [DB01349] Tasosartan: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Tasosartan. | [DB02968] Penicillin G Acyl-Serine: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Penicillin G Acyl-Serine. | [DB06271] Sulodexide: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Sulodexide. | [DB06754] Danaparoid: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Danaparoid. | [DB06763] Saralasin: Saralasin may decrease the antihypertensive activities of Amlodipine. | [DB06767] Ammonium chloride: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Ammonium chloride. | [DB06779] Dalteparin: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Dalteparin. | [DB06822] Tinzaparin: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Tinzaparin. | [DB08813] Nadroparin: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Nadroparin. | [DB08822] Azilsartan medoxomil: Amlodipine may increase the hypotensive activities of Azilsartan medoxomil. | [DB08836] Temocapril: Amlodipine may increase the hypotensive activities of Temocapril. | [DB08976] Floctafenine: Floctafenine may decrease the antihypertensive activities of Amlodipine. | [DB09015] Canrenoic acid: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Canrenoic acid. | [DB09258] Bemiparin: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Bemiparin. | [DB09259] Reviparin: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Reviparin. | [DB09260] Parnaparin: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Parnaparin. | [DB09261] Certoparin: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Certoparin. | [DB09477] Enalaprilat: Amlodipine may increase the hypotensive activities of Enalaprilat. | [DB11783] Imidapril: Amlodipine may increase the hypotensive activities of Imidapril. | [DB12097] Mannitol busulfan: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Mannitol busulfan. | [DB12221] Canrenone: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Canrenone. | [DB13166] Zofenopril: Amlodipine may increase the hypotensive activities of Zofenopril. | [DB13312] Delapril: Amlodipine may increase the hypotensive activities of Delapril. | [DB14125] Benazeprilat: Amlodipine may increase the hypotensive activities of Benazeprilat. | [DB14208] Ramiprilat: Amlodipine may increase the hypotensive activities of Ramiprilat. | [DB14213] Perindoprilat: Amlodipine may increase the hypotensive activities of Perindoprilat. | [DB14217] Quinaprilat: Amlodipine may increase the hypotensive activities of Quinaprilat. | [DB01395] Drospirenone: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Drospirenone. | [DB00700] Eplerenone: Amlodipine may increase the hypotensive activities of Eplerenone. | [DB00440] Trimethoprim: The metabolism of Trimethoprim can be decreased when combined with Amlodipine. | [DB06212] Tolvaptan: The metabolism of Tolvaptan can be decreased when combined with Amlodipine. | [DB13919] Candesartan: The metabolism of Candesartan can be decreased when combined with Amlodipine. | [DB16165] Finerenone: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Finerenone. | [DB09236] Lacidipine: Amlodipine may increase the hypotensive activities of Lacidipine. | [DB09227] Barnidipine: Amlodipine may increase the antihypertensive activities of Barnidipine. | [DB09204] Arotinolol: The risk or severity of hypotension can be increased when Arotinolol is combined with Amlodipine. | [DB06395] Abafungin: The therapeutic efficacy of Abafungin can be increased when used in combination with Amlodipine. | [DB06440] Ravuconazole: The therapeutic efficacy of Ravuconazole can be increased when used in combination with Amlodipine. | [DB12073] Albaconazole: The therapeutic efficacy of Albaconazole can be increased when used in combination with Amlodipine. | [DB04794] Bifonazole: The therapeutic efficacy of Bifonazole can be increased when used in combination with Amlodipine. | [DB05667] Levoketoconazole: The metabolism of Amlodipine can be decreased when combined with Levoketoconazole. | [DB13967] Patent Blue: The therapeutic efficacy of Amlodipine can be decreased when used in combination with Patent Blue. | [DB00681] Amphotericin B: Amlodipine may decrease the nephrotoxic activities of Amphotericin B. | [DB00581] Lactulose: The therapeutic efficacy of Lactulose can be decreased when used in combination with Amlodipine. | [DB01046] Lubiprostone: The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Amlodipine. | [DB01378] Magnesium cation: The therapeutic efficacy of Magnesium cation can be decreased when used in combination with Amlodipine. | [DB01638] Sorbitol: The therapeutic efficacy of Sorbitol can be decreased when used in combination with Amlodipine. | [DB04816] Dantron: The therapeutic efficacy of Dantron can be decreased when used in combination with Amlodipine. | [DB04823] Oxyphenisatin: The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Amlodipine. | [DB04824] Phenolphthalein: The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Amlodipine. | [DB07715] Emodin: The therapeutic efficacy of Emodin can be decreased when used in combination with Amlodipine. | [DB08890] Linaclotide: The therapeutic efficacy of Linaclotide can be decreased when used in combination with Amlodipine. | [DB09020] Bisacodyl: The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Amlodipine. | [DB09219] Bisoxatin: The therapeutic efficacy of Bisoxatin can be decreased when used in combination with Amlodipine. | [DB09268] Picosulfuric acid: The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Amlodipine. | [DB09311] Polycarbophil: The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Amlodipine. | [DB09409] Magnesium acetate tetrahydrate: The therapeutic efficacy of Magnesium acetate tetrahydrate can be decreased when used in combination with Amlodipine. | [DB09472] Sodium sulfate: The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Amlodipine. | [DB09484] Sodium fluorophosphate: The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Amlodipine. | [DB11057] Mineral oil: The therapeutic efficacy of Mineral oil can be decreased when used in combination with Amlodipine. | [DB11059] Carboxymethylcellulose: The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Amlodipine. | [DB11089] Docusate: The therapeutic efficacy of Docusate can be decreased when used in combination with Amlodipine. | [DB11097] Plantago seed: The therapeutic efficacy of Plantago seed can be decreased when used in combination with Amlodipine. | [DB11113] Castor oil: The therapeutic efficacy of Castor oil can be decreased when used in combination with Amlodipine. | [DB11189] Magnesium glycinate: The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Amlodipine. | [DB11228] Methylcellulose: The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Amlodipine. | [DB11365] Sennosides: The therapeutic efficacy of Sennosides can be decreased when used in combination with Amlodipine. | [DB12942] Lactitol: The therapeutic efficacy of Lactitol can be decreased when used in combination with Amlodipine. | [DB13170] Plecanatide: The therapeutic efficacy of Plecanatide can be decreased when used in combination with Amlodipine. | [DB13180] Gluconic Acid: The therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Amlodipine. | [DB13526] Pentaerithrityl: The therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Amlodipine. | [DB13707] Sodium tartrate: The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Amlodipine. | [DB13996] Magnesium acetate: The therapeutic efficacy of Magnesium acetate can be decreased when used in combination with Amlodipine. | [DB14232] Deacetylbisacodyl: The therapeutic efficacy of Deacetylbisacodyl can be decreased when used in combination with Amlodipine. | [DB14482] Sodium ascorbate: The therapeutic efficacy of Sodium ascorbate can be decreased when used in combination with Amlodipine. | [DB14502] Sodium phosphate, dibasic: The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Amlodipine. | [DB14503] Sodium phosphate, monobasic, unspecified form: The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Amlodipine. | [DB14504] Sodium phosphate, dibasic, unspecified form: The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Amlodipine. | [DB14516] Sodium cation: The therapeutic efficacy of Sodium cation can be decreased when used in combination with Amlodipine. | [DB14585] Plantago ovata seed: The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Amlodipine. | [DB14627] Oxyphenisatin acetate: The therapeutic efficacy of Oxyphenisatin acetate can be decreased when used in combination with Amlodipine. | [DB14684] Calcium polycarbophil: The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Amlodipine. | [DB14963] Konjac mannan: The therapeutic efficacy of Konjac mannan can be decreased when used in combination with Amlodipine. | [DB15477] Alloin: The therapeutic efficacy of Alloin can be decreased when used in combination with Amlodipine. | [DB15478] Frangula purshiana bark: The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Amlodipine. | [DB11622] Dehydrocholic acid: The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Amlodipine. | [DB00742] Mannitol: The risk or severity of adverse effects can be increased when Amlodipine is combined with Mannitol. | [DB01079] Tegaserod: The therapeutic efficacy of Tegaserod can be decreased when used in combination with Amlodipine. | [DB06480] Prucalopride: The therapeutic efficacy of Prucalopride can be decreased when used in combination with Amlodipine. | [DB09287] Polyethylene glycol: The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Amlodipine. | [DB09462] Glycerin: The therapeutic efficacy of Glycerin can be decreased when used in combination with Amlodipine. | [DB14546] Sulfate ion: The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Amlodipine. | [DB09046] Metreleptin: The metabolism of Amlodipine can be increased when combined with Metreleptin. | [DB00761] Potassium chloride: Potassium chloride may increase the hyperkalemic activities of Amlodipine. | [DB09125] Potassium citrate: Potassium citrate may increase the hyperkalemic activities of Amlodipine. | [DB11098] Potassium bicarbonate: Potassium bicarbonate may increase the hyperkalemic activities of Amlodipine. | [DB14498] Potassium acetate: Potassium acetate may increase the hyperkalemic activities of Amlodipine. | [DB09087] Potassium alum: Potassium alum may increase the hyperkalemic activities of Amlodipine. | [DB09418] Potassium perchlorate: Potassium perchlorate may increase the hyperkalemic activities of Amlodipine. | [DB11107] Potassium bitartrate: Potassium bitartrate may increase the hyperkalemic activities of Amlodipine. | [DB13620] Potassium gluconate: Potassium gluconate may increase the hyperkalemic activities of Amlodipine. | [DB13977] Potassium carbonate: Potassium carbonate may increase the hyperkalemic activities of Amlodipine. | [DB14492] Potassium triiodide: Potassium triiodide may increase the hyperkalemic activities of Amlodipine. | [DB14500] Potassium: Potassium may increase the hyperkalemic activities of Amlodipine. | [DB09413] Monopotassium phosphate: Monopotassium phosphate may increase the hyperkalemic activities of Amlodipine. | [DB09414] Dipotassium phosphate: Dipotassium phosphate may increase the hyperkalemic activities of Amlodipine. | [DB09449] Sodium phosphate, monobasic: Sodium phosphate, monobasic may increase the hyperkalemic activities of Amlodipine. | [DB09483] Potassium lactate: Potassium lactate may increase the hyperkalemic activities of Amlodipine. | [DB14499] Potassium sulfate: Potassium sulfate may increase the hyperkalemic activities of Amlodipine. | [DB06715] Potassium Iodide: Potassium Iodide may increase the hyperkalemic activities of Amlodipine. | [DB11090] Potassium nitrate: Potassium nitrate may increase the hyperkalemic activities of Amlodipine. | [DB11153] Potassium hydroxide: Potassium hydroxide may increase the hyperkalemic activities of Amlodipine. | [DB13735] Potassium guaiacolsulfonate: Potassium guaiacolsulfonate may increase the hyperkalemic activities of Amlodipine. | [DB01345] Potassium cation: Potassium cation may increase the hyperkalemic activities of Amlodipine. | [DB01015] Sulfamethoxazole: The metabolism of Sulfamethoxazole can be decreased when combined with Amlodipine. | [DB00030] Insulin human: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin human. | [DB00046] Insulin lispro: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin lispro. | [DB00047] Insulin glargine: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin glargine. | [DB00071] Insulin pork: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin pork. | [DB00284] Acarbose: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Acarbose. | [DB00331] Metformin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Metformin. | [DB00414] Acetohexamide: The metabolism of Acetohexamide can be decreased when combined with Amlodipine. | [DB00491] Miglitol: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Miglitol. | [DB00672] Chlorpropamide: The metabolism of Chlorpropamide can be decreased when combined with Amlodipine. | [DB00839] Tolazamide: The metabolism of Tolazamide can be decreased when combined with Amlodipine. | [DB01067] Glipizide: The metabolism of Glipizide can be decreased when combined with Amlodipine. | [DB01120] Gliclazide: The metabolism of Gliclazide can be decreased when combined with Amlodipine. | [DB01251] Gliquidone: The metabolism of Gliquidone can be decreased when combined with Amlodipine. | [DB01252] Mitiglinide: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Mitiglinide. | [DB01276] Exenatide: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Exenatide. | [DB01277] Mecasermin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Mecasermin. | [DB01278] Pramlintide: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Pramlintide. | [DB01289] Glisoxepide: The metabolism of Glisoxepide can be decreased when combined with Amlodipine. | [DB01306] Insulin aspart: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin aspart. | [DB01307] Insulin detemir: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin detemir. | [DB01309] Insulin glulisine: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin glulisine. | [DB01382] Glymidine: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Glymidine. | [DB01700] AICA ribonucleotide: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with AICA ribonucleotide. | [DB04830] Buformin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Buformin. | [DB04876] Vildagliptin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Vildagliptin. | [DB04878] Voglibose: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Voglibose. | [DB05115] NN344: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with NN344. | [DB06011] AMG-222: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with AMG-222. | [DB06127] Bisegliptin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Bisegliptin. | [DB06655] Liraglutide: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Liraglutide. | [DB08382] Gosogliptin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Gosogliptin. | [DB08962] Glibornuride: The metabolism of Glibornuride can be decreased when combined with Amlodipine. | [DB09022] Benfluorex: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Benfluorex. | [DB09043] Albiglutide: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Albiglutide. | [DB09045] Dulaglutide: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Dulaglutide. | [DB09265] Lixisenatide: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Lixisenatide. | [DB09456] Insulin beef: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin beef. | [DB09564] Insulin degludec: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin degludec. | [DB11567] Insulin peglispro: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin peglispro. | [DB11568] Insulin tregopil: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin tregopil. | [DB11698] Ipragliflozin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Ipragliflozin. | [DB11723] Dutogliptin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Dutogliptin. | [DB11780] Allicin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Allicin. | [DB11824] Tofogliflozin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Tofogliflozin. | [DB11898] 2,4-thiazolidinedione: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with 2,4-thiazolidinedione. | [DB11950] Teneligliptin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Teneligliptin. | [DB11992] Omarigliptin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Omarigliptin. | [DB12268] Carmegliptin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Carmegliptin. | [DB12412] Gemigliptin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Gemigliptin. | [DB12417] Anagliptin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Anagliptin. | [DB12625] Evogliptin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Evogliptin. | [DB12713] Sotagliflozin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Sotagliflozin. | [DB12935] Remogliflozin etabonate: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Remogliflozin etabonate. | [DB13406] Carbutamide: The metabolism of Carbutamide can be decreased when combined with Amlodipine. | [DB13446] Guar gum: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Guar gum. | [DB13675] Metahexamide: The metabolism of Metahexamide can be decreased when combined with Amlodipine. | [DB13928] Semaglutide: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Semaglutide. | [DB14027] Taspoglutide: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Taspoglutide. | [DB14035] Englitazone: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Englitazone. | [DB15171] Tirzepatide: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Tirzepatide. | [DB15217] Gastric inhibitory polypeptide: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Gastric inhibitory polypeptide. | [DB09038] Empagliflozin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Empagliflozin. | [DB00914] Phenformin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Phenformin. | [DB06203] Alogliptin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Alogliptin. | [DB06292] Dapagliflozin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Dapagliflozin. | [DB01200] Bromocriptine: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Bromocriptine. | [DB08882] Linagliptin: The metabolism of Amlodipine can be decreased when combined with Linagliptin. | [DB08907] Canagliflozin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Canagliflozin. | [DB11827] Ertugliflozin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Ertugliflozin. | [DB00738] Pentamidine: The metabolism of Pentamidine can be decreased when combined with Amlodipine. | [DB00263] Sulfisoxazole: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Sulfisoxazole. | [DB00731] Nateglinide: The metabolism of Nateglinide can be decreased when combined with Amlodipine. | [DB01016] Glyburide: The metabolism of Glyburide can be decreased when combined with Amlodipine. | [DB01268] Sunitinib: The metabolism of Sunitinib can be decreased when combined with Amlodipine. | [DB06335] Saxagliptin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Saxagliptin. | [DB00359] Sulfadiazine: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Sulfadiazine. | [DB00412] Rosiglitazone: The metabolism of Rosiglitazone can be decreased when combined with Amlodipine. | [DB00912] Repaglinide: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Repaglinide. | [DB01124] Tolbutamide: The metabolism of Tolbutamide can be decreased when combined with Amlodipine. | [DB01132] Pioglitazone: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Pioglitazone. | [DB01261] Sitagliptin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Sitagliptin. | [DB09198] Lobeglitazone: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Lobeglitazone. | [DB09199] Netoglitazone: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Netoglitazone. | [DB09200] Rivoglitazone: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Rivoglitazone. | [DB09201] Ciglitazone: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Ciglitazone. | [DB12781] Balaglitazone: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Balaglitazone. | [DB00222] Glimepiride: The metabolism of Glimepiride can be decreased when combined with Amlodipine. | [DB00181] Baclofen: The risk or severity of adverse effects can be increased when Baclofen is combined with Amlodipine. | [DB00190] Carbidopa: The risk or severity of hypotension can be increased when Carbidopa is combined with Amlodipine. | [DB00199] Erythromycin: The risk or severity of adverse effects can be increased when Erythromycin is combined with Amlodipine. | [DB00778] Roxithromycin: The risk or severity of adverse effects can be increased when Roxithromycin is combined with Amlodipine. | [DB00976] Telithromycin: The risk or severity of adverse effects can be increased when Telithromycin is combined with Amlodipine. | [DB01211] Clarithromycin: The risk or severity of adverse effects can be increased when Clarithromycin is combined with Amlodipine. | [DB06419] Cethromycin: The risk or severity of adverse effects can be increased when Cethromycin is combined with Amlodipine. | [DB00477] Chlorpromazine: The metabolism of Amlodipine can be increased when combined with Chlorpromazine. | [DB00834] Mifepristone: The metabolism of Amlodipine can be increased when combined with Mifepristone. | [DB00136] Calcitriol: The metabolism of Amlodipine can be increased when combined with Calcitriol. | [DB00163] Vitamin E: The metabolism of Amlodipine can be increased when combined with Vitamin E. | [DB00180] Flunisolide: The metabolism of Amlodipine can be increased when combined with Flunisolide. | [DB00197] Troglitazone: The metabolism of Amlodipine can be increased when combined with Troglitazone. | [DB00241] Butalbital: The metabolism of Amlodipine can be increased when combined with Butalbital. | [DB00301] Flucloxacillin: The metabolism of Amlodipine can be increased when combined with Flucloxacillin. | [DB00316] Acetaminophen: The metabolism of Amlodipine can be increased when combined with Acetaminophen. | [DB00357] Aminoglutethimide: The metabolism of Amlodipine can be increased when combined with Aminoglutethimide. | [DB00363] Clozapine: The metabolism of Amlodipine can be increased when combined with Clozapine. | [DB00394] Beclomethasone dipropionate: The metabolism of Amlodipine can be increased when combined with Beclomethasone dipropionate. | [DB00400] Griseofulvin: The metabolism of Amlodipine can be increased when combined with Griseofulvin. | [DB00418] Secobarbital: The metabolism of Amlodipine can be increased when combined with Secobarbital. | [DB00439] Cerivastatin: The metabolism of Amlodipine can be increased when combined with Cerivastatin. | [DB00443] Betamethasone: The metabolism of Amlodipine can be increased when combined with Betamethasone. | [DB00468] Quinine: The metabolism of Amlodipine can be increased when combined with Quinine. | [DB00485] Dicloxacillin: The metabolism of Amlodipine can be increased when combined with Dicloxacillin. | [DB00531] Cyclophosphamide: The metabolism of Amlodipine can be increased when combined with Cyclophosphamide. | [DB00533] Rofecoxib: The metabolism of Amlodipine can be increased when combined with Rofecoxib. | [DB00570] Vinblastine: The metabolism of Amlodipine can be increased when combined with Vinblastine. | [DB00591] Fluocinolone acetonide: The metabolism of Amlodipine can be increased when combined with Fluocinolone acetonide. | [DB00603] Medroxyprogesterone acetate: The metabolism of Amlodipine can be increased when combined with Medroxyprogesterone acetate. | [DB00620] Triamcinolone: The metabolism of Amlodipine can be increased when combined with Triamcinolone. | [DB00624] Testosterone: The metabolism of Amlodipine can be increased when combined with Testosterone. | [DB00636] Clofibrate: The metabolism of Amlodipine can be increased when combined with Clofibrate. | [DB00675] Tamoxifen: The metabolism of Amlodipine can be increased when combined with Tamoxifen. | [DB00741] Hydrocortisone: The metabolism of Amlodipine can be increased when combined with Hydrocortisone. | [DB00769] Hydrocortamate: The metabolism of Amlodipine can be increased when combined with Hydrocortamate. | [DB00812] Phenylbutazone: The metabolism of Amlodipine can be increased when combined with Phenylbutazone. | [DB00849] Methylphenobarbital: The metabolism of Amlodipine can be increased when combined with Methylphenobarbital. | [DB00857] Terbinafine: The metabolism of Amlodipine can be increased when combined with Terbinafine. | [DB00860] Prednisolone: The metabolism of Amlodipine can be increased when combined with Prednisolone. | [DB00898] Ethanol: The metabolism of Amlodipine can be increased when combined with Ethanol. | [DB00957] Norgestimate: The metabolism of Amlodipine can be increased when combined with Norgestimate. | [DB00959] Methylprednisolone: The metabolism of Amlodipine can be increased when combined with Methylprednisolone. | [DB01011] Metyrapone: The metabolism of Amlodipine can be increased when combined with Metyrapone. | [DB01032] Probenecid: The metabolism of Amlodipine can be increased when combined with Probenecid. | [DB01115] Nifedipine: Amlodipine may increase the arrhythmogenic activities of Nifedipine. | [DB01138] Sulfinpyrazone: The metabolism of Amlodipine can be increased when combined with Sulfinpyrazone. | [DB01154] Thiamylal: The metabolism of Amlodipine can be increased when combined with Thiamylal. | [DB01181] Ifosfamide: The metabolism of Amlodipine can be increased when combined with Ifosfamide. | [DB01201] Rifapentine: The metabolism of Amlodipine can be increased when combined with Rifapentine. | [DB01222] Budesonide: The metabolism of Amlodipine can be increased when combined with Budesonide. | [DB01229] Paclitaxel: The metabolism of Amlodipine can be increased when combined with Paclitaxel. | [DB01285] Corticotropin: The metabolism of Amlodipine can be increased when combined with Corticotropin. | [DB01333] Cefradine: The metabolism of Amlodipine can be increased when combined with Cefradine. | [DB01351] Amobarbital: The metabolism of Amlodipine can be increased when combined with Amobarbital. | [DB01352] Aprobarbital: The metabolism of Amlodipine can be increased when combined with Aprobarbital. | [DB01380] Cortisone acetate: The metabolism of Amlodipine can be increased when combined with Cortisone acetate. | [DB01384] Paramethasone: The metabolism of Amlodipine can be increased when combined with Paramethasone. | [DB01483] Barbital: The metabolism of Amlodipine can be increased when combined with Barbital. | [DB01609] Deferasirox: The metabolism of Amlodipine can be increased when combined with Deferasirox. | [DB04905] Tesmilifene: The metabolism of Amlodipine can be increased when combined with Tesmilifene. | [DB04920] Clevidipine: The metabolism of Amlodipine can be increased when combined with Clevidipine. | [DB06273] Tocilizumab: The metabolism of Amlodipine can be increased when combined with Tocilizumab. | [DB06636] Isavuconazonium: The metabolism of Amlodipine can be increased when combined with Isavuconazonium. | [DB06717] Fosaprepitant: The metabolism of Amlodipine can be increased when combined with Fosaprepitant. | [DB06739] Seratrodast: The metabolism of Amlodipine can be increased when combined with Seratrodast. | [DB08881] Vemurafenib: The metabolism of Amlodipine can be increased when combined with Vemurafenib. | [DB08883] Perampanel: The metabolism of Amlodipine can be increased when combined with Perampanel. | [DB08905] Formestane: The metabolism of Amlodipine can be increased when combined with Formestane. | [DB08970] Fluprednidene: The metabolism of Amlodipine can be increased when combined with Fluprednidene. | [DB09001] Barbexaclone: The metabolism of Amlodipine can be increased when combined with Barbexaclone. | [DB09383] Meprednisone: The metabolism of Amlodipine can be increased when combined with Meprednisone. | [DB11487] Dexamethasone isonicotinate: The metabolism of Amlodipine can be increased when combined with Dexamethasone isonicotinate. | [DB11642] Pitolisant: The serum concentration of Amlodipine can be decreased when it is combined with Pitolisant. | [DB11921] Deflazacort: The metabolism of Amlodipine can be increased when combined with Deflazacort. | [DB13003] Cortivazol: The metabolism of Amlodipine can be increased when combined with Cortivazol. | [DB13208] Prednylidene: The metabolism of Amlodipine can be increased when combined with Prednylidene. | [DB13843] Cloprednol: The metabolism of Amlodipine can be increased when combined with Cloprednol. | [DB13867] Fluticasone: The metabolism of Amlodipine can be increased when combined with Fluticasone. | [DB13874] Enasidenib: The metabolism of Amlodipine can be increased when combined with Enasidenib. | [DB13952] Estradiol acetate: The metabolism of Amlodipine can be increased when combined with Estradiol acetate. | [DB13953] Estradiol benzoate: The metabolism of Amlodipine can be increased when combined with Estradiol benzoate. | [DB13954] Estradiol cypionate: The metabolism of Amlodipine can be increased when combined with Estradiol cypionate. | [DB13955] Estradiol dienanthate: The metabolism of Amlodipine can be increased when combined with Estradiol dienanthate. | [DB13956] Estradiol valerate: The metabolism of Amlodipine can be increased when combined with Estradiol valerate. | [DB14512] Mometasone furoate: The metabolism of Amlodipine can be increased when combined with Mometasone furoate. | [DB14539] Hydrocortisone acetate: The metabolism of Amlodipine can be increased when combined with Hydrocortisone acetate. | [DB14545] Hydrocortisone succinate: The metabolism of Amlodipine can be increased when combined with Hydrocortisone succinate. | [DB14568] Ivosidenib: The metabolism of Amlodipine can be increased when combined with Ivosidenib. | [DB14631] Prednisolone phosphate: The metabolism of Amlodipine can be increased when combined with Prednisolone phosphate. | [DB14633] Prednisolone hemisuccinate: The metabolism of Amlodipine can be increased when combined with Prednisolone hemisuccinate. | [DB14646] Prednisone acetate: The metabolism of Amlodipine can be increased when combined with Prednisone acetate. | [DB14652] Clocortolone acetate: The metabolism of Amlodipine can be increased when combined with Clocortolone acetate. | [DB14659] Melengestrol acetate: The metabolism of Amlodipine can be increased when combined with Melengestrol acetate. | [DB14669] Betamethasone phosphate: The metabolism of Amlodipine can be increased when combined with Betamethasone phosphate. | [DB14681] Cortisone: The metabolism of Amlodipine can be increased when combined with Cortisone. | [DB00273] Topiramate: The metabolism of Amlodipine can be increased when combined with Topiramate. | [DB00349] Clobazam: The metabolism of Amlodipine can be increased when combined with Clobazam. | [DB00701] Amprenavir: The metabolism of Amlodipine can be decreased when combined with Amprenavir. | [DB00776] Oxcarbazepine: The metabolism of Amlodipine can be increased when combined with Oxcarbazepine. | [DB14575] Eslicarbazepine: The metabolism of Amlodipine can be increased when combined with Eslicarbazepine. | [DB00794] Primidone: The metabolism of Amlodipine can be increased when combined with Primidone. | [DB06119] Cenobamate: The metabolism of Amlodipine can be increased when combined with Cenobamate. | [DB01013] Clobetasol propionate: The metabolism of Amlodipine can be increased when combined with Clobetasol propionate. | [DB01047] Fluocinonide: The metabolism of Amlodipine can be increased when combined with Fluocinonide. | [DB14540] Hydrocortisone butyrate: The metabolism of Amlodipine can be increased when combined with Hydrocortisone butyrate. | [DB00764] Mometasone: The metabolism of Amlodipine can be increased when combined with Mometasone. | [DB15822] Pralsetinib: The metabolism of Amlodipine can be increased when combined with Pralsetinib. | [DB08971] Fluocortolone: The metabolism of Amlodipine can be increased when combined with Fluocortolone. | [DB15566] Prednisolone acetate: The metabolism of Amlodipine can be increased when combined with Prednisolone acetate. | [DB09095] Difluocortolone: The metabolism of Amlodipine can be increased when combined with Difluocortolone. | [DB08912] Dabrafenib: The metabolism of Amlodipine can be increased when combined with Dabrafenib. | [DB00615] Rifabutin: The metabolism of Amlodipine can be increased when combined with Rifabutin. | [DB00457] Prazosin: The risk or severity of hypotension can be increased when Prazosin is combined with Amlodipine. | [DB01238] Aripiprazole: The risk or severity of hypotension can be increased when Aripiprazole is combined with Amlodipine. | [DB14185] Aripiprazole lauroxil: The risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Amlodipine. | [DB00373] Timolol: The risk or severity of adverse effects can be increased when Amlodipine is combined with Timolol. | [DB00575] Clonidine: The risk or severity of hypotension can be increased when Clonidine is combined with Amlodipine. | [DB00656] Trazodone: Trazodone may decrease the antihypertensive activities of Amlodipine. | [DB01224] Quetiapine: Quetiapine may increase the hypotensive activities of Amlodipine. | [DB11732] Lasmiditan: Lasmiditan may increase the bradycardic activities of Amlodipine. | [DB00388] Phenylephrine: The risk or severity of hypertension can be decreased when Amlodipine is combined with Phenylephrine. | [DB00864] Tacrolimus: Amlodipine may increase the immunosuppressive activities of Tacrolimus. | [DB00877] Sirolimus: Amlodipine may increase the immunosuppressive activities of Sirolimus. | [DB01020] Isosorbide mononitrate: Amlodipine may increase the vasodilatory activities of Isosorbide mononitrate. | [DB00727] Nitroglycerin: Amlodipine may increase the vasodilatory activities of Nitroglycerin. | [DB00883] Isosorbide dinitrate: Amlodipine may increase the vasodilatory activities of Isosorbide dinitrate. | [DB01612] Amyl Nitrite: Amlodipine may increase the vasodilatory activities of Amyl Nitrite. | [DB01613] Erythrityl tetranitrate: Amlodipine may increase the vasodilatory activities of Erythrityl tetranitrate. | [DB06154] Pentaerythritol tetranitrate: Amlodipine may increase the vasodilatory activities of Pentaerythritol tetranitrate. | [DB09401] Isosorbide: Amlodipine may increase the vasodilatory activities of Isosorbide. | [DB13255] Propatyl nitrate: Amlodipine may increase the vasodilatory activities of Propatyl nitrate. | [DB13408] Methylpropylpropanediol dinitrate: Amlodipine may increase the vasodilatory activities of Methylpropylpropanediol dinitrate. | [DB13637] Tenitramine: Amlodipine may increase the vasodilatory activities of Tenitramine. | [DB13719] Trolnitrate: Amlodipine may increase the vasodilatory activities of Trolnitrate. | [DB14049] Nitrate: Amlodipine may increase the vasodilatory activities of Nitrate. | [DB00246] Ziprasidone: Ziprasidone may increase the antihypertensive activities of Amlodipine. | [DB14513] Magnesium: Magnesium can cause a decrease in the absorption of Amlodipine resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB01601] Lopinavir: The serum concentration of Amlodipine can be increased when it is combined with Lopinavir. | [DB00232] Methyclothiazide: The therapeutic efficacy of Amlodipine can be increased when used in combination with Methyclothiazide. | [DB00436] Bendroflumethiazide: The therapeutic efficacy of Amlodipine can be increased when used in combination with Bendroflumethiazide. | [DB00606] Cyclothiazide: The therapeutic efficacy of Amlodipine can be increased when used in combination with Cyclothiazide. | [DB00774] Hydroflumethiazide: The therapeutic efficacy of Amlodipine can be increased when used in combination with Hydroflumethiazide. | [DB00880] Chlorothiazide: The therapeutic efficacy of Amlodipine can be increased when used in combination with Chlorothiazide. | [DB01021] Trichlormethiazide: The therapeutic efficacy of Amlodipine can be increased when used in combination with Trichlormethiazide. | [DB01324] Polythiazide: The therapeutic efficacy of Amlodipine can be increased when used in combination with Polythiazide. | [DB13532] Cyclopenthiazide: The therapeutic efficacy of Amlodipine can be increased when used in combination with Cyclopenthiazide. | [DB00562] Benzthiazide: The therapeutic efficacy of Amlodipine can be increased when used in combination with Benzthiazide. | [DB13430] Mebutizide: The therapeutic efficacy of Amlodipine can be increased when used in combination with Mebutizide. | [DB15861] Buthiazide: The therapeutic efficacy of Amlodipine can be increased when used in combination with Buthiazide. | [DB00502] Haloperidol: The serum concentration of Haloperidol can be increased when it is combined with Amlodipine. | [DB11652] Tucatinib: The metabolism of Tucatinib can be decreased when combined with Amlodipine. | [DB00104] Octreotide: The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Amlodipine. | [DB11932] Abametapir: The serum concentration of Amlodipine can be increased when it is combined with Abametapir. | [DB15762] Satralizumab: The serum concentration of Amlodipine can be decreased when it is combined with Satralizumab. | [DB00935] Oxymetazoline: The therapeutic efficacy of Amlodipine can be decreased when used in combination with Oxymetazoline. | [DB16629] Serdexmethylphenidate: The therapeutic efficacy of Amlodipine can be decreased when used in combination with Serdexmethylphenidate. | [DB06207] Silodosin: The risk or severity of orthostatic hypotension and dizziness can be increased when Amlodipine is combined with Silodosin. | [DB12016] Ponesimod: The risk or severity of bradycardia can be increased when Ponesimod is combined with Amlodipine. | [DB12235] Estetrol: The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Estetrol. | [DB15569] Sotorasib: The serum concentration of Amlodipine can be decreased when it is combined with Sotorasib. | [DB00091] Cyclosporine: The metabolism of Cyclosporine can be decreased when combined with Amlodipine. | [DB08865] Crizotinib: Crizotinib may increase the bradycardic activities of Amlodipine. | [DB00196] Fluconazole: The metabolism of Amlodipine can be decreased when combined with Fluconazole. | [DB01110] Miconazole: The metabolism of Amlodipine can be decreased when combined with Miconazole. | [DB11633] Isavuconazole: The metabolism of Amlodipine can be decreased when combined with Isavuconazole. | [DB00176] Fluvoxamine: The metabolism of Amlodipine can be decreased when combined with Fluvoxamine. | [DB00537] Ciprofloxacin: The metabolism of Amlodipine can be decreased when combined with Ciprofloxacin. | [DB00673] Aprepitant: The metabolism of Amlodipine can be decreased when combined with Aprepitant. | [DB00951] Isoniazid: The metabolism of Amlodipine can be decreased when combined with Isoniazid. | [DB01087] Primaquine: The metabolism of Amlodipine can be decreased when combined with Primaquine. | [DB02703] Fusidic acid: The metabolism of Amlodipine can be decreased when combined with Fusidic acid. | [DB04832] Zimelidine: The metabolism of Amlodipine can be decreased when combined with Zimelidine. | [DB04896] Milnacipran: The metabolism of Amlodipine can be decreased when combined with Milnacipran. | [DB06290] Simeprevir: The metabolism of Amlodipine can be decreased when combined with Simeprevir. | [DB06700] Desvenlafaxine: The metabolism of Amlodipine can be decreased when combined with Desvenlafaxine. | [DB06731] Seproxetine: The metabolism of Amlodipine can be decreased when combined with Seproxetine. | [DB08953] Indalpine: The metabolism of Amlodipine can be decreased when combined with Indalpine. | [DB09048] Netupitant: The metabolism of Amlodipine can be decreased when combined with Netupitant. | [DB11581] Venetoclax: The metabolism of Venetoclax can be decreased when combined with Amlodipine. | [DB14019] Fosnetupitant: The metabolism of Amlodipine can be decreased when combined with Fosnetupitant. | [DB15982] Berotralstat: The metabolism of Amlodipine can be decreased when combined with Berotralstat. | [DB01118] Amiodarone: The metabolism of Amlodipine can be decreased when combined with Amiodarone. | [DB00763] Methimazole: The metabolism of Amlodipine can be decreased when combined with Methimazole. | [DB06595] Midostaurin: The metabolism of Amlodipine can be decreased when combined with Midostaurin. | [DB00503] Ritonavir: The metabolism of Amlodipine can be decreased when combined with Ritonavir. | [DB00582] Voriconazole: The metabolism of Amlodipine can be decreased when combined with Voriconazole. | [DB00705] Delavirdine: The metabolism of Amlodipine can be decreased when combined with Delavirdine. | [DB00836] Loperamide: Amlodipine may increase the arrhythmogenic activities of Loperamide. | [DB01026] Ketoconazole: The metabolism of Amlodipine can be decreased when combined with Ketoconazole. | [DB01072] Atazanavir: The metabolism of Amlodipine can be decreased when combined with Atazanavir. | [DB01149] Nefazodone: The metabolism of Amlodipine can be decreased when combined with Nefazodone. | [DB01167] Itraconazole: The metabolism of Amlodipine can be decreased when combined with Itraconazole. | [DB01263] Posaconazole: The metabolism of Amlodipine can be decreased when combined with Posaconazole. | [DB02520] Ditiocarb: The metabolism of Amlodipine can be decreased when combined with Ditiocarb. | [DB04868] Nilotinib: The metabolism of Amlodipine can be decreased when combined with Nilotinib. | [DB05521] Telaprevir: The metabolism of Amlodipine can be decreased when combined with Telaprevir. | [DB08873] Boceprevir: The serum concentration of Amlodipine can be increased when it is combined with Boceprevir. | [DB09101] Elvitegravir: The metabolism of Amlodipine can be decreased when combined with Elvitegravir. | [DB09118] Stiripentol: The metabolism of Amlodipine can be decreased when combined with Stiripentol. | [DB11730] Ribociclib: The metabolism of Amlodipine can be decreased when combined with Ribociclib. | [DB11779] Danoprevir: The metabolism of Amlodipine can be decreased when combined with Danoprevir. | [DB13179] Troleandomycin: The metabolism of Amlodipine can be decreased when combined with Troleandomycin. | [DB00342] Terfenadine: The metabolism of Amlodipine can be decreased when combined with Terfenadine. | [DB00696] Ergotamine: The metabolism of Amlodipine can be decreased when combined with Ergotamine. | [DB00872] Conivaptan: The metabolism of Amlodipine can be decreased when combined with Conivaptan. | [DB00932] Tipranavir: The metabolism of Amlodipine can be decreased when combined with Tipranavir. | [DB01232] Saquinavir: The metabolism of Amlodipine can be decreased when combined with Saquinavir. | [DB01264] Darunavir: The metabolism of Amlodipine can be decreased when combined with Darunavir. | [DB06448] Lonafarnib: The metabolism of Amlodipine can be decreased when combined with Lonafarnib. | [DB01406] Danazol: The metabolism of Amlodipine can be decreased when combined with Danazol. | [DB00220] Nelfinavir: The metabolism of Amlodipine can be decreased when combined with Nelfinavir. | [DB00224] Indinavir: The metabolism of Amlodipine can be decreased when combined with Indinavir. | [DB00312] Pentobarbital: The metabolism of Amlodipine can be increased when combined with Pentobarbital. | [DB00252] Phenytoin: The metabolism of Phenytoin can be decreased when combined with Amlodipine. | [DB01320] Fosphenytoin: The metabolism of Fosphenytoin can be decreased when combined with Amlodipine. | [DB01174] Phenobarbital: The metabolism of Phenobarbital can be decreased when combined with Amlodipine. | [DB00564] Carbamazepine: The metabolism of Carbamazepine can be decreased when combined with Amlodipine. | [DB00648] Mitotane: The metabolism of Amlodipine can be increased when combined with Mitotane. | [DB01045] Rifampin: The metabolism of Amlodipine can be increased when combined with Rifampicin. | [DB01234] Dexamethasone: The metabolism of Amlodipine can be increased when combined with Dexamethasone. | [DB01323] St. John's Wort: The metabolism of Amlodipine can be increased when combined with St. John's Wort. | [DB08899] Enzalutamide: The serum concentration of Amlodipine can be decreased when it is combined with Enzalutamide. | [DB09280] Lumacaftor: The metabolism of Amlodipine can be increased when combined with Lumacaftor. | [DB11901] Apalutamide: The serum concentration of Amlodipine can be decreased when it is combined with Apalutamide. | [DB12130] Lorlatinib: The metabolism of Amlodipine can be increased when combined with Lorlatinib. | [DB12265] Fexinidazole: The risk or severity of adverse effects can be increased when Amlodipine is combined with Fexinidazole. | [DB11672] Curcumin: The metabolism of Amlodipine can be decreased when combined with Curcumin. | [DB15226] Dasiglucagon: Amlodipine may increase the hypotensive activities of Dasiglucagon. | [DB14960] Somatrogon: The metabolism of Amlodipine can be increased when combined with Somatrogon. | [DB15889] Senna leaf: The therapeutic efficacy of Senna leaf can be decreased when used in combination with Amlodipine. | [DB16236] Mitapivat: The metabolism of Amlodipine can be increased when combined with Mitapivat. | [DB13055] Oteseconazole: The therapeutic efficacy of Oteseconazole can be increased when used in combination with Amlodipine. | [DB14921] Mavacamten: The metabolism of Amlodipine can be increased when combined with Mavacamten. | [DB09185] Viloxazine: The metabolism of Amlodipine can be decreased when combined with Viloxazine. | [DB00619] Imatinib: The serum concentration of Amlodipine can be increased when it is combined with Imatinib. | [DB09517] Sodium ferric gluconate complex: The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Amlodipine. | [DB12214] Luseogliflozin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Luseogliflozin. | [DB12095] Telotristat ethyl: The serum concentration of Amlodipine can be decreased when it is combined with Telotristat ethyl. | [DB12236] Bexagliflozin: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Bexagliflozin. | [DB05084] Abaloparatide: The risk or severity of adverse effects can be increased when Amlodipine is combined with Abaloparatide. | [DB16267] Olutasidenib: The metabolism of Amlodipine can be increased when combined with Olutasidenib. | [DB00208] Ticlopidine: The metabolism of Ticlopidine can be decreased when combined with Amlodipine. | [DB00213] Pantoprazole: The metabolism of Pantoprazole can be decreased when combined with Amlodipine. | [DB00215] Citalopram: Amlodipine may increase the QTc-prolonging activities of Citalopram. | [DB00313] Valproic acid: The metabolism of Valproic acid can be decreased when combined with Amlodipine. | [DB00333] Methadone: The metabolism of Methadone can be decreased when combined with Amlodipine. | [DB00338] Omeprazole: The metabolism of Omeprazole can be decreased when combined with Amlodipine. | [DB00395] Carisoprodol: The metabolism of Carisoprodol can be decreased when combined with Amlodipine. | [DB00396] Progesterone: The metabolism of Progesterone can be decreased when combined with Amlodipine. | [DB00425] Zolpidem: The metabolism of Zolpidem can be decreased when combined with Amlodipine. | [DB00444] Teniposide: The metabolism of Teniposide can be decreased when combined with Amlodipine. | [DB00448] Lansoprazole: The metabolism of Lansoprazole can be decreased when combined with Amlodipine. | [DB00472] Fluoxetine: The metabolism of Fluoxetine can be decreased when combined with Amlodipine. | [DB00518] Albendazole: The metabolism of Albendazole can be decreased when combined with Amlodipine. | [DB00665] Nilutamide: The metabolism of Nilutamide can be decreased when combined with Amlodipine. | [DB00715] Paroxetine: The metabolism of Paroxetine can be decreased when combined with Amlodipine. | [DB00736] Esomeprazole: The metabolism of Esomeprazole can be decreased when combined with Amlodipine. | [DB00783] Estradiol: The metabolism of Estradiol can be decreased when combined with Amlodipine. | [DB00829] Diazepam: The metabolism of Diazepam can be decreased when combined with Amlodipine. | [DB00980] Ramelteon: The metabolism of Ramelteon can be decreased when combined with Amlodipine. | [DB01058] Praziquantel: The metabolism of Praziquantel can be decreased when combined with Amlodipine. | [DB01086] Benzocaine: The metabolism of Benzocaine can be decreased when combined with Amlodipine. | [DB01104] Sertraline: The metabolism of Sertraline can be decreased when combined with Amlodipine. | [DB01129] Rabeprazole: The metabolism of Rabeprazole can be decreased when combined with Amlodipine. | [DB01131] Proguanil: The metabolism of Proguanil can be decreased when combined with Amlodipine. | [DB01175] Escitalopram: The metabolism of Escitalopram can be decreased when combined with Amlodipine. | [DB01259] Lapatinib: The metabolism of Lapatinib can be decreased when combined with Amlodipine. | [DB01418] Acenocoumarol: The metabolism of Acenocoumarol can be decreased when combined with Amlodipine. | [DB04951] Pirfenidone: The metabolism of Pirfenidone can be decreased when combined with Amlodipine. | [DB05351] Dexlansoprazole: The metabolism of Dexlansoprazole can be decreased when combined with Amlodipine. | [DB06414] Etravirine: The metabolism of Etravirine can be decreased when combined with Amlodipine. | [DB06605] Apixaban: The metabolism of Apixaban can be decreased when combined with Amlodipine. | [DB06626] Axitinib: The metabolism of Axitinib can be decreased when combined with Amlodipine. | [DB06697] Artemether: The metabolism of Artemether can be decreased when combined with Amlodipine. | [DB08496] (R)-warfarin: The metabolism of (R)-warfarin can be decreased when combined with Amlodipine. | [DB08864] Rilpivirine: The metabolism of Rilpivirine can be decreased when combined with Amlodipine. | [DB09166] Etizolam: The metabolism of Etizolam can be decreased when combined with Amlodipine. | [DB11689] Selumetinib: The metabolism of Selumetinib can be decreased when combined with Amlodipine. | [DB11823] Esketamine: The metabolism of Esketamine can be decreased when combined with Amlodipine. | [DB12245] Triclabendazole: The metabolism of Triclabendazole can be decreased when combined with Amlodipine. | [DB12474] Lynestrenol: The metabolism of Lynestrenol can be decreased when combined with Amlodipine. | [DB12500] Fedratinib: The serum concentration of Amlodipine can be increased when it is combined with Fedratinib. | [DB13762] Dexrabeprazole: The metabolism of Dexrabeprazole can be decreased when combined with Amlodipine. | [DB14009] Medical Cannabis: The metabolism of Medical Cannabis can be decreased when combined with Amlodipine. | [DB14055] (S)-Warfarin: The metabolism of (S)-Warfarin can be decreased when combined with Amlodipine. | [DB14973] Abrocitinib: The metabolism of Abrocitinib can be decreased when combined with Amlodipine. | [DB14975] Voxelotor: The metabolism of Voxelotor can be decreased when combined with Amlodipine. | [DB15463] Belzutifan: The metabolism of Belzutifan can be decreased when combined with Amlodipine. | [DB05109] Trabectedin: The metabolism of Trabectedin can be decreased when combined with Amlodipine. | [DB00188] Bortezomib: The metabolism of Bortezomib can be decreased when combined with Amlodipine. | [DB00238] Nevirapine: The metabolism of Nevirapine can be decreased when combined with Amlodipine. | [DB00250] Dapsone: The metabolism of Dapsone can be decreased when combined with Amlodipine. | [DB00266] Dicoumarol: The metabolism of Dicoumarol can be decreased when combined with Amlodipine. | [DB00304] Desogestrel: The metabolism of Desogestrel can be decreased when combined with Amlodipine. | [DB00307] Bexarotene: The metabolism of Bexarotene can be decreased when combined with Amlodipine. | [DB00327] Hydromorphone: The metabolism of Hydromorphone can be decreased when combined with Amlodipine. | [DB00470] Dronabinol: The serum concentration of Dronabinol can be increased when it is combined with Amlodipine. | [DB00471] Montelukast: The metabolism of Montelukast can be decreased when combined with Amlodipine. | [DB00495] Zidovudine: The metabolism of Zidovudine can be decreased when combined with Amlodipine. | [DB00514] Dextromethorphan: The metabolism of Dextromethorphan can be decreased when combined with Amlodipine. | [DB00532] Mephenytoin: The metabolism of Mephenytoin can be decreased when combined with Amlodipine. | [DB00549] Zafirlukast: The metabolism of Zafirlukast can be decreased when combined with Amlodipine. | [DB00617] Paramethadione: The metabolism of Paramethadione can be decreased when combined with Amlodipine. | [DB00682] Warfarin: The metabolism of Warfarin can be decreased when combined with Amlodipine. | [DB00744] Zileuton: The metabolism of Zileuton can be decreased when combined with Amlodipine. | [DB00904] Ondansetron: The metabolism of Ondansetron can be decreased when combined with Amlodipine. | [DB00921] Buprenorphine: The metabolism of Buprenorphine can be decreased when combined with Amlodipine. | [DB00946] Phenprocoumon: The metabolism of Phenprocoumon can be decreased when combined with Amlodipine. | [DB00969] Alosetron: The metabolism of Alosetron can be decreased when combined with Amlodipine. | [DB00972] Azelastine: The metabolism of Azelastine can be decreased when combined with Amlodipine. | [DB00977] Ethinylestradiol: The metabolism of Ethinylestradiol can be decreased when combined with Amlodipine. | [DB01036] Tolterodine: The metabolism of Tolterodine can be decreased when combined with Amlodipine. | [DB01075] Diphenhydramine: The metabolism of Diphenhydramine can be decreased when combined with Amlodipine. | [DB01095] Fluvastatin: The metabolism of Fluvastatin can be decreased when combined with Amlodipine. | [DB01097] Leflunomide: The metabolism of Leflunomide can be decreased when combined with Amlodipine. | [DB01156] Bupropion: The metabolism of Bupropion can be decreased when combined with Amlodipine. | [DB01177] Idarubicin: The metabolism of Idarubicin can be decreased when combined with Amlodipine. | [DB01198] Zopiclone: The metabolism of Zopiclone can be decreased when combined with Amlodipine. | [DB01221] Ketamine: The metabolism of Ketamine can be decreased when combined with Amlodipine. | [DB01357] Mestranol: The metabolism of Mestranol can be decreased when combined with Amlodipine. | [DB01544] Flunitrazepam: The metabolism of Flunitrazepam can be decreased when combined with Amlodipine. | [DB03756] Doconexent: The metabolism of Doconexent can be decreased when combined with Amlodipine. | [DB03783] Phenacetin: The metabolism of Phenacetin can be decreased when combined with Amlodipine. | [DB04557] Arachidonic Acid: The metabolism of Arachidonic Acid can be decreased when combined with Amlodipine. | [DB04574] Estrone sulfate: The metabolism of Estrone sulfate can be decreased when combined with Amlodipine. | [DB04665] Coumarin: The metabolism of Coumarin can be decreased when combined with Amlodipine. | [DB04725] Licofelone: The metabolism of Licofelone can be decreased when combined with Amlodipine. | [DB04898] Ximelagatran: The metabolism of Ximelagatran can be decreased when combined with Amlodipine. | [DB04938] Ospemifene: The metabolism of Ospemifene can be decreased when combined with Amlodipine. | [DB05541] Brivaracetam: The metabolism of Brivaracetam can be decreased when combined with Amlodipine. | [DB06209] Prasugrel: The metabolism of Prasugrel can be decreased when combined with Amlodipine. | [DB06370] Indisulam: The metabolism of Indisulam can be decreased when combined with Amlodipine. | [DB06652] Vicriviroc: The metabolism of Vicriviroc can be decreased when combined with Amlodipine. | [DB06738] Ketobemidone: The metabolism of Ketobemidone can be decreased when combined with Amlodipine. | [DB06803] Niclosamide: The metabolism of Niclosamide can be decreased when combined with Amlodipine. | [DB08875] Cabozantinib: The metabolism of Cabozantinib can be decreased when combined with Amlodipine. | [DB11560] Lesinurad: The metabolism of Lesinurad can be decreased when combined with Amlodipine. | [DB11586] Asunaprevir: The metabolism of Asunaprevir can be decreased when combined with Amlodipine. | [DB11614] Rupatadine: The metabolism of Rupatadine can be decreased when combined with Amlodipine. | [DB11757] Istradefylline: The metabolism of Istradefylline can be decreased when combined with Amlodipine. | [DB11963] Dacomitinib: The metabolism of Dacomitinib can be decreased when combined with Amlodipine. | [DB12147] Erdafitinib: The metabolism of Erdafitinib can be decreased when combined with Amlodipine. | [DB13136] Fluindione: The metabolism of Fluindione can be decreased when combined with Amlodipine. | [DB13941] Piperaquine: The metabolism of Piperaquine can be decreased when combined with Amlodipine. | [DB13943] Testosterone cypionate: The metabolism of Testosterone cypionate can be decreased when combined with Amlodipine. | [DB13944] Testosterone enanthate: The metabolism of Testosterone enanthate can be decreased when combined with Amlodipine. | [DB14011] Nabiximols: The metabolism of Nabiximols can be decreased when combined with Amlodipine. | [DB14737] Cannabinol: The metabolism of Cannabinol can be decreased when combined with Amlodipine. | [DB15233] Avapritinib: The metabolism of Avapritinib can be decreased when combined with Amlodipine. | [DB01101] Capecitabine: The metabolism of Capecitabine can be decreased when combined with Amlodipine. | [DB12513] Omaveloxolone: The serum concentration of Amlodipine can be decreased when it is combined with Omaveloxolone. | [DB08820] Ivacaftor: The serum concentration of Amlodipine can be increased when it is combined with Ivacaftor. | [DB16672] Epcoritamab: The serum concentration of Amlodipine can be increased when it is combined with Epcoritamab. | [DB12255] Vadadustat: The serum concentration of Amlodipine can be increased when it is combined with Vadadustat. | [DB16371] Glofitamab: The serum concentration of Amlodipine can be increased when it is combined with Glofitamab. | [DB14924] Ritlecitinib: The serum concentration of Amlodipine can be increased when it is combined with Ritlecitinib. | [DB05467] Palovarotene: The metabolism of Amlodipine can be increased when combined with Palovarotene. | [DB14766] Etrasimod: The risk or severity of QTc prolongation and torsade de pointes can be increased when Etrasimod is combined with Amlodipine. | [DB16826] Repotrectinib: The metabolism of Amlodipine can be increased when combined with Repotrectinib. | [DB11718] Encorafenib: The metabolism of Amlodipine can be increased when combined with Encorafenib. | [DB11967] Binimetinib: The metabolism of Binimetinib can be decreased when combined with Amlodipine. | [DB11679] Fruquintinib: The metabolism of Fruquintinib can be decreased when combined with Amlodipine. | [DB12005] Nirogacestat: The metabolism of Nirogacestat can be decreased when combined with Amlodipine. | [DB11995] Avatrombopag: The metabolism of Avatrombopag can be decreased when combined with Amlodipine. | [DB08827] Lomitapide: The metabolism of Lomitapide can be decreased when combined with Amlodipine. | [DB00207] Azithromycin: The metabolism of Azithromycin can be decreased when combined with Amlodipine. | [DB00454] Meperidine: The metabolism of Meperidine can be decreased when combined with Amlodipine. | [DB00567] Cephalexin: The metabolism of Cephalexin can be decreased when combined with Amlodipine. | [DB00604] Cisapride: The metabolism of Cisapride can be decreased when combined with Amlodipine. | [DB00637] Astemizole: The metabolism of Astemizole can be decreased when combined with Amlodipine. | [DB00717] Norethisterone: The metabolism of Norethisterone can be decreased when combined with Amlodipine. | [DB01039] Fenofibrate: The metabolism of Fenofibrate can be decreased when combined with Amlodipine. | [DB01100] Pimozide: The metabolism of Pimozide can be decreased when combined with Amlodipine. | [DB01431] Allylestrenol: The metabolism of Allylestrenol can be decreased when combined with Amlodipine. | [DB01656] Roflumilast: The metabolism of Roflumilast can be decreased when combined with Amlodipine. | [DB05154] Pretomanid: The metabolism of Pretomanid can be decreased when combined with Amlodipine. | [DB05239] Cobimetinib: The metabolism of Cobimetinib can be decreased when combined with Amlodipine. | [DB05316] Pimavanserin: The metabolism of Pimavanserin can be decreased when combined with Amlodipine. | [DB09030] Vorapaxar: The metabolism of Vorapaxar can be decreased when combined with Amlodipine. | [DB09034] Suvorexant: The metabolism of Suvorexant can be decreased when combined with Amlodipine. | [DB09054] Idelalisib: The metabolism of Idelalisib can be decreased when combined with Amlodipine. | [DB09071] Tasimelteon: The metabolism of Tasimelteon can be decreased when combined with Amlodipine. | [DB09079] Nintedanib: The metabolism of Nintedanib can be decreased when combined with Amlodipine. | [DB09299] Tenofovir alafenamide: The metabolism of Tenofovir alafenamide can be decreased when combined with Amlodipine. | [DB09330] Osimertinib: The metabolism of Osimertinib can be decreased when combined with Amlodipine. | [DB11742] Ebastine: The metabolism of Ebastine can be decreased when combined with Amlodipine. | [DB11886] Infigratinib: The metabolism of Infigratinib can be decreased when combined with Amlodipine. | [DB11952] Duvelisib: The metabolism of Duvelisib can be decreased when combined with Amlodipine. | [DB12015] Alpelisib: The metabolism of Alpelisib can be decreased when combined with Amlodipine. | [DB12141] Gilteritinib: The metabolism of Gilteritinib can be decreased when combined with Amlodipine. | [DB12515] 9-aminocamptothecin: The metabolism of 9-aminocamptothecin can be decreased when combined with Amlodipine. | [DB12825] Lefamulin: The metabolism of Lefamulin can be decreased when combined with Amlodipine. | [DB12887] Tazemetostat: The metabolism of Tazemetostat can be decreased when combined with Amlodipine. | [DB12952] Methylprednisone: The metabolism of Methylprednisone can be decreased when combined with Amlodipine. | [DB15444] Elexacaftor: The metabolism of Elexacaftor can be decreased when combined with Amlodipine. | [DB00277] Theophylline: The metabolism of Theophylline can be decreased when combined with Amlodipine. | [DB00309] Vindesine: The metabolism of Vindesine can be decreased when combined with Amlodipine. | [DB00361] Vinorelbine: The metabolism of Vinorelbine can be decreased when combined with Amlodipine. | [DB00398] Sorafenib: The metabolism of Sorafenib can be decreased when combined with Amlodipine. | [DB00530] Erlotinib: The metabolism of Erlotinib can be decreased when combined with Amlodipine. | [DB00541] Vincristine: The metabolism of Vincristine can be decreased when combined with Amlodipine. | [DB00563] Methotrexate: The metabolism of Methotrexate can be decreased when combined with Amlodipine. | [DB00762] Irinotecan: The metabolism of Irinotecan can be decreased when combined with Amlodipine. | [DB00773] Etoposide: The metabolism of Etoposide can be decreased when combined with Amlodipine. | [DB00997] Doxorubicin: The metabolism of Doxorubicin can be decreased when combined with Amlodipine. | [DB01008] Busulfan: The metabolism of Busulfan can be decreased when combined with Amlodipine. | [DB01128] Bicalutamide: The metabolism of Bicalutamide can be decreased when combined with Amlodipine. | [DB01223] Aminophylline: The metabolism of Aminophylline can be decreased when combined with Amlodipine. | [DB01227] Levacetylmethadol: The metabolism of Levacetylmethadol can be decreased when combined with Amlodipine. | [DB01248] Docetaxel: The metabolism of Docetaxel can be decreased when combined with Amlodipine. | [DB01254] Dasatinib: The metabolism of Dasatinib can be decreased when combined with Amlodipine. | [DB01590] Everolimus: The metabolism of Everolimus can be decreased when combined with Amlodipine. | [DB04572] Thiotepa: The metabolism of Thiotepa can be decreased when combined with Amlodipine. | [DB04845] Ixabepilone: The metabolism of Ixabepilone can be decreased when combined with Amlodipine. | [DB05294] Vandetanib: The metabolism of Vandetanib can be decreased when combined with Amlodipine. | [DB05773] Trastuzumab emtansine: The metabolism of Trastuzumab emtansine can be decreased when combined with Amlodipine. | [DB06176] Romidepsin: The metabolism of Romidepsin can be decreased when combined with Amlodipine. | [DB06287] Temsirolimus: The metabolism of Temsirolimus can be decreased when combined with Amlodipine. | [DB06589] Pazopanib: The metabolism of Pazopanib can be decreased when combined with Amlodipine. | [DB06603] Panobinostat: The metabolism of Panobinostat can be decreased when combined with Amlodipine. | [DB06616] Bosutinib: The metabolism of Bosutinib can be decreased when combined with Amlodipine. | [DB06772] Cabazitaxel: The metabolism of Cabazitaxel can be decreased when combined with Amlodipine. | [DB08870] Brentuximab vedotin: The metabolism of Brentuximab vedotin can be decreased when combined with Amlodipine. | [DB08901] Ponatinib: The metabolism of Ponatinib can be decreased when combined with Amlodipine. | [DB08910] Pomalidomide: The metabolism of Pomalidomide can be decreased when combined with Amlodipine. | [DB09073] Palbociclib: The metabolism of Palbociclib can be decreased when combined with Amlodipine. | [DB09074] Olaparib: The metabolism of Olaparib can be decreased when combined with Amlodipine. | [DB09143] Sonidegib: The metabolism of Sonidegib can be decreased when combined with Amlodipine. | [DB09570] Ixazomib: The metabolism of Ixazomib can be decreased when combined with Amlodipine. | [DB11363] Alectinib: The metabolism of Alectinib can be decreased when combined with Amlodipine. | [DB11641] Vinflunine: The metabolism of Vinflunine can be decreased when combined with Amlodipine. | [DB11703] Acalabrutinib: The metabolism of Acalabrutinib can be decreased when combined with Amlodipine. | [DB11828] Neratinib: The metabolism of Neratinib can be decreased when combined with Amlodipine. | [DB11986] Entrectinib: The metabolism of Entrectinib can be decreased when combined with Amlodipine. | [DB12001] Abemaciclib: The metabolism of Abemaciclib can be decreased when combined with Amlodipine. | [DB12267] Brigatinib: The metabolism of Brigatinib can be decreased when combined with Amlodipine. | [DB12483] Copanlisib: The metabolism of Copanlisib can be decreased when combined with Amlodipine. | [DB12978] Pexidartinib: The metabolism of Pexidartinib can be decreased when combined with Amlodipine. | [DB15035] Zanubrutinib: The metabolism of Zanubrutinib can be decreased when combined with Amlodipine. | [DB15328] Ubrogepant: The serum concentration of Ubrogepant can be increased when it is combined with Amlodipine. | [DB15266] Tovorafenib: The metabolism of Amlodipine can be increased when combined with Tovorafenib. | [DB15059] Aprocitentan: Amlodipine may increase the hypotensive activities of Aprocitentan. | [DB16693] Insulin icodec: The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin icodec. | [DB18847] Deuruxolitinib: The metabolism of Deuruxolitinib can be decreased when combined with Amlodipine. | [DB12390] Seladelpar: The metabolism of Seladelpar can be decreased when combined with Amlodipine. | [DB17097] Vorasidenib: The metabolism of Amlodipine can be increased when combined with Vorasidenib. | [DB19353] Benzgalantamine: Amlodipine may increase the bradycardic activities of Benzgalantamine.",1 mg / mL; 1 mg/1mL; 1.25 mg; 10 MG; 10 mg; 10 mg/1; 10.0 mg; 10.00 mg; 10.000 mg; 1000000 mg; 12.500 mg; 13.8 MG; 13.86 MG; 13.87 MG; 13.88 mg; 13.9 MG; 13868 MG; 14 MG; 1400000 mg; 150.000 mg; 160.000 mg; 2.5 mg; 2.5 mg/1; 2.500 mg; 250000 mg; 40.000 mg; 5 MG/160MG; 5 mg; 5 mg/1; 5. mg; 5.0 mg; 5.00 mg; 5.000 mg; 5.0000 mg; 500000 mg; 6.9 mg; 6.900 mg; 6.93 MG; 6.93 mg; 6.930 mg; 6.9350 mg; 6.94 mg; 6.940 mg; 6.943 mg; 6.95 MG; 6934 MG; 7 MG; 7.5 MG; 75.000 mg; 80.000 mg,Avoid grapefruit products.; Avoid natural licorice.; Take with or without food. The absorption is unaffected by food.
DB00852,Pseudoephedrine,NASAL DECONGESTANTS FOR SYSTEMIC USE; NASAL PREPARATIONS; RESPIRATORY SYSTEM; Sympathomimetics,"[DB00177] Valsartan: Pseudoephedrine may decrease the antihypertensive activities of Valsartan. | [DB00178] Ramipril: Pseudoephedrine may decrease the antihypertensive activities of Ramipril. | [DB00212] Remikiren: Pseudoephedrine may decrease the antihypertensive activities of Remikiren. | [DB00214] Torasemide: Pseudoephedrine may decrease the antihypertensive activities of Torasemide. | [DB00270] Isradipine: Pseudoephedrine may decrease the antihypertensive activities of Isradipine. | [DB00275] Olmesartan: Pseudoephedrine may decrease the antihypertensive activities of Olmesartan. | [DB00310] Chlorthalidone: Pseudoephedrine may decrease the antihypertensive activities of Chlorthalidone. | [DB00325] Nitroprusside: Pseudoephedrine may decrease the antihypertensive activities of Nitroprusside. | [DB00343] Diltiazem: Pseudoephedrine may decrease the antihypertensive activities of Diltiazem. | [DB00350] Minoxidil: Pseudoephedrine may decrease the antihypertensive activities of Minoxidil. | [DB00374] Treprostinil: Pseudoephedrine may decrease the antihypertensive activities of Treprostinil. | [DB00381] Amlodipine: Pseudoephedrine may decrease the antihypertensive activities of Amlodipine. | [DB00393] Nimodipine: Pseudoephedrine may decrease the antihypertensive activities of Nimodipine. | [DB00401] Nisoldipine: Pseudoephedrine may decrease the antihypertensive activities of Nisoldipine. | [DB00436] Bendroflumethiazide: Pseudoephedrine may decrease the antihypertensive activities of Bendroflumethiazide. | [DB00492] Fosinopril: Pseudoephedrine may decrease the antihypertensive activities of Fosinopril. | [DB00519] Trandolapril: Pseudoephedrine may decrease the antihypertensive activities of Trandolapril. | [DB00524] Metolazone: Pseudoephedrine may decrease the antihypertensive activities of Metolazone. | [DB00528] Lercanidipine: Pseudoephedrine may decrease the antihypertensive activities of Lercanidipine. | [DB00542] Benazepril: Pseudoephedrine may decrease the antihypertensive activities of Benazepril. | [DB00559] Bosentan: Pseudoephedrine may decrease the antihypertensive activities of Bosentan. | [DB00584] Enalapril: Pseudoephedrine may decrease the antihypertensive activities of Enalapril. | [DB00606] Cyclothiazide: Pseudoephedrine may decrease the antihypertensive activities of Cyclothiazide. | [DB00616] Candoxatril: Pseudoephedrine may decrease the antihypertensive activities of Candoxatril. | [DB00657] Mecamylamine: Pseudoephedrine may decrease the antihypertensive activities of Mecamylamine. | [DB00678] Losartan: Pseudoephedrine may decrease the antihypertensive activities of Losartan. | [DB00691] Moexipril: Pseudoephedrine may decrease the antihypertensive activities of Moexipril. | [DB00700] Eplerenone: Pseudoephedrine may decrease the antihypertensive activities of Eplerenone. | [DB00722] Lisinopril: Pseudoephedrine may decrease the antihypertensive activities of Lisinopril. | [DB00727] Nitroglycerin: Pseudoephedrine may decrease the antihypertensive activities of Nitroglycerin. | [DB00765] Metyrosine: Pseudoephedrine may decrease the antihypertensive activities of Metyrosine. | [DB00774] Hydroflumethiazide: Pseudoephedrine may decrease the antihypertensive activities of Hydroflumethiazide. | [DB00785] Cryptenamine: Pseudoephedrine may decrease the antihypertensive activities of Cryptenamine. | [DB00790] Perindopril: Pseudoephedrine may decrease the antihypertensive activities of Perindopril. | [DB00796] Candesartan cilexetil: Pseudoephedrine may decrease the antihypertensive activities of Candesartan cilexetil. | [DB00800] Fenoldopam: Pseudoephedrine may decrease the antihypertensive activities of Fenoldopam. | [DB00808] Indapamide: Pseudoephedrine may decrease the antihypertensive activities of Indapamide. | [DB00820] Tadalafil: Pseudoephedrine may decrease the antihypertensive activities of Tadalafil. | [DB00876] Eprosartan: Pseudoephedrine may decrease the antihypertensive activities of Eprosartan. | [DB00880] Chlorothiazide: Pseudoephedrine may decrease the antihypertensive activities of Chlorothiazide. | [DB00881] Quinapril: Pseudoephedrine may decrease the antihypertensive activities of Quinapril. | [DB00966] Telmisartan: Pseudoephedrine may decrease the antihypertensive activities of Telmisartan. | [DB00968] Methyldopa: Pseudoephedrine may decrease the antihypertensive activities of Methyldopa. | [DB00999] Hydrochlorothiazide: Pseudoephedrine may decrease the antihypertensive activities of Hydrochlorothiazide. | [DB01021] Trichlormethiazide: Pseudoephedrine may decrease the antihypertensive activities of Trichlormethiazide. | [DB01029] Irbesartan: Pseudoephedrine may decrease the antihypertensive activities of Irbesartan. | [DB01054] Nitrendipine: Pseudoephedrine may decrease the antihypertensive activities of Nitrendipine. | [DB01089] Deserpidine: Pseudoephedrine may decrease the antihypertensive activities of Deserpidine. | [DB01090] Pentolinium: Pseudoephedrine may decrease the antihypertensive activities of Pentolinium. | [DB01116] Trimethaphan: Pseudoephedrine may decrease the antihypertensive activities of Trimethaphan. | [DB01119] Diazoxide: Pseudoephedrine may decrease the antihypertensive activities of Diazoxide. | [DB01197] Captopril: Pseudoephedrine may decrease the antihypertensive activities of Captopril. | [DB01240] Epoprostenol: Pseudoephedrine may decrease the antihypertensive activities of Epoprostenol. | [DB01244] Bepridil: Pseudoephedrine may decrease the antihypertensive activities of Bepridil. | [DB01275] Hydralazine: Pseudoephedrine may decrease the antihypertensive activities of Hydralazine. | [DB01324] Polythiazide: Pseudoephedrine may decrease the antihypertensive activities of Polythiazide. | [DB01340] Cilazapril: Pseudoephedrine may decrease the antihypertensive activities of Cilazapril. | [DB01347] Saprisartan: Pseudoephedrine may decrease the antihypertensive activities of Saprisartan. | [DB01348] Spirapril: Pseudoephedrine may decrease the antihypertensive activities of Spirapril. | [DB01388] Mibefradil: Pseudoephedrine may decrease the antihypertensive activities of Mibefradil. | [DB04831] Tienilic acid: Pseudoephedrine may decrease the antihypertensive activities of Tienilic acid. | [DB04840] Debrisoquine: Pseudoephedrine may decrease the antihypertensive activities of Debrisoquine. | [DB06268] Sitaxentan: Pseudoephedrine may decrease the antihypertensive activities of Sitaxentan. | [DB06403] Ambrisentan: Pseudoephedrine may decrease the antihypertensive activities of Ambrisentan. | [DB06445] Diethylnorspermine: Pseudoephedrine may decrease the antihypertensive activities of Diethylnorspermine. | [DB06712] Nilvadipine: Pseudoephedrine may decrease the antihypertensive activities of Nilvadipine. | [DB06762] Pinacidil: Pseudoephedrine may decrease the antihypertensive activities of Pinacidil. | [DB08836] Temocapril: Pseudoephedrine may decrease the antihypertensive activities of Temocapril. | [DB08931] Riociguat: Pseudoephedrine may decrease the antihypertensive activities of Riociguat. | [DB08932] Macitentan: Pseudoephedrine may decrease the antihypertensive activities of Macitentan. | [DB08960] Hexamethonium: Pseudoephedrine may decrease the antihypertensive activities of Hexamethonium. | [DB09026] Aliskiren: Pseudoephedrine may decrease the antihypertensive activities of Aliskiren. | [DB09220] Nicorandil: Pseudoephedrine may decrease the antihypertensive activities of Nicorandil. | [DB09235] Efonidipine: Pseudoephedrine may decrease the antihypertensive activities of Efonidipine. | [DB09236] Lacidipine: Pseudoephedrine may decrease the antihypertensive activities of Lacidipine. | [DB09238] Manidipine: Pseudoephedrine may decrease the antihypertensive activities of Manidipine. | [DB09363] Rauwolfia serpentina root: Pseudoephedrine may decrease the antihypertensive activities of Rauwolfia serpentina root. | [DB09477] Enalaprilat: Pseudoephedrine may decrease the antihypertensive activities of Enalaprilat. | [DB11362] Selexipag: Pseudoephedrine may decrease the antihypertensive activities of Selexipag. | [DB11720] Angiotensin 1-7: Pseudoephedrine may decrease the antihypertensive activities of Angiotensin 1-7. | [DB11783] Imidapril: Pseudoephedrine may decrease the antihypertensive activities of Imidapril. | [DB12054] BQ-123: Pseudoephedrine may decrease the antihypertensive activities of BQ-123. | [DB12766] Cicletanine: Pseudoephedrine may decrease the antihypertensive activities of Cicletanine. | [DB12945] Dihydralazine: Pseudoephedrine may decrease the antihypertensive activities of Dihydralazine. | [DB13166] Zofenopril: Pseudoephedrine may decrease the antihypertensive activities of Zofenopril. | [DB13211] Guanoxan: Pseudoephedrine may decrease the antihypertensive activities of Guanoxan. | [DB13312] Delapril: Pseudoephedrine may decrease the antihypertensive activities of Delapril. | [DB13374] Vincamine: Pseudoephedrine may decrease the antihypertensive activities of Vincamine. | [DB13400] Linsidomine: Pseudoephedrine may decrease the antihypertensive activities of Linsidomine. | [DB13410] Guanoxabenz: Pseudoephedrine may decrease the antihypertensive activities of Guanoxabenz. | [DB13429] Tolonidine: Pseudoephedrine may decrease the antihypertensive activities of Tolonidine. | [DB13435] Endralazine: Pseudoephedrine may decrease the antihypertensive activities of Endralazine. | [DB13452] Cadralazine: Pseudoephedrine may decrease the antihypertensive activities of Cadralazine. | [DB13532] Cyclopenthiazide: Pseudoephedrine may decrease the antihypertensive activities of Cyclopenthiazide. | [DB13575] Bietaserpine: Pseudoephedrine may decrease the antihypertensive activities of Bietaserpine. | [DB13604] Guanazodine: Pseudoephedrine may decrease the antihypertensive activities of Guanazodine. | [DB13631] Methoserpidine: Pseudoephedrine may decrease the antihypertensive activities of Methoserpidine. | [DB13779] Guanoclor: Pseudoephedrine may decrease the antihypertensive activities of Guanoclor. | [DB13801] Muzolimine: Pseudoephedrine may decrease the antihypertensive activities of Muzolimine. | [DB13803] Xipamide: Pseudoephedrine may decrease the antihypertensive activities of Xipamide. | [DB13919] Candesartan: Pseudoephedrine may decrease the antihypertensive activities of Candesartan. | [DB14068] Dexniguldipine: Pseudoephedrine may decrease the antihypertensive activities of Dexniguldipine. | [DB14094] Tocopherylquinone: Pseudoephedrine may decrease the antihypertensive activities of Tocopherylquinone. | [DB14125] Benazeprilat: Pseudoephedrine may decrease the antihypertensive activities of Benazeprilat. | [DB14207] Fosinoprilat: Pseudoephedrine may decrease the antihypertensive activities of Fosinoprilat. | [DB14208] Ramiprilat: Pseudoephedrine may decrease the antihypertensive activities of Ramiprilat. | [DB14213] Perindoprilat: Pseudoephedrine may decrease the antihypertensive activities of Perindoprilat. | [DB14217] Quinaprilat: Pseudoephedrine may decrease the antihypertensive activities of Quinaprilat. | [DB01023] Felodipine: Pseudoephedrine may decrease the antihypertensive activities of Felodipine. | [DB00695] Furosemide: Pseudoephedrine may decrease the antihypertensive activities of Furosemide. | [DB09237] Levamlodipine: Pseudoephedrine may decrease the antihypertensive activities of Levamlodipine. | [DB15861] Buthiazide: Pseudoephedrine may decrease the antihypertensive activities of Buthiazide. | [DB08822] Azilsartan medoxomil: Pseudoephedrine may decrease the antihypertensive activities of Azilsartan medoxomil. | [DB00289] Atomoxetine: The risk or severity of hypertension can be increased when Atomoxetine is combined with Pseudoephedrine. | [DB00593] Ethosuximide: Pseudoephedrine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB08824] Ioflupane I-123: Pseudoephedrine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent. | [DB00601] Linezolid: The risk or severity of hypertension can be increased when Linezolid is combined with Pseudoephedrine. | [DB00794] Primidone: The serum concentration of Primidone can be decreased when it is combined with Pseudoephedrine. | [DB00849] Methylphenobarbital: The serum concentration of Methylphenobarbital can be decreased when it is combined with Pseudoephedrine. | [DB01174] Phenobarbital: The serum concentration of Phenobarbital can be decreased when it is combined with Pseudoephedrine. | [DB00252] Phenytoin: The therapeutic efficacy of Phenytoin can be decreased when used in combination with Pseudoephedrine. | [DB01320] Fosphenytoin: The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Pseudoephedrine. | [DB00895] Benzylpenicilloyl polylysine: Pseudoephedrine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. | [DB00035] Desmopressin: The risk or severity of hypertension can be increased when Desmopressin is combined with Pseudoephedrine. | [DB00091] Cyclosporine: The risk or severity of hypertension can be increased when Cyclosporine is combined with Pseudoephedrine. | [DB00159] Icosapent: The risk or severity of hypertension can be increased when Icosapent is combined with Pseudoephedrine. | [DB00217] Bethanidine: Pseudoephedrine may decrease the antihypertensive activities of Bethanidine. | [DB00221] Isoetharine: The risk or severity of hypertension can be increased when Isoetharine is combined with Pseudoephedrine. | [DB00244] Mesalazine: The risk or severity of hypertension can be increased when Mesalazine is combined with Pseudoephedrine. | [DB00292] Etomidate: The risk or severity of hypertension can be increased when Etomidate is combined with Pseudoephedrine. | [DB00328] Indomethacin: The risk or severity of hypertension can be increased when Indomethacin is combined with Pseudoephedrine. | [DB00422] Methylphenidate: The risk or severity of hypertension can be increased when Methylphenidate is combined with Pseudoephedrine. | [DB00461] Nabumetone: The risk or severity of hypertension can be increased when Nabumetone is combined with Pseudoephedrine. | [DB00465] Ketorolac: The risk or severity of hypertension can be increased when Ketorolac is combined with Pseudoephedrine. | [DB00469] Tenoxicam: The risk or severity of hypertension can be increased when Tenoxicam is combined with Pseudoephedrine. | [DB00482] Celecoxib: The risk or severity of hypertension can be increased when Celecoxib is combined with Pseudoephedrine. | [DB00500] Tolmetin: The risk or severity of hypertension can be increased when Tolmetin is combined with Pseudoephedrine. | [DB00533] Rofecoxib: The risk or severity of hypertension can be increased when Rofecoxib is combined with Pseudoephedrine. | [DB00554] Piroxicam: The risk or severity of hypertension can be increased when Piroxicam is combined with Pseudoephedrine. | [DB00561] Doxapram: The risk or severity of hypertension can be increased when Doxapram is combined with Pseudoephedrine. | [DB00572] Atropine: The risk or severity of hypertension can be increased when Atropine is combined with Pseudoephedrine. | [DB00573] Fenoprofen: The risk or severity of hypertension can be increased when Fenoprofen is combined with Pseudoephedrine. | [DB00575] Clonidine: Pseudoephedrine may decrease the antihypertensive activities of Clonidine. | [DB00580] Valdecoxib: The risk or severity of hypertension can be increased when Valdecoxib is combined with Pseudoephedrine. | [DB00586] Diclofenac: The risk or severity of hypertension can be increased when Diclofenac is combined with Pseudoephedrine. | [DB00605] Sulindac: The risk or severity of hypertension can be increased when Sulindac is combined with Pseudoephedrine. | [DB00629] Guanabenz: Pseudoephedrine may decrease the antihypertensive activities of Guanabenz. | [DB00633] Dexmedetomidine: The risk or severity of hypertension can be increased when Dexmedetomidine is combined with Pseudoephedrine. | [DB00712] Flurbiprofen: The risk or severity of hypertension can be increased when Flurbiprofen is combined with Pseudoephedrine. | [DB00749] Etodolac: The risk or severity of hypertension can be increased when Etodolac is combined with Pseudoephedrine. | [DB00753] Isoflurane: The risk or severity of hypertension can be increased when Isoflurane is combined with Pseudoephedrine. | [DB00784] Mefenamic acid: The risk or severity of hypertension can be increased when Mefenamic acid is combined with Pseudoephedrine. | [DB00795] Sulfasalazine: The risk or severity of hypertension can be increased when Sulfasalazine is combined with Pseudoephedrine. | [DB00812] Phenylbutazone: The risk or severity of hypertension can be increased when Phenylbutazone is combined with Pseudoephedrine. | [DB00814] Meloxicam: The risk or severity of hypertension can be increased when Meloxicam is combined with Pseudoephedrine. | [DB00818] Propofol: The risk or severity of hypertension can be increased when Propofol is combined with Pseudoephedrine. | [DB00821] Carprofen: The risk or severity of hypertension can be increased when Carprofen is combined with Pseudoephedrine. | [DB00861] Diflunisal: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Diflunisal. | [DB00886] Omapatrilat: Pseudoephedrine may decrease the antihypertensive activities of Omapatrilat. | [DB00901] Bitolterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Bitolterol. | [DB00936] Salicylic acid: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Salicylic acid. | [DB00938] Salmeterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Salmeterol. | [DB00939] Meclofenamic acid: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Meclofenamic acid. | [DB00991] Oxaprozin: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Oxaprozin. | [DB01001] Albuterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Salbutamol. | [DB01009] Ketoprofen: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Ketoprofen. | [DB01014] Balsalazide: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Balsalazide. | [DB01018] Guanfacine: Pseudoephedrine may decrease the antihypertensive activities of Guanfacine. | [DB01028] Methoxyflurane: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Methoxyflurane. | [DB01102] Arbutamine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Arbutamine. | [DB01159] Halothane: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Halothane. | [DB01180] Rescinnamine: Pseudoephedrine may decrease the antihypertensive activities of Rescinnamine. | [DB01189] Desflurane: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Desflurane. | [DB01236] Sevoflurane: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Sevoflurane. | [DB01274] Arformoterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Arformoterol. | [DB01283] Lumiracoxib: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Lumiracoxib. | [DB01291] Pirbuterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Pirbuterol. | [DB01363] Ephedra sinica root: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Ephedra sinica root. | [DB01397] Magnesium salicylate: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Magnesium salicylate. | [DB01399] Salsalate: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Salsalate. | [DB01401] Choline magnesium trisalicylate: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Choline magnesium trisalicylate. | [DB01408] Bambuterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Bambuterol. | [DB01419] Antrafenine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Antrafenine. | [DB01424] Aminophenazone: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Aminophenazone. | [DB01435] Antipyrine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Antipyrine. | [DB01472] 4-Methoxyamphetamine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with 4-Methoxyamphetamine. | [DB01579] Phendimetrazine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Phendimetrazine. | [DB01600] Tiaprofenic acid: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Tiaprofenic acid. | [DB01628] Etoricoxib: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Etoricoxib. | [DB02032] Epicaptopril: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Epicaptopril. | [DB02224] Taxifolin: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Taxifolin. | [DB03585] Oxyphenbutazone: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Oxyphenbutazone. | [DB04743] Nimesulide: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Nimesulide. | [DB04812] Benoxaprofen: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Benoxaprofen. | [DB04817] Metamizole: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Metamizole. | [DB04828] Zomepirac: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Zomepirac. | [DB05039] Indacaterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Indacaterol. | [DB05095] Cimicoxib: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Cimicoxib. | [DB05395] Amibegron: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Amibegron. | [DB05562] Naluzotan: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Naluzotan. | [DB06190] Solabegron: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Solabegron. | [DB06690] Nitrous oxide: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Nitrous oxide. | [DB06694] Xylometazoline: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Xylometazoline. | [DB06706] Isometheptene: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Isometheptene. | [DB06711] Naphazoline: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Naphazoline. | [DB06725] Lornoxicam: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Lornoxicam. | [DB06736] Aceclofenac: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Aceclofenac. | [DB06737] Zaltoprofen: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Zaltoprofen. | [DB06763] Saralasin: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Saralasin. | [DB07402] Azapropazone: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Azapropazone. | [DB08439] Parecoxib: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Parecoxib. | [DB08797] Salicylamide: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Salicylamide. | [DB08893] Mirabegron: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Mirabegron. | [DB08925] Adrafinil: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Adrafinil. | [DB08940] Kebuzone: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Kebuzone. | [DB08942] Isoxicam: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Isoxicam. | [DB08951] Indoprofen: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Indoprofen. | [DB08955] Ibuproxam: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Ibuproxam. | [DB08957] Hexoprenaline: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Hexoprenaline. | [DB08976] Floctafenine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Floctafenine. | [DB08981] Fenbufen: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Fenbufen. | [DB08984] Etofenamate: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Etofenamate. | [DB08991] Epirizole: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Epirizole. | [DB09080] Olodaterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Olodaterol. | [DB09082] Vilanterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Vilanterol. | [DB09084] Benzydamine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Benzydamine. | [DB09202] Cirazoline: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Cirazoline. | [DB09213] Dexibuprofen: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Dexibuprofen. | [DB09215] Droxicam: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Droxicam. | [DB09216] Tolfenamic acid: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Tolfenamic acid. | [DB09217] Firocoxib: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Firocoxib. | [DB09218] Clonixin: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Clonixin. | [DB09242] Moxonidine: Pseudoephedrine may decrease the antihypertensive activities of Moxonidine. | [DB09285] Morniflumate: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Morniflumate. | [DB09288] Propacetamol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Propacetamol. | [DB09295] Talniflumate: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Talniflumate. | [DB11278] DL-Methylephedrine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with DL-Methylephedrine. | [DB11373] Amitraz: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Amitraz. | [DB11428] Medetomidine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Medetomidine. | [DB11455] Robenacoxib: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Robenacoxib. | [DB11466] Tepoxalin: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Tepoxalin. | [DB11477] Xylazine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Xylazine. | [DB11518] Flunixin: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Flunixin. | [DB11541] Ractopamine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Ractopamine. | [DB11543] Romifidine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Romifidine. | [DB11556] Detomidine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Detomidine. | [DB11587] Etafedrine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Etafedrine. | [DB11738] Rilmenidine: Pseudoephedrine may decrease the antihypertensive activities of Rilmenidine. | [DB11755] Tetrahydrocannabivarin: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Tetrahydrocannabivarin. | [DB11871] PF-00610355: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with PF-00610355. | [DB12100] Abediterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Abediterol. | [DB12248] Tulobuterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Tulobuterol. | [DB12313] Dopexamine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Dopexamine. | [DB12361] Piclozotan: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Piclozotan. | [DB12371] Siponimod: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Siponimod. | [DB12445] Nitroaspirin: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Nitroaspirin. | [DB12545] Indobufen: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Indobufen. | [DB12610] Ebselen: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Ebselen. | [DB12779] Higenamine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Higenamine. | [DB12846] Reproterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Reproterol. | [DB13001] Tinoridine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Tinoridine. | [DB13139] Levosalbutamol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Levosalbutamol. | [DB13167] Alclofenac: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Alclofenac. | [DB13217] Fentiazac: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Fentiazac. | [DB13232] Suxibuzone: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Suxibuzone. | [DB13251] Octopamine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Octopamine. | [DB13286] Bumadizone: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Bumadizone. | [DB13314] Alminoprofen: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Alminoprofen. | [DB13323] Trichloroethylene: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Trichloroethylene. | [DB13371] Difenpiramide: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Difenpiramide. | [DB13378] Norfenefrine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Norfenefrine. | [DB13398] Oxyfedrine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Oxyfedrine. | [DB13407] Nifenazone: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Nifenazone. | [DB13432] Lonazolac: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Lonazolac. | [DB13453] Xenon: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Xenon. | [DB13481] Tenidap: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Tenidap. | [DB13524] Propyphenazone: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Propyphenazone. | [DB13527] Proglumetacin: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Proglumetacin. | [DB13538] Guacetisal: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Guacetisal. | [DB13544] Ethenzamide: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Ethenzamide. | [DB13559] Rimiterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Rimiterol. | [DB13598] Diethyl ether: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Diethyl ether. | [DB13612] Carbaspirin calcium: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Carbaspirin calcium. | [DB13629] Mofebutazone: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Mofebutazone. | [DB13649] Proquazone: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Proquazone. | [DB13657] Benorilate: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Benorilate. | [DB13722] Pirprofen: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Pirprofen. | [DB13781] Xamoterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Xamoterol. | [DB13783] Acemetacin: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Acemetacin. | [DB13860] Imidazole salicylate: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Imidazole salicylate. | [DB14059] SC-236: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with SC-236. | [DB14060] NS-398: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with NS-398. | [DB14231] Quinoline Yellow WS: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Quinoline Yellow WS. | [DB01591] Solifenacin: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Solifenacin. | [DB09214] Dexketoprofen: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Dexketoprofen. | [DB15685] Selpercatinib: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Selpercatinib. | [DB01216] Finasteride: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Finasteride. | [DB09212] Loxoprofen: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Loxoprofen. | [DB15965] Naxitamab: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Naxitamab. | [DB16629] Serdexmethylphenidate: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Serdexmethylphenidate. | [DB04552] Niflumic acid: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Niflumic acid. | [DB00421] Spironolactone: The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Spironolactone. | [DB00813] Fentanyl: The therapeutic efficacy of Fentanyl can be decreased when used in combination with Pseudoephedrine. | [DB06148] Mianserin: The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Mianserin. | [DB09042] Tedizolid phosphate: Tedizolid phosphate may increase the hypertensive activities of Pseudoephedrine. | [DB00370] Mirtazapine: Pseudoephedrine may increase the serotonergic activities of Mirtazapine. | [DB00295] Morphine: Pseudoephedrine may increase the analgesic activities of Morphine. | [DB00327] Hydromorphone: Pseudoephedrine may increase the analgesic activities of Hydromorphone. | [DB00333] Methadone: Pseudoephedrine may increase the analgesic activities of Methadone. | [DB00497] Oxycodone: Pseudoephedrine may increase the analgesic activities of Oxycodone. | [DB00611] Butorphanol: Pseudoephedrine may increase the analgesic activities of Butorphanol. | [DB00652] Pentazocine: Pseudoephedrine may increase the analgesic activities of Pentazocine. | [DB00704] Naltrexone: Pseudoephedrine may increase the analgesic activities of Naltrexone. | [DB00708] Sufentanil: Pseudoephedrine may increase the analgesic activities of Sufentanil. | [DB00802] Alfentanil: Pseudoephedrine may increase the analgesic activities of Alfentanil. | [DB00844] Nalbuphine: Pseudoephedrine may increase the analgesic activities of Nalbuphine. | [DB00854] Levorphanol: Pseudoephedrine may increase the analgesic activities of Levorphanol. | [DB00899] Remifentanil: Pseudoephedrine may increase the analgesic activities of Remifentanil. | [DB00921] Buprenorphine: Pseudoephedrine may increase the analgesic activities of Buprenorphine. | [DB01081] Diphenoxylate: Pseudoephedrine may increase the analgesic activities of Diphenoxylate. | [DB01192] Oxymorphone: Pseudoephedrine may increase the analgesic activities of Oxymorphone. | [DB01209] Dezocine: Pseudoephedrine may increase the analgesic activities of Dezocine. | [DB01227] Levacetylmethadol: Pseudoephedrine may increase the analgesic activities of Levacetylmethadol. | [DB01433] Methadyl acetate: Pseudoephedrine may increase the analgesic activities of Methadyl acetate. | [DB01450] Dihydroetorphine: Pseudoephedrine may increase the analgesic activities of Dihydroetorphine. | [DB01452] Diamorphine: Pseudoephedrine may increase the analgesic activities of Diamorphine. | [DB01459] Bezitramide: Pseudoephedrine may increase the analgesic activities of Bezitramide. | [DB01466] Ethylmorphine: Pseudoephedrine may increase the analgesic activities of Ethylmorphine. | [DB01497] Etorphine: Pseudoephedrine may increase the analgesic activities of Etorphine. | [DB01529] Dextromoramide: Pseudoephedrine may increase the analgesic activities of Dextromoramide. | [DB01531] Desomorphine: Pseudoephedrine may increase the analgesic activities of Desomorphine. | [DB01535] Carfentanil: Pseudoephedrine may increase the analgesic activities of Carfentanil. | [DB01551] Dihydrocodeine: Pseudoephedrine may increase the analgesic activities of Dihydrocodeine. | [DB01555] Alphacetylmethadol: Pseudoephedrine may increase the analgesic activities of Alphacetylmethadol. | [DB01565] Dihydromorphine: Pseudoephedrine may increase the analgesic activities of Dihydromorphine. | [DB06204] Tapentadol: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Tapentadol. | [DB06738] Ketobemidone: Pseudoephedrine may increase the analgesic activities of Ketobemidone. | [DB08861] DPDPE: Pseudoephedrine may increase the analgesic activities of DPDPE. | [DB09174] Lofentanil: Pseudoephedrine may increase the analgesic activities of Lofentanil. | [DB09272] Eluxadoline: Pseudoephedrine may increase the analgesic activities of Eluxadoline. | [DB11130] Opium: Pseudoephedrine may increase the analgesic activities of Opium. | [DB11609] Normethadone: Pseudoephedrine may increase the analgesic activities of Normethadone. | [DB12492] Piritramide: Pseudoephedrine may increase the analgesic activities of Piritramide. | [DB13160] Alphaprodine: Pseudoephedrine may increase the analgesic activities of Alphaprodine. | [DB13454] Nicomorphine: Pseudoephedrine may increase the analgesic activities of Nicomorphine. | [DB13478] Meptazinol: Pseudoephedrine may increase the analgesic activities of Meptazinol. | [DB13605] Phenoperidine: Pseudoephedrine may increase the analgesic activities of Phenoperidine. | [DB13606] Phenazocine: Pseudoephedrine may increase the analgesic activities of Phenazocine. | [DB13787] Tilidine: Pseudoephedrine may increase the analgesic activities of Tilidine. | [DB15360] Carfentanil, C-11: Pseudoephedrine may increase the analgesic activities of Carfentanil, C-11. | [DB15465] Benzhydrocodone: Pseudoephedrine may increase the analgesic activities of Benzhydrocodone. | [DB09049] Naloxegol: Pseudoephedrine may increase the analgesic activities of Naloxegol. | [DB00245] Benzatropine: Pseudoephedrine may decrease the sedative activities of Benzatropine. | [DB00283] Clemastine: Pseudoephedrine may decrease the sedative activities of Clemastine. | [DB00342] Terfenadine: Pseudoephedrine may decrease the sedative activities of Terfenadine. | [DB00354] Buclizine: Pseudoephedrine may decrease the sedative activities of Buclizine. | [DB00434] Cyproheptadine: Pseudoephedrine may decrease the sedative activities of Cyproheptadine. | [DB00501] Cimetidine: Pseudoephedrine may decrease the sedative activities of Cimetidine. | [DB00557] Hydroxyzine: Pseudoephedrine may decrease the sedative activities of Hydroxyzine. | [DB00568] Cinnarizine: Pseudoephedrine may decrease the sedative activities of Cinnarizine. | [DB00585] Nizatidine: Pseudoephedrine may decrease the sedative activities of Nizatidine. | [DB00737] Meclizine: Pseudoephedrine may decrease the sedative activities of Meclizine. | [DB00767] Benzquinamide: Pseudoephedrine may decrease the sedative activities of Benzquinamide. | [DB00792] Tripelennamine: Pseudoephedrine may decrease the sedative activities of Tripelennamine. | [DB00863] Ranitidine: Pseudoephedrine may decrease the sedative activities of Ranitidine. | [DB00902] Methdilazine: Pseudoephedrine may decrease the sedative activities of Methdilazine. | [DB00920] Ketotifen: Pseudoephedrine may decrease the sedative activities of Ketotifen. | [DB00927] Famotidine: Pseudoephedrine may decrease the sedative activities of Famotidine. | [DB00934] Maprotiline: Pseudoephedrine may decrease the sedative activities of Maprotiline. | [DB00940] Methantheline: Pseudoephedrine may decrease the sedative activities of Methantheline. | [DB00972] Azelastine: Pseudoephedrine may decrease the sedative activities of Azelastine. | [DB00985] Dimenhydrinate: Pseudoephedrine may decrease the sedative activities of Dimenhydrinate. | [DB01071] Mequitazine: Pseudoephedrine may decrease the sedative activities of Mequitazine. | [DB01146] Diphenylpyraline: Pseudoephedrine may decrease the sedative activities of Diphenylpyraline. | [DB01151] Desipramine: Pseudoephedrine may decrease the sedative activities of Desipramine. | [DB01173] Orphenadrine: Pseudoephedrine may decrease the sedative activities of Orphenadrine. | [DB01176] Cyclizine: Pseudoephedrine may decrease the sedative activities of Cyclizine. | [DB01239] Chlorprothixene: Pseudoephedrine may decrease the sedative activities of Chlorprothixene. | [DB01246] Alimemazine: Pseudoephedrine may decrease the sedative activities of Alimemazine. | [DB01615] Aceprometazine: Pseudoephedrine may decrease the sedative activities of Aceprometazine. | [DB01619] Phenindamine: Pseudoephedrine may decrease the sedative activities of Phenindamine. | [DB04819] Methapyrilene: Pseudoephedrine may decrease the sedative activities of Methapyrilene. | [DB04841] Flunarizine: Pseudoephedrine may decrease the sedative activities of Flunarizine. | [DB06016] Cariprazine: Cariprazine may decrease the stimulatory activities of Pseudoephedrine. | [DB06698] Betahistine: Pseudoephedrine may decrease the sedative activities of Betahistine. | [DB08799] Antazoline: Pseudoephedrine may decrease the sedative activities of Antazoline. | [DB08800] Chloropyramine: Pseudoephedrine may decrease the sedative activities of Chloropyramine. | [DB08801] Dimetindene: Pseudoephedrine may decrease the sedative activities of Dimetindene. | [DB08802] Isothipendyl: Pseudoephedrine may decrease the sedative activities of Isothipendyl. | [DB08805] Metiamide: Pseudoephedrine may decrease the sedative activities of Metiamide. | [DB08806] Roxatidine acetate: Pseudoephedrine may decrease the sedative activities of Roxatidine acetate. | [DB08967] Dimetotiazine: Pseudoephedrine may decrease the sedative activities of Dimetotiazine. | [DB09016] Butriptyline: Pseudoephedrine may decrease the sedative activities of Butriptyline. | [DB09167] Dosulepin: Pseudoephedrine may decrease the sedative activities of Dosulepin. | [DB11235] Thonzylamine: Pseudoephedrine may decrease the sedative activities of Thonzylamine. | [DB11591] Bilastine: Pseudoephedrine may decrease the sedative activities of Bilastine. | [DB11614] Rupatadine: Pseudoephedrine may decrease the sedative activities of Rupatadine. | [DB11642] Pitolisant: Pseudoephedrine may decrease the sedative activities of Pitolisant. | [DB11742] Ebastine: Pseudoephedrine may decrease the sedative activities of Ebastine. | [DB12523] Mizolastine: Pseudoephedrine may decrease the sedative activities of Mizolastine. | [DB12770] Lafutidine: Pseudoephedrine may decrease the sedative activities of Lafutidine. | [DB12806] GSK-1004723: Pseudoephedrine may decrease the sedative activities of GSK-1004723. | [DB12877] Oxatomide: Pseudoephedrine may decrease the sedative activities of Oxatomide. | [DB12884] Lavoltidine: Pseudoephedrine may decrease the sedative activities of Lavoltidine. | [DB13466] Deptropine: Pseudoephedrine may decrease the sedative activities of Deptropine. | [DB13679] Dexchlorpheniramine: Pseudoephedrine may decrease the sedative activities of Dexchlorpheniramine. | [DB13711] Tritoqualine: Pseudoephedrine may decrease the sedative activities of Tritoqualine. | [DB13713] Quifenadine: Pseudoephedrine may decrease the sedative activities of Quifenadine. | [DB13760] Niperotidine: Pseudoephedrine may decrease the sedative activities of Niperotidine. | [DB15120] GSK-239512: Pseudoephedrine may decrease the sedative activities of GSK-239512. | [DB15192] ABT-288: Pseudoephedrine may decrease the sedative activities of ABT-288. | [DB00246] Ziprasidone: Pseudoephedrine may decrease the sedative activities of Ziprasidone. | [DB00321] Amitriptyline: Pseudoephedrine may decrease the sedative activities of Amitriptyline. | [DB00334] Olanzapine: Pseudoephedrine may decrease the sedative activities of Olanzapine. | [DB00363] Clozapine: Pseudoephedrine may decrease the sedative activities of Clozapine. | [DB00420] Promazine: Pseudoephedrine may decrease the sedative activities of Promazine. | [DB00458] Imipramine: Pseudoephedrine may decrease the sedative activities of Imipramine. | [DB00540] Nortriptyline: Pseudoephedrine may decrease the sedative activities of Nortriptyline. | [DB00543] Amoxapine: Pseudoephedrine may decrease the sedative activities of Amoxapine. | [DB00726] Trimipramine: Pseudoephedrine may decrease the sedative activities of Trimipramine. | [DB00734] Risperidone: Pseudoephedrine may decrease the sedative activities of Risperidone. | [DB00777] Propiomazine: Pseudoephedrine may decrease the sedative activities of Propiomazine. | [DB01142] Doxepin: Pseudoephedrine may decrease the sedative activities of Doxepin. | [DB01224] Quetiapine: Pseudoephedrine may decrease the sedative activities of Quetiapine. | [DB01238] Aripiprazole: Pseudoephedrine may decrease the sedative activities of Aripiprazole. | [DB01403] Methotrimeprazine: Pseudoephedrine may decrease the sedative activities of Methotrimeprazine. | [DB01624] Zuclopenthixol: Pseudoephedrine may decrease the sedative activities of Zuclopenthixol. | [DB04946] Iloperidone: Pseudoephedrine may decrease the sedative activities of Iloperidone. | [DB06153] Pizotifen: Pseudoephedrine may decrease the sedative activities of Pizotifen. | [DB06216] Asenapine: Pseudoephedrine may decrease the sedative activities of Asenapine. | [DB06678] Esmirtazapine: Pseudoephedrine may decrease the sedative activities of Esmirtazapine. | [DB14185] Aripiprazole lauroxil: Pseudoephedrine may decrease the sedative activities of Aripiprazole lauroxil. | [DB01084] Emedastine: Pseudoephedrine may decrease the sedative activities of Emedastine. | [DB04890] Bepotastine: Pseudoephedrine may decrease the sedative activities of Bepotastine. | [DB09007] Chlorphenoxamine: Pseudoephedrine may decrease the sedative activities of Chlorphenoxamine. | [DB00277] Theophylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Theophylline. | [DB00651] Dyphylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Dyphylline. | [DB00806] Pentoxifylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Pentoxifylline. | [DB01033] Mercaptopurine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Mercaptopurine. | [DB01223] Aminophylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Aminophylline. | [DB01303] Oxtriphylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Oxtriphylline. | [DB01412] Theobromine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Theobromine. | [DB01482] Fenethylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Fenethylline. | [DB01667] 8-azaguanine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 8-azaguanine. | [DB01978] 7,9-Dimethylguanine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 7,9-Dimethylguanine. | [DB02134] Xanthine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Xanthine. | [DB02245] 7-Deazaguanine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 7-Deazaguanine. | [DB02377] Guanine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Guanine. | [DB02489] 9-Methylguanine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 9-Methylguanine. | [DB02568] Peldesine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Peldesine. | [DB04076] Hypoxanthine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Hypoxanthine. | [DB04356] 9-Deazaguanine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 9-Deazaguanine. | [DB06479] Propentofylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Propentofylline. | [DB06575] Valomaciclovir: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Valomaciclovir. | [DB07954] 3-isobutyl-1-methyl-7H-xanthine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 3-isobutyl-1-methyl-7H-xanthine. | [DB08844] Uric acid: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Uric acid. | [DB09273] Doxofylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Doxofylline. | [DB11919] 6-O-benzylguanine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 6-O-benzylguanine. | [DB12406] Lisofylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Lisofylline. | [DB12531] Lobucavir: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Lobucavir. | [DB12926] Cafedrine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Cafedrine. | [DB13203] Bamifylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Bamifylline. | [DB13449] Proxyphylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Proxyphylline. | [DB13573] Acefylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Acefylline. | [DB13592] Etamiphylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Etamiphylline. | [DB13634] Pentifylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Pentifylline. | [DB13812] Bufylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Bufylline. | [DB14018] Bromotheophylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Bromotheophylline. | [DB14029] Furafylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Furafylline. | [DB14132] 8-chlorotheophylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 8-chlorotheophylline. | [DB15122] PCS-499: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with PCS-499. | [DB06704] Iobenguane: Pseudoephedrine can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB06799] Methenamine: The serum concentration of Pseudoephedrine can be decreased when it is combined with Methenamine. | [DB00247] Methysergide: Methysergide may increase the hypertensive and vasoconstricting activities of Pseudoephedrine. | [DB00248] Cabergoline: Cabergoline may increase the hypertensive and vasoconstricting activities of Pseudoephedrine. | [DB00353] Methylergometrine: Methylergometrine may increase the hypertensive and vasoconstricting activities of Pseudoephedrine. | [DB00589] Lisuride: Lisuride may increase the hypertensive and vasoconstricting activities of Pseudoephedrine. | [DB01186] Pergolide: Pergolide may increase the hypertensive and vasoconstricting activities of Pseudoephedrine. | [DB01253] Ergometrine: Ergometrine may increase the hypertensive and vasoconstricting activities of Pseudoephedrine. | [DB04829] Lysergic acid diethylamide: Lysergic acid diethylamide may increase the hypertensive and vasoconstricting activities of Pseudoephedrine. | [DB11273] Dihydroergocornine: Dihydroergocornine may increase the hypertensive and vasoconstricting activities of Pseudoephedrine. | [DB13385] Dihydroergocryptine: Dihydroergocryptine may increase the hypertensive and vasoconstricting activities of Pseudoephedrine. | [DB13399] Terguride: Terguride may increase the hypertensive and vasoconstricting activities of Pseudoephedrine. | [DB13520] Metergoline: Metergoline may increase the hypertensive and vasoconstricting activities of Pseudoephedrine. | [DB09241] Methylene blue: Pseudoephedrine may increase the serotonergic activities of Methylene blue. | [DB00030] Insulin human: The therapeutic efficacy of Insulin human can be decreased when used in combination with Pseudoephedrine. | [DB00046] Insulin lispro: The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Pseudoephedrine. | [DB00047] Insulin glargine: The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Pseudoephedrine. | [DB00071] Insulin pork: The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pseudoephedrine. | [DB00197] Troglitazone: The therapeutic efficacy of Troglitazone can be decreased when used in combination with Pseudoephedrine. | [DB00222] Glimepiride: The therapeutic efficacy of Glimepiride can be decreased when used in combination with Pseudoephedrine. | [DB00263] Sulfisoxazole: The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Pseudoephedrine. | [DB00280] Disopyramide: The therapeutic efficacy of Disopyramide can be decreased when used in combination with Pseudoephedrine. | [DB00284] Acarbose: The therapeutic efficacy of Acarbose can be decreased when used in combination with Pseudoephedrine. | [DB00359] Sulfadiazine: The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Pseudoephedrine. | [DB00412] Rosiglitazone: The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Pseudoephedrine. | [DB00414] Acetohexamide: The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Pseudoephedrine. | [DB00468] Quinine: The therapeutic efficacy of Quinine can be decreased when used in combination with Pseudoephedrine. | [DB00491] Miglitol: The therapeutic efficacy of Miglitol can be decreased when used in combination with Pseudoephedrine. | [DB00672] Chlorpropamide: The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Pseudoephedrine. | [DB00731] Nateglinide: The therapeutic efficacy of Nateglinide can be decreased when used in combination with Pseudoephedrine. | [DB00738] Pentamidine: The therapeutic efficacy of Pentamidine can be decreased when used in combination with Pseudoephedrine. | [DB00834] Mifepristone: The therapeutic efficacy of Mifepristone can be decreased when used in combination with Pseudoephedrine. | [DB00839] Tolazamide: The therapeutic efficacy of Tolazamide can be decreased when used in combination with Pseudoephedrine. | [DB00912] Repaglinide: The therapeutic efficacy of Repaglinide can be decreased when used in combination with Pseudoephedrine. | [DB00914] Phenformin: The therapeutic efficacy of Phenformin can be decreased when used in combination with Pseudoephedrine. | [DB01015] Sulfamethoxazole: The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Pseudoephedrine. | [DB01067] Glipizide: The therapeutic efficacy of Glipizide can be decreased when used in combination with Pseudoephedrine. | [DB01120] Gliclazide: The therapeutic efficacy of Gliclazide can be decreased when used in combination with Pseudoephedrine. | [DB01124] Tolbutamide: The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Pseudoephedrine. | [DB01132] Pioglitazone: The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Pseudoephedrine. | [DB01251] Gliquidone: The therapeutic efficacy of Gliquidone can be decreased when used in combination with Pseudoephedrine. | [DB01252] Mitiglinide: The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Pseudoephedrine. | [DB01261] Sitagliptin: The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Pseudoephedrine. | [DB01268] Sunitinib: The therapeutic efficacy of Sunitinib can be decreased when used in combination with Pseudoephedrine. | [DB01276] Exenatide: The therapeutic efficacy of Exenatide can be decreased when used in combination with Pseudoephedrine. | [DB01277] Mecasermin: The therapeutic efficacy of Mecasermin can be decreased when used in combination with Pseudoephedrine. | [DB01278] Pramlintide: The therapeutic efficacy of Pramlintide can be decreased when used in combination with Pseudoephedrine. | [DB01289] Glisoxepide: The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Pseudoephedrine. | [DB01306] Insulin aspart: The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Pseudoephedrine. | [DB01307] Insulin detemir: The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Pseudoephedrine. | [DB01309] Insulin glulisine: The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Pseudoephedrine. | [DB01382] Glymidine: The therapeutic efficacy of Glymidine can be decreased when used in combination with Pseudoephedrine. | [DB01700] AICA ribonucleotide: The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Pseudoephedrine. | [DB04830] Buformin: The therapeutic efficacy of Buformin can be decreased when used in combination with Pseudoephedrine. | [DB04876] Vildagliptin: The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Pseudoephedrine. | [DB04878] Voglibose: The therapeutic efficacy of Voglibose can be decreased when used in combination with Pseudoephedrine. | [DB05115] NN344: The therapeutic efficacy of NN344 can be decreased when used in combination with Pseudoephedrine. | [DB06011] AMG-222: The therapeutic efficacy of AMG-222 can be decreased when used in combination with Pseudoephedrine. | [DB06127] Bisegliptin: The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Pseudoephedrine. | [DB06203] Alogliptin: The therapeutic efficacy of Alogliptin can be decreased when used in combination with Pseudoephedrine. | [DB06292] Dapagliflozin: The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Pseudoephedrine. | [DB06335] Saxagliptin: The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Pseudoephedrine. | [DB06655] Liraglutide: The therapeutic efficacy of Liraglutide can be decreased when used in combination with Pseudoephedrine. | [DB08382] Gosogliptin: The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Pseudoephedrine. | [DB08882] Linagliptin: The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pseudoephedrine. | [DB08907] Canagliflozin: The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pseudoephedrine. | [DB08962] Glibornuride: The therapeutic efficacy of Glibornuride can be decreased when used in combination with Pseudoephedrine. | [DB09022] Benfluorex: The therapeutic efficacy of Benfluorex can be decreased when used in combination with Pseudoephedrine. | [DB09038] Empagliflozin: The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pseudoephedrine. | [DB09043] Albiglutide: The therapeutic efficacy of Albiglutide can be decreased when used in combination with Pseudoephedrine. | [DB09045] Dulaglutide: The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Pseudoephedrine. | [DB09198] Lobeglitazone: The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Pseudoephedrine. | [DB09199] Netoglitazone: The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Pseudoephedrine. | [DB09200] Rivoglitazone: The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Pseudoephedrine. | [DB09201] Ciglitazone: The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Pseudoephedrine. | [DB09265] Lixisenatide: The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Pseudoephedrine. | [DB09456] Insulin beef: The therapeutic efficacy of Insulin beef can be decreased when used in combination with Pseudoephedrine. | [DB09564] Insulin degludec: The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Pseudoephedrine. | [DB11567] Insulin peglispro: The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Pseudoephedrine. | [DB11568] Insulin tregopil: The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Pseudoephedrine. | [DB11698] Ipragliflozin: The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Pseudoephedrine. | [DB11723] Dutogliptin: The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Pseudoephedrine. | [DB11780] Allicin: The therapeutic efficacy of Allicin can be decreased when used in combination with Pseudoephedrine. | [DB11824] Tofogliflozin: The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Pseudoephedrine. | [DB11827] Ertugliflozin: The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Pseudoephedrine. | [DB11898] 2,4-thiazolidinedione: The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Pseudoephedrine. | [DB11950] Teneligliptin: The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Pseudoephedrine. | [DB11992] Omarigliptin: The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Pseudoephedrine. | [DB12268] Carmegliptin: The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Pseudoephedrine. | [DB12412] Gemigliptin: The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Pseudoephedrine. | [DB12417] Anagliptin: The therapeutic efficacy of Anagliptin can be decreased when used in combination with Pseudoephedrine. | [DB12625] Evogliptin: The therapeutic efficacy of Evogliptin can be decreased when used in combination with Pseudoephedrine. | [DB12713] Sotagliflozin: The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Pseudoephedrine. | [DB12781] Balaglitazone: The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Pseudoephedrine. | [DB12935] Remogliflozin etabonate: The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Pseudoephedrine. | [DB13406] Carbutamide: The therapeutic efficacy of Carbutamide can be decreased when used in combination with Pseudoephedrine. | [DB13446] Guar gum: The therapeutic efficacy of Guar gum can be decreased when used in combination with Pseudoephedrine. | [DB13675] Metahexamide: The therapeutic efficacy of Metahexamide can be decreased when used in combination with Pseudoephedrine. | [DB13928] Semaglutide: The therapeutic efficacy of Semaglutide can be decreased when used in combination with Pseudoephedrine. | [DB14027] Taspoglutide: The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Pseudoephedrine. | [DB14035] Englitazone: The therapeutic efficacy of Englitazone can be decreased when used in combination with Pseudoephedrine. | [DB15171] Tirzepatide: The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Pseudoephedrine. | [DB15217] Gastric inhibitory polypeptide: The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Pseudoephedrine. | [DB00372] Thiethylperazine: Thiethylperazine may decrease the stimulatory activities of Pseudoephedrine. | [DB00391] Sulpiride: Sulpiride may decrease the stimulatory activities of Pseudoephedrine. | [DB00409] Remoxipride: Remoxipride may decrease the stimulatory activities of Pseudoephedrine. | [DB00433] Prochlorperazine: Prochlorperazine may decrease the stimulatory activities of Pseudoephedrine. | [DB00508] Triflupromazine: Triflupromazine may decrease the stimulatory activities of Pseudoephedrine. | [DB00623] Fluphenazine: Fluphenazine may decrease the stimulatory activities of Pseudoephedrine. | [DB00680] Moricizine: Moricizine may decrease the stimulatory activities of Pseudoephedrine. | [DB00850] Perphenazine: Perphenazine may decrease the stimulatory activities of Pseudoephedrine. | [DB00933] Mesoridazine: Mesoridazine may decrease the stimulatory activities of Pseudoephedrine. | [DB01063] Acetophenazine: Acetophenazine may decrease the stimulatory activities of Pseudoephedrine. | [DB01618] Molindone: Molindone may decrease the stimulatory activities of Pseudoephedrine. | [DB01621] Pipotiazine: Pipotiazine may decrease the stimulatory activities of Pseudoephedrine. | [DB01623] Thiothixene: Thiothixene may decrease the stimulatory activities of Pseudoephedrine. | [DB04872] Osanetant: Osanetant may decrease the stimulatory activities of Pseudoephedrine. | [DB04888] Bifeprunox: Bifeprunox may decrease the stimulatory activities of Pseudoephedrine. | [DB05687] BL-1020: BL-1020 may decrease the stimulatory activities of Pseudoephedrine. | [DB06077] Lumateperone: Lumateperone may decrease the stimulatory activities of Pseudoephedrine. | [DB06288] Amisulpride: Amisulpride may decrease the stimulatory activities of Pseudoephedrine. | [DB08922] Perospirone: Perospirone may decrease the stimulatory activities of Pseudoephedrine. | [DB08927] Amperozide: Amperozide may decrease the stimulatory activities of Pseudoephedrine. | [DB09000] Cyamemazine: Cyamemazine may decrease the stimulatory activities of Pseudoephedrine. | [DB09224] Melperone: Melperone may decrease the stimulatory activities of Pseudoephedrine. | [DB09226] Brilaroxazine: Brilaroxazine may decrease the stimulatory activities of Pseudoephedrine. | [DB11376] Azaperone: Azaperone may decrease the stimulatory activities of Pseudoephedrine. | [DB11540] Propiopromazine: Propiopromazine may decrease the stimulatory activities of Pseudoephedrine. | [DB12093] Tetrahydropalmatine: Tetrahydropalmatine may decrease the stimulatory activities of Pseudoephedrine. | [DB12273] Ecopipam: Ecopipam may decrease the stimulatory activities of Pseudoephedrine. | [DB12401] Bromperidol: Bromperidol may decrease the stimulatory activities of Pseudoephedrine. | [DB12518] Raclopride: Raclopride may decrease the stimulatory activities of Pseudoephedrine. | [DB12710] Perazine: Perazine may decrease the stimulatory activities of Pseudoephedrine. | [DB12867] Benperidol: Benperidol may decrease the stimulatory activities of Pseudoephedrine. | [DB12958] Prothipendyl: Prothipendyl may decrease the stimulatory activities of Pseudoephedrine. | [DB13025] Tiapride: Tiapride may decrease the stimulatory activities of Pseudoephedrine. | [DB13213] Butaperazine: Butaperazine may decrease the stimulatory activities of Pseudoephedrine. | [DB13256] Clothiapine: Clothiapine may decrease the stimulatory activities of Pseudoephedrine. | [DB13273] Sultopride: Sultopride may decrease the stimulatory activities of Pseudoephedrine. | [DB13382] Chlorproethazine: Chlorproethazine may decrease the stimulatory activities of Pseudoephedrine. | [DB13403] Oxypertine: Oxypertine may decrease the stimulatory activities of Pseudoephedrine. | [DB13420] Thiazinam: Thiazinam may decrease the stimulatory activities of Pseudoephedrine. | [DB13523] Veralipride: Veralipride may decrease the stimulatory activities of Pseudoephedrine. | [DB13552] Trifluperidol: Trifluperidol may decrease the stimulatory activities of Pseudoephedrine. | [DB13554] Moperone: Moperone may decrease the stimulatory activities of Pseudoephedrine. | [DB13557] Thiopropazate: Thiopropazate may decrease the stimulatory activities of Pseudoephedrine. | [DB13665] Fluanisone: Fluanisone may decrease the stimulatory activities of Pseudoephedrine. | [DB13676] Mosapramine: Mosapramine may decrease the stimulatory activities of Pseudoephedrine. | [DB13784] Dixyrazine: Dixyrazine may decrease the stimulatory activities of Pseudoephedrine. | [DB13791] Penfluridol: Penfluridol may decrease the stimulatory activities of Pseudoephedrine. | [DB13841] Clopenthixol: Clopenthixol may decrease the stimulatory activities of Pseudoephedrine. | [DB14651] Perphenazine enanthate: Perphenazine enanthate may decrease the stimulatory activities of Pseudoephedrine. | [DB01356] Lithium cation: Lithium cation may decrease the stimulatory activities of Pseudoephedrine. | [DB16021] Levosulpiride: Levosulpiride may decrease the stimulatory activities of Pseudoephedrine. | [DB00211] Midodrine: The risk or severity of hypertension can be increased when Midodrine is combined with Pseudoephedrine. | [DB00397] Phenylpropanolamine: The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Pseudoephedrine. | [DB00610] Metaraminol: The risk or severity of hypertension can be increased when Metaraminol is combined with Pseudoephedrine. | [DB00723] Methoxamine: The risk or severity of hypertension can be increased when Methoxamine is combined with Pseudoephedrine. | [DB00816] Orciprenaline: The risk or severity of hypertension can be increased when Orciprenaline is combined with Pseudoephedrine. | [DB00830] Phenmetrazine: The risk or severity of hypertension can be increased when Phenmetrazine is combined with Pseudoephedrine. | [DB00841] Dobutamine: The risk or severity of hypertension can be increased when Dobutamine is combined with Pseudoephedrine. | [DB00867] Ritodrine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Ritodrine. | [DB00871] Terbutaline: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Terbutaline. | [DB01064] Isoprenaline: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Isoprenaline. | [DB01288] Fenoterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Fenoterol. | [DB01366] Procaterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Procaterol. | [DB01407] Clenbuterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Clenbuterol. | [DB01566] Methylenedioxyethamphetamine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Methylenedioxyethamphetamine. | [DB06152] Nylidrin: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Nylidrin. | [DB06764] Tetryzoline: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Tetryzoline. | [DB08841] Tyramine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Tyramine. | [DB08941] Isoxsuprine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Isoxsuprine. | [DB08985] Etilefrine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Etilefrine. | [DB09203] Synephrine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Synephrine. | [DB13064] Tramazoline: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Tramazoline. | [DB13341] Fenozolone: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Fenozolone. | [DB13692] Tretoquinol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Tretoquinol. | [DB13777] Prenalterol: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Prenalterol. | [DB13852] Mefenorex: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Mefenorex. | [DB00206] Reserpine: The serum concentration of Pseudoephedrine can be decreased when it is combined with Reserpine. | [DB00142] Glutamic acid: The serum concentration of Pseudoephedrine can be decreased when it is combined with Glutamic acid. | [DB01170] Guanethidine: The serum concentration of Pseudoephedrine can be decreased when it is combined with Guanethidine. | [DB00311] Ethoxzolamide: Ethoxzolamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level. | [DB00703] Methazolamide: Methazolamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level. | [DB00909] Zonisamide: Zonisamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level. | [DB01144] Diclofenamide: Diclofenamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level. | [DB00470] Dronabinol: The risk or severity of Tachycardia can be increased when Dronabinol is combined with Pseudoephedrine. | [DB00486] Nabilone: The risk or severity of Tachycardia can be increased when Nabilone is combined with Pseudoephedrine. | [DB05077] SLV319: The risk or severity of Tachycardia can be increased when SLV319 is combined with Pseudoephedrine. | [DB06155] Rimonabant: The risk or severity of Tachycardia can be increased when Rimonabant is combined with Pseudoephedrine. | [DB06624] Taranabant: The risk or severity of Tachycardia can be increased when Taranabant is combined with Pseudoephedrine. | [DB11903] GW842166: The risk or severity of Tachycardia can be increased when GW842166 is combined with Pseudoephedrine. | [DB12193] Lenabasum: The risk or severity of Tachycardia can be increased when Ajulemic acid is combined with Pseudoephedrine. | [DB12649] Ibipinabant: The risk or severity of Tachycardia can be increased when Ibipinabant is combined with Pseudoephedrine. | [DB13070] Surinabant: The risk or severity of Tachycardia can be increased when Surinabant is combined with Pseudoephedrine. | [DB13950] WIN 55212-2: The risk or severity of Tachycardia can be increased when WIN 55212-2 is combined with Pseudoephedrine. | [DB14011] Nabiximols: The risk or severity of Tachycardia can be increased when Nabiximols is combined with Pseudoephedrine. | [DB14043] Palmidrol: The risk or severity of Tachycardia can be increased when Palmidrol is combined with Pseudoephedrine. | [DB14737] Cannabinol: The risk or severity of Tachycardia can be increased when Cannabinol is combined with Pseudoephedrine. | [DB00614] Furazolidone: Furazolidone may increase the hypertensive activities of Pseudoephedrine. | [DB00721] Procaine: Procaine may increase the hypertensive activities of Pseudoephedrine. | [DB00752] Tranylcypromine: Tranylcypromine may increase the hypertensive activities of Pseudoephedrine. | [DB00780] Phenelzine: Phenelzine may increase the hypertensive activities of Pseudoephedrine. | [DB00805] Minaprine: Minaprine may increase the hypertensive activities of Pseudoephedrine. | [DB01168] Procarbazine: Procarbazine may increase the hypertensive activities of Pseudoephedrine. | [DB01171] Moclobemide: Moclobemide may increase the hypertensive activities of Pseudoephedrine. | [DB01247] Isocarboxazid: Isocarboxazid may increase the hypertensive activities of Pseudoephedrine. | [DB01367] Rasagiline: Rasagiline may increase the hypertensive activities of Pseudoephedrine. | [DB01626] Pargyline: Pargyline may increase the hypertensive activities of Pseudoephedrine. | [DB04017] Clorgiline: Clorgiline may increase the hypertensive activities of Pseudoephedrine. | [DB04818] Iproniazid: Iproniazid may increase the hypertensive activities of Pseudoephedrine. | [DB04820] Nialamide: Nialamide may increase the hypertensive activities of Pseudoephedrine. | [DB06654] Safinamide: Safinamide may increase the hypertensive activities of Pseudoephedrine. | [DB08550] 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline: 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Pseudoephedrine. | [DB09243] Hydracarbazine: Hydracarbazine may increase the hypertensive activities of Pseudoephedrine. | [DB09244] Pirlindole: Pirlindole may increase the hypertensive activities of Pseudoephedrine. | [DB09245] Toloxatone: Toloxatone may increase the hypertensive activities of Pseudoephedrine. | [DB09246] Benmoxin: Benmoxin may increase the hypertensive activities of Pseudoephedrine. | [DB09248] Mebanazine: Mebanazine may increase the hypertensive activities of Pseudoephedrine. | [DB09249] Octamoxin: Octamoxin may increase the hypertensive activities of Pseudoephedrine. | [DB09250] Pheniprazine: Pheniprazine may increase the hypertensive activities of Pseudoephedrine. | [DB09251] Phenoxypropazine: Phenoxypropazine may increase the hypertensive activities of Pseudoephedrine. | [DB09252] Pivhydrazine: Pivhydrazine may increase the hypertensive activities of Pseudoephedrine. | [DB09253] Safrazine: Safrazine may increase the hypertensive activities of Pseudoephedrine. | [DB09254] Caroxazone: Caroxazone may increase the hypertensive activities of Pseudoephedrine. | [DB13875] Harmaline: Harmaline may increase the hypertensive activities of Pseudoephedrine. | [DB13876] Brofaromine: Brofaromine may increase the hypertensive activities of Pseudoephedrine. | [DB01377] Magnesium oxide: The serum concentration of Pseudoephedrine can be increased when it is combined with Magnesium oxide. | [DB01390] Sodium bicarbonate: The serum concentration of Pseudoephedrine can be increased when it is combined with Sodium bicarbonate. | [DB06723] Aluminum hydroxide: The serum concentration of Pseudoephedrine can be increased when it is combined with Aluminum hydroxide. | [DB06724] Calcium carbonate: The serum concentration of Pseudoephedrine can be increased when it is combined with Calcium carbonate. | [DB08938] Magaldrate: The serum concentration of Pseudoephedrine can be increased when it is combined with Magaldrate. | [DB09104] Magnesium hydroxide: The serum concentration of Pseudoephedrine can be increased when it is combined with Magnesium hydroxide. | [DB09281] Magnesium trisilicate: The serum concentration of Pseudoephedrine can be increased when it is combined with Magnesium trisilicate. | [DB09481] Magnesium carbonate: The serum concentration of Pseudoephedrine can be increased when it is combined with Magnesium carbonate. | [DB13209] Bismuth subnitrate: The serum concentration of Pseudoephedrine can be increased when it is combined with Bismuth subnitrate. | [DB13249] Magnesium silicate: The serum concentration of Pseudoephedrine can be increased when it is combined with Magnesium silicate. | [DB13280] Aluminium acetoacetate: The serum concentration of Pseudoephedrine can be increased when it is combined with Aluminium acetoacetate. | [DB13322] Hydrotalcite: The serum concentration of Pseudoephedrine can be increased when it is combined with Hydrotalcite. | [DB13486] Magnesium peroxide: The serum concentration of Pseudoephedrine can be increased when it is combined with Magnesium peroxide. | [DB13595] Almasilate: The serum concentration of Pseudoephedrine can be increased when it is combined with Almasilate. | [DB13626] Aluminium glycinate: The serum concentration of Pseudoephedrine can be increased when it is combined with Aluminium glycinate. | [DB13650] Aloglutamol: The serum concentration of Pseudoephedrine can be increased when it is combined with Aloglutamol. | [DB13829] Calcium silicate: The serum concentration of Pseudoephedrine can be increased when it is combined with Calcium silicate. | [DB14517] Aluminium phosphate: The serum concentration of Pseudoephedrine can be increased when it is combined with Aluminium phosphate. | [DB14485] Zinc ascorbate: The serum concentration of Pseudoephedrine can be decreased when it is combined with Zinc ascorbate. | [DB14490] Ferrous ascorbate: The serum concentration of Pseudoephedrine can be decreased when it is combined with Ferrous ascorbate. | [DB14484] Magnesium ascorbate: The serum concentration of Pseudoephedrine can be decreased when it is combined with Magnesium ascorbate. | [DB14486] Niacinamide ascorbate: The serum concentration of Pseudoephedrine can be decreased when it is combined with Niacinamide ascorbate. | [DB08830] Dehydroascorbic acid: The serum concentration of Pseudoephedrine can be decreased when it is combined with Dehydroascorbic acid. | [DB14482] Sodium ascorbate: The serum concentration of Pseudoephedrine can be decreased when it is combined with Sodium ascorbate. | [DB14483] Calcium ascorbate: The serum concentration of Pseudoephedrine can be decreased when it is combined with Calcium ascorbate. | [DB14502] Sodium phosphate, dibasic: The serum concentration of Pseudoephedrine can be decreased when it is combined with Sodium phosphate, dibasic. | [DB09449] Sodium phosphate, monobasic: The serum concentration of Pseudoephedrine can be decreased when it is combined with Sodium phosphate, monobasic. | [DB01037] Selegiline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Selegiline. | [DB13967] Patent Blue: The risk or severity of hypotension can be increased when Patent Blue is combined with Pseudoephedrine. | [DB04272] Citric acid: The excretion of Pseudoephedrine can be decreased when combined with Citric acid. | [DB09125] Potassium citrate: The excretion of Pseudoephedrine can be decreased when combined with Potassium citrate. | [DB09459] L-tartaric acid: The excretion of Pseudoephedrine can be decreased when combined with L-tartaric acid. | [DB00315] Zolmitriptan: The metabolism of Zolmitriptan can be decreased when combined with Pseudoephedrine. | [DB00388] Phenylephrine: The metabolism of Phenylephrine can be decreased when combined with Pseudoephedrine. | [DB00669] Sumatriptan: The metabolism of Sumatriptan can be decreased when combined with Pseudoephedrine. | [DB00918] Almotriptan: The metabolism of Almotriptan can be decreased when combined with Pseudoephedrine. | [DB00952] Naratriptan: The metabolism of Naratriptan can be decreased when combined with Pseudoephedrine. | [DB00953] Rizatriptan: The metabolism of Rizatriptan can be decreased when combined with Pseudoephedrine. | [DB00988] Dopamine: The metabolism of Dopamine can be decreased when combined with Pseudoephedrine. | [DB12329] Eravacycline: The metabolism of Eravacycline can be decreased when combined with Pseudoephedrine. | [DB01445] Bufotenine: The metabolism of Bufotenine can be decreased when combined with Pseudoephedrine. | [DB04889] Bicifadine: The metabolism of Bicifadine can be decreased when combined with Pseudoephedrine. | [DB00150] Tryptophan: The risk or severity of serotonin syndrome can be increased when Tryptophan is combined with Pseudoephedrine. | [DB00176] Fluvoxamine: The risk or severity of serotonin syndrome can be increased when Fluvoxamine is combined with Pseudoephedrine. | [DB00191] Phentermine: The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Pseudoephedrine. | [DB00215] Citalopram: The metabolism of Citalopram can be decreased when combined with Pseudoephedrine. | [DB00216] Eletriptan: The risk or severity of serotonin syndrome can be increased when Eletriptan is combined with Pseudoephedrine. | [DB00285] Venlafaxine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Venlafaxine. | [DB00313] Valproic acid: The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Pseudoephedrine. | [DB00377] Palonosetron: The risk or severity of serotonin syndrome can be increased when Palonosetron is combined with Pseudoephedrine. | [DB00408] Loxapine: Loxapine may decrease the stimulatory activities of Pseudoephedrine. | [DB00476] Duloxetine: Duloxetine may increase the tachycardic activities of Pseudoephedrine. | [DB00490] Buspirone: The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Pseudoephedrine. | [DB00564] Carbamazepine: The risk or severity of serotonin syndrome can be increased when Carbamazepine is combined with Pseudoephedrine. | [DB00579] Mazindol: The risk or severity of serotonin syndrome can be increased when Mazindol is combined with Pseudoephedrine. | [DB00604] Cisapride: The risk or severity of serotonin syndrome can be increased when Cisapride is combined with Pseudoephedrine. | [DB00660] Metaxalone: The risk or severity of serotonin syndrome can be increased when Metaxalone is combined with Pseudoephedrine. | [DB00714] Apomorphine: The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Pseudoephedrine. | [DB00715] Paroxetine: The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Pseudoephedrine. | [DB00757] Dolasetron: The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Pseudoephedrine. | [DB00865] Benzphetamine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Benzphetamine. | [DB00889] Granisetron: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Granisetron. | [DB00904] Ondansetron: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Ondansetron. | [DB00907] Cocaine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Cocaine. | [DB00915] Amantadine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Amantadine. | [DB00937] Diethylpropion: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Diethylpropion. | [DB00951] Isoniazid: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Isoniazid. | [DB00998] Frovatriptan: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Frovatriptan. | [DB01079] Tegaserod: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Tegaserod. | [DB01105] Sibutramine: Sibutramine may increase the tachycardic activities of Pseudoephedrine. | [DB01191] Dexfenfluramine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Dexfenfluramine. | [DB01233] Metoclopramide: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Metoclopramide. | [DB01235] Levodopa: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Levodopa. | [DB01255] Lisdexamfetamine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Lisdexamfetamine. | [DB01323] St. John's Wort: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with St. John's Wort. | [DB01365] Mephentermine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Mephentermine. | [DB01442] MMDA: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with MMDA. | [DB01454] Midomafetamine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Midomafetamine. | [DB01467] 2,5-Dimethoxy-4-ethylamphetamine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with 2,5-Dimethoxy-4-ethylamphetamine. | [DB01484] 4-Bromo-2,5-dimethoxyamphetamine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with 4-Bromo-2,5-dimethoxyamphetamine. | [DB01488] Dimethyltryptamine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Dimethyltryptamine. | [DB01509] Tenamfetamine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Tenamfetamine. | [DB01556] Chlorphentermine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Chlorphentermine. | [DB01576] Dextroamphetamine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Dextroamphetamine. | [DB01577] Metamfetamine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Metamfetamine. | [DB04832] Zimelidine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Zimelidine. | [DB04842] Fluspirilene: Fluspirilene may decrease the stimulatory activities of Pseudoephedrine. | [DB04871] Lorcaserin: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Lorcaserin. | [DB04884] Dapoxetine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Dapoxetine. | [DB04896] Milnacipran: Milnacipran may increase the tachycardic activities of Pseudoephedrine. | [DB04908] Flibanserin: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Flibanserin. | [DB04948] Lofexidine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Lofexidine. | [DB05271] Rotigotine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Rotigotine. | [DB06109] YKP-1358: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with YKP-1358. | [DB06144] Sertindole: Sertindole may decrease the stimulatory activities of Pseudoephedrine. | [DB06684] Vilazodone: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Vilazodone. | [DB06700] Desvenlafaxine: The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Pseudoephedrine. | [DB06701] Dexmethylphenidate: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Dexmethylphenidate. | [DB08167] Methylthioninium: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Methylthioninium. | [DB08810] Cinitapride: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Cinitapride. | [DB08839] Serotonin: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Serotonin. | [DB08918] Levomilnacipran: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Levomilnacipran. | [DB08953] Indalpine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Indalpine. | [DB09061] Cannabidiol: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Cannabidiol. | [DB09068] Vortioxetine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Vortioxetine. | [DB09194] Etoperidone: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Etoperidone. | [DB09223] Blonanserin: Blonanserin may decrease the stimulatory activities of Pseudoephedrine. | [DB09225] Zotepine: Zotepine may decrease the stimulatory activities of Pseudoephedrine. | [DB09286] Pipamperone: Pipamperone may decrease the stimulatory activities of Pseudoephedrine. | [DB09480] Iofetamine I-123: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Iofetamine I-123. | [DB11675] Mosapride: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Mosapride. | [DB12071] Vabicaserin: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Vabicaserin. | [DB12080] Ritobegron: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Ritobegron. | [DB12110] m-Chlorophenylpiperazine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with m-Chlorophenylpiperazine. | [DB12111] MK-212: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with MK-212. | [DB12184] Gepirone: The risk or severity of serotonin syndrome can be increased when Gepirone is combined with Pseudoephedrine. | [DB12693] Ritanserin: Ritanserin may decrease the stimulatory activities of Pseudoephedrine. | [DB12725] Felcisetrag: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with TD-8954. | [DB12833] Tandospirone: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Tandospirone. | [DB12883] Eltoprazine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Eltoprazine. | [DB13108] Mephedrone: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Mephedrone. | [DB13233] Alaproclate: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Alaproclate. | [DB13550] Bifemelane: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Bifemelane. | [DB13624] Methoxyphenamine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Methoxyphenamine. | [DB13703] Gepefrine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Gepefrine. | [DB13910] Valproate bismuth: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Valproate bismuth. | [DB13940] 2,5-Dimethoxy-4-ethylthioamphetamine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine. | [DB13948] N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. | [DB14010] 5-methoxy-N,N-dimethyltryptamine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with 5-methoxy-N,N-dimethyltryptamine. | [DB00924] Cyclobenzaprine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Cyclobenzaprine. | [DB01104] Sertraline: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Sertraline. | [DB00182] Amphetamine: The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Pseudoephedrine. | [DB00822] Disulfiram: The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Disulfiram. | [DB01364] Ephedrine: The therapeutic efficacy of Pseudoephedrine can be increased when used in combination with Ephedrine. | [DB00368] Norepinephrine: The therapeutic efficacy of Pseudoephedrine can be increased when used in combination with Norepinephrine. | [DB00668] Epinephrine: The therapeutic efficacy of Pseudoephedrine can be increased when used in combination with Epinephrine. | [DB06262] Droxidopa: The therapeutic efficacy of Pseudoephedrine can be increased when used in combination with Droxidopa. | [DB06707] Levonordefrin: The therapeutic efficacy of Pseudoephedrine can be increased when used in combination with Levonordefrin. | [DB06814] Protokylol: The therapeutic efficacy of Pseudoephedrine can be increased when used in combination with Protokylol. | [DB11124] Racepinephrine: The therapeutic efficacy of Pseudoephedrine can be increased when used in combination with Racepinephrine. | [DB12927] Theodrenaline: The therapeutic efficacy of Pseudoephedrine can be increased when used in combination with Theodrenaline. | [DB13917] Deoxyepinephrine: The therapeutic efficacy of Pseudoephedrine can be increased when used in combination with Deoxyepinephrine. | [DB00184] Nicotine: The risk or severity of Tachycardia can be increased when Nicotine is combined with Pseudoephedrine. | [DB00209] Trospium: The risk or severity of Tachycardia can be increased when Trospium is combined with Pseudoephedrine. | [DB00219] Oxyphenonium: The risk or severity of Tachycardia can be increased when Oxyphenonium is combined with Pseudoephedrine. | [DB00261] Anagrelide: The risk or severity of Tachycardia can be increased when Anagrelide is combined with Pseudoephedrine. | [DB00332] Ipratropium: The risk or severity of Tachycardia can be increased when Ipratropium is combined with Pseudoephedrine. | [DB00340] Metixene: The risk or severity of Tachycardia can be increased when Metixene is combined with Pseudoephedrine. | [DB00376] Trihexyphenidyl: The risk or severity of Tachycardia can be increased when Trihexyphenidyl is combined with Pseudoephedrine. | [DB00383] Oxyphencyclimine: The risk or severity of Tachycardia can be increased when Oxyphencyclimine is combined with Pseudoephedrine. | [DB00387] Procyclidine: The risk or severity of Tachycardia can be increased when Procyclidine is combined with Pseudoephedrine. | [DB00424] Hyoscyamine: The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Pseudoephedrine. | [DB00462] Methscopolamine bromide: The risk or severity of Tachycardia can be increased when Methscopolamine bromide is combined with Pseudoephedrine. | [DB00483] Gallamine triethiodide: The risk or severity of Tachycardia can be increased when Gallamine triethiodide is combined with Pseudoephedrine. | [DB00496] Darifenacin: The risk or severity of Tachycardia can be increased when Darifenacin is combined with Pseudoephedrine. | [DB00505] Tridihexethyl: The risk or severity of Tachycardia can be increased when Tridihexethyl is combined with Pseudoephedrine. | [DB00517] Anisotropine methylbromide: The risk or severity of Tachycardia can be increased when Anisotropine methylbromide is combined with Pseudoephedrine. | [DB00640] Adenosine: The risk or severity of Tachycardia can be increased when Adenosine is combined with Pseudoephedrine. | [DB00670] Pirenzepine: The risk or severity of Tachycardia can be increased when Pirenzepine is combined with Pseudoephedrine. | [DB00725] Homatropine methylbromide: The risk or severity of Tachycardia can be increased when Homatropine methylbromide is combined with Pseudoephedrine. | [DB00728] Rocuronium: The risk or severity of Tachycardia can be increased when Rocuronium is combined with Pseudoephedrine. | [DB00747] Scopolamine: The risk or severity of Tachycardia can be increased when Scopolamine is combined with Pseudoephedrine. | [DB00771] Clidinium: The risk or severity of Tachycardia can be increased when Clidinium is combined with Pseudoephedrine. | [DB00782] Propantheline: The risk or severity of Tachycardia can be increased when Propantheline is combined with Pseudoephedrine. | [DB00804] Dicyclomine: The risk or severity of Tachycardia can be increased when Dicyclomine is combined with Pseudoephedrine. | [DB00810] Biperiden: The risk or severity of Tachycardia can be increased when Biperiden is combined with Pseudoephedrine. | [DB00942] Cycrimine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Cycrimine. | [DB00986] Glycopyrronium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Glycopyrronium. | [DB01036] Tolterodine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Tolterodine. | [DB01062] Oxybutynin: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Oxybutynin. | [DB01148] Flavoxate: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Flavoxate. | [DB01166] Cilostazol: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Cilostazol. | [DB01221] Ketamine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Ketamine. | [DB01226] Mivacurium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Mivacurium. | [DB01231] Diphenidol: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Diphenidol. | [DB01336] Metocurine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Metocurine. | [DB01337] Pancuronium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Pancuronium. | [DB01338] Pipecuronium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Pipecuronium. | [DB01409] Tiotropium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Tiotropium. | [DB01625] Isopropamide: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Isopropamide. | [DB04834] Rapacuronium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Rapacuronium. | [DB04843] Mepenzolate: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Mepenzolate. | [DB06702] Fesoterodine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Fesoterodine. | [DB06787] Hexocyclium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Hexocyclium. | [DB08897] Aclidinium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Aclidinium. | [DB08997] Dexetimide: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Dexetimide. | [DB09023] Benactyzine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Benactyzine. | [DB09076] Umeclidinium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Umeclidinium. | [DB09089] Trimebutine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Trimebutine. | [DB09262] Imidafenacin: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Imidafenacin. | [DB09300] Butylscopolamine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Butylscopolamine. | [DB11315] Methscopolamine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Methscopolamine. | [DB12086] Oxitropium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Oxitropium. | [DB12554] Mebeverine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Mebeverine. | [DB13252] Tropatepine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Tropatepine. | [DB13254] Prifinium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Prifinium. | [DB13351] Piperidolate: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Piperidolate. | [DB13369] Benzilone: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Benzilone. | [DB13380] Difemerine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Difemerine. | [DB13413] Phenglutarimide: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Phenglutarimide. | [DB13448] Mazaticol: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Mazaticol. | [DB13468] Etybenzatropine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Etybenzatropine. | [DB13500] Otilonium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Otilonium. | [DB13505] Emepronium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Emepronium. | [DB13507] Poldine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Poldine. | [DB13542] Bevonium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Bevonium. | [DB13581] Rociverine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Rociverine. | [DB13619] Bornaprine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Bornaprine. | [DB13636] Etanautine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Etanautine. | [DB13666] Tiemonium iodide: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Tiemonium iodide. | [DB13678] Dihexyverine: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Dihexyverine. | [DB13695] Penthienate: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Penthienate. | [DB13720] Diphemanil: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Diphemanil. | [DB13738] Camylofin: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Camylofin. | [DB13759] Fenpiverinium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Fenpiverinium. | [DB13769] Emetonium iodide: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Emetonium iodide. | [DB13844] Pipenzolate: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Pipenzolate. | [DB13850] Timepidium: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Timepidium. | [DB14009] Medical Cannabis: The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Medical Cannabis. | [DB01100] Pimozide: The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Pimozide. | [DB00477] Chlorpromazine: The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Chlorpromazine. | [DB00745] Modafinil: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Modafinil. | [DB06413] Armodafinil: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Armodafinil. | [DB00187] Esmolol: The therapeutic efficacy of Esmolol can be decreased when used in combination with Pseudoephedrine. | [DB00195] Betaxolol: The therapeutic efficacy of Betaxolol can be decreased when used in combination with Pseudoephedrine. | [DB00226] Guanadrel: The therapeutic efficacy of Guanadrel can be decreased when used in combination with Pseudoephedrine. | [DB00264] Metoprolol: The therapeutic efficacy of Metoprolol can be decreased when used in combination with Pseudoephedrine. | [DB00320] Dihydroergotamine: The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Pseudoephedrine. | [DB00335] Atenolol: The therapeutic efficacy of Atenolol can be decreased when used in combination with Pseudoephedrine. | [DB00346] Alfuzosin: The therapeutic efficacy of Alfuzosin can be decreased when used in combination with Pseudoephedrine. | [DB00373] Timolol: The therapeutic efficacy of Timolol can be decreased when used in combination with Pseudoephedrine. | [DB00392] Profenamine: The therapeutic efficacy of Profenamine can be decreased when used in combination with Pseudoephedrine. | [DB00450] Droperidol: The therapeutic efficacy of Droperidol can be decreased when used in combination with Pseudoephedrine. | [DB00457] Prazosin: The therapeutic efficacy of Prazosin can be decreased when used in combination with Pseudoephedrine. | [DB00489] Sotalol: The therapeutic efficacy of Sotalol can be decreased when used in combination with Pseudoephedrine. | [DB00571] Propranolol: The therapeutic efficacy of Propranolol can be decreased when used in combination with Pseudoephedrine. | [DB00590] Doxazosin: The therapeutic efficacy of Doxazosin can be decreased when used in combination with Pseudoephedrine. | [DB00598] Labetalol: The therapeutic efficacy of Labetalol can be decreased when used in combination with Pseudoephedrine. | [DB00612] Bisoprolol: The therapeutic efficacy of Bisoprolol can be decreased when used in combination with Pseudoephedrine. | [DB00622] Nicardipine: The therapeutic efficacy of Nicardipine can be decreased when used in combination with Pseudoephedrine. | [DB00661] Verapamil: The therapeutic efficacy of Verapamil can be decreased when used in combination with Pseudoephedrine. | [DB00679] Thioridazine: The therapeutic efficacy of Thioridazine can be decreased when used in combination with Pseudoephedrine. | [DB00692] Phentolamine: The therapeutic efficacy of Phentolamine can be decreased when used in combination with Pseudoephedrine. | [DB00696] Ergotamine: The therapeutic efficacy of Ergotamine can be decreased when used in combination with Pseudoephedrine. | [DB00699] Nicergoline: The therapeutic efficacy of Nicergoline can be decreased when used in combination with Pseudoephedrine. | [DB00706] Tamsulosin: The therapeutic efficacy of Tamsulosin can be decreased when used in combination with Pseudoephedrine. | [DB00797] Tolazoline: The therapeutic efficacy of Tolazoline can be decreased when used in combination with Pseudoephedrine. | [DB00831] Trifluoperazine: The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Pseudoephedrine. | [DB00866] Alprenolol: The therapeutic efficacy of Alprenolol can be decreased when used in combination with Pseudoephedrine. | [DB00875] Flupentixol: The therapeutic efficacy of Flupentixol can be decreased when used in combination with Pseudoephedrine. | [DB00908] Quinidine: The therapeutic efficacy of Quinidine can be decreased when used in combination with Pseudoephedrine. | [DB00925] Phenoxybenzamine: The therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Pseudoephedrine. | [DB00960] Pindolol: The therapeutic efficacy of Pindolol can be decreased when used in combination with Pseudoephedrine. | [DB01049] Ergoloid mesylate: The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Pseudoephedrine. | [DB01126] Dutasteride: The therapeutic efficacy of Dutasteride can be decreased when used in combination with Pseudoephedrine. | [DB01136] Carvedilol: The therapeutic efficacy of Carvedilol can be decreased when used in combination with Pseudoephedrine. | [DB01149] Nefazodone: The therapeutic efficacy of Nefazodone can be decreased when used in combination with Pseudoephedrine. | [DB01158] Bretylium: The therapeutic efficacy of Bretylium can be decreased when used in combination with Pseudoephedrine. | [DB01162] Terazosin: The therapeutic efficacy of Terazosin can be decreased when used in combination with Pseudoephedrine. | [DB01182] Propafenone: The therapeutic efficacy of Propafenone can be decreased when used in combination with Pseudoephedrine. | [DB01193] Acebutolol: The therapeutic efficacy of Acebutolol can be decreased when used in combination with Pseudoephedrine. | [DB01203] Nadolol: The therapeutic efficacy of Nadolol can be decreased when used in combination with Pseudoephedrine. | [DB01267] Paliperidone: The therapeutic efficacy of Paliperidone can be decreased when used in combination with Pseudoephedrine. | [DB01295] Bevantolol: The therapeutic efficacy of Bevantolol can be decreased when used in combination with Pseudoephedrine. | [DB01297] Practolol: The therapeutic efficacy of Practolol can be decreased when used in combination with Pseudoephedrine. | [DB01359] Penbutolol: The therapeutic efficacy of Penbutolol can be decreased when used in combination with Pseudoephedrine. | [DB01392] Yohimbine: The therapeutic efficacy of Yohimbine can be decreased when used in combination with Pseudoephedrine. | [DB01580] Oxprenolol: The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Pseudoephedrine. | [DB01608] Periciazine: The therapeutic efficacy of Periciazine can be decreased when used in combination with Pseudoephedrine. | [DB01614] Acepromazine: The therapeutic efficacy of Acepromazine can be decreased when used in combination with Pseudoephedrine. | [DB01622] Thioproperazine: The therapeutic efficacy of Thioproperazine can be decreased when used in combination with Pseudoephedrine. | [DB03322] Dexpropranolol: The therapeutic efficacy of Dexpropranolol can be decreased when used in combination with Pseudoephedrine. | [DB04581] 1-benzylimidazole: The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Pseudoephedrine. | [DB04846] Celiprolol: The therapeutic efficacy of Celiprolol can be decreased when used in combination with Pseudoephedrine. | [DB04855] Dronedarone: The therapeutic efficacy of Dronedarone can be decreased when used in combination with Pseudoephedrine. | [DB04861] Nebivolol: The therapeutic efficacy of Nebivolol can be decreased when used in combination with Pseudoephedrine. | [DB06207] Silodosin: The therapeutic efficacy of Silodosin can be decreased when used in combination with Pseudoephedrine. | [DB06726] Bufuralol: The therapeutic efficacy of Bufuralol can be decreased when used in combination with Pseudoephedrine. | [DB08807] Bopindolol: The therapeutic efficacy of Bopindolol can be decreased when used in combination with Pseudoephedrine. | [DB08808] Bupranolol: The therapeutic efficacy of Bupranolol can be decreased when used in combination with Pseudoephedrine. | [DB08815] Lurasidone: The therapeutic efficacy of Lurasidone can be decreased when used in combination with Pseudoephedrine. | [DB08950] Indoramin: The therapeutic efficacy of Indoramin can be decreased when used in combination with Pseudoephedrine. | [DB08952] Indenolol: The therapeutic efficacy of Indenolol can be decreased when used in combination with Pseudoephedrine. | [DB08954] Ifenprodil: The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Pseudoephedrine. | [DB09128] Brexpiprazole: The therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Pseudoephedrine. | [DB09204] Arotinolol: The therapeutic efficacy of Arotinolol can be decreased when used in combination with Pseudoephedrine. | [DB09205] Moxisylyte: The therapeutic efficacy of Moxisylyte can be decreased when used in combination with Pseudoephedrine. | [DB09206] Trimazosin: The therapeutic efficacy of Trimazosin can be decreased when used in combination with Pseudoephedrine. | [DB09239] Niguldipine: The therapeutic efficacy of Niguldipine can be decreased when used in combination with Pseudoephedrine. | [DB09351] Levobetaxolol: The therapeutic efficacy of Levobetaxolol can be decreased when used in combination with Pseudoephedrine. | [DB11481] Atipamezole: The therapeutic efficacy of Atipamezole can be decreased when used in combination with Pseudoephedrine. | [DB11770] Talinolol: The therapeutic efficacy of Talinolol can be decreased when used in combination with Pseudoephedrine. | [DB11785] Anisodamine: The therapeutic efficacy of Anisodamine can be decreased when used in combination with Pseudoephedrine. | [DB12057] ORM-12741: The therapeutic efficacy of ORM-12741 can be decreased when used in combination with Pseudoephedrine. | [DB12092] Naftopidil: The therapeutic efficacy of Naftopidil can be decreased when used in combination with Pseudoephedrine. | [DB12212] Landiolol: The therapeutic efficacy of Landiolol can be decreased when used in combination with Pseudoephedrine. | [DB12230] Bunazosin: The therapeutic efficacy of Bunazosin can be decreased when used in combination with Pseudoephedrine. | [DB12278] Propiverine: The therapeutic efficacy of Propiverine can be decreased when used in combination with Pseudoephedrine. | [DB12551] Idazoxan: The therapeutic efficacy of Idazoxan can be decreased when used in combination with Pseudoephedrine. | [DB12661] Urapidil: The therapeutic efficacy of Urapidil can be decreased when used in combination with Pseudoephedrine. | [DB12752] Bucindolol: The therapeutic efficacy of Bucindolol can be decreased when used in combination with Pseudoephedrine. | [DB13345] Dihydroergocristine: The therapeutic efficacy of Dihydroergocristine can be decreased when used in combination with Pseudoephedrine. | [DB13443] Esatenolol: The therapeutic efficacy of Esatenolol can be decreased when used in combination with Pseudoephedrine. | [DB13508] Cloranolol: The therapeutic efficacy of Cloranolol can be decreased when used in combination with Pseudoephedrine. | [DB13510] Buflomedil: The therapeutic efficacy of Buflomedil can be decreased when used in combination with Pseudoephedrine. | [DB13530] Mepindolol: The therapeutic efficacy of Mepindolol can be decreased when used in combination with Pseudoephedrine. | [DB13757] Epanolol: The therapeutic efficacy of Epanolol can be decreased when used in combination with Pseudoephedrine. | [DB13775] Tertatolol: The therapeutic efficacy of Tertatolol can be decreased when used in combination with Pseudoephedrine. | [DB00344] Protriptyline: The therapeutic efficacy of Protriptyline can be increased when used in combination with Pseudoephedrine. | [DB01242] Clomipramine: The therapeutic efficacy of Clomipramine can be increased when used in combination with Pseudoephedrine. | [DB04836] Amineptine: The therapeutic efficacy of Amineptine can be increased when used in combination with Pseudoephedrine. | [DB08996] Dimetacrine: The therapeutic efficacy of Dimetacrine can be increased when used in combination with Pseudoephedrine. | [DB09289] Tianeptine: The therapeutic efficacy of Tianeptine can be increased when used in combination with Pseudoephedrine. | [DB09307] Oxaprotiline: The therapeutic efficacy of Oxaprotiline can be increased when used in combination with Pseudoephedrine. | [DB12930] Opipramol: The therapeutic efficacy of Opipramol can be increased when used in combination with Pseudoephedrine. | [DB13114] Amitriptylinoxide: The therapeutic efficacy of Amitriptylinoxide can be increased when used in combination with Pseudoephedrine. | [DB13225] Dibenzepin: The therapeutic efficacy of Dibenzepin can be increased when used in combination with Pseudoephedrine. | [DB13246] Quinupramine: The therapeutic efficacy of Quinupramine can be increased when used in combination with Pseudoephedrine. | [DB13384] Melitracen: The therapeutic efficacy of Melitracen can be increased when used in combination with Pseudoephedrine. | [DB13411] Lofepramine: The therapeutic efficacy of Lofepramine can be increased when used in combination with Pseudoephedrine. | [DB13496] Iprindole: The therapeutic efficacy of Iprindole can be increased when used in combination with Pseudoephedrine. | [DB13782] Imipramine oxide: The therapeutic efficacy of Imipramine oxide can be increased when used in combination with Pseudoephedrine. | [DB00502] Haloperidol: The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Haloperidol. | [DB14507] Lithium citrate: The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Lithium citrate. | [DB14509] Lithium carbonate: The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Lithium carbonate. | [DB14506] Lithium hydroxide: The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Lithium hydroxide. | [DB00017] Salmon calcitonin: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Salmon calcitonin. | [DB00024] Thyrotropin alfa: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Thyrotropin alfa. | [DB00066] Follitropin: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Follitropin. | [DB00279] Liothyronine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Liothyronine. | [DB00389] Carbimazole: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Carbimazole. | [DB00451] Levothyroxine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Levothyroxine. | [DB00550] Propylthiouracil: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Propylthiouracil. | [DB00763] Methimazole: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Methimazole. | [DB01583] Liotrix: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Liotrix. | [DB03374] 3,5-Diiodotyrosine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 3,5-Diiodotyrosine. | [DB03604] Tiratricol: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Tiratricol. | [DB05829] Parathyroid hormone: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Parathyroid hormone. | [DB06285] Teriparatide: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Teriparatide. | [DB06715] Potassium Iodide: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Potassium Iodide. | [DB07637] Dibromotyrosine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Dibromotyrosine. | [DB09100] Thyroid, porcine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Thyroid, porcine. | [DB09418] Potassium perchlorate: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Potassium perchlorate. | [DB09421] Protirelin: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Protirelin. | [DB12629] 3,5-diiodothyropropionic acid: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 3,5-diiodothyropropionic acid. | [DB13644] Methylthiouracil: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Methylthiouracil. | [DB13742] Elcatonin: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Elcatonin. | [DB13804] Benzylthiouracil: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Benzylthiouracil. | [DB15263] Thyrotropin: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Thyrotropin. | [DB11823] Esketamine: The risk or severity of hypertension can be increased when Esketamine is combined with Pseudoephedrine. | [DB00331] Metformin: The therapeutic efficacy of Metformin can be decreased when used in combination with Pseudoephedrine. | [DB14754] Solriamfetol: The risk or severity of hypertension can be increased when Solriamfetol is combined with Pseudoephedrine. | [DB13946] Testosterone undecanoate: Testosterone undecanoate may increase the hypertensive activities of Pseudoephedrine. | [DB00454] Meperidine: The therapeutic efficacy of Meperidine can be increased when used in combination with Pseudoephedrine. | [DB00281] Lidocaine: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Lidocaine. | [DB00697] Tizanidine: The risk or severity of adverse effects can be increased when Tizanidine is combined with Pseudoephedrine. | [DB01200] Bromocriptine: The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Bromocriptine. | [DB00656] Trazodone: The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Pseudoephedrine. | [DB01016] Glyburide: The therapeutic efficacy of Glyburide can be decreased when used in combination with Pseudoephedrine. | [DB01175] Escitalopram: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Escitalopram. | [DB11732] Lasmiditan: The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Pseudoephedrine. | [DB00983] Formoterol: Pseudoephedrine may increase the sympathomimetic activities of Formoterol. | [DB00193] Tramadol: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Tramadol. | [DB00472] Fluoxetine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Fluoxetine. | [DB00574] Fenfluramine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Fenfluramine. | [DB00819] Acetazolamide: Acetazolamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level. | [DB14881] Oliceridine: The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Oliceridine. | [DB00555] Lamotrigine: The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Pseudoephedrine. | [DB00935] Oxymetazoline: The absorption of Pseudoephedrine can be decreased when combined with Oxymetazoline. | [DB00107] Oxytocin: The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Oxytocin. | [DB15226] Dasiglucagon: Pseudoephedrine may decrease the antihypertensive activities of Dasiglucagon. | [DB12214] Luseogliflozin: The therapeutic efficacy of Luseogliflozin can be decreased when used in combination with Pseudoephedrine. | [DB01161] Chloroprocaine: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Chloroprocaine. | [DB12236] Bexagliflozin: The therapeutic efficacy of Bexagliflozin can be decreased when used in combination with Pseudoephedrine. | [DB00755] Tretinoin: The risk or severity of elevated intracranial pressure can be increased when Pseudoephedrine is combined with Tretinoin. | [DB12543] Samidorphan: Samidorphan may decrease the stimulatory activities of Pseudoephedrine. | [DB18002] Lomifylline: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Lomifylline. | [DB01237] Bromodiphenhydramine: Pseudoephedrine may decrease the sedative activities of Bromodiphenhydramine. | [DB15059] Aprocitentan: Pseudoephedrine may decrease the antihypertensive activities of Aprocitentan. | [DB18676] Palopegteriparatide: The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Palopegteriparatide. | [DB16693] Insulin icodec: The therapeutic efficacy of Insulin icodec can be decreased when used in combination with Pseudoephedrine.",0.050 g; 0.300 g; 0.5 mg/5mL; 0.5 mg/60mL; 1 mg/5ml; 1.200 g; 1.25 mg; 1.25 mg/5mL; 10 mg/5ml; 10.50 mg; 100 mg/5ml; 100 ml; 120 mg; 120 mg / cap; 120 mg / src; 120 mg / srt; 120 mg / tab; 120 mg/1; 120.00 mg; 1200.00 mg; 15 mg; 15 mg/15ml; 15 mg/5mL; 150 ml; 16.7 mg/5mL; 2 mg; 2 mg/5ml; 200 mg; 200.000 mg; 2166.79 mg; 240 mg / cap; 240 mg/1; 30 MG; 30 mg; 30 mg / 10 mL; 30 mg / 5 mL; 30 mg / tab; 30 mg/1; 30 mg/5mL; 30 mg/5ml; 4 mg; 5 mg; 5 mg/5ml; 5.00 mg; 5.000 mg; 50 mg/5mL; 60 mg; 60 mg / tab; 60 mg/1; 60 mg/60mL; 600 MG; 7.5 MG/0.8ML; 7.5 mg; 7.5 mg / .8 mL; 7.5 mg / 0.8 mL; 9.375 MG/ML,Take with or without food. The absorption is unaffected by food.
DB00945,Acetylsalicylic acid,"ALIMENTARY TRACT AND METABOLISM; ANALGESICS; ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS; ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION; ANTITHROMBOTIC AGENTS; Antiinflammatory/antirheumatic agents in combination with corticosteroids; BETA BLOCKING AGENTS; BETA BLOCKING AGENTS, OTHER COMBINATIONS; BLOOD AND BLOOD FORMING ORGANS; Beta blocking agents, other combinations; CARDIOVASCULAR SYSTEM; Direct factor Xa inhibitors; LIPID MODIFYING AGENTS; LIPID MODIFYING AGENTS, COMBINATIONS; Lipid modifying agents in combination with other drugs; MUSCULO-SKELETAL SYSTEM; NERVOUS SYSTEM; OPIOIDS; OTHER ANALGESICS AND ANTIPYRETICS; Opioids in combination with non-opioid analgesics; Other agents for local oral treatment; Platelet aggregation inhibitors excl. heparin; STOMATOLOGICAL PREPARATIONS; Salicylic acid and derivatives","[DB06605] Apixaban: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Apixaban. | [DB01254] Dasatinib: Dasatinib may increase the anticoagulant activities of Acetylsalicylic acid. | [DB01586] Ursodeoxycholic acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ursodeoxycholic acid. | [DB02123] Glycochenodeoxycholic Acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Glycochenodeoxycholic Acid. | [DB02659] Cholic Acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Cholic Acid. | [DB02691] Glycocholic acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Glycocholic acid. | [DB03619] Deoxycholic acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Deoxycholic acid. | [DB04348] Taurocholic acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Taurocholic acid. | [DB05990] Obeticholic acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Obeticholic acid. | [DB06777] Chenodeoxycholic acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Chenodeoxycholic acid. | [DB08833] Taurochenodeoxycholic acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Taurochenodeoxycholic acid. | [DB08834] Tauroursodeoxycholic acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tauroursodeoxycholic acid. | [DB08857] Bamet-UD2: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Bamet-UD2. | [DB11622] Dehydrocholic acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dehydrocholic acid. | [DB11789] Hyodeoxycholic Acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Hyodeoxycholic Acid. | [DB01296] Glucosamine: Glucosamine may increase the antiplatelet activities of Acetylsalicylic acid. | [DB00078] Ibritumomab tiuxetan: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibritumomab tiuxetan. | [DB09053] Ibrutinib: The risk or severity of adverse effects can be increased when Ibrutinib is combined with Acetylsalicylic acid. | [DB08935] Obinutuzumab: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Obinutuzumab. | [DB06228] Rivaroxaban: Acetylsalicylic acid may increase the anticoagulant activities of Rivaroxaban. | [DB00932] Tipranavir: Tipranavir may increase the antiplatelet activities of Acetylsalicylic acid. | [DB00013] Urokinase: Acetylsalicylic acid may increase the anticoagulant activities of Urokinase. | [DB00163] Vitamin E: Vitamin E may increase the antiplatelet activities of Acetylsalicylic acid. | [DB00393] Nimodipine: Acetylsalicylic acid may decrease the antihypertensive activities of Nimodipine. | [DB00457] Prazosin: Acetylsalicylic acid may decrease the antihypertensive activities of Prazosin. | [DB00575] Clonidine: Acetylsalicylic acid may decrease the antihypertensive activities of Clonidine. | [DB01054] Nitrendipine: Acetylsalicylic acid may decrease the antihypertensive activities of Nitrendipine. | [DB01162] Terazosin: Acetylsalicylic acid may decrease the antihypertensive activities of Terazosin. | [DB01244] Bepridil: Acetylsalicylic acid may decrease the antihypertensive activities of Bepridil. | [DB01388] Mibefradil: Acetylsalicylic acid may decrease the antihypertensive activities of Mibefradil. | [DB09239] Niguldipine: Acetylsalicylic acid may decrease the antihypertensive activities of Niguldipine. | [DB14068] Dexniguldipine: Acetylsalicylic acid may decrease the antihypertensive activities of Dexniguldipine. | [DB00212] Remikiren: Acetylsalicylic acid may decrease the antihypertensive activities of Remikiren. | [DB00217] Bethanidine: Acetylsalicylic acid may decrease the antihypertensive activities of Bethanidine. | [DB00226] Guanadrel: Acetylsalicylic acid may decrease the antihypertensive activities of Guanadrel. | [DB00350] Minoxidil: Acetylsalicylic acid may decrease the antihypertensive activities of Minoxidil. | [DB00528] Lercanidipine: Acetylsalicylic acid may decrease the antihypertensive activities of Lercanidipine. | [DB00616] Candoxatril: Acetylsalicylic acid may decrease the antihypertensive activities of Candoxatril. | [DB00629] Guanabenz: Acetylsalicylic acid may decrease the antihypertensive activities of Guanabenz. | [DB00765] Metyrosine: Acetylsalicylic acid may decrease the antihypertensive activities of Metyrosine. | [DB00785] Cryptenamine: Acetylsalicylic acid may decrease the antihypertensive activities of Cryptenamine. | [DB00797] Tolazoline: Acetylsalicylic acid may decrease the antihypertensive activities of Tolazoline. | [DB00925] Phenoxybenzamine: Acetylsalicylic acid may decrease the antihypertensive activities of Phenoxybenzamine. | [DB01089] Deserpidine: Acetylsalicylic acid may decrease the antihypertensive activities of Deserpidine. | [DB01090] Pentolinium: Acetylsalicylic acid may decrease the antihypertensive activities of Pentolinium. | [DB01116] Trimethaphan: Acetylsalicylic acid may decrease the antihypertensive activities of Trimethaphan. | [DB01158] Bretylium: Acetylsalicylic acid may decrease the antihypertensive activities of Bretylium. | [DB04840] Debrisoquine: Acetylsalicylic acid may decrease the antihypertensive activities of Debrisoquine. | [DB06403] Ambrisentan: Acetylsalicylic acid may decrease the antihypertensive activities of Ambrisentan. | [DB06445] Diethylnorspermine: Acetylsalicylic acid may decrease the antihypertensive activities of Diethylnorspermine. | [DB06712] Nilvadipine: Acetylsalicylic acid may decrease the antihypertensive activities of Nilvadipine. | [DB06762] Pinacidil: Acetylsalicylic acid may decrease the antihypertensive activities of Pinacidil. | [DB08931] Riociguat: Acetylsalicylic acid may decrease the antihypertensive activities of Riociguat. | [DB08950] Indoramin: Acetylsalicylic acid may decrease the antihypertensive activities of Indoramin. | [DB08960] Hexamethonium: Acetylsalicylic acid may decrease the antihypertensive activities of Hexamethonium. | [DB09206] Trimazosin: Acetylsalicylic acid may decrease the antihypertensive activities of Trimazosin. | [DB09236] Lacidipine: Acetylsalicylic acid may decrease the antihypertensive activities of Lacidipine. | [DB09242] Moxonidine: Acetylsalicylic acid may decrease the antihypertensive activities of Moxonidine. | [DB09363] Rauwolfia serpentina root: Acetylsalicylic acid may decrease the antihypertensive activities of Rauwolfia serpentina root. | [DB11362] Selexipag: Acetylsalicylic acid may decrease the antihypertensive activities of Selexipag. | [DB11720] Angiotensin 1-7: Acetylsalicylic acid may decrease the antihypertensive activities of Angiotensin 1-7. | [DB11738] Rilmenidine: Acetylsalicylic acid may decrease the antihypertensive activities of Rilmenidine. | [DB12054] BQ-123: Acetylsalicylic acid may decrease the antihypertensive activities of BQ-123. | [DB12093] Tetrahydropalmatine: Acetylsalicylic acid may decrease the antihypertensive activities of Tetrahydropalmatine. | [DB12661] Urapidil: Acetylsalicylic acid may decrease the antihypertensive activities of Urapidil. | [DB12945] Dihydralazine: Acetylsalicylic acid may decrease the antihypertensive activities of Dihydralazine. | [DB13211] Guanoxan: Acetylsalicylic acid may decrease the antihypertensive activities of Guanoxan. | [DB13374] Vincamine: Acetylsalicylic acid may decrease the antihypertensive activities of Vincamine. | [DB13410] Guanoxabenz: Acetylsalicylic acid may decrease the antihypertensive activities of Guanoxabenz. | [DB13429] Tolonidine: Acetylsalicylic acid may decrease the antihypertensive activities of Tolonidine. | [DB13435] Endralazine: Acetylsalicylic acid may decrease the antihypertensive activities of Endralazine. | [DB13452] Cadralazine: Acetylsalicylic acid may decrease the antihypertensive activities of Cadralazine. | [DB13575] Bietaserpine: Acetylsalicylic acid may decrease the antihypertensive activities of Bietaserpine. | [DB13604] Guanazodine: Acetylsalicylic acid may decrease the antihypertensive activities of Guanazodine. | [DB13631] Methoserpidine: Acetylsalicylic acid may decrease the antihypertensive activities of Methoserpidine. | [DB13779] Guanoclor: Acetylsalicylic acid may decrease the antihypertensive activities of Guanoclor. | [DB09237] Levamlodipine: Acetylsalicylic acid may decrease the antihypertensive activities of Levamlodipine. | [DB01119] Diazoxide: Acetylsalicylic acid may decrease the antihypertensive activities of Diazoxide. | [DB00191] Phentermine: The risk or severity of hypertension can be increased when Phentermine is combined with Acetylsalicylic acid. | [DB00211] Midodrine: The risk or severity of hypertension can be increased when Midodrine is combined with Acetylsalicylic acid. | [DB00221] Isoetharine: The risk or severity of hypertension can be increased when Isoetharine is combined with Acetylsalicylic acid. | [DB00246] Ziprasidone: The risk or severity of hypertension can be increased when Ziprasidone is combined with Acetylsalicylic acid. | [DB00247] Methysergide: The risk or severity of hypertension can be increased when Methysergide is combined with Acetylsalicylic acid. | [DB00315] Zolmitriptan: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Acetylsalicylic acid. | [DB00353] Methylergometrine: The risk or severity of hypertension can be increased when Methylergometrine is combined with Acetylsalicylic acid. | [DB00368] Norepinephrine: The risk or severity of hypertension can be increased when Norepinephrine is combined with Acetylsalicylic acid. | [DB00370] Mirtazapine: The risk or severity of hypertension can be increased when Mirtazapine is combined with Acetylsalicylic acid. | [DB00420] Promazine: The risk or severity of hypertension can be increased when Promazine is combined with Acetylsalicylic acid. | [DB00450] Droperidol: The risk or severity of hypertension can be increased when Droperidol is combined with Acetylsalicylic acid. | [DB00561] Doxapram: The risk or severity of hypertension can be increased when Doxapram is combined with Acetylsalicylic acid. | [DB00572] Atropine: The risk or severity of hypertension can be increased when Atropine is combined with Acetylsalicylic acid. | [DB00589] Lisuride: The risk or severity of hypertension can be increased when Lisuride is combined with Acetylsalicylic acid. | [DB00610] Metaraminol: The risk or severity of hypertension can be increased when Metaraminol is combined with Acetylsalicylic acid. | [DB00679] Thioridazine: The risk or severity of hypertension can be increased when Thioridazine is combined with Acetylsalicylic acid. | [DB00699] Nicergoline: The risk or severity of hypertension can be increased when Nicergoline is combined with Acetylsalicylic acid. | [DB00708] Sufentanil: The risk or severity of hypertension can be increased when Sufentanil is combined with Acetylsalicylic acid. | [DB00723] Methoxamine: The risk or severity of hypertension can be increased when Methoxamine is combined with Acetylsalicylic acid. | [DB00753] Isoflurane: The risk or severity of hypertension can be increased when Isoflurane is combined with Acetylsalicylic acid. | [DB00777] Propiomazine: The risk or severity of hypertension can be increased when Propiomazine is combined with Acetylsalicylic acid. | [DB00816] Orciprenaline: The risk or severity of hypertension can be increased when Orciprenaline is combined with Acetylsalicylic acid. | [DB00830] Phenmetrazine: The risk or severity of hypertension can be increased when Phenmetrazine is combined with Acetylsalicylic acid. | [DB00865] Benzphetamine: The risk or severity of hypertension can be increased when Benzphetamine is combined with Acetylsalicylic acid. | [DB00867] Ritodrine: The risk or severity of hypertension can be increased when Ritodrine is combined with Acetylsalicylic acid. | [DB00899] Remifentanil: The risk or severity of hypertension can be increased when Remifentanil is combined with Acetylsalicylic acid. | [DB00901] Bitolterol: The risk or severity of hypertension can be increased when Bitolterol is combined with Acetylsalicylic acid. | [DB00935] Oxymetazoline: The risk or severity of hypertension can be increased when Oxymetazoline is combined with Acetylsalicylic acid. | [DB00937] Diethylpropion: The risk or severity of hypertension can be increased when Diethylpropion is combined with Acetylsalicylic acid. | [DB00938] Salmeterol: The risk or severity of hypertension can be increased when Salmeterol is combined with Acetylsalicylic acid. | [DB00952] Naratriptan: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Naratriptan. | [DB00983] Formoterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Formoterol. | [DB00998] Frovatriptan: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Frovatriptan. | [DB01049] Ergoloid mesylate: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Ergoloid mesylate. | [DB01064] Isoprenaline: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Isoprenaline. | [DB01102] Arbutamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Arbutamine. | [DB01126] Dutasteride: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Dutasteride. | [DB01186] Pergolide: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Pergolide. | [DB01189] Desflurane: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Desflurane. | [DB01216] Finasteride: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Finasteride. | [DB01238] Aripiprazole: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Aripiprazole. | [DB01255] Lisdexamfetamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Lisdexamfetamine. | [DB01288] Fenoterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Fenoterol. | [DB01291] Pirbuterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Pirbuterol. | [DB01363] Ephedra sinica root: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Ephedra sinica root. | [DB01364] Ephedrine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Ephedrine. | [DB01365] Mephentermine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Mephentermine. | [DB01366] Procaterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Procaterol. | [DB01403] Methotrimeprazine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Methotrimeprazine. | [DB01407] Clenbuterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Clenbuterol. | [DB01408] Bambuterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Bambuterol. | [DB01442] MMDA: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with MMDA. | [DB01454] Midomafetamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Midomafetamine. | [DB01467] 2,5-Dimethoxy-4-ethylamphetamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with 2,5-Dimethoxy-4-ethylamphetamine. | [DB01472] 4-Methoxyamphetamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with 4-Methoxyamphetamine. | [DB01484] 4-Bromo-2,5-dimethoxyamphetamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with 4-Bromo-2,5-dimethoxyamphetamine. | [DB01509] Tenamfetamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Tenamfetamine. | [DB01556] Chlorphentermine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Chlorphentermine. | [DB01576] Dextroamphetamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Dextroamphetamine. | [DB01579] Phendimetrazine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Phendimetrazine. | [DB01591] Solifenacin: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Solifenacin. | [DB01608] Periciazine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Periciazine. | [DB01614] Acepromazine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Acepromazine. | [DB01622] Thioproperazine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Thioproperazine. | [DB01624] Zuclopenthixol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Zuclopenthixol. | [DB02032] Epicaptopril: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Epicaptopril. | [DB04581] 1-benzylimidazole: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with 1-benzylimidazole. | [DB04829] Lysergic acid diethylamide: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Lysergic acid diethylamide. | [DB04946] Iloperidone: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Iloperidone. | [DB05271] Rotigotine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Rotigotine. | [DB05395] Amibegron: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Amibegron. | [DB05562] Naluzotan: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Naluzotan. | [DB06016] Cariprazine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Cariprazine. | [DB06148] Mianserin: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Mianserin. | [DB06153] Pizotifen: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Pizotifen. | [DB06190] Solabegron: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Solabegron. | [DB06216] Asenapine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Asenapine. | [DB06678] Esmirtazapine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Esmirtazapine. | [DB06684] Vilazodone: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Vilazodone. | [DB06690] Nitrous oxide: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Nitrous oxide. | [DB06701] Dexmethylphenidate: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Dexmethylphenidate. | [DB06706] Isometheptene: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Isometheptene. | [DB06707] Levonordefrin: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Levonordefrin. | [DB06711] Naphazoline: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Naphazoline. | [DB06764] Tetryzoline: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Tetryzoline. | [DB08810] Cinitapride: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Cinitapride. | [DB08815] Lurasidone: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Lurasidone. | [DB08841] Tyramine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Tyramine. | [DB08925] Adrafinil: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Adrafinil. | [DB08941] Isoxsuprine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Isoxsuprine. | [DB08954] Ifenprodil: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Ifenprodil. | [DB08957] Hexoprenaline: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Hexoprenaline. | [DB08985] Etilefrine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Etilefrine. | [DB09080] Olodaterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Olodaterol. | [DB09128] Brexpiprazole: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Brexpiprazole. | [DB09202] Cirazoline: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Cirazoline. | [DB09203] Synephrine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Synephrine. | [DB09273] Doxofylline: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Doxofylline. | [DB09480] Iofetamine I-123: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Iofetamine I-123. | [DB11124] Racepinephrine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Racepinephrine. | [DB11273] Dihydroergocornine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Dihydroergocornine. | [DB11373] Amitraz: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Amitraz. | [DB11428] Medetomidine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Medetomidine. | [DB11477] Xylazine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Xylazine. | [DB11481] Atipamezole: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Atipamezole. | [DB11541] Ractopamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Ractopamine. | [DB11543] Romifidine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Romifidine. | [DB11556] Detomidine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Detomidine. | [DB11755] Tetrahydrocannabivarin: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Tetrahydrocannabivarin. | [DB11871] PF-00610355: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with PF-00610355. | [DB12080] Ritobegron: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Ritobegron. | [DB12100] Abediterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Abediterol. | [DB12248] Tulobuterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Tulobuterol. | [DB12313] Dopexamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Dopexamine. | [DB12361] Piclozotan: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Piclozotan. | [DB12551] Idazoxan: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Idazoxan. | [DB12779] Higenamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Higenamine. | [DB12846] Reproterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Reproterol. | [DB12927] Theodrenaline: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Theodrenaline. | [DB13064] Tramazoline: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Tramazoline. | [DB13108] Mephedrone: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Mephedrone. | [DB13251] Octopamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Octopamine. | [DB13323] Trichloroethylene: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Trichloroethylene. | [DB13341] Fenozolone: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Fenozolone. | [DB13345] Dihydroergocristine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Dihydroergocristine. | [DB13378] Norfenefrine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Norfenefrine. | [DB13385] Dihydroergocryptine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Dihydroergocryptine. | [DB13398] Oxyfedrine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Oxyfedrine. | [DB13399] Terguride: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Terguride. | [DB13453] Xenon: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Xenon. | [DB13520] Metergoline: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Metergoline. | [DB13559] Rimiterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Rimiterol. | [DB13624] Methoxyphenamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Methoxyphenamine. | [DB13692] Tretoquinol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Tretoquinol. | [DB13703] Gepefrine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Gepefrine. | [DB13777] Prenalterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Prenalterol. | [DB13781] Xamoterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Xamoterol. | [DB13852] Mefenorex: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Mefenorex. | [DB13917] Deoxyepinephrine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Deoxyepinephrine. | [DB13940] 2,5-Dimethoxy-4-ethylthioamphetamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with 2,5-Dimethoxy-4-ethylthioamphetamine. | [DB14010] 5-methoxy-N,N-dimethyltryptamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with 5-methoxy-N,N-dimethyltryptamine. | [DB14185] Aripiprazole lauroxil: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Aripiprazole lauroxil. | [DB06694] Xylometazoline: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Xylometazoline. | [DB00248] Cabergoline: The risk or severity of hypertension can be increased when Cabergoline is combined with Acetylsalicylic acid. | [DB00320] Dihydroergotamine: The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Acetylsalicylic acid. | [DB00734] Risperidone: The risk or severity of hypertension can be increased when Risperidone is combined with Acetylsalicylic acid. | [DB00802] Alfentanil: The risk or severity of hypertension can be increased when Alfentanil is combined with Acetylsalicylic acid. | [DB00831] Trifluoperazine: The risk or severity of hypertension can be increased when Trifluoperazine is combined with Acetylsalicylic acid. | [DB00875] Flupentixol: The risk or severity of hypertension can be increased when Flupentixol is combined with Acetylsalicylic acid. | [DB01253] Ergometrine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Ergometrine. | [DB01392] Yohimbine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Yohimbine. | [DB04855] Dronedarone: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Dronedarone. | [DB04908] Flibanserin: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Flibanserin. | [DB05039] Indacaterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Indacaterol. | [DB13598] Diethyl ether: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Diethyl ether. | [DB15685] Selpercatinib: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Selpercatinib. | [DB15965] Naxitamab: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Naxitamab. | [DB16629] Serdexmethylphenidate: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Serdexmethylphenidate. | [DB00422] Methylphenidate: The risk or severity of hypertension can be increased when Methylphenidate is combined with Acetylsalicylic acid. | [DB06767] Ammonium chloride: The serum concentration of Acetylsalicylic acid can be increased when it is combined with Ammonium chloride. | [DB01381] Ginkgo biloba: The risk or severity of bleeding can be increased when Ginkgo biloba is combined with Acetylsalicylic acid. | [DB00070] Hyaluronidase (ovine): The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Acetylsalicylic acid. | [DB06205] Hyaluronidase (human recombinant): The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Acetylsalicylic acid. | [DB14740] Hyaluronidase: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Acetylsalicylic acid. | [DB06813] Pralatrexate: The serum concentration of Pralatrexate can be increased when it is combined with Acetylsalicylic acid. | [DB09026] Aliskiren: The risk or severity of renal failure and hypertension can be increased when Acetylsalicylic acid is combined with Aliskiren. | [DB01609] Deferasirox: The risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Acetylsalicylic acid is combined with Deferasirox. | [DB00035] Desmopressin: The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Acetylsalicylic acid is combined with Desmopressin. | [DB01395] Drospirenone: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Drospirenone. | [DB00502] Haloperidol: The therapeutic efficacy of Haloperidol can be increased when used in combination with Acetylsalicylic acid. | [DB01275] Hydralazine: Acetylsalicylic acid may decrease the antihypertensive activities of Hydralazine. | [DB14507] Lithium citrate: Acetylsalicylic acid may decrease the excretion rate of Lithium citrate which could result in a higher serum level. | [DB14509] Lithium carbonate: Acetylsalicylic acid may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. | [DB14506] Lithium hydroxide: Acetylsalicylic acid may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level. | [DB00642] Pemetrexed: Acetylsalicylic acid may decrease the excretion rate of Pemetrexed which could result in a higher serum level. | [DB01032] Probenecid: Probenecid may decrease the excretion rate of Acetylsalicylic acid which could result in a higher serum level. | [DB00374] Treprostinil: The risk or severity of bleeding can be increased when Treprostinil is combined with Acetylsalicylic acid. | [DB00512] Vancomycin: Acetylsalicylic acid may decrease the excretion rate of Vancomycin which could result in a higher serum level. | [DB00529] Foscarnet: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Foscarnet. | [DB00300] Tenofovir disoproxil: Acetylsalicylic acid may increase the nephrotoxic activities of Tenofovir disoproxil. | [DB09299] Tenofovir alafenamide: The serum concentration of Tenofovir alafenamide can be increased when it is combined with Acetylsalicylic acid. | [DB14126] Tenofovir: Acetylsalicylic acid may increase the nephrotoxic activities of Tenofovir. | [DB00139] Succinic acid: The excretion of Succinic acid can be decreased when combined with Acetylsalicylic acid. | [DB00155] Citrulline: The excretion of Citrulline can be decreased when combined with Acetylsalicylic acid. | [DB00175] Pravastatin: The excretion of Pravastatin can be decreased when combined with Acetylsalicylic acid. | [DB00345] Aminohippuric acid: The excretion of Aminohippuric acid can be decreased when combined with Acetylsalicylic acid. | [DB00535] Cefdinir: The excretion of Cefdinir can be decreased when combined with Acetylsalicylic acid. | [DB00650] Leucovorin: The excretion of Leucovorin can be decreased when combined with Acetylsalicylic acid. | [DB00693] Fluorescein: The excretion of Fluorescein can be decreased when combined with Acetylsalicylic acid. | [DB00917] Dinoprostone: The excretion of Dinoprostone can be decreased when combined with Acetylsalicylic acid. | [DB00927] Famotidine: The excretion of Famotidine can be decreased when combined with Acetylsalicylic acid. | [DB01053] Benzylpenicillin: The excretion of Benzylpenicillin can be decreased when combined with Acetylsalicylic acid. | [DB02527] Cyclic adenosine monophosphate: The excretion of Cyclic adenosine monophosphate can be decreased when combined with Acetylsalicylic acid. | [DB03553] Glutaric Acid: The excretion of Glutaric Acid can be decreased when combined with Acetylsalicylic acid. | [DB03902] Oxalic Acid: The excretion of Oxalic Acid can be decreased when combined with Acetylsalicylic acid. | [DB08846] Ellagic acid: The excretion of Ellagic acid can be decreased when combined with Acetylsalicylic acid. | [DB09060] Avibactam: The excretion of Avibactam can be decreased when combined with Acetylsalicylic acid. | [DB09272] Eluxadoline: The excretion of Eluxadoline can be decreased when combined with Acetylsalicylic acid. | [DB09298] Silibinin: The excretion of Silibinin can be decreased when combined with Acetylsalicylic acid. | [DB12377] Relebactam: The excretion of Relebactam can be decreased when combined with Acetylsalicylic acid. | [DB00567] Cephalexin: The excretion of Cephalexin can be decreased when combined with Acetylsalicylic acid. | [DB00577] Valaciclovir: The excretion of Valaciclovir can be decreased when combined with Acetylsalicylic acid. | [DB00787] Acyclovir: The excretion of Acyclovir can be decreased when combined with Acetylsalicylic acid. | [DB00833] Cefaclor: The excretion of Cefaclor can be decreased when combined with Acetylsalicylic acid. | [DB00198] Oseltamivir: The excretion of Oseltamivir can be decreased when combined with Acetylsalicylic acid. | [DB00319] Piperacillin: The excretion of Piperacillin can be decreased when combined with Acetylsalicylic acid. | [DB00432] Trifluridine: The excretion of Trifluridine can be decreased when combined with Acetylsalicylic acid. | [DB00501] Cimetidine: The excretion of Cimetidine can be decreased when combined with Acetylsalicylic acid. | [DB00759] Tetracycline: The excretion of Tetracycline can be decreased when combined with Acetylsalicylic acid. | [DB01415] Ceftibuten: The excretion of Ceftibuten can be decreased when combined with Acetylsalicylic acid. | [DB06211] Doripenem: The excretion of Doripenem can be decreased when combined with Acetylsalicylic acid. | [DB11817] Baricitinib: The serum concentration of Baricitinib can be increased when it is combined with Acetylsalicylic acid. | [DB00863] Ranitidine: The excretion of Ranitidine can be decreased when combined with Acetylsalicylic acid. | [DB00950] Fexofenadine: The excretion of Fexofenadine can be decreased when combined with Acetylsalicylic acid. | [DB00595] Oxytetracycline: The excretion of Oxytetracycline can be decreased when combined with Acetylsalicylic acid. | [DB14649] Dexamethasone acetate: The risk or severity of gastrointestinal irritation can be increased when Dexamethasone acetate is combined with Acetylsalicylic acid. | [DB00286] Conjugated estrogens: The excretion of Conjugated estrogens can be decreased when combined with Acetylsalicylic acid. | [DB00583] Levocarnitine: The excretion of Levocarnitine can be decreased when combined with Acetylsalicylic acid. | [DB00783] Estradiol: The excretion of Estradiol can be decreased when combined with Acetylsalicylic acid. | [DB01606] Tazobactam: The excretion of Tazobactam can be decreased when combined with Acetylsalicylic acid. | [DB00659] Acamprosate: The excretion of Acamprosate can be decreased when combined with Acetylsalicylic acid. | [DB00630] Alendronic acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alendronic acid. | [DB00395] Carisoprodol: The metabolism of Carisoprodol can be increased when combined with Acetylsalicylic acid. | [DB08816] Ticagrelor: The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Acetylsalicylic acid. | [DB01133] Tiludronic acid: The serum concentration of Tiludronic acid can be decreased when it is combined with Acetylsalicylic acid. | [DB00686] Pentosan polysulfate: The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Acetylsalicylic acid. | [DB00285] Venlafaxine: Venlafaxine may increase the antiplatelet activities of Acetylsalicylic acid. | [DB00476] Duloxetine: Duloxetine may increase the antiplatelet activities of Acetylsalicylic acid. | [DB01105] Sibutramine: Sibutramine may increase the antiplatelet activities of Acetylsalicylic acid. | [DB01149] Nefazodone: Nefazodone may increase the antiplatelet activities of Acetylsalicylic acid. | [DB04896] Milnacipran: Milnacipran may increase the antiplatelet activities of Acetylsalicylic acid. | [DB06700] Desvenlafaxine: Desvenlafaxine may increase the antiplatelet activities of Acetylsalicylic acid. | [DB08918] Levomilnacipran: Levomilnacipran may increase the antiplatelet activities of Acetylsalicylic acid. | [DB00749] Etodolac: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etodolac. | [DB00821] Carprofen: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Carprofen. | [DB06736] Aceclofenac: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Aceclofenac. | [DB00533] Rofecoxib: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Rofecoxib. | [DB00580] Valdecoxib: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Valdecoxib. | [DB01283] Lumiracoxib: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Lumiracoxib. | [DB01628] Etoricoxib: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etoricoxib. | [DB05095] Cimicoxib: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Cimicoxib. | [DB08439] Parecoxib: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Parecoxib. | [DB09217] Firocoxib: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Firocoxib. | [DB09295] Talniflumate: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Talniflumate. | [DB11455] Robenacoxib: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Robenacoxib. | [DB12399] Polmacoxib: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Polmacoxib. | [DB04552] Niflumic acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Niflumic acid. | [DB09211] Limaprost: Acetylsalicylic acid may increase the anticoagulant activities of Limaprost. | [DB11133] Omega-3 fatty acids: Omega-3 fatty acids may increase the antiplatelet activities of Acetylsalicylic acid. | [DB00081] Tositumomab: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tositumomab. | [DB00177] Valsartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valsartan is combined with Acetylsalicylic acid. | [DB00275] Olmesartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Acetylsalicylic acid. | [DB00678] Losartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Acetylsalicylic acid. | [DB00796] Candesartan cilexetil: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan cilexetil is combined with Acetylsalicylic acid. | [DB00876] Eprosartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Acetylsalicylic acid. | [DB00966] Telmisartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Acetylsalicylic acid. | [DB01029] Irbesartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Irbesartan is combined with Acetylsalicylic acid. | [DB01342] Forasartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Forasartan is combined with Acetylsalicylic acid. | [DB01347] Saprisartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Acetylsalicylic acid. | [DB01349] Tasosartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Acetylsalicylic acid. | [DB06763] Saralasin: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saralasin is combined with Acetylsalicylic acid. | [DB08822] Azilsartan medoxomil: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Acetylsalicylic acid. | [DB09279] Fimasartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Acetylsalicylic acid. | [DB13919] Candesartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan is combined with Acetylsalicylic acid. | [DB00187] Esmolol: Acetylsalicylic acid may decrease the antihypertensive activities of Esmolol. | [DB00195] Betaxolol: Acetylsalicylic acid may decrease the antihypertensive activities of Betaxolol. | [DB00264] Metoprolol: Acetylsalicylic acid may decrease the antihypertensive activities of Metoprolol. | [DB00335] Atenolol: Acetylsalicylic acid may decrease the antihypertensive activities of Atenolol. | [DB00373] Timolol: Acetylsalicylic acid may decrease the antihypertensive activities of Timolol. | [DB00489] Sotalol: Acetylsalicylic acid may decrease the antihypertensive activities of Sotalol. | [DB00598] Labetalol: Acetylsalicylic acid may decrease the antihypertensive activities of Labetalol. | [DB00612] Bisoprolol: Acetylsalicylic acid may decrease the antihypertensive activities of Bisoprolol. | [DB00866] Alprenolol: Acetylsalicylic acid may decrease the antihypertensive activities of Alprenolol. | [DB00960] Pindolol: Acetylsalicylic acid may decrease the antihypertensive activities of Pindolol. | [DB01136] Carvedilol: Acetylsalicylic acid may decrease the antihypertensive activities of Carvedilol. | [DB01182] Propafenone: Acetylsalicylic acid may decrease the antihypertensive activities of Propafenone. | [DB01193] Acebutolol: Acetylsalicylic acid may decrease the antihypertensive activities of Acebutolol. | [DB01203] Nadolol: Acetylsalicylic acid may decrease the antihypertensive activities of Nadolol. | [DB01295] Bevantolol: Acetylsalicylic acid may decrease the antihypertensive activities of Bevantolol. | [DB01297] Practolol: Acetylsalicylic acid may decrease the antihypertensive activities of Practolol. | [DB01359] Penbutolol: Acetylsalicylic acid may decrease the antihypertensive activities of Penbutolol. | [DB01580] Oxprenolol: Acetylsalicylic acid may decrease the antihypertensive activities of Oxprenolol. | [DB03322] Dexpropranolol: Acetylsalicylic acid may decrease the antihypertensive activities of Dexpropranolol. | [DB04846] Celiprolol: Acetylsalicylic acid may decrease the antihypertensive activities of Celiprolol. | [DB04861] Nebivolol: Acetylsalicylic acid may decrease the antihypertensive activities of Nebivolol. | [DB06726] Bufuralol: Acetylsalicylic acid may decrease the antihypertensive activities of Bufuralol. | [DB08807] Bopindolol: Acetylsalicylic acid may decrease the antihypertensive activities of Bopindolol. | [DB08808] Bupranolol: Acetylsalicylic acid may decrease the antihypertensive activities of Bupranolol. | [DB08952] Indenolol: Acetylsalicylic acid may decrease the antihypertensive activities of Indenolol. | [DB09204] Arotinolol: Acetylsalicylic acid may decrease the antihypertensive activities of Arotinolol. | [DB09351] Levobetaxolol: Acetylsalicylic acid may decrease the antihypertensive activities of Levobetaxolol. | [DB11770] Talinolol: Acetylsalicylic acid may decrease the antihypertensive activities of Talinolol. | [DB11785] Anisodamine: Acetylsalicylic acid may decrease the antihypertensive activities of Anisodamine. | [DB12752] Bucindolol: Acetylsalicylic acid may decrease the antihypertensive activities of Bucindolol. | [DB13443] Esatenolol: Acetylsalicylic acid may decrease the antihypertensive activities of Esatenolol. | [DB13508] Cloranolol: Acetylsalicylic acid may decrease the antihypertensive activities of Cloranolol. | [DB13530] Mepindolol: Acetylsalicylic acid may decrease the antihypertensive activities of Mepindolol. | [DB13757] Epanolol: Acetylsalicylic acid may decrease the antihypertensive activities of Epanolol. | [DB13775] Tertatolol: Acetylsalicylic acid may decrease the antihypertensive activities of Tertatolol. | [DB12212] Landiolol: Acetylsalicylic acid may decrease the antihypertensive activities of Landiolol. | [DB00218] Moxifloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Moxifloxacin. | [DB00467] Enoxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Enoxacin. | [DB00487] Pefloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Pefloxacin. | [DB00685] Trovafloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Trovafloxacin. | [DB00779] Nalidixic acid: Acetylsalicylic acid may increase the neuroexcitatory activities of Nalidixic acid. | [DB00817] Rosoxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Rosoxacin. | [DB00827] Cinoxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Cinoxacin. | [DB00978] Lomefloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Lomefloxacin. | [DB01044] Gatifloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Gatifloxacin. | [DB01059] Norfloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Norfloxacin. | [DB01155] Gemifloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Gemifloxacin. | [DB01165] Ofloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Ofloxacin. | [DB01405] Temafloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Temafloxacin. | [DB04576] Fleroxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Fleroxacin. | [DB05488] Technetium Tc-99m ciprofloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Technetium Tc-99m ciprofloxacin. | [DB06160] Garenoxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Garenoxacin. | [DB06600] Nemonoxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Nemonoxacin. | [DB08972] Flumequine: Acetylsalicylic acid may increase the neuroexcitatory activities of Flumequine. | [DB11404] Enrofloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Enrofloxacin. | [DB11443] Orbifloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Orbifloxacin. | [DB11491] Sarafloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Sarafloxacin. | [DB11511] Difloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Difloxacin. | [DB11774] Pazufloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Pazufloxacin. | [DB11892] Prulifloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Prulifloxacin. | [DB13261] Sitafloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Sitafloxacin. | [DB13627] Oxolinic acid: Acetylsalicylic acid may increase the neuroexcitatory activities of Oxolinic acid. | [DB13772] Rufloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Rufloxacin. | [DB13823] Pipemidic acid: Acetylsalicylic acid may increase the neuroexcitatory activities of Pipemidic acid. | [DB01208] Sparfloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Sparfloxacin. | [DB01009] Ketoprofen: The risk or severity of bleeding and gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Ketoprofen. | [DB09214] Dexketoprofen: The risk or severity of bleeding and gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Dexketoprofen. | [DB00511] Acetyldigitoxin: The serum concentration of Acetyldigitoxin can be decreased when it is combined with Acetylsalicylic acid. | [DB01078] Deslanoside: The serum concentration of Deslanoside can be decreased when it is combined with Acetylsalicylic acid. | [DB01092] Ouabain: The serum concentration of Ouabain can be decreased when it is combined with Acetylsalicylic acid. | [DB12843] Oleandrin: The serum concentration of Oleandrin can be decreased when it is combined with Acetylsalicylic acid. | [DB13240] Cymarin: The serum concentration of Cymarin can be decreased when it is combined with Acetylsalicylic acid. | [DB13307] Proscillaridin: The serum concentration of Proscillaridin can be decreased when it is combined with Acetylsalicylic acid. | [DB13467] Lanatoside C: The serum concentration of Lanatoside C can be decreased when it is combined with Acetylsalicylic acid. | [DB13537] Gitoformate: The serum concentration of Gitoformate can be decreased when it is combined with Acetylsalicylic acid. | [DB13756] Peruvoside: The serum concentration of Peruvoside can be decreased when it is combined with Acetylsalicylic acid. | [DB01396] Digitoxin: The serum concentration of Digitoxin can be decreased when it is combined with Acetylsalicylic acid. | [DB00282] Pamidronic acid: The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Pamidronic acid. | [DB00399] Zoledronic acid: The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Zoledronic acid. | [DB00710] Ibandronate: The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Ibandronate. | [DB00720] Clodronic acid: The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Clodronic acid. | [DB00884] Risedronic acid: The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Risedronic acid. | [DB01077] Etidronic acid: The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Etidronic acid. | [DB06255] Incadronic acid: The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Incadronic acid. | [DB00287] Travoprost: The therapeutic efficacy of Travoprost can be decreased when used in combination with Acetylsalicylic acid. | [DB00654] Latanoprost: The therapeutic efficacy of Latanoprost can be decreased when used in combination with Acetylsalicylic acid. | [DB00905] Bimatoprost: The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Acetylsalicylic acid. | [DB02056] Prostaglandin D2: The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Acetylsalicylic acid. | [DB02304] Prostaglandin B2: The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Acetylsalicylic acid. | [DB03866] Prostaglandin G2: The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Acetylsalicylic acid. | [DB06826] Unoprostone: The therapeutic efficacy of Unoprostone can be decreased when used in combination with Acetylsalicylic acid. | [DB08819] Tafluprost: The therapeutic efficacy of Tafluprost can be decreased when used in combination with Acetylsalicylic acid. | [DB11411] Fenprostalene: The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Acetylsalicylic acid. | [DB11425] Luprostiol: The therapeutic efficacy of Luprostiol can be decreased when used in combination with Acetylsalicylic acid. | [DB11454] Prostalene: The therapeutic efficacy of Prostalene can be decreased when used in combination with Acetylsalicylic acid. | [DB11519] Fluprostenol: The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Acetylsalicylic acid. | [DB11660] Latanoprostene bunod: The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Acetylsalicylic acid. | [DB13824] Enprostil: The therapeutic efficacy of Enprostil can be decreased when used in combination with Acetylsalicylic acid. | [DB11507] Cloprostenol: The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Acetylsalicylic acid. | [DB00864] Tacrolimus: The risk or severity of renal failure can be increased when Acetylsalicylic acid is combined with Tacrolimus. | [DB00352] Tioguanine: The metabolism of Tioguanine can be decreased when combined with Acetylsalicylic acid. | [DB00993] Azathioprine: The metabolism of Azathioprine can be decreased when combined with Acetylsalicylic acid. | [DB00375] Colestipol: Colestipol can cause a decrease in the absorption of Acetylsalicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB00658] Sevelamer: Sevelamer can cause a decrease in the absorption of Acetylsalicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB00930] Colesevelam: Colesevelam can cause a decrease in the absorption of Acetylsalicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB01432] Cholestyramine: Cholestyramine can cause a decrease in the absorption of Acetylsalicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB00229] Cefotiam: The excretion of Cefotiam can be decreased when combined with Acetylsalicylic acid. | [DB00267] Cefmenoxime: The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Acetylsalicylic acid. | [DB00274] Cefmetazole: The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Acetylsalicylic acid. | [DB00430] Cefpiramide: The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Acetylsalicylic acid. | [DB00447] Loracarbef: The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Acetylsalicylic acid. | [DB00456] Cefalotin: The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Acetylsalicylic acid. | [DB00493] Cefotaxime: The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Acetylsalicylic acid. | [DB00626] Bacitracin: The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Acetylsalicylic acid. | [DB00681] Amphotericin B: The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Acetylsalicylic acid. | [DB00689] Cephaloglycin: The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Acetylsalicylic acid. | [DB00718] Adefovir dipivoxil: The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Acetylsalicylic acid. | [DB00923] Ceforanide: The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Acetylsalicylic acid. | [DB01066] Cefditoren: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefditoren. | [DB01111] Colistimethate: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Colistimethate. | [DB01112] Cefuroxime: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefuroxime. | [DB01139] Cefapirin: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefapirin. | [DB01150] Cefprozil: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefprozil. | [DB01326] Cefamandole: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefamandole. | [DB01327] Cefazolin: The excretion of Cefazolin can be decreased when combined with Acetylsalicylic acid. | [DB01328] Cefonicid: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefonicid. | [DB01331] Cefoxitin: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefoxitin. | [DB01332] Ceftizoxime: The excretion of Ceftizoxime can be decreased when combined with Acetylsalicylic acid. | [DB01413] Cefepime: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefepime. | [DB01414] Cefacetrile: The excretion of Cefacetrile can be decreased when combined with Acetylsalicylic acid. | [DB01416] Cefpodoxime: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefpodoxime. | [DB02247] Hydrolyzed Cephalothin: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Hydrolyzed Cephalothin. | [DB03450] Cephalothin Group: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cephalothin Group. | [DB04570] Latamoxef: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Latamoxef. | [DB04918] Ceftobiprole: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Ceftobiprole. | [DB06590] Ceftaroline fosamil: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Ceftaroline fosamil. | [DB09008] Cefaloridine: The excretion of Cefaloridine can be decreased when combined with Acetylsalicylic acid. | [DB09062] Cefminox: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefminox. | [DB11935] Flomoxef: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Flomoxef. | [DB13266] Cefatrizine: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefatrizine. | [DB13461] Cefcapene: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefcapene. | [DB13470] Cefodizime: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefodizime. | [DB13499] Cefsulodin: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefsulodin. | [DB13504] Cefetamet: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefetamet. | [DB13638] Cefbuperazone: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefbuperazone. | [DB13667] Cefozopran: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefozopran. | [DB13682] Cefpirome: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefpirome. | [DB13778] Cefazedone: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefazedone. | [DB13821] Ceftezole: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Ceftezole. | [DB13868] Adefovir: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Adefovir. | [DB14713] Inotersen: The risk or severity of thrombocytopenia can be increased when Inotersen is combined with Acetylsalicylic acid. | [DB00369] Cidofovir: The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Acetylsalicylic acid. | [DB00438] Ceftazidime: The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Acetylsalicylic acid. | [DB00958] Carboplatin: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Carboplatin. | [DB01140] Cefadroxil: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefadroxil. | [DB01330] Cefotetan: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefotetan. | [DB01333] Cefradine: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefradine. | [DB11367] Cefroxadine: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefroxadine. | [DB01438] Phenazopyridine: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Phenazopyridine. | [DB15066] Givosiran: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Givosiran. | [DB01601] Lopinavir: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Lopinavir. | [DB01212] Ceftriaxone: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Ceftriaxone. | [DB01329] Cefoperazone: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefoperazone. | [DB00452] Framycetin: The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Acetylsalicylic acid. | [DB01421] Paromomycin: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Paromomycin. | [DB04263] Geneticin: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Geneticin. | [DB04626] Apramycin: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Apramycin. | [DB04808] Neamine: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Neamine. | [DB08437] Puromycin: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Puromycin. | [DB11512] Dihydrostreptomycin: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Dihydrostreptomycin. | [DB11520] Hygromycin B: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Hygromycin B. | [DB01356] Lithium cation: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Lithium cation. | [DB00898] Ethanol: The risk or severity of adverse effects can be increased when Ethanol is combined with Acetylsalicylic acid. | [DB09220] Nicorandil: The risk or severity of hemorrhage, gastrointestinal bleeding, and gastrointestinal ulceration can be increased when Acetylsalicylic acid is combined with Nicorandil. | [DB04865] Omacetaxine mepesuccinate: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Omacetaxine mepesuccinate. | [DB00159] Icosapent: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Icosapent. | [DB00244] Mesalazine: The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Acetylsalicylic acid. | [DB00328] Indomethacin: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Indomethacin. | [DB00469] Tenoxicam: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Tenoxicam. | [DB00500] Tolmetin: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Tolmetin. | [DB00554] Piroxicam: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Piroxicam. | [DB00573] Fenoprofen: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Fenoprofen. | [DB00586] Diclofenac: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Diclofenac. | [DB00605] Sulindac: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Sulindac. | [DB00712] Flurbiprofen: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Flurbiprofen. | [DB00784] Mefenamic acid: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Mefenamic acid. | [DB00795] Sulfasalazine: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Sulfasalazine. | [DB00812] Phenylbutazone: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Phenylbutazone. | [DB00861] Diflunisal: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Diflunisal. | [DB00870] Suprofen: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Suprofen. | [DB00939] Meclofenamic acid: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Meclofenamic acid. | [DB00233] Aminosalicylic acid: The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Acetylsalicylic acid. | [DB01014] Balsalazide: The therapeutic efficacy of Balsalazide can be decreased when used in combination with Acetylsalicylic acid. | [DB01250] Olsalazine: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Olsalazine. | [DB01294] Bismuth subsalicylate: The therapeutic efficacy of Bismuth subsalicylate can be decreased when used in combination with Acetylsalicylic acid. | [DB06251] Dersalazine: The therapeutic efficacy of Dersalazine can be decreased when used in combination with Acetylsalicylic acid. | [DB06807] Phenyl aminosalicylate: The therapeutic efficacy of Phenyl aminosalicylate can be decreased when used in combination with Acetylsalicylic acid. | [DB09543] Methyl salicylate: The therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Acetylsalicylic acid. | [DB11079] Trolamine salicylate: The therapeutic efficacy of Trolamine salicylate can be decreased when used in combination with Acetylsalicylic acid. | [DB13509] Aloxiprin: The therapeutic efficacy of Aloxiprin can be decreased when used in combination with Acetylsalicylic acid. | [DB13538] Guacetisal: The therapeutic efficacy of Guacetisal can be decreased when used in combination with Acetylsalicylic acid. | [DB13612] Carbaspirin calcium: The therapeutic efficacy of Carbaspirin calcium can be decreased when used in combination with Acetylsalicylic acid. | [DB14006] Choline salicylate: The therapeutic efficacy of Choline salicylate can be decreased when used in combination with Acetylsalicylic acid. | [DB14026] Thiosalicylic acid: The therapeutic efficacy of Thiosalicylic acid can be decreased when used in combination with Acetylsalicylic acid. | [DB00963] Bromfenac: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Bromfenac. | [DB00991] Oxaprozin: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Oxaprozin. | [DB01397] Magnesium salicylate: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Magnesium salicylate. | [DB01399] Salsalate: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Salsalate. | [DB01401] Choline magnesium trisalicylate: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Choline magnesium trisalicylate. | [DB01419] Antrafenine: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Antrafenine. | [DB01435] Antipyrine: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Antipyrine. | [DB01600] Tiaprofenic acid: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Tiaprofenic acid. | [DB06725] Lornoxicam: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Lornoxicam. | [DB06802] Nepafenac: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Nepafenac. | [DB09215] Droxicam: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Droxicam. | [DB13346] Bufexamac: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Bufexamac. | [DB00343] Diltiazem: The risk or severity of bleeding can be increased when Diltiazem is combined with Acetylsalicylic acid. | [DB00661] Verapamil: The risk or severity of bleeding can be increased when Verapamil is combined with Acetylsalicylic acid. | [DB01118] Amiodarone: The metabolism of Acetylsalicylic acid can be decreased when combined with Amiodarone. | [DB00486] Nabilone: The metabolism of Acetylsalicylic acid can be decreased when combined with Nabilone. | [DB00619] Imatinib: The metabolism of Acetylsalicylic acid can be decreased when combined with Imatinib. | [DB00625] Efavirenz: The metabolism of Acetylsalicylic acid can be decreased when combined with Efavirenz. | [DB00949] Felbamate: The metabolism of Acetylsalicylic acid can be decreased when combined with Felbamate. | [DB04818] Iproniazid: The metabolism of Acetylsalicylic acid can be decreased when combined with Iproniazid. | [DB14009] Medical Cannabis: The metabolism of Acetylsalicylic acid can be decreased when combined with Medical Cannabis. | [DB08912] Dabrafenib: The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Dabrafenib. | [DB00196] Fluconazole: The metabolism of Acetylsalicylic acid can be decreased when combined with Fluconazole. | [DB00322] Floxuridine: The metabolism of Acetylsalicylic acid can be decreased when combined with Floxuridine. | [DB00398] Sorafenib: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Sorafenib. | [DB00622] Nicardipine: The metabolism of Acetylsalicylic acid can be decreased when combined with Nicardipine. | [DB00705] Delavirdine: The metabolism of Acetylsalicylic acid can be decreased when combined with Delavirdine. | [DB01110] Miconazole: The metabolism of Acetylsalicylic acid can be decreased when combined with Miconazole. | [DB01241] Gemfibrozil: The metabolism of Acetylsalicylic acid can be decreased when combined with Gemfibrozil. | [DB06729] Sulfaphenazole: The metabolism of Acetylsalicylic acid can be decreased when combined with Sulfaphenazole. | [DB00180] Flunisolide: The risk or severity of gastrointestinal irritation can be increased when Flunisolide is combined with Acetylsalicylic acid. | [DB00687] Fludrocortisone: The risk or severity of gastrointestinal irritation can be increased when Fludrocortisone is combined with Acetylsalicylic acid. | [DB00741] Hydrocortisone: The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Acetylsalicylic acid. | [DB00860] Prednisolone: The risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Acetylsalicylic acid. | [DB00959] Methylprednisolone: The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Acetylsalicylic acid. | [DB01108] Trilostane: The risk or severity of gastrointestinal irritation can be increased when Trilostane is combined with Acetylsalicylic acid. | [DB01222] Budesonide: The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Acetylsalicylic acid. | [DB01234] Dexamethasone: The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Acetylsalicylic acid. | [DB01285] Corticotropin: The risk or severity of gastrointestinal irritation can be increased when Corticotropin is combined with Acetylsalicylic acid. | [DB04630] Aldosterone: The risk or severity of gastrointestinal irritation can be increased when Aldosterone is combined with Acetylsalicylic acid. | [DB09378] Fluprednisolone: The risk or severity of gastrointestinal irritation can be increased when Fluprednisolone is combined with Acetylsalicylic acid. | [DB11529] Melengestrol: The risk or severity of gastrointestinal irritation can be increased when Melengestrol is combined with Acetylsalicylic acid. | [DB00591] Fluocinolone acetonide: The risk or severity of gastrointestinal irritation can be increased when Fluocinolone acetonide is combined with Acetylsalicylic acid. | [DB09091] Tixocortol: The risk or severity of gastrointestinal irritation can be increased when Tixocortol is combined with Acetylsalicylic acid. | [DB13223] Fluocortin: The risk or severity of gastrointestinal irritation can be increased when Fluocortin is combined with Acetylsalicylic acid. | [DB13491] Fluperolone: The risk or severity of gastrointestinal irritation can be increased when Fluperolone is combined with Acetylsalicylic acid. | [DB13856] Fluclorolone: The risk or severity of gastrointestinal irritation can be increased when Fluclorolone is combined with Acetylsalicylic acid. | [DB14539] Hydrocortisone acetate: The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Acetylsalicylic acid. | [DB14541] Hydrocortisone cypionate: The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone cypionate is combined with Acetylsalicylic acid. | [DB14545] Hydrocortisone succinate: The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone succinate is combined with Acetylsalicylic acid. | [DB00588] Fluticasone propionate: The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Acetylsalicylic acid. | [DB14540] Hydrocortisone butyrate: The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Acetylsalicylic acid. | [DB00547] Desoximetasone: The risk or severity of gastrointestinal irritation can be increased when Desoximetasone is combined with Acetylsalicylic acid. | [DB15566] Prednisolone acetate: The risk or severity of gastrointestinal irritation can be increased when Prednisolone acetate is combined with Acetylsalicylic acid. | [DB00324] Fluorometholone: The risk or severity of gastrointestinal irritation can be increased when Fluorometholone is combined with Acetylsalicylic acid. | [DB00663] Flumethasone: The risk or severity of gastrointestinal irritation can be increased when Flumethasone is combined with Acetylsalicylic acid. | [DB14643] Methylprednisolone aceponate: The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Acetylsalicylic acid. | [DB00202] Succinylcholine: The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Acetylsalicylic acid. | [DB01074] Perhexiline: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Perhexiline. | [DB01219] Dantrolene: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Dantrolene. | [DB02968] Penicillin G Acyl-Serine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Penicillin G Acyl-Serine. | [DB12097] Mannitol busulfan: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Mannitol busulfan. | [DB00347] Trimethadione: The risk or severity of hyperkalemia can be increased when Trimethadione is combined with Acetylsalicylic acid. | [DB00568] Cinnarizine: The risk or severity of hyperkalemia can be increased when Cinnarizine is combined with Acetylsalicylic acid. | [DB04841] Flunarizine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Flunarizine. | [DB00593] Ethosuximide: The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Acetylsalicylic acid. | [DB00653] Magnesium sulfate: The risk or severity of hyperkalemia can be increased when Magnesium sulfate is combined with Acetylsalicylic acid. | [DB04825] Prenylamine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Prenylamine. | [DB04838] Cyclandelate: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Cyclandelate. | [DB04842] Fluspirilene: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Fluspirilene. | [DB05246] Methsuximide: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Methsuximide. | [DB05885] Seletracetam: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Seletracetam. | [DB06152] Nylidrin: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Nylidrin. | [DB06446] Dotarizine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Dotarizine. | [DB08838] Agmatine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Agmatine. | [DB08980] Fendiline: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Fendiline. | [DB08992] Eperisone: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Eperisone. | [DB09090] Pinaverium: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Pinaverium. | [DB09227] Barnidipine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Barnidipine. | [DB09229] Aranidipine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Aranidipine. | [DB09230] Azelnidipine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Azelnidipine. | [DB09231] Benidipine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Benidipine. | [DB09232] Cilnidipine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Cilnidipine. | [DB09234] Darodipine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Darodipine. | [DB09240] Niludipine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Niludipine. | [DB11960] Carboxyamidotriazole: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Carboxyamidotriazole. | [DB12131] Vinpocetine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Vinpocetine. | [DB13488] Bencyclane: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Bencyclane. | [DB13500] Otilonium: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Otilonium. | [DB13725] Terodiline: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Terodiline. | [DB13766] Lidoflazine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Lidoflazine. | [DB13791] Penfluridol: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Penfluridol. | [DB13835] Caroverine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Caroverine. | [DB13950] WIN 55212-2: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with WIN 55212-2. | [DB13961] Fish oil: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Fish oil. | [DB00836] Loperamide: The risk or severity of hyperkalemia can be increased when Loperamide is combined with Acetylsalicylic acid. | [DB01026] Ketoconazole: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Ketoconazole. | [DB01167] Itraconazole: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Itraconazole. | [DB12923] Gallopamil: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Gallopamil. | [DB14063] Dexverapamil: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Dexverapamil. | [DB14064] Emopamil: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Emopamil. | [DB14065] Lomerizine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Lomerizine. | [DB14066] Tetrandrine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Tetrandrine. | [DB09261] Certoparin: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Certoparin. | [DB16165] Finerenone: Acetylsalicylic acid may decrease the excretion rate of Finerenone which could result in a higher serum level. | [DB09413] Monopotassium phosphate: The serum concentration of Acetylsalicylic acid can be increased when it is combined with Monopotassium phosphate. | [DB10318] Varicella zoster vaccine (live/attenuated): The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Varicella zoster vaccine (live/attenuated). | [DB09449] Sodium phosphate, monobasic: The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Acetylsalicylic acid. | [DB06695] Dabigatran etexilate: Acetylsalicylic acid may increase the anticoagulant activities of Dabigatran etexilate. | [DB00008] Peginterferon alfa-2a: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Peginterferon alfa-2a. | [DB00011] Interferon alfa-n1: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfa-n1. | [DB00018] Interferon alfa-n3: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfa-n3. | [DB00022] Peginterferon alfa-2b: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Peginterferon alfa-2b. | [DB00033] Interferon gamma-1b: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon gamma-1b. | [DB00034] Interferon alfa-2a: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfa-2a. | [DB00056] Gemtuzumab ozogamicin: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Gemtuzumab ozogamicin. | [DB00068] Interferon beta-1b: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon beta-1b. | [DB00069] Interferon alfacon-1: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfacon-1. | [DB00073] Rituximab: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Rituximab. | [DB00087] Alemtuzumab: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Alemtuzumab. | [DB00105] Interferon alfa-2b: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfa-2b. | [DB00120] Phenylalanine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Phenylalanine. | [DB00242] Cladribine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Cladribine. | [DB00293] Raltitrexed: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Raltitrexed. | [DB00309] Vindesine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Vindesine. | [DB00428] Streptozocin: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Streptozocin. | [DB00445] Epirubicin: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Epirubicin. | [DB00446] Chloramphenicol: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Chloramphenicol. | [DB00488] Altretamine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Altretamine. | [DB00526] Oxaliplatin: The risk or severity of nephrotoxicity can be increased when Oxaliplatin is combined with Acetylsalicylic acid. | [DB00859] Penicillamine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Penicillamine. | [DB00888] Mechlorethamine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Mechlorethamine. | [DB01008] Busulfan: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Busulfan. | [DB01041] Thalidomide: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Thalidomide. | [DB01073] Fludarabine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Fludarabine. | [DB01177] Idarubicin: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Idarubicin. | [DB01206] Lomustine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Lomustine. | [DB01262] Decitabine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Decitabine. | [DB01280] Nelarabine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Nelarabine. | [DB02546] Vorinostat: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Vorinostat. | [DB04572] Thiotepa: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Thiotepa. | [DB04845] Ixabepilone: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Ixabepilone. | [DB05258] Interferon alfa: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfa. | [DB05472] Human interferon omega-1: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Human interferon omega-1. | [DB06769] Bendamustine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Bendamustine. | [DB08871] Eribulin: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Eribulin. | [DB08895] Tofacitinib: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Tofacitinib. | [DB09042] Tedizolid phosphate: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Tedizolid phosphate. | [DB09052] Blinatumomab: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Blinatumomab. | [DB09077] Dinutuximab: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Dinutuximab. | [DB09122] Peginterferon beta-1a: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Peginterferon beta-1a. | [DB12814] Cepeginterferon alfa-2B: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Cepeginterferon alfa-2B. | [DB05015] Belinostat: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Belinostat. | [DB04868] Nilotinib: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Nilotinib. | [DB00550] Propylthiouracil: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Propylthiouracil. | [DB00276] Amsacrine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Amsacrine. | [DB00291] Chlorambucil: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Chlorambucil. | [DB00305] Mitomycin: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Mitomycin. | [DB00361] Vinorelbine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Vinorelbine. | [DB00570] Vinblastine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Vinblastine. | [DB00694] Daunorubicin: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Daunorubicin. | [DB00762] Irinotecan: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Irinotecan. | [DB00773] Etoposide: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Etoposide. | [DB00970] Dactinomycin: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Dactinomycin. | [DB00987] Cytarabine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Cytarabine. | [DB00997] Doxorubicin: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Doxorubicin. | [DB01005] Hydroxyurea: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Hydroxyurea. | [DB01042] Melphalan: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Melphalan. | [DB01204] Mitoxantrone: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Mitoxantrone. | [DB01229] Paclitaxel: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Paclitaxel. | [DB01248] Docetaxel: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Docetaxel. | [DB01590] Everolimus: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Everolimus. | [DB05773] Trastuzumab emtansine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Trastuzumab emtansine. | [DB06616] Bosutinib: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Bosutinib. | [DB06772] Cabazitaxel: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Cabazitaxel. | [DB08889] Carfilzomib: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Carfilzomib. | [DB08901] Ponatinib: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Ponatinib. | [DB09073] Palbociclib: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Palbociclib. | [DB09074] Olaparib: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Olaparib. | [DB12364] Betrixaban: The risk or severity of bleeding can be increased when Betrixaban is combined with Acetylsalicylic acid. | [DB00091] Cyclosporine: The risk or severity of renal failure and hypertension can be increased when Acetylsalicylic acid is combined with Cyclosporine. | [DB13615] Mifamurtide: The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Acetylsalicylic acid. | [DB11051] Azficel-T: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Azficel-T. | [DB11642] Pitolisant: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pitolisant. | [DB07477] Felbinac: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Felbinac. | [DB09212] Loxoprofen: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Loxoprofen. | [DB13514] Pranoprofen: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pranoprofen. | [DB12480] Betulinic Acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Betulinic Acid. | [DB13364] Feprazone: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Feprazone. | [DB13501] Bendazac: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Bendazac. | [DB04725] Licofelone: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Licofelone. | [DB14938] Flurbiprofen axetil: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Flurbiprofen axetil. | [DB00936] Salicylic acid: The risk or severity of adverse effects can be increased when Salicylic acid is combined with Acetylsalicylic acid. | [DB09084] Benzydamine: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Benzydamine. | [DB13167] Alclofenac: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alclofenac. | [DB01424] Aminophenazone: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Aminophenazone. | [DB03585] Oxyphenbutazone: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Oxyphenbutazone. | [DB04812] Benoxaprofen: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Benoxaprofen. | [DB04817] Metamizole: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Metamizole. | [DB04828] Zomepirac: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Zomepirac. | [DB06737] Zaltoprofen: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Zaltoprofen. | [DB08940] Kebuzone: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Kebuzone. | [DB08942] Isoxicam: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Isoxicam. | [DB08951] Indoprofen: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Indoprofen. | [DB08955] Ibuproxam: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibuproxam. | [DB08976] Floctafenine: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Floctafenine. | [DB08981] Fenbufen: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fenbufen. | [DB08984] Etofenamate: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etofenamate. | [DB08991] Epirizole: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Epirizole. | [DB09216] Tolfenamic acid: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tolfenamic acid. | [DB09218] Clonixin: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clonixin. | [DB09285] Morniflumate: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Morniflumate. | [DB11466] Tepoxalin: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tepoxalin. | [DB11518] Flunixin: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Flunixin. | [DB13001] Tinoridine: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tinoridine. | [DB13217] Fentiazac: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fentiazac. | [DB13232] Suxibuzone: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Suxibuzone. | [DB13286] Bumadizone: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Bumadizone. | [DB13314] Alminoprofen: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alminoprofen. | [DB13371] Difenpiramide: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Difenpiramide. | [DB13407] Nifenazone: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Nifenazone. | [DB13432] Lonazolac: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Lonazolac. | [DB13481] Tenidap: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tenidap. | [DB13524] Propyphenazone: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Propyphenazone. | [DB13527] Proglumetacin: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Proglumetacin. | [DB13544] Ethenzamide: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ethenzamide. | [DB13629] Mofebutazone: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Mofebutazone. | [DB13649] Proquazone: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Proquazone. | [DB13657] Benorilate: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Benorilate. | [DB13722] Pirprofen: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pirprofen. | [DB13783] Acemetacin: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Acemetacin. | [DB13860] Imidazole salicylate: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Imidazole salicylate. | [DB14059] SC-236: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with SC-236. | [DB14060] NS-398: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with NS-398. | [DB02224] Taxifolin: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Taxifolin. | [DB12610] Ebselen: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ebselen. | [DB01033] Mercaptopurine: The excretion of Mercaptopurine can be decreased when combined with Acetylsalicylic acid. | [DB00631] Clofarabine: The excretion of Clofarabine can be decreased when combined with Acetylsalicylic acid. | [DB00007] Leuprolide: Acetylsalicylic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level. | [DB00014] Goserelin: Acetylsalicylic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. | [DB00017] Salmon calcitonin: Acetylsalicylic acid may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level. | [DB00041] Aldesleukin: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Aldesleukin. | [DB00080] Daptomycin: Acetylsalicylic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level. | [DB00115] Cyanocobalamin: Acetylsalicylic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level. | [DB00165] Pyridoxine: Acetylsalicylic acid may decrease the excretion rate of Pyridoxine which could result in a higher serum level. | [DB00182] Amphetamine: The risk or severity of hypertension can be increased when Amphetamine is combined with Acetylsalicylic acid. | [DB00185] Cevimeline: Acetylsalicylic acid may decrease the excretion rate of Cevimeline which could result in a higher serum level. | [DB00186] Lorazepam: Acetylsalicylic acid may decrease the excretion rate of Lorazepam which could result in a higher serum level. | [DB00190] Carbidopa: Acetylsalicylic acid may decrease the excretion rate of Carbidopa which could result in a higher serum level. | [DB00193] Tramadol: Acetylsalicylic acid may decrease the excretion rate of Tramadol which could result in a higher serum level. | [DB00200] Hydroxocobalamin: Acetylsalicylic acid may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level. | [DB00225] Gadodiamide: Acetylsalicylic acid may decrease the excretion rate of Gadodiamide which could result in a higher serum level. | [DB00231] Temazepam: Acetylsalicylic acid may decrease the excretion rate of Temazepam which could result in a higher serum level. | [DB00235] Milrinone: Acetylsalicylic acid may decrease the excretion rate of Milrinone which could result in a higher serum level. | [DB00237] Butabarbital: Acetylsalicylic acid may decrease the excretion rate of Butabarbital which could result in a higher serum level. | [DB00245] Benzatropine: Acetylsalicylic acid may decrease the excretion rate of Benzatropine which could result in a higher serum level. | [DB00262] Carmustine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Carmustine. | [DB00271] Diatrizoate: Acetylsalicylic acid may decrease the excretion rate of Diatrizoate which could result in a higher serum level. | [DB00289] Atomoxetine: The risk or severity of hypertension can be increased when Atomoxetine is combined with Acetylsalicylic acid. | [DB00290] Bleomycin: Acetylsalicylic acid may decrease the excretion rate of Bleomycin which could result in a higher serum level. | [DB00292] Etomidate: The risk or severity of hypertension can be increased when Etomidate is combined with Acetylsalicylic acid. | [DB00296] Ropivacaine: Acetylsalicylic acid may decrease the excretion rate of Ropivacaine which could result in a higher serum level. | [DB00303] Ertapenem: Acetylsalicylic acid may decrease the excretion rate of Ertapenem which could result in a higher serum level. | [DB00308] Ibutilide: Acetylsalicylic acid may decrease the excretion rate of Ibutilide which could result in a higher serum level. | [DB00312] Pentobarbital: Acetylsalicylic acid may decrease the excretion rate of Pentobarbital which could result in a higher serum level. | [DB00323] Tolcapone: Acetylsalicylic acid may decrease the excretion rate of Tolcapone which could result in a higher serum level. | [DB00327] Hydromorphone: Acetylsalicylic acid may decrease the excretion rate of Hydromorphone which could result in a higher serum level. | [DB00330] Ethambutol: Acetylsalicylic acid may decrease the excretion rate of Ethambutol which could result in a higher serum level. | [DB00339] Pyrazinamide: Acetylsalicylic acid may decrease the excretion rate of Pyrazinamide which could result in a higher serum level. | [DB00349] Clobazam: The metabolism of Acetylsalicylic acid can be decreased when combined with Clobazam. | [DB00355] Aztreonam: Acetylsalicylic acid may decrease the excretion rate of Aztreonam which could result in a higher serum level. | [DB00356] Chlorzoxazone: Acetylsalicylic acid may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level. | [DB00363] Clozapine: The risk or severity of hypertension can be increased when Clozapine is combined with Acetylsalicylic acid. | [DB00372] Thiethylperazine: Acetylsalicylic acid may decrease the excretion rate of Thiethylperazine which could result in a higher serum level. | [DB00377] Palonosetron: Acetylsalicylic acid may decrease the excretion rate of Palonosetron which could result in a higher serum level. | [DB00380] Dexrazoxane: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Dexrazoxane. | [DB00402] Eszopiclone: Acetylsalicylic acid may decrease the excretion rate of Eszopiclone which could result in a higher serum level. | [DB00404] Alprazolam: Acetylsalicylic acid may decrease the excretion rate of Alprazolam which could result in a higher serum level. | [DB00413] Pramipexole: Acetylsalicylic acid may decrease the excretion rate of Pramipexole which could result in a higher serum level. | [DB00415] Ampicillin: Acetylsalicylic acid may decrease the excretion rate of Ampicillin which could result in a higher serum level. | [DB00418] Secobarbital: Acetylsalicylic acid may decrease the excretion rate of Secobarbital which could result in a higher serum level. | [DB00435] Nitric Oxide: Acetylsalicylic acid may decrease the excretion rate of Nitric Oxide which could result in a higher serum level. | [DB00441] Gemcitabine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Gemcitabine. | [DB00480] Lenalidomide: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Lenalidomide. | [DB00499] Flutamide: Acetylsalicylic acid may decrease the excretion rate of Flutamide which could result in a higher serum level. | [DB00537] Ciprofloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Ciprofloxacin. | [DB00548] Azelaic acid: Acetylsalicylic acid may decrease the excretion rate of Azelaic acid which could result in a higher serum level. | [DB00553] Methoxsalen: Acetylsalicylic acid may decrease the excretion rate of Methoxsalen which could result in a higher serum level. | [DB00558] Zanamivir: Acetylsalicylic acid may decrease the excretion rate of Zanamivir which could result in a higher serum level. | [DB00597] Gadoteridol: Acetylsalicylic acid may decrease the excretion rate of Gadoteridol which could result in a higher serum level. | [DB00628] Clorazepic acid: Acetylsalicylic acid may decrease the excretion rate of Clorazepic acid which could result in a higher serum level. | [DB00633] Dexmedetomidine: The risk or severity of hypertension can be increased when Dexmedetomidine is combined with Acetylsalicylic acid. | [DB00651] Dyphylline: Acetylsalicylic acid may decrease the excretion rate of Dyphylline which could result in a higher serum level. | [DB00660] Metaxalone: Acetylsalicylic acid may decrease the excretion rate of Metaxalone which could result in a higher serum level. | [DB00669] Sumatriptan: The risk or severity of hypertension can be increased when Sumatriptan is combined with Acetylsalicylic acid. | [DB00683] Midazolam: Acetylsalicylic acid may decrease the excretion rate of Midazolam which could result in a higher serum level. | [DB00688] Mycophenolate mofetil: Acetylsalicylic acid may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level. | [DB00698] Nitrofurantoin: The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Acetylsalicylic acid. | [DB00706] Tamsulosin: Acetylsalicylic acid may decrease the excretion rate of Tamsulosin which could result in a higher serum level. | [DB00709] Lamivudine: Acetylsalicylic acid may decrease the excretion rate of Lamivudine which could result in a higher serum level. | [DB00713] Oxacillin: Acetylsalicylic acid may decrease the excretion rate of Oxacillin which could result in a higher serum level. | [DB00716] Nedocromil: Acetylsalicylic acid may decrease the excretion rate of Nedocromil which could result in a higher serum level. | [DB00730] Thiabendazole: Acetylsalicylic acid may decrease the excretion rate of Thiabendazole which could result in a higher serum level. | [DB00733] Pralidoxime: Acetylsalicylic acid may decrease the excretion rate of Pralidoxime which could result in a higher serum level. | [DB00743] Gadobenic acid: Acetylsalicylic acid may decrease the excretion rate of Gadobenic acid which could result in a higher serum level. | [DB00760] Meropenem: Acetylsalicylic acid may decrease the excretion rate of Meropenem which could result in a higher serum level. | [DB00782] Propantheline: Acetylsalicylic acid may decrease the excretion rate of Propantheline which could result in a higher serum level. | [DB00789] Gadopentetic acid: Acetylsalicylic acid may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. | [DB00804] Dicyclomine: Acetylsalicylic acid may decrease the excretion rate of Dicyclomine which could result in a higher serum level. | [DB00811] Ribavirin: Acetylsalicylic acid may decrease the excretion rate of Ribavirin which could result in a higher serum level. | [DB00820] Tadalafil: Acetylsalicylic acid may decrease the antihypertensive activities of Tadalafil. | [DB00828] Fosfomycin: Acetylsalicylic acid may decrease the excretion rate of Fosfomycin which could result in a higher serum level. | [DB00829] Diazepam: Acetylsalicylic acid may decrease the excretion rate of Diazepam which could result in a higher serum level. | [DB00841] Dobutamine: The risk or severity of hypertension can be increased when Dobutamine is combined with Acetylsalicylic acid. | [DB00842] Oxazepam: Acetylsalicylic acid may decrease the excretion rate of Oxazepam which could result in a higher serum level. | [DB00851] Dacarbazine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Dacarbazine. | [DB00853] Temozolomide: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Temozolomide. | [DB00871] Terbutaline: The risk or severity of hypertension can be increased when Terbutaline is combined with Acetylsalicylic acid. | [DB00894] Testolactone: Acetylsalicylic acid may decrease the excretion rate of Testolactone which could result in a higher serum level. | [DB00897] Triazolam: Acetylsalicylic acid may decrease the excretion rate of Triazolam which could result in a higher serum level. | [DB00900] Didanosine: Acetylsalicylic acid may decrease the excretion rate of Didanosine which could result in a higher serum level. | [DB00911] Tinidazole: Acetylsalicylic acid may decrease the excretion rate of Tinidazole which could result in a higher serum level. | [DB00918] Almotriptan: The risk or severity of hypertension can be increased when Almotriptan is combined with Acetylsalicylic acid. | [DB00928] Azacitidine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Azacitidine. | [DB00934] Maprotiline: Acetylsalicylic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level. | [DB00953] Rizatriptan: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Rizatriptan. | [DB00961] Mepivacaine: Acetylsalicylic acid may decrease the excretion rate of Mepivacaine which could result in a higher serum level. | [DB00962] Zaleplon: Acetylsalicylic acid may decrease the excretion rate of Zaleplon which could result in a higher serum level. | [DB00980] Ramelteon: Acetylsalicylic acid may decrease the excretion rate of Ramelteon which could result in a higher serum level. | [DB00988] Dopamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Dopamine. | [DB00995] Auranofin: Acetylsalicylic acid may decrease the excretion rate of Auranofin which could result in a higher serum level. | [DB01001] Albuterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Salbutamol. | [DB01002] Levobupivacaine: Acetylsalicylic acid may decrease the excretion rate of Levobupivacaine which could result in a higher serum level. | [DB01004] Ganciclovir: Acetylsalicylic acid may decrease the excretion rate of Ganciclovir which could result in a higher serum level. | [DB01010] Edrophonium: Acetylsalicylic acid may decrease the excretion rate of Edrophonium which could result in a higher serum level. | [DB01011] Metyrapone: Acetylsalicylic acid may decrease the excretion rate of Metyrapone which could result in a higher serum level. | [DB01018] Guanfacine: Acetylsalicylic acid may decrease the antihypertensive activities of Guanfacine. | [DB01020] Isosorbide mononitrate: Acetylsalicylic acid may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level. | [DB01022] Phylloquinone: Acetylsalicylic acid may decrease the excretion rate of Phylloquinone which could result in a higher serum level. | [DB01024] Mycophenolic acid: Acetylsalicylic acid may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level. | [DB01030] Topotecan: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Topotecan. | [DB01036] Tolterodine: Acetylsalicylic acid may decrease the excretion rate of Tolterodine which could result in a higher serum level. | [DB01043] Memantine: Acetylsalicylic acid may decrease the excretion rate of Memantine which could result in a higher serum level. | [DB01046] Lubiprostone: Acetylsalicylic acid may decrease the excretion rate of Lubiprostone which could result in a higher serum level. | [DB01048] Abacavir: Acetylsalicylic acid may decrease the excretion rate of Abacavir which could result in a higher serum level. | [DB01060] Amoxicillin: Acetylsalicylic acid may decrease the excretion rate of Amoxicillin which could result in a higher serum level. | [DB01068] Clonazepam: Acetylsalicylic acid may decrease the excretion rate of Clonazepam which could result in a higher serum level. | [DB01093] Dimethyl sulfoxide: Acetylsalicylic acid may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level. | [DB01099] Flucytosine: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Flucytosine. | [DB01135] Doxacurium: Acetylsalicylic acid may decrease the excretion rate of Doxacurium which could result in a higher serum level. | [DB01148] Flavoxate: Acetylsalicylic acid may decrease the excretion rate of Flavoxate which could result in a higher serum level. | [DB01156] Bupropion: Acetylsalicylic acid may decrease the excretion rate of Bupropion which could result in a higher serum level. | [DB01157] Trimetrexate: Acetylsalicylic acid may decrease the excretion rate of Trimetrexate which could result in a higher serum level. | [DB01169] Arsenic trioxide: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Arsenic trioxide. | [DB01183] Naloxone: Acetylsalicylic acid may decrease the excretion rate of Naloxone which could result in a higher serum level. | [DB01205] Flumazenil: Acetylsalicylic acid may decrease the excretion rate of Flumazenil which could result in a higher serum level. | [DB01213] Fomepizole: Acetylsalicylic acid may decrease the excretion rate of Fomepizole which could result in a higher serum level. | [DB01215] Estazolam: Acetylsalicylic acid may decrease the excretion rate of Estazolam which could result in a higher serum level. | [DB01221] Ketamine: Acetylsalicylic acid may decrease the excretion rate of Ketamine which could result in a higher serum level. | [DB01224] Quetiapine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Quetiapine. | [DB01233] Metoclopramide: Acetylsalicylic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level. | [DB01249] Iodixanol: Acetylsalicylic acid may decrease the excretion rate of Iodixanol which could result in a higher serum level. | [DB01273] Varenicline: Acetylsalicylic acid may decrease the excretion rate of Varenicline which could result in a higher serum level. | [DB01274] Arformoterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Arformoterol. | [DB01409] Tiotropium: Acetylsalicylic acid may decrease the excretion rate of Tiotropium which could result in a higher serum level. | [DB01427] Amrinone: Acetylsalicylic acid may decrease the excretion rate of Amrinone which could result in a higher serum level. | [DB01428] Oxybenzone: Acetylsalicylic acid may decrease the excretion rate of Oxybenzone which could result in a higher serum level. | [DB01550] Fenproporex: Acetylsalicylic acid may decrease the excretion rate of Fenproporex which could result in a higher serum level. | [DB01558] Bromazepam: Acetylsalicylic acid may decrease the excretion rate of Bromazepam which could result in a higher serum level. | [DB01563] Chloral hydrate: Acetylsalicylic acid may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. | [DB01577] Metamfetamine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Metamfetamine. | [DB01587] Ketazolam: Acetylsalicylic acid may decrease the excretion rate of Ketazolam which could result in a higher serum level. | [DB01610] Valganciclovir: Acetylsalicylic acid may decrease the excretion rate of Valganciclovir which could result in a higher serum level. | [DB01638] Sorbitol: Acetylsalicylic acid may decrease the excretion rate of Sorbitol which could result in a higher serum level. | [DB01656] Roflumilast: Acetylsalicylic acid may decrease the excretion rate of Roflumilast which could result in a higher serum level. | [DB04871] Lorcaserin: Acetylsalicylic acid may decrease the excretion rate of Lorcaserin which could result in a higher serum level. | [DB04895] Pegaptanib: Acetylsalicylic acid may decrease the excretion rate of Pegaptanib which could result in a higher serum level. | [DB04948] Lofexidine: Acetylsalicylic acid may decrease the antihypertensive activities of Lofexidine. | [DB04953] Ezogabine: Acetylsalicylic acid may decrease the excretion rate of Ezogabine which could result in a higher serum level. | [DB05018] Migalastat: Acetylsalicylic acid may decrease the excretion rate of Migalastat which could result in a higher serum level. | [DB05541] Brivaracetam: Acetylsalicylic acid may decrease the excretion rate of Brivaracetam which could result in a higher serum level. | [DB06154] Pentaerythritol tetranitrate: Acetylsalicylic acid may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level. | [DB06186] Ipilimumab: Acetylsalicylic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. | [DB06230] Nalmefene: Acetylsalicylic acid may decrease the excretion rate of Nalmefene which could result in a higher serum level. | [DB06262] Droxidopa: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Droxidopa. | [DB06282] Levocetirizine: Acetylsalicylic acid may decrease the excretion rate of Levocetirizine which could result in a higher serum level. | [DB06402] Telavancin: Acetylsalicylic acid may decrease the excretion rate of Telavancin which could result in a higher serum level. | [DB06623] Flupirtine: Acetylsalicylic acid may decrease the excretion rate of Flupirtine which could result in a higher serum level. | [DB06637] Dalfampridine: Acetylsalicylic acid may decrease the excretion rate of Dalfampridine which could result in a higher serum level. | [DB06702] Fesoterodine: Acetylsalicylic acid may decrease the excretion rate of Fesoterodine which could result in a higher serum level. | [DB06705] Gadofosveset trisodium: Acetylsalicylic acid may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. | [DB06710] Methyltestosterone: Acetylsalicylic acid may decrease the excretion rate of Methyltestosterone which could result in a higher serum level. | [DB06782] Dimercaprol: Acetylsalicylic acid may decrease the excretion rate of Dimercaprol which could result in a higher serum level. | [DB06796] Mangafodipir: Acetylsalicylic acid may decrease the excretion rate of Mangafodipir which could result in a higher serum level. | [DB06800] Methylnaltrexone: Acetylsalicylic acid may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. | [DB06809] Plerixafor: Acetylsalicylic acid may decrease the excretion rate of Plerixafor which could result in a higher serum level. | [DB06823] Tiopronin: Acetylsalicylic acid may decrease the excretion rate of Tiopronin which could result in a higher serum level. | [DB06824] Triethylenetetramine: Acetylsalicylic acid may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. | [DB08824] Ioflupane I-123: Acetylsalicylic acid may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. | [DB08826] Deferiprone: Acetylsalicylic acid may decrease the excretion rate of Deferiprone which could result in a higher serum level. | [DB08840] N-methylnicotinamide: Acetylsalicylic acid may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level. | [DB08872] Gabapentin enacarbil: Acetylsalicylic acid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. | [DB08894] Peginesatide: Acetylsalicylic acid may decrease the excretion rate of Peginesatide which could result in a higher serum level. | [DB08897] Aclidinium: Acetylsalicylic acid may decrease the excretion rate of Aclidinium which could result in a higher serum level. | [DB08900] Teduglutide: Acetylsalicylic acid may decrease the excretion rate of Teduglutide which could result in a higher serum level. | [DB08905] Formestane: Acetylsalicylic acid may decrease the excretion rate of Formestane which could result in a higher serum level. | [DB08909] Glycerol phenylbutyrate: Acetylsalicylic acid may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level. | [DB08910] Pomalidomide: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Pomalidomide. | [DB08911] Trametinib: Acetylsalicylic acid may decrease the excretion rate of Trametinib which could result in a higher serum level. | [DB09050] Ceftolozane: Acetylsalicylic acid may decrease the excretion rate of Ceftolozane which could result in a higher serum level. | [DB09066] Corifollitropin alfa: Acetylsalicylic acid may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. | [DB09071] Tasimelteon: Acetylsalicylic acid may decrease the excretion rate of Tasimelteon which could result in a higher serum level. | [DB09081] Idebenone: Acetylsalicylic acid may decrease the excretion rate of Idebenone which could result in a higher serum level. | [DB09082] Vilanterol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Vilanterol. | [DB09103] Ancestim: Acetylsalicylic acid may decrease the excretion rate of Ancestim which could result in a higher serum level. | [DB09106] Hydroxyethyl Starch: Acetylsalicylic acid may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. | [DB09111] Pentastarch: Acetylsalicylic acid may decrease the excretion rate of Pentastarch which could result in a higher serum level. | [DB09121] Aurothioglucose: Acetylsalicylic acid may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. | [DB09129] Chromic chloride: Acetylsalicylic acid may decrease the excretion rate of Chromic chloride which could result in a higher serum level. | [DB09132] Gadoteric acid: Acetylsalicylic acid may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. | [DB09133] Iothalamic acid: Acetylsalicylic acid may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. | [DB09134] Ioversol: Acetylsalicylic acid may decrease the excretion rate of Ioversol which could result in a higher serum level. | [DB09135] Ioxilan: Acetylsalicylic acid may decrease the excretion rate of Ioxilan which could result in a higher serum level. | [DB09136] Isosulfan blue: Acetylsalicylic acid may decrease the excretion rate of Isosulfan blue which could result in a higher serum level. | [DB09137] Technetium Tc-99m mebrofenin: Acetylsalicylic acid may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level. | [DB09139] Technetium Tc-99m oxidronate: Acetylsalicylic acid may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level. | [DB09148] Florbetaben F-18: Acetylsalicylic acid may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. | [DB09149] Florbetapir F-18: Acetylsalicylic acid may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. | [DB09156] Iopromide: Acetylsalicylic acid may decrease the excretion rate of Iopromide which could result in a higher serum level. | [DB09163] Technetium Tc-99m exametazime: Acetylsalicylic acid may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level. | [DB09165] Technetium Tc-99m pyrophosphate: Acetylsalicylic acid may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. | [DB09185] Viloxazine: Acetylsalicylic acid may decrease the excretion rate of Viloxazine which could result in a higher serum level. | [DB09194] Etoperidone: Acetylsalicylic acid may decrease the excretion rate of Etoperidone which could result in a higher serum level. | [DB09195] Lorpiprazole: Acetylsalicylic acid may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. | [DB09205] Moxisylyte: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Moxisylyte. | [DB09209] Pholcodine: Acetylsalicylic acid may decrease the excretion rate of Pholcodine which could result in a higher serum level. | [DB09210] Piracetam: Acetylsalicylic acid may decrease the excretion rate of Piracetam which could result in a higher serum level. | [DB09219] Bisoxatin: Acetylsalicylic acid may decrease the excretion rate of Bisoxatin which could result in a higher serum level. | [DB09223] Blonanserin: Acetylsalicylic acid may decrease the excretion rate of Blonanserin which could result in a higher serum level. | [DB09224] Melperone: Acetylsalicylic acid may decrease the excretion rate of Melperone which could result in a higher serum level. | [DB09256] Tegafur: Acetylsalicylic acid may decrease the excretion rate of Tegafur which could result in a higher serum level. | [DB09257] Gimeracil: Acetylsalicylic acid may decrease the excretion rate of Gimeracil which could result in a higher serum level. | [DB09262] Imidafenacin: Acetylsalicylic acid may decrease the excretion rate of Imidafenacin which could result in a higher serum level. | [DB09264] Idarucizumab: Acetylsalicylic acid may decrease the excretion rate of Idarucizumab which could result in a higher serum level. | [DB09268] Picosulfuric acid: Acetylsalicylic acid may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. | [DB09276] Sodium aurothiomalate: Acetylsalicylic acid may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level. | [DB09277] Choline C 11: Acetylsalicylic acid may decrease the excretion rate of Choline C 11 which could result in a higher serum level. | [DB09281] Magnesium trisilicate: Acetylsalicylic acid may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. | [DB09301] Chondroitin sulfate: Acetylsalicylic acid may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. | [DB09320] Procaine benzylpenicillin: Acetylsalicylic acid may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. | [DB09324] Sulbactam: Acetylsalicylic acid may decrease the excretion rate of Sulbactam which could result in a higher serum level. | [DB09325] Sodium fluoride: Acetylsalicylic acid may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. | [DB09344] Invert sugar: Acetylsalicylic acid may decrease the excretion rate of Invert sugar which could result in a higher serum level. | [DB09357] Dexpanthenol: Acetylsalicylic acid may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. | [DB09394] Phosphoric acid: Acetylsalicylic acid may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. | [DB09395] Sodium acetate: Acetylsalicylic acid may decrease the excretion rate of Sodium acetate which could result in a higher serum level. | [DB09407] Magnesium chloride: Acetylsalicylic acid may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. | [DB09472] Sodium sulfate: Acetylsalicylic acid may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. | [DB09488] Acrivastine: Acetylsalicylic acid may decrease the excretion rate of Acrivastine which could result in a higher serum level. | [DB09496] Octinoxate: Acetylsalicylic acid may decrease the excretion rate of Octinoxate which could result in a higher serum level. | [DB09502] Fludeoxyglucose (18F): Acetylsalicylic acid may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. | [DB09546] Iobenguane sulfate I-123: Acetylsalicylic acid may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level. | [DB09570] Ixazomib: Acetylsalicylic acid may decrease the excretion rate of Ixazomib which could result in a higher serum level. | [DB11102] N-acetyltyrosine: Acetylsalicylic acid may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level. | [DB11114] Eucalyptus oil: Acetylsalicylic acid may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. | [DB11127] Selenious acid: Acetylsalicylic acid may decrease the excretion rate of Selenious acid which could result in a higher serum level. | [DB11130] Opium: Acetylsalicylic acid may decrease the excretion rate of Opium which could result in a higher serum level. | [DB11135] Selenium: Acetylsalicylic acid may decrease the excretion rate of Selenium which could result in a higher serum level. | [DB11136] Chromium: Acetylsalicylic acid may decrease the excretion rate of Chromium which could result in a higher serum level. | [DB11145] Oxyquinoline: Acetylsalicylic acid may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. | [DB11156] Pyrantel: Acetylsalicylic acid may decrease the excretion rate of Pyrantel which could result in a higher serum level. | [DB11164] Bicisate: Acetylsalicylic acid may decrease the excretion rate of Bicisate which could result in a higher serum level. | [DB11251] Tocopherol: Acetylsalicylic acid may decrease the excretion rate of Tocopherol which could result in a higher serum level. | [DB11278] DL-Methylephedrine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with DL-Methylephedrine. | [DB11328] Tetradecyl hydrogen sulfate (ester): Acetylsalicylic acid may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. | [DB11338] Clove oil: Acetylsalicylic acid may decrease the excretion rate of Clove oil which could result in a higher serum level. | [DB11358] Evening primrose oil: Acetylsalicylic acid may decrease the excretion rate of Evening primrose oil which could result in a higher serum level. | [DB11364] Pidotimod: Acetylsalicylic acid may decrease the excretion rate of Pidotimod which could result in a higher serum level. | [DB11577] Indigotindisulfonic acid: Acetylsalicylic acid may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level. | [DB11587] Etafedrine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Etafedrine. | [DB11691] Naldemedine: Acetylsalicylic acid may decrease the excretion rate of Naldemedine which could result in a higher serum level. | [DB11699] Tropisetron: Acetylsalicylic acid may decrease the excretion rate of Tropisetron which could result in a higher serum level. | [DB11915] Valbenazine: Acetylsalicylic acid may decrease the excretion rate of Valbenazine which could result in a higher serum level. | [DB11943] Delafloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Delafloxacin. | [DB11989] Benznidazole: Acetylsalicylic acid may decrease the excretion rate of Benznidazole which could result in a higher serum level. | [DB12007] Isoflavone: Acetylsalicylic acid may decrease the excretion rate of Isoflavone which could result in a higher serum level. | [DB12107] Vaborbactam: Acetylsalicylic acid may decrease the excretion rate of Vaborbactam which could result in a higher serum level. | [DB12161] Deutetrabenazine: Acetylsalicylic acid may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level. | [DB12278] Propiverine: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Propiverine. | [DB12783] Benserazide: Acetylsalicylic acid may decrease the excretion rate of Benserazide which could result in a higher serum level. | [DB13025] Tiapride: Acetylsalicylic acid may decrease the excretion rate of Tiapride which could result in a higher serum level. | [DB13139] Levosalbutamol: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Levosalbutamol. | [DB13156] Inosine pranobex: Acetylsalicylic acid may decrease the excretion rate of Inosine pranobex which could result in a higher serum level. | [DB13178] Inositol: Acetylsalicylic acid may decrease the excretion rate of Inositol which could result in a higher serum level. | [DB13185] Oxabolone cipionate: Acetylsalicylic acid may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level. | [DB13191] Phosphocreatine: Acetylsalicylic acid may decrease the excretion rate of Phosphocreatine which could result in a higher serum level. | [DB13269] Dichlorobenzyl alcohol: Acetylsalicylic acid may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. | [DB13293] Ipecac: Acetylsalicylic acid may decrease the excretion rate of Ipecac which could result in a higher serum level. | [DB13595] Almasilate: Acetylsalicylic acid may decrease the excretion rate of Almasilate which could result in a higher serum level. | [DB13873] Fenofibric acid: Acetylsalicylic acid may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. | [DB13909] Bismuth subgallate: Acetylsalicylic acid may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. | [DB13955] Estradiol dienanthate: Acetylsalicylic acid may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level. | [DB13967] Patent Blue: Acetylsalicylic acid may decrease the excretion rate of Patent Blue which could result in a higher serum level. | [DB14007] Pentetic acid: Acetylsalicylic acid may decrease the excretion rate of Pentetic acid which could result in a higher serum level. | [DB14526] Chromic citrate: Acetylsalicylic acid may decrease the excretion rate of Chromic citrate which could result in a higher serum level. | [DB14527] Chromic nitrate: Acetylsalicylic acid may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. | [DB14528] Chromium gluconate: Acetylsalicylic acid may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. | [DB14529] Chromium nicotinate: Acetylsalicylic acid may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. | [DB14530] Chromous sulfate: Acetylsalicylic acid may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. | [DB11085] Resorcinol: Acetylsalicylic acid may decrease the excretion rate of Resorcinol which could result in a higher serum level. | [DB09089] Trimebutine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Trimebutine. | [DB00273] Topiramate: Acetylsalicylic acid may decrease the excretion rate of Topiramate which could result in a higher serum level. | [DB15593] Golodirsen: Acetylsalicylic acid may decrease the excretion rate of Golodirsen which could result in a higher serum level. | [DB11901] Apalutamide: The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Apalutamide. | [DB00333] Methadone: Acetylsalicylic acid may decrease the excretion rate of Methadone which could result in a higher serum level. | [DB00440] Trimethoprim: The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Acetylsalicylic acid. | [DB01137] Levofloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Levofloxacin. | [DB00206] Reserpine: Acetylsalicylic acid may decrease the antihypertensive activities of Reserpine. | [DB00270] Isradipine: Acetylsalicylic acid may decrease the antihypertensive activities of Isradipine. | [DB00401] Nisoldipine: Acetylsalicylic acid may decrease the antihypertensive activities of Nisoldipine. | [DB00477] Chlorpromazine: The risk or severity of hypertension can be increased when Chlorpromazine is combined with Acetylsalicylic acid. | [DB00490] Buspirone: The risk or severity of hypertension can be increased when Buspirone is combined with Acetylsalicylic acid. | [DB01267] Paliperidone: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Paliperidone. | [DB08893] Mirabegron: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Mirabegron. | [DB00213] Pantoprazole: Acetylsalicylic acid may decrease the excretion rate of Pantoprazole which could result in a higher serum level. | [DB00243] Ranolazine: Acetylsalicylic acid may decrease the excretion rate of Ranolazine which could result in a higher serum level. | [DB00341] Cetirizine: Acetylsalicylic acid may decrease the excretion rate of Cetirizine which could result in a higher serum level. | [DB00555] Lamotrigine: The risk or severity of hyperkalemia can be increased when Lamotrigine is combined with Acetylsalicylic acid. | [DB00608] Chloroquine: Acetylsalicylic acid may decrease the excretion rate of Chloroquine which could result in a higher serum level. | [DB00690] Flurazepam: Acetylsalicylic acid may decrease the excretion rate of Flurazepam which could result in a higher serum level. | [DB01115] Nifedipine: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Nifedipine. | [DB01394] Colchicine: Acetylsalicylic acid may decrease the excretion rate of Colchicine which could result in a higher serum level. | [DB06480] Prucalopride: Acetylsalicylic acid may decrease the excretion rate of Prucalopride which could result in a higher serum level. | [DB08934] Sofosbuvir: Acetylsalicylic acid may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. | [DB09027] Ledipasvir: Acetylsalicylic acid may decrease the excretion rate of Ledipasvir which could result in a higher serum level. | [DB00325] Nitroprusside: Acetylsalicylic acid may decrease the antihypertensive activities of Nitroprusside. | [DB00657] Mecamylamine: Acetylsalicylic acid may decrease the antihypertensive activities of Mecamylamine. | [DB00692] Phentolamine: Acetylsalicylic acid may decrease the antihypertensive activities of Phentolamine. | [DB00800] Fenoldopam: Acetylsalicylic acid may decrease the antihypertensive activities of Fenoldopam. | [DB00968] Methyldopa: Acetylsalicylic acid may decrease the antihypertensive activities of Methyldopa. | [DB01170] Guanethidine: Acetylsalicylic acid may decrease the antihypertensive activities of Guanethidine. | [DB08932] Macitentan: Acetylsalicylic acid may decrease the antihypertensive activities of Macitentan. | [DB00813] Fentanyl: The risk or severity of hypertension can be increased when Fentanyl is combined with Acetylsalicylic acid. | [DB00454] Meperidine: Acetylsalicylic acid may decrease the excretion rate of Meperidine which could result in a higher serum level. | [DB13987] Strontium chloride: Acetylsalicylic acid may decrease the excretion rate of Strontium chloride which could result in a higher serum level. | [DB04890] Bepotastine: Acetylsalicylic acid may decrease the excretion rate of Bepotastine which could result in a higher serum level. | [DB00982] Isotretinoin: Acetylsalicylic acid may decrease the excretion rate of Isotretinoin which could result in a higher serum level. | [DB04930] Permethrin: Acetylsalicylic acid may decrease the excretion rate of Permethrin which could result in a higher serum level. | [DB01181] Ifosfamide: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Ifosfamide. | [DB00294] Etonogestrel: Acetylsalicylic acid may decrease the excretion rate of Etonogestrel which could result in a higher serum level. | [DB00351] Megestrol acetate: Acetylsalicylic acid may decrease the excretion rate of Megestrol acetate which could result in a higher serum level. | [DB00624] Testosterone: Acetylsalicylic acid may decrease the excretion rate of Testosterone which could result in a higher serum level. | [DB01420] Testosterone propionate: Acetylsalicylic acid may decrease the excretion rate of Testosterone propionate which could result in a higher serum level. | [DB01431] Allylestrenol: Acetylsalicylic acid may decrease the excretion rate of Allylestrenol which could result in a higher serum level. | [DB09123] Dienogest: Acetylsalicylic acid may decrease the excretion rate of Dienogest which could result in a higher serum level. | [DB09317] Synthetic Conjugated Estrogens, A: Acetylsalicylic acid may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level. | [DB09318] Synthetic Conjugated Estrogens, B: Acetylsalicylic acid may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level. | [DB09329] Antihemophilic factor (recombinant), PEGylated: Acetylsalicylic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. | [DB13884] Albutrepenonacog alfa: Acetylsalicylic acid may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. | [DB13943] Testosterone cypionate: Acetylsalicylic acid may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. | [DB13944] Testosterone enanthate: Acetylsalicylic acid may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. | [DB13952] Estradiol acetate: Acetylsalicylic acid may decrease the excretion rate of Estradiol acetate which could result in a higher serum level. | [DB13954] Estradiol cypionate: Acetylsalicylic acid may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level. | [DB13956] Estradiol valerate: Acetylsalicylic acid may decrease the excretion rate of Estradiol valerate which could result in a higher serum level. | [DB00254] Doxycycline: Acetylsalicylic acid may decrease the excretion rate of Doxycycline which could result in a higher serum level. | [DB01129] Rabeprazole: Acetylsalicylic acid may decrease the excretion rate of Rabeprazole which could result in a higher serum level. | [DB00314] Capreomycin: Acetylsalicylic acid may decrease the excretion rate of Capreomycin which could result in a higher serum level. | [DB00515] Cisplatin: Acetylsalicylic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. | [DB00564] Carbamazepine: Acetylsalicylic acid may decrease the excretion rate of Carbamazepine which could result in a higher serum level. | [DB01035] Procainamide: Acetylsalicylic acid may decrease the excretion rate of Procainamide which could result in a higher serum level. | [DB12615] Plazomicin: Acetylsalicylic acid may decrease the excretion rate of Plazomicin which could result in a higher serum level. | [DB00552] Pentostatin: Acetylsalicylic acid may decrease the excretion rate of Pentostatin which could result in a higher serum level. | [DB13145] Nedaplatin: Acetylsalicylic acid may decrease the excretion rate of Nedaplatin which could result in a higher serum level. | [DB00803] Colistin: Acetylsalicylic acid may decrease the excretion rate of Colistin which could result in a higher serum level. | [DB00479] Amikacin: Acetylsalicylic acid may decrease the excretion rate of Amikacin which could result in a higher serum level. | [DB00684] Tobramycin: Acetylsalicylic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level. | [DB00798] Gentamicin: Acetylsalicylic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level. | [DB00955] Netilmicin: Acetylsalicylic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level. | [DB01082] Streptomycin: Acetylsalicylic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level. | [DB01172] Kanamycin: Acetylsalicylic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level. | [DB03615] Ribostamycin: Acetylsalicylic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level. | [DB04729] Gentamicin C1a: Acetylsalicylic acid may decrease the excretion rate of Gentamicin C1a which could result in a higher serum level. | [DB06696] Arbekacin: Acetylsalicylic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level. | [DB12604] Sisomicin: Acetylsalicylic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level. | [DB13540] Isepamicin: Acetylsalicylic acid may decrease the excretion rate of Isepamicin which could result in a higher serum level. | [DB00908] Quinidine: Acetylsalicylic acid may decrease the excretion rate of Quinidine which could result in a higher serum level. | [DB00601] Linezolid: The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Acetylsalicylic acid. | [DB00614] Furazolidone: The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Acetylsalicylic acid. | [DB00721] Procaine: The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Acetylsalicylic acid. | [DB00752] Tranylcypromine: The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Acetylsalicylic acid. | [DB00805] Minaprine: The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Acetylsalicylic acid. | [DB01168] Procarbazine: The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Acetylsalicylic acid. | [DB01171] Moclobemide: The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Acetylsalicylic acid. | [DB01247] Isocarboxazid: The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Acetylsalicylic acid. | [DB04017] Clorgiline: The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Acetylsalicylic acid. | [DB04820] Nialamide: The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Acetylsalicylic acid. | [DB06654] Safinamide: The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Acetylsalicylic acid. | [DB08550] 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline: The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Acetylsalicylic acid. | [DB09243] Hydracarbazine: The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Acetylsalicylic acid. | [DB09246] Benmoxin: The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Acetylsalicylic acid. | [DB09248] Mebanazine: The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Acetylsalicylic acid. | [DB09249] Octamoxin: The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Acetylsalicylic acid. | [DB09250] Pheniprazine: The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Acetylsalicylic acid. | [DB09251] Phenoxypropazine: The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Acetylsalicylic acid. | [DB09252] Pivhydrazine: The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Acetylsalicylic acid. | [DB09253] Safrazine: The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Acetylsalicylic acid. | [DB09254] Caroxazone: The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Acetylsalicylic acid. | [DB13875] Harmaline: The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Acetylsalicylic acid. | [DB13876] Brofaromine: The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Acetylsalicylic acid. | [DB00780] Phenelzine: The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Acetylsalicylic acid. | [DB01367] Rasagiline: The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Acetylsalicylic acid. | [DB09241] Methylene blue: The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Acetylsalicylic acid. | [DB09244] Pirlindole: The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Acetylsalicylic acid. | [DB09245] Toloxatone: The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Acetylsalicylic acid. | [DB01037] Selegiline: The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Acetylsalicylic acid. | [DB01626] Pargyline: The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Acetylsalicylic acid. | [DB09087] Potassium alum: Potassium alum may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB09414] Dipotassium phosphate: Dipotassium phosphate may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB09483] Potassium lactate: Potassium lactate may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB11107] Potassium bitartrate: Potassium bitartrate may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB11153] Potassium hydroxide: Potassium hydroxide may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB13620] Potassium gluconate: Potassium gluconate may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB13735] Potassium guaiacolsulfonate: Potassium guaiacolsulfonate may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB13977] Potassium carbonate: Potassium carbonate may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB14492] Potassium triiodide: Potassium triiodide may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB00761] Potassium chloride: Potassium chloride may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB09418] Potassium perchlorate: Potassium perchlorate may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB11090] Potassium nitrate: Potassium nitrate may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB11098] Potassium bicarbonate: Potassium bicarbonate may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB14498] Potassium acetate: Potassium acetate may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB14499] Potassium sulfate: Potassium sulfate may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB06715] Potassium Iodide: Potassium Iodide may increase the hyperkalemic activities of Acetylsalicylic acid. | [DB00649] Stavudine: The excretion of Stavudine can be decreased when combined with Acetylsalicylic acid. | [DB00943] Zalcitabine: The excretion of Zalcitabine can be decreased when combined with Acetylsalicylic acid. | [DB00365] Grepafloxacin: Acetylsalicylic acid may increase the neuroexcitatory activities of Grepafloxacin. | [DB06245] Lanoteplase: The risk or severity of angioedema can be increased when Acetylsalicylic acid is combined with Lanoteplase. | [DB00230] Pregabalin: The risk or severity of angioedema can be increased when Pregabalin is combined with Acetylsalicylic acid. | [DB06196] Icatibant: The risk or severity of angioedema can be increased when Acetylsalicylic acid is combined with Icatibant. | [DB09292] Sacubitril: The risk or severity of angioedema can be increased when Acetylsalicylic acid is combined with Sacubitril. | [DB00877] Sirolimus: The risk or severity of angioedema can be increased when Sirolimus is combined with Acetylsalicylic acid. | [DB06287] Temsirolimus: The risk or severity of angioedema can be increased when Acetylsalicylic acid is combined with Temsirolimus. | [DB00599] Thiopental: The metabolism of Thiopental can be increased when combined with Acetylsalicylic acid. | [DB00444] Teniposide: The metabolism of Teniposide can be increased when combined with Acetylsalicylic acid. | [DB06626] Axitinib: The metabolism of Axitinib can be increased when combined with Acetylsalicylic acid. | [DB06210] Eltrombopag: The metabolism of Acetylsalicylic acid can be decreased when combined with Eltrombopag. | [DB08899] Enzalutamide: The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Enzalutamide. | [DB00559] Bosentan: The metabolism of Acetylsalicylic acid can be increased when combined with Bosentan. | [DB00503] Ritonavir: The metabolism of Acetylsalicylic acid can be increased when combined with Ritonavir. | [DB01023] Felodipine: The metabolism of Acetylsalicylic acid can be decreased when combined with Felodipine. | [DB00665] Nilutamide: The metabolism of Acetylsalicylic acid can be decreased when combined with Nilutamide. | [DB00763] Methimazole: The metabolism of Acetylsalicylic acid can be decreased when combined with Methimazole. | [DB00951] Isoniazid: The metabolism of Acetylsalicylic acid can be decreased when combined with Isoniazid. | [DB09118] Stiripentol: The metabolism of Acetylsalicylic acid can be decreased when combined with Stiripentol. | [DB00544] Fluorouracil: The metabolism of Acetylsalicylic acid can be decreased when combined with Fluorouracil. | [DB00549] Zafirlukast: The metabolism of Acetylsalicylic acid can be decreased when combined with Zafirlukast. | [DB00576] Sulfamethizole: The metabolism of Acetylsalicylic acid can be decreased when combined with Sulfamethizole. | [DB00621] Oxandrolone: The metabolism of Acetylsalicylic acid can be decreased when combined with Oxandrolone. | [DB00668] Epinephrine: The metabolism of Acetylsalicylic acid can be decreased when combined with Epinephrine. | [DB00745] Modafinil: The metabolism of Acetylsalicylic acid can be decreased when combined with Modafinil. | [DB00891] Sulfapyridine: The metabolism of Acetylsalicylic acid can be decreased when combined with Sulfapyridine. | [DB01095] Fluvastatin: The metabolism of Acetylsalicylic acid can be decreased when combined with Fluvastatin. | [DB01097] Leflunomide: The metabolism of Acetylsalicylic acid can be decreased when combined with Leflunomide. | [DB01117] Atovaquone: The metabolism of Acetylsalicylic acid can be decreased when combined with Atovaquone. | [DB01176] Cyclizine: The metabolism of Acetylsalicylic acid can be decreased when combined with Cyclizine. | [DB01195] Flecainide: The metabolism of Acetylsalicylic acid can be decreased when combined with Flecainide. | [DB01411] Pranlukast: The metabolism of Acetylsalicylic acid can be decreased when combined with Pranlukast. | [DB01685] Topiroxostat: The metabolism of Acetylsalicylic acid can be decreased when combined with Topiroxostat. | [DB03756] Doconexent: The metabolism of Acetylsalicylic acid can be decreased when combined with Doconexent. | [DB06174] Noscapine: The metabolism of Acetylsalicylic acid can be decreased when combined with Noscapine. | [DB06413] Armodafinil: The metabolism of Acetylsalicylic acid can be decreased when combined with Armodafinil. | [DB06414] Etravirine: The metabolism of Acetylsalicylic acid can be decreased when combined with Etravirine. | [DB06442] Avasimibe: The metabolism of Acetylsalicylic acid can be decreased when combined with Avasimibe. | [DB06594] Agomelatine: The metabolism of Acetylsalicylic acid can be decreased when combined with Agomelatine. | [DB08798] Sulfamoxole: The metabolism of Acetylsalicylic acid can be decreased when combined with Sulfamoxole. | [DB09063] Ceritinib: The metabolism of Acetylsalicylic acid can be decreased when combined with Ceritinib. | [DB11994] Diacerein: The metabolism of Acetylsalicylic acid can be decreased when combined with Diacerein. | [DB12245] Triclabendazole: The metabolism of Acetylsalicylic acid can be decreased when combined with Triclabendazole. | [DB04856] Dexloxiglumide: The metabolism of Acetylsalicylic acid can be decreased when combined with Dexloxiglumide. | [DB04920] Clevidipine: The metabolism of Acetylsalicylic acid can be decreased when combined with Clevidipine. | [DB09238] Manidipine: The metabolism of Acetylsalicylic acid can be decreased when combined with Manidipine. | [DB00439] Cerivastatin: The metabolism of Acetylsalicylic acid can be decreased when combined with Cerivastatin. | [DB00613] Amodiaquine: The metabolism of Acetylsalicylic acid can be decreased when combined with Amodiaquine. | [DB00916] Metronidazole: The metabolism of Acetylsalicylic acid can be decreased when combined with Metronidazole. | [DB01039] Fenofibrate: The metabolism of Acetylsalicylic acid can be decreased when combined with Fenofibrate. | [DB01069] Promethazine: The metabolism of Acetylsalicylic acid can be decreased when combined with Promethazine. | [DB01072] Atazanavir: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Atazanavir. | [DB01645] Genistein: The metabolism of Acetylsalicylic acid can be decreased when combined with Genistein. | [DB08881] Vemurafenib: The metabolism of Acetylsalicylic acid can be decreased when combined with Vemurafenib. | [DB08896] Regorafenib: The metabolism of Acetylsalicylic acid can be decreased when combined with Regorafenib. | [DB09280] Lumacaftor: The metabolism of Acetylsalicylic acid can be decreased when combined with Lumacaftor. | [DB11633] Isavuconazole: The metabolism of Acetylsalicylic acid can be decreased when combined with Isavuconazole. | [DB12332] Rucaparib: The metabolism of Acetylsalicylic acid can be decreased when combined with Rucaparib. | [DB06268] Sitaxentan: The metabolism of Acetylsalicylic acid can be decreased when combined with Sitaxentan. | [DB15822] Pralsetinib: The metabolism of Acetylsalicylic acid can be decreased when combined with Pralsetinib. | [DB00603] Medroxyprogesterone acetate: The metabolism of Acetylsalicylic acid can be decreased when combined with Medroxyprogesterone acetate. | [DB04574] Estrone sulfate: The metabolism of Acetylsalicylic acid can be decreased when combined with Estrone sulfate. | [DB00255] Diethylstilbestrol: The metabolism of Acetylsalicylic acid can be decreased when combined with Diethylstilbestrol. | [DB00396] Progesterone: The metabolism of Acetylsalicylic acid can be decreased when combined with Progesterone. | [DB08864] Rilpivirine: The metabolism of Acetylsalicylic acid can be decreased when combined with Rilpivirine. | [DB08995] Diosmin: The metabolism of Acetylsalicylic acid can be decreased when combined with Diosmin. | [DB04911] Oritavancin: The metabolism of Acetylsalicylic acid can be decreased when combined with Oritavancin. | [DB13174] Rhein: The metabolism of Acetylsalicylic acid can be decreased when combined with Rhein. | [DB14033] Acetyl sulfisoxazole: The metabolism of Acetylsalicylic acid can be decreased when combined with Acetyl sulfisoxazole. | [DB00334] Olanzapine: The metabolism of Acetylsalicylic acid can be decreased when combined with Olanzapine. | [DB00203] Sildenafil: The metabolism of Acetylsalicylic acid can be decreased when combined with Sildenafil. | [DB00250] Dapsone: The metabolism of Acetylsalicylic acid can be decreased when combined with Dapsone. | [DB00307] Bexarotene: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Bexarotene. | [DB00425] Zolpidem: The metabolism of Acetylsalicylic acid can be decreased when combined with Zolpidem. | [DB00471] Montelukast: The metabolism of Acetylsalicylic acid can be decreased when combined with Montelukast. | [DB00532] Mephenytoin: The metabolism of Acetylsalicylic acid can be decreased when combined with Mephenytoin. | [DB00617] Paramethadione: The metabolism of Acetylsalicylic acid can be decreased when combined with Paramethadione. | [DB00744] Zileuton: The metabolism of Acetylsalicylic acid can be decreased when combined with Zileuton. | [DB00755] Tretinoin: The risk or severity of elevated intracranial pressure can be increased when Acetylsalicylic acid is combined with Tretinoin. | [DB00794] Primidone: The metabolism of Acetylsalicylic acid can be decreased when combined with Primidone. | [DB00857] Terbinafine: The metabolism of Acetylsalicylic acid can be decreased when combined with Terbinafine. | [DB00969] Alosetron: The metabolism of Alosetron can be decreased when combined with Acetylsalicylic acid. | [DB01028] Methoxyflurane: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Methoxyflurane. | [DB01131] Proguanil: The metabolism of Proguanil can be decreased when combined with Acetylsalicylic acid. | [DB01154] Thiamylal: The metabolism of Thiamylal can be decreased when combined with Acetylsalicylic acid. | [DB01159] Halothane: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Halothane. | [DB01198] Zopiclone: The metabolism of Zopiclone can be decreased when combined with Acetylsalicylic acid. | [DB01355] Hexobarbital: The metabolism of Hexobarbital can be decreased when combined with Acetylsalicylic acid. | [DB01544] Flunitrazepam: The metabolism of Flunitrazepam can be decreased when combined with Acetylsalicylic acid. | [DB03783] Phenacetin: The metabolism of Phenacetin can be decreased when combined with Acetylsalicylic acid. | [DB04557] Arachidonic Acid: The metabolism of Arachidonic Acid can be decreased when combined with Acetylsalicylic acid. | [DB04938] Ospemifene: The metabolism of Ospemifene can be decreased when combined with Acetylsalicylic acid. | [DB06218] Lacosamide: The metabolism of Lacosamide can be decreased when combined with Acetylsalicylic acid. | [DB06652] Vicriviroc: The metabolism of Vicriviroc can be decreased when combined with Acetylsalicylic acid. | [DB06697] Artemether: The metabolism of Artemether can be decreased when combined with Acetylsalicylic acid. | [DB06738] Ketobemidone: The metabolism of Ketobemidone can be decreased when combined with Acetylsalicylic acid. | [DB06739] Seratrodast: The metabolism of Seratrodast can be decreased when combined with Acetylsalicylic acid. | [DB06803] Niclosamide: The metabolism of Niclosamide can be decreased when combined with Acetylsalicylic acid. | [DB09061] Cannabidiol: The metabolism of Acetylsalicylic acid can be decreased when combined with Cannabidiol. | [DB11614] Rupatadine: The metabolism of Rupatadine can be decreased when combined with Acetylsalicylic acid. | [DB13941] Piperaquine: The metabolism of Piperaquine can be decreased when combined with Acetylsalicylic acid. | [DB14011] Nabiximols: The metabolism of Nabiximols can be decreased when combined with Acetylsalicylic acid. | [DB00582] Voriconazole: The serum concentration of Acetylsalicylic acid can be increased when it is combined with Voriconazole. | [DB14975] Voxelotor: The metabolism of Voxelotor can be decreased when combined with Acetylsalicylic acid. | [DB00470] Dronabinol: The metabolism of Acetylsalicylic acid can be decreased when combined with Dronabinol. | [DB15233] Avapritinib: The metabolism of Acetylsalicylic acid can be decreased when combined with Avapritinib. | [DB00216] Eletriptan: The risk or severity of hypertension can be increased when Eletriptan is combined with Acetylsalicylic acid. | [DB00590] Doxazosin: Acetylsalicylic acid may decrease the antihypertensive activities of Doxazosin. | [DB00701] Amprenavir: The metabolism of Acetylsalicylic acid can be decreased when combined with Amprenavir. | [DB00818] Propofol: The risk or severity of hypertension can be increased when Propofol is combined with Acetylsalicylic acid. | [DB00843] Donepezil: The metabolism of Acetylsalicylic acid can be decreased when combined with Donepezil. | [DB00904] Ondansetron: The metabolism of Acetylsalicylic acid can be decreased when combined with Ondansetron. | [DB00921] Buprenorphine: The metabolism of Acetylsalicylic acid can be decreased when combined with Buprenorphine. | [DB00972] Azelastine: The metabolism of Azelastine can be decreased when combined with Acetylsalicylic acid. | [DB09048] Netupitant: The metabolism of Netupitant can be decreased when combined with Acetylsalicylic acid. | [DB11586] Asunaprevir: The metabolism of Asunaprevir can be decreased when combined with Acetylsalicylic acid. | [DB11757] Istradefylline: The metabolism of Istradefylline can be decreased when combined with Acetylsalicylic acid. | [DB11689] Selumetinib: The metabolism of Selumetinib can be decreased when combined with Acetylsalicylic acid. | [DB00188] Bortezomib: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Bortezomib. | [DB06448] Lonafarnib: The metabolism of Lonafarnib can be decreased when combined with Acetylsalicylic acid. | [DB00238] Nevirapine: The metabolism of Acetylsalicylic acid can be decreased when combined with Nevirapine. | [DB00448] Lansoprazole: The metabolism of Acetylsalicylic acid can be decreased when combined with Lansoprazole. | [DB00304] Desogestrel: The metabolism of Acetylsalicylic acid can be decreased when combined with Desogestrel. | [DB00957] Norgestimate: The metabolism of Norgestimate can be decreased when combined with Acetylsalicylic acid. | [DB00977] Ethinylestradiol: The metabolism of Ethinylestradiol can be decreased when combined with Acetylsalicylic acid. | [DB01357] Mestranol: The metabolism of Mestranol can be decreased when combined with Acetylsalicylic acid. | [DB12474] Lynestrenol: The metabolism of Lynestrenol can be decreased when combined with Acetylsalicylic acid. | [DB13953] Estradiol benzoate: The metabolism of Estradiol benzoate can be decreased when combined with Acetylsalicylic acid. | [DB06237] Avanafil: The metabolism of Avanafil can be decreased when combined with Acetylsalicylic acid. | [DB05109] Trabectedin: The metabolism of Trabectedin can be increased when combined with Acetylsalicylic acid. | [DB01101] Capecitabine: The serum concentration of Acetylsalicylic acid can be increased when it is combined with Capecitabine. | [DB08877] Ruxolitinib: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Ruxolitinib. | [DB00531] Cyclophosphamide: The metabolism of Cyclophosphamide can be increased when combined with Acetylsalicylic acid. | [DB08875] Cabozantinib: The metabolism of Cabozantinib can be decreased when combined with Acetylsalicylic acid. | [DB13874] Enasidenib: The metabolism of Enasidenib can be increased when combined with Acetylsalicylic acid. | [DB11963] Dacomitinib: The metabolism of Dacomitinib can be decreased when combined with Acetylsalicylic acid. | [DB12147] Erdafitinib: The metabolism of Erdafitinib can be decreased when combined with Acetylsalicylic acid. | [DB12371] Siponimod: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Siponimod. | [DB00675] Tamoxifen: The metabolism of Tamoxifen can be increased when combined with Acetylsalicylic acid. | [DB09213] Dexibuprofen: Dexibuprofen may decrease the antiplatelet activities of Acetylsalicylic acid. | [DB01050] Ibuprofen: Ibuprofen may decrease the antiplatelet activities of Acetylsalicylic acid. | [DB00252] Phenytoin: The serum concentration of Phenytoin can be increased when it is combined with Acetylsalicylic acid. | [DB00005] Etanercept: The metabolism of Acetylsalicylic acid can be increased when combined with Etanercept. | [DB00026] Anakinra: The metabolism of Acetylsalicylic acid can be increased when combined with Anakinra. | [DB00051] Adalimumab: The metabolism of Acetylsalicylic acid can be increased when combined with Adalimumab. | [DB00065] Infliximab: The metabolism of Acetylsalicylic acid can be increased when combined with Infliximab. | [DB01281] Abatacept: The metabolism of Acetylsalicylic acid can be increased when combined with Abatacept. | [DB04956] Afelimomab: The metabolism of Acetylsalicylic acid can be increased when combined with Afelimomab. | [DB05676] Apremilast: The metabolism of Acetylsalicylic acid can be increased when combined with Apremilast. | [DB06168] Canakinumab: The metabolism of Acetylsalicylic acid can be increased when combined with Canakinumab. | [DB06273] Tocilizumab: The metabolism of Acetylsalicylic acid can be increased when combined with Tocilizumab. | [DB06372] Rilonacept: The metabolism of Acetylsalicylic acid can be increased when combined with Rilonacept. | [DB06674] Golimumab: The metabolism of Acetylsalicylic acid can be increased when combined with Golimumab. | [DB08904] Certolizumab pegol: The metabolism of Acetylsalicylic acid can be increased when combined with Certolizumab pegol. | [DB09029] Secukinumab: The metabolism of Acetylsalicylic acid can be increased when combined with Secukinumab. | [DB09036] Siltuximab: The metabolism of Acetylsalicylic acid can be increased when combined with Siltuximab. | [DB14724] Emapalumab: The metabolism of Acetylsalicylic acid can be increased when combined with Emapalumab. | [DB02266] Flufenamic acid: Flufenamic acid may decrease the antiplatelet activities of Acetylsalicylic acid. | [DB13074] Macimorelin: The therapeutic efficacy of Macimorelin can be decreased when used in combination with Acetylsalicylic acid. | [DB00279] Liothyronine: The therapeutic efficacy of Liothyronine can be increased when used in combination with Acetylsalicylic acid. | [DB00024] Thyrotropin alfa: The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Acetylsalicylic acid. | [DB00451] Levothyroxine: The therapeutic efficacy of Levothyroxine can be increased when used in combination with Acetylsalicylic acid. | [DB01583] Liotrix: The therapeutic efficacy of Liotrix can be increased when used in combination with Acetylsalicylic acid. | [DB03604] Tiratricol: The therapeutic efficacy of Tiratricol can be increased when used in combination with Acetylsalicylic acid. | [DB09100] Thyroid, porcine: The therapeutic efficacy of Thyroid, porcine can be increased when used in combination with Acetylsalicylic acid. | [DB11823] Esketamine: The risk or severity of hypertension can be increased when Esketamine is combined with Acetylsalicylic acid. | [DB00781] Polymyxin B: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Polymyxin B. | [DB14754] Solriamfetol: The risk or severity of hypertension can be increased when Solriamfetol is combined with Acetylsalicylic acid. | [DB09288] Propacetamol: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Propacetamol. | [DB09539] Omega-3-acid ethyl esters: The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Acetylsalicylic acid. | [DB13946] Testosterone undecanoate: Testosterone undecanoate may increase the hypertensive activities of Acetylsalicylic acid. | [DB00054] Abciximab: Acetylsalicylic acid may increase the antiplatelet activities of Abciximab. | [DB00063] Eptifibatide: Acetylsalicylic acid may increase the antiplatelet activities of Eptifibatide. | [DB00208] Ticlopidine: Acetylsalicylic acid may increase the antiplatelet activities of Ticlopidine. | [DB00775] Tirofiban: Acetylsalicylic acid may increase the antiplatelet activities of Tirofiban. | [DB01088] Iloprost: Iloprost may increase the antiplatelet activities of Acetylsalicylic acid. | [DB01138] Sulfinpyrazone: Acetylsalicylic acid may increase the antiplatelet activities of Sulfinpyrazone. | [DB01166] Cilostazol: Acetylsalicylic acid may increase the antiplatelet activities of Cilostazol. | [DB01207] Ridogrel: Acetylsalicylic acid may increase the antiplatelet activities of Ridogrel. | [DB01236] Sevoflurane: The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Sevoflurane. | [DB01240] Epoprostenol: Acetylsalicylic acid may increase the antiplatelet activities of Epoprostenol. | [DB02709] Resveratrol: Acetylsalicylic acid may increase the antiplatelet activities of Resveratrol. | [DB04743] Nimesulide: Acetylsalicylic acid may increase the antiplatelet activities of Nimesulide. | [DB04905] Tesmilifene: Acetylsalicylic acid may increase the antiplatelet activities of Tesmilifene. | [DB04932] Defibrotide: Acetylsalicylic acid may increase the antiplatelet activities of Defibrotide. | [DB05229] Beraprost: Acetylsalicylic acid may increase the antiplatelet activities of Beraprost. | [DB05266] Ibudilast: Acetylsalicylic acid may increase the antiplatelet activities of Ibudilast. | [DB05767] Andrographolide: Acetylsalicylic acid may increase the antiplatelet activities of Andrographolide. | [DB06081] Caplacizumab: Acetylsalicylic acid may increase the antiplatelet activities of Caplacizumab. | [DB06209] Prasugrel: Acetylsalicylic acid may increase the antiplatelet activities of Prasugrel. | [DB06441] Cangrelor: Acetylsalicylic acid may increase the antiplatelet activities of Cangrelor. | [DB07615] Tranilast: Acetylsalicylic acid may increase the antiplatelet activities of Tranilast. | [DB08814] Triflusal: Acetylsalicylic acid may increase the antiplatelet activities of Triflusal. | [DB08887] Icosapent ethyl: Acetylsalicylic acid may increase the antiplatelet activities of Icosapent ethyl. | [DB09283] Trapidil: Acetylsalicylic acid may increase the antiplatelet activities of Trapidil. | [DB12092] Naftopidil: Acetylsalicylic acid may increase the antiplatelet activities of Naftopidil. | [DB12163] Sarpogrelate: Acetylsalicylic acid may increase the antiplatelet activities of Sarpogrelate. | [DB12321] Ifetroban: Acetylsalicylic acid may increase the antiplatelet activities of Ifetroban. | [DB12445] Nitroaspirin: Acetylsalicylic acid may increase the antiplatelet activities of Nitroaspirin. | [DB12545] Indobufen: Acetylsalicylic acid may increase the antiplatelet activities of Indobufen. | [DB12749] Butylphthalide: Acetylsalicylic acid may increase the antiplatelet activities of Butylphthalide. | [DB12771] Hydroxytyrosol: Acetylsalicylic acid may increase the antiplatelet activities of Hydroxytyrosol. | [DB13036] Ramatroban: Acetylsalicylic acid may increase the antiplatelet activities of Ramatroban. | [DB13327] Picotamide: Acetylsalicylic acid may increase the antiplatelet activities of Picotamide. | [DB13367] Cloricromen: Acetylsalicylic acid may increase the antiplatelet activities of Cloricromen. | [DB13400] Linsidomine: Acetylsalicylic acid may increase the antiplatelet activities of Linsidomine. | [DB13510] Buflomedil: Acetylsalicylic acid may increase the antiplatelet activities of Buflomedil. | [DB13929] Relcovaptan: Acetylsalicylic acid may increase the antiplatelet activities of Relcovaptan. | [DB15786] Maritime pine extract: Acetylsalicylic acid may increase the antiplatelet activities of Maritime pine extract. | [DB09030] Vorapaxar: Acetylsalicylic acid may increase the antiplatelet activities of Vorapaxar. | [DB00806] Pentoxifylline: Acetylsalicylic acid may increase the antiplatelet activities of Pentoxifylline. | [DB00974] Edetic acid: Acetylsalicylic acid may increase the anticoagulant activities of Edetic acid. | [DB13124] Troxerutin: Acetylsalicylic acid may increase the anticoagulant activities of Troxerutin. | [DB00001] Lepirudin: Acetylsalicylic acid may increase the anticoagulant activities of Lepirudin. | [DB00006] Bivalirudin: Acetylsalicylic acid may increase the anticoagulant activities of Bivalirudin. | [DB00009] Alteplase: Acetylsalicylic acid may increase the anticoagulant activities of Alteplase. | [DB00015] Reteplase: Acetylsalicylic acid may increase the anticoagulant activities of Reteplase. | [DB00029] Anistreplase: Acetylsalicylic acid may increase the anticoagulant activities of Anistreplase. | [DB00031] Tenecteplase: Acetylsalicylic acid may increase the anticoagulant activities of Tenecteplase. | [DB00055] Drotrecogin alfa: Acetylsalicylic acid may increase the anticoagulant activities of Drotrecogin alfa. | [DB00086] Streptokinase: Acetylsalicylic acid may increase the anticoagulant activities of Streptokinase. | [DB00266] Dicoumarol: Acetylsalicylic acid may increase the anticoagulant activities of Dicoumarol. | [DB00278] Argatroban: Acetylsalicylic acid may increase the anticoagulant activities of Argatroban. | [DB00407] Ardeparin: Acetylsalicylic acid may increase the anticoagulant activities of Ardeparin. | [DB00498] Phenindione: Acetylsalicylic acid may increase the anticoagulant activities of Phenindione. | [DB00569] Fondaparinux: Acetylsalicylic acid may increase the anticoagulant activities of Fondaparinux. | [DB00682] Warfarin: Acetylsalicylic acid may increase the anticoagulant activities of Warfarin. | [DB00946] Phenprocoumon: Acetylsalicylic acid may increase the anticoagulant activities of Phenprocoumon. | [DB01109] Heparin: Acetylsalicylic acid may increase the anticoagulant activities of Heparin. | [DB01225] Enoxaparin: Acetylsalicylic acid may increase the anticoagulant activities of Enoxaparin. | [DB01418] Acenocoumarol: Acetylsalicylic acid may increase the anticoagulant activities of Acenocoumarol. | [DB03410] 4-hydroxycoumarin: Acetylsalicylic acid may increase the anticoagulant activities of 4-hydroxycoumarin. | [DB04665] Coumarin: Acetylsalicylic acid may increase the anticoagulant activities of Coumarin. | [DB04898] Ximelagatran: Acetylsalicylic acid may increase the anticoagulant activities of Ximelagatran. | [DB04925] Desmoteplase: Acetylsalicylic acid may increase the anticoagulant activities of Desmoteplase. | [DB05099] Ancrod: Acetylsalicylic acid may increase the anticoagulant activities of Ancrod. | [DB06271] Sulodexide: Acetylsalicylic acid may increase the anticoagulant activities of Sulodexide. | [DB06294] Semuloparin: Acetylsalicylic acid may increase the anticoagulant activities of Semuloparin. | [DB06406] Idraparinux: Acetylsalicylic acid may increase the anticoagulant activities of Idraparinux. | [DB06543] Astaxanthin: Acetylsalicylic acid may increase the anticoagulant activities of Astaxanthin. | [DB06635] Otamixaban: Acetylsalicylic acid may increase the anticoagulant activities of Otamixaban. | [DB06679] Amediplase: Acetylsalicylic acid may increase the anticoagulant activities of Amediplase. | [DB06754] Danaparoid: Acetylsalicylic acid may increase the anticoagulant activities of Danaparoid. | [DB06779] Dalteparin: Acetylsalicylic acid may increase the anticoagulant activities of Dalteparin. | [DB06822] Tinzaparin: Acetylsalicylic acid may increase the anticoagulant activities of Tinzaparin. | [DB08496] (R)-warfarin: Acetylsalicylic acid may increase the anticoagulant activities of (R)-warfarin. | [DB08794] Ethyl biscoumacetate: Acetylsalicylic acid may increase the anticoagulant activities of Ethyl biscoumacetate. | [DB08813] Nadroparin: Acetylsalicylic acid may increase the anticoagulant activities of Nadroparin. | [DB08994] Ditazole: Acetylsalicylic acid may increase the anticoagulant activities of Ditazole. | [DB09125] Potassium citrate: Acetylsalicylic acid may decrease the excretion rate of Potassium citrate which could result in a higher serum level. | [DB09154] Sodium citrate: Acetylsalicylic acid may increase the anticoagulant activities of Sodium citrate. | [DB09255] Dextran: Acetylsalicylic acid may increase the anticoagulant activities of Dextran. | [DB09258] Bemiparin: Acetylsalicylic acid may increase the anticoagulant activities of Bemiparin. | [DB09260] Parnaparin: Acetylsalicylic acid may increase the anticoagulant activities of Parnaparin. | [DB11095] Desirudin: Acetylsalicylic acid may increase the anticoagulant activities of Desirudin. | [DB11166] Antithrombin Alfa: Acetylsalicylic acid may increase the anticoagulant activities of Antithrombin Alfa. | [DB11312] Protein C: Acetylsalicylic acid may increase the anticoagulant activities of Protein C. | [DB11598] Antithrombin III human: Acetylsalicylic acid may increase the anticoagulant activities of Antithrombin III human. | [DB11984] Letaxaban: Acetylsalicylic acid may increase the anticoagulant activities of Letaxaban. | [DB12289] Darexaban: Acetylsalicylic acid may increase the anticoagulant activities of Darexaban. | [DB12598] Nafamostat: Acetylsalicylic acid may increase the anticoagulant activities of Nafamostat. | [DB12726] Monteplase: Acetylsalicylic acid may increase the anticoagulant activities of Monteplase. | [DB12831] Gabexate: Acetylsalicylic acid may increase the anticoagulant activities of Gabexate. | [DB13136] Fluindione: Acetylsalicylic acid may increase the anticoagulant activities of Fluindione. | [DB13149] Protein S human: Acetylsalicylic acid may increase the anticoagulant activities of Protein S human. | [DB13199] Brinase: Acetylsalicylic acid may increase the anticoagulant activities of Brinase. | [DB13275] Clorindione: Acetylsalicylic acid may increase the anticoagulant activities of Clorindione. | [DB13347] Diphenadione: Acetylsalicylic acid may increase the anticoagulant activities of Diphenadione. | [DB13451] Tioclomarol: Acetylsalicylic acid may increase the anticoagulant activities of Tioclomarol. | [DB13616] Melagatran: Acetylsalicylic acid may increase the anticoagulant activities of Melagatran. | [DB13646] Saruplase: Acetylsalicylic acid may increase the anticoagulant activities of Saruplase. | [DB14055] (S)-Warfarin: Acetylsalicylic acid may increase the anticoagulant activities of (S)-Warfarin. | [DB14094] Tocopherylquinone: Acetylsalicylic acid may increase the anticoagulant activities of Tocopherylquinone. | [DB14726] Dabigatran: Acetylsalicylic acid may increase the anticoagulant activities of Dabigatran. | [DB09259] Reviparin: Acetylsalicylic acid may increase the anticoagulant activities of Reviparin. | [DB15880] Dermatan sulfate: Acetylsalicylic acid may increase the anticoagulant activities of Dermatan sulfate. | [DB09075] Edoxaban: Acetylsalicylic acid may increase the anticoagulant activities of Edoxaban. | [DB05361] SR-123781A: Acetylsalicylic acid may increase the anticoagulant activities of SR-123781A. | [DB00563] Methotrexate: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Methotrexate. | [DB00030] Insulin human: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin human. | [DB00046] Insulin lispro: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin lispro. | [DB00047] Insulin glargine: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin glargine. | [DB00071] Insulin pork: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin pork. | [DB00197] Troglitazone: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Troglitazone. | [DB00222] Glimepiride: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Glimepiride. | [DB00263] Sulfisoxazole: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Sulfisoxazole. | [DB00280] Disopyramide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Disopyramide. | [DB00284] Acarbose: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Acarbose. | [DB00331] Metformin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Metformin. | [DB00412] Rosiglitazone: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Rosiglitazone. | [DB00414] Acetohexamide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Acetohexamide. | [DB00468] Quinine: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Quinine. | [DB00491] Miglitol: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Miglitol. | [DB00672] Chlorpropamide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Chlorpropamide. | [DB00731] Nateglinide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Nateglinide. | [DB00738] Pentamidine: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Pentamidine. | [DB00834] Mifepristone: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Mifepristone. | [DB00839] Tolazamide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Tolazamide. | [DB00912] Repaglinide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Repaglinide. | [DB00914] Phenformin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Phenformin. | [DB01015] Sulfamethoxazole: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Sulfamethoxazole. | [DB01016] Glyburide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Glyburide. | [DB01067] Glipizide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Glipizide. | [DB01120] Gliclazide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Gliclazide. | [DB01124] Tolbutamide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Tolbutamide. | [DB01132] Pioglitazone: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Pioglitazone. | [DB01200] Bromocriptine: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Bromocriptine. | [DB01251] Gliquidone: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Gliquidone. | [DB01252] Mitiglinide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Mitiglinide. | [DB01261] Sitagliptin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Sitagliptin. | [DB01268] Sunitinib: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Sunitinib. | [DB01276] Exenatide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Exenatide. | [DB01277] Mecasermin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Mecasermin. | [DB01278] Pramlintide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Pramlintide. | [DB01289] Glisoxepide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Glisoxepide. | [DB01306] Insulin aspart: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin aspart. | [DB01307] Insulin detemir: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin detemir. | [DB01309] Insulin glulisine: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin glulisine. | [DB01382] Glymidine: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Glymidine. | [DB01700] AICA ribonucleotide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with AICA ribonucleotide. | [DB04830] Buformin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Buformin. | [DB04876] Vildagliptin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Vildagliptin. | [DB04878] Voglibose: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Voglibose. | [DB05115] NN344: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with NN344. | [DB06011] AMG-222: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with AMG-222. | [DB06127] Bisegliptin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Bisegliptin. | [DB06203] Alogliptin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Alogliptin. | [DB06292] Dapagliflozin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Dapagliflozin. | [DB06335] Saxagliptin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Saxagliptin. | [DB06655] Liraglutide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Liraglutide. | [DB08382] Gosogliptin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Gosogliptin. | [DB08882] Linagliptin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Linagliptin. | [DB08907] Canagliflozin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Canagliflozin. | [DB08962] Glibornuride: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Glibornuride. | [DB09022] Benfluorex: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Benfluorex. | [DB09038] Empagliflozin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Empagliflozin. | [DB09043] Albiglutide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Albiglutide. | [DB09045] Dulaglutide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Dulaglutide. | [DB09198] Lobeglitazone: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Lobeglitazone. | [DB09199] Netoglitazone: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Netoglitazone. | [DB09200] Rivoglitazone: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Rivoglitazone. | [DB09201] Ciglitazone: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Ciglitazone. | [DB09265] Lixisenatide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Lixisenatide. | [DB09456] Insulin beef: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin beef. | [DB09564] Insulin degludec: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin degludec. | [DB11567] Insulin peglispro: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin peglispro. | [DB11568] Insulin tregopil: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin tregopil. | [DB11698] Ipragliflozin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Ipragliflozin. | [DB11723] Dutogliptin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Dutogliptin. | [DB11780] Allicin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Allicin. | [DB11824] Tofogliflozin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Tofogliflozin. | [DB11898] 2,4-thiazolidinedione: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with 2,4-thiazolidinedione. | [DB11950] Teneligliptin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Teneligliptin. | [DB11992] Omarigliptin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Omarigliptin. | [DB12268] Carmegliptin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Carmegliptin. | [DB12412] Gemigliptin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Gemigliptin. | [DB12417] Anagliptin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Anagliptin. | [DB12625] Evogliptin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Evogliptin. | [DB12713] Sotagliflozin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Sotagliflozin. | [DB12781] Balaglitazone: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Balaglitazone. | [DB12935] Remogliflozin etabonate: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Remogliflozin etabonate. | [DB13406] Carbutamide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Carbutamide. | [DB13446] Guar gum: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Guar gum. | [DB13675] Metahexamide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Metahexamide. | [DB13928] Semaglutide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Semaglutide. | [DB14027] Taspoglutide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Taspoglutide. | [DB14035] Englitazone: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Englitazone. | [DB15171] Tirzepatide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Tirzepatide. | [DB15217] Gastric inhibitory polypeptide: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Gastric inhibitory polypeptide. | [DB00742] Mannitol: Acetylsalicylic acid may decrease the excretion rate of Mannitol which could result in a higher serum level. | [DB00214] Torasemide: Acetylsalicylic acid may decrease the excretion rate of Torasemide which could result in a higher serum level. | [DB00232] Methyclothiazide: Acetylsalicylic acid may decrease the excretion rate of Methyclothiazide which could result in a higher serum level. | [DB00310] Chlorthalidone: Acetylsalicylic acid may decrease the excretion rate of Chlorthalidone which could result in a higher serum level. | [DB00311] Ethoxzolamide: Acetylsalicylic acid may decrease the excretion rate of Ethoxzolamide which could result in a higher serum level. | [DB00384] Triamterene: Acetylsalicylic acid may decrease the excretion rate of Triamterene which could result in a higher serum level. | [DB00421] Spironolactone: The therapeutic efficacy of Spironolactone can be decreased when used in combination with Acetylsalicylic acid. | [DB00436] Bendroflumethiazide: Acetylsalicylic acid may decrease the excretion rate of Bendroflumethiazide which could result in a higher serum level. | [DB00524] Metolazone: Acetylsalicylic acid may decrease the excretion rate of Metolazone which could result in a higher serum level. | [DB00562] Benzthiazide: Acetylsalicylic acid may decrease the excretion rate of Benzthiazide which could result in a higher serum level. | [DB00594] Amiloride: Acetylsalicylic acid may decrease the excretion rate of Amiloride which could result in a higher serum level. | [DB00606] Cyclothiazide: Acetylsalicylic acid may decrease the excretion rate of Cyclothiazide which could result in a higher serum level. | [DB00700] Eplerenone: Acetylsalicylic acid may decrease the excretion rate of Eplerenone which could result in a higher serum level. | [DB00703] Methazolamide: Acetylsalicylic acid may decrease the excretion rate of Methazolamide which could result in a higher serum level. | [DB00774] Hydroflumethiazide: Acetylsalicylic acid may decrease the excretion rate of Hydroflumethiazide which could result in a higher serum level. | [DB00808] Indapamide: Acetylsalicylic acid may decrease the excretion rate of Indapamide which could result in a higher serum level. | [DB00819] Acetazolamide: Acetylsalicylic acid may decrease the excretion rate of Acetazolamide which could result in a higher serum level. | [DB00872] Conivaptan: Acetylsalicylic acid may decrease the excretion rate of Conivaptan which could result in a higher serum level. | [DB00880] Chlorothiazide: Acetylsalicylic acid may decrease the excretion rate of Chlorothiazide which could result in a higher serum level. | [DB00887] Bumetanide: Acetylsalicylic acid may decrease the excretion rate of Bumetanide which could result in a higher serum level. | [DB00903] Etacrynic acid: Acetylsalicylic acid may decrease the excretion rate of Etacrynic acid which could result in a higher serum level. | [DB00909] Zonisamide: Acetylsalicylic acid may decrease the excretion rate of Zonisamide which could result in a higher serum level. | [DB01021] Trichlormethiazide: Acetylsalicylic acid may decrease the excretion rate of Trichlormethiazide which could result in a higher serum level. | [DB01144] Diclofenamide: Acetylsalicylic acid may decrease the excretion rate of Diclofenamide which could result in a higher serum level. | [DB01324] Polythiazide: Acetylsalicylic acid may decrease the excretion rate of Polythiazide which could result in a higher serum level. | [DB01325] Quinethazone: Acetylsalicylic acid may decrease the excretion rate of Quinethazone which could result in a higher serum level. | [DB01412] Theobromine: Acetylsalicylic acid may decrease the excretion rate of Theobromine which could result in a higher serum level. | [DB02925] Piretanide: Acetylsalicylic acid may decrease the excretion rate of Piretanide which could result in a higher serum level. | [DB04831] Tienilic acid: Acetylsalicylic acid may decrease the excretion rate of Tienilic acid which could result in a higher serum level. | [DB05034] Ularitide: Acetylsalicylic acid may decrease the excretion rate of Ularitide which could result in a higher serum level. | [DB06212] Tolvaptan: Acetylsalicylic acid may decrease the excretion rate of Tolvaptan which could result in a higher serum level. | [DB06370] Indisulam: Acetylsalicylic acid may decrease the excretion rate of Indisulam which could result in a higher serum level. | [DB08961] Azosemide: Acetylsalicylic acid may decrease the excretion rate of Azosemide which could result in a higher serum level. | [DB09015] Canrenoic acid: Acetylsalicylic acid may decrease the excretion rate of Canrenoic acid which could result in a higher serum level. | [DB09235] Efonidipine: Acetylsalicylic acid may decrease the excretion rate of Efonidipine which could result in a higher serum level. | [DB09338] Mersalyl: Acetylsalicylic acid may decrease the excretion rate of Mersalyl which could result in a higher serum level. | [DB09401] Isosorbide: Acetylsalicylic acid may decrease the excretion rate of Isosorbide which could result in a higher serum level. | [DB11827] Ertugliflozin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Ertugliflozin. | [DB12221] Canrenone: Acetylsalicylic acid may decrease the excretion rate of Canrenone which could result in a higher serum level. | [DB12670] Rolofylline: Acetylsalicylic acid may decrease the excretion rate of Rolofylline which could result in a higher serum level. | [DB12704] Spiradoline: Acetylsalicylic acid may decrease the excretion rate of Spiradoline which could result in a higher serum level. | [DB12766] Cicletanine: Acetylsalicylic acid may decrease the excretion rate of Cicletanine which could result in a higher serum level. | [DB13284] Meticrane: Acetylsalicylic acid may decrease the excretion rate of Meticrane which could result in a higher serum level. | [DB13405] Mefruside: Acetylsalicylic acid may decrease the excretion rate of Mefruside which could result in a higher serum level. | [DB13430] Mebutizide: Acetylsalicylic acid may decrease the excretion rate of Mebutizide which could result in a higher serum level. | [DB13532] Cyclopenthiazide: Acetylsalicylic acid may decrease the excretion rate of Cyclopenthiazide which could result in a higher serum level. | [DB13617] Clorexolone: Acetylsalicylic acid may decrease the excretion rate of Clorexolone which could result in a higher serum level. | [DB13663] Clofenamide: Acetylsalicylic acid may decrease the excretion rate of Clofenamide which could result in a higher serum level. | [DB13708] Fenquizone: Acetylsalicylic acid may decrease the excretion rate of Fenquizone which could result in a higher serum level. | [DB13792] Clopamide: Acetylsalicylic acid may decrease the excretion rate of Clopamide which could result in a higher serum level. | [DB13801] Muzolimine: Acetylsalicylic acid may decrease the excretion rate of Muzolimine which could result in a higher serum level. | [DB13803] Xipamide: Acetylsalicylic acid may decrease the excretion rate of Xipamide which could result in a higher serum level. | [DB13989] Epitizide: Acetylsalicylic acid may decrease the excretion rate of Epitizide which could result in a higher serum level. | [DB14018] Bromotheophylline: Acetylsalicylic acid may decrease the excretion rate of Bromotheophylline which could result in a higher serum level. | [DB14500] Potassium: Acetylsalicylic acid may decrease the excretion rate of Potassium which could result in a higher serum level. | [DB01345] Potassium cation: Acetylsalicylic acid may decrease the excretion rate of Potassium cation which could result in a higher serum level. | [DB15861] Buthiazide: Acetylsalicylic acid may decrease the excretion rate of Buthiazide which could result in a higher serum level. | [DB15959] Tripamide: Acetylsalicylic acid may decrease the excretion rate of Tripamide which could result in a higher serum level. | [DB07402] Azapropazone: The therapeutic efficacy of Azapropazone can be decreased when used in combination with Acetylsalicylic acid. | [DB11560] Lesinurad: The therapeutic efficacy of Lesinurad can be decreased when used in combination with Acetylsalicylic acid. | [DB12319] Benzbromarone: The therapeutic efficacy of Benzbromarone can be decreased when used in combination with Acetylsalicylic acid. | [DB13277] Benziodarone: The therapeutic efficacy of Benziodarone can be decreased when used in combination with Acetylsalicylic acid. | [DB00437] Allopurinol: The therapeutic efficacy of Allopurinol can be decreased when used in combination with Acetylsalicylic acid. | [DB00313] Valproic acid: The metabolism of Valproic acid can be decreased when combined with Acetylsalicylic acid. | [DB00394] Beclomethasone dipropionate: The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Acetylsalicylic acid. | [DB00443] Betamethasone: The risk or severity of adverse effects can be increased when Betamethasone is combined with Acetylsalicylic acid. | [DB00620] Triamcinolone: The risk or severity of adverse effects can be increased when Triamcinolone is combined with Acetylsalicylic acid. | [DB00635] Prednisone: The risk or severity of adverse effects can be increased when Prednisone is combined with Acetylsalicylic acid. | [DB01380] Cortisone acetate: The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Acetylsalicylic acid. | [DB01384] Paramethasone: The risk or severity of adverse effects can be increased when Paramethasone is combined with Acetylsalicylic acid. | [DB01410] Ciclesonide: The risk or severity of adverse effects can be increased when Ciclesonide is combined with Acetylsalicylic acid. | [DB08906] Fluticasone furoate: The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Acetylsalicylic acid. | [DB08970] Fluprednidene: The risk or severity of adverse effects can be increased when Fluprednidene is combined with Acetylsalicylic acid. | [DB09383] Meprednisone: The risk or severity of adverse effects can be increased when Meprednisone is combined with Acetylsalicylic acid. | [DB11487] Dexamethasone isonicotinate: The risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Acetylsalicylic acid. | [DB11921] Deflazacort: The risk or severity of adverse effects can be increased when Deflazacort is combined with Acetylsalicylic acid. | [DB13003] Cortivazol: The risk or severity of adverse effects can be increased when Cortivazol is combined with Acetylsalicylic acid. | [DB13208] Prednylidene: The risk or severity of adverse effects can be increased when Prednylidene is combined with Acetylsalicylic acid. | [DB13843] Cloprednol: The risk or severity of adverse effects can be increased when Cloprednol is combined with Acetylsalicylic acid. | [DB13867] Fluticasone: The risk or severity of adverse effects can be increased when Fluticasone is combined with Acetylsalicylic acid. | [DB14512] Mometasone furoate: The risk or severity of adverse effects can be increased when Mometasone furoate is combined with Acetylsalicylic acid. | [DB14631] Prednisolone phosphate: The risk or severity of adverse effects can be increased when Prednisolone phosphate is combined with Acetylsalicylic acid. | [DB14633] Prednisolone hemisuccinate: The risk or severity of adverse effects can be increased when Prednisolone hemisuccinate is combined with Acetylsalicylic acid. | [DB14644] Methylprednisolone hemisuccinate: The risk or severity of adverse effects can be increased when Methylprednisolone hemisuccinate is combined with Acetylsalicylic acid. | [DB14646] Prednisone acetate: The risk or severity of adverse effects can be increased when Prednisone acetate is combined with Acetylsalicylic acid. | [DB14652] Clocortolone acetate: The risk or severity of adverse effects can be increased when Clocortolone acetate is combined with Acetylsalicylic acid. | [DB14659] Melengestrol acetate: The risk or severity of adverse effects can be increased when Melengestrol acetate is combined with Acetylsalicylic acid. | [DB14669] Betamethasone phosphate: The risk or severity of adverse effects can be increased when Betamethasone phosphate is combined with Acetylsalicylic acid. | [DB14681] Cortisone: The risk or severity of adverse effects can be increased when Cortisone is combined with Acetylsalicylic acid. | [DB01013] Clobetasol propionate: The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Acetylsalicylic acid. | [DB01047] Fluocinonide: The risk or severity of adverse effects can be increased when Fluocinonide is combined with Acetylsalicylic acid. | [DB00764] Mometasone: The risk or severity of adverse effects can be increased when Mometasone is combined with Acetylsalicylic acid. | [DB08971] Fluocortolone: The risk or severity of adverse effects can be increased when Fluocortolone is combined with Acetylsalicylic acid. | [DB09095] Difluocortolone: The risk or severity of adverse effects can be increased when Difluocortolone is combined with Acetylsalicylic acid. | [DB00492] Fosinopril: The therapeutic efficacy of Fosinopril can be decreased when used in combination with Acetylsalicylic acid. | [DB00519] Trandolapril: The therapeutic efficacy of Trandolapril can be decreased when used in combination with Acetylsalicylic acid. | [DB00542] Benazepril: The therapeutic efficacy of Benazepril can be decreased when used in combination with Acetylsalicylic acid. | [DB00584] Enalapril: The therapeutic efficacy of Enalapril can be decreased when used in combination with Acetylsalicylic acid. | [DB00691] Moexipril: The therapeutic efficacy of Moexipril can be decreased when used in combination with Acetylsalicylic acid. | [DB00722] Lisinopril: The therapeutic efficacy of Lisinopril can be decreased when used in combination with Acetylsalicylic acid. | [DB00790] Perindopril: The therapeutic efficacy of Perindopril can be decreased when used in combination with Acetylsalicylic acid. | [DB00881] Quinapril: The therapeutic efficacy of Quinapril can be decreased when used in combination with Acetylsalicylic acid. | [DB00886] Omapatrilat: The therapeutic efficacy of Omapatrilat can be decreased when used in combination with Acetylsalicylic acid. | [DB01180] Rescinnamine: The therapeutic efficacy of Rescinnamine can be decreased when used in combination with Acetylsalicylic acid. | [DB01197] Captopril: The therapeutic efficacy of Captopril can be decreased when used in combination with Acetylsalicylic acid. | [DB01340] Cilazapril: The therapeutic efficacy of Cilazapril can be decreased when used in combination with Acetylsalicylic acid. | [DB01348] Spirapril: The therapeutic efficacy of Spirapril can be decreased when used in combination with Acetylsalicylic acid. | [DB08836] Temocapril: The therapeutic efficacy of Temocapril can be decreased when used in combination with Acetylsalicylic acid. | [DB09477] Enalaprilat: The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Acetylsalicylic acid. | [DB11783] Imidapril: The therapeutic efficacy of Imidapril can be decreased when used in combination with Acetylsalicylic acid. | [DB13166] Zofenopril: The therapeutic efficacy of Zofenopril can be decreased when used in combination with Acetylsalicylic acid. | [DB13312] Delapril: The therapeutic efficacy of Delapril can be decreased when used in combination with Acetylsalicylic acid. | [DB14125] Benazeprilat: The therapeutic efficacy of Benazeprilat can be decreased when used in combination with Acetylsalicylic acid. | [DB14207] Fosinoprilat: The therapeutic efficacy of Fosinoprilat can be decreased when used in combination with Acetylsalicylic acid. | [DB14208] Ramiprilat: The therapeutic efficacy of Ramiprilat can be decreased when used in combination with Acetylsalicylic acid. | [DB14209] Trandolaprilat: The therapeutic efficacy of Trandolaprilat can be decreased when used in combination with Acetylsalicylic acid. | [DB14210] Moexiprilat: The therapeutic efficacy of Moexiprilat can be decreased when used in combination with Acetylsalicylic acid. | [DB14213] Perindoprilat: The therapeutic efficacy of Perindoprilat can be decreased when used in combination with Acetylsalicylic acid. | [DB14217] Quinaprilat: The therapeutic efficacy of Quinaprilat can be decreased when used in combination with Acetylsalicylic acid. | [DB14231] Quinoline Yellow WS: The risk or severity of angioedema can be increased when Acetylsalicylic acid is combined with Quinoline Yellow WS. | [DB15565] Cilazaprilat: The therapeutic efficacy of Cilazaprilat can be decreased when used in combination with Acetylsalicylic acid. | [DB00176] Fluvoxamine: The risk or severity of gastrointestinal bleeding can be increased when Fluvoxamine is combined with Acetylsalicylic acid. | [DB00215] Citalopram: The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Acetylsalicylic acid. | [DB00472] Fluoxetine: The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Acetylsalicylic acid. | [DB00656] Trazodone: The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Acetylsalicylic acid. | [DB00715] Paroxetine: The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Acetylsalicylic acid. | [DB01175] Escitalopram: The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Acetylsalicylic acid. | [DB04832] Zimelidine: The risk or severity of gastrointestinal bleeding can be increased when Zimelidine is combined with Acetylsalicylic acid. | [DB04884] Dapoxetine: The risk or severity of gastrointestinal bleeding can be increased when Dapoxetine is combined with Acetylsalicylic acid. | [DB06731] Seproxetine: The risk or severity of gastrointestinal bleeding can be increased when Seproxetine is combined with Acetylsalicylic acid. | [DB08953] Indalpine: The risk or severity of gastrointestinal bleeding can be increased when Indalpine is combined with Acetylsalicylic acid. | [DB12693] Ritanserin: The risk or severity of gastrointestinal bleeding can be increased when Ritanserin is combined with Acetylsalicylic acid. | [DB13233] Alaproclate: The risk or severity of gastrointestinal bleeding can be increased when Alaproclate is combined with Acetylsalicylic acid. | [DB00390] Digoxin: Acetylsalicylic acid may decrease the excretion rate of Digoxin which could result in a higher serum level. | [DB13401] Metildigoxin: Acetylsalicylic acid may decrease the excretion rate of Metildigoxin which could result in a higher serum level. | [DB13691] Acetyldigoxin: Acetylsalicylic acid may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level. | [DB00788] Naproxen: The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Naproxen. | [DB00181] Baclofen: Acetylsalicylic acid may decrease the excretion rate of Baclofen which could result in a higher serum level. | [DB00461] Nabumetone: The protein binding of Nabumetone can be decreased when combined with Acetylsalicylic acid. | [DB00495] Zidovudine: The risk or severity of bleeding can be increased when Zidovudine is combined with Acetylsalicylic acid. | [DB12015] Alpelisib: The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Alpelisib. | [DB00571] Propranolol: The serum concentration of Propranolol can be decreased when it is combined with Acetylsalicylic acid. | [DB00727] Nitroglycerin: The serum concentration of Nitroglycerin can be increased when it is combined with Acetylsalicylic acid. | [DB00482] Celecoxib: The risk or severity of gastrointestinal irritation can be increased when Celecoxib is combined with Acetylsalicylic acid. | [DB01104] Sertraline: The risk or severity of bleeding can be increased when Sertraline is combined with Acetylsalicylic acid. | [DB00695] Furosemide: The risk or severity of increased serum creatinine can be increased when Acetylsalicylic acid is combined with Furosemide. | [DB01320] Fosphenytoin: The protein binding of Fosphenytoin can be decreased when combined with Acetylsalicylic acid. | [DB00814] Meloxicam: The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Acetylsalicylic acid. | [DB00869] Dorzolamide: The risk or severity of metabolic acidosis can be increased when Dorzolamide is combined with Acetylsalicylic acid. | [DB00994] Neomycin: The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Neomycin. | [DB09146] Iron sucrose: The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Iron sucrose. | [DB00261] Anagrelide: The risk or severity of bleeding can be increased when Anagrelide is combined with Acetylsalicylic acid. | [DB00465] Ketorolac: The risk or severity of adverse effects can be increased when Ketorolac is combined with Acetylsalicylic acid. | [DB15762] Satralizumab: The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Satralizumab. | [DB04836] Amineptine: The risk or severity of gastrointestinal bleeding can be increased when Amineptine is combined with Acetylsalicylic acid. | [DB09016] Butriptyline: The risk or severity of gastrointestinal bleeding can be increased when Butriptyline is combined with Acetylsalicylic acid. | [DB09289] Tianeptine: The risk or severity of gastrointestinal bleeding can be increased when Tianeptine is combined with Acetylsalicylic acid. | [DB09307] Oxaprotiline: The risk or severity of gastrointestinal bleeding can be increased when Oxaprotiline is combined with Acetylsalicylic acid. | [DB12930] Opipramol: The risk or severity of gastrointestinal bleeding can be increased when Opipramol is combined with Acetylsalicylic acid. | [DB13114] Amitriptylinoxide: The risk or severity of gastrointestinal bleeding can be increased when Amitriptylinoxide is combined with Acetylsalicylic acid. | [DB13225] Dibenzepin: The risk or severity of gastrointestinal bleeding can be increased when Dibenzepin is combined with Acetylsalicylic acid. | [DB13246] Quinupramine: The risk or severity of gastrointestinal bleeding can be increased when Quinupramine is combined with Acetylsalicylic acid. | [DB13384] Melitracen: The risk or severity of gastrointestinal bleeding can be increased when Melitracen is combined with Acetylsalicylic acid. | [DB13411] Lofepramine: The risk or severity of gastrointestinal bleeding can be increased when Lofepramine is combined with Acetylsalicylic acid. | [DB13496] Iprindole: The risk or severity of gastrointestinal bleeding can be increased when Iprindole is combined with Acetylsalicylic acid. | [DB13782] Imipramine oxide: The risk or severity of gastrointestinal bleeding can be increased when Imipramine oxide is combined with Acetylsalicylic acid. | [DB00321] Amitriptyline: The risk or severity of gastrointestinal bleeding can be increased when Amitriptyline is combined with Acetylsalicylic acid. | [DB00726] Trimipramine: The risk or severity of gastrointestinal bleeding can be increased when Trimipramine is combined with Acetylsalicylic acid. | [DB01142] Doxepin: The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Acetylsalicylic acid. | [DB00344] Protriptyline: The risk or severity of gastrointestinal bleeding can be increased when Protriptyline is combined with Acetylsalicylic acid. | [DB00458] Imipramine: The risk or severity of gastrointestinal bleeding can be increased when Imipramine is combined with Acetylsalicylic acid. | [DB00540] Nortriptyline: The risk or severity of gastrointestinal bleeding can be increased when Nortriptyline is combined with Acetylsalicylic acid. | [DB00543] Amoxapine: The risk or severity of gastrointestinal bleeding can be increased when Amoxapine is combined with Acetylsalicylic acid. | [DB01151] Desipramine: The risk or severity of gastrointestinal bleeding can be increased when Desipramine is combined with Acetylsalicylic acid. | [DB01242] Clomipramine: The risk or severity of gastrointestinal bleeding can be increased when Clomipramine is combined with Acetylsalicylic acid. | [DB08996] Dimetacrine: The risk or severity of gastrointestinal bleeding can be increased when Dimetacrine is combined with Acetylsalicylic acid. | [DB09167] Dosulepin: The risk or severity of gastrointestinal bleeding can be increased when Dosulepin is combined with Acetylsalicylic acid. | [DB09068] Vortioxetine: The risk or severity of bleeding can be increased when Vortioxetine is combined with Acetylsalicylic acid. | [DB12235] Estetrol: The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Estetrol. | [DB11201] Menthyl salicylate: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Menthyl salicylate. | [DB11323] Glycol salicylate: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Glycol salicylate. | [DB12597] Asciminib: The metabolism of Acetylsalicylic acid can be decreased when combined with Asciminib. | [DB15226] Dasiglucagon: Acetylsalicylic acid may decrease the antihypertensive activities of Dasiglucagon. | [DB15119] Ropeginterferon alfa-2b: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Ropeginterferon alfa-2b. | [DB12789] Dinoprost: The therapeutic efficacy of Dinoprost can be decreased when used in combination with Acetylsalicylic acid. | [DB12917] Bimekizumab: The metabolism of Acetylsalicylic acid can be increased when combined with Bimekizumab. | [DB14973] Abrocitinib: The risk or severity of bleeding and thrombocytopenia can be increased when Acetylsalicylic acid is combined with Abrocitinib. | [DB15575] Padeliporfin: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Padeliporfin. | [DB04216] Quercetin: The metabolism of Acetylsalicylic acid can be decreased when combined with Quercetin. | [DB14737] Cannabinol: The metabolism of Acetylsalicylic acid can be decreased when combined with Cannabinol. | [DB14921] Mavacamten: The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Mavacamten. | [DB14568] Ivosidenib: The metabolism of Acetylsalicylic acid can be increased when combined with Ivosidenib. | [DB15434] Mosunetuzumab: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Mosunetuzumab. | [DB11564] Insulin argine: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin argine. | [DB15133] Tepotinib: The metabolism of Acetylsalicylic acid can be decreased when combined with Tepotinib. | [DB04951] Pirfenidone: The metabolism of Pirfenidone can be decreased when combined with Acetylsalicylic acid. | [DB16901] Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen: The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen is combined with Acetylsalicylic acid. | [DB12214] Luseogliflozin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Luseogliflozin. | [DB09368] Corticotropin zinc hydroxide: The risk or severity of gastrointestinal irritation can be increased when Corticotropin zinc hydroxide is combined with Acetylsalicylic acid. | [DB15777] Fluocortolone pivalate: The risk or severity of gastrointestinal irritation can be increased when Fluocortolone pivalate is combined with Acetylsalicylic acid. | [DB15821] Fluocortolone caproate: The risk or severity of gastrointestinal irritation can be increased when Fluocortolone caproate is combined with Acetylsalicylic acid. | [DB15972] Desoxycortone: The risk or severity of gastrointestinal irritation can be increased when Desoxycortone is combined with Acetylsalicylic acid. | [DB12236] Bexagliflozin: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Bexagliflozin. | [DB17472] Pirtobrutinib: The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Pirtobrutinib. | [DB15568] Adagrasib: The metabolism of Acetylsalicylic acid can be decreased when combined with Adagrasib. | [DB12548] Sparsentan: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Sparsentan. | [DB00862] Vardenafil: The metabolism of Acetylsalicylic acid can be decreased when combined with Vardenafil. | [DB08820] Ivacaftor: The serum concentration of Acetylsalicylic acid can be increased when it is combined with Ivacaftor. | [DB16672] Epcoritamab: The serum concentration of Acetylsalicylic acid can be increased when it is combined with Epcoritamab. | [DB12255] Vadadustat: The serum concentration of Vadadustat can be increased when it is combined with Acetylsalicylic acid. | [DB16371] Glofitamab: The serum concentration of Acetylsalicylic acid can be increased when it is combined with Glofitamab. | [DB01194] Brinzolamide: The risk or severity of electrolyte abnormality can be increased when Brinzolamide is combined with Acetylsalicylic acid. | [DB18661] Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen: The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is combined with Acetylsalicylic acid. | [DB14766] Etrasimod: The metabolism of Etrasimod can be decreased when combined with Acetylsalicylic acid. | [DB11967] Binimetinib: The metabolism of Binimetinib can be increased when combined with Acetylsalicylic acid. | [DB11718] Encorafenib: The metabolism of Acetylsalicylic acid can be decreased when combined with Encorafenib. | [DB11679] Fruquintinib: The metabolism of Fruquintinib can be decreased when combined with Acetylsalicylic acid. | [DB15114] Vamorolone: The risk or severity of adverse effects can be increased when Vamorolone is combined with Acetylsalicylic acid. | [DB12005] Nirogacestat: The metabolism of Nirogacestat can be decreased when combined with Acetylsalicylic acid. | [DB06636] Isavuconazonium: The metabolism of Acetylsalicylic acid can be decreased when combined with Isavuconazonium. | [DB11995] Avatrombopag: The metabolism of Avatrombopag can be decreased when combined with Acetylsalicylic acid. | [DB15059] Aprocitentan: Acetylsalicylic acid may decrease the antihypertensive activities of Aprocitentan. | [DB01045] Rifampin: The metabolism of Acetylsalicylic acid can be increased when combined with Rifampin. | [DB16693] Insulin icodec: The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin icodec. | [DB18847] Deuruxolitinib: The metabolism of Deuruxolitinib can be decreased when combined with Acetylsalicylic acid. | [DB12390] Seladelpar: The excretion of Seladelpar can be decreased when combined with Acetylsalicylic acid. | [DB19413] Influenza A Virus A/Thailand/8/2022 IVR-237 (H3N2) whole: The risk or severity of Reye's syndrome can be increased when Influenza A Virus A/Thailand/8/2022 IVR-237 (H3N2) whole is combined with Acetylsalicylic acid. | [DB16335] Sulopenem etzadroxil: The serum concentration of Sulopenem etzadroxil can be increased when it is combined with Acetylsalicylic acid.",0.5 G; 0.6 g; 1 G; 1 g/5ml; 1.3 g; 10.400 mg; 100 MG; 100 mg; 100.0 mg; 100.00 mg; 100.000 mg; 1000 mg; 10000000 mg; 105.000 mg; 125 MG; 1300 mg; 150 mg; 160 MG; 160 mg; 162 mg; 162 mg/1621; 162 mg/1sachet; 162.5 mg/1; 20 mg; 200 mg; 25.000 MG; 250 MG; 250 mg; 250.000 mg; 30 MG; 30 mg; 300 MG; 300 mg; 300 mg / tab; 300 mg/1; 300.00 mg; 300.000 mg; 320 mg; 324 MG; 324 mg; 32400000 mg; 325 1/1; 325 g/1; 325 mg; 325 mg / ect; 325 mg / gum; 325 mg / tab; 325 mg/1; 325 mg/3251; 325 mg/325mg; 325 ng/1; 32500000 mg; 35000000 mg; 400 MG; 450 mg; 50 MG; 50 mg; 500 MG; 500 mg; 500 mg / pck; 500 mg / sachet; 500 mg / tab; 500 mg/1; 500 mg/2.5ml; 500 mg/5001; 500.00 mg; 500.000 mg; 50000000 mg; 6 mg/0.1mL; 60 mg; 600 mg; 600 mg / tab; 600 mg/1; 650 mg; 650 mg / tab; 650 mg/1sachet; 75 MG; 75 mg; 75.000 mg; 80 mg; 80 mg / tab; 81 mg; 81 mg/1; 81 mg/811; 81 mg/81mg; 8100000 mg; 975 mg; 975 mg / tab; 988000 g,"Avoid alcohol. Alcohol increases the risk of gastrointestinal bleeding.; Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.; Take after a meal. This reduces irritating gastrointestinal effects.; Take with a full glass of water."
DB01050,Ibuprofen,"ANALGESICS; ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS; ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS; Antiinflammatory preparations, non-steroids for topical use; Antiinflammatory products for vaginal administration; CARDIAC THERAPY; CARDIOVASCULAR SYSTEM; GENITO URINARY SYSTEM AND SEX HORMONES; MUSCULO-SKELETAL SYSTEM; NERVOUS SYSTEM; OPIOIDS; OTHER CARDIAC PREPARATIONS; OTHER GYNECOLOGICALS; Opioids in combination with non-opioid analgesics; Other cardiac preparations; Other throat preparations; Propionic acid derivatives; RESPIRATORY SYSTEM; THROAT PREPARATIONS; TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN","[DB00381] Amlodipine: The metabolism of Ibuprofen can be decreased when combined with Amlodipine. | [DB00211] Midodrine: The risk or severity of hypertension can be increased when Midodrine is combined with Ibuprofen. | [DB00221] Isoetharine: The risk or severity of hypertension can be increased when Isoetharine is combined with Ibuprofen. | [DB00315] Zolmitriptan: The risk or severity of hypertension can be increased when Zolmitriptan is combined with Ibuprofen. | [DB00368] Norepinephrine: The risk or severity of hypertension can be increased when Norepinephrine is combined with Ibuprofen. | [DB00450] Droperidol: The risk or severity of hypertension can be increased when Droperidol is combined with Ibuprofen. | [DB00561] Doxapram: The risk or severity of hypertension can be increased when Doxapram is combined with Ibuprofen. | [DB00572] Atropine: The risk or severity of hypertension can be increased when Atropine is combined with Ibuprofen. | [DB00601] Linezolid: The risk or severity of hypertension can be increased when Linezolid is combined with Ibuprofen. | [DB00610] Metaraminol: The risk or severity of hypertension can be increased when Metaraminol is combined with Ibuprofen. | [DB00614] Furazolidone: The risk or severity of hypertension can be increased when Furazolidone is combined with Ibuprofen. | [DB00699] Nicergoline: The risk or severity of hypertension can be increased when Nicergoline is combined with Ibuprofen. | [DB00723] Methoxamine: The risk or severity of hypertension can be increased when Methoxamine is combined with Ibuprofen. | [DB00753] Isoflurane: The risk or severity of hypertension can be increased when Isoflurane is combined with Ibuprofen. | [DB00777] Propiomazine: The risk or severity of hypertension can be increased when Propiomazine is combined with Ibuprofen. | [DB00805] Minaprine: The risk or severity of hypertension can be increased when Minaprine is combined with Ibuprofen. | [DB00816] Orciprenaline: The risk or severity of hypertension can be increased when Orciprenaline is combined with Ibuprofen. | [DB00830] Phenmetrazine: The risk or severity of hypertension can be increased when Phenmetrazine is combined with Ibuprofen. | [DB00867] Ritodrine: The risk or severity of hypertension can be increased when Ritodrine is combined with Ibuprofen. | [DB00901] Bitolterol: The risk or severity of hypertension can be increased when Bitolterol is combined with Ibuprofen. | [DB00935] Oxymetazoline: The risk or severity of hypertension can be increased when Oxymetazoline is combined with Ibuprofen. | [DB00952] Naratriptan: The risk or severity of hypertension can be increased when Naratriptan is combined with Ibuprofen. | [DB00998] Frovatriptan: The risk or severity of hypertension can be increased when Frovatriptan is combined with Ibuprofen. | [DB01064] Isoprenaline: The risk or severity of hypertension can be increased when Ibuprofen is combined with Isoprenaline. | [DB01102] Arbutamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Arbutamine. | [DB01126] Dutasteride: The risk or severity of hypertension can be increased when Ibuprofen is combined with Dutasteride. | [DB01189] Desflurane: The risk or severity of hypertension can be increased when Ibuprofen is combined with Desflurane. | [DB01247] Isocarboxazid: The risk or severity of hypertension can be increased when Ibuprofen is combined with Isocarboxazid. | [DB01288] Fenoterol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Fenoterol. | [DB01291] Pirbuterol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Pirbuterol. | [DB01363] Ephedra sinica root: The risk or severity of hypertension can be increased when Ibuprofen is combined with Ephedra sinica root. | [DB01364] Ephedrine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Ephedrine. | [DB01366] Procaterol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Procaterol. | [DB01407] Clenbuterol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Clenbuterol. | [DB01408] Bambuterol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Bambuterol. | [DB01472] 4-Methoxyamphetamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with 4-Methoxyamphetamine. | [DB01579] Phendimetrazine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Phendimetrazine. | [DB02032] Epicaptopril: The risk or severity of hypertension can be increased when Ibuprofen is combined with Epicaptopril. | [DB04017] Clorgiline: The risk or severity of hypertension can be increased when Ibuprofen is combined with Clorgiline. | [DB04581] 1-benzylimidazole: The risk or severity of hypertension can be increased when Ibuprofen is combined with 1-benzylimidazole. | [DB04820] Nialamide: The risk or severity of hypertension can be increased when Ibuprofen is combined with Nialamide. | [DB05395] Amibegron: The risk or severity of hypertension can be increased when Ibuprofen is combined with Amibegron. | [DB05562] Naluzotan: The risk or severity of hypertension can be increased when Ibuprofen is combined with Naluzotan. | [DB06153] Pizotifen: The risk or severity of hypertension can be increased when Ibuprofen is combined with Pizotifen. | [DB06190] Solabegron: The risk or severity of hypertension can be increased when Ibuprofen is combined with Solabegron. | [DB06678] Esmirtazapine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Esmirtazapine. | [DB06690] Nitrous oxide: The risk or severity of hypertension can be increased when Ibuprofen is combined with Nitrous oxide. | [DB06694] Xylometazoline: The risk or severity of hypertension can be increased when Ibuprofen is combined with Xylometazoline. | [DB06701] Dexmethylphenidate: The risk or severity of hypertension can be increased when Ibuprofen is combined with Dexmethylphenidate. | [DB06706] Isometheptene: The risk or severity of hypertension can be increased when Ibuprofen is combined with Isometheptene. | [DB06707] Levonordefrin: The risk or severity of hypertension can be increased when Ibuprofen is combined with Levonordefrin. | [DB06764] Tetryzoline: The risk or severity of hypertension can be increased when Ibuprofen is combined with Tetryzoline. | [DB08810] Cinitapride: The risk or severity of hypertension can be increased when Ibuprofen is combined with Cinitapride. | [DB08841] Tyramine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Tyramine. | [DB08925] Adrafinil: The risk or severity of hypertension can be increased when Ibuprofen is combined with Adrafinil. | [DB08941] Isoxsuprine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Isoxsuprine. | [DB08954] Ifenprodil: The risk or severity of hypertension can be increased when Ibuprofen is combined with Ifenprodil. | [DB08957] Hexoprenaline: The risk or severity of hypertension can be increased when Ibuprofen is combined with Hexoprenaline. | [DB08985] Etilefrine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Etilefrine. | [DB09202] Cirazoline: The risk or severity of hypertension can be increased when Ibuprofen is combined with Cirazoline. | [DB09203] Synephrine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Synephrine. | [DB09243] Hydracarbazine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Hydracarbazine. | [DB09246] Benmoxin: The risk or severity of hypertension can be increased when Ibuprofen is combined with Benmoxin. | [DB09248] Mebanazine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Mebanazine. | [DB09249] Octamoxin: The risk or severity of hypertension can be increased when Ibuprofen is combined with Octamoxin. | [DB09250] Pheniprazine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Pheniprazine. | [DB09251] Phenoxypropazine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Phenoxypropazine. | [DB09252] Pivhydrazine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Pivhydrazine. | [DB09253] Safrazine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Safrazine. | [DB09254] Caroxazone: The risk or severity of hypertension can be increased when Ibuprofen is combined with Caroxazone. | [DB09273] Doxofylline: The risk or severity of hypertension can be increased when Ibuprofen is combined with Doxofylline. | [DB11124] Racepinephrine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Racepinephrine. | [DB11373] Amitraz: The risk or severity of hypertension can be increased when Ibuprofen is combined with Amitraz. | [DB11428] Medetomidine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Medetomidine. | [DB11481] Atipamezole: The risk or severity of hypertension can be increased when Ibuprofen is combined with Atipamezole. | [DB11541] Ractopamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Ractopamine. | [DB11543] Romifidine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Romifidine. | [DB11556] Detomidine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Detomidine. | [DB11755] Tetrahydrocannabivarin: The risk or severity of hypertension can be increased when Ibuprofen is combined with Tetrahydrocannabivarin. | [DB11871] PF-00610355: The risk or severity of hypertension can be increased when Ibuprofen is combined with PF-00610355. | [DB12100] Abediterol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Abediterol. | [DB12248] Tulobuterol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Tulobuterol. | [DB12313] Dopexamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Dopexamine. | [DB12361] Piclozotan: The risk or severity of hypertension can be increased when Ibuprofen is combined with Piclozotan. | [DB12551] Idazoxan: The risk or severity of hypertension can be increased when Ibuprofen is combined with Idazoxan. | [DB12779] Higenamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Higenamine. | [DB12846] Reproterol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Reproterol. | [DB12927] Theodrenaline: The risk or severity of hypertension can be increased when Ibuprofen is combined with Theodrenaline. | [DB13064] Tramazoline: The risk or severity of hypertension can be increased when Ibuprofen is combined with Tramazoline. | [DB13251] Octopamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Octopamine. | [DB13323] Trichloroethylene: The risk or severity of hypertension can be increased when Ibuprofen is combined with Trichloroethylene. | [DB13341] Fenozolone: The risk or severity of hypertension can be increased when Ibuprofen is combined with Fenozolone. | [DB13378] Norfenefrine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Norfenefrine. | [DB13398] Oxyfedrine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Oxyfedrine. | [DB13453] Xenon: The risk or severity of hypertension can be increased when Ibuprofen is combined with Xenon. | [DB13520] Metergoline: The risk or severity of hypertension can be increased when Ibuprofen is combined with Metergoline. | [DB13559] Rimiterol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Rimiterol. | [DB13692] Tretoquinol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Tretoquinol. | [DB13777] Prenalterol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Prenalterol. | [DB13781] Xamoterol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Xamoterol. | [DB13852] Mefenorex: The risk or severity of hypertension can be increased when Ibuprofen is combined with Mefenorex. | [DB13875] Harmaline: The risk or severity of hypertension can be increased when Ibuprofen is combined with Harmaline. | [DB13917] Deoxyepinephrine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Deoxyepinephrine. | [DB14010] 5-methoxy-N,N-dimethyltryptamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with 5-methoxy-N,N-dimethyltryptamine. | [DB00679] Thioridazine: The risk or severity of hypertension can be increased when Thioridazine is combined with Ibuprofen. | [DB00899] Remifentanil: The risk or severity of hypertension can be increased when Remifentanil is combined with Ibuprofen. | [DB00937] Diethylpropion: The risk or severity of hypertension can be increased when Diethylpropion is combined with Ibuprofen. | [DB01255] Lisdexamfetamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Lisdexamfetamine. | [DB01365] Mephentermine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Mephentermine. | [DB01403] Methotrimeprazine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Methotrimeprazine. | [DB01442] MMDA: The risk or severity of hypertension can be increased when Ibuprofen is combined with MMDA. | [DB01454] Midomafetamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Midomafetamine. | [DB01467] 2,5-Dimethoxy-4-ethylamphetamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with 2,5-Dimethoxy-4-ethylamphetamine. | [DB01484] 4-Bromo-2,5-dimethoxyamphetamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with 4-Bromo-2,5-dimethoxyamphetamine. | [DB01509] Tenamfetamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Tenamfetamine. | [DB01556] Chlorphentermine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Chlorphentermine. | [DB01576] Dextroamphetamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Dextroamphetamine. | [DB01608] Periciazine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Periciazine. | [DB01614] Acepromazine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Acepromazine. | [DB01622] Thioproperazine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Thioproperazine. | [DB06711] Naphazoline: The risk or severity of hypertension can be increased when Ibuprofen is combined with Naphazoline. | [DB09480] Iofetamine I-123: The risk or severity of hypertension can be increased when Ibuprofen is combined with Iofetamine I-123. | [DB11477] Xylazine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Xylazine. | [DB12080] Ritobegron: The risk or severity of hypertension can be increased when Ibuprofen is combined with Ritobegron. | [DB13108] Mephedrone: The risk or severity of hypertension can be increased when Ibuprofen is combined with Mephedrone. | [DB13624] Methoxyphenamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Methoxyphenamine. | [DB13703] Gepefrine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Gepefrine. | [DB13940] 2,5-Dimethoxy-4-ethylthioamphetamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with 2,5-Dimethoxy-4-ethylthioamphetamine. | [DB00191] Phentermine: The risk or severity of hypertension can be increased when Phentermine is combined with Ibuprofen. | [DB00247] Methysergide: The risk or severity of hypertension can be increased when Methysergide is combined with Ibuprofen. | [DB00353] Methylergometrine: The risk or severity of hypertension can be increased when Methylergometrine is combined with Ibuprofen. | [DB00370] Mirtazapine: The risk or severity of hypertension can be increased when Mirtazapine is combined with Ibuprofen. | [DB00589] Lisuride: The risk or severity of hypertension can be increased when Lisuride is combined with Ibuprofen. | [DB00708] Sufentanil: The risk or severity of hypertension can be increased when Sufentanil is combined with Ibuprofen. | [DB00865] Benzphetamine: The risk or severity of hypertension can be increased when Benzphetamine is combined with Ibuprofen. | [DB01049] Ergoloid mesylate: The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Ibuprofen. | [DB01186] Pergolide: The risk or severity of hypertension can be increased when Ibuprofen is combined with Pergolide. | [DB01216] Finasteride: The risk or severity of hypertension can be increased when Ibuprofen is combined with Finasteride. | [DB01238] Aripiprazole: The risk or severity of hypertension can be increased when Ibuprofen is combined with Aripiprazole. | [DB01591] Solifenacin: The risk or severity of hypertension can be increased when Ibuprofen is combined with Solifenacin. | [DB01624] Zuclopenthixol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Zuclopenthixol. | [DB04829] Lysergic acid diethylamide: The risk or severity of hypertension can be increased when Ibuprofen is combined with Lysergic acid diethylamide. | [DB04946] Iloperidone: The risk or severity of hypertension can be increased when Ibuprofen is combined with Iloperidone. | [DB05271] Rotigotine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Rotigotine. | [DB06016] Cariprazine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Cariprazine. | [DB06148] Mianserin: The risk or severity of hypertension can be increased when Ibuprofen is combined with Mianserin. | [DB06216] Asenapine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Asenapine. | [DB06684] Vilazodone: The risk or severity of hypertension can be increased when Ibuprofen is combined with Vilazodone. | [DB08815] Lurasidone: The risk or severity of hypertension can be increased when Ibuprofen is combined with Lurasidone. | [DB09128] Brexpiprazole: The risk or severity of hypertension can be increased when Ibuprofen is combined with Brexpiprazole. | [DB11273] Dihydroergocornine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Dihydroergocornine. | [DB13345] Dihydroergocristine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Dihydroergocristine. | [DB13385] Dihydroergocryptine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Dihydroergocryptine. | [DB13399] Terguride: The risk or severity of hypertension can be increased when Ibuprofen is combined with Terguride. | [DB14185] Aripiprazole lauroxil: The risk or severity of hypertension can be increased when Ibuprofen is combined with Aripiprazole lauroxil. | [DB00248] Cabergoline: The risk or severity of hypertension can be increased when Cabergoline is combined with Ibuprofen. | [DB00320] Dihydroergotamine: The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Ibuprofen. | [DB00734] Risperidone: The risk or severity of hypertension can be increased when Risperidone is combined with Ibuprofen. | [DB00802] Alfentanil: The risk or severity of hypertension can be increased when Alfentanil is combined with Ibuprofen. | [DB00831] Trifluoperazine: The risk or severity of hypertension can be increased when Trifluoperazine is combined with Ibuprofen. | [DB00875] Flupentixol: The risk or severity of hypertension can be increased when Flupentixol is combined with Ibuprofen. | [DB01200] Bromocriptine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Bromocriptine. | [DB01253] Ergometrine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Ergometrine. | [DB01392] Yohimbine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Yohimbine. | [DB04908] Flibanserin: The risk or severity of hypertension can be increased when Ibuprofen is combined with Flibanserin. | [DB05039] Indacaterol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Indacaterol. | [DB13598] Diethyl ether: The risk or severity of hypertension can be increased when Ibuprofen is combined with Diethyl ether. | [DB15965] Naxitamab: The risk or severity of hypertension can be increased when Ibuprofen is combined with Naxitamab. | [DB01171] Moclobemide: The risk or severity of hypertension can be increased when Ibuprofen is combined with Moclobemide. | [DB06654] Safinamide: The risk or severity of hypertension can be increased when Ibuprofen is combined with Safinamide. | [DB16629] Serdexmethylphenidate: The risk or severity of hypertension can be increased when Ibuprofen is combined with Serdexmethylphenidate. | [DB00422] Methylphenidate: The risk or severity of hypertension can be increased when Methylphenidate is combined with Ibuprofen. | [DB09026] Aliskiren: The risk or severity of renal failure and hypertension can be increased when Ibuprofen is combined with Aliskiren. | [DB01609] Deferasirox: The risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Ibuprofen is combined with Deferasirox. | [DB00035] Desmopressin: The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Ibuprofen is combined with Desmopressin. | [DB01395] Drospirenone: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Drospirenone. | [DB01275] Hydralazine: Ibuprofen may decrease the antihypertensive activities of Hydralazine. | [DB14507] Lithium citrate: Ibuprofen may decrease the excretion rate of Lithium citrate which could result in a higher serum level. | [DB14509] Lithium carbonate: Ibuprofen may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. | [DB14506] Lithium hydroxide: Ibuprofen may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level. | [DB00563] Methotrexate: The serum concentration of Methotrexate can be increased when it is combined with Ibuprofen. | [DB00642] Pemetrexed: Ibuprofen may decrease the excretion rate of Pemetrexed which could result in a higher serum level. | [DB06813] Pralatrexate: Ibuprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. | [DB01032] Probenecid: Probenecid may decrease the excretion rate of Ibuprofen which could result in a higher serum level. | [DB00374] Treprostinil: The risk or severity of bleeding can be increased when Treprostinil is combined with Ibuprofen. | [DB00512] Vancomycin: Ibuprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level. | [DB00834] Mifepristone: The serum concentration of Ibuprofen can be increased when it is combined with Mifepristone. | [DB00529] Foscarnet: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Foscarnet. | [DB00742] Mannitol: The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ibuprofen. | [DB00300] Tenofovir disoproxil: Ibuprofen may increase the nephrotoxic activities of Tenofovir disoproxil. | [DB09299] Tenofovir alafenamide: The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ibuprofen. | [DB14126] Tenofovir: Ibuprofen may increase the nephrotoxic activities of Tenofovir. | [DB00139] Succinic acid: The excretion of Succinic acid can be decreased when combined with Ibuprofen. | [DB00155] Citrulline: The excretion of Citrulline can be decreased when combined with Ibuprofen. | [DB00345] Aminohippuric acid: The excretion of Aminohippuric acid can be decreased when combined with Ibuprofen. | [DB00501] Cimetidine: The excretion of Cimetidine can be decreased when combined with Ibuprofen. | [DB00535] Cefdinir: The excretion of Cefdinir can be decreased when combined with Ibuprofen. | [DB00650] Leucovorin: The excretion of Leucovorin can be decreased when combined with Ibuprofen. | [DB00693] Fluorescein: The excretion of Fluorescein can be decreased when combined with Ibuprofen. | [DB00917] Dinoprostone: The excretion of Dinoprostone can be decreased when combined with Ibuprofen. | [DB01053] Benzylpenicillin: The excretion of Benzylpenicillin can be decreased when combined with Ibuprofen. | [DB01098] Rosuvastatin: The excretion of Rosuvastatin can be decreased when combined with Ibuprofen. | [DB01606] Tazobactam: The excretion of Tazobactam can be decreased when combined with Ibuprofen. | [DB02527] Cyclic adenosine monophosphate: The excretion of Cyclic adenosine monophosphate can be decreased when combined with Ibuprofen. | [DB02659] Cholic Acid: The excretion of Cholic Acid can be decreased when combined with Ibuprofen. | [DB03553] Glutaric Acid: The excretion of Glutaric Acid can be decreased when combined with Ibuprofen. | [DB03902] Oxalic Acid: The excretion of Oxalic Acid can be decreased when combined with Ibuprofen. | [DB08846] Ellagic acid: The excretion of Ellagic acid can be decreased when combined with Ibuprofen. | [DB09060] Avibactam: The excretion of Avibactam can be decreased when combined with Ibuprofen. | [DB12377] Relebactam: The excretion of Relebactam can be decreased when combined with Ibuprofen. | [DB00229] Cefotiam: The excretion of Cefotiam can be decreased when combined with Ibuprofen. | [DB00567] Cephalexin: The excretion of Cephalexin can be decreased when combined with Ibuprofen. | [DB00577] Valaciclovir: The excretion of Valaciclovir can be decreased when combined with Ibuprofen. | [DB00787] Acyclovir: The excretion of Acyclovir can be decreased when combined with Ibuprofen. | [DB00833] Cefaclor: The excretion of Cefaclor can be decreased when combined with Ibuprofen. | [DB00198] Oseltamivir: The excretion of Oseltamivir can be decreased when combined with Ibuprofen. | [DB00319] Piperacillin: The excretion of Piperacillin can be decreased when combined with Ibuprofen. | [DB00432] Trifluridine: The excretion of Trifluridine can be decreased when combined with Ibuprofen. | [DB00437] Allopurinol: The excretion of Allopurinol can be decreased when combined with Ibuprofen. | [DB00583] Levocarnitine: The excretion of Levocarnitine can be decreased when combined with Ibuprofen. | [DB01415] Ceftibuten: The excretion of Ceftibuten can be decreased when combined with Ibuprofen. | [DB06211] Doripenem: The excretion of Doripenem can be decreased when combined with Ibuprofen. | [DB06335] Saxagliptin: The excretion of Saxagliptin can be decreased when combined with Ibuprofen. | [DB01327] Cefazolin: The excretion of Cefazolin can be decreased when combined with Ibuprofen. | [DB01332] Ceftizoxime: The excretion of Ceftizoxime can be decreased when combined with Ibuprofen. | [DB01414] Cefacetrile: The excretion of Cefacetrile can be decreased when combined with Ibuprofen. | [DB09008] Cefaloridine: The excretion of Cefaloridine can be decreased when combined with Ibuprofen. | [DB09272] Eluxadoline: The excretion of Eluxadoline can be decreased when combined with Ibuprofen. | [DB00175] Pravastatin: The excretion of Pravastatin can be decreased when combined with Ibuprofen. | [DB00286] Conjugated estrogens: The excretion of Conjugated estrogens can be decreased when combined with Ibuprofen. | [DB00759] Tetracycline: The excretion of Tetracycline can be decreased when combined with Ibuprofen. | [DB00783] Estradiol: The excretion of Estradiol can be decreased when combined with Ibuprofen. | [DB00863] Ranitidine: The excretion of Ranitidine can be decreased when combined with Ibuprofen. | [DB00950] Fexofenadine: The excretion of Fexofenadine can be decreased when combined with Ibuprofen. | [DB01261] Sitagliptin: The excretion of Sitagliptin can be decreased when combined with Ibuprofen. | [DB04348] Taurocholic acid: The excretion of Taurocholic acid can be decreased when combined with Ibuprofen. | [DB11817] Baricitinib: The serum concentration of Baricitinib can be increased when it is combined with Ibuprofen. | [DB00595] Oxytetracycline: The excretion of Oxytetracycline can be decreased when combined with Ibuprofen. | [DB14649] Dexamethasone acetate: The risk or severity of gastrointestinal irritation can be increased when Dexamethasone acetate is combined with Ibuprofen. | [DB00659] Acamprosate: The excretion of Acamprosate can be decreased when combined with Ibuprofen. | [DB00582] Voriconazole: The serum concentration of Ibuprofen can be increased when it is combined with Voriconazole. | [DB00619] Imatinib: The serum concentration of Imatinib can be decreased when it is combined with Ibuprofen. | [DB00304] Desogestrel: The metabolism of Ibuprofen can be increased when combined with Desogestrel. | [DB00555] Lamotrigine: The metabolism of Ibuprofen can be increased when combined with Lamotrigine. | [DB00977] Ethinylestradiol: The metabolism of Ibuprofen can be increased when combined with Ethinylestradiol. | [DB01420] Testosterone propionate: The metabolism of Ibuprofen can be increased when combined with Testosterone propionate. | [DB00630] Alendronic acid: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Alendronic acid. | [DB00177] Valsartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valsartan is combined with Ibuprofen. | [DB00275] Olmesartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Ibuprofen. | [DB00678] Losartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Ibuprofen. | [DB00796] Candesartan cilexetil: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan cilexetil is combined with Ibuprofen. | [DB00876] Eprosartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Ibuprofen. | [DB00966] Telmisartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Ibuprofen. | [DB01029] Irbesartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Irbesartan is combined with Ibuprofen. | [DB01342] Forasartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Forasartan is combined with Ibuprofen. | [DB01347] Saprisartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Ibuprofen. | [DB01349] Tasosartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Ibuprofen. | [DB06763] Saralasin: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saralasin is combined with Ibuprofen. | [DB08822] Azilsartan medoxomil: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Ibuprofen. | [DB09279] Fimasartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Ibuprofen. | [DB13919] Candesartan: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan is combined with Ibuprofen. | [DB00178] Ramipril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Ramipril. | [DB00492] Fosinopril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Fosinopril. | [DB00519] Trandolapril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Trandolapril. | [DB00542] Benazepril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Benazepril. | [DB00584] Enalapril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Enalapril. | [DB00691] Moexipril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Moexipril. | [DB00722] Lisinopril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Lisinopril. | [DB00790] Perindopril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Perindopril. | [DB00881] Quinapril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Quinapril. | [DB00886] Omapatrilat: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Omapatrilat. | [DB01180] Rescinnamine: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Rescinnamine. | [DB01197] Captopril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Captopril. | [DB01340] Cilazapril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Cilazapril. | [DB01348] Spirapril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Spirapril. | [DB08836] Temocapril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Temocapril. | [DB09477] Enalaprilat: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Enalaprilat. | [DB11783] Imidapril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Imidapril. | [DB13166] Zofenopril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Zofenopril. | [DB13312] Delapril: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Delapril. | [DB14125] Benazeprilat: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Benazeprilat. | [DB14207] Fosinoprilat: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Fosinoprilat. | [DB14208] Ramiprilat: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Ramiprilat. | [DB14209] Trandolaprilat: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Trandolaprilat. | [DB14210] Moexiprilat: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Moexiprilat. | [DB14213] Perindoprilat: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Perindoprilat. | [DB14217] Quinaprilat: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Quinaprilat. | [DB14231] Quinoline Yellow WS: The risk or severity of angioedema can be increased when Ibuprofen is combined with Quinoline Yellow WS. | [DB15565] Cilazaprilat: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Cilazaprilat. | [DB00187] Esmolol: Ibuprofen may decrease the antihypertensive activities of Esmolol. | [DB00195] Betaxolol: Ibuprofen may decrease the antihypertensive activities of Betaxolol. | [DB00264] Metoprolol: Ibuprofen may decrease the antihypertensive activities of Metoprolol. | [DB00335] Atenolol: Ibuprofen may decrease the antihypertensive activities of Atenolol. | [DB00373] Timolol: Ibuprofen may decrease the antihypertensive activities of Timolol. | [DB00489] Sotalol: Ibuprofen may decrease the antihypertensive activities of Sotalol. | [DB00571] Propranolol: Ibuprofen may decrease the antihypertensive activities of Propranolol. | [DB00598] Labetalol: Ibuprofen may decrease the antihypertensive activities of Labetalol. | [DB00612] Bisoprolol: Ibuprofen may decrease the antihypertensive activities of Bisoprolol. | [DB00866] Alprenolol: Ibuprofen may decrease the antihypertensive activities of Alprenolol. | [DB00960] Pindolol: Ibuprofen may decrease the antihypertensive activities of Pindolol. | [DB01136] Carvedilol: Ibuprofen may decrease the antihypertensive activities of Carvedilol. | [DB01182] Propafenone: Ibuprofen may decrease the antihypertensive activities of Propafenone. | [DB01193] Acebutolol: Ibuprofen may decrease the antihypertensive activities of Acebutolol. | [DB01203] Nadolol: Ibuprofen may decrease the antihypertensive activities of Nadolol. | [DB01295] Bevantolol: Ibuprofen may decrease the antihypertensive activities of Bevantolol. | [DB01297] Practolol: Ibuprofen may decrease the antihypertensive activities of Practolol. | [DB01359] Penbutolol: Ibuprofen may decrease the antihypertensive activities of Penbutolol. | [DB01580] Oxprenolol: Ibuprofen may decrease the antihypertensive activities of Oxprenolol. | [DB03322] Dexpropranolol: Ibuprofen may decrease the antihypertensive activities of Dexpropranolol. | [DB04846] Celiprolol: Ibuprofen may decrease the antihypertensive activities of Celiprolol. | [DB04861] Nebivolol: Ibuprofen may decrease the antihypertensive activities of Nebivolol. | [DB06726] Bufuralol: Ibuprofen may decrease the antihypertensive activities of Bufuralol. | [DB08807] Bopindolol: Ibuprofen may decrease the antihypertensive activities of Bopindolol. | [DB08808] Bupranolol: Ibuprofen may decrease the antihypertensive activities of Bupranolol. | [DB08952] Indenolol: Ibuprofen may decrease the antihypertensive activities of Indenolol. | [DB09204] Arotinolol: Ibuprofen may decrease the antihypertensive activities of Arotinolol. | [DB09351] Levobetaxolol: Ibuprofen may decrease the antihypertensive activities of Levobetaxolol. | [DB11770] Talinolol: Ibuprofen may decrease the antihypertensive activities of Talinolol. | [DB11785] Anisodamine: Ibuprofen may decrease the antihypertensive activities of Anisodamine. | [DB12752] Bucindolol: Ibuprofen may decrease the antihypertensive activities of Bucindolol. | [DB13443] Esatenolol: Ibuprofen may decrease the antihypertensive activities of Esatenolol. | [DB13508] Cloranolol: Ibuprofen may decrease the antihypertensive activities of Cloranolol. | [DB13530] Mepindolol: Ibuprofen may decrease the antihypertensive activities of Mepindolol. | [DB13757] Epanolol: Ibuprofen may decrease the antihypertensive activities of Epanolol. | [DB13775] Tertatolol: Ibuprofen may decrease the antihypertensive activities of Tertatolol. | [DB12212] Landiolol: Ibuprofen may decrease the antihypertensive activities of Landiolol. | [DB00214] Torasemide: The therapeutic efficacy of Torasemide can be decreased when used in combination with Ibuprofen. | [DB00695] Furosemide: The therapeutic efficacy of Furosemide can be decreased when used in combination with Ibuprofen. | [DB00887] Bumetanide: The therapeutic efficacy of Bumetanide can be decreased when used in combination with Ibuprofen. | [DB00903] Etacrynic acid: The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ibuprofen. | [DB02925] Piretanide: The therapeutic efficacy of Piretanide can be decreased when used in combination with Ibuprofen. | [DB08961] Azosemide: The therapeutic efficacy of Azosemide can be decreased when used in combination with Ibuprofen. | [DB15959] Tripamide: The therapeutic efficacy of Tripamide can be decreased when used in combination with Ibuprofen. | [DB00218] Moxifloxacin: Ibuprofen may increase the neuroexcitatory activities of Moxifloxacin. | [DB00467] Enoxacin: Ibuprofen may increase the neuroexcitatory activities of Enoxacin. | [DB00487] Pefloxacin: Ibuprofen may increase the neuroexcitatory activities of Pefloxacin. | [DB00685] Trovafloxacin: Ibuprofen may increase the neuroexcitatory activities of Trovafloxacin. | [DB00779] Nalidixic acid: Ibuprofen may increase the neuroexcitatory activities of Nalidixic acid. | [DB00817] Rosoxacin: Ibuprofen may increase the neuroexcitatory activities of Rosoxacin. | [DB00827] Cinoxacin: Ibuprofen may increase the neuroexcitatory activities of Cinoxacin. | [DB00978] Lomefloxacin: Ibuprofen may increase the neuroexcitatory activities of Lomefloxacin. | [DB01044] Gatifloxacin: Ibuprofen may increase the neuroexcitatory activities of Gatifloxacin. | [DB01155] Gemifloxacin: Ibuprofen may increase the neuroexcitatory activities of Gemifloxacin. | [DB01165] Ofloxacin: Ibuprofen may increase the neuroexcitatory activities of Ofloxacin. | [DB01405] Temafloxacin: Ibuprofen may increase the neuroexcitatory activities of Temafloxacin. | [DB04576] Fleroxacin: Ibuprofen may increase the neuroexcitatory activities of Fleroxacin. | [DB05488] Technetium Tc-99m ciprofloxacin: Ibuprofen may increase the neuroexcitatory activities of Technetium Tc-99m ciprofloxacin. | [DB06160] Garenoxacin: Ibuprofen may increase the neuroexcitatory activities of Garenoxacin. | [DB06600] Nemonoxacin: Ibuprofen may increase the neuroexcitatory activities of Nemonoxacin. | [DB08972] Flumequine: Ibuprofen may increase the neuroexcitatory activities of Flumequine. | [DB11404] Enrofloxacin: Ibuprofen may increase the neuroexcitatory activities of Enrofloxacin. | [DB11443] Orbifloxacin: Ibuprofen may increase the neuroexcitatory activities of Orbifloxacin. | [DB11491] Sarafloxacin: Ibuprofen may increase the neuroexcitatory activities of Sarafloxacin. | [DB11511] Difloxacin: Ibuprofen may increase the neuroexcitatory activities of Difloxacin. | [DB11774] Pazufloxacin: Ibuprofen may increase the neuroexcitatory activities of Pazufloxacin. | [DB11892] Prulifloxacin: Ibuprofen may increase the neuroexcitatory activities of Prulifloxacin. | [DB13261] Sitafloxacin: Ibuprofen may increase the neuroexcitatory activities of Sitafloxacin. | [DB13627] Oxolinic acid: Ibuprofen may increase the neuroexcitatory activities of Oxolinic acid. | [DB13772] Rufloxacin: Ibuprofen may increase the neuroexcitatory activities of Rufloxacin. | [DB13823] Pipemidic acid: Ibuprofen may increase the neuroexcitatory activities of Pipemidic acid. | [DB01059] Norfloxacin: Ibuprofen may increase the neuroexcitatory activities of Norfloxacin. | [DB01208] Sparfloxacin: Ibuprofen may increase the neuroexcitatory activities of Sparfloxacin. | [DB00232] Methyclothiazide: The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ibuprofen. | [DB00310] Chlorthalidone: The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ibuprofen. | [DB00436] Bendroflumethiazide: The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ibuprofen. | [DB00524] Metolazone: The therapeutic efficacy of Metolazone can be decreased when used in combination with Ibuprofen. | [DB00562] Benzthiazide: The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Ibuprofen. | [DB00774] Hydroflumethiazide: The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ibuprofen. | [DB00808] Indapamide: The therapeutic efficacy of Indapamide can be decreased when used in combination with Ibuprofen. | [DB00880] Chlorothiazide: The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ibuprofen. | [DB00999] Hydrochlorothiazide: The excretion of Hydrochlorothiazide can be decreased when combined with Ibuprofen. | [DB01021] Trichlormethiazide: The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ibuprofen. | [DB01324] Polythiazide: The excretion of Polythiazide can be decreased when combined with Ibuprofen. | [DB01325] Quinethazone: The therapeutic efficacy of Quinethazone can be decreased when used in combination with Ibuprofen. | [DB13532] Cyclopenthiazide: The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Ibuprofen. | [DB13989] Epitizide: The therapeutic efficacy of Epitizide can be decreased when used in combination with Ibuprofen. | [DB00282] Pamidronic acid: The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Pamidronic acid. | [DB00399] Zoledronic acid: The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Zoledronic acid. | [DB00710] Ibandronate: The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Ibandronate. | [DB00720] Clodronic acid: The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Clodronic acid. | [DB00884] Risedronic acid: The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Risedronic acid. | [DB01077] Etidronic acid: The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Etidronic acid. | [DB01133] Tiludronic acid: The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Tiludronic acid. | [DB06255] Incadronic acid: The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Incadronic acid. | [DB00287] Travoprost: The therapeutic efficacy of Travoprost can be decreased when used in combination with Ibuprofen. | [DB00654] Latanoprost: The therapeutic efficacy of Latanoprost can be decreased when used in combination with Ibuprofen. | [DB00905] Bimatoprost: The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ibuprofen. | [DB02056] Prostaglandin D2: The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Ibuprofen. | [DB02304] Prostaglandin B2: The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Ibuprofen. | [DB03866] Prostaglandin G2: The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Ibuprofen. | [DB06826] Unoprostone: The therapeutic efficacy of Unoprostone can be decreased when used in combination with Ibuprofen. | [DB08819] Tafluprost: The therapeutic efficacy of Tafluprost can be decreased when used in combination with Ibuprofen. | [DB09211] Limaprost: The therapeutic efficacy of Limaprost can be decreased when used in combination with Ibuprofen. | [DB11411] Fenprostalene: The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Ibuprofen. | [DB11425] Luprostiol: The therapeutic efficacy of Luprostiol can be decreased when used in combination with Ibuprofen. | [DB11454] Prostalene: The therapeutic efficacy of Prostalene can be decreased when used in combination with Ibuprofen. | [DB11507] Cloprostenol: The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Ibuprofen. | [DB11519] Fluprostenol: The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Ibuprofen. | [DB11660] Latanoprostene bunod: The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Ibuprofen. | [DB13824] Enprostil: The therapeutic efficacy of Enprostil can be decreased when used in combination with Ibuprofen. | [DB04865] Omacetaxine mepesuccinate: The risk or severity of bleeding can be increased when Ibuprofen is combined with Omacetaxine mepesuccinate. | [DB00864] Tacrolimus: The risk or severity of renal failure can be increased when Ibuprofen is combined with Tacrolimus. | [DB00375] Colestipol: Colestipol can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB00658] Sevelamer: Sevelamer can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB00930] Colesevelam: Colesevelam can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB01432] Cholestyramine: Cholestyramine can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. | [DB00384] Triamterene: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Triamterene. | [DB00421] Spironolactone: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Spironolactone. | [DB00594] Amiloride: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Amiloride. | [DB00626] Bacitracin: The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Ibuprofen. | [DB00267] Cefmenoxime: The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Ibuprofen. | [DB00274] Cefmetazole: The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Ibuprofen. | [DB00369] Cidofovir: The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Ibuprofen. | [DB00430] Cefpiramide: The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Ibuprofen. | [DB00438] Ceftazidime: The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Ibuprofen. | [DB00447] Loracarbef: The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Ibuprofen. | [DB00456] Cefalotin: The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Ibuprofen. | [DB00493] Cefotaxime: The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Ibuprofen. | [DB00681] Amphotericin B: The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ibuprofen. | [DB00689] Cephaloglycin: The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Ibuprofen. | [DB00718] Adefovir dipivoxil: The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Ibuprofen. | [DB00738] Pentamidine: The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Ibuprofen. | [DB00923] Ceforanide: The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Ibuprofen. | [DB00958] Carboplatin: The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Ibuprofen. | [DB01140] Cefadroxil: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefadroxil. | [DB01330] Cefotetan: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefotetan. | [DB01333] Cefradine: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefradine. | [DB11367] Cefroxadine: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefroxadine. | [DB01066] Cefditoren: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefditoren. | [DB01111] Colistimethate: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Colistimethate. | [DB01112] Cefuroxime: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefuroxime. | [DB01139] Cefapirin: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefapirin. | [DB01150] Cefprozil: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefprozil. | [DB01326] Cefamandole: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefamandole. | [DB01328] Cefonicid: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefonicid. | [DB01331] Cefoxitin: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefoxitin. | [DB01413] Cefepime: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefepime. | [DB01416] Cefpodoxime: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefpodoxime. | [DB02247] Hydrolyzed Cephalothin: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Hydrolyzed Cephalothin. | [DB03450] Cephalothin Group: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cephalothin Group. | [DB04570] Latamoxef: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Latamoxef. | [DB04918] Ceftobiprole: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Ceftobiprole. | [DB06590] Ceftaroline fosamil: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Ceftaroline fosamil. | [DB09062] Cefminox: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefminox. | [DB11935] Flomoxef: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Flomoxef. | [DB13266] Cefatrizine: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefatrizine. | [DB13461] Cefcapene: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefcapene. | [DB13470] Cefodizime: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefodizime. | [DB13499] Cefsulodin: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefsulodin. | [DB13504] Cefetamet: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefetamet. | [DB13638] Cefbuperazone: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefbuperazone. | [DB13667] Cefozopran: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefozopran. | [DB13682] Cefpirome: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefpirome. | [DB13778] Cefazedone: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefazedone. | [DB13821] Ceftezole: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Ceftezole. | [DB13868] Adefovir: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Adefovir. | [DB14713] Inotersen: The risk or severity of nephrotoxicity can be increased when Inotersen is combined with Ibuprofen. | [DB01438] Phenazopyridine: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Phenazopyridine. | [DB15066] Givosiran: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Givosiran. | [DB01212] Ceftriaxone: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Ceftriaxone. | [DB01329] Cefoperazone: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefoperazone. | [DB00452] Framycetin: The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Ibuprofen. | [DB01421] Paromomycin: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Paromomycin. | [DB04263] Geneticin: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Geneticin. | [DB04626] Apramycin: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Apramycin. | [DB04808] Neamine: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Neamine. | [DB08437] Puromycin: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Puromycin. | [DB11512] Dihydrostreptomycin: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Dihydrostreptomycin. | [DB11520] Hygromycin B: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Hygromycin B. | [DB01356] Lithium cation: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Lithium cation. | [DB00656] Trazodone: The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Ibuprofen. | [DB01175] Escitalopram: The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Ibuprofen. | [DB04884] Dapoxetine: The risk or severity of gastrointestinal bleeding can be increased when Dapoxetine is combined with Ibuprofen. | [DB08953] Indalpine: The risk or severity of gastrointestinal bleeding can be increased when Indalpine is combined with Ibuprofen. | [DB12693] Ritanserin: The risk or severity of gastrointestinal bleeding can be increased when Ritanserin is combined with Ibuprofen. | [DB13233] Alaproclate: The risk or severity of gastrointestinal bleeding can be increased when Alaproclate is combined with Ibuprofen. | [DB00215] Citalopram: The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Ibuprofen. | [DB00476] Duloxetine: The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Ibuprofen. | [DB00715] Paroxetine: The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Ibuprofen. | [DB08918] Levomilnacipran: Ibuprofen may decrease the excretion rate of Levomilnacipran which could result in a higher serum level. | [DB04832] Zimelidine: The risk or severity of gastrointestinal bleeding can be increased when Zimelidine is combined with Ibuprofen. | [DB00176] Fluvoxamine: The risk or severity of gastrointestinal bleeding can be increased when Fluvoxamine is combined with Ibuprofen. | [DB00472] Fluoxetine: The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Ibuprofen. | [DB01105] Sibutramine: The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Ibuprofen. | [DB04896] Milnacipran: The risk or severity of gastrointestinal bleeding can be increased when Milnacipran is combined with Ibuprofen. | [DB06700] Desvenlafaxine: The risk or severity of gastrointestinal bleeding can be increased when Desvenlafaxine is combined with Ibuprofen. | [DB06731] Seproxetine: The risk or severity of gastrointestinal bleeding can be increased when Seproxetine is combined with Ibuprofen. | [DB00486] Nabilone: The metabolism of Ibuprofen can be decreased when combined with Nabilone. | [DB00949] Felbamate: The metabolism of Ibuprofen can be decreased when combined with Felbamate. | [DB04818] Iproniazid: The metabolism of Ibuprofen can be decreased when combined with Iproniazid. | [DB05812] Abiraterone: The metabolism of Ibuprofen can be decreased when combined with Abiraterone. | [DB14009] Medical Cannabis: The metabolism of Ibuprofen can be decreased when combined with Medical Cannabis. | [DB00197] Troglitazone: The metabolism of Ibuprofen can be decreased when combined with Troglitazone. | [DB00196] Fluconazole: The metabolism of Ibuprofen can be decreased when combined with Fluconazole. | [DB00322] Floxuridine: The metabolism of Ibuprofen can be decreased when combined with Floxuridine. | [DB00622] Nicardipine: The metabolism of Ibuprofen can be decreased when combined with Nicardipine. | [DB01110] Miconazole: The metabolism of Ibuprofen can be decreased when combined with Miconazole. | [DB01241] Gemfibrozil: The metabolism of Ibuprofen can be decreased when combined with Gemfibrozil. | [DB06729] Sulfaphenazole: The metabolism of Ibuprofen can be decreased when combined with Sulfaphenazole. | [DB00418] Secobarbital: The metabolism of Ibuprofen can be increased when combined with Secobarbital. | [DB01045] Rifampin: The metabolism of Ibuprofen can be increased when combined with Rifampicin. | [DB13223] Fluocortin: The risk or severity of gastrointestinal irritation can be increased when Fluocortin is combined with Ibuprofen. | [DB13491] Fluperolone: The risk or severity of gastrointestinal irritation can be increased when Fluperolone is combined with Ibuprofen. | [DB13856] Fluclorolone: The risk or severity of gastrointestinal irritation can be increased when Fluclorolone is combined with Ibuprofen. | [DB00588] Fluticasone propionate: The risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Ibuprofen. | [DB08906] Fluticasone furoate: The risk or severity of gastrointestinal irritation can be increased when Fluticasone furoate is combined with Ibuprofen. | [DB13867] Fluticasone: The risk or severity of gastrointestinal irritation can be increased when Fluticasone is combined with Ibuprofen. | [DB14512] Mometasone furoate: The risk or severity of gastrointestinal irritation can be increased when Mometasone furoate is combined with Ibuprofen. | [DB00591] Fluocinolone acetonide: The risk or severity of gastrointestinal irritation can be increased when Fluocinolone acetonide is combined with Ibuprofen. | [DB09091] Tixocortol: The risk or severity of gastrointestinal irritation can be increased when Tixocortol is combined with Ibuprofen. | [DB14539] Hydrocortisone acetate: The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Ibuprofen. | [DB14545] Hydrocortisone succinate: The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone succinate is combined with Ibuprofen. | [DB00180] Flunisolide: The risk or severity of gastrointestinal irritation can be increased when Flunisolide is combined with Ibuprofen. | [DB00620] Triamcinolone: The risk or severity of gastrointestinal irritation can be increased when Triamcinolone is combined with Ibuprofen. | [DB00687] Fludrocortisone: The risk or severity of gastrointestinal irritation can be increased when Fludrocortisone is combined with Ibuprofen. | [DB01108] Trilostane: The risk or severity of gastrointestinal irritation can be increased when Trilostane is combined with Ibuprofen. | [DB01285] Corticotropin: The risk or severity of gastrointestinal irritation can be increased when Corticotropin is combined with Ibuprofen. | [DB01380] Cortisone acetate: The risk or severity of gastrointestinal irritation can be increased when Cortisone acetate is combined with Ibuprofen. | [DB01384] Paramethasone: The risk or severity of gastrointestinal irritation can be increased when Paramethasone is combined with Ibuprofen. | [DB01410] Ciclesonide: The risk or severity of gastrointestinal irritation can be increased when Ciclesonide is combined with Ibuprofen. | [DB08970] Fluprednidene: The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Ibuprofen. | [DB09378] Fluprednisolone: The risk or severity of gastrointestinal irritation can be increased when Fluprednisolone is combined with Ibuprofen. | [DB09383] Meprednisone: The risk or severity of gastrointestinal irritation can be increased when Meprednisone is combined with Ibuprofen. | [DB11487] Dexamethasone isonicotinate: The risk or severity of gastrointestinal irritation can be increased when Dexamethasone isonicotinate is combined with Ibuprofen. | [DB11529] Melengestrol: The risk or severity of gastrointestinal irritation can be increased when Melengestrol is combined with Ibuprofen. | [DB11921] Deflazacort: The risk or severity of gastrointestinal irritation can be increased when Deflazacort is combined with Ibuprofen. | [DB13003] Cortivazol: The risk or severity of gastrointestinal irritation can be increased when Cortivazol is combined with Ibuprofen. | [DB13208] Prednylidene: The risk or severity of gastrointestinal irritation can be increased when Prednylidene is combined with Ibuprofen. | [DB13843] Cloprednol: The risk or severity of gastrointestinal irritation can be increased when Cloprednol is combined with Ibuprofen. | [DB14541] Hydrocortisone cypionate: The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone cypionate is combined with Ibuprofen. | [DB14631] Prednisolone phosphate: The risk or severity of gastrointestinal irritation can be increased when Prednisolone phosphate is combined with Ibuprofen. | [DB14633] Prednisolone hemisuccinate: The risk or severity of gastrointestinal irritation can be increased when Prednisolone hemisuccinate is combined with Ibuprofen. | [DB14644] Methylprednisolone hemisuccinate: The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Ibuprofen. | [DB14646] Prednisone acetate: The risk or severity of gastrointestinal irritation can be increased when Prednisone acetate is combined with Ibuprofen. | [DB14652] Clocortolone acetate: The risk or severity of gastrointestinal irritation can be increased when Clocortolone acetate is combined with Ibuprofen. | [DB14659] Melengestrol acetate: The risk or severity of gastrointestinal irritation can be increased when Melengestrol acetate is combined with Ibuprofen. | [DB14669] Betamethasone phosphate: The risk or severity of gastrointestinal irritation can be increased when Betamethasone phosphate is combined with Ibuprofen. | [DB14681] Cortisone: The risk or severity of gastrointestinal irritation can be increased when Cortisone is combined with Ibuprofen. | [DB00741] Hydrocortisone: The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Ibuprofen. | [DB01234] Dexamethasone: The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Ibuprofen. | [DB00635] Prednisone: The risk or severity of gastrointestinal irritation can be increased when Prednisone is combined with Ibuprofen. | [DB00394] Beclomethasone dipropionate: The risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Ibuprofen. | [DB00443] Betamethasone: The risk or severity of gastrointestinal irritation can be increased when Betamethasone is combined with Ibuprofen. | [DB00860] Prednisolone: The risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Ibuprofen. | [DB00959] Methylprednisolone: The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Ibuprofen. | [DB01222] Budesonide: The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Ibuprofen. | [DB04630] Aldosterone: The risk or severity of gastrointestinal irritation can be increased when Aldosterone is combined with Ibuprofen. | [DB01013] Clobetasol propionate: The risk or severity of gastrointestinal irritation can be increased when Clobetasol propionate is combined with Ibuprofen. | [DB01047] Fluocinonide: The risk or severity of gastrointestinal irritation can be increased when Fluocinonide is combined with Ibuprofen. | [DB14540] Hydrocortisone butyrate: The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Ibuprofen. | [DB00547] Desoximetasone: The risk or severity of gastrointestinal irritation can be increased when Desoximetasone is combined with Ibuprofen. | [DB00764] Mometasone: The risk or severity of gastrointestinal irritation can be increased when Mometasone is combined with Ibuprofen. | [DB08971] Fluocortolone: The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Ibuprofen. | [DB15566] Prednisolone acetate: The risk or severity of gastrointestinal irritation can be increased when Prednisolone acetate is combined with Ibuprofen. | [DB00324] Fluorometholone: The risk or severity of gastrointestinal irritation can be increased when Fluorometholone is combined with Ibuprofen. | [DB09095] Difluocortolone: The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Ibuprofen. | [DB00663] Flumethasone: The risk or severity of gastrointestinal irritation can be increased when Flumethasone is combined with Ibuprofen. | [DB14643] Methylprednisolone aceponate: The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Ibuprofen. | [DB00307] Bexarotene: The metabolism of Ibuprofen can be decreased when combined with Bexarotene. | [DB00603] Medroxyprogesterone acetate: The metabolism of Ibuprofen can be decreased when combined with Medroxyprogesterone acetate. | [DB01062] Oxybutynin: The metabolism of Ibuprofen can be decreased when combined with Oxybutynin. | [DB01095] Fluvastatin: The metabolism of Ibuprofen can be decreased when combined with Fluvastatin. | [DB01132] Pioglitazone: The metabolism of Ibuprofen can be decreased when combined with Pioglitazone. | [DB01685] Topiroxostat: The metabolism of Ibuprofen can be decreased when combined with Topiroxostat. | [DB08880] Teriflunomide: The metabolism of Ibuprofen can be decreased when combined with Teriflunomide. | [DB00451] Levothyroxine: The metabolism of Ibuprofen can be decreased when combined with Levothyroxine. | [DB00440] Trimethoprim: The metabolism of Ibuprofen can be decreased when combined with Trimethoprim. | [DB00468] Quinine: The metabolism of Ibuprofen can be decreased when combined with Quinine. | [DB01023] Felodipine: The metabolism of Ibuprofen can be decreased when combined with Felodipine. | [DB00938] Salmeterol: The metabolism of Ibuprofen can be decreased when combined with Salmeterol. | [DB08911] Trametinib: Ibuprofen may decrease the excretion rate of Trametinib which could result in a higher serum level. | [DB00407] Ardeparin: The risk or severity of hyperkalemia can be increased when Ardeparin is combined with Ibuprofen. | [DB00568] Cinnarizine: The risk or severity of hyperkalemia can be increased when Cinnarizine is combined with Ibuprofen. | [DB00653] Magnesium sulfate: The risk or severity of hyperkalemia can be increased when Magnesium sulfate is combined with Ibuprofen. | [DB00825] Levomenthol: The risk or severity of hyperkalemia can be increased when Levomenthol is combined with Ibuprofen. | [DB01074] Perhexiline: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Perhexiline. | [DB01109] Heparin: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Heparin. | [DB01219] Dantrolene: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Dantrolene. | [DB01225] Enoxaparin: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Enoxaparin. | [DB02968] Penicillin G Acyl-Serine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Penicillin G Acyl-Serine. | [DB04825] Prenylamine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Prenylamine. | [DB04838] Cyclandelate: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Cyclandelate. | [DB04841] Flunarizine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Flunarizine. | [DB04842] Fluspirilene: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Fluspirilene. | [DB05246] Methsuximide: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Methsuximide. | [DB05885] Seletracetam: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Seletracetam. | [DB06152] Nylidrin: The risk or severity of hypertension can be increased when Ibuprofen is combined with Nylidrin. | [DB06271] Sulodexide: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Sulodexide. | [DB06446] Dotarizine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Dotarizine. | [DB06754] Danaparoid: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Danaparoid. | [DB06779] Dalteparin: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Dalteparin. | [DB06822] Tinzaparin: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Tinzaparin. | [DB08813] Nadroparin: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Nadroparin. | [DB08838] Agmatine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Agmatine. | [DB08980] Fendiline: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Fendiline. | [DB08992] Eperisone: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Eperisone. | [DB09090] Pinaverium: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Pinaverium. | [DB09229] Aranidipine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Aranidipine. | [DB09230] Azelnidipine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Azelnidipine. | [DB09232] Cilnidipine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Cilnidipine. | [DB09234] Darodipine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Darodipine. | [DB09240] Niludipine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Niludipine. | [DB09258] Bemiparin: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Bemiparin. | [DB09259] Reviparin: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Reviparin. | [DB09260] Parnaparin: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Parnaparin. | [DB09261] Certoparin: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Certoparin. | [DB11960] Carboxyamidotriazole: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Carboxyamidotriazole. | [DB12097] Mannitol busulfan: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Mannitol busulfan. | [DB12131] Vinpocetine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Vinpocetine. | [DB13488] Bencyclane: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Bencyclane. | [DB13500] Otilonium: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Otilonium. | [DB13725] Terodiline: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Terodiline. | [DB13766] Lidoflazine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Lidoflazine. | [DB13791] Penfluridol: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Penfluridol. | [DB13835] Caroverine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Caroverine. | [DB13950] WIN 55212-2: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with WIN 55212-2. | [DB13961] Fish oil: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Fish oil. | [DB00202] Succinylcholine: The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Ibuprofen. | [DB00593] Ethosuximide: The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Ibuprofen. | [DB12923] Gallopamil: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Gallopamil. | [DB14063] Dexverapamil: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Dexverapamil. | [DB14064] Emopamil: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Emopamil. | [DB14065] Lomerizine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Lomerizine. | [DB14066] Tetrandrine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Tetrandrine. | [DB09449] Sodium phosphate, monobasic: The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Ibuprofen. | [DB12364] Betrixaban: The risk or severity of bleeding can be increased when Betrixaban is combined with Ibuprofen. | [DB00212] Remikiren: The therapeutic efficacy of Remikiren can be decreased when used in combination with Ibuprofen. | [DB00217] Bethanidine: The therapeutic efficacy of Bethanidine can be decreased when used in combination with Ibuprofen. | [DB00226] Guanadrel: The therapeutic efficacy of Guanadrel can be decreased when used in combination with Ibuprofen. | [DB00325] Nitroprusside: The therapeutic efficacy of Nitroprusside can be decreased when used in combination with Ibuprofen. | [DB00343] Diltiazem: The metabolism of Ibuprofen can be decreased when combined with Diltiazem. | [DB00350] Minoxidil: The therapeutic efficacy of Minoxidil can be decreased when used in combination with Ibuprofen. | [DB00528] Lercanidipine: The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Ibuprofen. | [DB00559] Bosentan: The therapeutic efficacy of Bosentan can be decreased when used in combination with Ibuprofen. | [DB00606] Cyclothiazide: The therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Ibuprofen. | [DB00616] Candoxatril: The therapeutic efficacy of Candoxatril can be decreased when used in combination with Ibuprofen. | [DB00629] Guanabenz: The therapeutic efficacy of Guanabenz can be decreased when used in combination with Ibuprofen. | [DB00657] Mecamylamine: The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Ibuprofen. | [DB00692] Phentolamine: The therapeutic efficacy of Phentolamine can be decreased when used in combination with Ibuprofen. | [DB00727] Nitroglycerin: The therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Ibuprofen. | [DB00765] Metyrosine: The therapeutic efficacy of Metyrosine can be decreased when used in combination with Ibuprofen. | [DB00785] Cryptenamine: The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Ibuprofen. | [DB00797] Tolazoline: The therapeutic efficacy of Tolazoline can be decreased when used in combination with Ibuprofen. | [DB00800] Fenoldopam: The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Ibuprofen. | [DB00925] Phenoxybenzamine: The therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Ibuprofen. | [DB00968] Methyldopa: The therapeutic efficacy of Methyldopa can be decreased when used in combination with Ibuprofen. | [DB01018] Guanfacine: The therapeutic efficacy of Guanfacine can be decreased when used in combination with Ibuprofen. | [DB01089] Deserpidine: The therapeutic efficacy of Deserpidine can be decreased when used in combination with Ibuprofen. | [DB01090] Pentolinium: The therapeutic efficacy of Pentolinium can be decreased when used in combination with Ibuprofen. | [DB01116] Trimethaphan: The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Ibuprofen. | [DB01119] Diazoxide: The therapeutic efficacy of Diazoxide can be decreased when used in combination with Ibuprofen. | [DB01158] Bretylium: The therapeutic efficacy of Bretylium can be decreased when used in combination with Ibuprofen. | [DB01170] Guanethidine: The therapeutic efficacy of Guanethidine can be decreased when used in combination with Ibuprofen. | [DB01626] Pargyline: The therapeutic efficacy of Pargyline can be decreased when used in combination with Ibuprofen. | [DB04831] Tienilic acid: The therapeutic efficacy of Tienilic acid can be decreased when used in combination with Ibuprofen. | [DB04948] Lofexidine: The therapeutic efficacy of Lofexidine can be decreased when used in combination with Ibuprofen. | [DB06268] Sitaxentan: The therapeutic efficacy of Sitaxentan can be decreased when used in combination with Ibuprofen. | [DB06445] Diethylnorspermine: The therapeutic efficacy of Diethylnorspermine can be decreased when used in combination with Ibuprofen. | [DB06712] Nilvadipine: The metabolism of Ibuprofen can be decreased when combined with Nilvadipine. | [DB06762] Pinacidil: The therapeutic efficacy of Pinacidil can be decreased when used in combination with Ibuprofen. | [DB08931] Riociguat: The therapeutic efficacy of Riociguat can be decreased when used in combination with Ibuprofen. | [DB08932] Macitentan: The therapeutic efficacy of Macitentan can be decreased when used in combination with Ibuprofen. | [DB08950] Indoramin: The therapeutic efficacy of Indoramin can be decreased when used in combination with Ibuprofen. | [DB08960] Hexamethonium: The therapeutic efficacy of Hexamethonium can be decreased when used in combination with Ibuprofen. | [DB09206] Trimazosin: The therapeutic efficacy of Trimazosin can be decreased when used in combination with Ibuprofen. | [DB09220] Nicorandil: The therapeutic efficacy of Nicorandil can be decreased when used in combination with Ibuprofen. | [DB09235] Efonidipine: The therapeutic efficacy of Efonidipine can be decreased when used in combination with Ibuprofen. | [DB09236] Lacidipine: The therapeutic efficacy of Lacidipine can be decreased when used in combination with Ibuprofen. | [DB09238] Manidipine: The therapeutic efficacy of Manidipine can be decreased when used in combination with Ibuprofen. | [DB09242] Moxonidine: The therapeutic efficacy of Moxonidine can be decreased when used in combination with Ibuprofen. | [DB09363] Rauwolfia serpentina root: The therapeutic efficacy of Rauwolfia serpentina root can be decreased when used in combination with Ibuprofen. | [DB11720] Angiotensin 1-7: The therapeutic efficacy of Angiotensin 1-7 can be decreased when used in combination with Ibuprofen. | [DB11738] Rilmenidine: The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Ibuprofen. | [DB12054] BQ-123: The therapeutic efficacy of BQ-123 can be decreased when used in combination with Ibuprofen. | [DB12093] Tetrahydropalmatine: The therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Ibuprofen. | [DB12661] Urapidil: The therapeutic efficacy of Urapidil can be decreased when used in combination with Ibuprofen. | [DB12766] Cicletanine: The therapeutic efficacy of Cicletanine can be decreased when used in combination with Ibuprofen. | [DB12945] Dihydralazine: The therapeutic efficacy of Dihydralazine can be decreased when used in combination with Ibuprofen. | [DB13211] Guanoxan: The therapeutic efficacy of Guanoxan can be decreased when used in combination with Ibuprofen. | [DB13374] Vincamine: The therapeutic efficacy of Vincamine can be decreased when used in combination with Ibuprofen. | [DB13410] Guanoxabenz: The therapeutic efficacy of Guanoxabenz can be decreased when used in combination with Ibuprofen. | [DB13429] Tolonidine: The therapeutic efficacy of Tolonidine can be decreased when used in combination with Ibuprofen. | [DB13435] Endralazine: The therapeutic efficacy of Endralazine can be decreased when used in combination with Ibuprofen. | [DB13452] Cadralazine: The therapeutic efficacy of Cadralazine can be decreased when used in combination with Ibuprofen. | [DB13575] Bietaserpine: The therapeutic efficacy of Bietaserpine can be decreased when used in combination with Ibuprofen. | [DB13604] Guanazodine: The therapeutic efficacy of Guanazodine can be decreased when used in combination with Ibuprofen. | [DB13631] Methoserpidine: The therapeutic efficacy of Methoserpidine can be decreased when used in combination with Ibuprofen. | [DB13779] Guanoclor: The therapeutic efficacy of Guanoclor can be decreased when used in combination with Ibuprofen. | [DB13801] Muzolimine: The therapeutic efficacy of Muzolimine can be decreased when used in combination with Ibuprofen. | [DB13803] Xipamide: The therapeutic efficacy of Xipamide can be decreased when used in combination with Ibuprofen. | [DB14094] Tocopherylquinone: The therapeutic efficacy of Tocopherylquinone can be decreased when used in combination with Ibuprofen. | [DB00700] Eplerenone: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Eplerenone. | [DB00820] Tadalafil: The therapeutic efficacy of Tadalafil can be decreased when used in combination with Ibuprofen. | [DB00590] Doxazosin: The therapeutic efficacy of Doxazosin can be decreased when used in combination with Ibuprofen. | [DB00206] Reserpine: The therapeutic efficacy of Reserpine can be decreased when used in combination with Ibuprofen. | [DB00270] Isradipine: The metabolism of Ibuprofen can be decreased when combined with Isradipine. | [DB00393] Nimodipine: The therapeutic efficacy of Nimodipine can be decreased when used in combination with Ibuprofen. | [DB00401] Nisoldipine: The therapeutic efficacy of Nisoldipine can be decreased when used in combination with Ibuprofen. | [DB00457] Prazosin: The therapeutic efficacy of Prazosin can be decreased when used in combination with Ibuprofen. | [DB00575] Clonidine: The therapeutic efficacy of Clonidine can be decreased when used in combination with Ibuprofen. | [DB01054] Nitrendipine: The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Ibuprofen. | [DB01162] Terazosin: The therapeutic efficacy of Terazosin can be decreased when used in combination with Ibuprofen. | [DB01244] Bepridil: The therapeutic efficacy of Bepridil can be decreased when used in combination with Ibuprofen. | [DB01388] Mibefradil: The therapeutic efficacy of Mibefradil can be decreased when used in combination with Ibuprofen. | [DB04840] Debrisoquine: The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Ibuprofen. | [DB06403] Ambrisentan: The therapeutic efficacy of Ambrisentan can be decreased when used in combination with Ibuprofen. | [DB09239] Niguldipine: The therapeutic efficacy of Niguldipine can be decreased when used in combination with Ibuprofen. | [DB14068] Dexniguldipine: The therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Ibuprofen. | [DB09237] Levamlodipine: The therapeutic efficacy of Levamlodipine can be decreased when used in combination with Ibuprofen. | [DB15861] Buthiazide: The therapeutic efficacy of Buthiazide can be decreased when used in combination with Ibuprofen. | [DB00091] Cyclosporine: The risk or severity of renal failure and hypertension can be increased when Ibuprofen is combined with Cyclosporine. | [DB00222] Glimepiride: The protein binding of Glimepiride can be decreased when combined with Ibuprofen. | [DB00414] Acetohexamide: The protein binding of Acetohexamide can be decreased when combined with Ibuprofen. | [DB00672] Chlorpropamide: The protein binding of Chlorpropamide can be decreased when combined with Ibuprofen. | [DB00839] Tolazamide: The protein binding of Tolazamide can be decreased when combined with Ibuprofen. | [DB01067] Glipizide: The protein binding of Glipizide can be decreased when combined with Ibuprofen. | [DB01120] Gliclazide: The protein binding of Gliclazide can be decreased when combined with Ibuprofen. | [DB01124] Tolbutamide: The protein binding of Tolbutamide can be decreased when combined with Ibuprofen. | [DB01251] Gliquidone: The protein binding of Gliquidone can be decreased when combined with Ibuprofen. | [DB01289] Glisoxepide: The protein binding of Glisoxepide can be decreased when combined with Ibuprofen. | [DB08962] Glibornuride: The protein binding of Glibornuride can be decreased when combined with Ibuprofen. | [DB13406] Carbutamide: The protein binding of Carbutamide can be decreased when combined with Ibuprofen. | [DB13675] Metahexamide: The protein binding of Metahexamide can be decreased when combined with Ibuprofen. | [DB13615] Mifamurtide: The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Ibuprofen. | [DB11051] Azficel-T: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Azficel-T. | [DB11642] Pitolisant: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Pitolisant. | [DB00586] Diclofenac: The risk or severity of adverse effects can be increased when Diclofenac is combined with Ibuprofen. | [DB00712] Flurbiprofen: The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ibuprofen. | [DB00963] Bromfenac: The risk or severity of adverse effects can be increased when Bromfenac is combined with Ibuprofen. | [DB06802] Nepafenac: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Nepafenac. | [DB00328] Indomethacin: The risk or severity of adverse effects can be increased when Indomethacin is combined with Ibuprofen. | [DB00461] Nabumetone: The risk or severity of adverse effects can be increased when Nabumetone is combined with Ibuprofen. | [DB00469] Tenoxicam: The risk or severity of adverse effects can be increased when Tenoxicam is combined with Ibuprofen. | [DB00482] Celecoxib: The risk or severity of adverse effects can be increased when Celecoxib is combined with Ibuprofen. | [DB00500] Tolmetin: The risk or severity of adverse effects can be increased when Tolmetin is combined with Ibuprofen. | [DB00533] Rofecoxib: The risk or severity of adverse effects can be increased when Rofecoxib is combined with Ibuprofen. | [DB00554] Piroxicam: The risk or severity of adverse effects can be increased when Piroxicam is combined with Ibuprofen. | [DB00573] Fenoprofen: The risk or severity of adverse effects can be increased when Fenoprofen is combined with Ibuprofen. | [DB00580] Valdecoxib: The risk or severity of adverse effects can be increased when Valdecoxib is combined with Ibuprofen. | [DB00605] Sulindac: The risk or severity of adverse effects can be increased when Sulindac is combined with Ibuprofen. | [DB00749] Etodolac: The risk or severity of adverse effects can be increased when Etodolac is combined with Ibuprofen. | [DB00784] Mefenamic acid: The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibuprofen. | [DB00788] Naproxen: The risk or severity of adverse effects can be increased when Naproxen is combined with Ibuprofen. | [DB00795] Sulfasalazine: The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibuprofen. | [DB00812] Phenylbutazone: The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibuprofen. | [DB00814] Meloxicam: The risk or severity of adverse effects can be increased when Meloxicam is combined with Ibuprofen. | [DB00821] Carprofen: The risk or severity of adverse effects can be increased when Carprofen is combined with Ibuprofen. | [DB00861] Diflunisal: The risk or severity of adverse effects can be increased when Diflunisal is combined with Ibuprofen. | [DB00870] Suprofen: The risk or severity of adverse effects can be increased when Suprofen is combined with Ibuprofen. | [DB00936] Salicylic acid: The risk or severity of adverse effects can be increased when Salicylic acid is combined with Ibuprofen. | [DB00939] Meclofenamic acid: The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibuprofen. | [DB00991] Oxaprozin: The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibuprofen. | [DB01009] Ketoprofen: The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibuprofen. | [DB01014] Balsalazide: The risk or severity of adverse effects can be increased when Balsalazide is combined with Ibuprofen. | [DB01250] Olsalazine: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Olsalazine. | [DB01283] Lumiracoxib: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Lumiracoxib. | [DB01397] Magnesium salicylate: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Magnesium salicylate. | [DB01399] Salsalate: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Salsalate. | [DB01401] Choline magnesium trisalicylate: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Choline magnesium trisalicylate. | [DB01435] Antipyrine: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Antipyrine. | [DB01600] Tiaprofenic acid: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Tiaprofenic acid. | [DB01628] Etoricoxib: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Etoricoxib. | [DB03585] Oxyphenbutazone: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Oxyphenbutazone. | [DB04552] Niflumic acid: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Niflumic acid. | [DB04812] Benoxaprofen: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Benoxaprofen. | [DB04817] Metamizole: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Metamizole. | [DB04828] Zomepirac: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Zomepirac. | [DB06725] Lornoxicam: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Lornoxicam. | [DB06736] Aceclofenac: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Aceclofenac. | [DB06737] Zaltoprofen: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Zaltoprofen. | [DB07402] Azapropazone: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Azapropazone. | [DB07477] Felbinac: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Felbinac. | [DB08439] Parecoxib: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Parecoxib. | [DB08797] Salicylamide: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Salicylamide. | [DB08940] Kebuzone: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Kebuzone. | [DB08942] Isoxicam: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Isoxicam. | [DB08951] Indoprofen: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Indoprofen. | [DB08955] Ibuproxam: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Ibuproxam. | [DB08976] Floctafenine: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Floctafenine. | [DB08981] Fenbufen: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Fenbufen. | [DB08984] Etofenamate: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Etofenamate. | [DB08991] Epirizole: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Epirizole. | [DB09212] Loxoprofen: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Loxoprofen. | [DB09215] Droxicam: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Droxicam. | [DB09216] Tolfenamic acid: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Tolfenamic acid. | [DB09218] Clonixin: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Clonixin. | [DB11466] Tepoxalin: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Tepoxalin. | [DB11518] Flunixin: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Flunixin. | [DB13001] Tinoridine: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Tinoridine. | [DB13167] Alclofenac: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Alclofenac. | [DB13217] Fentiazac: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Fentiazac. | [DB13232] Suxibuzone: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Suxibuzone. | [DB13286] Bumadizone: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Bumadizone. | [DB13314] Alminoprofen: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Alminoprofen. | [DB13346] Bufexamac: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Bufexamac. | [DB13364] Feprazone: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Feprazone. | [DB13371] Difenpiramide: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Difenpiramide. | [DB13407] Nifenazone: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Nifenazone. | [DB13432] Lonazolac: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Lonazolac. | [DB13481] Tenidap: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Tenidap. | [DB13501] Bendazac: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Bendazac. | [DB13514] Pranoprofen: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Pranoprofen. | [DB13524] Propyphenazone: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Propyphenazone. | [DB13527] Proglumetacin: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Proglumetacin. | [DB13538] Guacetisal: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Guacetisal. | [DB13544] Ethenzamide: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Ethenzamide. | [DB13612] Carbaspirin calcium: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Carbaspirin calcium. | [DB13629] Mofebutazone: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Mofebutazone. | [DB13649] Proquazone: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Proquazone. | [DB13657] Benorilate: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Benorilate. | [DB13722] Pirprofen: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Pirprofen. | [DB13783] Acemetacin: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Acemetacin. | [DB13860] Imidazole salicylate: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Imidazole salicylate. | [DB09084] Benzydamine: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Benzydamine. | [DB00159] Icosapent: The risk or severity of adverse effects can be increased when Icosapent is combined with Ibuprofen. | [DB01419] Antrafenine: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Antrafenine. | [DB09213] Dexibuprofen: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Dexibuprofen. | [DB11079] Trolamine salicylate: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Trolamine salicylate. | [DB05095] Cimicoxib: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Cimicoxib. | [DB11455] Robenacoxib: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Robenacoxib. | [DB01424] Aminophenazone: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Aminophenazone. | [DB00244] Mesalazine: The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ibuprofen. | [DB14059] SC-236: The risk or severity of adverse effects can be increased when Ibuprofen is combined with SC-236. | [DB14060] NS-398: The risk or severity of adverse effects can be increased when Ibuprofen is combined with NS-398. | [DB09217] Firocoxib: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Firocoxib. | [DB09285] Morniflumate: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Morniflumate. | [DB09295] Talniflumate: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Talniflumate. | [DB09214] Dexketoprofen: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Dexketoprofen. | [DB02224] Taxifolin: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Taxifolin. | [DB12480] Betulinic Acid: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Betulinic Acid. | [DB12610] Ebselen: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Ebselen. | [DB14938] Flurbiprofen axetil: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Flurbiprofen axetil. | [DB12399] Polmacoxib: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Polmacoxib. | [DB04725] Licofelone: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Licofelone. | [DB04743] Nimesulide: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Nimesulide. | [DB12445] Nitroaspirin: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Nitroaspirin. | [DB12545] Indobufen: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Indobufen. | [DB01033] Mercaptopurine: The excretion of Mercaptopurine can be decreased when combined with Ibuprofen. | [DB00631] Clofarabine: The excretion of Clofarabine can be decreased when combined with Ibuprofen. | [DB00007] Leuprolide: Ibuprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level. | [DB00014] Goserelin: Ibuprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. | [DB00017] Salmon calcitonin: Ibuprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level. | [DB00041] Aldesleukin: Ibuprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level. | [DB00080] Daptomycin: Ibuprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level. | [DB00081] Tositumomab: Ibuprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level. | [DB00158] Folic acid: Ibuprofen may decrease the excretion rate of Folic acid which could result in a higher serum level. | [DB00182] Amphetamine: The risk or severity of hypertension can be increased when Amphetamine is combined with Ibuprofen. | [DB00185] Cevimeline: Ibuprofen may decrease the excretion rate of Cevimeline which could result in a higher serum level. | [DB00190] Carbidopa: Ibuprofen may decrease the excretion rate of Carbidopa which could result in a higher serum level. | [DB00200] Hydroxocobalamin: Ibuprofen may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level. | [DB00225] Gadodiamide: Ibuprofen may decrease the excretion rate of Gadodiamide which could result in a higher serum level. | [DB00235] Milrinone: Ibuprofen may decrease the excretion rate of Milrinone which could result in a higher serum level. | [DB00237] Butabarbital: Ibuprofen may decrease the excretion rate of Butabarbital which could result in a higher serum level. | [DB00245] Benzatropine: Ibuprofen may decrease the excretion rate of Benzatropine which could result in a higher serum level. | [DB00262] Carmustine: Ibuprofen may decrease the excretion rate of Carmustine which could result in a higher serum level. | [DB00271] Diatrizoate: Ibuprofen may decrease the excretion rate of Diatrizoate which could result in a higher serum level. | [DB00279] Liothyronine: Ibuprofen may decrease the excretion rate of Liothyronine which could result in a higher serum level. | [DB00280] Disopyramide: Ibuprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level. | [DB00289] Atomoxetine: The risk or severity of hypertension can be increased when Atomoxetine is combined with Ibuprofen. | [DB00290] Bleomycin: Ibuprofen may decrease the excretion rate of Bleomycin which could result in a higher serum level. | [DB00292] Etomidate: The risk or severity of hypertension can be increased when Etomidate is combined with Ibuprofen. | [DB00294] Etonogestrel: Ibuprofen may decrease the excretion rate of Etonogestrel which could result in a higher serum level. | [DB00296] Ropivacaine: Ibuprofen may decrease the excretion rate of Ropivacaine which could result in a higher serum level. | [DB00303] Ertapenem: Ibuprofen may decrease the excretion rate of Ertapenem which could result in a higher serum level. | [DB00308] Ibutilide: Ibuprofen may decrease the excretion rate of Ibutilide which could result in a higher serum level. | [DB00323] Tolcapone: Ibuprofen may decrease the excretion rate of Tolcapone which could result in a higher serum level. | [DB00330] Ethambutol: Ibuprofen may decrease the excretion rate of Ethambutol which could result in a higher serum level. | [DB00331] Metformin: Ibuprofen may decrease the excretion rate of Metformin which could result in a higher serum level. | [DB00339] Pyrazinamide: Ibuprofen may decrease the excretion rate of Pyrazinamide which could result in a higher serum level. | [DB00355] Aztreonam: Ibuprofen may decrease the excretion rate of Aztreonam which could result in a higher serum level. | [DB00356] Chlorzoxazone: Ibuprofen may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level. | [DB00364] Sucralfate: Ibuprofen may decrease the excretion rate of Sucralfate which could result in a higher serum level. | [DB00372] Thiethylperazine: Ibuprofen may decrease the excretion rate of Thiethylperazine which could result in a higher serum level. | [DB00377] Palonosetron: Ibuprofen may decrease the excretion rate of Palonosetron which could result in a higher serum level. | [DB00380] Dexrazoxane: Ibuprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. | [DB00413] Pramipexole: Ibuprofen may decrease the excretion rate of Pramipexole which could result in a higher serum level. | [DB00415] Ampicillin: Ibuprofen may decrease the excretion rate of Ampicillin which could result in a higher serum level. | [DB00435] Nitric Oxide: Ibuprofen may decrease the excretion rate of Nitric Oxide which could result in a higher serum level. | [DB00441] Gemcitabine: Ibuprofen may decrease the excretion rate of Gemcitabine which could result in a higher serum level. | [DB00499] Flutamide: Ibuprofen may decrease the excretion rate of Flutamide which could result in a higher serum level. | [DB00548] Azelaic acid: Ibuprofen may decrease the excretion rate of Azelaic acid which could result in a higher serum level. | [DB00553] Methoxsalen: Ibuprofen may decrease the excretion rate of Methoxsalen which could result in a higher serum level. | [DB00558] Zanamivir: Ibuprofen may decrease the excretion rate of Zanamivir which could result in a higher serum level. | [DB00569] Fondaparinux: Ibuprofen may decrease the excretion rate of Fondaparinux which could result in a higher serum level. | [DB00597] Gadoteridol: Ibuprofen may decrease the excretion rate of Gadoteridol which could result in a higher serum level. | [DB00633] Dexmedetomidine: The risk or severity of hypertension can be increased when Dexmedetomidine is combined with Ibuprofen. | [DB00651] Dyphylline: Ibuprofen may decrease the excretion rate of Dyphylline which could result in a higher serum level. | [DB00660] Metaxalone: Ibuprofen may decrease the excretion rate of Metaxalone which could result in a higher serum level. | [DB00698] Nitrofurantoin: The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Ibuprofen. | [DB00706] Tamsulosin: Ibuprofen may decrease the excretion rate of Tamsulosin which could result in a higher serum level. | [DB00713] Oxacillin: Ibuprofen may decrease the excretion rate of Oxacillin which could result in a higher serum level. | [DB00716] Nedocromil: Ibuprofen may decrease the excretion rate of Nedocromil which could result in a higher serum level. | [DB00730] Thiabendazole: Ibuprofen may decrease the excretion rate of Thiabendazole which could result in a higher serum level. | [DB00731] Nateglinide: Ibuprofen may decrease the excretion rate of Nateglinide which could result in a higher serum level. | [DB00733] Pralidoxime: Ibuprofen may decrease the excretion rate of Pralidoxime which could result in a higher serum level. | [DB00743] Gadobenic acid: Ibuprofen may decrease the excretion rate of Gadobenic acid which could result in a higher serum level. | [DB00760] Meropenem: Ibuprofen may decrease the excretion rate of Meropenem which could result in a higher serum level. | [DB00780] Phenelzine: The risk or severity of hypertension can be increased when Phenelzine is combined with Ibuprofen. | [DB00782] Propantheline: Ibuprofen may decrease the excretion rate of Propantheline which could result in a higher serum level. | [DB00789] Gadopentetic acid: Ibuprofen may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. | [DB00804] Dicyclomine: Ibuprofen may decrease the excretion rate of Dicyclomine which could result in a higher serum level. | [DB00811] Ribavirin: Ibuprofen may decrease the excretion rate of Ribavirin which could result in a higher serum level. | [DB00828] Fosfomycin: Ibuprofen may decrease the excretion rate of Fosfomycin which could result in a higher serum level. | [DB00841] Dobutamine: The risk or severity of hypertension can be increased when Dobutamine is combined with Ibuprofen. | [DB00851] Dacarbazine: Ibuprofen may decrease the excretion rate of Dacarbazine which could result in a higher serum level. | [DB00853] Temozolomide: Ibuprofen may decrease the excretion rate of Temozolomide which could result in a higher serum level. | [DB00871] Terbutaline: The risk or severity of hypertension can be increased when Terbutaline is combined with Ibuprofen. | [DB00894] Testolactone: Ibuprofen may decrease the excretion rate of Testolactone which could result in a higher serum level. | [DB00900] Didanosine: Ibuprofen may decrease the excretion rate of Didanosine which could result in a higher serum level. | [DB00911] Tinidazole: Ibuprofen may decrease the excretion rate of Tinidazole which could result in a higher serum level. | [DB00915] Amantadine: Ibuprofen may decrease the excretion rate of Amantadine which could result in a higher serum level. | [DB00928] Azacitidine: Ibuprofen may decrease the excretion rate of Azacitidine which could result in a higher serum level. | [DB00934] Maprotiline: Ibuprofen may decrease the excretion rate of Maprotiline which could result in a higher serum level. | [DB00953] Rizatriptan: The risk or severity of hypertension can be increased when Rizatriptan is combined with Ibuprofen. | [DB00961] Mepivacaine: Ibuprofen may decrease the excretion rate of Mepivacaine which could result in a higher serum level. | [DB00962] Zaleplon: Ibuprofen may decrease the excretion rate of Zaleplon which could result in a higher serum level. | [DB00980] Ramelteon: Ibuprofen may decrease the excretion rate of Ramelteon which could result in a higher serum level. | [DB00988] Dopamine: The risk or severity of hypertension can be increased when Dopamine is combined with Ibuprofen. | [DB00993] Azathioprine: Ibuprofen may decrease the excretion rate of Azathioprine which could result in a higher serum level. | [DB00995] Auranofin: Ibuprofen may decrease the excretion rate of Auranofin which could result in a higher serum level. | [DB01001] Albuterol: The risk or severity of hypertension can be increased when Salbutamol is combined with Ibuprofen. | [DB01002] Levobupivacaine: Ibuprofen may decrease the excretion rate of Levobupivacaine which could result in a higher serum level. | [DB01004] Ganciclovir: Ibuprofen may decrease the excretion rate of Ganciclovir which could result in a higher serum level. | [DB01010] Edrophonium: Ibuprofen may decrease the excretion rate of Edrophonium which could result in a higher serum level. | [DB01011] Metyrapone: Ibuprofen may decrease the excretion rate of Metyrapone which could result in a higher serum level. | [DB01020] Isosorbide mononitrate: Ibuprofen may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level. | [DB01022] Phylloquinone: Ibuprofen may decrease the excretion rate of Phylloquinone which could result in a higher serum level. | [DB01024] Mycophenolic acid: Ibuprofen may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level. | [DB01036] Tolterodine: Ibuprofen may decrease the excretion rate of Tolterodine which could result in a higher serum level. | [DB01043] Memantine: Ibuprofen may decrease the excretion rate of Memantine which could result in a higher serum level. | [DB01046] Lubiprostone: Ibuprofen may decrease the excretion rate of Lubiprostone which could result in a higher serum level. | [DB01048] Abacavir: Ibuprofen may decrease the excretion rate of Abacavir which could result in a higher serum level. | [DB01060] Amoxicillin: Ibuprofen may decrease the excretion rate of Amoxicillin which could result in a higher serum level. | [DB01093] Dimethyl sulfoxide: Ibuprofen may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level. | [DB01099] Flucytosine: Ibuprofen may decrease the excretion rate of Flucytosine which could result in a higher serum level. | [DB01135] Doxacurium: Ibuprofen may decrease the excretion rate of Doxacurium which could result in a higher serum level. | [DB01148] Flavoxate: Ibuprofen may decrease the excretion rate of Flavoxate which could result in a higher serum level. | [DB01156] Bupropion: Ibuprofen may decrease the excretion rate of Bupropion which could result in a higher serum level. | [DB01157] Trimetrexate: Ibuprofen may decrease the excretion rate of Trimetrexate which could result in a higher serum level. | [DB01205] Flumazenil: Ibuprofen may decrease the excretion rate of Flumazenil which could result in a higher serum level. | [DB01213] Fomepizole: Ibuprofen may decrease the excretion rate of Fomepizole which could result in a higher serum level. | [DB01249] Iodixanol: Ibuprofen may decrease the excretion rate of Iodixanol which could result in a higher serum level. | [DB01273] Varenicline: Ibuprofen may decrease the excretion rate of Varenicline which could result in a higher serum level. | [DB01274] Arformoterol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Arformoterol. | [DB01367] Rasagiline: The risk or severity of hypertension can be increased when Ibuprofen is combined with Rasagiline. | [DB01409] Tiotropium: Ibuprofen may decrease the excretion rate of Tiotropium which could result in a higher serum level. | [DB01427] Amrinone: Ibuprofen may decrease the excretion rate of Amrinone which could result in a higher serum level. | [DB01428] Oxybenzone: Ibuprofen may decrease the excretion rate of Oxybenzone which could result in a higher serum level. | [DB01431] Allylestrenol: Ibuprofen may decrease the excretion rate of Allylestrenol which could result in a higher serum level. | [DB01550] Fenproporex: Ibuprofen may decrease the excretion rate of Fenproporex which could result in a higher serum level. | [DB01563] Chloral hydrate: Ibuprofen may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. | [DB01577] Metamfetamine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Metamfetamine. | [DB01610] Valganciclovir: Ibuprofen may decrease the excretion rate of Valganciclovir which could result in a higher serum level. | [DB01638] Sorbitol: Ibuprofen may decrease the excretion rate of Sorbitol which could result in a higher serum level. | [DB01656] Roflumilast: Ibuprofen may decrease the excretion rate of Roflumilast which could result in a higher serum level. | [DB04871] Lorcaserin: Ibuprofen may decrease the excretion rate of Lorcaserin which could result in a higher serum level. | [DB04895] Pegaptanib: Ibuprofen may decrease the excretion rate of Pegaptanib which could result in a higher serum level. | [DB04953] Ezogabine: Ibuprofen may decrease the excretion rate of Ezogabine which could result in a higher serum level. | [DB05018] Migalastat: Ibuprofen may decrease the excretion rate of Migalastat which could result in a higher serum level. | [DB05541] Brivaracetam: Ibuprofen may decrease the excretion rate of Brivaracetam which could result in a higher serum level. | [DB06154] Pentaerythritol tetranitrate: Ibuprofen may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level. | [DB06186] Ipilimumab: Ibuprofen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. | [DB06230] Nalmefene: Ibuprofen may decrease the excretion rate of Nalmefene which could result in a higher serum level. | [DB06262] Droxidopa: The risk or severity of hypertension can be increased when Ibuprofen is combined with Droxidopa. | [DB06402] Telavancin: Ibuprofen may decrease the excretion rate of Telavancin which could result in a higher serum level. | [DB06623] Flupirtine: Ibuprofen may decrease the excretion rate of Flupirtine which could result in a higher serum level. | [DB06637] Dalfampridine: Ibuprofen may decrease the excretion rate of Dalfampridine which could result in a higher serum level. | [DB06705] Gadofosveset trisodium: Ibuprofen may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. | [DB06710] Methyltestosterone: Ibuprofen may decrease the excretion rate of Methyltestosterone which could result in a higher serum level. | [DB06782] Dimercaprol: Ibuprofen may decrease the excretion rate of Dimercaprol which could result in a higher serum level. | [DB06796] Mangafodipir: Ibuprofen may decrease the excretion rate of Mangafodipir which could result in a higher serum level. | [DB06800] Methylnaltrexone: Ibuprofen may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. | [DB06809] Plerixafor: Ibuprofen may decrease the excretion rate of Plerixafor which could result in a higher serum level. | [DB06823] Tiopronin: Ibuprofen may decrease the excretion rate of Tiopronin which could result in a higher serum level. | [DB06824] Triethylenetetramine: Ibuprofen may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. | [DB08824] Ioflupane I-123: Ibuprofen may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. | [DB08826] Deferiprone: Ibuprofen may decrease the excretion rate of Deferiprone which could result in a higher serum level. | [DB08840] N-methylnicotinamide: Ibuprofen may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level. | [DB08872] Gabapentin enacarbil: Ibuprofen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. | [DB08894] Peginesatide: Ibuprofen may decrease the excretion rate of Peginesatide which could result in a higher serum level. | [DB08897] Aclidinium: Ibuprofen may decrease the excretion rate of Aclidinium which could result in a higher serum level. | [DB08900] Teduglutide: Ibuprofen may decrease the excretion rate of Teduglutide which could result in a higher serum level. | [DB08905] Formestane: Ibuprofen may decrease the excretion rate of Formestane which could result in a higher serum level. | [DB08909] Glycerol phenylbutyrate: Ibuprofen may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level. | [DB09050] Ceftolozane: Ibuprofen may decrease the excretion rate of Ceftolozane which could result in a higher serum level. | [DB09066] Corifollitropin alfa: Ibuprofen may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. | [DB09071] Tasimelteon: Ibuprofen may decrease the excretion rate of Tasimelteon which could result in a higher serum level. | [DB09081] Idebenone: Ibuprofen may decrease the excretion rate of Idebenone which could result in a higher serum level. | [DB09082] Vilanterol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Vilanterol. | [DB09089] Trimebutine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Trimebutine. | [DB09103] Ancestim: Ibuprofen may decrease the excretion rate of Ancestim which could result in a higher serum level. | [DB09104] Magnesium hydroxide: Ibuprofen may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. | [DB09106] Hydroxyethyl Starch: Ibuprofen may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. | [DB09111] Pentastarch: Ibuprofen may decrease the excretion rate of Pentastarch which could result in a higher serum level. | [DB09121] Aurothioglucose: Ibuprofen may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. | [DB09123] Dienogest: Ibuprofen may decrease the excretion rate of Dienogest which could result in a higher serum level. | [DB09129] Chromic chloride: Ibuprofen may decrease the excretion rate of Chromic chloride which could result in a higher serum level. | [DB09132] Gadoteric acid: Ibuprofen may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. | [DB09133] Iothalamic acid: Ibuprofen may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. | [DB09134] Ioversol: Ibuprofen may decrease the excretion rate of Ioversol which could result in a higher serum level. | [DB09135] Ioxilan: Ibuprofen may decrease the excretion rate of Ioxilan which could result in a higher serum level. | [DB09136] Isosulfan blue: Ibuprofen may decrease the excretion rate of Isosulfan blue which could result in a higher serum level. | [DB09137] Technetium Tc-99m mebrofenin: Ibuprofen may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level. | [DB09139] Technetium Tc-99m oxidronate: Ibuprofen may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level. | [DB09148] Florbetaben F-18: Ibuprofen may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. | [DB09149] Florbetapir F-18: Ibuprofen may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. | [DB09156] Iopromide: Ibuprofen may decrease the excretion rate of Iopromide which could result in a higher serum level. | [DB09163] Technetium Tc-99m exametazime: Ibuprofen may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level. | [DB09165] Technetium Tc-99m pyrophosphate: Ibuprofen may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. | [DB09185] Viloxazine: The metabolism of Ibuprofen can be decreased when combined with Viloxazine. | [DB09194] Etoperidone: Ibuprofen may decrease the excretion rate of Etoperidone which could result in a higher serum level. | [DB09195] Lorpiprazole: Ibuprofen may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. | [DB09205] Moxisylyte: The risk or severity of hypertension can be increased when Ibuprofen is combined with Moxisylyte. | [DB09209] Pholcodine: Ibuprofen may decrease the excretion rate of Pholcodine which could result in a higher serum level. | [DB09210] Piracetam: Ibuprofen may decrease the excretion rate of Piracetam which could result in a higher serum level. | [DB09219] Bisoxatin: Ibuprofen may decrease the excretion rate of Bisoxatin which could result in a higher serum level. | [DB09223] Blonanserin: Ibuprofen may decrease the excretion rate of Blonanserin which could result in a higher serum level. | [DB09224] Melperone: Ibuprofen may decrease the excretion rate of Melperone which could result in a higher serum level. | [DB09244] Pirlindole: The risk or severity of hypertension can be increased when Ibuprofen is combined with Pirlindole. | [DB09245] Toloxatone: The risk or severity of hypertension can be increased when Ibuprofen is combined with Toloxatone. | [DB09255] Dextran: Ibuprofen may decrease the excretion rate of Dextran which could result in a higher serum level. | [DB09257] Gimeracil: Ibuprofen may decrease the excretion rate of Gimeracil which could result in a higher serum level. | [DB09262] Imidafenacin: Ibuprofen may decrease the excretion rate of Imidafenacin which could result in a higher serum level. | [DB09264] Idarucizumab: Ibuprofen may decrease the excretion rate of Idarucizumab which could result in a higher serum level. | [DB09265] Lixisenatide: Ibuprofen may decrease the excretion rate of Lixisenatide which could result in a higher serum level. | [DB09268] Picosulfuric acid: Ibuprofen may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. | [DB09277] Choline C 11: Ibuprofen may decrease the excretion rate of Choline C 11 which could result in a higher serum level. | [DB09281] Magnesium trisilicate: Ibuprofen may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. | [DB09317] Synthetic Conjugated Estrogens, A: Ibuprofen may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level. | [DB09318] Synthetic Conjugated Estrogens, B: Ibuprofen may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level. | [DB09320] Procaine benzylpenicillin: Ibuprofen may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. | [DB09324] Sulbactam: Ibuprofen may decrease the excretion rate of Sulbactam which could result in a higher serum level. | [DB09325] Sodium fluoride: Ibuprofen may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. | [DB09329] Antihemophilic factor (recombinant), PEGylated: Ibuprofen may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. | [DB09344] Invert sugar: Ibuprofen may decrease the excretion rate of Invert sugar which could result in a higher serum level. | [DB09357] Dexpanthenol: Ibuprofen may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. | [DB09394] Phosphoric acid: Ibuprofen may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. | [DB09395] Sodium acetate: Ibuprofen may decrease the excretion rate of Sodium acetate which could result in a higher serum level. | [DB09407] Magnesium chloride: Ibuprofen may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. | [DB09472] Sodium sulfate: Ibuprofen may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. | [DB09481] Magnesium carbonate: Ibuprofen may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. | [DB09488] Acrivastine: Ibuprofen may decrease the excretion rate of Acrivastine which could result in a higher serum level. | [DB09496] Octinoxate: Ibuprofen may decrease the excretion rate of Octinoxate which could result in a higher serum level. | [DB09502] Fludeoxyglucose (18F): Ibuprofen may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. | [DB09546] Iobenguane sulfate I-123: Ibuprofen may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level. | [DB09570] Ixazomib: Ibuprofen may decrease the excretion rate of Ixazomib which could result in a higher serum level. | [DB11102] N-acetyltyrosine: Ibuprofen may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level. | [DB11114] Eucalyptus oil: Ibuprofen may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. | [DB11127] Selenious acid: Ibuprofen may decrease the excretion rate of Selenious acid which could result in a higher serum level. | [DB11135] Selenium: Ibuprofen may decrease the excretion rate of Selenium which could result in a higher serum level. | [DB11136] Chromium: Ibuprofen may decrease the excretion rate of Chromium which could result in a higher serum level. | [DB11145] Oxyquinoline: Ibuprofen may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. | [DB11156] Pyrantel: Ibuprofen may decrease the excretion rate of Pyrantel which could result in a higher serum level. | [DB11164] Bicisate: Ibuprofen may decrease the excretion rate of Bicisate which could result in a higher serum level. | [DB11251] Tocopherol: Ibuprofen may decrease the excretion rate of Tocopherol which could result in a higher serum level. | [DB11278] DL-Methylephedrine: The risk or severity of hypertension can be increased when Ibuprofen is combined with DL-Methylephedrine. | [DB11328] Tetradecyl hydrogen sulfate (ester): Ibuprofen may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. | [DB11338] Clove oil: Ibuprofen may decrease the excretion rate of Clove oil which could result in a higher serum level. | [DB11358] Evening primrose oil: Ibuprofen may decrease the excretion rate of Evening primrose oil which could result in a higher serum level. | [DB11364] Pidotimod: Ibuprofen may decrease the excretion rate of Pidotimod which could result in a higher serum level. | [DB11560] Lesinurad: Ibuprofen may decrease the excretion rate of Lesinurad which could result in a higher serum level. | [DB11577] Indigotindisulfonic acid: Ibuprofen may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level. | [DB11587] Etafedrine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Etafedrine. | [DB11598] Antithrombin III human: Ibuprofen may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. | [DB11691] Naldemedine: Ibuprofen may decrease the excretion rate of Naldemedine which could result in a higher serum level. | [DB11699] Tropisetron: Ibuprofen may decrease the excretion rate of Tropisetron which could result in a higher serum level. | [DB11915] Valbenazine: Ibuprofen may decrease the excretion rate of Valbenazine which could result in a higher serum level. | [DB11943] Delafloxacin: Ibuprofen may increase the neuroexcitatory activities of Delafloxacin. | [DB11989] Benznidazole: Ibuprofen may decrease the excretion rate of Benznidazole which could result in a higher serum level. | [DB12007] Isoflavone: Ibuprofen may decrease the excretion rate of Isoflavone which could result in a higher serum level. | [DB12107] Vaborbactam: Ibuprofen may decrease the excretion rate of Vaborbactam which could result in a higher serum level. | [DB12161] Deutetrabenazine: Ibuprofen may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level. | [DB12278] Propiverine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Propiverine. | [DB12783] Benserazide: Ibuprofen may decrease the excretion rate of Benserazide which could result in a higher serum level. | [DB13025] Tiapride: Ibuprofen may decrease the excretion rate of Tiapride which could result in a higher serum level. | [DB13139] Levosalbutamol: The risk or severity of hypertension can be increased when Ibuprofen is combined with Levosalbutamol. | [DB13156] Inosine pranobex: Ibuprofen may decrease the excretion rate of Inosine pranobex which could result in a higher serum level. | [DB13178] Inositol: Ibuprofen may decrease the excretion rate of Inositol which could result in a higher serum level. | [DB13185] Oxabolone cipionate: Ibuprofen may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level. | [DB13191] Phosphocreatine: Ibuprofen may decrease the excretion rate of Phosphocreatine which could result in a higher serum level. | [DB13269] Dichlorobenzyl alcohol: Ibuprofen may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. | [DB13293] Ipecac: Ibuprofen may decrease the excretion rate of Ipecac which could result in a higher serum level. | [DB13595] Almasilate: Ibuprofen may decrease the excretion rate of Almasilate which could result in a higher serum level. | [DB13873] Fenofibric acid: Ibuprofen may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. | [DB13884] Albutrepenonacog alfa: Ibuprofen may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. | [DB13909] Bismuth subgallate: Ibuprofen may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. | [DB13967] Patent Blue: Ibuprofen may decrease the excretion rate of Patent Blue which could result in a higher serum level. | [DB14006] Choline salicylate: Ibuprofen may decrease the excretion rate of Choline salicylate which could result in a higher serum level. | [DB14007] Pentetic acid: Ibuprofen may decrease the excretion rate of Pentetic acid which could result in a higher serum level. | [DB14526] Chromic citrate: Ibuprofen may decrease the excretion rate of Chromic citrate which could result in a higher serum level. | [DB14527] Chromic nitrate: Ibuprofen may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. | [DB14528] Chromium gluconate: Ibuprofen may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. | [DB14529] Chromium nicotinate: Ibuprofen may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. | [DB14530] Chromous sulfate: Ibuprofen may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. | [DB00254] Doxycycline: Ibuprofen may decrease the excretion rate of Doxycycline which could result in a higher serum level. | [DB00327] Hydromorphone: Ibuprofen may decrease the excretion rate of Hydromorphone which could result in a higher serum level. | [DB00186] Lorazepam: Ibuprofen may decrease the excretion rate of Lorazepam which could result in a higher serum level. | [DB00628] Clorazepic acid: Ibuprofen may decrease the excretion rate of Clorazepic acid which could result in a higher serum level. | [DB00842] Oxazepam: Ibuprofen may decrease the excretion rate of Oxazepam which could result in a higher serum level. | [DB01068] Clonazepam: Ibuprofen may decrease the excretion rate of Clonazepam which could result in a higher serum level. | [DB01215] Estazolam: Ibuprofen may decrease the excretion rate of Estazolam which could result in a higher serum level. | [DB01233] Metoclopramide: Ibuprofen may decrease the excretion rate of Metoclopramide which could result in a higher serum level. | [DB01558] Bromazepam: Ibuprofen may decrease the excretion rate of Bromazepam which could result in a higher serum level. | [DB06767] Ammonium chloride: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Ammonium chloride. | [DB11130] Opium: Ibuprofen may decrease the excretion rate of Opium which could result in a higher serum level. | [DB00231] Temazepam: Ibuprofen may decrease the excretion rate of Temazepam which could result in a higher serum level. | [DB11085] Resorcinol: Ibuprofen may decrease the excretion rate of Resorcinol which could result in a higher serum level. | [DB00404] Alprazolam: Ibuprofen may decrease the excretion rate of Alprazolam which could result in a higher serum level. | [DB00683] Midazolam: Ibuprofen may decrease the excretion rate of Midazolam which could result in a higher serum level. | [DB00897] Triazolam: Ibuprofen may decrease the excretion rate of Triazolam which could result in a higher serum level. | [DB15593] Golodirsen: Ibuprofen may decrease the excretion rate of Golodirsen which could result in a higher serum level. | [DB00285] Venlafaxine: Ibuprofen may decrease the excretion rate of Venlafaxine which could result in a higher serum level. | [DB00624] Testosterone: Ibuprofen may decrease the excretion rate of Testosterone which could result in a higher serum level. | [DB00829] Diazepam: Ibuprofen may decrease the excretion rate of Diazepam which could result in a higher serum level. | [DB00709] Lamivudine: Ibuprofen may decrease the excretion rate of Lamivudine which could result in a higher serum level. | [DB01137] Levofloxacin: Ibuprofen may increase the neuroexcitatory activities of Levofloxacin. | [DB00477] Chlorpromazine: The risk or severity of hypertension can be increased when Chlorpromazine is combined with Ibuprofen. | [DB00490] Buspirone: The risk or severity of hypertension can be increased when Buspirone is combined with Ibuprofen. | [DB00669] Sumatriptan: The risk or severity of hypertension can be increased when Sumatriptan is combined with Ibuprofen. | [DB01224] Quetiapine: The risk or severity of hypertension can be increased when Ibuprofen is combined with Quetiapine. | [DB01267] Paliperidone: The risk or severity of hypertension can be increased when Ibuprofen is combined with Paliperidone. | [DB08893] Mirabegron: The risk or severity of hypertension can be increased when Ibuprofen is combined with Mirabegron. | [DB00193] Tramadol: Ibuprofen may decrease the excretion rate of Tramadol which could result in a higher serum level. | [DB00213] Pantoprazole: Ibuprofen may decrease the excretion rate of Pantoprazole which could result in a higher serum level. | [DB00243] Ranolazine: Ibuprofen may decrease the excretion rate of Ranolazine which could result in a higher serum level. | [DB00273] Topiramate: Ibuprofen may decrease the excretion rate of Topiramate which could result in a higher serum level. | [DB00349] Clobazam: Ibuprofen may decrease the excretion rate of Clobazam which could result in a higher serum level. | [DB00351] Megestrol acetate: Ibuprofen may decrease the excretion rate of Megestrol acetate which could result in a higher serum level. | [DB00480] Lenalidomide: Ibuprofen may decrease the excretion rate of Lenalidomide which could result in a higher serum level. | [DB00690] Flurazepam: Ibuprofen may decrease the excretion rate of Flurazepam which could result in a higher serum level. | [DB01030] Topotecan: Ibuprofen may decrease the excretion rate of Topotecan which could result in a higher serum level. | [DB01169] Arsenic trioxide: Ibuprofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level. | [DB01587] Ketazolam: Ibuprofen may decrease the excretion rate of Ketazolam which could result in a higher serum level. | [DB06228] Rivaroxaban: Ibuprofen may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. | [DB06480] Prucalopride: Ibuprofen may decrease the excretion rate of Prucalopride which could result in a higher serum level. | [DB06695] Dabigatran etexilate: Ibuprofen may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level. | [DB06702] Fesoterodine: Ibuprofen may decrease the excretion rate of Fesoterodine which could result in a higher serum level. | [DB08910] Pomalidomide: Ibuprofen may decrease the excretion rate of Pomalidomide which could result in a higher serum level. | [DB08934] Sofosbuvir: Ibuprofen may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. | [DB09027] Ledipasvir: Ibuprofen may decrease the excretion rate of Ledipasvir which could result in a higher serum level. | [DB09075] Edoxaban: Ibuprofen may decrease the excretion rate of Edoxaban which could result in a higher serum level. | [DB00813] Fentanyl: The risk or severity of hypertension can be increased when Fentanyl is combined with Ibuprofen. | [DB00454] Meperidine: Ibuprofen may decrease the excretion rate of Meperidine which could result in a higher serum level. | [DB13987] Strontium chloride: Ibuprofen may decrease the excretion rate of Strontium chloride which could result in a higher serum level. | [DB04890] Bepotastine: Ibuprofen may decrease the excretion rate of Bepotastine which could result in a higher serum level. | [DB00982] Isotretinoin: Ibuprofen may decrease the excretion rate of Isotretinoin which could result in a higher serum level. | [DB04930] Permethrin: Ibuprofen may decrease the excretion rate of Permethrin which could result in a higher serum level. | [DB00333] Methadone: Ibuprofen may decrease the excretion rate of Methadone which could result in a higher serum level. | [DB01394] Colchicine: Ibuprofen may decrease the excretion rate of Colchicine which could result in a higher serum level. | [DB01129] Rabeprazole: Ibuprofen may decrease the excretion rate of Rabeprazole which could result in a higher serum level. | [DB00314] Capreomycin: Ibuprofen may decrease the excretion rate of Capreomycin which could result in a higher serum level. | [DB00515] Cisplatin: Ibuprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. | [DB01035] Procainamide: Ibuprofen may decrease the excretion rate of Procainamide which could result in a higher serum level. | [DB12615] Plazomicin: Ibuprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level. | [DB00552] Pentostatin: Ibuprofen may decrease the excretion rate of Pentostatin which could result in a higher serum level. | [DB13145] Nedaplatin: Ibuprofen may decrease the excretion rate of Nedaplatin which could result in a higher serum level. | [DB00803] Colistin: Ibuprofen may decrease the excretion rate of Colistin which could result in a higher serum level. | [DB00908] Quinidine: Ibuprofen may decrease the excretion rate of Quinidine which could result in a higher serum level. | [DB00479] Amikacin: Ibuprofen may decrease the excretion rate of Amikacin which could result in a higher serum level. | [DB00684] Tobramycin: Ibuprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level. | [DB00798] Gentamicin: Ibuprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level. | [DB00955] Netilmicin: Ibuprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level. | [DB01082] Streptomycin: Ibuprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level. | [DB01172] Kanamycin: Ibuprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level. | [DB03615] Ribostamycin: Ibuprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level. | [DB04729] Gentamicin C1a: Ibuprofen may decrease the excretion rate of Gentamicin C1a which could result in a higher serum level. | [DB06696] Arbekacin: Ibuprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level. | [DB12604] Sisomicin: Ibuprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level. | [DB13540] Isepamicin: Ibuprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level. | [DB09015] Canrenoic acid: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Canrenoic acid. | [DB09125] Potassium citrate: Potassium citrate may increase the hyperkalemic activities of Ibuprofen. | [DB12221] Canrenone: The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Canrenone. | [DB00311] Ethoxzolamide: Ethoxzolamide may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00703] Methazolamide: Methazolamide may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB01144] Diclofenamide: Diclofenamide may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB01412] Theobromine: Theobromine may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB05034] Ularitide: Ularitide may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB09401] Isosorbide: Isosorbide may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB12670] Rolofylline: Rolofylline may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB12704] Spiradoline: Spiradoline may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13284] Meticrane: Meticrane may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13405] Mefruside: Mefruside may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13430] Mebutizide: Mebutizide may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13617] Clorexolone: Clorexolone may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13663] Clofenamide: Clofenamide may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13708] Fenquizone: Fenquizone may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB13792] Clopamide: Clopamide may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB14500] Potassium: Potassium may increase the hyperkalemic activities of Ibuprofen. | [DB09338] Mersalyl: Ibuprofen may decrease the excretion rate of Mersalyl which could result in a higher serum level. | [DB06370] Indisulam: Indisulam may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00819] Acetazolamide: Acetazolamide may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. | [DB00909] Zonisamide: The risk or severity of hyperkalemia can be increased when Zonisamide is combined with Ibuprofen. | [DB08907] Canagliflozin: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Canagliflozin. | [DB06212] Tolvaptan: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Tolvaptan. | [DB01345] Potassium cation: Potassium cation may increase the hyperkalemic activities of Ibuprofen. | [DB09046] Metreleptin: The metabolism of Ibuprofen can be increased when combined with Metreleptin. | [DB06715] Potassium Iodide: Potassium Iodide may increase the hyperkalemic activities of Ibuprofen. | [DB09087] Potassium alum: Potassium alum may increase the hyperkalemic activities of Ibuprofen. | [DB09413] Monopotassium phosphate: Monopotassium phosphate may increase the hyperkalemic activities of Ibuprofen. | [DB09414] Dipotassium phosphate: Dipotassium phosphate may increase the hyperkalemic activities of Ibuprofen. | [DB09483] Potassium lactate: Potassium lactate may increase the hyperkalemic activities of Ibuprofen. | [DB11107] Potassium bitartrate: Potassium bitartrate may increase the hyperkalemic activities of Ibuprofen. | [DB11153] Potassium hydroxide: Potassium hydroxide may increase the hyperkalemic activities of Ibuprofen. | [DB13620] Potassium gluconate: Potassium gluconate may increase the hyperkalemic activities of Ibuprofen. | [DB13735] Potassium guaiacolsulfonate: Potassium guaiacolsulfonate may increase the hyperkalemic activities of Ibuprofen. | [DB13977] Potassium carbonate: Potassium carbonate may increase the hyperkalemic activities of Ibuprofen. | [DB14492] Potassium triiodide: Potassium triiodide may increase the hyperkalemic activities of Ibuprofen. | [DB00761] Potassium chloride: Potassium chloride may increase the hyperkalemic activities of Ibuprofen. | [DB09418] Potassium perchlorate: Potassium perchlorate may increase the hyperkalemic activities of Ibuprofen. | [DB11090] Potassium nitrate: Potassium nitrate may increase the hyperkalemic activities of Ibuprofen. | [DB11098] Potassium bicarbonate: Potassium bicarbonate may increase the hyperkalemic activities of Ibuprofen. | [DB14498] Potassium acetate: Potassium acetate may increase the hyperkalemic activities of Ibuprofen. | [DB14499] Potassium sulfate: Potassium sulfate may increase the hyperkalemic activities of Ibuprofen. | [DB00649] Stavudine: The excretion of Stavudine can be decreased when combined with Ibuprofen. | [DB00943] Zalcitabine: The excretion of Zalcitabine can be decreased when combined with Ibuprofen. | [DB00365] Grepafloxacin: Ibuprofen may increase the neuroexcitatory activities of Grepafloxacin. | [DB00009] Alteplase: The risk or severity of angioedema can be increased when Alteplase is combined with Ibuprofen. | [DB00013] Urokinase: The risk or severity of angioedema can be increased when Urokinase is combined with Ibuprofen. | [DB00015] Reteplase: The risk or severity of angioedema can be increased when Reteplase is combined with Ibuprofen. | [DB00029] Anistreplase: The risk or severity of angioedema can be increased when Anistreplase is combined with Ibuprofen. | [DB00031] Tenecteplase: The risk or severity of angioedema can be increased when Tenecteplase is combined with Ibuprofen. | [DB00086] Streptokinase: The risk or severity of angioedema can be increased when Streptokinase is combined with Ibuprofen. | [DB04876] Vildagliptin: The risk or severity of angioedema can be increased when Ibuprofen is combined with Vildagliptin. | [DB06011] AMG-222: The risk or severity of angioedema can be increased when Ibuprofen is combined with AMG-222. | [DB06127] Bisegliptin: The risk or severity of angioedema can be increased when Ibuprofen is combined with Bisegliptin. | [DB06245] Lanoteplase: The risk or severity of angioedema can be increased when Ibuprofen is combined with Lanoteplase. | [DB06679] Amediplase: The risk or severity of angioedema can be increased when Ibuprofen is combined with Amediplase. | [DB08382] Gosogliptin: The risk or severity of angioedema can be increased when Ibuprofen is combined with Gosogliptin. | [DB11723] Dutogliptin: The risk or severity of angioedema can be increased when Ibuprofen is combined with Dutogliptin. | [DB11950] Teneligliptin: The risk or severity of angioedema can be increased when Ibuprofen is combined with Teneligliptin. | [DB11992] Omarigliptin: The risk or severity of angioedema can be increased when Ibuprofen is combined with Omarigliptin. | [DB12268] Carmegliptin: The risk or severity of angioedema can be increased when Ibuprofen is combined with Carmegliptin. | [DB12412] Gemigliptin: The risk or severity of angioedema can be increased when Ibuprofen is combined with Gemigliptin. | [DB12417] Anagliptin: The risk or severity of angioedema can be increased when Ibuprofen is combined with Anagliptin. | [DB12625] Evogliptin: The risk or severity of angioedema can be increased when Ibuprofen is combined with Evogliptin. | [DB13646] Saruplase: The risk or severity of angioedema can be increased when Ibuprofen is combined with Saruplase. | [DB00230] Pregabalin: The risk or severity of angioedema can be increased when Pregabalin is combined with Ibuprofen. | [DB06196] Icatibant: The risk or severity of angioedema can be increased when Ibuprofen is combined with Icatibant. | [DB06203] Alogliptin: The risk or severity of angioedema can be increased when Ibuprofen is combined with Alogliptin. | [DB09292] Sacubitril: The risk or severity of angioedema can be increased when Ibuprofen is combined with Sacubitril. | [DB00877] Sirolimus: The risk or severity of angioedema can be increased when Sirolimus is combined with Ibuprofen. | [DB06287] Temsirolimus: The risk or severity of angioedema can be increased when Ibuprofen is combined with Temsirolimus. | [DB08882] Linagliptin: The metabolism of Ibuprofen can be decreased when combined with Linagliptin. | [DB00173] Adenine: The metabolism of Ibuprofen can be decreased when combined with Adenine. | [DB00818] Propofol: The metabolism of Ibuprofen can be decreased when combined with Propofol. | [DB06210] Eltrombopag: The metabolism of Ibuprofen can be decreased when combined with Eltrombopag. | [DB08896] Regorafenib: The metabolism of Ibuprofen can be decreased when combined with Regorafenib. | [DB09183] Dasabuvir: The metabolism of Ibuprofen can be decreased when combined with Dasabuvir. | [DB09276] Sodium aurothiomalate: The metabolism of Ibuprofen can be decreased when combined with Sodium aurothiomalate. | [DB09296] Ombitasvir: The metabolism of Ibuprofen can be decreased when combined with Ombitasvir. | [DB09297] Paritaprevir: The metabolism of Ibuprofen can be decreased when combined with Paritaprevir. | [DB09298] Silibinin: The excretion of Silibinin can be decreased when combined with Ibuprofen. | [DB12010] Fostamatinib: The metabolism of Ibuprofen can be decreased when combined with Fostamatinib. | [DB12332] Rucaparib: The metabolism of Ibuprofen can be decreased when combined with Rucaparib. | [DB13878] Pibrentasvir: The metabolism of Ibuprofen can be decreased when combined with Pibrentasvir. | [DB13879] Glecaprevir: The metabolism of Ibuprofen can be decreased when combined with Glecaprevir. | [DB12978] Pexidartinib: The metabolism of Ibuprofen can be decreased when combined with Pexidartinib. | [DB00205] Pyrimethamine: The metabolism of Ibuprofen can be decreased when combined with Pyrimethamine. | [DB01079] Tegaserod: The metabolism of Ibuprofen can be decreased when combined with Tegaserod. | [DB00665] Nilutamide: The metabolism of Ibuprofen can be decreased when combined with Nilutamide. | [DB09241] Methylene blue: The metabolism of Ibuprofen can be decreased when combined with Methylene blue. | [DB00481] Raloxifene: The metabolism of Ibuprofen can be decreased when combined with Raloxifene. | [DB01393] Bezafibrate: The metabolism of Ibuprofen can be decreased when combined with Bezafibrate. | [DB12245] Triclabendazole: The metabolism of Ibuprofen can be decreased when combined with Triclabendazole. | [DB00661] Verapamil: The metabolism of Ibuprofen can be decreased when combined with Verapamil. | [DB01115] Nifedipine: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Nifedipine. | [DB04216] Quercetin: The metabolism of Ibuprofen can be decreased when combined with Quercetin. | [DB12070] Letermovir: The metabolism of Ibuprofen can be decreased when combined with Letermovir. | [DB12466] Favipiravir: The metabolism of Ibuprofen can be decreased when combined with Favipiravir. | [DB15822] Pralsetinib: The metabolism of Ibuprofen can be decreased when combined with Pralsetinib. | [DB08864] Rilpivirine: The metabolism of Ibuprofen can be decreased when combined with Rilpivirine. | [DB00615] Rifabutin: The metabolism of Ibuprofen can be increased when combined with Rifabutin. | [DB01181] Ifosfamide: The metabolism of Ibuprofen can be increased when combined with Ifosfamide. | [DB01201] Rifapentine: The metabolism of Ibuprofen can be increased when combined with Rifapentine. | [DB00359] Sulfadiazine: The metabolism of Ibuprofen can be decreased when combined with Sulfadiazine. | [DB00402] Eszopiclone: The metabolism of Ibuprofen can be decreased when combined with Eszopiclone. | [DB00918] Almotriptan: The metabolism of Ibuprofen can be decreased when combined with Almotriptan. | [DB09068] Vortioxetine: The metabolism of Vortioxetine can be decreased when combined with Ibuprofen. | [DB00250] Dapsone: The metabolism of Ibuprofen can be decreased when combined with Dapsone. | [DB00347] Trimethadione: The metabolism of Ibuprofen can be decreased when combined with Trimethadione. | [DB00532] Mephenytoin: The metabolism of Ibuprofen can be decreased when combined with Mephenytoin. | [DB00617] Paramethadione: The metabolism of Ibuprofen can be decreased when combined with Paramethadione. | [DB00755] Tretinoin: The risk or severity of elevated intracranial pressure can be increased when Ibuprofen is combined with Tretinoin. | [DB00799] Tazarotene: The metabolism of Ibuprofen can be decreased when combined with Tazarotene. | [DB00857] Terbinafine: The metabolism of Ibuprofen can be decreased when combined with Terbinafine. | [DB00912] Repaglinide: The metabolism of Ibuprofen can be decreased when combined with Repaglinide. | [DB01198] Zopiclone: The metabolism of Zopiclone can be decreased when combined with Ibuprofen. | [DB01218] Halofantrine: The metabolism of Halofantrine can be decreased when combined with Ibuprofen. | [DB01221] Ketamine: The metabolism of Ketamine can be decreased when combined with Ibuprofen. | [DB01357] Mestranol: The metabolism of Mestranol can be decreased when combined with Ibuprofen. | [DB06510] Muraglitazar: The metabolism of Muraglitazar can be decreased when combined with Ibuprofen. | [DB06739] Seratrodast: The metabolism of Seratrodast can be decreased when combined with Ibuprofen. | [DB08496] (R)-warfarin: The metabolism of (R)-warfarin can be decreased when combined with Ibuprofen. | [DB08922] Perospirone: The metabolism of Perospirone can be decreased when combined with Ibuprofen. | [DB09080] Olodaterol: The metabolism of Olodaterol can be decreased when combined with Ibuprofen. | [DB09198] Lobeglitazone: The metabolism of Ibuprofen can be decreased when combined with Lobeglitazone. | [DB09199] Netoglitazone: The metabolism of Ibuprofen can be decreased when combined with Netoglitazone. | [DB09200] Rivoglitazone: The metabolism of Ibuprofen can be decreased when combined with Rivoglitazone. | [DB09201] Ciglitazone: The metabolism of Ibuprofen can be decreased when combined with Ciglitazone. | [DB12781] Balaglitazone: The metabolism of Ibuprofen can be decreased when combined with Balaglitazone. | [DB14055] (S)-Warfarin: The metabolism of (S)-Warfarin can be decreased when combined with Ibuprofen. | [DB06738] Ketobemidone: The metabolism of Ketobemidone can be decreased when combined with Ibuprofen. | [DB11757] Istradefylline: The metabolism of Istradefylline can be decreased when combined with Ibuprofen. | [DB08502] Capravirine: The metabolism of Capravirine can be decreased when combined with Ibuprofen. | [DB00277] Theophylline: The metabolism of Ibuprofen can be decreased when combined with Theophylline. | [DB00921] Buprenorphine: The metabolism of Ibuprofen can be decreased when combined with Buprenorphine. | [DB00972] Azelastine: The metabolism of Ibuprofen can be decreased when combined with Azelastine. | [DB01037] Selegiline: The metabolism of Ibuprofen can be decreased when combined with Selegiline. | [DB13943] Testosterone cypionate: The metabolism of Testosterone cypionate can be decreased when combined with Ibuprofen. | [DB13944] Testosterone enanthate: The metabolism of Testosterone enanthate can be decreased when combined with Ibuprofen. | [DB13952] Estradiol acetate: The metabolism of Estradiol acetate can be decreased when combined with Ibuprofen. | [DB13953] Estradiol benzoate: The metabolism of Estradiol benzoate can be decreased when combined with Ibuprofen. | [DB13954] Estradiol cypionate: The metabolism of Estradiol cypionate can be decreased when combined with Ibuprofen. | [DB13955] Estradiol dienanthate: The metabolism of Estradiol dienanthate can be decreased when combined with Ibuprofen. | [DB13956] Estradiol valerate: The metabolism of Estradiol valerate can be decreased when combined with Ibuprofen. | [DB00295] Morphine: The metabolism of Ibuprofen can be decreased when combined with Morphine. | [DB00608] Chloroquine: The metabolism of Ibuprofen can be decreased when combined with Chloroquine. | [DB00688] Mycophenolate mofetil: The metabolism of Ibuprofen can be decreased when combined with Mycophenolate mofetil. | [DB01076] Atorvastatin: The metabolism of Atorvastatin can be decreased when combined with Ibuprofen. | [DB01184] Domperidone: The metabolism of Domperidone can be decreased when combined with Ibuprofen. | [DB01217] Anastrozole: The metabolism of Anastrozole can be decreased when combined with Ibuprofen. | [DB06670] Odanacatib: The metabolism of Odanacatib can be decreased when combined with Ibuprofen. | [DB06770] Benzyl alcohol: The metabolism of Benzyl alcohol can be decreased when combined with Ibuprofen. | [DB11362] Selexipag: The therapeutic efficacy of Selexipag can be decreased when used in combination with Ibuprofen. | [DB11613] Velpatasvir: The metabolism of Velpatasvir can be decreased when combined with Ibuprofen. | [DB11978] Glasdegib: The metabolism of Glasdegib can be decreased when combined with Ibuprofen. | [DB11979] Elagolix: The metabolism of Elagolix can be decreased when combined with Ibuprofen. | [DB12026] Voxilaprevir: The metabolism of Voxilaprevir can be decreased when combined with Ibuprofen. | [DB12612] Ozanimod: The metabolism of Ozanimod can be decreased when combined with Ibuprofen. | [DB11689] Selumetinib: The metabolism of Selumetinib can be decreased when combined with Ibuprofen. | [DB00714] Apomorphine: The metabolism of Ibuprofen can be decreased when combined with Apomorphine. | [DB01611] Hydroxychloroquine: The metabolism of Hydroxychloroquine can be decreased when combined with Ibuprofen. | [DB00604] Cisapride: The metabolism of Ibuprofen can be decreased when combined with Cisapride. | [DB00471] Montelukast: The metabolism of Ibuprofen can be decreased when combined with Montelukast. | [DB01259] Lapatinib: The metabolism of Lapatinib can be decreased when combined with Ibuprofen. | [DB00448] Lansoprazole: The metabolism of Ibuprofen can be decreased when combined with Lansoprazole. | [DB00412] Rosiglitazone: The metabolism of Ibuprofen can be decreased when combined with Rosiglitazone. | [DB16165] Finerenone: The metabolism of Finerenone can be decreased when combined with Ibuprofen. | [DB08912] Dabrafenib: The serum concentration of Ibuprofen can be decreased when it is combined with Dabrafenib. | [DB00398] Sorafenib: The metabolism of Ibuprofen can be decreased when combined with Sorafenib. | [DB00530] Erlotinib: The metabolism of Erlotinib can be decreased when combined with Ibuprofen. | [DB09256] Tegafur: The metabolism of Tegafur can be decreased when combined with Ibuprofen. | [DB13874] Enasidenib: The metabolism of Enasidenib can be decreased when combined with Ibuprofen. | [DB00544] Fluorouracil: The metabolism of Fluorouracil can be decreased when combined with Ibuprofen. | [DB12267] Brigatinib: The metabolism of Brigatinib can be decreased when combined with Ibuprofen. | [DB00946] Phenprocoumon: The metabolism of Phenprocoumon can be decreased when combined with Ibuprofen. | [DB06589] Pazopanib: The metabolism of Pazopanib can be decreased when combined with Ibuprofen. | [DB08901] Ponatinib: The metabolism of Ponatinib can be decreased when combined with Ibuprofen. | [DB01229] Paclitaxel: The metabolism of Paclitaxel can be decreased when combined with Ibuprofen. | [DB06772] Cabazitaxel: The metabolism of Cabazitaxel can be decreased when combined with Ibuprofen. | [DB06605] Apixaban: The risk or severity of bleeding and gastrointestinal bleeding can be increased when Ibuprofen is combined with Apixaban. | [DB00022] Peginterferon alfa-2b: The metabolism of Ibuprofen can be increased when combined with Peginterferon alfa-2b. | [DB00951] Isoniazid: The metabolism of Ibuprofen can be decreased when combined with Isoniazid. | [DB04574] Estrone sulfate: The metabolism of Ibuprofen can be decreased when combined with Estrone sulfate. | [DB04920] Clevidipine: The metabolism of Ibuprofen can be decreased when combined with Clevidipine. | [DB00263] Sulfisoxazole: The metabolism of Ibuprofen can be decreased when combined with Sulfisoxazole. | [DB00576] Sulfamethizole: The metabolism of Ibuprofen can be decreased when combined with Sulfamethizole. | [DB00621] Oxandrolone: The metabolism of Ibuprofen can be decreased when combined with Oxandrolone. | [DB00668] Epinephrine: The metabolism of Ibuprofen can be decreased when combined with Epinephrine. | [DB00745] Modafinil: The metabolism of Ibuprofen can be decreased when combined with Modafinil. | [DB00752] Tranylcypromine: The metabolism of Ibuprofen can be decreased when combined with Tranylcypromine. | [DB00891] Sulfapyridine: The metabolism of Ibuprofen can be decreased when combined with Sulfapyridine. | [DB01097] Leflunomide: The metabolism of Ibuprofen can be decreased when combined with Leflunomide. | [DB01117] Atovaquone: The metabolism of Ibuprofen can be decreased when combined with Atovaquone. | [DB01176] Cyclizine: The metabolism of Ibuprofen can be decreased when combined with Cyclizine. | [DB01195] Flecainide: The metabolism of Ibuprofen can be decreased when combined with Flecainide. | [DB01381] Ginkgo biloba: The metabolism of Ibuprofen can be decreased when combined with Ginkgo biloba. | [DB01411] Pranlukast: The metabolism of Ibuprofen can be decreased when combined with Pranlukast. | [DB03756] Doconexent: The metabolism of Ibuprofen can be decreased when combined with Doconexent. | [DB06174] Noscapine: The metabolism of Ibuprofen can be decreased when combined with Noscapine. | [DB06413] Armodafinil: The metabolism of Ibuprofen can be decreased when combined with Armodafinil. | [DB06414] Etravirine: The metabolism of Ibuprofen can be decreased when combined with Etravirine. | [DB06442] Avasimibe: The metabolism of Ibuprofen can be decreased when combined with Avasimibe. | [DB06594] Agomelatine: The metabolism of Ibuprofen can be decreased when combined with Agomelatine. | [DB08798] Sulfamoxole: The metabolism of Ibuprofen can be decreased when combined with Sulfamoxole. | [DB11994] Diacerein: The metabolism of Ibuprofen can be decreased when combined with Diacerein. | [DB12319] Benzbromarone: The metabolism of Ibuprofen can be decreased when combined with Benzbromarone. | [DB04856] Dexloxiglumide: The metabolism of Ibuprofen can be decreased when combined with Dexloxiglumide. | [DB01015] Sulfamethoxazole: The metabolism of Ibuprofen can be decreased when combined with Sulfamethoxazole. | [DB00255] Diethylstilbestrol: The metabolism of Ibuprofen can be decreased when combined with Diethylstilbestrol. | [DB00396] Progesterone: The metabolism of Ibuprofen can be decreased when combined with Progesterone. | [DB00439] Cerivastatin: The metabolism of Ibuprofen can be decreased when combined with Cerivastatin. | [DB00444] Teniposide: The metabolism of Ibuprofen can be decreased when combined with Teniposide. | [DB00613] Amodiaquine: The metabolism of Ibuprofen can be decreased when combined with Amodiaquine. | [DB00641] Simvastatin: The metabolism of Ibuprofen can be decreased when combined with Simvastatin. | [DB00916] Metronidazole: The metabolism of Ibuprofen can be decreased when combined with Metronidazole. | [DB01016] Glyburide: The protein binding of Glyburide can be decreased when combined with Ibuprofen. | [DB01039] Fenofibrate: The metabolism of Ibuprofen can be decreased when combined with Fenofibrate. | [DB01069] Promethazine: The metabolism of Ibuprofen can be decreased when combined with Promethazine. | [DB01645] Genistein: The metabolism of Ibuprofen can be decreased when combined with Genistein. | [DB08881] Vemurafenib: The metabolism of Ibuprofen can be decreased when combined with Vemurafenib. | [DB09063] Ceritinib: The metabolism of Ibuprofen can be decreased when combined with Ceritinib. | [DB11633] Isavuconazole: The metabolism of Ibuprofen can be decreased when combined with Isavuconazole. | [DB00549] Zafirlukast: The metabolism of Ibuprofen can be decreased when combined with Zafirlukast. | [DB08995] Diosmin: The metabolism of Ibuprofen can be decreased when combined with Diosmin. | [DB13174] Rhein: The metabolism of Ibuprofen can be decreased when combined with Rhein. | [DB14033] Acetyl sulfisoxazole: The metabolism of Ibuprofen can be decreased when combined with Acetyl sulfisoxazole. | [DB04911] Oritavancin: The metabolism of Ibuprofen can be decreased when combined with Oritavancin. | [DB00203] Sildenafil: The metabolism of Ibuprofen can be decreased when combined with Sildenafil. | [DB00334] Olanzapine: The metabolism of Ibuprofen can be decreased when combined with Olanzapine. | [DB00983] Formoterol: The risk or severity of hypertension can be increased when Formoterol is combined with Ibuprofen. | [DB01041] Thalidomide: The metabolism of Ibuprofen can be decreased when combined with Thalidomide. | [DB01131] Proguanil: The metabolism of Proguanil can be decreased when combined with Ibuprofen. | [DB01177] Idarubicin: The metabolism of Idarubicin can be decreased when combined with Ibuprofen. | [DB04557] Arachidonic Acid: The metabolism of Arachidonic Acid can be decreased when combined with Ibuprofen. | [DB04665] Coumarin: The metabolism of Coumarin can be decreased when combined with Ibuprofen. | [DB04898] Ximelagatran: The metabolism of Ximelagatran can be decreased when combined with Ibuprofen. | [DB06803] Niclosamide: The metabolism of Niclosamide can be decreased when combined with Ibuprofen. | [DB01355] Hexobarbital: The metabolism of Hexobarbital can be decreased when combined with Ibuprofen. | [DB00420] Promazine: The risk or severity of hypertension can be increased when Promazine is combined with Ibuprofen. | [DB00425] Zolpidem: The metabolism of Ibuprofen can be decreased when combined with Zolpidem. | [DB00744] Zileuton: The metabolism of Ibuprofen can be decreased when combined with Zileuton. | [DB00969] Alosetron: The metabolism of Ibuprofen can be decreased when combined with Alosetron. | [DB01028] Methoxyflurane: The risk or severity of hypertension can be increased when Methoxyflurane is combined with Ibuprofen. | [DB01154] Thiamylal: The metabolism of Thiamylal can be decreased when combined with Ibuprofen. | [DB01159] Halothane: The risk or severity of hypertension can be increased when Ibuprofen is combined with Halothane. | [DB03783] Phenacetin: The metabolism of Phenacetin can be decreased when combined with Ibuprofen. | [DB04938] Ospemifene: The metabolism of Ospemifene can be decreased when combined with Ibuprofen. | [DB06218] Lacosamide: The metabolism of Lacosamide can be decreased when combined with Ibuprofen. | [DB06652] Vicriviroc: The metabolism of Vicriviroc can be decreased when combined with Ibuprofen. | [DB06697] Artemether: The metabolism of Artemether can be decreased when combined with Ibuprofen. | [DB11614] Rupatadine: The metabolism of Rupatadine can be decreased when combined with Ibuprofen. | [DB12474] Lynestrenol: The metabolism of Lynestrenol can be decreased when combined with Ibuprofen. | [DB13941] Piperaquine: The metabolism of Piperaquine can be decreased when combined with Ibuprofen. | [DB14011] Nabiximols: The metabolism of Nabiximols can be decreased when combined with Ibuprofen. | [DB14975] Voxelotor: The metabolism of Voxelotor can be decreased when combined with Ibuprofen. | [DB15233] Avapritinib: The metabolism of Ibuprofen can be decreased when combined with Avapritinib. | [DB00216] Eletriptan: The risk or severity of hypertension can be increased when Eletriptan is combined with Ibuprofen. | [DB00843] Donepezil: The metabolism of Ibuprofen can be decreased when combined with Donepezil. | [DB00904] Ondansetron: The metabolism of Ibuprofen can be decreased when combined with Ondansetron. | [DB11586] Asunaprevir: The metabolism of Asunaprevir can be decreased when combined with Ibuprofen. | [DB00188] Bortezomib: The metabolism of Ibuprofen can be decreased when combined with Bortezomib. | [DB00957] Norgestimate: The metabolism of Ibuprofen can be decreased when combined with Norgestimate. | [DB00238] Nevirapine: The metabolism of Ibuprofen can be decreased when combined with Nevirapine. | [DB06237] Avanafil: The serum concentration of Avanafil can be increased when it is combined with Ibuprofen. | [DB00682] Warfarin: Ibuprofen may decrease the excretion rate of Warfarin which could result in a higher serum level. | [DB01101] Capecitabine: The serum concentration of Ibuprofen can be increased when it is combined with Capecitabine. | [DB01174] Phenobarbital: The metabolism of Ibuprofen can be increased when combined with Phenobarbital. | [DB08877] Ruxolitinib: Ibuprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level. | [DB11963] Dacomitinib: The metabolism of Ibuprofen can be decreased when combined with Dacomitinib. | [DB00531] Cyclophosphamide: The metabolism of Ibuprofen can be increased when combined with Cyclophosphamide. | [DB00266] Dicoumarol: The metabolism of Ibuprofen can be decreased when combined with Dicoumarol. | [DB01418] Acenocoumarol: The metabolism of Acenocoumarol can be decreased when combined with Ibuprofen. | [DB13136] Fluindione: The metabolism of Fluindione can be decreased when combined with Ibuprofen. | [DB01320] Fosphenytoin: The metabolism of Fosphenytoin can be decreased when combined with Ibuprofen. | [DB05109] Trabectedin: The metabolism of Trabectedin can be decreased when combined with Ibuprofen. | [DB08875] Cabozantinib: The metabolism of Ibuprofen can be decreased when combined with Cabozantinib. | [DB00675] Tamoxifen: The metabolism of Ibuprofen can be decreased when combined with Tamoxifen. | [DB12147] Erdafitinib: The metabolism of Erdafitinib can be decreased when combined with Ibuprofen. | [DB12371] Siponimod: The risk or severity of hypertension can be increased when Ibuprofen is combined with Siponimod. | [DB09061] Cannabidiol: The metabolism of Ibuprofen can be decreased when combined with Cannabidiol. | [DB13609] Umifenovir: The metabolism of Ibuprofen can be decreased when combined with Umifenovir. | [DB00945] Acetylsalicylic acid: Ibuprofen may decrease the antiplatelet activities of Acetylsalicylic acid. | [DB00252] Phenytoin: The serum concentration of Phenytoin can be increased when it is combined with Ibuprofen. | [DB00005] Etanercept: The metabolism of Ibuprofen can be increased when combined with Etanercept. | [DB00026] Anakinra: The metabolism of Ibuprofen can be increased when combined with Anakinra. | [DB00051] Adalimumab: The metabolism of Ibuprofen can be increased when combined with Adalimumab. | [DB00065] Infliximab: The metabolism of Ibuprofen can be increased when combined with Infliximab. | [DB01281] Abatacept: The metabolism of Ibuprofen can be increased when combined with Abatacept. | [DB04956] Afelimomab: The metabolism of Ibuprofen can be increased when combined with Afelimomab. | [DB05676] Apremilast: The metabolism of Ibuprofen can be increased when combined with Apremilast. | [DB06168] Canakinumab: The metabolism of Ibuprofen can be increased when combined with Canakinumab. | [DB06273] Tocilizumab: The metabolism of Ibuprofen can be increased when combined with Tocilizumab. | [DB06372] Rilonacept: The metabolism of Ibuprofen can be increased when combined with Rilonacept. | [DB06674] Golimumab: The metabolism of Ibuprofen can be increased when combined with Golimumab. | [DB08904] Certolizumab pegol: The metabolism of Ibuprofen can be increased when combined with Certolizumab pegol. | [DB09029] Secukinumab: The metabolism of Ibuprofen can be increased when combined with Secukinumab. | [DB09036] Siltuximab: The metabolism of Ibuprofen can be increased when combined with Siltuximab. | [DB14724] Emapalumab: The metabolism of Ibuprofen can be increased when combined with Emapalumab. | [DB13074] Macimorelin: The therapeutic efficacy of Macimorelin can be decreased when used in combination with Ibuprofen. | [DB11823] Esketamine: The risk or severity of hypertension can be increased when Esketamine is combined with Ibuprofen. | [DB00781] Polymyxin B: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Polymyxin B. | [DB01544] Flunitrazepam: The metabolism of Ibuprofen can be decreased when combined with Flunitrazepam. | [DB06777] Chenodeoxycholic acid: The metabolism of Ibuprofen can be decreased when combined with Chenodeoxycholic acid. | [DB05928] Dovitinib: The metabolism of Ibuprofen can be decreased when combined with Dovitinib. | [DB14754] Solriamfetol: The risk or severity of hypertension can be increased when Solriamfetol is combined with Ibuprofen. | [DB09288] Propacetamol: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Propacetamol. | [DB13946] Testosterone undecanoate: Testosterone undecanoate may increase the hypertensive activities of Ibuprofen. | [DB00181] Baclofen: Ibuprofen may decrease the excretion rate of Baclofen which could result in a higher serum level. | [DB00390] Digoxin: The serum concentration of Digoxin can be increased when it is combined with Ibuprofen. | [DB13401] Metildigoxin: The serum concentration of Metildigoxin can be increased when it is combined with Ibuprofen. | [DB13691] Acetyldigoxin: The serum concentration of Acetyldigoxin can be increased when it is combined with Ibuprofen. | [DB00898] Ethanol: The risk or severity of gastrointestinal irritation can be increased when Ethanol is combined with Ibuprofen. | [DB00495] Zidovudine: The risk or severity of bleeding can be increased when Zidovudine is combined with Ibuprofen. | [DB00054] Abciximab: The risk or severity of bleeding can be increased when Ibuprofen is combined with Abciximab. | [DB00063] Eptifibatide: The risk or severity of bleeding can be increased when Ibuprofen is combined with Eptifibatide. | [DB00208] Ticlopidine: The risk or severity of bleeding can be increased when Ibuprofen is combined with Ticlopidine. | [DB00261] Anagrelide: The risk or severity of bleeding can be increased when Ibuprofen is combined with Anagrelide. | [DB00775] Tirofiban: The risk or severity of bleeding can be increased when Ibuprofen is combined with Tirofiban. | [DB00806] Pentoxifylline: The risk or severity of bleeding can be increased when Ibuprofen is combined with Pentoxifylline. | [DB00975] Dipyridamole: The risk or severity of bleeding can be increased when Ibuprofen is combined with Dipyridamole. | [DB01138] Sulfinpyrazone: The risk or severity of bleeding can be increased when Ibuprofen is combined with Sulfinpyrazone. | [DB01166] Cilostazol: The risk or severity of bleeding can be increased when Ibuprofen is combined with Cilostazol. | [DB01207] Ridogrel: The risk or severity of bleeding can be increased when Ibuprofen is combined with Ridogrel. | [DB01236] Sevoflurane: The risk or severity of hypertension can be increased when Ibuprofen is combined with Sevoflurane. | [DB01240] Epoprostenol: The risk or severity of bleeding can be increased when Ibuprofen is combined with Epoprostenol. | [DB02709] Resveratrol: The risk or severity of bleeding can be increased when Ibuprofen is combined with Resveratrol. | [DB04905] Tesmilifene: The risk or severity of bleeding can be increased when Ibuprofen is combined with Tesmilifene. | [DB04932] Defibrotide: The risk or severity of bleeding can be increased when Ibuprofen is combined with Defibrotide. | [DB05229] Beraprost: The risk or severity of bleeding can be increased when Ibuprofen is combined with Beraprost. | [DB05266] Ibudilast: The risk or severity of bleeding can be increased when Ibuprofen is combined with Ibudilast. | [DB05767] Andrographolide: The risk or severity of bleeding can be increased when Ibuprofen is combined with Andrographolide. | [DB06081] Caplacizumab: The risk or severity of bleeding can be increased when Ibuprofen is combined with Caplacizumab. | [DB06209] Prasugrel: The risk or severity of bleeding can be increased when Ibuprofen is combined with Prasugrel. | [DB06441] Cangrelor: The risk or severity of bleeding can be increased when Ibuprofen is combined with Cangrelor. | [DB07615] Tranilast: The risk or severity of bleeding can be increased when Ibuprofen is combined with Tranilast. | [DB08814] Triflusal: The risk or severity of bleeding can be increased when Ibuprofen is combined with Triflusal. | [DB08816] Ticagrelor: The risk or severity of bleeding can be increased when Ibuprofen is combined with Ticagrelor. | [DB08887] Icosapent ethyl: The risk or severity of bleeding can be increased when Ibuprofen is combined with Icosapent ethyl. | [DB09030] Vorapaxar: The risk or severity of bleeding can be increased when Ibuprofen is combined with Vorapaxar. | [DB09283] Trapidil: The risk or severity of bleeding can be increased when Ibuprofen is combined with Trapidil. | [DB12092] Naftopidil: The risk or severity of bleeding can be increased when Ibuprofen is combined with Naftopidil. | [DB12163] Sarpogrelate: The risk or severity of bleeding can be increased when Ibuprofen is combined with Sarpogrelate. | [DB12321] Ifetroban: The risk or severity of bleeding can be increased when Ibuprofen is combined with Ifetroban. | [DB12749] Butylphthalide: The risk or severity of bleeding can be increased when Ibuprofen is combined with Butylphthalide. | [DB12771] Hydroxytyrosol: The risk or severity of bleeding can be increased when Ibuprofen is combined with Hydroxytyrosol. | [DB13036] Ramatroban: The risk or severity of bleeding can be increased when Ibuprofen is combined with Ramatroban. | [DB13327] Picotamide: The risk or severity of bleeding can be increased when Ibuprofen is combined with Picotamide. | [DB13367] Cloricromen: The risk or severity of bleeding can be increased when Ibuprofen is combined with Cloricromen. | [DB13400] Linsidomine: The risk or severity of bleeding can be increased when Ibuprofen is combined with Linsidomine. | [DB13510] Buflomedil: The risk or severity of bleeding can be increased when Ibuprofen is combined with Buflomedil. | [DB13929] Relcovaptan: The risk or severity of bleeding can be increased when Ibuprofen is combined with Relcovaptan. | [DB00758] Clopidogrel: The risk or severity of bleeding can be increased when Ibuprofen is combined with Clopidogrel. | [DB15786] Maritime pine extract: The risk or severity of bleeding can be increased when Ibuprofen is combined with Maritime pine extract. | [DB12015] Alpelisib: The serum concentration of Ibuprofen can be decreased when it is combined with Alpelisib. | [DB06119] Cenobamate: The serum concentration of Ibuprofen can be decreased when it is combined with Cenobamate. | [DB01104] Sertraline: The risk or severity of bleeding can be increased when Ibuprofen is combined with Sertraline. | [DB00994] Neomycin: The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Neomycin. | [DB00503] Ritonavir: The serum concentration of Ibuprofen can be increased when it is combined with Ritonavir. | [DB00502] Haloperidol: The serum concentration of Haloperidol can be increased when it is combined with Ibuprofen. | [DB11652] Tucatinib: The metabolism of Tucatinib can be decreased when combined with Ibuprofen. | [DB15685] Selpercatinib: The serum concentration of Ibuprofen can be increased when it is combined with Selpercatinib. | [DB00465] Ketorolac: The risk or severity of adverse effects can be increased when Ketorolac is combined with Ibuprofen. | [DB00313] Valproic acid: The protein binding of Valproic acid can be decreased when combined with Ibuprofen. | [DB11932] Abametapir: The serum concentration of Ibuprofen can be increased when it is combined with Abametapir. | [DB15762] Satralizumab: The serum concentration of Ibuprofen can be decreased when it is combined with Satralizumab. | [DB04836] Amineptine: The risk or severity of gastrointestinal bleeding can be increased when Amineptine is combined with Ibuprofen. | [DB09016] Butriptyline: The risk or severity of gastrointestinal bleeding can be increased when Butriptyline is combined with Ibuprofen. | [DB09307] Oxaprotiline: The risk or severity of gastrointestinal bleeding can be increased when Oxaprotiline is combined with Ibuprofen. | [DB12930] Opipramol: The risk or severity of gastrointestinal bleeding can be increased when Opipramol is combined with Ibuprofen. | [DB13114] Amitriptylinoxide: The risk or severity of gastrointestinal bleeding can be increased when Amitriptylinoxide is combined with Ibuprofen. | [DB13225] Dibenzepin: The risk or severity of gastrointestinal bleeding can be increased when Dibenzepin is combined with Ibuprofen. | [DB13246] Quinupramine: The risk or severity of gastrointestinal bleeding can be increased when Quinupramine is combined with Ibuprofen. | [DB13384] Melitracen: The risk or severity of gastrointestinal bleeding can be increased when Melitracen is combined with Ibuprofen. | [DB13411] Lofepramine: The risk or severity of gastrointestinal bleeding can be increased when Lofepramine is combined with Ibuprofen. | [DB13496] Iprindole: The risk or severity of gastrointestinal bleeding can be increased when Iprindole is combined with Ibuprofen. | [DB13782] Imipramine oxide: The risk or severity of gastrointestinal bleeding can be increased when Imipramine oxide is combined with Ibuprofen. | [DB09289] Tianeptine: The risk or severity of gastrointestinal bleeding can be increased when Tianeptine is combined with Ibuprofen. | [DB00321] Amitriptyline: The risk or severity of gastrointestinal bleeding can be increased when Amitriptyline is combined with Ibuprofen. | [DB00726] Trimipramine: The risk or severity of gastrointestinal bleeding can be increased when Trimipramine is combined with Ibuprofen. | [DB01142] Doxepin: The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Ibuprofen. | [DB00344] Protriptyline: The risk or severity of gastrointestinal bleeding can be increased when Protriptyline is combined with Ibuprofen. | [DB00458] Imipramine: The risk or severity of gastrointestinal bleeding can be increased when Imipramine is combined with Ibuprofen. | [DB00540] Nortriptyline: The risk or severity of gastrointestinal bleeding can be increased when Nortriptyline is combined with Ibuprofen. | [DB00543] Amoxapine: The risk or severity of gastrointestinal bleeding can be increased when Amoxapine is combined with Ibuprofen. | [DB01151] Desipramine: The risk or severity of gastrointestinal bleeding can be increased when Desipramine is combined with Ibuprofen. | [DB01242] Clomipramine: The risk or severity of gastrointestinal bleeding can be increased when Clomipramine is combined with Ibuprofen. | [DB08996] Dimetacrine: The risk or severity of gastrointestinal bleeding can be increased when Dimetacrine is combined with Ibuprofen. | [DB09167] Dosulepin: The risk or severity of gastrointestinal bleeding can be increased when Dosulepin is combined with Ibuprofen. | [DB12235] Estetrol: The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Estetrol. | [DB15569] Sotorasib: The serum concentration of Ibuprofen can be decreased when it is combined with Sotorasib. | [DB09227] Barnidipine: The metabolism of Ibuprofen can be decreased when combined with Barnidipine. | [DB09231] Benidipine: The metabolism of Ibuprofen can be decreased when combined with Benidipine. | [DB00246] Ziprasidone: The metabolism of Ibuprofen can be decreased when combined with Ziprasidone. | [DB00363] Clozapine: The metabolism of Ibuprofen can be decreased when combined with Clozapine. | [DB09048] Netupitant: The metabolism of Ibuprofen can be decreased when combined with Netupitant. | [DB04855] Dronedarone: The metabolism of Ibuprofen can be decreased when combined with Dronedarone. | [DB00537] Ciprofloxacin: The metabolism of Ibuprofen can be decreased when combined with Ciprofloxacin. | [DB00199] Erythromycin: The serum concentration of Ibuprofen can be increased when it is combined with Erythromycin. | [DB00673] Aprepitant: The metabolism of Ibuprofen can be decreased when combined with Aprepitant. | [DB01087] Primaquine: The metabolism of Ibuprofen can be decreased when combined with Primaquine. | [DB02703] Fusidic acid: The metabolism of Ibuprofen can be decreased when combined with Fusidic acid. | [DB06290] Simeprevir: The metabolism of Ibuprofen can be decreased when combined with Simeprevir. | [DB06636] Isavuconazonium: The metabolism of Ibuprofen can be decreased when combined with Isavuconazonium. | [DB11581] Venetoclax: The metabolism of Ibuprofen can be decreased when combined with Venetoclax. | [DB14019] Fosnetupitant: The metabolism of Ibuprofen can be decreased when combined with Fosnetupitant. | [DB15982] Berotralstat: The metabolism of Ibuprofen can be decreased when combined with Berotralstat. | [DB00220] Nelfinavir: The metabolism of Ibuprofen can be decreased when combined with Nelfinavir. | [DB00705] Delavirdine: The metabolism of Ibuprofen can be decreased when combined with Delavirdine. | [DB01149] Nefazodone: The metabolism of Ibuprofen can be decreased when combined with Nefazodone. | [DB01118] Amiodarone: The metabolism of Ibuprofen can be decreased when combined with Amiodarone. | [DB00763] Methimazole: The metabolism of Ibuprofen can be decreased when combined with Methimazole. | [DB09118] Stiripentol: The metabolism of Ibuprofen can be decreased when combined with Stiripentol. | [DB00625] Efavirenz: The metabolism of Ibuprofen can be decreased when combined with Efavirenz. | [DB01072] Atazanavir: The metabolism of Ibuprofen can be decreased when combined with Atazanavir. | [DB00701] Amprenavir: The metabolism of Ibuprofen can be decreased when combined with Amprenavir. | [DB01026] Ketoconazole: The metabolism of Ibuprofen can be decreased when combined with Ketoconazole. | [DB01232] Saquinavir: The metabolism of Ibuprofen can be decreased when combined with Saquinavir. | [DB00342] Terfenadine: The metabolism of Ibuprofen can be decreased when combined with Terfenadine. | [DB00836] Loperamide: The metabolism of Ibuprofen can be decreased when combined with Loperamide. | [DB00696] Ergotamine: The metabolism of Ibuprofen can be decreased when combined with Ergotamine. | [DB01183] Naloxone: Ibuprofen may decrease the excretion rate of Naloxone which could result in a higher serum level. | [DB01601] Lopinavir: The metabolism of Ibuprofen can be decreased when combined with Lopinavir. | [DB00872] Conivaptan: The metabolism of Ibuprofen can be decreased when combined with Conivaptan. | [DB01167] Itraconazole: The metabolism of Ibuprofen can be decreased when combined with Itraconazole. | [DB00932] Tipranavir: The metabolism of Ibuprofen can be decreased when combined with Tipranavir. | [DB00224] Indinavir: The metabolism of Ibuprofen can be decreased when combined with Indinavir. | [DB06448] Lonafarnib: The metabolism of Ibuprofen can be decreased when combined with Lonafarnib. | [DB04868] Nilotinib: The metabolism of Ibuprofen can be decreased when combined with Nilotinib. | [DB06595] Midostaurin: The metabolism of Ibuprofen can be decreased when combined with Midostaurin. | [DB01406] Danazol: The metabolism of Ibuprofen can be decreased when combined with Danazol. | [DB00976] Telithromycin: The metabolism of Ibuprofen can be decreased when combined with Telithromycin. | [DB01211] Clarithromycin: The metabolism of Ibuprofen can be decreased when combined with Clarithromycin. | [DB01263] Posaconazole: The metabolism of Ibuprofen can be decreased when combined with Posaconazole. | [DB01264] Darunavir: The metabolism of Ibuprofen can be decreased when combined with Darunavir. | [DB02520] Ditiocarb: The metabolism of Ibuprofen can be decreased when combined with Ditiocarb. | [DB05521] Telaprevir: The metabolism of Ibuprofen can be decreased when combined with Telaprevir. | [DB08873] Boceprevir: The metabolism of Ibuprofen can be decreased when combined with Boceprevir. | [DB09101] Elvitegravir: The metabolism of Ibuprofen can be decreased when combined with Elvitegravir. | [DB11730] Ribociclib: The metabolism of Ibuprofen can be decreased when combined with Ribociclib. | [DB11779] Danoprevir: The metabolism of Ibuprofen can be decreased when combined with Danoprevir. | [DB13179] Troleandomycin: The metabolism of Ibuprofen can be decreased when combined with Troleandomycin. | [DB00564] Carbamazepine: The metabolism of Ibuprofen can be increased when combined with Carbamazepine. | [DB00312] Pentobarbital: The metabolism of Ibuprofen can be increased when combined with Pentobarbital. | [DB00794] Primidone: The metabolism of Ibuprofen can be increased when combined with Primidone. | [DB08899] Enzalutamide: The serum concentration of Ibuprofen can be decreased when it is combined with Enzalutamide. | [DB11901] Apalutamide: The serum concentration of Ibuprofen can be decreased when it is combined with Apalutamide. | [DB09280] Lumacaftor: The serum concentration of Ibuprofen can be decreased when it is combined with Lumacaftor. | [DB00648] Mitotane: The metabolism of Ibuprofen can be increased when combined with Mitotane. | [DB01323] St. John's Wort: The metabolism of Ibuprofen can be increased when combined with St. John's Wort. | [DB11672] Curcumin: The metabolism of Ibuprofen can be decreased when combined with Curcumin. | [DB11201] Menthyl salicylate: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Menthyl salicylate. | [DB11323] Glycol salicylate: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Glycol salicylate. | [DB12597] Asciminib: The metabolism of Ibuprofen can be decreased when combined with Asciminib. | [DB15226] Dasiglucagon: The therapeutic efficacy of Dasiglucagon can be decreased when used in combination with Ibuprofen. | [DB12789] Dinoprost: The therapeutic efficacy of Dinoprost can be decreased when used in combination with Ibuprofen. | [DB14960] Somatrogon: The metabolism of Ibuprofen can be increased when combined with Somatrogon. | [DB05667] Levoketoconazole: The metabolism of Ibuprofen can be decreased when combined with Levoketoconazole. | [DB12917] Bimekizumab: The metabolism of Ibuprofen can be increased when combined with Bimekizumab. | [DB14973] Abrocitinib: The metabolism of Abrocitinib can be decreased when combined with Ibuprofen. | [DB04847] Roxadustat: The metabolism of Roxadustat can be decreased when combined with Ibuprofen. | [DB16236] Mitapivat: The metabolism of Ibuprofen can be increased when combined with Mitapivat. | [DB14737] Cannabinol: The metabolism of Ibuprofen can be decreased when combined with Cannabinol. | [DB14921] Mavacamten: The serum concentration of Ibuprofen can be decreased when it is combined with Mavacamten. | [DB14568] Ivosidenib: The metabolism of Ibuprofen can be increased when combined with Ivosidenib. | [DB15133] Tepotinib: The metabolism of Ibuprofen can be decreased when combined with Tepotinib. | [DB12020] Tecovirimat: The metabolism of Ibuprofen can be increased when combined with Tecovirimat. | [DB04951] Pirfenidone: The metabolism of Pirfenidone can be decreased when combined with Ibuprofen. | [DB12095] Telotristat ethyl: The serum concentration of Ibuprofen can be decreased when it is combined with Telotristat ethyl. | [DB17083] Linzagolix: The serum concentration of Ibuprofen can be increased when it is combined with Linzagolix. | [DB09368] Corticotropin zinc hydroxide: The risk or severity of gastrointestinal irritation can be increased when Corticotropin zinc hydroxide is combined with Ibuprofen. | [DB15777] Fluocortolone pivalate: The risk or severity of gastrointestinal irritation can be increased when Fluocortolone pivalate is combined with Ibuprofen. | [DB15821] Fluocortolone caproate: The risk or severity of gastrointestinal irritation can be increased when Fluocortolone caproate is combined with Ibuprofen. | [DB15972] Desoxycortone: The risk or severity of gastrointestinal irritation can be increased when Desoxycortone is combined with Ibuprofen. | [DB17472] Pirtobrutinib: The metabolism of Ibuprofen can be decreased when combined with Pirtobrutinib. | [DB11682] Daprodustat: The metabolism of Daprodustat can be decreased when combined with Ibuprofen. | [DB15568] Adagrasib: The metabolism of Ibuprofen can be decreased when combined with Adagrasib. | [DB12548] Sparsentan: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Sparsentan. | [DB12513] Omaveloxolone: The serum concentration of Ibuprofen can be decreased when it is combined with Omaveloxolone. | [DB00862] Vardenafil: The metabolism of Ibuprofen can be decreased when combined with Vardenafil. | [DB08820] Ivacaftor: The serum concentration of Ibuprofen can be increased when it is combined with Ivacaftor. | [DB16672] Epcoritamab: The serum concentration of Ibuprofen can be increased when it is combined with Epcoritamab. | [DB12255] Vadadustat: The serum concentration of Vadadustat can be increased when it is combined with Ibuprofen. | [DB12500] Fedratinib: The serum concentration of Ibuprofen can be increased when it is combined with Fedratinib. | [DB16371] Glofitamab: The serum concentration of Ibuprofen can be increased when it is combined with Glofitamab. | [DB14924] Ritlecitinib: The serum concentration of Ibuprofen can be increased when it is combined with Ritlecitinib. | [DB00526] Oxaliplatin: The risk or severity of nephrotoxicity can be increased when Oxaliplatin is combined with Ibuprofen. | [DB12874] Quizartinib: The metabolism of Ibuprofen can be decreased when combined with Quizartinib. | [DB14766] Etrasimod: The metabolism of Etrasimod can be decreased when combined with Ibuprofen. | [DB16826] Repotrectinib: The metabolism of Ibuprofen can be decreased when combined with Repotrectinib. | [DB11718] Encorafenib: The metabolism of Ibuprofen can be decreased when combined with Encorafenib. | [DB11679] Fruquintinib: The metabolism of Fruquintinib can be decreased when combined with Ibuprofen. | [DB15114] Vamorolone: The risk or severity of gastrointestinal irritation can be increased when Vamorolone is combined with Ibuprofen. | [DB12005] Nirogacestat: The metabolism of Ibuprofen can be increased when combined with Nirogacestat. | [DB16200] Iptacopan: The metabolism of Iptacopan can be decreased when combined with Ibuprofen. | [DB11995] Avatrombopag: The metabolism of Avatrombopag can be decreased when combined with Ibuprofen. | [DB12914] Resmetirom: The metabolism of Ibuprofen can be decreased when combined with Resmetirom. | [DB15266] Tovorafenib: The metabolism of Tovorafenib can be decreased when combined with Ibuprofen. | [DB15059] Aprocitentan: The therapeutic efficacy of Aprocitentan can be decreased when used in combination with Ibuprofen. | [DB18847] Deuruxolitinib: The metabolism of Deuruxolitinib can be decreased when combined with Ibuprofen. | [DB12390] Seladelpar: The excretion of Seladelpar can be decreased when combined with Ibuprofen. | [DB16335] Sulopenem etzadroxil: The serum concentration of Sulopenem etzadroxil can be increased when it is combined with Ibuprofen.",0.2 g; 0.2 g/1g; 0.5 g; 10 %; 10 G/100G; 10 MG/ML; 10 mg; 10 mg/1mL; 10 mg/2ml; 100 MG; 100 MG/5ML; 100 MG/G; 100 MG/ML; 100 mg; 100 mg / 5 mL; 100 mg / mL; 100 mg/1; 100 mg/100mL; 100 mg/10mL; 100 mg/1mL; 100 mg/5mL; 100 mg/5ml; 100 ml; 1000 MG; 1000000 mg; 10000000 mg; 1212.100 mg; 125 MG; 125 mg; 1333000 g; 136 MG; 2 %; 2 %w/v; 2 g; 2 mg; 2.000 g; 20 G/100ML; 20 MG; 20 MG/ML; 20 mg/2ml; 20.0 mg; 20.000 mg; 200 1/1; 200 1/2001; 200 MG; 200 MG/ML; 200 mg; 200 mg / tab; 200 mg/1; 200 mg/1 1; 200 mg/1000mg; 200 mg/10mL; 200 mg/1201; 200 mg/2001; 200 mg/5mL; 200 mg/5ml; 200.00 mg; 200.000 mg; 2000.00 mg; 2000.000 mg; 200000 g; 2000000 mg; 20000000 g; 20000000 mg; 200000000 mg; 208320 g; 220000 g; 250 MG; 256 mg/1; 26.600 mg; 292.6 mg; 293 MG; 30 G; 30 MG; 30.000 mg; 300 MG; 300 mg; 325.000 mg; 342 mg; 350 mg; 4 mg/ml; 4.000 g; 40 MG; 40 MG/ML; 40 mg / mL; 40.000 mg; 400 MG; 400 MG/3ML; 400 mg; 400 mg/1; 400 mg/100ml; 400 mg/301; 400 mg/3ml; 400 mg/400mg; 400 mg/4ml; 400 mg/537mg; 400.00 mg; 400.000 mg; 400.000000 mg; 400000 g; 400000 mg/mL; 4000000 mg; 40000000 mg; 40000000 mg (titer); 400000000 mg; 47058820 mg; 5 %; 5 %w/w; 5 g; 5 mg/mL; 5 mg/ml; 5.00 g; 50 mg; 50 mg/1.25mL; 50 mg/g; 500 MG; 500000 g; 6 mg/ml; 60 mg; 600 MG; 600 mg; 600 mg/1; 600 mg/600mg; 600.000 mg; 600.0000 mg; 60000000 mg; 65.000 mg; 66 mg/100mg; 684 MG; 684 mg; 7.500 mg; 800 MG; 800 mg; 800 mg/1; 800 mg/200mL; 800 mg/800mg; 800 mg/8mL; 800 mg/8ml; 800.00 mg; 800.000 mg; 80000000 mg; 85 mg/100mg,Avoid alcohol.; Take with food. Food reduces irritation.
